src_assay_id,confidence_score,cell_id,description,assay_strain,assay_id,doc_id,assay_subcellular_fraction,src_id,assay_organism,curated_by,tid,assay_category,assay_tax_id,assay_tissue,relationship_type,tissue_id,assay_test_type,assay_cell_type,bao_format,assay_type,variant_id,chembl_id
,8,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,1,11087,,1,,Autocuration,12052,,,,H,,,,BAO_0000019,B,,CHEMBL615117
,0,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,2,684,,1,,Autocuration,22226,,,,U,,,,BAO_0000219,F,,CHEMBL615118
,0,,,,3,15453,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL615119
,4,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,4,17841,,1,Bos taurus,Autocuration,104729,,9913.0,,H,,,,BAO_0000249,B,,CHEMBL615120
,1,163.0,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,5,17430,,1,Homo sapiens,Intermediate,80001,,9606.0,,N,,,143B,BAO_0000219,F,,CHEMBL615121
,1,163.0,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,6,17430,,1,Homo sapiens,Intermediate,80001,,9606.0,,N,,,143B,BAO_0000219,F,,CHEMBL615122
,1,163.0,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,7,13799,,1,Mus musculus,Intermediate,80001,,10090.0,,N,,,143B,BAO_0000219,F,,CHEMBL615123
,1,163.0,In vitro cell cytotoxicity was determined against 143B cell line,,8,17774,,1,Homo sapiens,Expert,80001,,9606.0,,N,,,143B,BAO_0000219,F,,CHEMBL615124
,1,163.0,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,9,3801,,1,Homo sapiens,Intermediate,80001,,9606.0,,N,,,143B,BAO_0000219,F,,CHEMBL615125
,1,163.0,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,10,17430,,1,Homo sapiens,Intermediate,80001,,9606.0,,N,,,143B,BAO_0000219,F,,CHEMBL615126
,1,163.0,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,11,17430,,1,Homo sapiens,Intermediate,80001,,9606.0,,N,,,143B,BAO_0000219,F,,CHEMBL615127
,1,163.0,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,12,17774,,1,Homo sapiens,Expert,80001,,9606.0,,N,,,143B,BAO_0000219,F,,CHEMBL615128
,1,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,13,11324,,1,Staphylococcus aureus,Intermediate,50185,,1280.0,,N,,,,BAO_0000218,F,,CHEMBL857900
,1,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,14,11324,,1,Staphylococcus aureus,Intermediate,50185,,1280.0,,N,,,,BAO_0000218,F,,CHEMBL615129
,1,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,15,11324,,1,Staphylococcus aureus,Intermediate,50185,,1280.0,,N,,,,BAO_0000218,F,,CHEMBL615130
,1,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,16,11324,,1,Staphylococcus aureus,Intermediate,50185,,1280.0,,N,,,,BAO_0000218,F,,CHEMBL615131
,9,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,17,11347,,1,Rattus norvegicus,Expert,100122,,10116.0,,D,,,,BAO_0000357,A,,CHEMBL884521
,8,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,18,16474,,1,,Autocuration,12054,,,,H,,,,BAO_0000357,B,,CHEMBL615132
,8,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,19,10091,,1,,Autocuration,12054,,,,H,,,,BAO_0000019,B,,CHEMBL615133
,8,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,20,16474,,1,,Autocuration,12054,,,,H,,,,BAO_0000357,B,,CHEMBL615134
,8,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,21,16474,,1,,Autocuration,12054,,,,H,,,,BAO_0000357,B,,CHEMBL615135
,8,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,22,16474,,1,,Autocuration,12054,,,,H,,,,BAO_0000357,B,,CHEMBL615136
,8,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,23,16474,,1,,Autocuration,12054,,,,H,,,,BAO_0000357,B,,CHEMBL615137
,8,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,24,16474,,1,,Autocuration,12054,,,,H,,,,BAO_0000357,B,,CHEMBL615138
,0,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,25,14352,,1,,Autocuration,22226,,,,U,,,,BAO_0000219,B,,CHEMBL836324
,8,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,26,5646,,1,Oryctolagus cuniculus,Autocuration,12054,,9986.0,,H,,,,BAO_0000357,B,,CHEMBL615139
,8,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,27,5646,,1,Oryctolagus cuniculus,Autocuration,12054,,9986.0,,H,,,,BAO_0000357,B,,CHEMBL615140
,8,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,28,10997,,1,,Autocuration,12426,,,,H,,,,BAO_0000219,B,,CHEMBL615141
,8,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,29,6309,,1,soya bean,Autocuration,12054,,3847.0,,H,,,,BAO_0000357,B,,CHEMBL615142
,8,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,30,167,,1,Glycine max,Autocuration,12054,,3847.0,,H,,,,BAO_0000357,B,,CHEMBL615143
,8,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,31,167,,1,Glycine max,Autocuration,12054,,3847.0,,H,,,,BAO_0000357,B,,CHEMBL615144
,8,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,32,11087,,1,Glycine max,Autocuration,12054,,3847.0,,H,,,,BAO_0000357,B,,CHEMBL872867
,8,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,33,11087,,1,Glycine max,Autocuration,12054,,3847.0,,H,,,,BAO_0000357,B,,CHEMBL615145
,8,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,34,13622,,1,Glycine max,Autocuration,12054,,3847.0,,H,,,,BAO_0000357,B,,CHEMBL615146
,8,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,35,13622,,1,Glycine max,Autocuration,12054,,3847.0,,H,,,,BAO_0000357,B,,CHEMBL615147
,0,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,36,11347,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000019,A,,CHEMBL615148
,0,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,37,5926,,1,Escherichia coli,Autocuration,22226,,562.0,,U,,,,BAO_0000019,B,,CHEMBL615149
,0,,Dissociation constant with dimeric 16S rRNA RNA construct B,,38,4567,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL615150
,3,,Dissociation constant towards 16S rRNA construct A,,39,3782,,1,,Intermediate,22222,,,,M,,,,BAO_0000225,B,,CHEMBL615151
,3,,Dissociation constant towards 16S rRNA construct B,,40,3782,,1,,Intermediate,22222,,,,M,,,,BAO_0000225,B,,CHEMBL615152
,3,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,41,4466,,1,Escherichia coli,Expert,100263,,562.0,,M,,,,BAO_0000225,B,,CHEMBL615153
,3,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,42,6592,,1,Escherichia coli,Expert,100263,,562.0,,M,,,,BAO_0000225,B,,CHEMBL615154
,8,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,43,898,,1,,Autocuration,13053,,,,H,,,,BAO_0000019,B,,CHEMBL615155
,8,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,44,898,,1,,Autocuration,13053,,,,H,,,,BAO_0000019,B,,CHEMBL615156
,8,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,45,13163,,1,Homo sapiens,Autocuration,20001,,9606.0,,H,,,,BAO_0000019,B,,CHEMBL615157
,8,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,46,13163,,1,Homo sapiens,Autocuration,20001,,9606.0,,H,,,,BAO_0000019,B,,CHEMBL615158
,9,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,47,10691,,1,Rattus norvegicus,Expert,12971,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL615159
,9,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,48,10691,,1,Rattus norvegicus,Expert,12971,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL615172
,9,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,49,10691,,1,Rattus norvegicus,Expert,12971,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL615173
,9,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,50,10691,,1,Rattus norvegicus,Expert,12971,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL615174
,8,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,51,898,,1,,Autocuration,13053,,,,H,,,,BAO_0000019,B,,CHEMBL884518
,8,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,52,912,,1,,Autocuration,11512,,,,H,,,,BAO_0000357,B,,CHEMBL615175
,8,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,53,912,,1,,Autocuration,11512,,,,H,,,,BAO_0000357,B,,CHEMBL615176
,8,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,54,912,,1,,Autocuration,11512,,,,H,,,,BAO_0000357,B,,CHEMBL615177
,5,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,55,15103,Membranes,1,Rattus norvegicus,Autocuration,104740,,10116.0,,D,,,,BAO_0000249,B,,CHEMBL615178
,1,506.0,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,56,5116,,1,Homo sapiens,Intermediate,80002,,9606.0,,N,,,1A9,BAO_0000219,F,,CHEMBL615179
,7,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,57,14578,,1,Rattus norvegicus,Autocuration,104835,,10116.0,,D,,,Oocytes,BAO_0000219,F,,CHEMBL615180
,7,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,58,14578,,1,Rattus norvegicus,Autocuration,104821,,10116.0,,D,,,Oocytes,BAO_0000219,F,,CHEMBL615181
,7,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,59,14578,,1,Rattus norvegicus,Autocuration,104848,,10116.0,,D,,,Oocytes,BAO_0000219,F,,CHEMBL615182
,1,506.0,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,60,4787,,1,Homo sapiens,Expert,80002,,9606.0,,N,,,1A9,BAO_0000219,F,,CHEMBL615183
,1,506.0,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,61,4787,,1,Homo sapiens,Intermediate,80002,,9606.0,,N,,,1A9,BAO_0000219,F,,CHEMBL615184
,1,506.0,Cytotoxic activity against human ovarian cancer (1A9) cell line,,62,3547,,1,Homo sapiens,Intermediate,80002,,9606.0,,N,,,1A9,BAO_0000219,F,,CHEMBL615185
,1,506.0,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,63,3547,,1,Homo sapiens,Intermediate,80002,,9606.0,,N,,,1A9,BAO_0000219,F,,CHEMBL615186
,1,506.0,Effective dose of compound against replication of 1A9 cell line was evaluated,,64,6726,,1,Homo sapiens,Intermediate,80002,,9606.0,,N,,,1A9,BAO_0000219,F,,CHEMBL615187
,1,506.0,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,65,3455,,1,Homo sapiens,Expert,80002,,9606.0,,N,,,1A9,BAO_0000219,F,,CHEMBL885343
,1,506.0,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,66,5726,,1,Homo sapiens,Intermediate,80002,,9606.0,,N,,,1A9,BAO_0000219,F,,CHEMBL615188
,1,506.0,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,67,5726,,1,Homo sapiens,Intermediate,80002,,9606.0,,N,,,1A9,BAO_0000219,F,,CHEMBL615189
,1,506.0,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,68,5726,,1,Homo sapiens,Intermediate,80002,,9606.0,,N,,,1A9,BAO_0000219,F,,CHEMBL615190
,1,506.0,Inhibitory activity against Taxol resistant 1A9 cell lines,,69,3395,,1,Homo sapiens,Intermediate,80002,,9606.0,,N,,,1A9,BAO_0000219,F,,CHEMBL615191
,1,506.0,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,70,3415,,1,Homo sapiens,Expert,80002,,9606.0,,N,,,1A9,BAO_0000219,F,,CHEMBL615192
,1,506.0,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,71,3415,,1,Homo sapiens,Expert,80002,,9606.0,,N,,,1A9,BAO_0000219,F,,CHEMBL827083
,1,506.0,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,72,17099,,1,Homo sapiens,Expert,80002,,9606.0,,N,,,1A9,BAO_0000219,F,,CHEMBL615193
,1,506.0,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,73,17099,,1,Homo sapiens,Intermediate,80002,,9606.0,,N,,,1A9,BAO_0000219,F,,CHEMBL615194
,1,506.0,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,74,17099,,1,Homo sapiens,Intermediate,80002,,9606.0,,N,,,1A9,BAO_0000219,F,,CHEMBL615195
,1,506.0,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,75,17099,,1,Homo sapiens,Intermediate,80002,,9606.0,,N,,,1A9,BAO_0000219,F,,CHEMBL615196
,1,503.0,Inhibitory concentration against Jurkat cells,,76,17721,,1,Homo sapiens,Intermediate,81072,,9606.0,,N,,,Jurkat,BAO_0000219,F,,CHEMBL615197
,0,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,77,1229,,1,,Intermediate,22226,,,,U,,,,BAO_0000019,F,,CHEMBL615198
,9,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,78,11347,,1,Rattus norvegicus,Expert,100121,,10116.0,,D,,,,BAO_0000357,A,,CHEMBL615199
,8,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,79,17117,,1,,Expert,11231,,,,H,,,,BAO_0000357,B,,CHEMBL615200
,8,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,80,17117,,1,,Expert,11231,,,,H,,,,BAO_0000357,B,,CHEMBL615201
,8,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,81,17117,,1,,Expert,11231,,,,H,,,,BAO_0000357,B,,CHEMBL615202
,8,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,82,11375,Microsomes,1,Candida albicans,Autocuration,11231,,5476.0,,H,,,,BAO_0000251,B,,CHEMBL615203
,8,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,83,11375,Microsomes,1,Candida albicans,Autocuration,11231,,5476.0,,H,,,,BAO_0000251,B,,CHEMBL615204
,8,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,84,11375,Microsomes,1,Saccharomyces cerevisiae,Autocuration,11231,,4932.0,,H,,,,BAO_0000251,B,,CHEMBL615205
,8,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,85,11375,Microsomes,1,Saccharomyces cerevisiae,Autocuration,11231,,4932.0,,H,,,,BAO_0000251,B,,CHEMBL615206
,8,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,86,11375,Microsomes,1,Sus scrofa,Autocuration,12083,,9823.0,Liver,H,2107.0,,,BAO_0000251,B,,CHEMBL615207
,8,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,87,791,,1,Rattus norvegicus,Autocuration,11231,,10116.0,,H,,,,BAO_0000019,B,,CHEMBL827084
,8,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,88,791,,1,Rattus norvegicus,Autocuration,11231,,10116.0,,H,,,,BAO_0000019,B,,CHEMBL615208
,8,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,89,791,,1,Rattus norvegicus,Autocuration,11231,,10116.0,,H,,,,BAO_0000019,B,,CHEMBL615209
,9,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,90,11375,Microsomes,1,Rattus norvegicus,Autocuration,12083,,10116.0,Liver,D,2107.0,,,BAO_0000251,B,,CHEMBL615210
,9,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,91,11375,Microsomes,1,Rattus norvegicus,Autocuration,12083,,10116.0,Liver,D,2107.0,,,BAO_0000251,B,,CHEMBL615211
,9,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,92,153,Microsomes,1,Rattus norvegicus,Autocuration,12083,,10116.0,Liver,D,2107.0,,,BAO_0000251,B,,CHEMBL615212
,8,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,93,8269,,1,,Expert,11377,,,,H,,,,BAO_0000357,B,,CHEMBL615213
,8,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,94,8269,,1,,Expert,11377,,,,H,,,,BAO_0000357,B,,CHEMBL615273
,1,726.0,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,95,17653,,1,Homo sapiens,Expert,81020,,9606.0,,N,,,HepG2,BAO_0000219,F,,CHEMBL615274
,1,726.0,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,96,14277,,1,Homo sapiens,Intermediate,81020,,9606.0,,N,,,HepG2,BAO_0000219,F,,CHEMBL615275
,1,726.0,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,97,1717,,1,Homo sapiens,Intermediate,81020,,9606.0,,N,,,HepG2,BAO_0000219,F,,CHEMBL615276
,1,726.0,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,98,14091,,1,Homo sapiens,Intermediate,81020,,9606.0,,N,,,HepG2,BAO_0000219,F,,CHEMBL615277
,1,726.0,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,99,14091,,1,Homo sapiens,Intermediate,81020,,9606.0,,N,,,HepG2,BAO_0000219,F,,CHEMBL615326
,1,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,100,17653,,1,Hepatitis B virus,Expert,50606,,10407.0,,N,,,,BAO_0000218,F,,CHEMBL883130
,1,726.0,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,101,13105,,1,Homo sapiens,Intermediate,81020,,9606.0,,N,,,HepG2,BAO_0000219,F,,CHEMBL884519
,1,726.0,Concentration required to inhibit 50% of 2.2.15 cell line,,102,1717,,1,Homo sapiens,Intermediate,81020,,9606.0,,N,,,HepG2,BAO_0000219,F,,CHEMBL615327
,1,726.0,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,103,13105,,1,Homo sapiens,Intermediate,81020,,9606.0,,N,,,HepG2,BAO_0000219,A,,CHEMBL615328
,1,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,104,13600,,1,Homo sapiens,Intermediate,50587,,9606.0,,N,,,2.2.15,BAO_0000218,F,,CHEMBL615329
,1,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,105,13467,,1,Homo sapiens,Intermediate,50587,,9606.0,,N,,,2.2.15,BAO_0000218,F,,CHEMBL615330
,1,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,106,17477,,1,Hepatitis B virus,Expert,50606,,10407.0,,N,,,2.2.15,BAO_0000218,F,,CHEMBL615331
,1,,In vitro anti-HBV activity in 2.2.15 cells,,107,1593,,1,Homo sapiens,Intermediate,50587,,9606.0,,N,,,2.2.15,BAO_0000218,F,,CHEMBL615332
,1,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,108,1593,,1,Homo sapiens,Intermediate,50587,,9606.0,,N,,,2.2.15,BAO_0000218,F,,CHEMBL615333
,1,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,109,15089,,1,Homo sapiens,Intermediate,50587,,9606.0,,N,,,2.2.15,BAO_0000218,F,,CHEMBL615334
,1,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,110,15089,,1,Homo sapiens,Intermediate,50587,,9606.0,,N,,,2.2.15,BAO_0000218,F,,CHEMBL615335
,1,,Cytotoxicity in 2.2.15 cells,,111,1593,,1,Homo sapiens,Intermediate,50587,,9606.0,,N,,,2.2.15,BAO_0000218,F,,CHEMBL615336
,1,,Cytotoxicity in 2.2.15 cells; Not determined,,112,1593,,1,Homo sapiens,Intermediate,50587,,9606.0,,N,,,2.2.15,BAO_0000218,F,,CHEMBL615337
,1,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,113,13600,,1,Homo sapiens,Intermediate,50587,,9606.0,,N,,,2.2.15,BAO_0000218,F,,CHEMBL615338
,1,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,114,13467,,1,Homo sapiens,Intermediate,50587,,9606.0,,N,,,2.2.15,BAO_0000218,F,,CHEMBL615339
,1,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,115,13467,,1,Homo sapiens,Intermediate,50587,,9606.0,,N,,,2.2.15,BAO_0000218,F,,CHEMBL615340
,1,726.0,Antiviral activity against HBV was determined in 2.215 cell line,,116,14764,,1,Homo sapiens,Intermediate,81020,,9606.0,,N,,,HepG2,BAO_0000219,F,,CHEMBL615341
,0,,Inhibition of 20-HETE synthesis in human renal microsomes,,117,6531,Microsomes,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000251,B,,CHEMBL615342
,0,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,118,17322,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL615343
,1,388.0,Inhibitory concentration against 2008 (ovarian) cells,,119,17072,,1,Homo sapiens,Intermediate,80612,,9606.0,,N,,,2008,BAO_0000219,F,,CHEMBL615344
,1,388.0,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,120,16936,,1,Homo sapiens,Intermediate,80612,,9606.0,,N,,,2008,BAO_0000219,F,,CHEMBL615345
,1,388.0,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,121,16936,,1,Homo sapiens,Intermediate,80612,,9606.0,,N,,,2008,BAO_0000219,F,,CHEMBL615346
,1,388.0,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,122,17146,,1,Homo sapiens,Intermediate,80612,,9606.0,,N,,,2008,BAO_0000219,F,,CHEMBL615347
,1,388.0,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,123,17146,,1,Homo sapiens,Intermediate,80612,,9606.0,,N,,,2008,BAO_0000219,F,,CHEMBL615348
,1,561.0,In vitro inhibition of 2008/R ovarian cancer cell line,,124,10797,,1,Homo sapiens,Intermediate,80613,,9606.0,,N,,,2008/R,BAO_0000219,F,,CHEMBL827085
,1,561.0,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,125,10797,,1,Homo sapiens,Intermediate,80613,,9606.0,,N,,,2008/R,BAO_0000219,F,,CHEMBL615349
,1,389.0,In vitro inhibition of 2008/S ovarian cancer cell line,,126,10797,,1,Homo sapiens,Intermediate,80614,,9606.0,,N,,,2008/S,BAO_0000219,F,,CHEMBL615350
,1,389.0,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,127,10797,,1,Homo sapiens,Intermediate,80614,,9606.0,,N,,,2008/S,BAO_0000219,F,,CHEMBL615351
,2,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,128,4823,,1,Homo sapiens,Expert,100256,,9606.0,,S,,,,BAO_0000220,B,,CHEMBL615352
,2,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,129,12912,,1,Homo sapiens,Intermediate,100256,,9606.0,,S,,,,BAO_0000220,B,,CHEMBL615353
,2,,Inhibition of chymotrypsin-like activity of 20S proteasome,,130,2957,,1,,Expert,100256,,,,S,,,,BAO_0000220,B,,CHEMBL615354
,2,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,131,2957,,1,,Expert,100256,,,,S,,,,BAO_0000220,B,,CHEMBL615355
,2,,Inhibitory activity against 20S proteosome,,132,3260,,1,,Intermediate,100256,,,,S,,,,BAO_0000220,B,,CHEMBL615356
,0,,Compound was tested for inhibitory activity against tryptase,,133,3451,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000019,B,,CHEMBL615357
,1,726.0,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,134,13885,,1,Homo sapiens,Intermediate,81020,,9606.0,,N,,,HepG2,BAO_0000219,F,,CHEMBL615358
,1,726.0,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,135,13885,,1,Homo sapiens,Intermediate,81020,,9606.0,,N,,,HepG2,BAO_0000219,F,,CHEMBL827086
,0,,Compound was tested for the inhibition of Alpha-glucosidase,,136,3676,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL615359
,8,,Inhibitory concentration against human neutrophil elastase (HNE),,137,6043,,1,,Autocuration,235,,,,H,,,,BAO_0000357,B,,CHEMBL615360
,0,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,138,11140,,1,Rattus norvegicus,Autocuration,22226,,10116.0,Heart,U,948.0,,,BAO_0000218,F,,CHEMBL615361
,8,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,139,10543,,1,,Autocuration,19640,,,,H,,,,BAO_0000019,F,,CHEMBL615362
,8,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,140,10543,,1,,Expert,19640,,,,H,,,,BAO_0000019,F,,CHEMBL615363
,8,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,141,10543,,1,,Autocuration,19640,,,,H,,,,BAO_0000357,B,,CHEMBL615364
,8,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,142,10543,,1,,Expert,19640,,,,H,,,,BAO_0000019,F,,CHEMBL615365
,1,524.0,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,143,11365,,1,Mus musculus,Intermediate,80360,,10090.0,,N,,,P338,BAO_0000219,F,,CHEMBL615366
,1,524.0,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,144,11365,,1,Mus musculus,Intermediate,80360,,10090.0,,N,,,P338,BAO_0000219,F,,CHEMBL615367
,1,554.0,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,145,11803,,1,Homo sapiens,Intermediate,80384,,9606.0,,N,,,PBL,BAO_0000219,F,,CHEMBL615368
,0,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,146,11803,,1,Ovis aries,Autocuration,22226,,9940.0,,U,,,,BAO_0000019,F,,CHEMBL615369
,0,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,147,11803,,1,Ovis aries,Autocuration,22226,,9940.0,,U,,,,BAO_0000019,F,,CHEMBL615370
,8,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,148,12278,,1,,Autocuration,191,,,,H,,,,BAO_0000357,B,,CHEMBL615673
,0,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,149,8249,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000019,F,,CHEMBL615674
,0,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,150,8249,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000019,F,,CHEMBL615675
,0,635.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,151,8249,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,CCRF-CEM,BAO_0000219,F,,CHEMBL615676
,0,635.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,152,8249,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,CCRF-CEM,BAO_0000219,F,,CHEMBL615677
,0,635.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,153,8249,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,CCRF-CEM,BAO_0000219,F,,CHEMBL615678
,0,635.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,154,8249,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,CCRF-CEM,BAO_0000219,F,,CHEMBL615679
,0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,155,8249,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000019,F,,CHEMBL615680
,0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,156,8249,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000019,F,,CHEMBL615681
,6,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,157,16992,,1,,Autocuration,104290,,,,H,,,,BAO_0000249,B,,CHEMBL857972
,1,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,158,10543,,1,Streptococcus pyogenes,Intermediate,50264,,1314.0,,N,,,,BAO_0000218,F,,CHEMBL857899
,1,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,159,17833,,1,Human herpesvirus 3,Intermediate,50527,,10335.0,,N,,,,BAO_0000218,F,,CHEMBL615371
,1,468.0,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,160,17290,,1,vericilla zoster virus,Expert,50527,,10335.0,,N,,,HEL,BAO_0000218,F,,CHEMBL615372
,1,,Antiviral activity against 07/1 strain of VZV; ND: No data,,161,17290,,1,vericilla zoster virus,Intermediate,50527,,10335.0,,N,,,,BAO_0000218,F,,CHEMBL615373
,1,,Antiviral activity against 07/1 strain of VZV; ND=No data,,162,17290,,1,vericilla zoster virus,Intermediate,50527,,10335.0,,N,,,,BAO_0000218,F,,CHEMBL615374
,1,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,163,10932,,1,escherichia cloac,Intermediate,50145,,561.0,,N,,,,BAO_0000218,F,,CHEMBL615375
,0,,Ratio of Ki at A2 to Ki at A1 receptors,,164,9707,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL615376
,8,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,165,2346,,1,Candida albicans,Expert,11143,,5476.0,,H,,,,BAO_0000249,B,,CHEMBL615377
,8,,"Inhibition of 1,3-beta-glucan synthase",,166,2205,,1,Candida glabrata CBS 138,Expert,18077,,284593.0,,H,,,,BAO_0000357,B,,CHEMBL615378
,1,832.0,Inhibition of growth of 1-87 human tumor cell line,,167,11900,,1,Homo sapiens,Intermediate,80609,,9606.0,,N,,,1-87 tumor cell line,BAO_0000219,F,,CHEMBL615379
,9,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,168,14864,,1,Rattus norvegicus,Expert,12166,,10116.0,,D,,,,BAO_0000219,B,,CHEMBL615380
,9,,Inhibitory activity against soybean 1-lipoxygenase (SLO),,169,16474,,1,Glycine max,Autocuration,100171,,3847.0,,D,,,,BAO_0000357,B,,CHEMBL615381
,9,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,170,16474,,1,Glycine max,Autocuration,100171,,3847.0,,D,,,,BAO_0000357,B,,CHEMBL615382
,9,,% inhibition against soybean 1-lipoxygenase (SLO),,171,16474,,1,Glycine max,Autocuration,100171,,3847.0,,D,,,,BAO_0000357,B,,CHEMBL615383
,9,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,172,16474,,1,Glycine max,Autocuration,100171,,3847.0,,D,,,,BAO_0000357,B,,CHEMBL615384
,9,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,173,3094,,1,Glycine max,Autocuration,100171,,3847.0,,D,,,,BAO_0000357,B,,CHEMBL615385
,9,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,174,3094,,1,Glycine max,Autocuration,100171,,3847.0,,D,,,,BAO_0000357,B,,CHEMBL615386
,9,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,175,3094,,1,Glycine max,Autocuration,100171,,3847.0,,D,,,,BAO_0000357,B,,CHEMBL615387
,9,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,176,3094,,1,Glycine max,Autocuration,100171,,3847.0,,D,,,,BAO_0000357,B,,CHEMBL615388
,9,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,177,3094,,1,Glycine max,Autocuration,100171,,3847.0,,D,,,,BAO_0000357,B,,CHEMBL615214
,9,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,178,3094,,1,Glycine max,Autocuration,100171,,3847.0,,D,,,,BAO_0000357,B,,CHEMBL827087
,9,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,179,3094,,1,Glycine max,Autocuration,100171,,3847.0,,D,,,,BAO_0000357,B,,CHEMBL615215
,9,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,180,3094,,1,Glycine max,Autocuration,100171,,3847.0,,D,,,,BAO_0000357,B,,CHEMBL615216
,9,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,181,3094,,1,Glycine max,Autocuration,100171,,3847.0,,D,,,,BAO_0000357,B,,CHEMBL615217
,9,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,182,3094,,1,Glycine max,Autocuration,100171,,3847.0,,D,,,,BAO_0000357,B,,CHEMBL615218
,9,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,183,3094,,1,Glycine max,Autocuration,100171,,3847.0,,D,,,,BAO_0000357,B,,CHEMBL615219
,0,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,184,10413,,1,Mus musculus,Autocuration,22226,,10090.0,,U,,,,BAO_0000019,B,,CHEMBL615220
,1,294.0,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,185,16929,,1,Mus musculus,Intermediate,80049,,10090.0,,N,,,C3H 10T1/2,BAO_0000219,F,,CHEMBL615221
,0,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,186,1229,,1,,Intermediate,22226,,,,U,,,,BAO_0000019,F,,CHEMBL615222
,8,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,187,16587,,1,,Autocuration,11489,,,,H,,,,BAO_0000357,B,,CHEMBL615223
,8,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,188,16587,,1,,Autocuration,11862,,,,H,,,,BAO_0000357,B,,CHEMBL615224
,8,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,189,16587,,1,,Autocuration,11862,,,,H,,,,BAO_0000357,B,,CHEMBL615225
,8,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,190,16587,,1,,Autocuration,11489,,,,H,,,,BAO_0000357,B,,CHEMBL615226
,8,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,191,16587,,1,,Autocuration,11862,,,,H,,,,BAO_0000357,B,,CHEMBL615227
,9,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,192,8058,,1,Bos taurus,Expert,12347,,9913.0,,D,,,,BAO_0000019,F,,CHEMBL615228
,9,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,193,9065,,1,Rattus norvegicus,Expert,100120,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL615229
,9,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,194,8865,,1,Rattus norvegicus,Expert,100120,,10116.0,Adrenal gland,D,2369.0,,,BAO_0000357,B,,CHEMBL615230
,9,,Inhibition of rat adrenal 11-beta-hydroxylase,,195,9066,,1,Rattus norvegicus,Expert,100120,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL615231
,9,,Inhibition of rat adrenal 11-beta-hydroxylase,,196,8394,,1,Rattus norvegicus,Expert,100120,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL884520
,9,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,197,8394,,1,Rattus norvegicus,Expert,100120,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL615232
,8,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,198,6431,,1,,Autocuration,10328,,,,H,,,,BAO_0000019,B,,CHEMBL615233
,8,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,199,6431,,1,,Autocuration,11490,,,,H,,,,BAO_0000357,B,,CHEMBL827088
,8,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,200,6431,,1,,Autocuration,11490,,,,H,,,,BAO_0000357,B,,CHEMBL615234
,8,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,201,9295,,1,,Autocuration,11134,,,,H,,,,BAO_0000019,F,,CHEMBL615235
,8,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,202,10193,,1,,Autocuration,12052,,,,H,,,,BAO_0000019,B,,CHEMBL615236
,8,,Compound was tested in vitro for inhibition of 12-LO human platelet,,203,13622,,1,,Autocuration,11134,,,,H,,,,BAO_0000019,B,,CHEMBL615237
,8,,Inhibitory concentration against human platelet 12-lipoxygenase,,204,12079,,1,,Autocuration,11134,,,,H,,,,BAO_0000019,F,,CHEMBL615238
,8,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,205,13622,,1,,Autocuration,11134,,,,H,,,,BAO_0000019,B,,CHEMBL615239
,9,,Inhibitory concentration against human platelet 12-lipoxygenase,,206,12079,,1,Homo sapiens,Autocuration,11134,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL615240
,8,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,207,13500,,1,,Expert,11835,,,,H,,,,BAO_0000019,B,,CHEMBL615241
,8,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,208,13723,,1,,Expert,11601,,,,H,,,,BAO_0000357,B,,CHEMBL615242
,8,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,209,16474,,1,,Autocuration,11134,,,,H,,,,BAO_0000019,B,,CHEMBL615243
,8,,Inhibitory activity against human platelet 12-lipoxygenase,,210,1630,,1,,Autocuration,11134,,,,H,,,,BAO_0000019,B,,CHEMBL615244
,8,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,211,167,,1,,Autocuration,11134,,,,H,,,,BAO_0000019,B,,CHEMBL615245
,8,,% inhibition against human platelet 12-lipoxygenase (12-HLO),,212,16474,,1,,Autocuration,11134,,,,H,,,,BAO_0000019,B,,CHEMBL615246
,8,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,213,167,,1,,Autocuration,11134,,,,H,,,,BAO_0000019,B,,CHEMBL615247
,8,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,214,16474,,1,,Autocuration,11134,,,,H,,,,BAO_0000019,B,,CHEMBL615248
,8,,Inhibitory activity towards porcine 12-lipoxygenase,,215,10091,,1,,Autocuration,11601,,,,H,,,,BAO_0000357,B,,CHEMBL615249
,8,,Tested for inhibition against porcine 12-LO,,216,11966,,1,,Autocuration,11601,,,,H,,,,BAO_0000357,B,,CHEMBL615250
,8,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,217,951,,1,,Autocuration,12052,,,,H,,,,BAO_0000019,B,,CHEMBL615251
,8,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,218,10997,,1,,Autocuration,12052,,,,H,,,,BAO_0000019,B,,CHEMBL615252
,8,,In vitro inhibition of rat platelet 12-lipoxygenase,,219,10193,,1,,Expert,12052,,,,H,,,,BAO_0000019,B,,CHEMBL828340
,8,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,220,10193,,1,,Autocuration,12052,,,,H,,,,BAO_0000019,B,,CHEMBL615253
,8,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,221,10193,,1,,Autocuration,12052,,,,H,,,,BAO_0000019,B,,CHEMBL615254
,8,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,222,10193,,1,,Autocuration,12052,,,,H,,,,BAO_0000019,B,,CHEMBL615255
,8,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,223,10193,,1,,Autocuration,12052,,,,H,,,,BAO_0000019,B,,CHEMBL615256
,8,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,224,10193,,1,,Autocuration,12052,,,,H,,,,BAO_0000019,B,,CHEMBL615257
,8,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,225,11087,,1,,Autocuration,12052,,,,H,,,,BAO_0000019,B,,CHEMBL615258
,1,621.0,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,226,15569,,1,Homo sapiens,Intermediate,80007,,9606.0,,N,,,41M,BAO_0000219,F,,CHEMBL615259
,1,621.0,In vitro antitumor activity against 41M cell line.,,227,12989,,1,Homo sapiens,Expert,80007,,9606.0,,N,,,41M,BAO_0000219,F,,CHEMBL615260
,1,621.0,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,228,16745,,1,Homo sapiens,Intermediate,80007,,9606.0,,N,,,41M,BAO_0000219,F,,CHEMBL615261
,1,621.0,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,229,15569,,1,Homo sapiens,Intermediate,80007,,9606.0,,N,,,41M,BAO_0000219,F,,CHEMBL615262
,1,621.0,In vitro antitumor activity against 41McisR cell line.,,230,12989,,1,Homo sapiens,Expert,80007,,9606.0,,N,,,41M,BAO_0000219,F,,CHEMBL615263
,1,621.0,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,231,12989,,1,Homo sapiens,Expert,80007,,9606.0,,N,,,41M,BAO_0000219,F,,CHEMBL838393
,1,621.0,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,232,16745,,1,Homo sapiens,Intermediate,80007,,9606.0,,N,,,41M,BAO_0000219,F,,CHEMBL615264
,9,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,233,6210,,1,Homo sapiens,Expert,84,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL615265
,9,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,234,6210,,1,Homo sapiens,Expert,68,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL615266
,8,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,235,6226,,1,,Expert,68,,,,H,,,,BAO_0000357,B,,CHEMBL615267
,8,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,236,17855,,1,,Expert,10201,,,,H,,,,BAO_0000357,B,,CHEMBL615268
,8,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,237,17855,,1,,Expert,10201,,,,H,,,,BAO_0000357,B,,CHEMBL615269
,8,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,238,17855,,1,,Expert,10201,,,,H,,,,BAO_0000357,B,,CHEMBL615270
,8,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,239,10413,,1,,Autocuration,12220,,,,H,,,,BAO_0000357,B,,CHEMBL615271
,8,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,240,10413,,1,Escherichia coli,Autocuration,11303,,562.0,,H,,,,BAO_0000357,B,,CHEMBL615272
,8,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,241,10413,,1,Escherichia coli,Autocuration,11303,,562.0,,H,,,,BAO_0000357,B,,CHEMBL615103
,8,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,242,10413,,1,Escherichia coli,Autocuration,11303,,562.0,,H,,,,BAO_0000357,B,,CHEMBL615104
,8,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,243,10413,,1,,Autocuration,12220,,,,H,,,,BAO_0000357,B,,CHEMBL615105
,8,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,244,10413,,1,,Autocuration,12220,,,,H,,,,BAO_0000357,B,,CHEMBL872866
,8,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,245,7587,,1,Sus scrofa,Autocuration,11303,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL615106
,8,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,246,7587,,1,Sus scrofa,Autocuration,11303,,9823.0,,H,,,,BAO_0000019,B,,CHEMBL615107
,8,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,247,7587,,1,Sus scrofa,Autocuration,11303,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL615108
,8,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,248,7587,,1,Sus scrofa,Autocuration,11303,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL615109
,8,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,249,7587,,1,Sus scrofa,Autocuration,11303,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL615110
,8,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,250,7587,,1,Sus scrofa,Autocuration,11303,,9823.0,,H,,,,BAO_0000019,B,,CHEMBL840105
,8,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,251,7587,,1,Sus scrofa,Autocuration,11303,,9823.0,,H,,,,BAO_0000019,B,,CHEMBL615111
,8,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,252,7587,,1,Sus scrofa,Autocuration,11303,,9823.0,,H,,,,BAO_0000019,B,,CHEMBL615112
,8,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,253,7587,,1,Sus scrofa,Autocuration,11303,,9823.0,,H,,,,BAO_0000019,B,,CHEMBL615113
,8,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,254,7587,,1,Sus scrofa,Autocuration,11303,,9823.0,,H,,,,BAO_0000019,B,,CHEMBL615114
,8,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,255,7587,,1,Sus scrofa,Autocuration,11303,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL615115
,8,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,256,7587,,1,Sus scrofa,Autocuration,11303,,9823.0,,H,,,,BAO_0000019,B,,CHEMBL615116
,8,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,257,7323,,1,,Autocuration,11303,,,,H,,,,BAO_0000357,B,,CHEMBL615698
,0,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,258,7587,,1,Sus scrofa,Autocuration,22226,,9823.0,,U,,,,BAO_0000019,B,,CHEMBL615699
,0,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,259,7587,,1,Sus scrofa,Autocuration,22226,,9823.0,,U,,,,BAO_0000019,B,,CHEMBL615700
,8,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,260,13750,,1,Saccharomyces cerevisiae,Expert,100249,,4932.0,,H,,,,BAO_0000357,B,,CHEMBL615701
,0,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,261,7662,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000019,B,,CHEMBL615702
,0,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,262,7662,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000019,B,,CHEMBL615703
,0,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,263,7662,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000019,B,,CHEMBL615704
,6,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,264,12211,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,F,,CHEMBL615705
,6,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,265,12211,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,F,,CHEMBL615706
,9,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,266,12211,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL615707
,8,,Stimulatory activity of intragastric pressure was tested in the rat,,267,12211,,1,,Expert,10623,,,,H,,,,BAO_0000019,F,,CHEMBL615708
,8,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,268,15453,,1,,Autocuration,121,,,,H,,,,BAO_0000357,B,,CHEMBL615709
,0,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,269,11884,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000218,F,,CHEMBL615710
,8,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,270,7185,,1,,Autocuration,12688,,,,H,,,,BAO_0000019,F,,CHEMBL615711
,9,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,271,6876,,1,Homo sapiens,Expert,121,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL615712
,9,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,272,6876,,1,Homo sapiens,Expert,121,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL836325
,8,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,273,11863,,1,,Autocuration,12198,,,,H,,,,BAO_0000019,F,,CHEMBL615713
,8,,Inhibition constant of high-affinity 5-HT uptake,,274,11863,,1,,Autocuration,12198,,,,H,,,,BAO_0000357,B,,CHEMBL615714
,8,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,275,11863,,1,,Autocuration,12198,,,,H,,,,BAO_0000019,F,,CHEMBL615715
,8,,Maximum rate was determined for high affinity transport of 5-HT,,276,11863,,1,,Autocuration,12198,,,,H,,,,BAO_0000019,F,,CHEMBL615716
,4,,Compound was tested for agonistic activity against 5-HT uptake,,277,4639,,1,,Autocuration,104714,,,,H,,,,BAO_0000019,F,,CHEMBL615717
,8,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,278,15796,,1,,Expert,10577,,,,H,,,,BAO_0000019,B,,CHEMBL881818
,8,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,279,15796,,1,Bos taurus,Expert,105,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL884540
,5,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,280,12801,,1,Rattus norvegicus,Autocuration,104744,,10116.0,,D,,,,BAO_0000224,B,,CHEMBL615718
,4,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,281,12801,,1,,Autocuration,104744,,,,H,,,,BAO_0000224,B,,CHEMBL615719
,4,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,282,12120,Membranes,1,,Autocuration,104744,,,,H,,,,BAO_0000249,B,,CHEMBL615720
,4,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,283,12120,Membranes,1,,Autocuration,104744,,,,H,,,,BAO_0000249,B,,CHEMBL615721
,4,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,284,11963,,1,,Autocuration,104744,,,,H,,,,BAO_0000019,B,,CHEMBL615722
,8,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,285,11701,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL615723
,8,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,286,9995,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615724
,8,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,287,9995,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615725
,8,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,288,9995,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615726
,8,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,289,16394,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615727
,9,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,290,11574,,1,Cavia porcellus,Intermediate,105570,,10141.0,,D,,,,BAO_0000019,F,,CHEMBL615728
,8,449.0,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,291,15779,,1,,Autocuration,279,,,,H,,,CHO,BAO_0000219,B,,CHEMBL857971
,8,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,292,15363,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL615729
,9,,Efficacy against 5-hydroxytryptamine 2A receptor,,293,15363,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL615730
,8,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,294,15329,,1,,Expert,12687,,,,H,,,,BAO_0000019,F,,CHEMBL615731
,8,,Relative potency towards 5-HT2A receptor of rat tail artery,,295,15329,,1,,Expert,12687,,,,H,,,,BAO_0000019,F,,CHEMBL615732
,8,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,296,15329,,1,,Expert,12687,,,,H,,,,BAO_0000019,F,,CHEMBL615733
,8,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,297,15329,,1,,Expert,12687,,,,H,,,,BAO_0000019,F,,CHEMBL615734
,8,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,298,15329,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,F,,CHEMBL615735
,8,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,299,15329,,1,,Expert,12687,,,,H,,,,BAO_0000019,F,,CHEMBL615736
,9,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,300,273,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL615737
,9,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,301,273,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL615738
,9,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,302,273,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL615739
,8,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,303,12092,,1,,Autocuration,10623,,,,H,,,,BAO_0000357,B,,CHEMBL615278
,9,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,304,1317,,1,Rattus norvegicus,Expert,10623,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL615279
,8,,Binding affinity against 5-hydroxytryptamine 4 receptor,,305,12409,,1,,Expert,168,,,,H,,,,BAO_0000357,B,,CHEMBL615280
,0,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,306,11126,,1,Gallus gallus,Autocuration,22226,,9031.0,,U,,,,BAO_0000019,B,,CHEMBL615281
,0,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,307,11126,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000019,F,,CHEMBL615282
,0,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,308,11126,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000019,F,,CHEMBL615283
,1,649.0,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,309,11126,,1,Homo sapiens,Autocuration,80156,,9606.0,,N,,,HL-60,BAO_0000219,B,,CHEMBL615284
,0,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,310,11126,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000019,B,,CHEMBL615285
,0,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,311,11126,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000019,B,,CHEMBL615286
,7,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,312,17807,,1,Homo sapiens,Autocuration,104703,,9606.0,,D,,,Oocytes,BAO_0000219,B,,CHEMBL615287
,2,,Chymotryptic inhibitory activity against 26S proteasome,,313,16575,,1,,Intermediate,100256,,,,S,,,,BAO_0000220,F,,CHEMBL615288
,2,,Inhibitory activity against 26S proteasome degradation of IkB,,314,15407,,1,,Intermediate,100256,,,,S,,,,BAO_0000220,B,,CHEMBL615289
,1,478.0,In vitro inhibition of 2780/DOX ovarian cancer cell line,,315,10797,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL615290
,1,478.0,In vitro inhibition of 2780/S ovarian cancer cell line,,316,10797,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL884522
,0,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,317,3469,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000019,F,,CHEMBL615291
,3,,Association constant for binding to AATT 28-mer AATT hairpin,,318,16037,,1,,Intermediate,22222,,,,M,,,,BAO_0000225,B,,CHEMBL615292
,3,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,319,16037,,1,,Intermediate,22222,,,,M,,,,BAO_0000225,B,,CHEMBL615293
,3,,Reaction Rate Parameter for 28-mer AATT hairpin,,320,16037,,1,,Intermediate,22222,,,,M,,,,BAO_0000225,B,,CHEMBL615294
,3,,Reaction Rate Parameter for 28-mer AATT hairpin,,321,16037,,1,,Intermediate,22222,,,,M,,,,BAO_0000225,B,,CHEMBL615295
,0,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,322,16524,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000019,F,,CHEMBL825021
,0,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,323,16524,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000019,F,,CHEMBL615296
,0,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,324,16524,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000019,F,,CHEMBL615297
,0,,Cytotoxicity against cell line 2SC/20 determined by MTT test,,325,16758,,1,Cricetulus griseus,Autocuration,22226,,10029.0,,U,,,,BAO_0000019,F,,CHEMBL615298
,0,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,326,16758,,1,Cricetulus griseus,Autocuration,22226,,10029.0,,U,,,,BAO_0000019,F,,CHEMBL615299
,0,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,327,16758,,1,Cricetulus griseus,Autocuration,22226,,10029.0,,U,,,,BAO_0000019,F,,CHEMBL615300
,8,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,328,14360,,1,,Autocuration,241,,,,H,,,,BAO_0000357,B,,CHEMBL615301
,9,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,329,14360,,1,Homo sapiens,Expert,241,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL615302
,0,,Selectivity ratio of ID50 in liver and heart,,330,9964,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000019,B,,CHEMBL615303
,8,,"Selectivity, ratio of relative ID50 in liver and heart",,331,9964,,1,,Autocuration,12132,,,,H,,,,BAO_0000019,B,,CHEMBL615304
,8,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,332,9964,,1,,Autocuration,12132,,,,H,,,,BAO_0000019,B,,CHEMBL615305
,8,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,333,9964,,1,,Autocuration,12132,,,,H,,,,BAO_0000218,B,,CHEMBL615306
,8,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,334,9964,,1,,Autocuration,12132,,,,H,,,,BAO_0000218,B,,CHEMBL615307
,8,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,335,9964,,1,,Autocuration,12132,,,,H,,In vivo,,BAO_0000218,B,,CHEMBL615308
,8,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,336,9964,,1,,Autocuration,12132,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615309
,0,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,337,9964,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL615310
,8,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,338,9964,,1,,Autocuration,12132,,,,H,,,,BAO_0000019,B,,CHEMBL615311
,0,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,339,9964,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000019,B,,CHEMBL615312
,8,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,340,9964,,1,,Autocuration,12132,,,,H,,,,BAO_0000019,B,,CHEMBL615313
,8,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,341,9964,,1,,Autocuration,12132,,,,H,,,,BAO_0000019,F,,CHEMBL615314
,8,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,342,9964,,1,,Autocuration,12132,,,,H,,,,BAO_0000019,B,,CHEMBL615315
,0,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,343,9964,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000218,B,,CHEMBL615316
,8,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,344,9964,,1,,Autocuration,12132,,,,H,,In vivo,,BAO_0000218,B,,CHEMBL615317
,8,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,345,9964,,1,,Autocuration,12132,,,,H,,,,BAO_0000218,B,,CHEMBL615318
,0,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,346,9964,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000218,B,,CHEMBL615319
,8,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,347,9964,,1,,Autocuration,12132,,,,H,,,,BAO_0000019,B,,CHEMBL615320
,8,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,348,9964,,1,,Autocuration,12132,,,,H,,,,BAO_0000019,F,,CHEMBL615321
,0,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,349,3796,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000019,B,,CHEMBL615322
,8,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,350,4251,,1,Escherichia coli,Autocuration,19690,,562.0,,H,,,,BAO_0000357,B,,CHEMBL615323
,8,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,351,4251,,1,Escherichia coli,Autocuration,19690,,562.0,,H,,,,BAO_0000357,B,,CHEMBL615407
,8,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,352,4251,,1,Escherichia coli,Autocuration,19690,,562.0,,H,,,,BAO_0000357,B,,CHEMBL857267
,8,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,353,4251,,1,Escherichia coli,Autocuration,19690,,562.0,,H,,,,BAO_0000357,B,,CHEMBL615408
,8,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,354,166,,1,,Autocuration,19690,,,,H,,,,BAO_0000357,B,,CHEMBL615409
,8,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,355,17861,,1,,Autocuration,19690,,,,H,,,,BAO_0000357,B,,CHEMBL615410
,8,,Inhibition constant against 3-dehydroquinate synthase,,356,166,,1,,Autocuration,19690,,,,H,,,,BAO_0000357,B,,CHEMBL615411
,8,,Association rate constant against 3-dehydroquinate synthase,,357,166,,1,,Autocuration,19690,,,,H,,,,BAO_0000357,B,,CHEMBL615412
,8,,Rate constant against 3-dehydroquinate synthase,,358,166,,1,,Autocuration,19690,,,,H,,,,BAO_0000357,B,,CHEMBL615413
,0,,Inhibitory activity against fuc-TVII,,359,3548,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL615414
,9,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,360,9877,Microsomes,1,Rattus norvegicus,Autocuration,12236,,10116.0,Liver,D,2107.0,,,BAO_0000251,B,,CHEMBL615415
,9,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,361,9877,Microsomes,1,Rattus norvegicus,Autocuration,12236,,10116.0,Liver,D,2107.0,,,BAO_0000251,B,,CHEMBL615416
,9,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,362,9877,Microsomes,1,Rattus norvegicus,Autocuration,12236,,10116.0,Liver,D,2107.0,,,BAO_0000251,B,,CHEMBL615417
,9,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,363,9877,Microsomes,1,Rattus norvegicus,Autocuration,12236,,10116.0,Liver,D,2107.0,,,BAO_0000251,B,,CHEMBL615418
,9,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,364,9877,Microsomes,1,Rattus norvegicus,Autocuration,12236,,10116.0,Liver,D,2107.0,,,BAO_0000251,B,,CHEMBL615419
,9,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,365,9877,Microsomes,1,Rattus norvegicus,Autocuration,12236,,10116.0,Liver,D,2107.0,,,BAO_0000251,B,,CHEMBL615420
,9,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,366,9877,Microsomes,1,Rattus norvegicus,Autocuration,12236,,10116.0,Liver,D,2107.0,,,BAO_0000251,B,,CHEMBL615421
,9,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,367,9877,Microsomes,1,Rattus norvegicus,Autocuration,12236,,10116.0,Liver,D,2107.0,,,BAO_0000251,B,,CHEMBL615422
,9,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,368,9877,Microsomes,1,Rattus norvegicus,Autocuration,12236,,10116.0,Liver,D,2107.0,,,BAO_0000251,B,,CHEMBL615423
,9,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,369,9877,Microsomes,1,Rattus norvegicus,Autocuration,12236,,10116.0,Liver,D,2107.0,,,BAO_0000251,B,,CHEMBL872868
,9,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,370,9877,Microsomes,1,Rattus norvegicus,Autocuration,12236,,10116.0,Liver,D,2107.0,,,BAO_0000251,B,,CHEMBL615424
,4,,Inhibitory activity against 3-phosphoglycerate kinase.,,371,3003,,1,,Autocuration,104832,,,,H,,,,BAO_0000224,B,,CHEMBL825022
,4,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,372,3003,,1,,Autocuration,104832,,,,H,,,,BAO_0000224,B,,CHEMBL615425
,4,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,373,3003,,1,,Autocuration,104832,,,,H,,,,BAO_0000224,B,,CHEMBL615426
,9,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,374,17185,,1,Homo sapiens,Expert,10612,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL615427
,1,844.0,Cytotoxicity on 3677 melanoma cells,,375,6072,,1,Homo sapiens,Intermediate,80616,,9606.0,,N,,,3677 melanoma cell line,BAO_0000219,F,,CHEMBL615428
,1,844.0,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,376,6072,,1,Homo sapiens,Intermediate,80616,,9606.0,,N,,,3677 melanoma cell line,BAO_0000219,F,,CHEMBL615429
,1,700.0,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,377,5018,,1,Mus musculus,Intermediate,80617,,10090.0,,N,,,MC-38,BAO_0000219,F,,CHEMBL615430
,0,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,378,2852,,1,Homo sapiens,Intermediate,22226,,9606.0,,U,,,,BAO_0000019,F,,CHEMBL615431
,0,798.0,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,379,8663,,1,,Autocuration,22226,,,,U,,,B16,BAO_0000218,F,,CHEMBL615432
,0,798.0,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,380,8663,,1,,Autocuration,22226,,,,U,,,B16,BAO_0000218,F,,CHEMBL615433
,9,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,381,3245,,1,Human rhinovirus 14,Expert,12464,,12131.0,,D,,,,BAO_0000019,F,,CHEMBL615434
,1,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,382,3245,,1,Human rhinovirus sp.,Intermediate,50085,,169066.0,,N,,,,BAO_0000218,F,,CHEMBL615435
,1,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,383,3877,,1,human rhinovirus type 14,Intermediate,50679,,169066.0,,N,,,,BAO_0000218,F,,CHEMBL615436
,1,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,384,3877,,1,human rhinovirus type 14,Intermediate,50679,,169066.0,,N,,,,BAO_0000218,F,,CHEMBL615437
,9,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,385,5861,,1,Human rhinovirus 14,Expert,12464,,12131.0,,D,,,,BAO_0000019,F,,CHEMBL615438
,9,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,386,5861,,1,Human rhinovirus 14,Expert,12464,,12131.0,,D,,,,BAO_0000019,F,,CHEMBL615439
,9,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,387,5861,,1,Human rhinovirus 14,Expert,12464,,12131.0,,D,,,,BAO_0000019,F,,CHEMBL615440
,9,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,388,5861,,1,Human rhinovirus 14,Expert,12464,,12131.0,,D,,,,BAO_0000019,F,,CHEMBL615441
,1,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,389,13748,,1,Enterovirus,Intermediate,50665,,12059.0,,N,,,,BAO_0000218,F,,CHEMBL615641
,1,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,390,13748,,1,Enterovirus,Intermediate,50665,,12059.0,,N,,,,BAO_0000218,F,,CHEMBL872065
,1,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,391,13748,,1,Enterovirus,Intermediate,50665,,12059.0,,N,,,,BAO_0000218,F,,CHEMBL825023
,1,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,392,13748,,1,Enterovirus,Intermediate,50665,,12059.0,,N,,,,BAO_0000218,F,,CHEMBL615642
,8,,Inhibition of human rhinovirus 3C protease,,393,13748,,1,Human rhinovirus B,Expert,12464,,147712.0,,H,,,,BAO_0000357,B,,CHEMBL615643
,0,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,394,17699,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000019,B,,CHEMBL615644
,1,833.0,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,395,7145,,1,Mus musculus,Intermediate,80619,,10090.0,,N,,,3EM 37,BAO_0000218,F,,CHEMBL615645
,1,833.0,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,396,7145,,1,Mus musculus,Intermediate,80619,,10090.0,,N,,,3EM 37,BAO_0000218,F,,CHEMBL615646
,1,833.0,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,397,7145,,1,Mus musculus,Intermediate,80619,,10090.0,,N,,,3EM 37,BAO_0000218,F,,CHEMBL615647
,1,833.0,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,398,7145,,1,Mus musculus,Intermediate,80619,,10090.0,,N,,,3EM 37,BAO_0000218,F,,CHEMBL615648
,1,833.0,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,399,7145,,1,Mus musculus,Intermediate,80619,,10090.0,,N,,,3EM 37,BAO_0000218,F,,CHEMBL615649
,1,833.0,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,400,7145,,1,Mus musculus,Intermediate,80619,,10090.0,,N,,,3EM 37,BAO_0000218,F,,CHEMBL615650
,1,847.0,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,401,5325,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000218,F,,CHEMBL615651
,1,847.0,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,402,5325,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000218,F,,CHEMBL615652
,1,847.0,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,403,5325,,1,Mus musculus,Expert,80620,,10090.0,,N,,,3LL cell line,BAO_0000218,F,,CHEMBL615653
,1,847.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,404,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615654
,1,847.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,405,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615655
,1,847.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,406,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL825024
,1,847.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,407,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615656
,1,847.0,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,408,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615657
,1,847.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,409,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615658
,1,847.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,410,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615659
,1,847.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,411,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615660
,1,847.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,412,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615661
,1,847.0,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,413,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615662
,1,847.0,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,414,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615663
,1,847.0,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,415,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615664
,1,847.0,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,416,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615665
,1,847.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,417,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615666
,1,847.0,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,418,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615667
,1,847.0,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,419,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615668
,1,847.0,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,420,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615669
,1,847.0,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,421,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615670
,1,847.0,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,422,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL836739
,1,847.0,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,423,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615671
,1,847.0,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,424,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615672
,1,847.0,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,425,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615791
,1,847.0,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,426,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615792
,1,847.0,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,427,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615793
,1,847.0,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,428,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615794
,1,847.0,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,429,16169,,1,Mus musculus,Intermediate,80620,,10090.0,,N,,,3LL cell line,BAO_0000219,F,,CHEMBL615795
,1,971.0,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,430,15547,,1,Homo sapiens,Intermediate,80621,,9606.0,,N,,,3LLD122,BAO_0000219,F,,CHEMBL615590
,0,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,431,8663,,1,,Autocuration,22226,,,,U,,,,BAO_0000218,F,,CHEMBL615591
,0,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,432,8663,,1,,Autocuration,22226,,,,U,,,,BAO_0000218,F,,CHEMBL615592
,0,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,433,8663,,1,,Autocuration,22226,,,,U,,,,BAO_0000218,F,,CHEMBL615593
,0,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,434,8663,,1,,Autocuration,22226,,,,U,,,,BAO_0000218,F,,CHEMBL615594
,1,723.0,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,435,4504,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615595
,1,723.0,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,436,4504,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615596
,8,723.0,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,437,12695,,1,,Expert,11169,,,,H,,,NIH3T3,BAO_0000219,F,,CHEMBL615597
,1,723.0,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,438,12695,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615598
,1,723.0,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,439,12695,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615599
,1,723.0,Effective dose against murine 3T3 fibroblasts cells,,440,17642,,1,Mus musculus,Expert,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615600
,1,723.0,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,441,17642,,1,Mus musculus,Expert,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615601
,1,723.0,Cytotoxic effect on 3T3 cells,,442,12340,,1,Mus musculus,Expert,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615602
,1,723.0,Cytotoxic effect on 3T3 cells,,443,12340,,1,Mus musculus,Expert,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615603
,1,723.0,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,444,12716,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615604
,1,723.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,445,6277,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615605
,1,723.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,446,6277,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615606
,1,723.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,447,6277,,1,Mus musculus,Expert,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL884526
,1,723.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,448,6277,,1,Mus musculus,Expert,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615607
,1,723.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,449,6277,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615608
,1,723.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,450,6277,,1,Mus musculus,Expert,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615609
,1,723.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,451,6277,,1,Mus musculus,Expert,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615682
,1,723.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,452,6277,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615683
,1,723.0,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,453,17780,,1,Mus musculus,Expert,80951,,10090.0,,N,,,NIH3T3,BAO_0000218,F,,CHEMBL615684
,7,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,454,12751,,1,Mus musculus,Autocuration,104860,,10090.0,,D,,,,BAO_0000219,F,,CHEMBL615685
,1,723.0,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,455,12380,,1,Mus musculus,Expert,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615686
,1,723.0,Inhibitory activity against 3T3 cell line,,456,14892,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615687
,1,723.0,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,457,12695,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL884523
,8,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,458,12695,,1,,Expert,11169,,,,H,,,,BAO_0000019,F,,CHEMBL615688
,1,723.0,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,459,12695,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615689
,1,723.0,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,460,12695,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615690
,8,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,461,12695,,1,,Expert,11169,,,,H,,,,BAO_0000019,F,,CHEMBL615691
,8,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,462,12695,,1,,Expert,11169,,,,H,,,,BAO_0000019,F,,CHEMBL615692
,1,723.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,463,6277,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615693
,1,723.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,464,6277,,1,Mus musculus,Expert,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615324
,9,723.0,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,465,4959,,1,Homo sapiens,Expert,9,,9606.0,,D,,,NIH3T3,BAO_0000219,F,,CHEMBL615325
,9,723.0,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,466,4959,,1,Homo sapiens,Expert,9,,9606.0,,D,,,NIH3T3,BAO_0000219,F,,CHEMBL615490
,9,723.0,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,467,4959,,1,Homo sapiens,Expert,188,,9606.0,,D,,,NIH3T3,BAO_0000219,F,,CHEMBL615491
,9,723.0,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,468,4959,,1,Homo sapiens,Expert,188,,9606.0,,D,,,NIH3T3,BAO_0000219,F,,CHEMBL615492
,1,723.0,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,469,12082,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615493
,1,723.0,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,470,12082,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615494
,1,723.0,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,471,12082,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615495
,1,723.0,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,472,12082,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615496
,1,723.0,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,473,2643,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615497
,1,723.0,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,474,11926,,1,Mus musculus,Expert,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615498
,1,723.0,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,475,15204,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,A,,CHEMBL615499
,1,723.0,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,476,15992,,1,Mus musculus,Expert,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL835522
,1,723.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,477,16279,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615500
,1,723.0,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,478,16279,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615501
,1,723.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,479,16279,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615502
,1,723.0,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,480,16279,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615503
,1,723.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,481,16279,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615504
,1,723.0,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,482,16279,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615505
,1,723.0,Inhibition of swiss 3T3 mouse fibroblast proliferation,,483,12831,,1,Mus musculus,Expert,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615506
,1,723.0,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,484,13497,,1,Mus musculus,Intermediate,80951,,10090.0,,N,,,NIH3T3,BAO_0000219,F,,CHEMBL615507
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,485,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000218,F,,CHEMBL615508
,1,620.0,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,486,13618,,1,Mus musculus,Intermediate,80006,,10090.0,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615509
,1,620.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,487,11902,,1,Mus musculus,Intermediate,80006,,10090.0,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615510
,1,620.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,488,11902,,1,Mus musculus,Intermediate,80006,,10090.0,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615511
,1,620.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,489,11902,,1,Mus musculus,Intermediate,80006,,10090.0,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615512
,1,620.0,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,490,14840,,1,Mus musculus,Intermediate,80006,,10090.0,,N,,,3T3-L1,BAO_0000218,F,,CHEMBL615513
,1,620.0,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,491,14840,,1,Mus musculus,Intermediate,80006,,10090.0,,N,,,3T3-L1,BAO_0000218,F,,CHEMBL615514
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,492,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615515
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,493,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615516
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,494,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615517
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,495,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615518
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,496,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615519
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,497,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000218,F,,CHEMBL615520
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,498,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000218,F,,CHEMBL615521
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,499,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000218,F,,CHEMBL615522
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,500,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000218,F,,CHEMBL615523
,1,620.0,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,501,13715,,1,,Expert,80006,,,,N,,,3T3-L1,BAO_0000218,F,,CHEMBL615524
,1,620.0,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,502,13715,,1,,Expert,80006,,,,N,,,3T3-L1,BAO_0000218,F,,CHEMBL615525
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,503,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000218,F,,CHEMBL615526
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,504,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000218,F,,CHEMBL615527
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,505,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000218,F,,CHEMBL615528
,1,620.0,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,506,13715,,1,,Expert,80006,,,,N,,,3T3-L1,BAO_0000218,F,,CHEMBL615529
,1,620.0,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,507,13715,,1,,Expert,80006,,,,N,,,3T3-L1,BAO_0000218,F,,CHEMBL615530
,1,620.0,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,508,13715,,1,,Expert,80006,,,,N,,,3T3-L1,BAO_0000218,F,,CHEMBL615531
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,509,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615532
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,510,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615533
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,511,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615534
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,512,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000218,F,,CHEMBL615535
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,513,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000218,F,,CHEMBL615536
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,514,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000218,F,,CHEMBL615537
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,515,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000218,F,,CHEMBL615538
,1,620.0,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,516,13715,,1,,Intermediate,80006,,,,N,,,3T3-L1,BAO_0000218,F,,CHEMBL836166
,8,620.0,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,517,6411,,1,,Expert,11214,,,,H,,,3T3-L1,BAO_0000219,F,,CHEMBL615539
,1,620.0,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,518,6411,,1,Mus musculus,Intermediate,80006,,10090.0,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615540
,8,620.0,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,519,6411,,1,,Expert,11214,,,,H,,,3T3-L1,BAO_0000219,F,,CHEMBL615541
,1,620.0,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,520,3966,,1,Mus musculus,Expert,80006,,10090.0,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615542
,1,620.0,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,521,3966,,1,Mus musculus,Intermediate,80006,,10090.0,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615543
,1,620.0,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,522,15556,,1,Mus musculus,Expert,80006,,10090.0,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615544
,1,620.0,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,523,5845,,1,Mus musculus,Expert,80006,,10090.0,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615545
,1,620.0,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,524,14422,,1,Mus musculus,Expert,80006,,10090.0,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615546
,1,620.0,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,525,5845,,1,Mus musculus,Expert,80006,,10090.0,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615547
,1,620.0,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,526,14508,,1,Mus musculus,Expert,80006,,10090.0,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615548
,1,620.0,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,527,14508,,1,Mus musculus,Expert,80006,,10090.0,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615549
,1,620.0,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,528,14508,,1,Mus musculus,Expert,80006,,10090.0,,N,,,3T3-L1,BAO_0000219,F,,CHEMBL615550
,1,1118.0,Inhibitory activity against rat fibroblast (3Y1) cell line,,529,6349,,1,Rattus norvegicus,Intermediate,80622,,10116.0,,N,,,3Y1 cell line,BAO_0000219,F,,CHEMBL615551
,1,1118.0,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,530,15899,,1,Rattus norvegicus,Expert,80622,,10116.0,,N,,,3Y1 cell line,BAO_0000219,F,,CHEMBL615552
,1,1118.0,Cytotoxicity in 3Y1 cells.,,531,15899,,1,Rattus norvegicus,Expert,80622,,10116.0,,N,,,3Y1 cell line,BAO_0000219,F,,CHEMBL615553
,1,1118.0,Cytostatic effect in 3Y1 cells.,,532,15899,,1,Rattus norvegicus,Expert,80622,,10116.0,,N,,,3Y1 cell line,BAO_0000219,F,,CHEMBL615554
,1,1118.0,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,533,15899,,1,Rattus norvegicus,Intermediate,80622,,10116.0,,N,,,3Y1 cell line,BAO_0000219,F,,CHEMBL615555
,1,1118.0,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,534,17038,,1,Rattus norvegicus,Expert,80622,,10116.0,,N,,,3Y1 cell line,BAO_0000219,F,,CHEMBL615556
,0,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,535,12421,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL615557
,0,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,536,12947,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL615558
,0,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,537,12947,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL872066
,9,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,538,4896,,1,Sus scrofa,Expert,11607,,9823.0,,D,,,,BAO_0000019,B,,CHEMBL615559
,8,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,539,6148,,1,,Autocuration,11607,,,,H,,,,BAO_0000019,B,,CHEMBL615560
,8,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,540,16432,,1,,Autocuration,11607,,,,H,,,,BAO_0000019,B,,CHEMBL615561
,8,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,541,4978,,1,,Expert,11607,,,,H,,,,BAO_0000019,B,,CHEMBL857062
,8,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,542,4978,,1,,Expert,11607,,,,H,,,,BAO_0000019,B,,CHEMBL615562
,8,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,543,3723,,1,,Autocuration,11607,,,,H,,,,BAO_0000019,B,,CHEMBL615563
,8,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,544,3518,,1,,Autocuration,11607,,,,H,,,,BAO_0000357,B,,CHEMBL615564
,8,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,545,4164,,1,,Autocuration,11607,,,,H,,,,BAO_0000019,B,,CHEMBL615565
,8,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,546,3518,,1,,Autocuration,11607,,,,H,,,,BAO_0000019,B,,CHEMBL615566
,9,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,547,4164,,1,Sus scrofa,Expert,11607,,9823.0,,D,,,,BAO_0000019,B,,CHEMBL615567
,8,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,548,3518,,1,,Autocuration,11607,,,,H,,,,BAO_0000019,B,,CHEMBL615568
,8,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,549,3518,,1,,Autocuration,11607,,,,H,,,,BAO_0000357,B,,CHEMBL615569
,8,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,550,4978,,1,,Autocuration,11607,,,,H,,,,BAO_0000019,B,,CHEMBL615570
,8,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,551,4978,,1,,Autocuration,11607,,,,H,,,,BAO_0000019,B,,CHEMBL615571
,4,,Binding affinity against melatonin (MT1) receptor (pC1),,552,6455,,1,,Autocuration,104733,,,,H,,,,BAO_0000224,B,,CHEMBL615572
,0,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,553,2222,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL615573
,0,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,554,13020,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL615574
,0,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,555,13021,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL615575
,8,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,556,14532,,1,,Autocuration,10619,,,,H,,,,BAO_0000357,B,,CHEMBL615576
,8,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,557,14118,,1,,Autocuration,10619,,,,H,,,,BAO_0000357,B,,CHEMBL615577
,8,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,558,11884,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615578
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,559,13969,,1,,Expert,51,,,,H,,,,BAO_0000357,B,,CHEMBL615579
,8,,Binding affinity for 5-hydroxytryptamine 1A receptor,,560,13392,,1,,Expert,51,,,,H,,,,BAO_0000357,B,,CHEMBL615580
,8,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,561,14430,,1,,Expert,51,,,,H,,,,BAO_0000019,B,,CHEMBL615581
,8,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,562,12248,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615582
,8,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,563,12249,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615583
,8,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,564,9995,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615584
,8,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,565,9995,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL833691
,8,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,566,9995,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615585
,8,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,567,9995,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615586
,8,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,568,9995,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL884524
,8,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,569,12249,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615587
,8,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,570,11799,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615588
,9,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,571,14331,Membranes,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000249,B,,CHEMBL615589
,8,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,572,11884,,1,Bos taurus,Expert,51,,9913.0,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615442
,8,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,573,14331,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615443
,8,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,574,11701,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615444
,8,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,575,11701,,1,,Expert,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615445
,8,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,576,12248,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615446
,8,449.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,577,12248,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,B,,CHEMBL615447
,8,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,578,12248,,1,,Expert,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615448
,8,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,579,12249,,1,,Expert,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615449
,8,449.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,580,12248,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,B,,CHEMBL615450
,8,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,581,11799,,1,,Expert,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615451
,8,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,582,634,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615452
,8,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,583,9995,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615453
,8,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,584,9995,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615454
,8,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,585,9995,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615455
,8,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,586,9995,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615456
,8,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,587,9995,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615457
,8,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,588,12210,,1,,Expert,51,,,Hippocampus,H,10000000.0,,,BAO_0000218,B,,CHEMBL615458
,8,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,589,13311,,1,,Expert,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615459
,9,449.0,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,590,2331,,1,Homo sapiens,Expert,51,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL615460
,8,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,591,1375,,1,Cavia porcellus,Autocuration,51,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL615461
,8,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,592,1375,,1,Cavia porcellus,Autocuration,51,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL615462
,8,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,593,11574,,1,Cavia porcellus,Autocuration,51,,10141.0,Hippocampus,H,10000000.0,,,BAO_0000221,F,,CHEMBL615463
,8,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,594,12867,,1,Cavia porcellus,Autocuration,51,,10141.0,Ileum,H,2116.0,,,BAO_0000221,B,,CHEMBL615464
,8,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,595,12867,,1,Cavia porcellus,Autocuration,51,,10141.0,Ileum,H,2116.0,,,BAO_0000221,B,,CHEMBL615465
,8,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,596,12867,,1,Cavia porcellus,Autocuration,51,,10141.0,Ileum,H,2116.0,,,BAO_0000221,B,,CHEMBL615466
,8,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,597,12867,,1,Cavia porcellus,Autocuration,51,,10141.0,Ileum,H,2116.0,,,BAO_0000221,B,,CHEMBL615467
,8,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,598,12867,,1,Cavia porcellus,Autocuration,51,,10141.0,Ileum,H,2116.0,,,BAO_0000221,B,,CHEMBL615468
,8,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,599,12867,,1,Cavia porcellus,Autocuration,51,,10141.0,Ileum,H,2116.0,,,BAO_0000221,B,,CHEMBL615469
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor,,600,11574,,1,Cavia porcellus,Autocuration,51,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL615470
,8,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,601,13114,,1,Cavia porcellus,Autocuration,51,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL615471
,8,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,602,13181,,1,Cavia porcellus,Autocuration,51,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL615472
,8,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,603,10639,,1,Cavia porcellus,Autocuration,106,,10141.0,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL883242
,8,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,604,10639,,1,Cavia porcellus,Autocuration,106,,10141.0,Hippocampus,H,10000000.0,,,BAO_0000221,F,,CHEMBL615473
,8,449.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,605,11883,,1,Cricetulus griseus,Autocuration,11863,,10029.0,,H,,,CHO,BAO_0000218,B,,CHEMBL615474
,8,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,606,17785,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615475
,8,308.0,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,607,1558,,1,,Autocuration,51,,,,H,,,HeLa,BAO_0000219,F,,CHEMBL615476
,8,308.0,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,608,1558,,1,,Autocuration,51,,,,H,,,HeLa,BAO_0000219,F,,CHEMBL615477
,8,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,609,15740,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL615478
,8,449.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,610,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615160
,8,449.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,611,17624,,1,,Expert,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615161
,8,449.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,612,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615162
,8,449.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,613,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615163
,8,449.0,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,614,17624,,1,,Expert,51,,,,H,,,CHO,BAO_0000219,B,,CHEMBL615164
,8,449.0,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,615,17624,,1,,Expert,51,,,,H,,,CHO,BAO_0000219,B,,CHEMBL615165
,8,449.0,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,616,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,B,,CHEMBL615166
,8,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,617,14256,,1,,Autocuration,51,,,,H,,,,BAO_0000219,F,,CHEMBL615167
,9,308.0,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,618,3445,,1,Homo sapiens,Expert,51,,9606.0,,D,,,HeLa,BAO_0000219,B,,CHEMBL615168
,9,308.0,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,619,3445,,1,Homo sapiens,Expert,51,,9606.0,,D,,,HeLa,BAO_0000219,B,,CHEMBL615169
,9,449.0,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,620,17200,,1,Homo sapiens,Expert,51,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL615170
,9,449.0,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,621,17200,,1,Homo sapiens,Expert,51,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL615171
,8,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,622,15180,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL615694
,8,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,623,15180,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL615695
,8,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,624,16026,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL615696
,8,449.0,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,625,2759,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615697
,9,449.0,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,626,2759,,1,Homo sapiens,Expert,51,,9606.0,,D,,,CHO,BAO_0000219,F,,CHEMBL859410
,8,449.0,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,627,2759,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615841
,9,449.0,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,628,2759,,1,Homo sapiens,Expert,51,,9606.0,,D,,,CHO,BAO_0000219,F,,CHEMBL615842
,8,449.0,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,629,2759,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL835003
,8,449.0,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,630,2759,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615843
,9,449.0,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,631,2759,,1,Homo sapiens,Expert,51,,9606.0,,D,,,CHO,BAO_0000219,F,,CHEMBL615979
,8,449.0,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,632,2759,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615980
,9,449.0,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,633,2759,,1,Homo sapiens,Expert,51,,9606.0,,D,,,CHO,BAO_0000219,F,,CHEMBL615981
,9,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,634,3445,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL615982
,9,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,635,5272,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL615983
,9,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,636,5272,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL615984
,9,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,637,5272,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL615985
,8,449.0,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,638,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615986
,8,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,639,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615987
,8,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,640,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615988
,8,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,641,17624,,1,,Expert,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615989
,8,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,642,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615990
,8,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,643,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615991
,8,449.0,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,644,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615992
,8,449.0,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,645,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615993
,8,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,646,17624,,1,,Expert,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615994
,8,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,647,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615995
,8,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,648,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615996
,8,449.0,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,649,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615997
,8,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,650,6563,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL615998
,8,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,651,6563,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL615999
,8,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,652,6563,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616000
,8,722.0,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,653,17296,,1,,Autocuration,51,,,,H,,,HEK293,BAO_0000219,F,,CHEMBL616001
,9,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,654,6876,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL616002
,8,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,655,6876,,1,,Expert,51,,,,H,,,,BAO_0000019,F,,CHEMBL616003
,9,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,656,5272,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL616004
,9,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,657,5272,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL616005
,8,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,658,5548,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616006
,8,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,659,5548,,1,,Expert,51,,,,H,,,,BAO_0000019,F,,CHEMBL616007
,8,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,660,5548,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616008
,8,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,661,5548,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616009
,8,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,662,5929,,1,,Expert,51,,,,H,,,,BAO_0000019,F,,CHEMBL616010
,9,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,663,5929,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL616011
,9,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,664,5929,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL615740
,8,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,665,16245,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL615741
,8,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,666,5640,,1,,Expert,51,,,,H,,,,BAO_0000019,F,,CHEMBL615742
,8,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,667,5640,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL615743
,8,449.0,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,668,14509,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615744
,8,449.0,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,669,14509,,1,,Expert,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615745
,8,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,670,15331,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615746
,8,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,671,15331,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615747
,8,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,672,6563,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL615748
,8,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,673,6563,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL615749
,8,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,674,6563,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL615750
,9,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,675,6563,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL616259
,8,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,676,6563,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616260
,9,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,677,5272,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL616261
,9,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,678,5272,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL616262
,9,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,679,5272,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL616263
,9,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,680,5272,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL616264
,9,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,681,5272,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL616265
,9,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,682,5272,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL616266
,9,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,683,5272,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL616267
,9,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,684,5272,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL616268
,9,,Inhibition of human 5-hydroxytryptamine 1A receptor,,685,16146,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616269
,8,449.0,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,686,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,B,,CHEMBL884528
,9,722.0,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,687,13706,,1,,Expert,105,,,,D,,,HEK293,BAO_0000219,B,,CHEMBL616270
,8,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,688,15250,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616271
,8,449.0,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,689,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL616272
,8,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,690,6861,,1,,Expert,51,,,,H,,,,BAO_0000357,B,,CHEMBL616273
,9,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,691,17200,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616274
,8,449.0,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,692,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616275
,8,449.0,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,693,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616276
,0,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,694,12058,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL616277
,0,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,695,12058,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL616278
,0,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,696,12058,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL616279
,0,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,697,12058,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL616280
,0,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,698,12058,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL616281
,0,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,699,12058,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL616282
,0,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,700,12058,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL616283
,0,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,701,12058,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL616284
,0,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,702,12058,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL616285
,0,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,703,12058,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL616286
,0,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,704,12058,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL616287
,0,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,705,12058,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL616288
,0,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,706,12058,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL616289
,0,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,707,12058,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL615610
,0,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,708,12058,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL615611
,0,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,709,12058,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL615612
,0,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,710,12058,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL615613
,0,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,711,12058,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL615614
,0,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,712,12058,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL615615
,4,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,713,11440,,1,,Autocuration,105093,,,,H,,,,BAO_0000019,B,,CHEMBL615616
,8,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,714,6238,,1,,Autocuration,11923,,,Hypothalamus,H,1898.0,,,BAO_0000249,B,,CHEMBL615617
,8,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,715,10046,,1,,Autocuration,10577,,,,H,,,,BAO_0000019,B,,CHEMBL615618
,8,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,716,10046,,1,,Autocuration,10577,,,,H,,,,BAO_0000019,B,,CHEMBL615619
,8,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,717,10046,,1,,Expert,10577,,,,H,,,,BAO_0000019,B,,CHEMBL615620
,8,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,718,167,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL615621
,8,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,719,167,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL615622
,8,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,720,11520,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,F,,CHEMBL615623
,8,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,721,11520,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,F,,CHEMBL615624
,8,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,722,11520,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,F,,CHEMBL615625
,8,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,723,11520,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,F,,CHEMBL767045
,8,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,724,135,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL615626
,8,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,725,135,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL615627
,8,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,726,11311,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000019,B,,CHEMBL615628
,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,727,10193,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL615629
,9,,Inhibitory concentration against 5-lipoxygenase from human whole blood,,728,12281,,1,Homo sapiens,Expert,55,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL615630
,8,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,729,11311,,1,,Autocuration,55,,,,H,,,,BAO_0000219,B,,CHEMBL615631
,8,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,730,12576,,1,,Autocuration,17087,,,,H,,,,BAO_0000218,F,,CHEMBL615632
,8,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,731,12281,,1,,Autocuration,17087,,,,H,,,,BAO_0000357,B,,CHEMBL615633
,8,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,732,12576,,1,,Autocuration,17087,,,,H,,,,BAO_0000218,F,,CHEMBL615634
,8,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,733,11089,,1,Sus scrofa,Expert,55,,9823.0,,H,,,,BAO_0000019,B,,CHEMBL615635
,8,,In vitro inhibition of rat 5-Lipoxygenase,,734,11006,,1,,Expert,12166,,,,H,,,,BAO_0000357,B,,CHEMBL615636
,9,,Inhibitory activity against 5-Lipoxygenase,,735,11481,,1,Rattus norvegicus,Expert,12166,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL615637
,8,702.0,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,736,10864,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL615638
,8,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,737,3595,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL615639
,8,702.0,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,738,11311,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL615640
,8,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,739,11311,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL615796
,8,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,740,11311,,1,,Autocuration,12166,,,,H,,,,BAO_0000219,B,,CHEMBL615845
,8,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,741,11006,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL615846
,8,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,742,3595,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL615847
,8,,The compound was tested for inhibition of isolated 5-Lipoxygenase,,743,11311,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL615848
,0,,Ratio of IC50 against 5-LO and COX,,744,11481,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000019,B,,CHEMBL615849
,8,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,745,11006,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL615850
,8,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,746,11006,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL615851
,8,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,747,11311,,1,,Autocuration,12166,,,,H,,,,BAO_0000219,B,,CHEMBL615852
,8,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,748,11006,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,F,,CHEMBL615853
,8,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,749,4288,,1,,Autocuration,120,,,Prostate gland,H,2367.0,,,BAO_0000357,B,,CHEMBL884527
,0,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,750,7587,,1,Columba livia,Autocuration,22226,,8932.0,,U,,,,BAO_0000019,B,,CHEMBL872871
,0,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,751,7587,,1,Columba livia,Autocuration,22226,,8932.0,,U,,,,BAO_0000019,B,,CHEMBL615854
,0,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,752,7587,,1,Columba livia,Autocuration,22226,,8932.0,,U,,,,BAO_0000019,B,,CHEMBL767046
,8,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,753,11249,,1,,Autocuration,10732,,,,H,,,,BAO_0000357,B,,CHEMBL615855
,9,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,754,8003,,1,Rattus norvegicus,Expert,12198,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL615856
,9,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,755,8003,,1,Rattus norvegicus,Expert,12198,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL615857
,9,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,756,8003,,1,Rattus norvegicus,Expert,12198,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL615858
,8,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,757,12416,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615859
,8,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,758,16293,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615860
,0,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,759,13047,,1,Oryctolagus cuniculus,Autocuration,22226,,9986.0,,U,,,,BAO_0000019,B,,CHEMBL615861
,0,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,760,13047,,1,Oryctolagus cuniculus,Autocuration,22226,,9986.0,,U,,,,BAO_0000019,B,,CHEMBL615862
,0,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,761,13047,,1,Oryctolagus cuniculus,Autocuration,22226,,9986.0,,U,,,,BAO_0000019,B,,CHEMBL615863
,0,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,762,13047,,1,Oryctolagus cuniculus,Autocuration,22226,,9986.0,,U,,,,BAO_0000019,B,,CHEMBL615864
,4,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,763,10085,,1,,Autocuration,104744,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615865
,4,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,764,10085,,1,,Autocuration,104744,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615866
,4,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,765,10085,,1,,Autocuration,104744,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615867
,4,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,766,9841,Membranes,1,,Autocuration,104744,,,,H,,,,BAO_0000249,B,,CHEMBL615868
,5,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,767,8822,,1,Rattus norvegicus,Autocuration,104744,,10116.0,,D,,,,BAO_0000249,B,,CHEMBL615869
,5,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,768,9806,,1,Rattus norvegicus,Autocuration,104744,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL615870
,5,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,769,9806,,1,Rattus norvegicus,Autocuration,104744,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL615871
,4,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,770,8868,,1,,Autocuration,104744,,,,H,,,,BAO_0000224,B,,CHEMBL615872
,4,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,771,9036,,1,,Autocuration,104744,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL833492
,4,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,772,11374,,1,,Autocuration,104744,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615873
,4,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,773,10881,,1,,Autocuration,104744,,,,H,,,,BAO_0000224,B,,CHEMBL615479
,4,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,774,8822,,1,,Autocuration,104744,,,,H,,,,BAO_0000019,B,,CHEMBL615480
,5,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,775,9806,,1,Rattus norvegicus,Autocuration,104744,,10116.0,,D,,,,BAO_0000249,B,,CHEMBL615481
,4,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,776,15463,,1,,Autocuration,104744,,,,H,,,,BAO_0000019,B,,CHEMBL872869
,4,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,777,15463,,1,,Autocuration,104744,,,,H,,,,BAO_0000019,B,,CHEMBL615482
,4,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,778,14542,,1,,Autocuration,104744,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL615483
,4,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,779,14542,,1,,Autocuration,104744,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL615484
,4,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,780,8569,,1,,Autocuration,104744,,,,H,,,,BAO_0000019,B,,CHEMBL615485
,5,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,781,10062,,1,Rattus norvegicus,Autocuration,104744,,10116.0,,D,,,,BAO_0000224,B,,CHEMBL615486
,4,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,782,4771,,1,,Autocuration,104744,,,,H,,,,BAO_0000224,B,,CHEMBL615487
,4,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,783,10062,,1,,Autocuration,104744,,,,H,,,,BAO_0000224,B,,CHEMBL615488
,4,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,784,10062,,1,,Autocuration,104744,,,,H,,,,BAO_0000224,B,,CHEMBL615489
,4,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,785,10062,,1,,Autocuration,104744,,,,H,,,,BAO_0000224,B,,CHEMBL615389
,4,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,786,15463,,1,,Autocuration,104744,,,,H,,,,BAO_0000019,B,,CHEMBL615390
,4,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,787,15463,,1,,Autocuration,104744,,,,H,,,,BAO_0000019,B,,CHEMBL615391
,4,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,788,9098,,1,,Autocuration,104744,,,,H,,,,BAO_0000224,B,,CHEMBL615392
,0,,Affinity for 5-hydroxytryptamine 1 receptor,,789,3070,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000019,B,,CHEMBL615393
,4,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,790,14542,,1,,Autocuration,104744,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL615394
,4,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,791,14542,,1,,Autocuration,104744,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL615395
,4,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,792,6398,,1,,Autocuration,104744,,,,H,,,,BAO_0000224,B,,CHEMBL615396
,4,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,793,1344,,1,,Autocuration,104744,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL615397
,4,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,794,11963,,1,,Autocuration,104744,,,,H,,,,BAO_0000019,B,,CHEMBL615398
,0,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,795,8908,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000019,B,,CHEMBL615399
,4,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,796,9098,,1,,Autocuration,104744,,,,H,,,,BAO_0000019,B,,CHEMBL615400
,5,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,797,8841,,1,Rattus norvegicus,Autocuration,104744,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL615401
,0,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,798,8814,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000019,B,,CHEMBL615402
,4,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,799,11752,,1,,Autocuration,104744,,,,H,,,,BAO_0000019,B,,CHEMBL615403
,4,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,800,11642,,1,,Autocuration,104744,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL615404
,4,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,801,11642,,1,,Autocuration,104744,,,,H,,,,BAO_0000019,B,,CHEMBL615781
,4,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,802,9231,,1,,Autocuration,104744,,,Brain,H,955.0,,,BAO_0000220,B,,CHEMBL615782
,4,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,803,11351,,1,,Autocuration,104744,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL615783
,0,,Compound was tested for binding affinity against 5-HT1 receptor,,804,4639,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL873481
,0,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,805,1205,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL615784
,8,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,806,10025,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL615785
,8,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,807,13241,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,F,,CHEMBL615786
,8,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,808,16245,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615787
,8,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,809,16245,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615788
,8,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,810,12438,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL767044
,8,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,811,16245,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615789
,8,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,812,16245,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615790
,8,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,813,15740,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL615813
,8,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,814,15535,,1,,Autocuration,10576,,,,H,,,,BAO_0000219,F,,CHEMBL615814
,8,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,815,15535,,1,,Expert,51,,,,H,,,,BAO_0000219,F,,CHEMBL615815
,8,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,816,15535,,1,,Autocuration,10576,,,,H,,,,BAO_0000219,F,,CHEMBL615816
,8,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,817,9888,,1,,Expert,10576,,,,H,,,,BAO_0000249,B,,CHEMBL615817
,8,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,818,10085,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615818
,8,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,819,10085,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615819
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,820,17331,Membranes,1,,Expert,10576,,,,H,,,,BAO_0000249,B,,CHEMBL615820
,9,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,821,10845,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL615821
,9,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,822,10845,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL615822
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,823,10845,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615823
,9,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,824,10845,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL615824
,9,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,825,10845,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL615825
,8,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,826,13730,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL615826
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,827,13508,,1,,Expert,10576,,,,H,,,,BAO_0000249,B,,CHEMBL615827
,8,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,828,13508,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000249,B,,CHEMBL615828
,8,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,829,12073,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615829
,8,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,830,4671,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615830
,8,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,831,13631,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615831
,8,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,832,12438,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL615832
,8,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,833,10483,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615833
,8,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,834,10483,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615834
,8,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,835,12352,,1,,Intermediate,10576,,,,H,,,,BAO_0000249,B,,CHEMBL615835
,8,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,836,14732,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000249,B,,CHEMBL615836
,9,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,837,11049,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL615837
,9,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,838,11049,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL615838
,8,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,839,13657,,1,,Expert,10576,,,,H,,,,BAO_0000249,B,,CHEMBL615839
,8,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,840,11473,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL884525
,8,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,841,2014,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,B,,CHEMBL615840
,8,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,842,3086,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615405
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,843,15854,,1,,Expert,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615406
,8,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,844,10922,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615900
,8,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,845,13346,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615901
,8,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,846,15311,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL615902
,8,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,847,10922,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615903
,8,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,848,10025,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL615904
,8,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,849,10025,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL615905
,8,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,850,9742,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615906
,8,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,851,9742,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL615907
,8,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,852,12304,,1,,Expert,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615908
,8,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,853,15789,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615909
,8,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,854,9912,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615910
,8,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,855,9912,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615911
,8,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,856,9912,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615912
,8,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,857,16693,,1,,Expert,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615913
,8,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,858,13276,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL615914
,8,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,859,12678,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615915
,8,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,860,11825,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL615916
,8,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,861,12443,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL615917
,8,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,862,13830,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL615918
,8,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,863,14286,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000249,B,,CHEMBL615919
,9,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,864,14356,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL615920
,8,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,865,15306,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL615921
,8,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,866,15306,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL615922
,9,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,867,16616,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000249,F,,CHEMBL881290
,8,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,868,3651,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615923
,8,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,869,14331,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,F,,CHEMBL615924
,8,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,870,14331,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,F,,CHEMBL615925
,9,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,871,14178,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL615926
,9,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,872,10639,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL615927
,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,873,12306,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615928
,9,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,874,1348,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL615929
,8,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,875,13605,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615930
,8,449.0,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,876,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,B,,CHEMBL615931
,8,449.0,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,877,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615932
,8,449.0,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,878,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL615933
,8,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,879,15267,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615934
,8,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,880,16532,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615935
,8,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,881,6563,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL615936
,8,449.0,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,882,4751,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,B,,CHEMBL615937
,8,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,883,15463,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615938
,8,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,884,3805,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615797
,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,885,5640,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615798
,8,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,886,6563,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL872870
,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,887,5548,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615799
,8,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,888,6347,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615800
,8,722.0,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,889,17296,,1,,Autocuration,51,,,,H,,,HEK293,BAO_0000219,F,,CHEMBL615801
,8,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,890,13047,,1,,Autocuration,51,,,,H,,,,BAO_0000019,B,,CHEMBL615802
,8,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,891,15740,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615803
,8,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,892,5640,,1,,Expert,51,,,,H,,,,BAO_0000019,F,,CHEMBL835002
,8,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,893,5640,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL615804
,8,308.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,894,17211,,1,,Expert,51,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL615805
,8,449.0,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,895,4751,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,B,,CHEMBL615806
,9,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,896,6491,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL615807
,8,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,897,4707,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615808
,9,,Binding affinity against 5-hydroxytryptamine 1A receptor,,898,13910,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL615809
,8,308.0,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,899,16190,,1,,Autocuration,51,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL615810
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,900,16633,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615811
,8,449.0,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,901,11898,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,B,,CHEMBL615812
,8,449.0,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,902,11898,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,B,,CHEMBL615751
,8,,Binding affinity against human 5-hydroxytryptamine 1A receptor,,903,14331,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615752
,8,449.0,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,904,17624,,1,,Expert,51,,,,H,,,CHO,BAO_0000219,B,,CHEMBL615753
,8,449.0,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,905,17624,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,B,,CHEMBL615754
,8,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,906,3307,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615755
,9,449.0,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,907,6563,,1,Homo sapiens,Expert,51,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL615756
,8,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,908,14165,,1,,Autocuration,51,,,,H,,,,BAO_0000019,B,,CHEMBL615757
,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,909,5732,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615758
,8,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,910,13366,,1,,Expert,51,,,,H,,,,BAO_0000357,B,,CHEMBL615759
,8,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,911,17626,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615760
,8,308.0,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,912,6588,,1,,Expert,51,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL615761
,8,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,913,16209,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL872104
,8,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,914,15463,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615762
,8,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,915,15463,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615763
,8,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,916,14770,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615764
,8,1167.0,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,917,16245,,1,,Autocuration,51,,,,H,,,Cell line,BAO_0000219,B,,CHEMBL615765
,8,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,918,16245,,1,,Autocuration,51,,,,H,,,,BAO_0000019,B,,CHEMBL615766
,8,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,919,5548,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615767
,8,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,920,5548,,1,,Expert,51,,,,H,,,,BAO_0000357,B,,CHEMBL615768
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,921,5548,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615769
,8,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,922,6876,,1,,Expert,51,,,,H,,,,BAO_0000357,B,,CHEMBL615770
,8,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,923,2598,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615771
,8,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,924,17785,,1,,Expert,51,,,,H,,,,BAO_0000357,B,,CHEMBL615772
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,925,6013,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615773
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,926,5929,,1,,Expert,51,,,,H,,,,BAO_0000357,B,,CHEMBL615774
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,927,16633,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615775
,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,928,1558,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615776
,8,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,929,16026,,1,,Expert,51,,,,H,,,,BAO_0000357,B,,CHEMBL615777
,8,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,930,12469,,1,,Autocuration,51,,,,H,,,,BAO_0000219,B,,CHEMBL615778
,9,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,931,15874,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL615779
,8,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,932,15874,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL615780
,8,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,933,3935,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616298
,8,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,934,15818,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616299
,8,485.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,935,13706,,1,,Autocuration,51,,,,H,,,CHO-K1,BAO_0000219,B,,CHEMBL616300
,8,485.0,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,936,13729,,1,,Expert,51,,,,H,,,CHO-K1,BAO_0000219,F,,CHEMBL616301
,8,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,937,15413,,1,,Autocuration,51,,,,H,,,,BAO_0000019,B,,CHEMBL616302
,8,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,938,15413,,1,,Autocuration,51,,,,H,,,,BAO_0000019,B,,CHEMBL616117
,8,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,939,15413,,1,,Autocuration,51,,,,H,,,,BAO_0000019,B,,CHEMBL616118
,8,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,940,15413,,1,,Autocuration,51,,,,H,,,,BAO_0000019,B,,CHEMBL616119
,9,308.0,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,941,3445,,1,Homo sapiens,Expert,51,,9606.0,,D,,,HeLa,BAO_0000219,B,,CHEMBL616120
,8,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,942,15740,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616121
,8,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,943,15740,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616122
,8,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,944,17626,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616123
,9,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,945,4234,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616124
,8,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,946,5640,,1,,Expert,51,,,,H,,,,BAO_0000357,B,,CHEMBL616125
,8,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,947,5272,,1,Rattus norvegicus,Expert,51,,10116.0,,H,,,,BAO_0000357,B,,CHEMBL616126
,8,449.0,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,948,4622,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616127
,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,949,17085,,1,,Expert,51,,,,H,,,,BAO_0000019,B,,CHEMBL616128
,8,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,950,3025,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616129
,8,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,951,15315,,1,,Expert,51,,,,H,,,,BAO_0000357,B,,CHEMBL616130
,8,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,952,15267,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616131
,8,308.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,953,17158,,1,,Autocuration,51,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL616132
,9,308.0,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,954,14214,,1,Homo sapiens,Expert,51,,9606.0,,D,,,HeLa,BAO_0000219,B,,CHEMBL616133
,8,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,955,17133,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616134
,8,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,956,16532,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616135
,9,,Affinity for 5-hydroxytryptamine 1A receptor subtype,,957,2391,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616136
,8,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,958,14447,,1,,Autocuration,51,,,,H,,,,BAO_0000019,B,,CHEMBL616137
,8,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,959,14447,,1,,Autocuration,51,,,,H,,,,BAO_0000019,B,,CHEMBL872105
,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,960,15086,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616138
,9,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,961,13051,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616139
,8,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,962,16026,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616140
,8,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,963,17085,,1,,Expert,51,,,,H,,,,BAO_0000019,B,,CHEMBL616141
,8,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,964,17133,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616142
,8,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,965,17133,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616143
,8,308.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,966,17211,,1,,Autocuration,51,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL616144
,8,308.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,967,17211,,1,,Autocuration,51,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL616145
,8,308.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,968,17211,,1,,Autocuration,51,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL616012
,8,308.0,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,969,17211,,1,,Autocuration,51,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL616013
,8,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,970,16394,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616014
,8,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,971,16394,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616015
,8,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,972,16394,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616016
,8,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,973,16394,,1,,Autocuration,51,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL616017
,8,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,974,16394,,1,,Autocuration,51,,,,H,,,,BAO_0000019,B,,CHEMBL616018
,8,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,975,15740,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616019
,8,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,976,15740,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616020
,8,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,977,15740,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL858018
,8,722.0,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,978,17296,,1,,Autocuration,51,,,,H,,,HEK293,BAO_0000219,F,,CHEMBL616021
,8,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,979,5640,,1,,Expert,51,,,,H,,,,BAO_0000019,F,,CHEMBL616022
,8,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,980,5640,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616023
,8,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,981,5640,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616024
,8,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,982,5640,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616025
,8,449.0,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,983,2759,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL616026
,8,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,984,16394,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616027
,9,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,985,16394,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL616028
,9,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,986,3445,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL616029
,8,449.0,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,987,4316,,1,,Expert,51,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616030
,8,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,988,4316,,1,,Expert,51,,,,H,,,,BAO_0000019,B,,CHEMBL616031
,9,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,989,15180,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL616032
,9,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,990,15180,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL616033
,8,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,991,15042,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616034
,8,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,992,15042,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616035
,8,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,993,15042,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616036
,8,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,994,15042,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616037
,8,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,995,15042,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616038
,8,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,996,15042,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616039
,8,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,997,15042,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616040
,9,308.0,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,998,15180,,1,Homo sapiens,Expert,51,,9606.0,,D,,,HeLa,BAO_0000219,F,,CHEMBL616041
,9,308.0,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,999,15180,,1,Homo sapiens,Expert,51,,9606.0,,D,,,HeLa,BAO_0000219,F,,CHEMBL616042
,9,308.0,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,1000,15180,,1,Homo sapiens,Expert,51,,9606.0,,D,,,HeLa,BAO_0000219,F,,CHEMBL616043
,8,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,1001,16245,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616044
,8,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,1002,16026,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616045
,8,722.0,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,1003,17296,,1,,Autocuration,51,,,,H,,,HEK293,BAO_0000219,F,,CHEMBL616046
,8,449.0,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,1004,2759,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL616047
,8,449.0,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,1005,2759,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL616048
,9,449.0,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,1006,2759,,1,Homo sapiens,Expert,51,,9606.0,,D,,,CHO,BAO_0000219,F,,CHEMBL616049
,8,449.0,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,1007,2759,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,F,,CHEMBL616050
,8,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,1008,15419,,1,,Expert,51,,,,H,,,,BAO_0000219,F,,CHEMBL616051
,8,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,1009,15419,,1,,Autocuration,51,,,,H,,,,BAO_0000219,F,,CHEMBL616212
,8,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,1010,16026,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616213
,8,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,1011,1414,,1,,Expert,51,,,,H,,In vitro,,BAO_0000219,B,,CHEMBL616214
,8,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,1012,1414,,1,,Expert,51,,,,H,,In vitro,,BAO_0000219,B,,CHEMBL616215
,8,,Binding activity radioligand.,,1013,12861,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616216
,8,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,1014,12861,,1,,Autocuration,51,,,,H,,,,BAO_0000019,B,,CHEMBL616217
,8,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,1015,5104,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616218
,8,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,1016,5105,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616219
,8,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,1017,16312,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616220
,9,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,1018,15180,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL833493
,8,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,1019,5033,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616221
,9,449.0,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,1020,16909,,1,Homo sapiens,Expert,51,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL616222
,8,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,1021,2590,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616223
,8,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,1022,2590,,1,,Autocuration,51,,,,H,,,,BAO_0000019,F,,CHEMBL616224
,8,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,1023,16394,,1,,Expert,51,,,,H,,,,BAO_0000019,B,,CHEMBL616225
,9,722.0,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,1024,4540,,1,Homo sapiens,Expert,51,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL616226
,8,722.0,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,1025,17296,,1,,Autocuration,51,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616227
,8,722.0,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,1026,17296,,1,,Autocuration,51,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616228
,8,722.0,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,1027,15779,,1,,Autocuration,51,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616229
,8,722.0,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,1028,15779,,1,,Autocuration,51,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616230
,8,722.0,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,1029,15779,,1,,Autocuration,51,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616231
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,1030,6166,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616232
,8,722.0,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,1031,15779,,1,,Autocuration,51,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616233
,8,722.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,1032,4199,,1,,Autocuration,51,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL857973
,8,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,1033,15316,,1,,Autocuration,51,,,,H,,,,BAO_0000219,B,,CHEMBL616234
,8,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,1034,14875,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616235
,8,308.0,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,1035,14727,,1,,Expert,51,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL616236
,8,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,1036,14727,,1,,Expert,51,,,,H,,,,BAO_0000019,B,,CHEMBL616237
,8,722.0,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,1037,15146,,1,,Autocuration,51,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616238
,8,722.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,1038,5213,,1,,Autocuration,51,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616239
,8,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,1039,16429,,1,,Autocuration,51,,,,H,,,,BAO_0000219,B,,CHEMBL616240
,9,308.0,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,1040,15042,,1,Homo sapiens,Expert,51,,9606.0,,D,,,HeLa,BAO_0000219,B,,CHEMBL616241
,8,722.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,1041,14818,,1,,Autocuration,51,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616242
,8,722.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,1042,4829,,1,,Autocuration,51,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616243
,9,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,1043,17200,,1,,Expert,51,,,,D,,,,BAO_0000357,B,,CHEMBL616244
,9,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,1044,13051,,1,Homo sapiens,Autocuration,51,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616245
,8,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,1045,5486,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616246
,8,,Binding affinity against 5-HT1D receptor,,1046,5254,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616247
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor,,1047,5254,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616248
,8,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,1048,15331,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL616249
,8,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,1049,13506,,1,Homo sapiens,Autocuration,10576,,9606.0,,H,,,,BAO_0000357,B,,CHEMBL616250
,8,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,1050,15267,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616251
,8,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,1051,16616,,1,,Autocuration,11863,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL616252
,8,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,1052,16616,,1,,Autocuration,11863,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL616253
,8,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,1053,16616,,1,,Autocuration,11863,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL616254
,9,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,1054,16616,,1,Mus musculus,Expert,11863,,10090.0,,D,,,,BAO_0000218,F,,CHEMBL616255
,9,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,1055,16616,,1,Mus musculus,Expert,11863,,10090.0,,D,,,,BAO_0000218,F,,CHEMBL832872
,9,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,1056,16616,,1,Mus musculus,Expert,11863,,10090.0,,D,,,,BAO_0000218,F,,CHEMBL616256
,9,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,1057,16616,,1,Mus musculus,Expert,11863,,10090.0,,D,,,,BAO_0000218,F,,CHEMBL616257
,9,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,1058,16616,,1,Mus musculus,Expert,11863,,10090.0,,D,,,,BAO_0000218,F,,CHEMBL616258
,9,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,1059,16616,,1,Mus musculus,Expert,11863,,10090.0,,D,,,,BAO_0000218,F,,CHEMBL616384
,8,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,1060,10297,,1,,Autocuration,11863,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616385
,8,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,1061,13704,,1,,Expert,11863,,,,H,,,,BAO_0000357,B,,CHEMBL616386
,9,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,1062,10297,,1,Mus musculus,Expert,11863,,10090.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL616387
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,1063,10297,,1,,Autocuration,11863,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616388
,9,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,1064,10297,,1,Mus musculus,Expert,11863,,10090.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL616389
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,1065,10297,,1,,Autocuration,11863,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616390
,8,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,1066,217,,1,,Autocuration,11863,,,,H,,,,BAO_0000357,B,,CHEMBL616391
,9,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,1067,10297,,1,Mus musculus,Expert,11863,,10090.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL616392
,8,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,1068,4921,,1,Sus scrofa,Autocuration,51,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL616393
,8,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,1069,4921,,1,Sus scrofa,Autocuration,51,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL616394
,8,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,1070,4996,,1,Sus scrofa,Autocuration,51,,9823.0,,H,,,,BAO_0000019,B,,CHEMBL616395
,8,,Compound was evaluated for the binding affinity at 5- HT1A receptor,,1071,12918,,1,Sus scrofa,Autocuration,51,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL616396
,8,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,1072,5333,,1,Sus scrofa,Autocuration,51,,9823.0,,H,,,,BAO_0000019,B,,CHEMBL872907
,8,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,1073,4437,,1,Sus scrofa,Autocuration,51,,9823.0,,H,,,,BAO_0000019,B,,CHEMBL616397
,8,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,1074,1742,,1,Sus scrofa,Autocuration,51,,9823.0,,H,,,,BAO_0000019,B,,CHEMBL616398
,8,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,1075,16688,,1,Sus scrofa,Expert,51,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL616399
,8,,Binding activity radioligand.,,1076,12861,,1,Sus scrofa,Autocuration,51,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL857065
,8,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,1077,12861,,1,Sus scrofa,Expert,51,,9823.0,,H,,,,BAO_0000019,B,,CHEMBL616400
,8,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,1078,12861,,1,Sus scrofa,Autocuration,51,,9823.0,,H,,,,BAO_0000019,B,,CHEMBL616401
,8,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,1079,12490,,1,,Expert,10624,,,,H,,,,BAO_0000019,B,,CHEMBL616402
,8,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,1080,11828,,1,Sus scrofa,Expert,51,,9823.0,,H,,,,BAO_0000019,B,,CHEMBL616403
,8,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,1081,11866,,1,Sus scrofa,Autocuration,51,,9823.0,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616404
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,1082,12827,,1,Sus scrofa,Autocuration,51,,9823.0,,H,,,,BAO_0000249,B,,CHEMBL616405
,8,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,1083,12918,,1,Sus scrofa,Autocuration,51,,9823.0,,H,,,,BAO_0000019,B,,CHEMBL616406
,8,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,1084,12919,,1,Sus scrofa,Expert,51,,9823.0,,H,,,,BAO_0000019,F,,CHEMBL616407
,8,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,1085,13047,,1,Oryctolagus cuniculus,Autocuration,51,,9986.0,,H,,,,BAO_0000019,B,,CHEMBL616408
,9,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,1086,15796,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000249,B,,CHEMBL616409
,9,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,1087,3651,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL616410
,8,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,1088,188,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616411
,9,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,1089,16616,Membranes,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000249,F,,CHEMBL616412
,9,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,1090,16616,Membranes,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000249,F,,CHEMBL616413
,8,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,1091,12306,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616414
,9,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,1092,17167,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL616415
,8,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,1093,14776,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616416
,8,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,1094,12158,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616417
,8,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,1095,13481,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616418
,8,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,1096,13427,,1,,Autocuration,10576,,,,H,,In vitro,,BAO_0000219,B,,CHEMBL616419
,8,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,1097,10210,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616420
,8,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,1098,10205,Membranes,1,,Autocuration,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616421
,8,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,1099,10205,Membranes,1,,Autocuration,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616422
,8,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,1100,10205,Membranes,1,,Expert,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616423
,9,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,1101,12280,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL616424
,8,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,1102,17386,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616425
,8,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,1103,13654,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616426
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,1104,14423,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616427
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,1105,15412,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616428
,8,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,1106,12073,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616290
,9,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,1107,4101,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL616052
,8,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,1108,10062,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616053
,8,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,1109,6238,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616054
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,1110,16273,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616055
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,1111,11139,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616056
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,1112,16796,,1,,Expert,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616057
,9,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,1113,9548,,1,Rattus norvegicus,Expert,10576,,10116.0,Brain,D,955.0,,,BAO_0000221,B,,CHEMBL616058
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,1114,10381,,1,,Autocuration,10576,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL616059
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,1115,13408,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616060
,9,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,1116,13825,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL616061
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,1117,11147,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616062
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,1118,10552,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616063
,8,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,1119,10552,,1,,Autocuration,10576,,,Striatum,H,2435.0,,,BAO_0000249,B,,CHEMBL616064
,9,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,1120,17136,Membranes,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000249,B,,CHEMBL616065
,9,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,1121,5778,Membranes,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000249,B,,CHEMBL616066
,8,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,1122,13481,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616067
,8,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,1123,13481,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616068
,8,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,1124,13630,,1,,Intermediate,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616069
,8,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,1125,16245,,1,,Expert,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616070
,8,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,1126,14509,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616071
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,1127,14509,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616072
,8,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,1128,14509,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616073
,8,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,1129,14509,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616074
,8,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,1130,14256,,1,,Expert,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616075
,8,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,1131,11139,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616076
,9,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,1132,11047,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL616077
,9,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,1133,11047,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL616078
,9,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,1134,11047,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL616079
,9,485.0,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,1135,2395,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,CHO-K1,BAO_0000219,B,,CHEMBL616080
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,1136,9699,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616081
,9,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,1137,12028,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL616082
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,1138,12028,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616083
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,1139,5815,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616084
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,1140,16616,,1,,Expert,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616085
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,1141,5815,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616086
,8,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,1142,2761,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616087
,8,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,1143,13133,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616088
,8,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,1144,10444,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616089
,9,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,1145,13278,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL616090
,8,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,1146,15874,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616091
,8,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,1147,10552,Membranes,1,,Autocuration,10576,,,Striatum,H,2435.0,,,BAO_0000249,B,,CHEMBL616092
,8,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,1148,11130,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616093
,8,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,1149,11130,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,B,,CHEMBL616094
,8,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,1150,14542,,1,,Autocuration,10576,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL616095
,9,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,1151,13670,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL616096
,8,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,1152,9888,,1,,Expert,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616097
,9,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,1153,3678,Membranes,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000249,B,,CHEMBL616098
,8,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,1154,11332,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616099
,8,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,1155,11332,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616100
,8,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,1156,1185,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616101
,8,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,1157,2014,,1,,Expert,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616102
,8,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,1158,1185,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616103
,8,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,1159,14429,,1,,Expert,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616104
,8,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,1160,16288,,1,,Expert,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616105
,9,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,1161,5432,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL616106
,8,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,1162,14429,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616107
,8,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,1163,13672,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616108
,8,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,1164,11296,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616109
,8,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,1165,11296,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616110
,8,449.0,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,1166,14749,,1,,Expert,10576,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616111
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,1167,15086,,1,,Expert,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616112
,8,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,1168,13462,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616113
,8,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,1169,15363,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616114
,8,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,1170,15363,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616115
,8,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,1171,10796,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616116
,8,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,1172,12816,,1,,Expert,10576,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL615844
,8,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,1173,13542,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615939
,8,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,1174,13308,,1,,Expert,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615940
,8,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,1175,13541,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615941
,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,1176,10058,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615942
,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,1177,10058,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615943
,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,1178,10058,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615944
,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,1179,10058,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615945
,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,1180,10058,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615946
,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,1181,10058,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615947
,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,1182,10058,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615948
,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,1183,10058,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615949
,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,1184,10058,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615950
,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,1185,10058,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615951
,8,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,1186,10058,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615952
,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,1187,10058,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615953
,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,1188,10058,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615954
,9,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,1189,10058,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL615955
,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,1190,10058,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615956
,8,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,1191,10058,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL615957
,8,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,1192,12879,,1,,Expert,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615958
,8,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,1193,11964,,1,,Expert,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615959
,8,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,1194,11964,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615960
,8,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,1195,11964,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615961
,8,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,1196,9548,,1,,Expert,10576,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL615962
,8,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,1197,9098,,1,,Expert,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615963
,8,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,1198,9098,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615964
,8,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,1199,9098,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615965
,8,449.0,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,1200,13248,,1,,Expert,10576,,,,H,,,CHO,BAO_0000219,B,,CHEMBL615966
,8,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,1201,3147,,1,,Expert,10576,,,,H,,,,BAO_0000249,B,,CHEMBL615967
,8,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,1202,13949,,1,,Expert,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615968
,8,449.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,1203,11883,,1,,Autocuration,10576,,,,H,,,CHO,BAO_0000218,B,,CHEMBL615969
,8,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,1204,11883,,1,,Autocuration,10576,,,,H,,,,BAO_0000218,B,,CHEMBL615970
,9,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,1205,11883,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL615971
,8,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,1206,15535,Membranes,1,,Expert,10576,,,,H,,,,BAO_0000249,B,,CHEMBL615972
,8,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,1207,15535,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,B,,CHEMBL615973
,8,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,1208,15535,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,B,,CHEMBL615974
,9,449.0,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,1209,16372,,1,Homo sapiens,Expert,51,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL615975
,8,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,1210,14608,,1,,Expert,10576,,,,H,,,,BAO_0000249,B,,CHEMBL615976
,9,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,1211,4795,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL872106
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,1212,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL615977
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,1213,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL615978
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,1214,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616166
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,1215,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616167
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,1216,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616168
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,1217,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616169
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,1218,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616170
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,1219,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616171
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,1220,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616172
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,1221,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616173
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,1222,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616174
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,1223,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616175
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,1224,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616176
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,1225,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616177
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,1226,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616178
,8,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,1227,9742,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616179
,8,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,1228,12073,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616180
,8,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,1229,4101,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616181
,8,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,1230,15360,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616182
,8,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,1231,11576,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616183
,8,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,1232,5834,,1,,Expert,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615874
,9,485.0,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,1233,2395,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,CHO-K1,BAO_0000219,B,,CHEMBL615875
,8,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,1234,1375,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615876
,8,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,1235,1375,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615877
,8,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,1236,3967,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL615878
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,1237,12884,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL615879
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,1238,2343,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL615880
,8,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,1239,11511,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615881
,9,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,1240,11511,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL615882
,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,1241,16394,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615883
,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,1242,16394,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615884
,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,1243,16394,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615885
,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,1244,16394,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615886
,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,1245,16394,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615887
,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,1246,16394,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615888
,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,1247,16394,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615889
,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,1248,16394,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615890
,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,1249,16394,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615891
,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,1250,16394,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615892
,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,1251,16394,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615893
,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,1252,16394,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615894
,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,1253,16394,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615895
,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,1254,16394,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615896
,8,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,1255,16394,,1,,Autocuration,10576,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL615897
,9,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,1256,16616,Membranes,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000249,F,,CHEMBL615898
,8,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,1257,16796,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL615899
,8,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,1258,16796,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616291
,8,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,1259,15629,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616292
,8,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,1260,13241,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,F,,CHEMBL616293
,8,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,1261,12073,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616294
,8,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,1262,14286,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000249,B,,CHEMBL616295
,8,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,1263,14542,,1,,Autocuration,10576,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL616296
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,1264,13630,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616297
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,1265,13630,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616605
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,1266,13630,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616606
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,1267,13630,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616607
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,1268,13630,,1,,Expert,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616608
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,1269,13630,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616609
,9,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,1270,13630,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL616610
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,1271,13630,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616611
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,1272,13630,,1,,Expert,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616612
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,1273,13630,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616613
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,1274,13630,,1,,Expert,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616614
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,1275,13630,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616615
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,1276,13630,,1,,Expert,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616616
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,1277,13630,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616617
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,1278,13630,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616618
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,1279,13630,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616619
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,1280,13630,,1,,Expert,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616620
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,1281,13630,,1,,Expert,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616621
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,1282,13630,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616622
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,1283,13630,,1,,Expert,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616146
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,1284,13630,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL832873
,8,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,1285,13630,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616147
,8,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,1286,13630,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL872872
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,1287,13630,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616148
,8,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,1288,9783,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616149
,8,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,1289,9783,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616150
,9,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,1290,14331,Membranes,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000249,B,,CHEMBL616151
,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,1291,15260,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL872873
,8,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,1292,15260,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616670
,8,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,1293,15260,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616671
,9,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,1294,16616,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000249,F,,CHEMBL884861
,8,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,1295,15629,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616672
,8,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,1296,15086,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616673
,8,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,1297,5717,,1,,Expert,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616674
,8,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,1298,12652,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616675
,8,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,1299,14608,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616676
,8,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,1300,12306,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616677
,8,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,1301,12306,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616678
,9,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,1302,15247,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL616679
,8,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,1303,17529,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616680
,8,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,1304,14826,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616681
,8,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,1305,14826,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616682
,8,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,1306,13241,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616683
,8,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,1307,14093,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616684
,8,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,1308,14093,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616685
,8,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,1309,14442,,1,,Autocuration,10576,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL616686
,8,,Affinity for 5-hydroxytryptamine 1A receptor site,,1310,9919,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616687
,8,,Affinity for 5-hydroxytryptamine 1A receptor site,,1311,9919,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616688
,8,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,1312,11440,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616689
,8,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,1313,11257,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616690
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,1314,10330,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616691
,9,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,1315,17331,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL616692
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,1316,16567,,1,,Expert,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616693
,9,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,1317,12058,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL616694
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,1318,9699,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616695
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,1319,9547,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616696
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,1320,10330,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616697
,8,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,1321,14331,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616698
,9,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,1322,14060,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL616949
,8,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,1323,14744,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616950
,8,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,1324,13506,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL832875
,8,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,1325,10862,,1,,Expert,10576,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL616951
,8,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,1326,10862,,1,,Expert,10576,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL616952
,8,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,1327,10062,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616953
,8,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,1328,12073,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616954
,8,,GTPgammaS radioligand binding assay,,1329,14875,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616955
,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,1330,2391,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616956
,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,1331,2391,,1,,Autocuration,106,,,,H,,,,BAO_0000019,F,,CHEMBL616957
,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,1332,2391,,1,,Autocuration,106,,,,H,,,,BAO_0000019,F,,CHEMBL616958
,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,1333,2391,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616959
,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,1334,2391,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616960
,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,1335,2391,,1,,Autocuration,106,,,,H,,,,BAO_0000019,F,,CHEMBL616961
,8,308.0,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,1336,17211,,1,,Expert,106,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL616962
,8,308.0,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,1337,17211,,1,,Autocuration,106,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL616963
,9,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,1338,6491,,1,Homo sapiens,Expert,106,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616524
,8,449.0,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,1339,16190,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616525
,8,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,1340,14165,,1,,Autocuration,106,,,,H,,,,BAO_0000019,B,,CHEMBL872908
,8,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,1341,14165,,1,,Autocuration,106,,,,H,,,,BAO_0000019,B,,CHEMBL616526
,9,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,1342,4234,,1,Homo sapiens,Expert,106,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616527
,8,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,1343,6328,,1,,Expert,106,,,,H,,,,BAO_0000219,B,,CHEMBL616528
,8,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,1344,14770,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616529
,8,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,1345,2598,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616530
,8,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,1346,6897,,1,,Expert,106,,,,H,,,,BAO_0000357,B,,CHEMBL616531
,8,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,1347,6897,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616532
,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,1348,6013,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616533
,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,1349,5843,,1,,Expert,106,,,,H,,,,BAO_0000357,B,,CHEMBL616534
,8,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,1350,14454,,1,,Expert,106,,,,H,,,,BAO_0000357,B,,CHEMBL616535
,8,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,1351,16209,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616536
,8,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,1352,3935,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616537
,8,485.0,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,1353,13729,,1,,Expert,106,,,,H,,,CHO-K1,BAO_0000219,F,,CHEMBL616538
,8,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,1354,14251,,1,,Expert,106,,,,H,,,,BAO_0000019,F,,CHEMBL616539
,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,1355,17085,,1,,Expert,106,,,,H,,,,BAO_0000019,B,,CHEMBL616540
,8,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,1356,3025,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616429
,8,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,1357,15315,,1,,Expert,106,,,,H,,,,BAO_0000357,B,,CHEMBL616430
,9,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,1358,14214,,1,Homo sapiens,Expert,106,,9606.0,,D,,,,BAO_0000219,B,,CHEMBL616431
,9,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,1359,3804,,1,Homo sapiens,Expert,106,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616432
,9,,Affinity for 5-hydroxytryptamine 1B receptor subtype,,1360,2391,,1,Homo sapiens,Expert,106,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616433
,9,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,1361,4175,,1,Homo sapiens,Expert,106,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616434
,8,449.0,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,1362,17296,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616435
,8,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,1363,17085,,1,,Expert,106,,,,H,,,,BAO_0000019,B,,CHEMBL616436
,8,308.0,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,1364,17211,,1,,Autocuration,106,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL616437
,8,308.0,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,1365,17211,,1,,Autocuration,106,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL616438
,8,308.0,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,1366,17211,,1,,Autocuration,106,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL616439
,9,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,1367,15926,,1,Homo sapiens,Expert,106,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616440
,8,485.0,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,1368,16312,,1,,Autocuration,106,,,,H,,,CHO-K1,BAO_0000219,B,,CHEMBL616441
,8,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,1369,5843,,1,,Expert,106,,,,H,,,,BAO_0000357,B,,CHEMBL616442
,8,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,1370,5843,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616443
,8,485.0,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,1371,16312,,1,,Expert,106,,,,H,,,CHO-K1,BAO_0000219,B,,CHEMBL616444
,9,,Binding activity against human 5-hydroxytryptamine 1B receptor,,1372,15926,,1,Homo sapiens,Expert,106,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616445
,9,,Binding activity against human 5-hydroxytryptamine 1B receptor,,1373,15926,,1,Homo sapiens,Expert,106,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616446
,9,449.0,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,1374,4540,,1,Homo sapiens,Expert,106,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL616447
,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,1375,6166,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616448
,8,449.0,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,1376,17296,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616449
,8,449.0,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,1377,17296,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616450
,8,449.0,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,1378,17296,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL857974
,8,449.0,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,1379,15779,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616451
,8,449.0,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,1380,15779,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616452
,8,449.0,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,1381,15779,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616453
,8,449.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,1382,4199,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616454
,9,,Binding affinity for human 5-hydroxytryptamine 1B receptor,,1383,14875,,1,Homo sapiens,Expert,106,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616455
,8,449.0,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,1384,15146,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616456
,8,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,1385,5213,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616457
,8,449.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,1386,14818,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616458
,8,449.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,1387,4829,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616459
,8,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,1388,14454,,1,,Expert,106,,,,H,,,,BAO_0000019,F,,CHEMBL616460
,8,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,1389,14454,,1,,Expert,106,,,,H,,,,BAO_0000019,F,,CHEMBL616461
,8,449.0,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,1390,14875,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,F,,CHEMBL616462
,8,449.0,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,1391,14875,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,F,,CHEMBL616463
,8,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,1392,15250,,1,,Autocuration,105,,,,H,,,,BAO_0000019,F,,CHEMBL616464
,8,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,1393,15250,,1,,Autocuration,105,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616465
,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,1394,15086,,1,,Autocuration,17105,,,,H,,,,BAO_0000357,B,,CHEMBL832874
,8,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,1395,3025,,1,Oryctolagus cuniculus,Autocuration,106,,9986.0,,H,,,,BAO_0000019,F,,CHEMBL616184
,8,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,1396,14998,,1,Oryctolagus cuniculus,Autocuration,106,,9986.0,,H,,,,BAO_0000019,B,,CHEMBL616185
,8,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,1397,14998,,1,Oryctolagus cuniculus,Intermediate,106,,9986.0,,H,,,,BAO_0000019,B,,CHEMBL616186
,8,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,1398,14998,,1,Oryctolagus cuniculus,Autocuration,106,,9986.0,,H,,,,BAO_0000019,B,,CHEMBL616187
,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,1399,13969,,1,,Expert,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616188
,9,,Binding affinity for 5-hydroxytryptamine 1B receptor,,1400,13392,,1,,Intermediate,10577,,,,D,,,,BAO_0000357,B,,CHEMBL873475
,9,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,1401,3651,,1,Rattus norvegicus,Expert,10577,,10116.0,Striatum,D,2435.0,,,BAO_0000019,B,,CHEMBL616189
,8,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,1402,10025,,1,,Expert,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616190
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,1403,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616191
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,1404,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616192
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,1405,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616193
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,1406,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616194
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,1407,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616195
,8,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,1408,13863,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616196
,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,1409,4622,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000249,B,,CHEMBL616197
,8,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,1410,14911,,1,,Intermediate,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616198
,8,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,1411,12678,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616199
,8,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,1412,12678,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616200
,8,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,1413,14235,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616201
,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,1414,14949,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616202
,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,1415,14949,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616203
,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,1416,14949,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616204
,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,1417,14949,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616205
,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,1418,14949,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616206
,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,1419,16118,,1,,Expert,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616207
,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,1420,3268,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616208
,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,1421,3268,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616209
,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,1422,16117,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616210
,8,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,1423,9783,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616211
,8,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,1424,9783,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616504
,9,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,1425,14356,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL616505
,8,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,1426,15740,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616506
,8,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,1427,12306,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL872107
,9,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,1428,13348,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL616507
,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,1429,10394,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616303
,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,1430,15260,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616304
,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,1431,10046,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616305
,8,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,1432,15260,,1,,Intermediate,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,F,,CHEMBL616306
,8,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,1433,12851,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616307
,9,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,1434,2148,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL881829
,8,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,1435,13134,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616308
,8,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,1436,12462,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616309
,8,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,1437,12462,,1,,Expert,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616310
,8,449.0,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,1438,12462,,1,,Autocuration,10576,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616311
,8,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,1439,11933,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616312
,8,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,1440,11933,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616313
,9,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,1441,403,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL616314
,8,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,1442,15538,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616315
,8,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,1443,15538,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616567
,8,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,1444,15538,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616568
,8,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,1445,12464,,1,,Intermediate,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616569
,8,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,1446,1455,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616570
,8,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,1447,12652,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616571
,8,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,1448,12639,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616572
,8,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,1449,13949,,1,,Expert,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616573
,9,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,1450,12463,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL616574
,8,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,1451,14829,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616575
,8,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,1452,14829,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL872108
,8,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,1453,12092,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616576
,8,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,1454,403,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616577
,8,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,1455,403,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616578
,8,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,1456,3967,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616579
,9,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,1457,12771,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL616580
,8,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,1458,15086,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616581
,8,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,1459,14909,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616582
,8,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,1460,14949,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616583
,9,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,1461,2309,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL616584
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,1462,4170,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616585
,9,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,1463,11642,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL616586
,8,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,1464,11642,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616587
,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,1465,12953,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616588
,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,1466,12953,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616589
,8,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,1467,12953,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616590
,8,449.0,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,1468,12903,,1,,Expert,10576,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616591
,8,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,1469,12536,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616592
,8,,The inhibition activity of 5-HT1A at 1 uM,,1470,10058,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616593
,8,485.0,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,1471,12902,,1,,Expert,10576,,,,H,,,CHO-K1,BAO_0000219,B,,CHEMBL616594
,8,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,1472,14057,,1,,Expert,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616595
,8,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,1473,11296,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616596
,8,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,1474,11296,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616597
,8,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,1475,11296,,1,,Expert,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616598
,9,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,1476,16616,Membranes,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000249,F,,CHEMBL616599
,9,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,1477,16616,Membranes,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000249,F,,CHEMBL616600
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,1478,16567,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616601
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,1479,16567,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616602
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,1480,16567,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616603
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,1481,16567,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616604
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,1482,17136,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616316
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,1483,17136,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616317
,9,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,1484,16616,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL616318
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,1485,17331,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616319
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,1486,17331,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616320
,9,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,1487,17167,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL616321
,8,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,1488,15740,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616322
,8,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,1489,15740,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616323
,8,,Ratio of binding affinity to 5-HT 1A and D2 receptor,,1490,4671,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616324
,8,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,1491,10058,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616325
,8,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,1492,10058,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616326
,8,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,1493,10058,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616327
,8,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,1494,12073,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616328
,8,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,1495,2759,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,B,,CHEMBL858110
,8,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,1496,2759,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,F,,CHEMBL616329
,8,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,1497,2759,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616330
,8,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,1498,2759,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,F,,CHEMBL616331
,8,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,1499,2759,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,F,,CHEMBL616332
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,1500,9737,,1,,Autocuration,10576,,,Brain,H,955.0,,,BAO_0000249,B,,CHEMBL857063
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,1501,9737,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616333
,8,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,1502,5717,,1,,Expert,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616334
,8,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,1503,12253,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616335
,8,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,1504,14025,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616336
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,1505,10425,,1,,Expert,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616337
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,1506,14998,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616338
,8,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,1507,13694,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616339
,8,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,1508,13694,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616340
,8,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,1509,4342,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616341
,9,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,1510,12936,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL616342
,9,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,1511,13144,,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL616343
,8,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,1512,13343,,1,,Expert,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616344
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,1513,12132,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616345
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,1514,15419,,1,,Expert,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616346
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,1515,1479,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616347
,8,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,1516,14287,,1,,Expert,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616348
,8,,Binding affinity at 5-hydroxytryptamine 1A receptor,,1517,13116,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616349
,9,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,1518,2759,Membranes,1,Rattus norvegicus,Expert,10576,,10116.0,,D,,,,BAO_0000249,B,,CHEMBL616152
,8,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,1519,2759,,1,,Autocuration,10576,,,,H,,,,BAO_0000249,B,,CHEMBL616153
,8,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,1520,14748,,1,,Expert,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616154
,8,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,1521,12304,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616155
,9,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,1522,12409,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL616156
,9,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,1523,12409,,1,Rattus norvegicus,Expert,10576,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL616157
,8,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,1524,13267,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616158
,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,1525,15194,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616159
,8,,pKi value against rat 5-hydroxytryptamine 1A receptor.,,1526,14256,,1,,Expert,10576,,,,H,,,,BAO_0000357,B,,CHEMBL616160
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,1527,16567,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616161
,8,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,1528,15740,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616162
,9,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,1529,13278,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL616163
,8,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,1530,1970,Membranes,1,,Expert,10626,,,,H,,,,BAO_0000249,B,,CHEMBL616164
,8,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,1531,10034,,1,,Autocuration,10576,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL616165
,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,1532,13348,,1,Rattus norvegicus,Autocuration,51,,10116.0,,H,,,,BAO_0000019,B,,CHEMBL616355
,8,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,1533,13630,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,F,,CHEMBL616356
,8,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,1534,10862,,1,,Autocuration,10576,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL616357
,8,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,1535,12058,,1,,Autocuration,10576,,,,H,,,,BAO_0000019,B,,CHEMBL616358
,8,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,1536,4639,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616359
,8,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,1537,15453,,1,,Expert,51,,,,H,,,,BAO_0000357,B,,CHEMBL616360
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,1538,4820,,1,,Expert,51,,,,H,,,,BAO_0000357,B,,CHEMBL616361
,8,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,1539,1089,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616362
,8,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,1540,386,Brain membranes,1,,Autocuration,51,,,,H,,,,BAO_0000249,B,,CHEMBL616363
,8,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,1541,6011,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616364
,8,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,1542,5014,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616365
,8,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,1543,4402,,1,,Expert,51,,,,H,,,,BAO_0000357,B,,CHEMBL616366
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,1544,17066,,1,,Expert,51,,,,H,,,,BAO_0000357,B,,CHEMBL872906
,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,1545,17515,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616367
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor,,1546,2474,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616368
,8,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,1547,4775,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616369
,9,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,1548,14294,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616370
,9,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,1549,14294,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616371
,8,449.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,1550,12249,,1,,Autocuration,51,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616372
,8,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,1551,11376,,1,,Expert,51,,,,H,,,,BAO_0000219,B,,CHEMBL616373
,8,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,1552,2474,,1,,Autocuration,51,,,,H,,In vivo,,BAO_0000218,B,,CHEMBL616374
,8,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,1553,13311,,1,,Autocuration,51,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL616375
,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,1554,4373,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616376
,8,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,1555,1633,,1,,Expert,51,,,,H,,,,BAO_0000357,B,,CHEMBL857064
,8,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,1556,11866,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616377
,8,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,1557,4373,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616378
,8,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,1558,4687,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616379
,8,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,1559,16946,,1,,Autocuration,11863,,,,H,,,,BAO_0000357,B,,CHEMBL616380
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,1560,13291,,1,,Autocuration,11863,,,,H,,,,BAO_0000357,B,,CHEMBL616381
,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,1561,14159,,1,,Autocuration,11863,,,,H,,,,BAO_0000357,B,,CHEMBL616382
,8,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,1562,10812,,1,,Autocuration,11863,,,,H,,,,BAO_0000357,B,,CHEMBL616383
,9,449.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,1563,3032,,1,Mus musculus,Expert,11863,,10090.0,,D,,,CHO,BAO_0000219,B,,CHEMBL616350
,8,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,1564,16655,,1,,Autocuration,11863,,,,H,,,,BAO_0000357,B,,CHEMBL616351
,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,1565,14532,,1,,Autocuration,11863,,,,H,,,,BAO_0000357,B,,CHEMBL616352
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor,,1566,13944,,1,,Autocuration,11863,,,,H,,,,BAO_0000357,B,,CHEMBL616353
,8,,Binding affinity against serotonergic 5-HT1a receptor,,1567,13033,,1,,Autocuration,11863,,,,H,,,,BAO_0000357,B,,CHEMBL616354
,8,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,1568,10321,,1,,Autocuration,11863,,,,H,,,,BAO_0000357,B,,CHEMBL616508
,9,,Binding affinity for 5-hydroxytryptamine 1A receptor,,1569,2968,,1,Mus musculus,Expert,11863,,10090.0,,D,,,,BAO_0000357,B,,CHEMBL616559
,8,,Binding affinity at 5-hydroxytryptamine 1A receptor,,1570,13964,,1,,Autocuration,11863,,,,H,,,,BAO_0000357,B,,CHEMBL616560
,8,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,1571,15527,,1,,Autocuration,11863,,,,H,,,,BAO_0000357,B,,CHEMBL616561
,8,449.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,1572,12248,,1,,Autocuration,11863,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616562
,8,449.0,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,1573,12249,,1,,Autocuration,11863,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616563
,8,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,1574,15120,,1,,Autocuration,11863,,,,H,,,,BAO_0000357,B,,CHEMBL616564
,8,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,1575,13313,,1,,Autocuration,11863,,,,H,,,,BAO_0000357,B,,CHEMBL616565
,8,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,1576,2613,,1,,Autocuration,11863,,,,H,,,,BAO_0000218,B,,CHEMBL616566
,8,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,1577,16700,,1,,Autocuration,11863,,,,H,,,,BAO_0000357,B,,CHEMBL616989
,8,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,1578,2201,,1,,Autocuration,11863,,,,H,,,,BAO_0000357,B,,CHEMBL857975
,9,,Binding affinity against 5-hydroxytryptamine 1A receptor,,1579,1274,,1,Mus musculus,Expert,11863,,10090.0,,D,,,,BAO_0000357,B,,CHEMBL616990
,8,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,1580,1317,,1,,Autocuration,11863,,,,H,,,,BAO_0000357,B,,CHEMBL616991
,8,,Tested against 5-hydroxytryptamine 1A receptor,,1581,12146,,1,,Autocuration,11863,,,,H,,,,BAO_0000357,B,,CHEMBL616992
,8,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,1582,14059,,1,,Autocuration,11863,,,,H,,,,BAO_0000357,B,,CHEMBL616993
,8,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,1583,14025,,1,Oryctolagus cuniculus,Expert,106,,9986.0,,H,,,,BAO_0000019,B,,CHEMBL616994
,8,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,1584,14025,,1,Oryctolagus cuniculus,Autocuration,106,,9986.0,,H,,,,BAO_0000019,B,,CHEMBL616995
,9,722.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,1585,14447,,1,Gorilla gorilla,Intermediate,105571,,9593.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL616996
,8,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,1586,3025,,1,Cavia porcellus,Autocuration,106,,10141.0,,H,,In vivo,,BAO_0000218,F,,CHEMBL616997
,8,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,1587,3025,,1,Cavia porcellus,Autocuration,106,,10141.0,,H,,In vivo,,BAO_0000218,F,,CHEMBL616998
,8,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,1588,15329,,1,Cavia porcellus,Autocuration,106,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL616999
,8,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,1589,15329,,1,Cavia porcellus,Autocuration,106,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL617000
,8,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,1590,15847,,1,Cavia porcellus,Autocuration,106,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL617001
,8,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,1591,15847,,1,Cavia porcellus,Autocuration,106,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL858111
,8,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,1592,14165,,1,,Autocuration,106,,,,H,,,,BAO_0000019,F,,CHEMBL617002
,8,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,1593,14214,,1,,Autocuration,106,,,,H,,,,BAO_0000019,F,,CHEMBL617003
,8,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,1594,14214,,1,,Autocuration,106,,,,H,,,,BAO_0000019,F,,CHEMBL617004
,9,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,1595,14214,,1,Homo sapiens,Expert,106,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL617005
,9,485.0,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,1596,13729,,1,Homo sapiens,Expert,106,,9606.0,,D,,,CHO-K1,BAO_0000219,F,,CHEMBL616623
,8,449.0,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,1597,3025,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,F,,CHEMBL616624
,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,1598,2391,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL883243
,8,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,1599,2391,,1,,Autocuration,106,,,,H,,,,BAO_0000019,F,,CHEMBL616625
,8,449.0,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,1600,14956,,1,,Expert,106,,,,H,,,CHO,BAO_0000219,F,,CHEMBL616626
,8,449.0,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,1601,2598,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,F,,CHEMBL616627
,8,449.0,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,1602,2598,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,F,,CHEMBL616628
,8,449.0,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,1603,2598,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,F,,CHEMBL616629
,8,449.0,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,1604,2598,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,F,,CHEMBL616630
,8,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,1605,14956,,1,,Expert,106,,,,H,,,,BAO_0000019,F,,CHEMBL616631
,8,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,1606,14956,,1,,Autocuration,106,,,,H,,,,BAO_0000019,F,,CHEMBL616632
,9,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,1607,14214,,1,Homo sapiens,Expert,106,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616633
,8,449.0,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,1608,3463,,1,,Expert,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616634
,8,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,1609,15331,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616635
,9,,Binding affinity against 5-hydroxytryptamine 1B receptor,,1610,16146,,1,Homo sapiens,Expert,106,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL885358
,9,449.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,1611,14159,,1,Homo sapiens,Expert,106,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL616636
,8,449.0,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,1612,14158,,1,,Expert,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616637
,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,1613,14159,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616638
,8,449.0,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,1614,15250,,1,,Expert,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616639
,8,449.0,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,1615,15250,,1,,Expert,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616640
,8,449.0,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,1616,15331,,1,,Expert,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616641
,8,449.0,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,1617,15332,,1,,Expert,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616642
,8,449.0,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,1618,14956,,1,,Expert,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616643
,8,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,1619,3805,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616644
,8,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,1620,14875,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616645
,8,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,1621,14454,,1,Oryctolagus cuniculus,Autocuration,105,,9986.0,,H,,,,BAO_0000019,F,,CHEMBL616646
,8,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,1622,14454,,1,Oryctolagus cuniculus,Expert,105,,9986.0,,H,,,,BAO_0000019,F,,CHEMBL616647
,8,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,1623,16288,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616509
,8,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,1624,16288,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616510
,8,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,1625,16312,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616511
,8,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,1626,1348,,1,Bos taurus,Expert,105,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL616512
,8,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,1627,5834,,1,Bos taurus,Autocuration,105,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL616513
,8,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,1628,13366,,1,Bos taurus,Autocuration,105,,9913.0,Striatum,H,2435.0,,,BAO_0000019,B,,CHEMBL616514
,8,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,1629,1414,,1,Bos taurus,Expert,105,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL616515
,8,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,1630,14998,,1,Bos taurus,Autocuration,105,,9913.0,,H,,,,BAO_0000019,B,,CHEMBL616516
,8,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,1631,11473,,1,Bos taurus,Autocuration,105,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL616517
,8,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,1632,11473,,1,Bos taurus,Autocuration,105,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL616518
,8,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,1633,10639,,1,Bos taurus,Autocuration,105,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL616519
,8,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,1634,10639,,1,Bos taurus,Autocuration,105,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL616520
,8,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,1635,1375,,1,Bos taurus,Autocuration,105,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL616521
,8,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,1636,1375,,1,Bos taurus,Autocuration,105,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL616522
,8,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,1637,16532,,1,Bos taurus,Autocuration,105,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL884531
,8,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,1638,11147,,1,Bos taurus,Autocuration,105,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL616523
,8,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,1639,13366,,1,Bos taurus,Autocuration,105,,9913.0,Striatum,H,2435.0,,,BAO_0000019,B,,CHEMBL616731
,8,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,1640,10444,,1,Bos taurus,Autocuration,105,,9913.0,,H,,,,BAO_0000019,B,,CHEMBL616732
,8,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,1641,16532,,1,Bos taurus,Autocuration,105,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL616733
,8,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,1642,16532,,1,Bos taurus,Autocuration,105,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL616734
,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,1643,12827,,1,Bos taurus,Autocuration,105,,9913.0,,H,,,,BAO_0000249,B,,CHEMBL616735
,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,1644,12827,,1,Bos taurus,Autocuration,105,,9913.0,,H,,,,BAO_0000249,B,,CHEMBL616736
,8,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,1645,12919,,1,Bos taurus,Expert,105,,9913.0,,H,,,,BAO_0000019,F,,CHEMBL616737
,8,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,1646,14025,,1,Bos taurus,Autocuration,105,,9913.0,,H,,,,BAO_0000019,B,,CHEMBL616738
,8,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,1647,12919,,1,Bos taurus,Expert,105,,9913.0,,H,,,,BAO_0000019,F,,CHEMBL616739
,8,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,1648,12919,,1,Bos taurus,Expert,105,,9913.0,,H,,,,BAO_0000019,F,,CHEMBL616740
,8,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,1649,12919,,1,Bos taurus,Expert,105,,9913.0,,H,,,,BAO_0000019,F,,CHEMBL616741
,8,722.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,1650,14447,,1,Gorilla gorilla,Autocuration,105,,9593.0,,H,,,HEK293,BAO_0000219,B,,CHEMBL616742
,9,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,1651,1375,,1,Cavia porcellus,Intermediate,105570,,10141.0,,D,,,,BAO_0000019,B,,CHEMBL616743
,9,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,1652,1375,,1,Cavia porcellus,Intermediate,105570,,10141.0,,D,,,,BAO_0000019,B,,CHEMBL616744
,9,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,1653,12409,,1,Cavia porcellus,Intermediate,105570,,10141.0,,D,,,,BAO_0000019,F,,CHEMBL616745
,9,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,1654,12409,,1,Cavia porcellus,Intermediate,105570,,10141.0,,D,,,,BAO_0000019,F,,CHEMBL616746
,9,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,1655,12409,,1,Cavia porcellus,Intermediate,105570,,10141.0,,D,,,,BAO_0000019,F,,CHEMBL616747
,9,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,1656,12409,,1,Cavia porcellus,Intermediate,105570,,10141.0,,D,,,,BAO_0000019,F,,CHEMBL616748
,9,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,1657,12409,,1,Cavia porcellus,Intermediate,105570,,10141.0,,D,,,,BAO_0000019,F,,CHEMBL616648
,9,,Binding affinity against 5-hydroxytryptamine 1D receptor,,1658,11574,,1,Cavia porcellus,Intermediate,105570,,10141.0,,D,,,,BAO_0000357,B,,CHEMBL616649
,9,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,1659,1558,,1,Cavia porcellus,Intermediate,105570,,10141.0,,D,,,,BAO_0000357,B,,CHEMBL616650
,9,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,1660,12409,,1,Cavia porcellus,Intermediate,105570,,10141.0,,D,,,,BAO_0000218,F,,CHEMBL616651
,9,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,1661,12409,,1,Cavia porcellus,Intermediate,105570,,10141.0,,D,,,,BAO_0000218,F,,CHEMBL616652
,9,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,1662,12409,,1,Cavia porcellus,Intermediate,105570,,10141.0,,D,,,,BAO_0000218,F,,CHEMBL616653
,9,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,1663,12409,,1,Cavia porcellus,Intermediate,105570,,10141.0,,D,,,,BAO_0000218,F,,CHEMBL616654
,9,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,1664,12253,,1,Cavia porcellus,Intermediate,105570,,10141.0,,D,,,,BAO_0000019,B,,CHEMBL616655
,9,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,1665,12936,,1,Cavia porcellus,Intermediate,105570,,10141.0,,D,,,,BAO_0000357,B,,CHEMBL616656
,8,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,1666,13181,,1,Cavia porcellus,Autocuration,105,,10141.0,,H,,,,BAO_0000019,B,,CHEMBL616657
,9,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,1667,12409,,1,Cavia porcellus,Intermediate,105570,,10141.0,Striatum,D,2435.0,,,BAO_0000357,B,,CHEMBL616658
,9,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,1668,10639,,1,Cavia porcellus,Intermediate,105570,,10141.0,,D,,,,BAO_0000357,B,,CHEMBL616659
,8,,Binding affinity against 5-hydroxytryptamine 1D receptor,,1669,5254,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL616660
,8,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,1670,13051,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616661
,8,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,1671,3463,,1,,Expert,105,,,,H,,,,BAO_0000019,F,,CHEMBL616662
,8,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,1672,15315,,1,,Autocuration,105,,,,H,,,,BAO_0000019,F,,CHEMBL616663
,8,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,1673,6011,,1,,Autocuration,105,,,,H,,,,BAO_0000019,F,,CHEMBL616664
,9,449.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,1674,14159,,1,Homo sapiens,Expert,105,,9606.0,,D,,,CHO,BAO_0000219,F,,CHEMBL881820
,8,449.0,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,1675,14159,,1,,Autocuration,105,,,,H,,,CHO,BAO_0000219,F,,CHEMBL616665
,8,449.0,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,1676,15250,,1,,Expert,105,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616666
,8,449.0,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,1677,15250,,1,,Autocuration,105,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616667
,8,449.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,1678,15331,,1,,Expert,105,,,,H,,,CHO,BAO_0000219,F,,CHEMBL616668
,9,449.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,1679,15332,,1,Homo sapiens,Expert,105,,9606.0,,D,,,CHO,BAO_0000219,F,,CHEMBL616669
,8,449.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,1680,15332,,1,,Expert,105,,,,H,,,CHO,BAO_0000219,F,,CHEMBL617040
,8,449.0,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,1681,3294,,1,,Autocuration,105,,,,H,,,CHO,BAO_0000219,F,,CHEMBL617041
,8,449.0,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,1682,14158,,1,,Expert,105,,,,H,,,CHO,BAO_0000219,F,,CHEMBL617042
,8,449.0,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,1683,14956,,1,,Expert,105,,,,H,,,CHO,BAO_0000219,F,,CHEMBL617043
,8,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,1684,12469,,1,,Autocuration,105,,,,H,,,,BAO_0000019,F,,CHEMBL617044
,8,449.0,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,1685,3463,,1,,Expert,105,,,,H,,,CHO,BAO_0000219,F,,CHEMBL617045
,9,449.0,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,1686,15250,,1,Homo sapiens,Expert,105,,9606.0,,D,,,CHO,BAO_0000219,F,,CHEMBL617046
,9,449.0,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,1687,15250,,1,Homo sapiens,Expert,105,,9606.0,,D,,,CHO,BAO_0000219,F,,CHEMBL617047
,8,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,1688,14956,,1,,Expert,105,,,,H,,,,BAO_0000019,F,,CHEMBL617048
,8,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,1689,14159,,1,,Autocuration,105,,,,H,,,,BAO_0000019,F,,CHEMBL616897
,9,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,1690,14159,,1,Homo sapiens,Expert,105,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL616898
,9,449.0,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,1691,14499,,1,Homo sapiens,Expert,105,,9606.0,,D,,,CHO,BAO_0000219,F,,CHEMBL858201
,8,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,1692,15315,,1,,Autocuration,105,,,,H,,,,BAO_0000019,F,,CHEMBL616899
,8,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,1693,3294,,1,,Autocuration,105,,,,H,,In vitro,,BAO_0000219,B,,CHEMBL616900
,8,449.0,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,1694,3463,,1,,Expert,105,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616901
,8,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,1695,15331,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616902
,9,449.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,1696,14159,,1,Homo sapiens,Expert,105,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL616903
,8,449.0,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,1697,14158,,1,,Expert,105,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616904
,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,1698,14159,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616905
,8,449.0,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,1699,15250,,1,,Expert,105,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616906
,8,449.0,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,1700,15250,,1,,Expert,105,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616907
,8,449.0,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,1701,15331,,1,,Expert,105,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616908
,9,449.0,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,1702,15332,,1,Homo sapiens,Expert,105,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL616909
,9,449.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,1703,14499,,1,Homo sapiens,Expert,105,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL616910
,8,449.0,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,1704,15332,,1,,Expert,105,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616911
,8,449.0,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,1705,14956,,1,,Expert,105,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616912
,8,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,1706,3805,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616913
,9,449.0,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,1707,6011,,1,Homo sapiens,Expert,105,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL616914
,8,449.0,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,1708,16190,,1,,Autocuration,105,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616915
,8,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,1709,14165,,1,,Autocuration,105,,,,H,,,,BAO_0000019,B,,CHEMBL616916
,9,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,1710,4234,,1,Homo sapiens,Expert,105,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616917
,8,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,1711,15527,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616918
,8,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,1712,6328,,1,,Expert,105,,,,H,,,,BAO_0000219,B,,CHEMBL616919
,8,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,1713,16209,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616920
,8,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,1714,14770,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL872914
,8,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,1715,2598,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616921
,8,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,1716,6897,,1,,Expert,105,,,,H,,,,BAO_0000357,B,,CHEMBL616922
,8,,Binding affinity towards 5-hydroxytryptamine 1D receptor,,1717,6013,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616923
,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,1718,5843,,1,,Expert,105,,,,H,,,,BAO_0000357,B,,CHEMBL616924
,8,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,1719,14454,,1,,Expert,105,,,,H,,,,BAO_0000357,B,,CHEMBL875909
,8,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,1720,14454,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616925
,8,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,1721,14454,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616926
,8,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,1722,15818,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616927
,8,485.0,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,1723,13729,,1,,Expert,105,,,,H,,,CHO-K1,BAO_0000219,F,,CHEMBL616928
,9,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,1724,6011,,1,Homo sapiens,Expert,105,,9606.0,,D,,In vitro,,BAO_0000219,B,,CHEMBL616929
,9,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,1725,4234,,1,Homo sapiens,Expert,105,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616930
,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,1726,17085,,1,,Expert,105,,,,H,,,,BAO_0000019,B,,CHEMBL616931
,8,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,1727,3025,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616932
,8,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,1728,15315,,1,,Expert,105,,,,H,,,,BAO_0000357,B,,CHEMBL616933
,9,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,1729,14214,,1,Homo sapiens,Expert,105,,9606.0,,D,,,,BAO_0000219,B,,CHEMBL616934
,9,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,1730,3804,,1,Homo sapiens,Expert,105,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616935
,8,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,1731,16700,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616936
,9,,Affinity for 5-hydroxytryptamine 1D receptor subtype,,1732,2391,,1,Homo sapiens,Expert,105,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616937
,9,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,1733,4175,,1,Homo sapiens,Expert,105,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616938
,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,1734,17085,,1,,Autocuration,105,,,,H,,,,BAO_0000019,B,,CHEMBL616939
,8,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,1735,17085,,1,,Expert,105,,,,H,,,,BAO_0000019,B,,CHEMBL616940
,9,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,1736,15926,,1,Homo sapiens,Expert,105,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616941
,8,485.0,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,1737,16312,,1,,Autocuration,105,,,,H,,,CHO-K1,BAO_0000219,B,,CHEMBL616942
,8,485.0,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,1738,16312,,1,,Autocuration,105,,,,H,,,CHO-K1,BAO_0000219,B,,CHEMBL616943
,4,449.0,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,1739,14956,,1,,Autocuration,104802,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616944
,8,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,1740,3294,,1,,Autocuration,105,,,,H,,,,BAO_0000019,F,,CHEMBL616945
,8,,Binding activity radioligand.,,1741,12861,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616946
,8,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,1742,12861,,1,,Autocuration,105,,,,H,,,,BAO_0000019,B,,CHEMBL616947
,8,485.0,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,1743,16312,,1,,Expert,105,,,,H,,,CHO-K1,BAO_0000219,B,,CHEMBL616948
,8,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,1744,5104,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616851
,8,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,1745,5105,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616852
,8,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,1746,14499,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616853
,9,,Binding activity against human 5-hydroxytryptamine 1D receptor,,1747,15926,,1,Homo sapiens,Expert,105,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616854
,9,449.0,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,1748,4540,,1,Homo sapiens,Expert,105,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL616855
,8,449.0,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,1749,15779,,1,,Autocuration,105,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616856
,8,449.0,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,1750,15779,,1,,Autocuration,105,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616857
,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,1751,6166,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616858
,8,449.0,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,1752,15779,,1,,Autocuration,105,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616859
,8,449.0,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,1753,15779,,1,,Autocuration,105,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616860
,8,722.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,1754,17451,,1,,Autocuration,105,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616861
,8,722.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,1755,17451,,1,,Autocuration,105,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616541
,8,722.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,1756,17451,,1,,Autocuration,105,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616542
,8,449.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,1757,4199,,1,,Autocuration,105,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616543
,9,,Binding affinity for human 5-hydroxytryptamine 1D receptor,,1758,14875,,1,Homo sapiens,Expert,105,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616544
,8,449.0,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,1759,15146,,1,,Autocuration,105,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616545
,8,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,1760,5213,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616546
,8,449.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,1761,14818,,1,,Autocuration,105,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616547
,8,449.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,1762,4829,,1,,Autocuration,105,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616548
,8,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,1763,14454,,1,,Expert,105,,,,H,,,,BAO_0000019,F,,CHEMBL616549
,8,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,1764,14454,,1,,Expert,105,,,,H,,,,BAO_0000019,F,,CHEMBL616550
,8,,Binding affinity against 5-HT2C receptor,,1765,5254,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL857066
,8,,Binding affinity against 5-hydroxytryptamine 1D receptor,,1766,5254,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL616551
,8,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,1767,10639,,1,,Autocuration,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616552
,8,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,1768,10639,,1,,Autocuration,10577,,,,H,,,,BAO_0000019,F,,CHEMBL832876
,8,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,1769,12352,,1,,Expert,10577,,,,H,,,,BAO_0000019,B,,CHEMBL616553
,8,,Binding affinity towards 5-HT1B was determined,,1770,9098,,1,,Autocuration,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616554
,8,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,1771,14430,,1,,Expert,10577,,,,H,,,,BAO_0000019,B,,CHEMBL616555
,8,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,1772,13657,,1,,Expert,10577,,,,H,,,,BAO_0000019,B,,CHEMBL616556
,8,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,1773,13657,,1,,Autocuration,10577,,,,H,,,,BAO_0000019,B,,CHEMBL616557
,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,1774,15854,,1,,Expert,10577,,,,H,,,,BAO_0000019,B,,CHEMBL616558
,9,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,1775,10639,,1,Rattus norvegicus,Expert,10577,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL616749
,8,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,1776,10025,,1,,Autocuration,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616750
,8,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,1777,10025,,1,,Autocuration,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616751
,8,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,1778,14286,,1,,Autocuration,10577,,,,H,,,,BAO_0000249,B,,CHEMBL616752
,8,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,1779,3651,,1,,Autocuration,10577,,,Striatum,H,2435.0,,,BAO_0000019,B,,CHEMBL616753
,9,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,1780,14178,,1,Rattus norvegicus,Expert,10577,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL616754
,8,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,1781,10639,,1,,Autocuration,10577,,,,H,,,,BAO_0000019,B,,CHEMBL616755
,8,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,1782,13605,,1,,Autocuration,10577,,,Striatum,H,2435.0,,,BAO_0000019,B,,CHEMBL616756
,8,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,1783,5834,,1,,Autocuration,10577,,,Striatum,H,2435.0,,,BAO_0000019,B,,CHEMBL616757
,8,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,1784,10922,,1,,Autocuration,10577,,,Striatum,H,2435.0,,,BAO_0000357,B,,CHEMBL616758
,8,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,1785,14286,,1,,Autocuration,10577,,,,H,,,,BAO_0000249,B,,CHEMBL616759
,8,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,1786,11825,,1,,Autocuration,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616760
,8,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,1787,14826,,1,,Autocuration,10577,,,Striatum,H,2435.0,,,BAO_0000019,B,,CHEMBL616761
,8,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,1788,9699,,1,,Autocuration,10577,,,Striatum,H,2435.0,,,BAO_0000019,B,,CHEMBL616762
,8,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,1789,14423,,1,,Autocuration,10577,,,,H,,,,BAO_0000019,B,,CHEMBL616763
,8,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,1790,10062,,1,,Expert,10577,,,,H,,,,BAO_0000357,B,,CHEMBL872909
,8,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,1791,10062,,1,,Autocuration,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616764
,9,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,1792,12280,,1,Rattus norvegicus,Expert,10577,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL616765
,8,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,1793,15412,,1,,Autocuration,10577,,,Striatum,H,2435.0,,,BAO_0000357,B,,CHEMBL616766
,8,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,1794,15412,,1,,Autocuration,10577,,,Striatum,H,2435.0,,,BAO_0000357,B,,CHEMBL616767
,8,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,1795,10062,,1,,Autocuration,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616768
,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,1796,11147,,1,,Autocuration,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616769
,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,1797,9547,,1,,Autocuration,10577,,,,H,,,,BAO_0000019,B,,CHEMBL616770
,8,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,1798,10444,,1,,Autocuration,10577,,,,H,,,,BAO_0000019,B,,CHEMBL616771
,8,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,1799,12469,,1,,Autocuration,10577,,,Striatum,H,2435.0,,,BAO_0000019,B,,CHEMBL616772
,8,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,1800,9098,,1,,Expert,10577,,,,H,,,,BAO_0000019,B,,CHEMBL616773
,8,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,1801,9098,,1,,Autocuration,10577,,,,H,,,,BAO_0000019,B,,CHEMBL616774
,8,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,1802,9699,,1,,Autocuration,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616775
,8,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,1803,10394,,1,,Autocuration,10577,,,,H,,,,BAO_0000249,B,,CHEMBL616776
,8,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,1804,12092,,1,,Autocuration,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616777
,8,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,1805,16700,,1,,Autocuration,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616778
,9,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,1806,403,,1,Rattus norvegicus,Expert,10577,,10116.0,,D,,,,BAO_0000249,B,,CHEMBL616779
,9,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,1807,12771,,1,Rattus norvegicus,Expert,10577,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL616780
,8,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,1808,11642,,1,,Autocuration,10577,,,,H,,,,BAO_0000019,B,,CHEMBL616781
,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,1809,12953,,1,,Autocuration,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616782
,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,1810,12953,,1,,Autocuration,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616783
,8,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,1811,12953,,1,,Expert,10577,,,Striatum,H,2435.0,,,BAO_0000019,B,,CHEMBL616784
,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,1812,12953,,1,,Autocuration,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616785
,8,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,1813,9737,,1,,Autocuration,10577,,,Brain,H,955.0,,,BAO_0000249,B,,CHEMBL857067
,8,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,1814,9737,,1,,Autocuration,10577,,,,H,,,,BAO_0000019,B,,CHEMBL616786
,8,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,1815,9737,,1,,Autocuration,10577,,,Brain,H,955.0,,,BAO_0000249,B,,CHEMBL616787
,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,1816,12827,,1,,Autocuration,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616788
,8,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,1817,5033,,1,,Autocuration,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616789
,9,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,1818,9786,,1,Rattus norvegicus,Expert,10577,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL616790
,8,,Binding affinity at 5-hydroxytryptamine 1B receptor,,1819,13116,,1,,Expert,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616791
,8,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,1820,16429,,1,,Autocuration,10577,,,,H,,,,BAO_0000019,B,,CHEMBL616792
,9,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,1821,12409,,1,Rattus norvegicus,Expert,10577,,10116.0,,D,,,,BAO_0000249,B,,CHEMBL616793
,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,1822,15194,,1,,Autocuration,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616794
,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,1823,15194,,1,,Autocuration,10577,,,,H,,,,BAO_0000357,B,,CHEMBL616795
,4,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,1824,5486,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL616796
,8,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,1825,4639,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616797
,8,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,1826,386,Brain membranes,1,,Autocuration,106,,,,H,,,,BAO_0000249,B,,CHEMBL616798
,8,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,1827,2474,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616799
,8,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,1828,6011,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616800
,8,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,1829,5014,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616801
,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,1830,17515,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616802
,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,1831,4373,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616803
,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,1832,1633,,1,,Expert,106,,,,H,,,,BAO_0000357,B,,CHEMBL857068
,8,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,1833,1633,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616804
,8,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,1834,4373,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616805
,8,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,1835,4687,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616806
,8,,Binding affinity against 5-hydroxytryptamine 1B receptor,,1836,11574,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616807
,8,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,1837,10321,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616808
,8,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,1838,15527,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616809
,8,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,1839,17200,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616810
,4,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,1840,14423,,1,,Autocuration,104802,,,,H,,,,BAO_0000224,B,,CHEMBL616811
,8,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,1841,5834,,1,Bos taurus,Autocuration,108,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL616812
,8,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,1842,11473,,1,Sus scrofa,Autocuration,108,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL616813
,8,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,1843,11473,,1,Sus scrofa,Autocuration,108,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL616814
,8,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,1844,10639,,1,Sus scrofa,Autocuration,108,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL616815
,8,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,1845,10639,,1,Sus scrofa,Autocuration,108,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL616816
,8,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,1846,14331,,1,Sus scrofa,Autocuration,108,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL616817
,8,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,1847,10796,,1,Sus scrofa,Autocuration,108,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL616818
,8,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,1848,9098,,1,Sus scrofa,Expert,108,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL616819
,8,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,1849,14331,,1,Sus scrofa,Expert,108,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL616820
,8,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,1850,11828,,1,Sus scrofa,Expert,108,,9823.0,,H,,,,BAO_0000019,B,,CHEMBL616821
,8,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,1851,11866,,1,Sus scrofa,Autocuration,108,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL616822
,8,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,1852,13047,,1,Oryctolagus cuniculus,Autocuration,108,,9986.0,,H,,,,BAO_0000019,B,,CHEMBL616823
,9,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,1853,188,,1,Rattus norvegicus,Autocuration,12689,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL616824
,9,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,1854,11825,,1,Rattus norvegicus,Autocuration,12689,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL616825
,9,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,1855,11825,,1,Rattus norvegicus,Autocuration,12689,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL616826
,9,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,1856,11624,,1,Rattus norvegicus,Expert,12689,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL616827
,9,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,1857,11139,,1,Rattus norvegicus,Autocuration,12689,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL616828
,9,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,1858,11147,,1,Rattus norvegicus,Autocuration,12689,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL616829
,9,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,1859,10444,,1,Rattus norvegicus,Autocuration,12689,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL616830
,9,,Binding affinity against 5-hydroxytryptamine 1C receptor,,1860,11624,,1,Rattus norvegicus,Expert,12689,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL616831
,9,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,1861,11662,,1,Rattus norvegicus,Autocuration,12689,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL616832
,9,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,1862,11662,,1,Rattus norvegicus,Autocuration,12689,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL616833
,9,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,1863,11662,,1,Rattus norvegicus,Expert,12689,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL616834
,9,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,1864,11662,,1,Rattus norvegicus,Autocuration,12689,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL829595
,9,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,1865,9098,,1,Rattus norvegicus,Autocuration,12689,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL616835
,9,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,1866,10394,,1,Rattus norvegicus,Autocuration,12689,,10116.0,,D,,,,BAO_0000249,B,,CHEMBL872910
,8,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,1867,11933,,1,,Expert,12689,,,,H,,,,BAO_0000357,B,,CHEMBL616836
,9,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,1868,12092,,1,Rattus norvegicus,Autocuration,12689,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL616837
,9,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,1869,12253,,1,Rattus norvegicus,Autocuration,12689,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL616466
,9,722.0,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,1870,12253,,1,Rattus norvegicus,Autocuration,12689,,10116.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL616467
,8,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,1871,1558,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL616468
,8,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,1872,2474,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL616469
,8,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,1873,2474,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL616470
,8,,Binding affinity against 5-hydroxytryptamine 1C receptor,,1874,11574,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL616471
,8,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,1875,1558,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL616472
,8,,Binding affinity against 5-hydroxytryptamine 1C receptor,,1876,13944,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL616473
,8,,Binding affinity against serotonergic 5-HT1c receptor,,1877,13033,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL616474
,8,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,1878,10321,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL616475
,8,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,1879,11866,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL616476
,8,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,1880,14454,,1,Oryctolagus cuniculus,Autocuration,105,,9986.0,,H,,,,BAO_0000019,B,,CHEMBL616477
,4,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,1881,11574,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616478
,4,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,1882,11574,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616479
,4,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,1883,13631,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL616480
,5,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,1884,9630,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL616481
,5,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,1885,8822,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000249,B,,CHEMBL616482
,5,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,1886,9064,,1,Rattus norvegicus,Autocuration,104686,,10116.0,Brain,D,955.0,,,BAO_0000221,B,,CHEMBL884713
,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,1887,8868,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616483
,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,1888,9064,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616484
,4,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,1889,9806,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL616485
,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,1890,9098,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616486
,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,1891,8868,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616487
,4,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,1892,12765,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616488
,4,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,1893,11049,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL616489
,4,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,1894,11049,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL616490
,4,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,1895,11049,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL616491
,4,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,1896,11049,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL616492
,4,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,1897,11049,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL616493
,4,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,1898,11473,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL616494
,4,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,1899,11473,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL616495
,4,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,1900,3086,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL616496
,4,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,1901,11049,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL616497
,4,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,1902,11049,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL616498
,4,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,1903,10639,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL616499
,4,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,1904,10922,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL616500
,5,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,1905,9064,,1,Rattus norvegicus,Autocuration,104686,,10116.0,Brain,D,955.0,,,BAO_0000221,B,,CHEMBL616501
,4,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,1906,10748,,1,,Autocuration,104686,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL616502
,4,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,1907,11614,Membranes,1,,Autocuration,104686,,,,H,,,,BAO_0000249,B,,CHEMBL884529
,4,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,1908,11615,Membranes,1,,Autocuration,104686,,,,H,,,,BAO_0000249,B,,CHEMBL616503
,4,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,1909,11615,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616964
,4,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,1910,11614,Membranes,1,,Autocuration,104686,,,,H,,,,BAO_0000249,B,,CHEMBL616965
,4,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,1911,11702,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616966
,4,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,1912,11702,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616967
,5,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,1913,11702,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000224,B,,CHEMBL616968
,4,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,1914,11702,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616969
,4,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,1915,13346,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL884530
,4,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,1916,10025,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616970
,4,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,1917,10025,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616971
,4,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,1918,10025,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616972
,4,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,1919,9036,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616973
,4,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,1920,9036,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616974
,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,1921,9161,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL616975
,4,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,1922,12304,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL616976
,4,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,1923,13276,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616977
,4,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,1924,11825,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616978
,4,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,1925,12443,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616979
,4,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,1926,13830,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616980
,4,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,1927,9592,Membranes,1,,Autocuration,104686,,,,H,,,,BAO_0000249,B,,CHEMBL616981
,4,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,1928,9592,Membranes,1,,Autocuration,104686,,,,H,,,,BAO_0000249,B,,CHEMBL616982
,4,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,1929,10881,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616983
,4,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,1930,13605,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL616984
,5,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,1931,11624,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000224,B,,CHEMBL616985
,4,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,1932,4101,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616986
,4,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,1933,4101,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL616987
,4,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,1934,15360,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL616988
,4,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,1935,11576,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617243
,4,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,1936,5834,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617244
,5,485.0,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,1937,2395,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,CHO-K1,BAO_0000219,B,,CHEMBL617245
,4,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,1938,11965,Membranes,1,,Autocuration,104686,,,,H,,,,BAO_0000249,B,,CHEMBL617246
,4,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,1939,3967,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617546
,4,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,1940,11130,Brain membranes,1,,Autocuration,104686,,,,H,,,,BAO_0000249,B,,CHEMBL617547
,4,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,1941,13427,,1,,Autocuration,104686,,,,H,,In vitro,,BAO_0000219,B,,CHEMBL617548
,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,1942,9443,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617549
,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,1943,9443,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617550
,4,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,1944,11825,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617551
,4,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,1945,12120,Membranes,1,,Autocuration,104686,,,,H,,,,BAO_0000249,B,,CHEMBL617552
,4,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,1946,12120,Membranes,1,,Autocuration,104686,,,,H,,,,BAO_0000249,B,,CHEMBL617553
,4,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,1947,11963,,1,,Autocuration,104686,,,Thoracic aorta,H,1515.0,,,BAO_0000019,F,,CHEMBL617554
,4,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,1948,9069,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617555
,4,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,1949,8868,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617556
,8,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,1950,17200,,1,,Autocuration,10624,,,,H,,,,BAO_0000357,B,,CHEMBL617557
,8,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,1951,17200,,1,,Autocuration,10624,,,,H,,,,BAO_0000357,B,,CHEMBL617558
,8,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,1952,13969,,1,,Expert,17106,,,,H,,,,BAO_0000357,B,,CHEMBL617559
,9,,Binding affinity for 5-hydroxytryptamine 1D receptor,,1953,13392,,1,,Expert,17106,,,,D,,,,BAO_0000357,B,,CHEMBL617560
,8,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,1954,1742,,1,,Autocuration,17106,,,,H,,,,BAO_0000249,B,,CHEMBL617561
,8,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,1955,1742,,1,,Autocuration,17106,,,,H,,,,BAO_0000249,B,,CHEMBL617562
,8,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,1956,14331,,1,,Autocuration,17106,,,Striatum,H,2435.0,,,BAO_0000357,B,,CHEMBL617563
,8,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,1957,12861,,1,,Autocuration,17106,,,,H,,,,BAO_0000019,F,,CHEMBL617564
,8,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,1958,12861,,1,,Expert,17106,,,,H,,,,BAO_0000019,B,,CHEMBL617565
,8,,Binding activity radioligand.,,1959,12861,,1,,Autocuration,17106,,,,H,,,,BAO_0000357,B,,CHEMBL856076
,8,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,1960,12861,,1,,Autocuration,17106,,,,H,,,,BAO_0000019,B,,CHEMBL617566
,8,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,1961,12861,,1,,Expert,17106,,,,H,,,,BAO_0000019,B,,CHEMBL875911
,8,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,1962,12861,,1,,Autocuration,17106,,,,H,,,,BAO_0000019,B,,CHEMBL617567
,8,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,1963,675,,1,,Autocuration,17106,,,,H,,,,BAO_0000249,B,,CHEMBL617568
,8,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,1964,12490,,1,,Expert,17106,,,,H,,,,BAO_0000019,B,,CHEMBL617569
,8,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,1965,11828,,1,,Expert,17106,,,,H,,,,BAO_0000249,B,,CHEMBL617570
,8,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,1966,11866,,1,,Autocuration,17106,,,,H,,,,BAO_0000357,B,,CHEMBL617571
,8,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,1967,773,,1,Sus scrofa,Autocuration,105,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL617572
,8,,The compound was tested for intrinsic activity against 5-HT1D receptor,,1968,13047,,1,Oryctolagus cuniculus,Expert,105,,9986.0,,H,,,,BAO_0000357,B,,CHEMBL617573
,8,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,1969,13047,,1,Oryctolagus cuniculus,Autocuration,105,,9986.0,,H,,,,BAO_0000019,B,,CHEMBL617574
,8,,The compound was tested for binding affinity against 5-HT1D receptor,,1970,13047,,1,Oryctolagus cuniculus,Expert,105,,9986.0,,H,,,,BAO_0000357,B,,CHEMBL617575
,8,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,1971,188,,1,,Autocuration,10578,,,,H,,,,BAO_0000357,B,,CHEMBL617576
,8,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,1972,10639,,1,,Autocuration,10578,,,,H,,,,BAO_0000019,F,,CHEMBL617577
,8,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,1973,12438,,1,,Autocuration,10578,,,,H,,,,BAO_0000019,F,,CHEMBL617578
,8,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,1974,12438,,1,,Autocuration,10578,,,,H,,,,BAO_0000357,B,,CHEMBL617579
,8,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,1975,15854,,1,,Expert,10578,,,,H,,,,BAO_0000019,B,,CHEMBL617580
,8,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,1976,10394,,1,,Autocuration,10578,,,,H,,,,BAO_0000249,B,,CHEMBL617581
,8,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,1977,12092,,1,,Autocuration,10578,,,,H,,,,BAO_0000357,B,,CHEMBL617582
,8,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,1978,3389,,1,,Expert,10578,,,,H,,,,BAO_0000019,B,,CHEMBL617583
,8,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,1979,6011,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL617584
,8,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,1980,4639,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL617585
,8,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,1981,2474,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL875912
,8,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,1982,5014,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL617586
,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,1983,17515,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL617587
,8,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,1984,11866,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL617588
,8,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,1985,4687,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL857980
,8,,Tested against 5-hydroxytryptamine 1D receptor,,1986,12146,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL617589
,8,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,1987,10321,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL617590
,8,722.0,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,1988,13267,,1,,Autocuration,105,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617591
,9,,Binding affinity against 5-Hydroxytryptamine 1D receptor,,1989,1274,,1,Homo sapiens,Expert,105,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL617592
,8,,,,1990,15250,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL617593
,8,485.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,1991,13706,,1,,Autocuration,106,,,,H,,,CHO-K1,BAO_0000219,B,,CHEMBL617594
,8,485.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,1992,13706,,1,,Autocuration,105,,,,H,,,CHO-K1,BAO_0000219,B,,CHEMBL617595
,8,722.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,1993,13706,,1,,Autocuration,105,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617596
,8,722.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,1994,13706,,1,,Autocuration,105,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617597
,8,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,1995,13047,,1,,Autocuration,105,,,,H,,,,BAO_0000019,B,,CHEMBL617598
,8,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,1996,13366,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL872916
,8,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,1997,13366,,1,,Expert,105,,,,H,,,,BAO_0000357,B,,CHEMBL617599
,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,1998,1558,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL617091
,8,485.0,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,1999,12902,,1,,Expert,105,,,,H,,,CHO-K1,BAO_0000219,B,,CHEMBL617092
,8,485.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,2000,13706,,1,,Autocuration,105,,,,H,,,CHO-K1,BAO_0000219,B,,CHEMBL617093
,8,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,2001,13706,,1,,Autocuration,105,,,,H,,,,BAO_0000019,F,,CHEMBL617094
,8,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,2002,13706,,1,,Autocuration,105,,,,H,,,,BAO_0000019,F,,CHEMBL617095
,8,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,2003,14251,,1,,Autocuration,105,,,,H,,,,BAO_0000019,F,,CHEMBL617096
,8,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,2004,14251,,1,,Autocuration,105,,,,H,,,,BAO_0000019,F,,CHEMBL617097
,8,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,2005,14251,,1,,Autocuration,105,,,,H,,,,BAO_0000019,F,,CHEMBL617098
,8,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,2006,13313,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL617301
,8,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,2007,13313,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL617302
,8,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,2008,13366,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL617303
,8,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,2009,13051,,1,,Expert,105,,,,H,,,,BAO_0000357,B,,CHEMBL617304
,8,449.0,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,2010,12903,,1,,Expert,105,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617305
,9,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,2011,12469,,1,Homo sapiens,Autocuration,105,,9606.0,,D,,,,BAO_0000219,B,,CHEMBL617306
,8,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,2012,5619,,1,,Autocuration,17106,,,,H,,,,BAO_0000357,B,,CHEMBL617307
,8,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,2013,13047,,1,Oryctolagus cuniculus,Autocuration,105,,9986.0,,H,,,,BAO_0000019,B,,CHEMBL617308
,8,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,2014,16633,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL617309
,8,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,2015,16633,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL617310
,8,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,2016,16633,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL617311
,8,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,2017,16633,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL617312
,8,,Affinity against 5-hydroxytryptamine 1D receptor alpha,,2018,3269,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL617313
,8,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,2019,12409,,1,,Expert,105,,,,H,,,,BAO_0000357,B,,CHEMBL617314
,8,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,2020,13706,,1,,Autocuration,106,,,,H,,,,BAO_0000019,F,,CHEMBL617315
,8,722.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,2021,13706,,1,,Autocuration,106,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617316
,8,722.0,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,2022,13706,,1,,Autocuration,106,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617317
,8,449.0,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,2023,12903,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617318
,8,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,2024,13047,,1,,Autocuration,106,,,,H,,,,BAO_0000019,B,,CHEMBL617319
,9,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,2025,13366,,1,,Expert,106,,,,D,,,,BAO_0000357,B,,CHEMBL617320
,9,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,2026,13366,,1,,Expert,106,,,,D,,,,BAO_0000357,B,,CHEMBL617321
,9,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,2027,13366,,1,,Expert,106,,,,D,,,,BAO_0000357,B,,CHEMBL617322
,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,2028,13366,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616862
,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,2029,13366,,1,,Autocuration,106,,,,H,,,,BAO_0000357,B,,CHEMBL616863
,8,449.0,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,2030,12469,,1,,Autocuration,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616864
,8,485.0,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,2031,13706,,1,,Autocuration,106,,,,H,,,CHO-K1,BAO_0000219,B,,CHEMBL616865
,8,485.0,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,2032,13706,,1,,Autocuration,106,,,,H,,,CHO-K1,BAO_0000219,B,,CHEMBL616866
,8,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,2033,13706,,1,,Autocuration,106,,,,H,,,,BAO_0000019,F,,CHEMBL616867
,8,485.0,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,2034,12902,,1,,Expert,106,,,,H,,,CHO-K1,BAO_0000219,B,,CHEMBL616868
,8,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,2035,13051,,1,,Expert,105,,,,H,,,,BAO_0000357,B,,CHEMBL616869
,8,449.0,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,2036,12903,,1,,Expert,106,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616870
,8,485.0,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,2037,1558,,1,,Autocuration,105,,,,H,,,CHO-K1,BAO_0000219,F,,CHEMBL616871
,8,485.0,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,2038,1558,,1,,Autocuration,105,,,,H,,,CHO-K1,BAO_0000219,F,,CHEMBL616872
,8,485.0,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,2039,1558,,1,,Autocuration,105,,,,H,,,CHO-K1,BAO_0000219,F,,CHEMBL616873
,8,485.0,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,2040,1558,,1,,Autocuration,105,,,,H,,,CHO-K1,BAO_0000219,F,,CHEMBL616838
,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,2041,1558,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616839
,8,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,2042,13047,,1,Oryctolagus cuniculus,Autocuration,106,,9986.0,,H,,,,BAO_0000019,B,,CHEMBL616840
,8,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,2043,13313,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616841
,8,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,2044,13313,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL616842
,8,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,2045,12409,,1,,Expert,105,,,,H,,,,BAO_0000357,B,,CHEMBL857976
,8,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,2046,15250,,1,,Autocuration,10618,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616843
,9,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,2047,1348,,1,Homo sapiens,Expert,10618,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616844
,8,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,2048,1348,,1,,Autocuration,10618,,,,H,,,,BAO_0000357,B,,CHEMBL616845
,9,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,2049,4234,,1,Homo sapiens,Expert,10618,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616846
,8,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,2050,16209,,1,,Autocuration,10618,,,,H,,,,BAO_0000357,B,,CHEMBL616847
,8,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,2051,10444,,1,,Autocuration,10618,,,,H,,,,BAO_0000019,B,,CHEMBL616848
,8,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,2052,3935,,1,,Autocuration,10618,,,,H,,,,BAO_0000357,B,,CHEMBL616849
,8,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,2053,15818,,1,,Autocuration,10618,,,,H,,,,BAO_0000357,B,,CHEMBL872911
,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,2054,17085,,1,,Autocuration,10618,,,,H,,,,BAO_0000019,B,,CHEMBL616850
,9,449.0,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,2055,12936,,1,Homo sapiens,Expert,10618,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL616699
,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,2056,6166,,1,,Autocuration,10618,,,,H,,,,BAO_0000357,B,,CHEMBL616700
,8,449.0,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,2057,15779,,1,,Autocuration,10618,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616701
,8,449.0,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,2058,15779,,1,,Autocuration,10618,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616702
,8,449.0,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,2059,15779,,1,,Autocuration,10618,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616703
,8,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,2060,13181,,1,,Autocuration,10618,,,,H,,,,BAO_0000357,B,,CHEMBL616704
,8,449.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,2061,4199,,1,,Autocuration,10618,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616705
,8,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,2062,14875,,1,,Autocuration,10618,,,,H,,,,BAO_0000357,B,,CHEMBL616706
,8,449.0,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,2063,15146,,1,,Autocuration,10618,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616707
,8,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,2064,5213,,1,,Autocuration,10618,,,,H,,,,BAO_0000357,B,,CHEMBL616708
,8,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,2065,12146,,1,,Autocuration,10618,,,,H,,,,BAO_0000357,B,,CHEMBL616709
,8,449.0,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,2066,13267,,1,,Autocuration,10618,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616710
,8,449.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,2067,14818,,1,,Autocuration,10618,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616711
,8,449.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,2068,4829,,1,,Autocuration,10618,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616712
,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,2069,4373,,1,,Autocuration,10618,,,,H,,,,BAO_0000357,B,,CHEMBL616713
,8,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,2070,4373,,1,,Autocuration,10618,,,,H,,,,BAO_0000357,B,,CHEMBL616714
,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,2071,14159,,1,,Autocuration,10618,,,,H,,,,BAO_0000357,B,,CHEMBL616715
,8,,Binding affinity towards 5-hydroxytryptamine 1E receptor,,2072,16633,,1,,Autocuration,10618,,,,H,,,,BAO_0000357,B,,CHEMBL616716
,8,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,2073,17085,,1,,Autocuration,279,,,,H,,,,BAO_0000019,F,,CHEMBL616717
,8,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,2074,17085,,1,,Expert,279,,,,H,,,,BAO_0000019,F,,CHEMBL616718
,8,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,2075,16209,,1,,Autocuration,279,,,,H,,,,BAO_0000019,F,,CHEMBL875905
,8,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,2076,16209,,1,,Autocuration,279,,,,H,,,,BAO_0000019,F,,CHEMBL616719
,8,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,2077,17085,,1,,Expert,279,,,,H,,,,BAO_0000019,F,,CHEMBL616720
,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,2078,14159,,1,,Autocuration,279,,,,H,,,,BAO_0000357,B,,CHEMBL616721
,8,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,2079,15250,,1,,Autocuration,279,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616722
,8,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,2080,3805,,1,,Autocuration,279,,,,H,,,,BAO_0000357,B,,CHEMBL616723
,8,449.0,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,2081,16190,,1,,Autocuration,279,,,,H,,,CHO,BAO_0000219,B,,CHEMBL616724
,8,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,2082,16190,,1,,Autocuration,279,,,,H,,,,BAO_0000357,B,,CHEMBL616725
,8,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,2083,16209,,1,,Autocuration,279,,,,H,,,,BAO_0000357,B,,CHEMBL616726
,8,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,2084,16209,,1,,Autocuration,279,,,,H,,,,BAO_0000357,B,,CHEMBL616727
,8,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,2085,16209,,1,,Autocuration,279,,,,H,,,,BAO_0000357,B,,CHEMBL616728
,8,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,2086,6866,,1,,Autocuration,279,,,,H,,,,BAO_0000357,B,,CHEMBL616729
,8,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,2087,17085,,1,,Expert,279,,,,H,,,,BAO_0000019,B,,CHEMBL616730
,8,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,2088,16312,,1,,Autocuration,279,,,,H,,,,BAO_0000357,B,,CHEMBL617125
,8,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,2089,6166,,1,,Autocuration,279,,,,H,,,,BAO_0000357,B,,CHEMBL857977
,8,449.0,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,2090,15779,,1,,Autocuration,279,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617126
,8,449.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,2091,4199,,1,,Autocuration,279,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617127
,8,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,2092,14875,,1,,Autocuration,279,,,,H,,,,BAO_0000357,B,,CHEMBL617128
,8,449.0,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,2093,15146,,1,,Autocuration,279,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617129
,8,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,2094,5213,,1,,Autocuration,279,,,,H,,,,BAO_0000357,B,,CHEMBL617130
,8,449.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,2095,14818,,1,,Autocuration,279,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617131
,8,449.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,2096,4829,,1,,Autocuration,279,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617132
,8,449.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,2097,4829,,1,,Autocuration,279,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617133
,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,2098,4373,,1,,Autocuration,279,,,,H,,,,BAO_0000357,B,,CHEMBL617134
,8,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,2099,4373,,1,,Autocuration,279,,,,H,,,,BAO_0000357,B,,CHEMBL617135
,8,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,2100,5014,,1,,Autocuration,279,,,,H,,,,BAO_0000357,B,,CHEMBL617136
,4,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,2101,11662,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617137
,4,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,2102,11662,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617138
,4,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,2103,11662,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617139
,8,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,2104,14093,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617140
,4,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,2105,11200,,1,,Autocuration,104686,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617141
,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,2106,11200,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,F,,CHEMBL858112
,8,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,2107,12352,,1,,Intermediate,17005,,,,H,,,,BAO_0000019,B,,CHEMBL617142
,0,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,2108,13657,,1,Bos taurus,Autocuration,22226,,9913.0,,U,,,,BAO_0000019,B,,CHEMBL617143
,0,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,2109,14331,,1,Bos taurus,Autocuration,22226,,9913.0,,U,,,,BAO_0000019,B,,CHEMBL617144
,0,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,2110,14331,,1,Bos taurus,Autocuration,22226,,9913.0,,U,,,,BAO_0000019,B,,CHEMBL617145
,0,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,2111,14331,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL617146
,4,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,2112,12685,,1,Cavia porcellus,Autocuration,104784,,10141.0,,H,,,,BAO_0000019,B,,CHEMBL617147
,4,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,2113,14389,,1,Cavia porcellus,Autocuration,104784,,10141.0,,H,,,,BAO_0000019,B,,CHEMBL617148
,4,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,2114,14386,,1,Cavia porcellus,Autocuration,104784,,10141.0,,H,,,,BAO_0000019,B,,CHEMBL617149
,4,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,2115,5732,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL617150
,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,2116,16293,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL617151
,4,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,2117,2078,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL617201
,8,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,2118,5486,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL617202
,4,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,2119,11820,,1,,Autocuration,104826,,,,H,,In vivo,,BAO_0000218,B,,CHEMBL617203
,4,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,2120,10297,,1,,Autocuration,104826,,,,H,,,,BAO_0000019,B,,CHEMBL617204
,4,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,2121,13704,,1,,Autocuration,104826,,,,H,,,,BAO_0000224,B,,CHEMBL617205
,5,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,2122,10297,,1,Mus musculus,Autocuration,104826,,10090.0,,D,,,,BAO_0000019,B,,CHEMBL617206
,4,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,2123,11820,,1,,Autocuration,104826,,,,H,,In vivo,,BAO_0000218,B,,CHEMBL617207
,5,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,2124,10297,,1,Mus musculus,Autocuration,104826,,10090.0,,D,,,,BAO_0000019,B,,CHEMBL617208
,4,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,2125,11555,,1,,Autocuration,104826,,,,H,,,,BAO_0000224,B,,CHEMBL617209
,4,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,2126,11555,,1,,Autocuration,104826,,,,H,,,,BAO_0000224,B,,CHEMBL617210
,4,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,2127,11555,,1,,Autocuration,104826,,,,H,,,,BAO_0000224,B,,CHEMBL617211
,5,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,2128,10297,,1,Mus musculus,Autocuration,104826,,10090.0,,D,,,,BAO_0000019,B,,CHEMBL617212
,4,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,2129,16688,,1,Sus scrofa,Autocuration,104784,,9823.0,,H,,,,BAO_0000224,B,,CHEMBL617213
,4,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,2130,16688,,1,Sus scrofa,Autocuration,104784,,9823.0,,H,,,,BAO_0000224,B,,CHEMBL617214
,0,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,2131,5333,,1,,Autocuration,22226,,,,U,,,,BAO_0000221,B,,CHEMBL617215
,0,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,2132,4437,,1,,Autocuration,22226,,,,U,,,,BAO_0000221,B,,CHEMBL617216
,8,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,2133,5033,,1,Sus scrofa,Autocuration,17005,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL617217
,4,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,2134,15267,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617218
,4,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,2135,15267,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL872913
,4,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,2136,11820,,1,,Autocuration,104826,,,,H,,,,BAO_0000019,B,,CHEMBL617219
,4,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,2137,9069,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL873482
,5,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,2138,9162,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617220
,4,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,2139,9162,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617221
,4,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,2140,9162,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617222
,4,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,2141,10428,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,F,,CHEMBL875906
,4,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,2142,9628,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617223
,4,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,2143,12704,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617224
,5,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,2144,15453,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000224,B,,CHEMBL617225
,4,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,2145,188,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617226
,4,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,2146,10349,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617227
,4,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,2147,10349,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617228
,4,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,2148,8868,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617229
,4,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,2149,10025,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617230
,4,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,2150,10025,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617231
,4,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,2151,11702,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617232
,4,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,2152,11702,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617233
,4,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,2153,11702,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617234
,4,,Compound was tested for the inhibition of quipazine induced head twitches in rats,,2154,11702,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,F,,CHEMBL617235
,4,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,2155,11702,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,F,,CHEMBL617236
,4,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,2156,10085,,1,,Autocuration,104686,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL617237
,4,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,2157,10085,,1,,Autocuration,104686,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL617238
,5,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,2158,9630,,1,Rattus norvegicus,Autocuration,104686,,10116.0,Brain,D,955.0,,,BAO_0000221,B,,CHEMBL617239
,4,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,2159,11070,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617240
,4,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,2160,9841,Membranes,1,,Autocuration,104686,,,,H,,,,BAO_0000249,B,,CHEMBL617241
,4,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,2161,9841,Membranes,1,,Autocuration,104686,,,,H,,,,BAO_0000249,B,,CHEMBL875907
,4,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,2162,13291,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617242
,4,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,2163,10590,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,F,,CHEMBL617152
,5,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,2164,9064,,1,Rattus norvegicus,Autocuration,104686,,10116.0,Brain,D,955.0,,,BAO_0000221,B,,CHEMBL617153
,5,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,2165,12268,Membranes,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000249,B,,CHEMBL617154
,4,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,2166,13508,,1,,Autocuration,104686,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL617155
,4,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,2167,11279,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,F,,CHEMBL617156
,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,2168,11200,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,F,,CHEMBL617157
,4,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,2169,11200,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,F,,CHEMBL617158
,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,2170,11200,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,F,,CHEMBL617159
,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,2171,11200,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,F,,CHEMBL617160
,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,2172,11200,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,F,,CHEMBL858113
,4,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,2173,9231,,1,,Autocuration,104686,,,Brain,H,955.0,,,BAO_0000220,B,,CHEMBL617247
,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,2174,9737,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617248
,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,2175,9737,,1,,Autocuration,104686,,,Brain,H,955.0,,,BAO_0000249,B,,CHEMBL617249
,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,2176,9737,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617250
,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,2177,9737,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617251
,5,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,2178,11828,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617252
,4,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,2179,12253,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617006
,4,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,2180,12253,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617007
,4,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,2181,11279,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,F,,CHEMBL617008
,4,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,2182,11866,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617009
,5,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,2183,14424,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000224,B,,CHEMBL617010
,5,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,2184,15180,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL857978
,5,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,2185,15180,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617011
,5,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,2186,9786,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617012
,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,2187,12132,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617013
,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,2188,5486,,1,,Autocuration,104686,,,,H,,,,BAO_0000249,B,,CHEMBL617014
,4,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,2189,15316,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617015
,4,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,2190,16429,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617016
,4,,pKi value for 5-hydroxytryptamine 2 receptor binding site,,2191,14617,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617017
,4,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,2192,11351,,1,,Autocuration,104686,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL617018
,4,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,2193,11279,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,F,,CHEMBL617019
,4,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,2194,9523,,1,,Autocuration,105075,,,,H,,,,BAO_0000019,B,,CHEMBL617020
,4,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,2195,9523,,1,,Autocuration,105075,,,,H,,,,BAO_0000019,B,,CHEMBL617021
,4,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,2196,9523,,1,,Autocuration,105075,,,,H,,,,BAO_0000019,B,,CHEMBL617022
,4,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,2197,9523,,1,,Autocuration,105075,,,,H,,,,BAO_0000019,B,,CHEMBL617023
,4,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,2198,9523,,1,,Autocuration,105075,,,,H,,,,BAO_0000019,B,,CHEMBL617024
,4,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,2199,9523,,1,,Autocuration,105075,,,,H,,,,BAO_0000019,B,,CHEMBL617025
,4,,Hill coefficient of compound was determined,,2200,9523,,1,,Autocuration,105075,,,,H,,,,BAO_0000224,B,,CHEMBL617026
,0,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,2201,4771,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL617027
,5,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,2202,5033,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617028
,8,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,2203,10845,,1,,Expert,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617029
,8,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,2204,10845,,1,,Expert,12687,,,,H,,,,BAO_0000019,B,,CHEMBL875908
,8,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,2205,16288,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617030
,8,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,2206,16288,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617031
,8,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,2207,16190,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617032
,5,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,2208,12463,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000224,B,,CHEMBL617033
,4,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,2209,9699,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617034
,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,2210,9699,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617035
,4,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,2211,11662,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617036
,4,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,2212,1205,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL617037
,0,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,2213,11376,,1,,Autocuration,22226,,,,U,,,,BAO_0000219,B,,CHEMBL617038
,4,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,2214,11376,,1,,Autocuration,104784,,,,H,,,,BAO_0000219,B,,CHEMBL617039
,4,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,2215,4639,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL617161
,4,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,2216,2222,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL617162
,4,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,2217,1558,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL617163
,4,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,2218,1089,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL617164
,4,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,2219,386,Brain membranes,1,,Autocuration,104784,,,,H,,,,BAO_0000249,B,,CHEMBL617165
,4,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,2220,2474,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL617166
,4,,Binding affinity towards 5-HT2 receptor,,2221,17066,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL617167
,4,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,2222,959,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL872912
,4,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,2223,6398,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL617168
,4,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,2224,11889,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617169
,4,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,2225,4221,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL617170
,4,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,2226,11026,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL617171
,4,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,2227,11866,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL617172
,4,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,2228,4221,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL617173
,0,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,2229,13950,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL617174
,4,,5-hydroxytryptamine 2 receptor binding affinity,,2230,1263,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL617175
,8,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,2231,13291,,1,,Autocuration,17005,,,,H,,,,BAO_0000357,B,,CHEMBL617176
,8,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,2232,10812,,1,,Autocuration,17005,,,,H,,,,BAO_0000357,B,,CHEMBL617177
,4,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,2233,13020,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL617178
,4,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,2234,13021,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL617179
,4,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,2235,13020,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL617180
,8,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,2236,14532,,1,,Autocuration,17005,,,,H,,,,BAO_0000357,B,,CHEMBL617181
,8,,Binding affinity against 5-hydroxytryptamine 2 receptor,,2237,13944,,1,,Autocuration,17005,,,,H,,,,BAO_0000357,B,,CHEMBL617182
,8,,Binding affinity against 5-hydroxytryptamine 2 receptor,,2238,14331,,1,,Autocuration,17005,,,,H,,,,BAO_0000357,B,,CHEMBL617183
,8,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,2239,14118,,1,,Autocuration,17005,,,,H,,,,BAO_0000357,B,,CHEMBL617184
,8,,Binding affinity against serotonergic 5-HT2 receptor,,2240,13033,,1,,Autocuration,17005,,,,H,,,,BAO_0000357,B,,CHEMBL617185
,8,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,2241,10321,,1,,Autocuration,17005,,,,H,,,,BAO_0000357,B,,CHEMBL617186
,8,,Compound was evaluated for the binding affinity at 5- HT2 receptor,,2242,12918,,1,,Autocuration,17005,,,,H,,,,BAO_0000357,B,,CHEMBL617187
,8,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,2243,15120,,1,,Autocuration,17005,,,,H,,,,BAO_0000357,B,,CHEMBL617188
,8,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,2244,2613,,1,,Autocuration,17005,,,,H,,,,BAO_0000218,B,,CHEMBL617189
,5,,Inhibitory activity against cloned human 5-HT2 receptor,,2245,13378,,1,Homo sapiens,Autocuration,104784,,9606.0,,D,,,,BAO_0000224,B,,CHEMBL617190
,5,449.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,2246,2331,,1,Homo sapiens,Autocuration,104784,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL617191
,5,449.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,2247,2331,,1,Homo sapiens,Autocuration,104784,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL617192
,5,449.0,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,2248,2331,,1,Homo sapiens,Autocuration,104784,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL617193
,5,449.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,2249,2331,,1,Homo sapiens,Autocuration,104784,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL617194
,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,2250,4170,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL617195
,4,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,2251,15453,,1,,Autocuration,104784,,,,H,,,,BAO_0000224,B,,CHEMBL881830
,8,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,2252,1479,,1,,Autocuration,17005,,,,H,,,,BAO_0000357,B,,CHEMBL617196
,4,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,2253,11139,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617197
,8,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,2254,13969,,1,,Expert,17005,,,,H,,,,BAO_0000357,B,,CHEMBL617198
,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,2255,13392,,1,,Expert,17005,,,,H,,,,BAO_0000357,B,,CHEMBL873476
,8,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,2256,14430,,1,,Expert,17005,,,,H,,,,BAO_0000019,B,,CHEMBL617199
,8,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,2257,13181,,1,Cavia porcellus,Autocuration,107,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL617200
,8,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,2258,17200,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL617484
,8,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,2259,17200,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617485
,8,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,2260,17200,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL617486
,8,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,2261,13463,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL858022
,8,449.0,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,2262,6347,,1,,Autocuration,107,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617049
,9,449.0,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,2263,6857,,1,Homo sapiens,Expert,107,,9606.0,,D,,,CHO,BAO_0000219,F,,CHEMBL617050
,8,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,2264,4176,,1,,Autocuration,107,,,,H,,,,BAO_0000219,F,,CHEMBL617051
,8,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,2265,4176,,1,,Autocuration,107,,,,H,,,,BAO_0000219,F,,CHEMBL617052
,8,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,2266,4176,,1,,Autocuration,107,,,,H,,,,BAO_0000219,F,,CHEMBL617053
,8,449.0,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,2267,6347,,1,,Autocuration,107,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617054
,8,449.0,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,2268,6347,,1,,Autocuration,107,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617055
,8,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,2269,15331,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL882924
,9,,Inhibition of human 5-hydroxytryptamine 2A receptor,,2270,16146,,1,Homo sapiens,Expert,107,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL617056
,8,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,2271,15250,,1,,Autocuration,107,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617057
,8,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,2272,13631,,1,,Expert,107,,,,H,,,,BAO_0000219,B,,CHEMBL617058
,8,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,2273,3805,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617059
,8,449.0,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,2274,4011,,1,,Autocuration,107,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617060
,8,449.0,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,2275,4012,,1,,Expert,107,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617061
,8,307.0,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,2276,6366,,1,,Expert,107,,,,H,,,L929,BAO_0000219,B,,CHEMBL617062
,8,449.0,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,2277,15949,,1,,Expert,107,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617063
,8,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,2278,14093,,1,,Autocuration,107,,,,H,,,,BAO_0000019,F,,CHEMBL617064
,8,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,2279,13481,,1,,Autocuration,107,,,,H,,,,BAO_0000019,F,,CHEMBL617065
,8,449.0,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,2280,6347,,1,,Autocuration,107,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617066
,8,449.0,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,2281,6347,,1,,Autocuration,107,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617067
,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,2282,14093,,1,,Autocuration,107,,,,H,,,,BAO_0000019,F,,CHEMBL617068
,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,2283,14093,,1,,Autocuration,107,,,,H,,,,BAO_0000019,F,,CHEMBL617069
,8,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,2284,13481,,1,,Autocuration,107,,,,H,,,,BAO_0000019,F,,CHEMBL617070
,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,2285,14442,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617071
,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,2286,14442,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL872915
,8,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,2287,14755,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617072
,8,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,2288,16441,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617073
,8,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,2289,14744,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617074
,8,449.0,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,2290,16659,,1,,Expert,107,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617075
,8,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,2291,3307,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617076
,9,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,2292,6857,,1,Homo sapiens,Expert,107,,9606.0,,D,,,,BAO_0000019,B,,CHEMBL617077
,8,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,2293,5635,,1,,Expert,107,,,,H,,,,BAO_0000357,B,,CHEMBL617078
,9,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,2294,4234,,1,Homo sapiens,Expert,107,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL617079
,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,2295,15527,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617080
,8,449.0,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,2296,6588,,1,,Expert,107,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617081
,8,,Binding affinity towards human 5-HT2A receptor in BEK cells,,2297,13631,,1,,Expert,107,,,,H,,,,BAO_0000219,B,,CHEMBL617082
,8,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,2298,17723,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617083
,8,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,2299,14770,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617084
,9,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,2300,16293,,1,Homo sapiens,Expert,107,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL617085
,8,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,2301,16209,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617086
,8,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,2302,12469,,1,,Autocuration,107,,,,H,,,,BAO_0000219,B,,CHEMBL617087
,8,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,2303,15363,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617088
,8,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,2304,15363,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617089
,8,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,2305,16441,,1,,Expert,107,,,,H,,,,BAO_0000019,B,,CHEMBL617090
,8,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,2306,8,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617513
,8,722.0,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,2307,4176,,1,,Autocuration,107,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617514
,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,2308,17085,,1,,Autocuration,107,,,,H,,,,BAO_0000019,B,,CHEMBL617515
,8,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,2309,17200,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617516
,9,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,2310,17200,,1,Homo sapiens,Expert,107,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL617517
,9,449.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,2311,4013,,1,Homo sapiens,Expert,107,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL617518
,8,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,2312,5088,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617519
,9,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,2313,5088,,1,Homo sapiens,Expert,107,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL617520
,8,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,2314,5088,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617521
,9,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,2315,5088,,1,Homo sapiens,Expert,107,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL617522
,8,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,2316,5088,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617523
,8,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,2317,5088,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617524
,4,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,2318,9786,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617525
,5,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,2319,9205,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617526
,4,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,2320,11257,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617527
,4,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,2321,9362,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617528
,4,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,2322,9362,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617529
,4,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,2323,10590,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617530
,4,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,2324,10468,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617531
,4,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,2325,13050,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617532
,4,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,2326,11624,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617533
,4,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,2327,10468,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617534
,4,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,2328,10330,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617535
,4,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,2329,10062,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617536
,4,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,2330,11642,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617537
,4,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,2331,10062,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617538
,4,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,2332,13427,,1,,Autocuration,104686,,,,H,,In vitro,,BAO_0000219,B,,CHEMBL617539
,5,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,2333,12280,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000224,B,,CHEMBL617540
,5,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,2334,4101,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000224,B,,CHEMBL617541
,4,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,2335,10062,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617542
,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,2336,11147,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617543
,5,485.0,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,2337,2395,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,CHO-K1,BAO_0000219,B,,CHEMBL617544
,5,485.0,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,2338,2395,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,CHO-K1,BAO_0000219,B,,CHEMBL617545
,5,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,2339,9098,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617413
,4,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,2340,9098,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617414
,5,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,2341,9098,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617415
,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,2342,9443,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617416
,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,2343,9443,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617417
,4,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,2344,9699,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617418
,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,2345,9699,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617419
,4,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,2346,9098,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617420
,5,,Affinity for 5-hydroxytryptamine 2 receptor,,2347,3070,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000224,B,,CHEMBL617421
,4,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,2348,9547,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617422
,4,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,2349,10444,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617423
,4,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,2350,14617,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617424
,4,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,2351,14617,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617425
,4,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,2352,11130,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617426
,4,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,2353,11130,,1,,Autocuration,104686,,,,H,,In vivo,,BAO_0000218,B,,CHEMBL617427
,4,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,2354,14542,,1,,Autocuration,104686,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL617428
,4,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,2355,2797,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617429
,4,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,2356,11332,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617430
,4,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,2357,11332,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617431
,4,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,2358,10752,,1,,Autocuration,104686,,,Frontal cortex,H,1870.0,,,BAO_0000019,B,,CHEMBL617432
,4,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,2359,1185,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617433
,4,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,2360,1185,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617434
,5,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,2361,11624,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000224,B,,CHEMBL617435
,4,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,2362,1344,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617436
,5,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,2363,15453,,1,Rattus norvegicus,Autocuration,104686,,10116.0,Striatum,D,2435.0,,,BAO_0000019,B,,CHEMBL617437
,4,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,2364,11662,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617438
,4,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,2365,11662,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617439
,4,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,2366,10796,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617440
,4,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,2367,9069,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617441
,5,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,2368,8814,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL872918
,5,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,2369,8908,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617442
,4,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,2370,9098,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617443
,4,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,2371,9098,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617444
,4,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,2372,9098,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617445
,4,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,2373,9098,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617446
,4,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,2374,9098,,1,,Autocuration,104686,,,,H,,,,BAO_0000249,B,,CHEMBL617447
,4,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,2375,9098,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617448
,4,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,2376,9098,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617449
,4,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,2377,9161,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617450
,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,2378,9161,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617451
,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,2379,9161,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617452
,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,2380,9161,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617453
,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,2381,9161,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617660
,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,2382,9161,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617661
,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,2383,9161,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617662
,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,2384,9161,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL872919
,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,2385,9161,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617663
,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,2386,9161,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617664
,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,2387,9161,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617665
,4,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,2388,9161,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617666
,4,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,2389,12094,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617667
,4,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,2390,12018,,1,,Autocuration,104686,,,,H,,,,BAO_0000249,B,,CHEMBL617668
,4,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,2391,10394,,1,,Autocuration,104686,,,,H,,,,BAO_0000249,B,,CHEMBL617669
,4,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,2392,15260,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617670
,5,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,2393,11624,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000224,B,,CHEMBL617671
,4,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,2394,13654,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617672
,4,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,2395,9541,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617673
,4,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,2396,11933,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617674
,4,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,2397,15538,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617675
,4,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,2398,15538,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617676
,4,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,2399,15538,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617677
,5,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,2400,8841,,1,,Autocuration,104686,,,,D,,,,BAO_0000019,B,,CHEMBL617678
,4,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,2401,1455,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617679
,4,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,2402,1455,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617680
,4,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,2403,11752,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617681
,4,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,2404,11642,,1,,Autocuration,104686,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL617682
,4,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,2405,12092,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617683
,4,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,2406,3967,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617684
,5,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,2407,12771,,1,Rattus norvegicus,Autocuration,104686,,10116.0,,D,,,,BAO_0000224,B,,CHEMBL617685
,4,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,2408,11642,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,B,,CHEMBL617686
,4,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,2409,11628,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617687
,4,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,2410,13654,,1,,Autocuration,104686,,,,H,,,,BAO_0000224,B,,CHEMBL617688
,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,2411,11200,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,F,,CHEMBL617689
,4,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,2412,11200,,1,,Autocuration,104686,,,,H,,,,BAO_0000019,F,,CHEMBL617690
,4,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,2413,11200,,1,,Autocuration,104686,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617691
,4,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,2414,11200,,1,,Autocuration,104686,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617692
,4,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,2415,11200,,1,,Autocuration,104686,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617693
,4,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,2416,11200,,1,,Autocuration,104686,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617694
,8,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,2417,15436,,1,,Expert,12687,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL857985
,9,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,2418,15436,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617695
,8,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,2419,14025,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617696
,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,2420,4342,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617697
,9,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,2421,13735,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617257
,9,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,2422,5816,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL617258
,8,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,2423,14287,,1,,Expert,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617259
,8,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,2424,15738,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617260
,9,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,2425,15738,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL617261
,8,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,2426,15026,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617262
,8,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,2427,16647,,1,,Expert,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617263
,8,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,2428,16647,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617264
,9,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,2429,13345,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617265
,8,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,2430,1543,Membranes,1,,Autocuration,12687,,,,H,,,,BAO_0000249,B,,CHEMBL617266
,8,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,2431,12444,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617267
,8,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,2432,16404,,1,,Expert,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617268
,8,449.0,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,2433,16404,,1,,Autocuration,12687,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617269
,8,,Kinetic inhibition constant evaluated by measuring serotonergic activity,,2434,15577,,1,,Expert,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617323
,8,,Serotonergic activity of the compound.,,2435,15577,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617324
,8,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,2436,2495,,1,,Autocuration,12687,,,,H,,,,BAO_0000249,B,,CHEMBL617325
,9,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,2437,15042,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617326
,8,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,2438,15026,,1,,Expert,12687,,,,H,,,,BAO_0000249,B,,CHEMBL617327
,9,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,2439,12919,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL617328
,9,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,2440,12919,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL617329
,9,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,2441,12919,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL617330
,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,2442,15194,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617331
,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,2443,15194,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617332
,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,2444,4820,,1,,Expert,107,,,,H,,,,BAO_0000357,B,,CHEMBL617333
,8,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,2445,6736,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617334
,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,2446,5163,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617335
,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,2447,5163,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617336
,8,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,2448,6011,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617337
,9,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,2449,14294,,1,Homo sapiens,Expert,107,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL617338
,8,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,2450,5014,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617339
,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,2451,17066,,1,,Expert,107,,,,H,,,,BAO_0000357,B,,CHEMBL617340
,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,2452,17515,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617341
,8,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,2453,6736,,1,,Expert,107,,,,H,,,,BAO_0000357,B,,CHEMBL617342
,8,,Affinity for 5-hydroxytryptamine 2A receptor,,2454,5163,,1,,Expert,107,,,,H,,,,BAO_0000357,B,,CHEMBL617343
,8,723.0,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,2455,16911,,1,,Expert,107,,,,H,,,NIH3T3,BAO_0000219,B,,CHEMBL617344
,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,2456,6841,,1,,Expert,107,,,,H,,,,BAO_0000357,B,,CHEMBL617345
,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,2457,6119,,1,,Expert,107,,,,H,,,,BAO_0000357,B,,CHEMBL617346
,8,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,2458,3962,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617347
,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,2459,4373,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617348
,8,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,2460,4373,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617349
,8,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,2461,3962,,1,,Autocuration,107,,,,H,,,,BAO_0000019,F,,CHEMBL617350
,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,2462,1633,,1,,Expert,107,,,,H,,,,BAO_0000357,B,,CHEMBL872339
,8,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,2463,4373,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617351
,8,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,2464,6576,,1,,Expert,107,,,,H,,,,BAO_0000357,B,,CHEMBL617352
,8,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,2465,4687,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617353
,8,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,2466,16946,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617354
,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,2467,14159,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617355
,8,449.0,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,2468,3032,,1,Mus musculus,Expert,107,,10090.0,,H,,,CHO,BAO_0000219,B,,CHEMBL617356
,8,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,2469,16655,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617357
,8,,Binding affinity at 5-hydroxytryptamine 2A receptor,,2470,13964,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617358
,8,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,2471,16989,,1,,Expert,107,,,,H,,,,BAO_0000357,B,,CHEMBL617359
,8,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,2472,16117,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617360
,8,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,2473,16700,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL875913
,8,,Affinity against 5-hydroxytryptamine 2A receptor,,2474,3269,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617361
,9,,Binding affinity against 5-Hydroxytryptamine 2A receptor,,2475,1274,,1,Homo sapiens,Expert,107,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL617362
,8,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,2476,1317,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617363
,8,,Tested against 5-hydroxytryptamine 2A receptor,,2477,12146,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617364
,4,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,2478,12652,,1,,Autocuration,105075,,,,H,,,,BAO_0000224,B,,CHEMBL617365
,4,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,2479,12652,,1,,Autocuration,105075,,,,H,,,,BAO_0000224,B,,CHEMBL617366
,4,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,2480,12652,,1,,Autocuration,105075,,,,H,,,,BAO_0000224,B,,CHEMBL617367
,4,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,2481,12652,,1,,Autocuration,105075,,,,H,,,,BAO_0000224,B,,CHEMBL617368
,8,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,2482,16647,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617369
,9,722.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,2483,15851,,1,Homo sapiens,Expert,227,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL617370
,9,449.0,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,2484,6857,,1,Homo sapiens,Expert,227,,9606.0,,D,,,CHO,BAO_0000219,F,,CHEMBL617371
,8,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,2485,3805,,1,,Autocuration,227,,,,H,,,,BAO_0000357,B,,CHEMBL617372
,9,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,2486,6491,,1,Homo sapiens,Expert,227,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL617373
,8,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,2487,14093,,1,,Autocuration,227,,,,H,,,,BAO_0000019,F,,CHEMBL617374
,8,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,2488,13481,,1,,Autocuration,227,,,,H,,,,BAO_0000019,F,,CHEMBL617375
,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,2489,14093,,1,,Autocuration,227,,,,H,,,,BAO_0000019,F,,CHEMBL617376
,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,2490,14093,,1,,Autocuration,227,,,,H,,,,BAO_0000019,F,,CHEMBL617377
,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,2491,14093,,1,,Autocuration,227,,,,H,,,,BAO_0000019,F,,CHEMBL617378
,8,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,2492,13481,,1,,Autocuration,227,,,,H,,,,BAO_0000019,F,,CHEMBL617379
,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,2493,14442,,1,,Autocuration,227,,,,H,,,,BAO_0000357,B,,CHEMBL617380
,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,2494,14442,,1,,Autocuration,227,,,,H,,,,BAO_0000357,B,,CHEMBL617381
,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,2495,14442,,1,,Autocuration,227,,,,H,,,,BAO_0000357,B,,CHEMBL617382
,8,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,2496,12369,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617383
,8,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,2497,12369,,1,,Expert,107,,,,H,,,,BAO_0000357,B,,CHEMBL617384
,8,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,2498,12369,,1,,Expert,107,,,,H,,,,BAO_0000357,B,,CHEMBL617385
,8,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,2499,14447,,1,,Autocuration,107,,,,H,,,,BAO_0000019,B,,CHEMBL617386
,8,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,2500,14447,,1,,Autocuration,107,,,,H,,,,BAO_0000019,B,,CHEMBL617387
,8,723.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,2501,17451,,1,,Autocuration,107,,,,H,,,NIH3T3,BAO_0000219,B,,CHEMBL617388
,8,449.0,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,2502,6857,,1,,Autocuration,107,,,,H,,,CHO,BAO_0000219,F,,CHEMBL617389
,9,449.0,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,2503,6857,,1,Homo sapiens,Expert,107,,9606.0,,D,,,CHO,BAO_0000219,F,,CHEMBL617390
,4,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,2504,5635,,1,,Autocuration,104817,,,,H,,,,BAO_0000224,B,,CHEMBL617391
,8,,Binding activity radioligand.,,2505,12861,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617392
,8,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,2506,12861,,1,,Autocuration,107,,,,H,,,,BAO_0000019,B,,CHEMBL617393
,8,307.0,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,2507,5105,,1,,Autocuration,107,,,,H,,,L929,BAO_0000219,B,,CHEMBL617394
,8,307.0,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,2508,5104,,1,,Expert,107,,,,H,,,L929,BAO_0000219,B,,CHEMBL617395
,8,307.0,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,2509,5105,,1,,Expert,107,,,,H,,,L929,BAO_0000219,B,,CHEMBL617396
,8,307.0,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,2510,5105,,1,,Autocuration,107,,,,H,,,L929,BAO_0000219,B,,CHEMBL617397
,8,,Binding affinity against 5-HT2A receptor,,2511,5254,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617398
,8,,Binding affinity against 5-hydroxytryptamine 2A receptor,,2512,5254,,1,,Autocuration,107,,,,H,,,,BAO_0000357,B,,CHEMBL617399
,8,722.0,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,2513,13267,,1,,Autocuration,107,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617400
,8,722.0,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,2514,13267,,1,,Autocuration,107,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617401
,9,722.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,2515,14157,,1,Homo sapiens,Expert,107,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL617402
,9,722.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,2516,12936,,1,Homo sapiens,Expert,107,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL617403
,8,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,2517,14068,,1,,Expert,107,,,,H,,,,BAO_0000357,B,,CHEMBL617404
,9,722.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,2518,12936,,1,Homo sapiens,Expert,107,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL857981
,9,722.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,2519,12936,,1,Homo sapiens,Expert,107,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL617405
,9,722.0,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,2520,4540,,1,Homo sapiens,Expert,107,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL617253
,8,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,2521,6166,,1,,Expert,107,,,,H,,,,BAO_0000357,B,,CHEMBL617254
,8,722.0,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,2522,17296,,1,,Autocuration,107,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617255
,8,722.0,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,2523,17296,,1,,Autocuration,107,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617256
,8,722.0,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,2524,17296,,1,,Autocuration,107,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616874
,9,722.0,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,2525,15779,,1,Homo sapiens,Expert,107,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL616875
,8,722.0,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,2526,14391,,1,,Expert,107,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616876
,8,722.0,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,2527,15851,,1,,Expert,107,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616877
,9,722.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,2528,15851,,1,Homo sapiens,Expert,107,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL616878
,8,722.0,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,2529,3832,,1,,Expert,107,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616879
,8,722.0,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,2530,3833,,1,,Expert,107,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616880
,9,722.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,2531,12936,,1,Homo sapiens,Expert,107,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL616881
,8,723.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,2532,17451,,1,,Autocuration,107,,,,H,,,NIH3T3,BAO_0000219,B,,CHEMBL616882
,8,723.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,2533,17451,,1,,Autocuration,107,,,,H,,,NIH3T3,BAO_0000219,B,,CHEMBL616883
,8,723.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,2534,17451,,1,,Autocuration,107,,,,H,,,NIH3T3,BAO_0000219,B,,CHEMBL616884
,8,722.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,2535,4199,,1,,Autocuration,107,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616885
,8,485.0,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,2536,1883,,1,,Autocuration,107,,,,H,,,CHO-K1,BAO_0000219,B,,CHEMBL616886
,8,485.0,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,2537,1883,,1,,Expert,107,,,,H,,,CHO-K1,BAO_0000219,B,,CHEMBL616887
,9,,Binding affinity for human 5-hydroxytryptamine 2A receptor,,2538,14875,,1,Homo sapiens,Expert,107,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL616888
,8,722.0,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,2539,15146,,1,,Autocuration,107,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616889
,8,722.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,2540,5213,,1,,Autocuration,107,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616890
,9,449.0,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,2541,16404,,1,Homo sapiens,Expert,107,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL616891
,8,722.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,2542,14818,,1,,Autocuration,107,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616892
,8,722.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,2543,4829,,1,,Autocuration,107,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL616893
,8,723.0,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,2544,12652,,1,,Autocuration,10620,,,,H,,,NIH3T3,BAO_0000219,F,,CHEMBL616894
,8,723.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,2545,4682,,1,,Expert,107,,,,H,,,NIH3T3,BAO_0000219,B,,CHEMBL616895
,8,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,2546,12652,,1,,Autocuration,10620,,,,H,,,,BAO_0000019,F,,CHEMBL616896
,8,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,2547,4921,,1,,Autocuration,10621,,,,H,,,,BAO_0000357,B,,CHEMBL617099
,8,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,2548,4921,,1,,Autocuration,10621,,,,H,,,,BAO_0000357,B,,CHEMBL617100
,8,,Binding affinity against rabbit aorta 5-HT2A receptor,,2549,16312,,1,Oryctolagus cuniculus,Autocuration,107,,9986.0,,H,,,,BAO_0000357,B,,CHEMBL884532
,8,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,2550,14998,,1,Oryctolagus cuniculus,Expert,107,,9986.0,,H,,,,BAO_0000357,B,,CHEMBL617101
,8,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,2551,14025,,1,Oryctolagus cuniculus,Expert,107,,9986.0,,H,,,,BAO_0000357,B,,CHEMBL617102
,8,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,2552,13047,,1,Oryctolagus cuniculus,Autocuration,107,,9986.0,,H,,,,BAO_0000019,B,,CHEMBL617103
,8,,The compound was tested for binding affinity against 5-HT2A receptor,,2553,13047,,1,Oryctolagus cuniculus,Expert,107,,9986.0,,H,,,,BAO_0000357,B,,CHEMBL617104
,8,485.0,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,2554,1883,,1,,Autocuration,10576,,,,H,,,CHO-K1,BAO_0000219,B,,CHEMBL857979
,8,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,2555,13463,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL857502
,8,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,2556,13463,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617105
,8,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,2557,13463,,1,,Autocuration,12687,,,Stomach,H,945.0,,,BAO_0000019,B,,CHEMBL858021
,9,,Binding affinity for 5-HT 2A in rat stomach fundus,,2558,13463,,1,Rattus norvegicus,Expert,12687,,10116.0,Stomach,D,945.0,,,BAO_0000019,B,,CHEMBL875910
,8,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,2559,13463,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617106
,8,723.0,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,2560,16326,,1,,Expert,12687,,,,H,,,NIH3T3,BAO_0000219,B,,CHEMBL617107
,8,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,2561,14093,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,F,,CHEMBL617108
,8,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,2562,14093,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,F,,CHEMBL617109
,8,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,2563,15740,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617110
,8,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,2564,16633,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617111
,9,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,2565,17200,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL617112
,8,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,2566,17133,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617113
,8,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,2567,17133,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617114
,8,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,2568,17133,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617115
,8,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,2569,17200,,1,,Autocuration,12687,,,,H,,,,BAO_0000219,F,,CHEMBL617116
,8,,Efficacy at 5-hydroxytryptamine 2A receptor,,2570,15363,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,F,,CHEMBL617117
,8,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,2571,17200,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617118
,9,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,2572,17200,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL617119
,9,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,2573,17200,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL617120
,9,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,2574,17200,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000219,F,,CHEMBL617121
,8,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,2575,17200,,1,,Autocuration,12687,,,,H,,,,BAO_0000219,F,,CHEMBL617122
,8,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,2576,17211,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617123
,8,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,2577,17331,,1,,Expert,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617124
,8,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,2578,13565,,1,,Expert,12687,,,,H,,,,BAO_0000249,B,,CHEMBL617600
,8,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,2579,13730,,1,,Expert,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617601
,8,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,2580,12416,,1,,Expert,12687,,,,H,,,,BAO_0000019,B,,CHEMBL882923
,8,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,2581,15295,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617602
,8,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,2582,1742,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617603
,8,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,2583,15295,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617604
,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,2584,14970,,1,,Expert,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617605
,8,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,2585,16693,,1,,Expert,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617606
,9,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,2586,14776,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617607
,8,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,2587,14286,,1,,Autocuration,12687,,,,H,,,,BAO_0000249,B,,CHEMBL617455
,9,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,2588,17200,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617456
,8,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,2589,15306,,1,,Expert,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617457
,9,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,2590,14178,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL617458
,9,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,2591,14229,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617459
,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,2592,12884,,1,,Expert,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617460
,8,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,2593,13149,,1,,Expert,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617461
,9,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,2594,15295,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617462
,8,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,2595,15740,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617463
,8,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,2596,15185,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617464
,8,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,2597,15185,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617465
,8,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,2598,17529,,1,,Expert,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617466
,8,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,2599,14826,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617467
,8,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,2600,17211,,1,,Expert,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617468
,8,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,2601,14826,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617469
,8,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,2602,14093,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617470
,8,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,2603,14093,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617471
,8,723.0,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,2604,13246,,1,,Expert,12687,,,,H,,,NIH3T3,BAO_0000219,B,,CHEMBL617472
,8,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,2605,13246,,1,,Expert,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617473
,9,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,2606,15436,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617474
,9,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,2607,15436,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617475
,8,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,2608,14442,,1,,Autocuration,12687,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL617476
,8,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,2609,12457,,1,,Expert,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617477
,8,723.0,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,2610,12457,,1,,Expert,12687,,,,H,,,NIH3T3,BAO_0000219,B,,CHEMBL617478
,8,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,2611,14755,,1,,Autocuration,12687,,,,H,,,,BAO_0000221,F,,CHEMBL617479
,8,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,2612,4707,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617480
,8,,Binding affinity against 5-hydroxytryptamine 2A receptor,,2613,13297,,1,,Expert,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617481
,8,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,2614,17331,,1,,Expert,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617482
,8,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,2615,4664,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617483
,8,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,2616,16633,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL621528
,9,723.0,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,2617,4664,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,NIH3T3,BAO_0000219,B,,CHEMBL621529
,8,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,2618,16133,,1,,Expert,12687,,,,H,,,,BAO_0000357,B,,CHEMBL621530
,8,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,2619,16133,,1,,Expert,12687,,,,H,,,,BAO_0000357,B,,CHEMBL621531
,9,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,2620,14060,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL621532
,8,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,2621,16326,,1,,Expert,12687,,,,H,,,,BAO_0000357,B,,CHEMBL621533
,8,449.0,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,2622,16659,,1,,Expert,12687,,,,H,,,CHO,BAO_0000219,B,,CHEMBL621534
,8,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,2623,14776,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL621535
,8,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,2624,13481,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL621536
,8,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,2625,17386,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL621537
,9,,Binding affinity for 5-hydroxytryptamine 2A receptor,,2626,6611,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL621538
,8,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,2627,14423,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL621539
,8,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,2628,15412,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL621540
,8,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,2629,15412,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL621541
,8,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,2630,6238,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL621542
,8,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,2631,6648,,1,,Expert,12687,,,,H,,,,BAO_0000357,B,,CHEMBL621543
,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,2632,5667,,1,,Expert,12687,,,,H,,,,BAO_0000357,B,,CHEMBL621544
,9,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,2633,6611,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL621545
,8,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,2634,13481,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL621546
,8,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,2635,13481,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL621547
,8,723.0,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,2636,15558,,1,,Expert,12687,,,,H,,,NIH3T3,BAO_0000219,B,,CHEMBL618692
,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,2637,6013,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL618693
,8,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,2638,16633,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL872922
,8,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,2639,6013,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL618694
,9,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,2640,6013,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL618695
,8,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,2641,6013,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL618696
,8,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,2642,6013,,1,,Expert,12687,,,,H,,,,BAO_0000357,B,,CHEMBL618697
,8,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,2643,6013,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL618892
,8,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,2644,6013,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL618893
,8,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,2645,16293,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL618894
,8,723.0,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,2646,17175,,1,,Expert,12687,,,,H,,,NIH3T3,BAO_0000219,B,,CHEMBL618895
,9,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,2647,13278,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL618896
,8,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,2648,3682,,1,,Autocuration,12687,,,Caudate-putamen,H,5383.0,,,BAO_0000019,B,,CHEMBL618897
,8,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,2649,2014,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL618898
,8,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,2650,2014,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL618899
,8,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,2651,4932,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL618900
,8,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,2652,4932,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL618901
,8,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,2653,3935,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL618902
,9,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,2654,5432,,1,Rattus norvegicus,Expert,12687,,10116.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL618903
,8,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,2655,15818,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL618904
,8,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,2656,13672,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL618905
,8,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,2657,13672,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL618906
,8,723.0,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,2658,14749,,1,,Expert,12687,,,,H,,,NIH3T3,BAO_0000219,B,,CHEMBL618907
,8,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,2659,13462,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL618908
,8,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,2660,15740,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617909
,8,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,2661,16647,,1,,Expert,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617910
,8,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,2662,13345,,1,,Autocuration,12687,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL617911
,8,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,2663,16740,,1,,Autocuration,12687,,,,H,,,,BAO_0000249,B,,CHEMBL872923
,8,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,2664,16740,,1,,Autocuration,12687,,,,H,,,,BAO_0000249,B,,CHEMBL617912
,9,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,2665,15535,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617913
,8,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,2666,16740,,1,,Expert,12687,,,,H,,,,BAO_0000249,B,,CHEMBL617914
,8,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,2667,16740,,1,,Autocuration,12687,,,,H,,,,BAO_0000249,B,,CHEMBL617915
,8,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,2668,16740,,1,,Autocuration,12687,,,,H,,,,BAO_0000249,B,,CHEMBL617916
,9,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,2669,4795,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617917
,8,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,2670,8,,1,,Expert,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617918
,8,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,2671,8,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617919
,9,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,2672,17200,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617920
,9,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,2673,2148,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617921
,5,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,2674,13345,,1,Rattus norvegicus,Expert,105102,,10116.0,,D,,,,BAO_0000224,B,,CHEMBL617922
,8,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,2675,5088,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617923
,8,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,2676,5088,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617924
,8,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,2677,17133,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617925
,9,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,2678,17133,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL617926
,8,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,2679,16532,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617927
,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,2680,15086,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617928
,9,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,2681,2309,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617929
,8,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,2682,12953,,1,,Expert,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617930
,8,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,2683,12953,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617931
,8,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,2684,12953,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617932
,8,449.0,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,2685,16659,,1,,Autocuration,12687,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617933
,8,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,2686,16740,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617934
,8,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,2687,16740,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617935
,8,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,2688,17133,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617936
,8,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,2689,17211,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617937
,8,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,2690,17331,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617938
,8,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,2691,16633,,1,,Autocuration,12687,,,,H,,,,BAO_0000218,B,,CHEMBL617939
,8,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,2692,16633,,1,,Autocuration,12687,,,,H,,,,BAO_0000218,B,,CHEMBL617940
,8,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,2693,16633,,1,,Autocuration,12687,,,,H,,,,BAO_0000218,B,,CHEMBL617941
,8,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,2694,15026,,1,,Expert,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617942
,8,,Ratio of pKi of 5-HT2A to that of D2 receptor,,2695,15026,,1,,Expert,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617943
,4,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,2696,16404,,1,,Expert,105093,,,,H,,,,BAO_0000224,B,,CHEMBL617944
,4,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,2697,16404,,1,,Expert,105093,,,,H,,,,BAO_0000224,B,,CHEMBL617945
,4,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,2698,16404,,1,,Expert,105075,,,,H,,,,BAO_0000224,B,,CHEMBL617946
,8,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,2699,16404,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617947
,8,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,2700,16326,,1,,Expert,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617948
,8,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,2701,15847,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,F,,CHEMBL858116
,8,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,2702,15847,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,F,,CHEMBL617949
,8,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,2703,15329,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,F,,CHEMBL617950
,8,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,2704,16404,,1,,Expert,12687,,,Thoracic aorta,H,1515.0,,,BAO_0000019,F,,CHEMBL617951
,8,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,2705,16404,,1,,Expert,12687,,,Thoracic aorta,H,1515.0,,,BAO_0000019,F,,CHEMBL617952
,8,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,2706,16404,,1,,Autocuration,12687,,,Thoracic aorta,H,1515.0,,,BAO_0000019,F,,CHEMBL617953
,8,,Binding activity radioligand.,,2707,12861,,1,,Autocuration,12687,,,,H,,,,BAO_0000357,B,,CHEMBL617954
,8,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,2708,12861,,1,,Expert,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617955
,8,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,2709,12861,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL857071
,8,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,2710,12490,,1,,Expert,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617270
,8,339.0,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,2711,12827,,1,,Autocuration,12687,,,,H,,,N1E-115,BAO_0000219,B,,CHEMBL617271
,8,339.0,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,2712,12827,,1,,Autocuration,12687,,,,H,,,N1E-115,BAO_0000219,B,,CHEMBL617272
,8,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,2713,12918,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617273
,9,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,2714,12919,,1,Rattus norvegicus,Expert,12687,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL617274
,8,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,2715,17723,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617275
,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,2716,6013,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617276
,8,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,2717,16293,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617277
,8,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,2718,3857,,1,,Expert,108,,,,H,,,,BAO_0000019,B,,CHEMBL617278
,8,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,2719,3857,,1,,Expert,108,,,,H,,,,BAO_0000019,B,,CHEMBL617279
,8,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,2720,3857,,1,,Expert,108,,,,H,,,,BAO_0000019,B,,CHEMBL617280
,8,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,2721,15363,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617281
,8,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,2722,15363,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617282
,8,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,2723,16441,,1,,Expert,108,,,,H,,,,BAO_0000019,B,,CHEMBL617283
,8,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,2724,16441,,1,,Expert,108,,,,H,,,,BAO_0000019,B,,CHEMBL617284
,8,722.0,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,2725,4176,,1,,Autocuration,108,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617285
,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,2726,17085,,1,,Autocuration,108,,,,H,,,,BAO_0000019,B,,CHEMBL617286
,9,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,2727,17200,,1,Homo sapiens,Expert,108,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL617287
,8,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,2728,5088,,1,,Expert,108,,,,H,,,,BAO_0000357,B,,CHEMBL617288
,8,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,2729,5088,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617289
,8,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,2730,5088,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL872917
,8,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,2731,5088,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617290
,8,449.0,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,2732,16659,,1,,Autocuration,108,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617291
,8,449.0,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,2733,16659,,1,,Autocuration,108,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617292
,8,723.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,2734,17451,,1,,Autocuration,108,,,,H,,,NIH3T3,BAO_0000219,B,,CHEMBL617293
,9,449.0,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,2735,6857,,1,Homo sapiens,Expert,108,,9606.0,,D,,,CHO,BAO_0000219,F,,CHEMBL617294
,8,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,2736,3857,,1,,Expert,108,,,,H,,,,BAO_0000019,B,,CHEMBL617295
,8,,Binding activity radioligand.,,2737,12861,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617296
,8,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,2738,12861,,1,,Autocuration,108,,,,H,,,,BAO_0000019,B,,CHEMBL617297
,8,449.0,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,2739,5104,,1,,Expert,108,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617298
,8,449.0,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,2740,5105,,1,,Expert,108,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617299
,8,449.0,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,2741,5105,,1,,Autocuration,108,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617300
,8,,Binding affinity against 5-HT2C receptor,,2742,5254,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617454
,8,722.0,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,2743,13267,,1,,Autocuration,108,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617505
,9,722.0,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,2744,14157,,1,Homo sapiens,Expert,108,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL617506
,9,722.0,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,2745,12936,,1,Homo sapiens,Expert,108,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL617507
,8,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,2746,14068,,1,,Expert,108,,,,H,,,,BAO_0000357,B,,CHEMBL617508
,9,722.0,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,2747,12936,,1,Homo sapiens,Expert,108,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL857982
,9,722.0,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,2748,4540,,1,Homo sapiens,Expert,108,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL617509
,9,722.0,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,2749,4540,,1,Homo sapiens,Expert,108,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL617510
,8,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,2750,6166,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617511
,8,722.0,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,2751,17296,,1,,Autocuration,108,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617512
,8,722.0,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,2752,17296,,1,,Autocuration,108,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617749
,8,722.0,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,2753,15779,,1,,Autocuration,108,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617750
,8,722.0,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,2754,15779,,1,,Autocuration,108,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617751
,8,722.0,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,2755,14391,,1,,Expert,108,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617752
,8,722.0,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,2756,15779,,1,,Autocuration,108,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617753
,8,722.0,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,2757,15851,,1,,Expert,108,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617754
,9,722.0,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,2758,15851,,1,Homo sapiens,Expert,108,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL617755
,8,722.0,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,2759,15779,,1,,Autocuration,108,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617756
,8,722.0,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,2760,3832,,1,,Expert,108,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617757
,8,722.0,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,2761,3833,,1,,Expert,108,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617758
,8,723.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,2762,17451,,1,,Autocuration,108,,,,H,,,NIH3T3,BAO_0000219,B,,CHEMBL617759
,8,722.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,2763,4199,,1,,Autocuration,108,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617760
,8,485.0,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,2764,1883,,1,,Expert,108,,,,H,,,CHO-K1,BAO_0000219,B,,CHEMBL617761
,9,,Binding affinity against 5-hydroxytryptamine 2C receptor,,2765,4321,,1,Homo sapiens,Expert,108,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL617762
,8,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,2766,14875,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617763
,8,722.0,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,2767,15146,,1,,Autocuration,108,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL857983
,8,722.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,2768,5213,,1,,Autocuration,108,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617764
,8,308.0,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,2769,16404,,1,,Autocuration,108,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL617765
,8,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,2770,13267,,1,,Autocuration,108,,,,H,,,,BAO_0000019,F,,CHEMBL617766
,8,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,2771,13267,,1,,Autocuration,108,,,Hippocampus,H,10000000.0,,,BAO_0000221,F,,CHEMBL617767
,8,722.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,2772,14818,,1,,Autocuration,108,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617768
,8,722.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,2773,4829,,1,,Autocuration,108,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617769
,8,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,2774,13463,,1,,Autocuration,11864,,,,H,,,,BAO_0000357,B,,CHEMBL858023
,8,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,2775,13463,,1,,Autocuration,11864,,,Stomach,H,945.0,,,BAO_0000019,B,,CHEMBL617770
,8,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,2776,13463,,1,,Autocuration,11864,,,Stomach,H,945.0,,,BAO_0000019,B,,CHEMBL617771
,8,625.0,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,2777,12652,,1,,Autocuration,11864,,,,H,,,A9,BAO_0000219,F,,CHEMBL617772
,8,723.0,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,2778,4682,,1,,Autocuration,11864,,,,H,,,NIH3T3,BAO_0000219,B,,CHEMBL617773
,8,723.0,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,2779,4682,,1,,Autocuration,11864,,,,H,,,NIH3T3,BAO_0000219,B,,CHEMBL617850
,8,723.0,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,2780,4682,,1,,Autocuration,11864,,,,H,,,NIH3T3,BAO_0000219,B,,CHEMBL617851
,8,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,2781,12652,,1,,Autocuration,11864,,,,H,,,,BAO_0000019,F,,CHEMBL617852
,8,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,2782,13463,,1,Mus musculus,Autocuration,12689,,10090.0,Stomach,H,945.0,,,BAO_0000019,B,,CHEMBL858024
,9,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,2783,13463,,1,Rattus norvegicus,Expert,12689,,10116.0,Stomach,D,945.0,,,BAO_0000019,B,,CHEMBL617853
,8,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,2784,13969,,1,,Expert,108,,,,H,,,,BAO_0000357,B,,CHEMBL617854
,8,,Binding affinity for 5-hydroxytryptamine 2C receptor,,2785,13392,,1,Sus scrofa,Expert,108,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL873477
,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,2786,13392,,1,,Expert,108,,,,H,,,,BAO_0000357,B,,CHEMBL617855
,8,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,2787,14430,,1,,Expert,108,,,,H,,,,BAO_0000019,B,,CHEMBL617856
,8,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,2788,1742,,1,,Autocuration,108,,,,H,,,,BAO_0000019,B,,CHEMBL617857
,8,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,2789,14286,,1,,Autocuration,108,,,,H,,,,BAO_0000249,B,,CHEMBL617858
,8,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,2790,5619,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617859
,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,2791,15086,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617860
,8,,Binding activity radioligand.,,2792,12861,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617861
,8,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,2793,12861,,1,,Expert,108,,,,H,,,,BAO_0000019,B,,CHEMBL617862
,8,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,2794,12861,,1,,Autocuration,108,,,,H,,,,BAO_0000019,B,,CHEMBL617863
,8,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,2795,12827,,1,,Autocuration,108,,,,H,,,,BAO_0000249,B,,CHEMBL617864
,8,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,2796,12827,,1,,Autocuration,108,,,,H,,,,BAO_0000249,B,,CHEMBL617649
,8,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,2797,12919,,1,Sus scrofa,Expert,108,,9823.0,,H,,,,BAO_0000019,F,,CHEMBL617650
,8,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,2798,12919,,1,Sus scrofa,Expert,108,,9823.0,,H,,,,BAO_0000019,F,,CHEMBL617651
,8,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,2799,16429,,1,Sus scrofa,Autocuration,108,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL617652
,8,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,2800,773,,1,Sus scrofa,Autocuration,108,,9823.0,,H,,,,BAO_0000019,B,,CHEMBL857072
,8,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,2801,5033,,1,Sus scrofa,Autocuration,108,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL617653
,8,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,2802,12861,,1,,Autocuration,12687,,,,H,,,,BAO_0000019,B,,CHEMBL617654
,8,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,2803,14093,,1,,Autocuration,12689,,,,H,,,,BAO_0000019,F,,CHEMBL617655
,8,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,2804,14970,,1,,Expert,12689,,,,H,,,,BAO_0000357,B,,CHEMBL617656
,8,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,2805,14970,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL617657
,8,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,2806,14970,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL617658
,9,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,2807,14178,,1,Rattus norvegicus,Expert,12689,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL617659
,9,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,2808,14178,,1,Rattus norvegicus,Expert,12689,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL617838
,9,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,2809,14229,Brain membranes,1,Rattus norvegicus,Expert,12689,,10116.0,,D,,,,BAO_0000249,B,,CHEMBL617839
,8,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,2810,16532,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL617840
,8,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,2811,14826,,1,,Autocuration,12689,,,,H,,,,BAO_0000019,B,,CHEMBL617841
,8,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,2812,17211,,1,,Autocuration,12689,,,,H,,,,BAO_0000019,B,,CHEMBL875915
,8,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,2813,17211,,1,,Expert,12689,,,,H,,In vitro,,BAO_0000219,B,,CHEMBL617842
,8,723.0,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,2814,13246,,1,,Expert,12689,,,,H,,,NIH3T3,BAO_0000219,B,,CHEMBL617843
,8,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,2815,13246,,1,,Expert,12689,,,,H,,,,BAO_0000357,B,,CHEMBL617844
,8,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,2816,12457,,1,,Expert,12689,,,,H,,,,BAO_0000357,B,,CHEMBL617845
,8,723.0,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,2817,12457,,1,,Expert,12689,,,,H,,,NIH3T3,BAO_0000219,B,,CHEMBL617846
,8,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,2818,4707,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL617847
,8,,Binding affinity against 5-hydroxytryptamine 2C receptor,,2819,13297,,1,,Expert,12689,,,,H,,,,BAO_0000357,B,,CHEMBL617848
,8,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,2820,16633,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL617849
,8,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,2821,16133,,1,,Expert,12689,,,,H,,,,BAO_0000357,B,,CHEMBL621507
,8,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,2822,16326,,1,,Expert,12689,,,,H,,,,BAO_0000357,B,,CHEMBL621508
,8,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,2823,14423,,1,,Autocuration,12689,,,,H,,,,BAO_0000019,B,,CHEMBL621509
,8,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,2824,15412,,1,,Autocuration,12689,,,,H,,,,BAO_0000019,B,,CHEMBL621510
,8,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,2825,15412,,1,,Autocuration,12689,,,,H,,,,BAO_0000019,B,,CHEMBL621511
,8,625.0,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,2826,15558,,1,,Expert,12689,,,,H,,,A9,BAO_0000219,B,,CHEMBL621512
,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,2827,16633,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL621513
,8,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,2828,6013,,1,,Expert,12689,,,,H,,,,BAO_0000357,B,,CHEMBL621514
,8,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,2829,17175,,1,,Expert,12689,,,,H,,In vitro,,BAO_0000219,B,,CHEMBL621515
,8,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,2830,12469,,1,,Autocuration,12689,,,,H,,,,BAO_0000219,B,,CHEMBL621516
,8,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,2831,3682,,1,,Autocuration,12689,,,Caudate-putamen,H,5383.0,,,BAO_0000019,B,,CHEMBL621517
,8,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,2832,4932,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL621518
,8,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,2833,4932,,1,,Autocuration,12689,,,,H,,,,BAO_0000019,B,,CHEMBL621519
,8,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,2834,3935,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL621520
,8,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,2835,15818,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL621521
,8,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,2836,15818,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL621522
,8,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,2837,14749,,1,,Expert,12689,,,,H,,,,BAO_0000219,B,,CHEMBL621523
,8,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,2838,15740,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL621524
,9,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,2839,17133,,1,Rattus norvegicus,Expert,12689,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL621525
,8,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,2840,16532,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL872921
,8,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,2841,12369,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL621526
,8,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,2842,12369,,1,,Expert,12689,,,,H,,,,BAO_0000219,B,,CHEMBL621527
,9,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,2843,2309,,1,Rattus norvegicus,Expert,12689,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617865
,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,2844,12953,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL617866
,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,2845,12953,,1,,Autocuration,12689,,,,H,,,,BAO_0000019,B,,CHEMBL617867
,8,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,2846,12953,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL617487
,8,,Binding affinity for 5-hydroxytryptamine 2C receptor,,2847,12953,,1,,Expert,12689,,,,H,,,,BAO_0000357,B,,CHEMBL617488
,8,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,2848,17133,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL617489
,8,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,2849,17211,,1,,Autocuration,12689,,,,H,,,,BAO_0000019,B,,CHEMBL617490
,8,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,2850,17211,,1,,Autocuration,12689,,,,H,,,,BAO_0000019,B,,CHEMBL617491
,8,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,2851,14025,,1,,Autocuration,12689,,,,H,,,,BAO_0000019,B,,CHEMBL617492
,8,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,2852,14998,,1,,Autocuration,12689,,,,H,,,,BAO_0000019,B,,CHEMBL617493
,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,2853,4342,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL617494
,9,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,2854,13735,,1,Rattus norvegicus,Expert,12689,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617495
,8,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,2855,13181,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL617496
,8,485.0,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,2856,1883,,1,,Autocuration,12689,,,,H,,,CHO-K1,BAO_0000219,B,,CHEMBL617497
,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,2857,15194,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL617498
,8,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,2858,15194,,1,,Autocuration,12689,,,,H,,,,BAO_0000357,B,,CHEMBL617499
,8,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,2859,14579,,1,,Autocuration,12689,,,,H,,,,BAO_0000019,F,,CHEMBL617500
,8,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,2860,4639,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617501
,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,2861,4820,,1,,Expert,108,,,,H,,,,BAO_0000357,B,,CHEMBL617502
,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,2862,14442,,1,,Autocuration,227,,,,H,,,,BAO_0000357,B,,CHEMBL617503
,8,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,2863,14755,,1,,Autocuration,227,,,,H,,,,BAO_0000357,B,,CHEMBL617504
,8,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,2864,14744,,1,,Autocuration,227,,,,H,,,,BAO_0000357,B,,CHEMBL617406
,9,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,2865,6857,,1,Homo sapiens,Expert,227,,9606.0,,D,,,,BAO_0000019,B,,CHEMBL617407
,8,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,2866,16209,,1,,Autocuration,227,,,,H,,,,BAO_0000357,B,,CHEMBL617408
,8,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,2867,15363,,1,,Autocuration,227,,,,H,,,,BAO_0000357,B,,CHEMBL617409
,8,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,2868,15363,,1,,Autocuration,227,,,,H,,,,BAO_0000357,B,,CHEMBL617410
,8,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,2869,15363,,1,,Autocuration,227,,,,H,,,,BAO_0000357,B,,CHEMBL617411
,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,2870,17085,,1,,Autocuration,227,,,,H,,,,BAO_0000019,B,,CHEMBL617412
,9,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,2871,17200,,1,Homo sapiens,Expert,227,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL617774
,9,722.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,2872,15851,,1,Homo sapiens,Expert,227,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL617775
,9,722.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,2873,15851,,1,Homo sapiens,Expert,227,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL617776
,9,449.0,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,2874,6857,,1,Homo sapiens,Expert,227,,9606.0,,D,,,CHO,BAO_0000219,F,,CHEMBL617777
,9,449.0,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,2875,6857,,1,Homo sapiens,Expert,227,,9606.0,,D,,,CHO,BAO_0000219,F,,CHEMBL617778
,8,722.0,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,2876,15779,,1,,Autocuration,227,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617779
,8,722.0,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,2877,15851,,1,,Expert,227,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617780
,8,722.0,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,2878,15779,,1,,Autocuration,227,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617781
,9,722.0,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,2879,14157,,1,Homo sapiens,Expert,227,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL617782
,9,722.0,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,2880,4540,,1,Homo sapiens,Expert,227,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL617783
,8,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,2881,6166,,1,,Autocuration,227,,,,H,,,,BAO_0000357,B,,CHEMBL617784
,8,722.0,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,2882,15779,,1,,Autocuration,227,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617785
,8,722.0,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,2883,14391,,1,,Expert,227,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL857984
,8,722.0,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,2884,3832,,1,,Expert,227,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617786
,8,722.0,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,2885,3833,,1,,Expert,227,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617787
,9,722.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,2886,15851,,1,Homo sapiens,Expert,227,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL617788
,9,722.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,2887,15851,,1,Homo sapiens,Expert,227,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL617789
,8,722.0,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,2888,4199,,1,,Autocuration,227,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617790
,8,485.0,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,2889,1883,,1,,Expert,227,,,,H,,,CHO-K1,BAO_0000219,B,,CHEMBL617791
,8,,Binding affinity against 5-hydroxytryptamine 2B receptor,,2890,4321,,1,,Expert,227,,,,H,,,,BAO_0000357,B,,CHEMBL617608
,8,722.0,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,2891,15146,,1,,Autocuration,227,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617609
,8,722.0,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,2892,5213,,1,,Autocuration,227,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617610
,8,722.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,2893,14818,,1,,Autocuration,227,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617611
,8,722.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,2894,4829,,1,,Autocuration,227,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617612
,8,722.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,2895,4829,,1,,Autocuration,227,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL617613
,8,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,2896,14025,,1,Oryctolagus cuniculus,Autocuration,227,,9986.0,,H,,,,BAO_0000019,B,,CHEMBL617614
,8,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,2897,13463,,1,,Expert,12688,,,Stomach,H,945.0,,,BAO_0000019,B,,CHEMBL617615
,8,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,2898,7259,,1,,Expert,12688,,,Stomach,H,945.0,,,BAO_0000357,B,,CHEMBL858114
,8,,Affinity against serotonergic receptor in the isolated rat stomach fundus,,2899,7259,,1,,Autocuration,12688,,,Stomach,H,945.0,,,BAO_0000357,B,,CHEMBL617616
,9,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,2900,7185,,1,Rattus norvegicus,Expert,12688,,10116.0,Stomach,D,945.0,,,BAO_0000019,F,,CHEMBL617617
,9,,Antagonistic against 5-hydroxytryptamine 2B receptor,,2901,7185,,1,Rattus norvegicus,Expert,12688,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL875914
,8,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,2902,13267,,1,,Autocuration,12688,,,Stomach,H,945.0,,,BAO_0000019,F,,CHEMBL617618
,9,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,2903,13735,,1,Rattus norvegicus,Expert,12688,,10116.0,Stomach,D,945.0,,,BAO_0000357,B,,CHEMBL617619
,8,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,2904,15738,,1,,Autocuration,12688,,,,H,,,,BAO_0000019,F,,CHEMBL617620
,8,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,2905,15738,,1,,Autocuration,12688,,,,H,,,,BAO_0000019,F,,CHEMBL617621
,8,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,2906,15738,,1,,Autocuration,12688,,,,H,,,,BAO_0000019,F,,CHEMBL617622
,9,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,2907,12936,,1,Rattus norvegicus,Expert,12688,,10116.0,Stomach,D,945.0,,,BAO_0000357,B,,CHEMBL617623
,9,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,2908,12936,,1,Rattus norvegicus,Expert,12688,,10116.0,Stomach,D,945.0,,,BAO_0000357,B,,CHEMBL617624
,9,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,2909,12936,,1,Rattus norvegicus,Expert,12688,,10116.0,Stomach,D,945.0,,,BAO_0000357,B,,CHEMBL617625
,9,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,2910,12936,,1,Rattus norvegicus,Expert,12688,,10116.0,Stomach,D,945.0,,,BAO_0000357,B,,CHEMBL617626
,8,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,2911,16404,,1,,Autocuration,12688,,,Stomach,H,945.0,,,BAO_0000019,F,,CHEMBL617627
,8,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,2912,16404,,1,,Expert,12688,,,Stomach,H,945.0,,,BAO_0000019,F,,CHEMBL617628
,8,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,2913,16404,,1,,Autocuration,12688,,,Stomach,H,945.0,,,BAO_0000019,F,,CHEMBL617629
,8,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,2914,16404,,1,,Autocuration,12688,,,Stomach,H,945.0,,,BAO_0000019,F,,CHEMBL858115
,9,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,2915,16404,,1,Rattus norvegicus,Expert,12688,,10116.0,Stomach,D,945.0,,,BAO_0000019,F,,CHEMBL617630
,8,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,2916,16404,,1,,Autocuration,12688,,,Thoracic aorta,H,1515.0,,,BAO_0000019,F,,CHEMBL617631
,8,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,2917,7483,,1,,Autocuration,12688,,,,H,,,,BAO_0000357,B,,CHEMBL617632
,8,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,2918,7483,,1,,Expert,12688,,,,H,,,,BAO_0000357,B,,CHEMBL617633
,8,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,2919,7483,,1,,Autocuration,12688,,,,H,,,,BAO_0000357,B,,CHEMBL617634
,8,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,2920,7483,,1,,Autocuration,12688,,,,H,,,,BAO_0000357,B,,CHEMBL617635
,9,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,2922,16404,,1,Rattus norvegicus,Autocuration,12688,,10116.0,Stomach,D,945.0,,,BAO_0000019,F,,CHEMBL617637
,8,,Binding affinity against 5-hydroxytryptamine 1A receptor,,2923,6347,,1,,Autocuration,227,,,,H,,,,BAO_0000357,B,,CHEMBL617638
,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,2924,4373,,1,,Autocuration,227,,,,H,,,,BAO_0000357,B,,CHEMBL617639
,8,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,2925,4373,,1,,Autocuration,227,,,,H,,,,BAO_0000357,B,,CHEMBL617640
,8,,Evaluated for the binding affinity to 5-HT 2B receptor,,2926,4687,,1,,Autocuration,227,,,,H,,,,BAO_0000357,B,,CHEMBL617641
,8,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,2927,16946,,1,,Autocuration,227,,,,H,,,,BAO_0000357,B,,CHEMBL617642
,8,,Binding affinities against 5-hydroxytryptamine 2B receptor,,2928,16633,,1,,Autocuration,227,,,,H,,,,BAO_0000357,B,,CHEMBL617643
,8,,Binding affinities towards 5-hydroxytryptamine 2B receptor,,2929,16633,,1,,Autocuration,227,,,,H,,,,BAO_0000357,B,,CHEMBL617644
,8,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,2930,16633,,1,,Autocuration,227,,,,H,,,,BAO_0000357,B,,CHEMBL617645
,8,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,2931,15026,,1,,Expert,108,,,,H,,,,BAO_0000357,B,,CHEMBL617646
,8,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,2932,15738,,1,Bos taurus,Autocuration,108,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL617647
,8,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,2933,15738,,1,Bos taurus,Autocuration,108,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL617648
,8,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,2934,15738,,1,Bos taurus,Autocuration,108,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL617875
,8,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,2935,15738,,1,Bos taurus,Autocuration,108,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL617876
,8,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,2936,16404,,1,Bos taurus,Expert,108,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL617877
,8,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,2937,15026,,1,Bos taurus,Expert,108,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL617878
,8,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,2938,15738,,1,Bos taurus,Autocuration,108,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL617879
,8,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,2939,16312,,1,Cavia porcellus,Autocuration,108,,10141.0,,H,,,,BAO_0000019,B,,CHEMBL617880
,9,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,2940,5486,,1,Cavia porcellus,Intermediate,20033,,10141.0,Striatum,D,2435.0,,,BAO_0000357,B,,CHEMBL617881
,8,,Binding affinity against 5-HT1A receptor,,2941,5254,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL857073
,8,449.0,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,2942,3857,,1,,Expert,108,,,,H,,,CHO,BAO_0000219,F,,CHEMBL617882
,9,449.0,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,2943,6857,,1,Homo sapiens,Expert,108,,9606.0,,D,,,CHO,BAO_0000219,F,,CHEMBL617883
,8,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,2944,4176,,1,,Autocuration,108,,,,H,,,,BAO_0000219,F,,CHEMBL617884
,8,449.0,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,2945,6347,,1,,Autocuration,108,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617885
,8,449.0,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,2946,6347,,1,,Autocuration,108,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617886
,9,,Inhibition of human 5-hydroxytryptamine 2C receptor,,2947,16146,,1,Homo sapiens,Expert,108,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL617887
,8,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,2948,3805,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617888
,8,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,2949,3857,,1,,Autocuration,108,,,,H,,,,BAO_0000019,B,,CHEMBL617889
,8,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,2950,5635,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617890
,8,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,2951,5635,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617891
,8,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,2952,5635,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617892
,8,449.0,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,2953,4012,,1,,Expert,108,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617893
,8,449.0,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,2954,6366,,1,,Expert,108,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617894
,8,449.0,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,2955,15949,,1,,Expert,108,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617895
,8,449.0,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,2956,17211,,1,,Autocuration,108,,,,H,,,CHO,BAO_0000219,B,,CHEMBL617896
,9,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,2957,6491,,1,Homo sapiens,Expert,108,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL617897
,8,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,2958,14093,,1,,Autocuration,108,,,,H,,,,BAO_0000019,F,,CHEMBL617898
,8,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,2959,13481,,1,,Autocuration,108,,,,H,,,,BAO_0000019,F,,CHEMBL617899
,8,449.0,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,2960,6347,,1,Rattus norvegicus,Expert,108,,10116.0,,H,,,CHO,BAO_0000219,B,,CHEMBL617900
,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,2961,14093,,1,,Autocuration,108,,,,H,,,,BAO_0000019,F,,CHEMBL617901
,8,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,2962,14093,,1,,Autocuration,108,,,,H,,,,BAO_0000019,F,,CHEMBL617902
,8,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,2963,13481,,1,,Autocuration,108,,,,H,,,,BAO_0000019,F,,CHEMBL617903
,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,2964,14442,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617904
,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,2965,14442,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617905
,8,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,2966,14442,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617906
,8,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,2967,14755,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617907
,8,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,2968,14744,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL617908
,8,449.0,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,2969,16659,,1,,Expert,108,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620617
,9,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,2970,6857,,1,Homo sapiens,Expert,108,,9606.0,,D,,,,BAO_0000019,B,,CHEMBL620618
,8,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,2971,5635,,1,,Expert,108,,,,H,,,,BAO_0000357,B,,CHEMBL620619
,9,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,2972,4234,,1,Homo sapiens,Expert,108,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL620620
,8,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,2973,16209,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL620621
,7,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,2974,5778,Membranes,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000249,B,,CHEMBL872920
,6,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,2975,5094,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL620622
,7,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,2976,809,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL620623
,6,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,2977,1578,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL620624
,6,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,2978,809,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL620625
,6,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,2979,12469,,1,,Autocuration,104698,,,,H,,,,BAO_0000219,B,,CHEMBL620626
,6,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,2980,14290,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL621307
,6,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,2981,14290,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL621308
,6,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,2982,10609,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL621309
,6,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,2983,10609,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL621310
,6,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,2984,10609,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL621311
,6,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,2985,15253,,1,,Autocuration,104698,,,,H,,,,BAO_0000249,B,,CHEMBL621502
,6,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,2986,15253,,1,,Autocuration,104698,,,,H,,,,BAO_0000249,B,,CHEMBL621503
,6,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,2987,11683,Membranes,1,,Autocuration,104698,,,,H,,,,BAO_0000249,B,,CHEMBL621504
,6,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,2988,12092,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL621505
,6,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,2989,1946,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL621506
,6,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,2990,11623,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL619781
,6,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,2991,11623,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL619782
,6,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,2992,14788,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL619783
,7,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,2993,5432,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL619784
,6,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,2994,14826,,1,,Autocuration,104698,,,,H,,,,BAO_0000249,B,,CHEMBL619785
,6,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,2995,2222,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL619786
,6,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,2996,11963,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL619787
,6,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,2997,14145,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL872925
,6,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,2998,17819,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL619788
,6,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,2999,10394,,1,,Autocuration,104698,,,,H,,,,BAO_0000249,B,,CHEMBL619789
,6,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,3000,10394,,1,,Autocuration,104698,,,,H,,,,BAO_0000249,B,,CHEMBL619790
,6,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,3001,15034,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL619791
,6,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,3002,691,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL619792
,6,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,3003,12092,Membranes,1,,Autocuration,104698,,,,H,,,,BAO_0000249,B,,CHEMBL619793
,7,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,3004,11752,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000223,B,,CHEMBL619794
,6,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,3005,11752,,1,,Autocuration,104698,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL619795
,6,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,3006,301,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL619796
,6,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,3007,16532,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL620448
,6,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,3008,16532,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL620449
,6,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,3009,12092,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL620450
,6,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,3010,11684,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL620451
,6,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,3011,11684,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL620631
,6,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,3012,12953,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL620632
,6,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,3013,12953,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL620633
,6,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,3014,12953,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL620634
,6,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,3015,12861,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL620635
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,3016,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620636
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,3017,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620637
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,3018,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620638
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,3019,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620639
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,3020,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620640
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,3021,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620641
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,3022,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620642
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,3023,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620643
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,3024,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620644
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,3025,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620645
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,3026,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620646
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,3027,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620647
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,3028,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620648
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,3029,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620649
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,3030,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620650
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,3031,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620651
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,3032,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL872875
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,3033,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620652
,6,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,3034,10609,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,F,,CHEMBL620653
,6,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,3035,12861,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL857076
,7,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,3036,12861,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL620654
,6,,Binding activity radioligand.,,3037,12861,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL620655
,6,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,3038,10728,Brain membranes,1,,Autocuration,104698,,,,H,,,,BAO_0000249,B,,CHEMBL620656
,6,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,3039,10728,Brain membranes,1,,Autocuration,104698,,,,H,,,,BAO_0000249,B,,CHEMBL620657
,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,3040,5163,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL620658
,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,3041,5163,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL620659
,8,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,3042,6011,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL620660
,8,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,3043,5014,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL620661
,8,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,3044,5635,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL620662
,8,,Affinity for 5-hydroxytryptamine 2C receptor,,3045,5163,,1,,Expert,108,,,,H,,,,BAO_0000357,B,,CHEMBL620663
,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,3046,6841,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL620664
,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,3047,6119,,1,,Expert,108,,,,H,,,,BAO_0000357,B,,CHEMBL620665
,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,3048,4373,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL620666
,8,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,3049,1633,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL620667
,8,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,3050,1633,,1,,Expert,108,,,,H,,,,BAO_0000357,B,,CHEMBL620668
,8,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,3051,4373,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL620669
,8,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,3052,6576,,1,,Expert,108,,,,H,,,,BAO_0000357,B,,CHEMBL620670
,8,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,3053,4687,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL620671
,8,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,3054,12146,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL620672
,8,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,3055,12146,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL620673
,8,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,3056,16946,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL620674
,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,3057,14159,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL620675
,8,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,3058,16700,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL620676
,8,,Affinity against 5-hydroxytryptamine 2C receptor,,3059,3269,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL621382
,9,,Binding affinity against 5-hydroxytryptamine 2C receptor,,3060,1274,,1,Homo sapiens,Expert,108,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL621383
,8,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,3061,1317,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL621384
,8,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,3062,5834,,1,Bos taurus,Autocuration,144,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL621385
,8,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,3063,11147,,1,Bos taurus,Autocuration,144,,9913.0,,H,,,,BAO_0000357,B,,CHEMBL617989
,4,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,3064,14145,,1,Cavia porcellus,Expert,104714,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL617990
,4,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,3065,10561,,1,Cavia porcellus,Autocuration,104714,,10141.0,Ileum,H,2116.0,,,BAO_0000221,B,,CHEMBL875085
,4,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,3066,15847,,1,Cavia porcellus,Autocuration,104714,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL617991
,4,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,3067,15847,,1,Cavia porcellus,Autocuration,104714,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL617992
,4,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,3068,10561,,1,Cavia porcellus,Autocuration,104714,,10141.0,Ileum,H,2116.0,,,BAO_0000221,B,,CHEMBL617993
,4,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,3069,11454,,1,Cavia porcellus,Autocuration,104714,,10141.0,Ileum,H,2116.0,,,BAO_0000221,B,,CHEMBL617994
,4,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,3070,4639,,1,Cavia porcellus,Autocuration,104714,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL617995
,4,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,3071,4639,,1,Cavia porcellus,Autocuration,104714,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL617996
,4,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,3072,4639,,1,Cavia porcellus,Autocuration,104714,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL617997
,4,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,3073,4639,,1,Cavia porcellus,Autocuration,104714,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL617998
,4,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,3074,4639,,1,Cavia porcellus,Autocuration,104714,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL617999
,4,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,3075,4639,,1,Cavia porcellus,Autocuration,104714,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL618000
,4,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,3076,15253,,1,Cavia porcellus,Autocuration,104714,,10141.0,Ileum,H,2116.0,,,BAO_0000221,F,,CHEMBL617815
,4,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,3077,15253,,1,Cavia porcellus,Autocuration,104714,,10141.0,Ileum,H,2116.0,,,BAO_0000221,F,,CHEMBL617816
,4,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,3078,11963,,1,Cavia porcellus,Autocuration,104714,,10141.0,Ileum,H,2116.0,,,BAO_0000221,F,,CHEMBL617817
,4,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,3079,1946,,1,Cavia porcellus,Autocuration,104714,,10141.0,Ileum,H,2116.0,,,BAO_0000221,B,,CHEMBL617818
,4,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,3080,1946,,1,Cavia porcellus,Autocuration,104714,,10141.0,Ileum,H,2116.0,,,BAO_0000221,B,,CHEMBL617819
,4,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,3081,12045,,1,Cavia porcellus,Autocuration,104714,,10141.0,,H,,,,BAO_0000223,B,,CHEMBL617820
,4,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,3082,1559,,1,Cavia porcellus,Autocuration,104714,,10141.0,Ileum,H,2116.0,,,BAO_0000221,B,,CHEMBL617821
,4,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,3083,273,,1,Cavia porcellus,Autocuration,104714,,10141.0,Ileum,H,2116.0,,,BAO_0000221,F,,CHEMBL617822
,4,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,3084,273,,1,Cavia porcellus,Autocuration,104714,,10141.0,Ileum,H,2116.0,,,BAO_0000221,F,,CHEMBL617823
,4,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,3085,188,,1,Cavia porcellus,Autocuration,104714,,10141.0,Ileum,H,2116.0,,,BAO_0000221,F,,CHEMBL617824
,4,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,3086,12919,,1,Cavia porcellus,Autocuration,104714,,10141.0,Ileum,H,2116.0,,,BAO_0000221,F,,CHEMBL617825
,4,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,3087,12918,,1,Cavia porcellus,Autocuration,104714,,10141.0,Ileum,H,2116.0,,,BAO_0000221,F,,CHEMBL617826
,4,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,3088,1559,,1,Cavia porcellus,Autocuration,104714,,10141.0,Ileum,H,2116.0,,,BAO_0000221,B,,CHEMBL617827
,4,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,3089,273,,1,Cavia porcellus,Autocuration,104714,,10141.0,Ileum,H,2116.0,,,BAO_0000221,F,,CHEMBL617828
,4,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,3090,1559,,1,Cavia porcellus,Autocuration,104714,,10141.0,Ileum,H,2116.0,,,BAO_0000221,B,,CHEMBL617829
,4,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,3091,1559,,1,Cavia porcellus,Autocuration,104714,,10141.0,Ileum,H,2116.0,,,BAO_0000221,B,,CHEMBL617830
,4,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,3092,1559,,1,Cavia porcellus,Autocuration,104714,,10141.0,Ileum,H,2116.0,,,BAO_0000221,B,,CHEMBL617831
,4,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,3093,14424,,1,Cavia porcellus,Autocuration,104714,,10141.0,Ileum,H,2116.0,,,BAO_0000221,B,,CHEMBL617832
,0,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,3094,13181,,1,Cavia porcellus,Autocuration,22226,,10141.0,,U,,,,BAO_0000019,B,,CHEMBL617833
,8,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,3095,5486,,1,,Autocuration,51,,,,H,,,,BAO_0000357,B,,CHEMBL617834
,5,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,3096,6491,,1,Homo sapiens,Expert,104714,,9606.0,,D,,,,BAO_0000223,B,,CHEMBL617835
,4,,Binding affinity towards 5-HT3 receptor,,3097,6013,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL617836
,4,,Binding activity radioligand.,,3098,12861,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL617837
,4,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,3099,12861,,1,,Autocuration,104714,,,,H,,,,BAO_0000019,B,,CHEMBL620392
,4,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,3100,5104,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL620393
,4,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,3101,5105,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL620394
,4,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,3102,5104,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL620395
,0,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,3103,3935,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL620396
,4,433.0,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,3104,13657,,1,,Expert,105030,,,,H,,,NG108-15,BAO_0000219,B,,CHEMBL620582
,4,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,3105,10369,,1,,Autocuration,105030,,,,H,,In vivo,,BAO_0000218,B,,CHEMBL620583
,4,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,3106,10369,,1,,Autocuration,105030,,,,H,,,,BAO_0000019,B,,CHEMBL620584
,4,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,3107,12918,,1,,Autocuration,105030,,,,H,,,,BAO_0000224,B,,CHEMBL620585
,4,,Compound was evaluated for the binding affinity at 5- HT3 receptor,,3108,12918,,1,,Autocuration,105030,,,,H,,,,BAO_0000224,B,,CHEMBL620586
,4,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,3109,10369,,1,,Autocuration,105030,,,,H,,,,BAO_0000019,B,,CHEMBL620587
,4,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,3110,773,,1,,Autocuration,105030,,,,H,,,,BAO_0000019,B,,CHEMBL620588
,4,,5-hydroxytryptamine 3 receptor agonism in mouse,,3111,12918,,1,,Autocuration,105030,,,,H,,,,BAO_0000218,F,,CHEMBL620589
,4,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,3112,10561,,1,,Autocuration,105030,,,,H,,,,BAO_0000219,B,,CHEMBL620590
,4,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,3113,12827,,1,,Autocuration,105030,,,,H,,,,BAO_0000019,B,,CHEMBL617956
,4,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,3114,12827,,1,,Autocuration,105030,,,,H,,,,BAO_0000019,B,,CHEMBL617957
,4,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,3115,12918,,1,,Autocuration,105030,,,,H,,,,BAO_0000224,B,,CHEMBL617958
,4,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,3116,273,,1,,Autocuration,105030,,,,H,,,,BAO_0000219,B,,CHEMBL617959
,4,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,3117,273,,1,,Autocuration,105030,,,,H,,,,BAO_0000219,B,,CHEMBL617960
,4,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,3118,10561,,1,,Autocuration,105030,,,,H,,,,BAO_0000224,B,,CHEMBL617961
,4,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,3119,5033,,1,,Autocuration,105030,,,,H,,In vitro,,BAO_0000219,B,,CHEMBL617962
,4,339.0,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,3120,16429,,1,,Autocuration,105030,,,,H,,,N1E-115,BAO_0000219,B,,CHEMBL617963
,8,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,3121,10322,,1,,Autocuration,11765,,,,H,,,,BAO_0000019,B,,CHEMBL617964
,8,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,3122,14331,,1,,Autocuration,11765,,,,H,,,,BAO_0000219,B,,CHEMBL617965
,9,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,3123,13462,,1,Mus musculus,Autocuration,10630,,10090.0,,D,,,,BAO_0000357,B,,CHEMBL617966
,8,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,3124,12861,,1,,Autocuration,17106,,,,H,,,,BAO_0000019,B,,CHEMBL857074
,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,3125,15086,,1,Sus scrofa,Autocuration,144,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL617967
,8,,Binding activity radioligand.,,3126,12861,,1,Sus scrofa,Autocuration,144,,9823.0,,H,,,,BAO_0000357,B,,CHEMBL617968
,4,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,3127,10561,,1,Oryctolagus cuniculus,Autocuration,104714,,9986.0,,H,,,,BAO_0000223,B,,CHEMBL617969
,4,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,3128,10561,,1,Oryctolagus cuniculus,Autocuration,104714,,9986.0,,H,,,,BAO_0000223,B,,CHEMBL617970
,4,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,3129,10561,,1,Oryctolagus cuniculus,Autocuration,104714,,9986.0,,H,,,,BAO_0000223,B,,CHEMBL617971
,4,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,3130,10561,,1,Oryctolagus cuniculus,Autocuration,104714,,9986.0,,H,,,,BAO_0000019,B,,CHEMBL617972
,4,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,3131,273,,1,Oryctolagus cuniculus,Autocuration,104714,,9986.0,,H,,,,BAO_0000019,F,,CHEMBL617973
,4,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,3132,273,,1,Oryctolagus cuniculus,Autocuration,104714,,9986.0,,H,,,,BAO_0000019,F,,CHEMBL617974
,4,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,3133,273,,1,Oryctolagus cuniculus,Autocuration,104714,,9986.0,Ileum,H,2116.0,,,BAO_0000221,F,,CHEMBL617975
,4,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,3134,273,,1,Oryctolagus cuniculus,Autocuration,104714,,9986.0,,H,,,,BAO_0000019,F,,CHEMBL617976
,4,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,3135,273,,1,Oryctolagus cuniculus,Autocuration,104714,,9986.0,,H,,,,BAO_0000019,F,,CHEMBL617977
,4,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,3136,273,,1,Oryctolagus cuniculus,Autocuration,104714,,9986.0,,H,,,,BAO_0000019,F,,CHEMBL617978
,4,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,3137,273,,1,Oryctolagus cuniculus,Autocuration,104714,,9986.0,,H,,,,BAO_0000019,F,,CHEMBL617979
,4,449.0,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,3138,13047,,1,Oryctolagus cuniculus,Autocuration,104714,,9986.0,,H,,,CHO,BAO_0000219,B,,CHEMBL617980
,7,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,3139,1650,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617981
,8,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,3140,16288,,1,,Autocuration,12020,,,,H,,,,BAO_0000019,B,,CHEMBL617982
,8,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,3141,16288,,1,,Autocuration,12020,,,,H,,,,BAO_0000357,B,,CHEMBL617983
,7,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,3142,10254,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617984
,6,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,3143,14532,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL617985
,6,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,3144,13392,,1,,Autocuration,104698,,,Heart,H,948.0,In vivo,,BAO_0000218,F,,CHEMBL617986
,6,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,3145,13392,,1,,Autocuration,104698,,,Heart,H,948.0,,,BAO_0000019,F,,CHEMBL617987
,6,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,3146,13392,,1,,Autocuration,104698,,,Heart,H,948.0,,,BAO_0000019,F,,CHEMBL617988
,6,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,3147,13392,,1,,Autocuration,104698,,,Heart,H,948.0,,,BAO_0000019,F,,CHEMBL617792
,6,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,3148,13392,,1,,Autocuration,104698,,,Heart,H,948.0,,,BAO_0000019,F,,CHEMBL617793
,6,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,3149,13392,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,F,,CHEMBL617794
,6,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,3150,13392,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,F,,CHEMBL617795
,6,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,3151,13392,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,F,,CHEMBL617796
,6,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,3152,13392,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,F,,CHEMBL617797
,7,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,3153,1089,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,In vivo,,BAO_0000218,F,,CHEMBL617798
,6,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,3154,1089,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617799
,7,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,3155,11454,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,In vivo,,BAO_0000218,F,,CHEMBL617800
,7,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,3156,11454,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL617801
,7,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,3157,12205,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,In vivo,,BAO_0000218,F,,CHEMBL617802
,7,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,3158,1089,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL617803
,6,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,3159,5094,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL617804
,7,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,3160,2622,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617805
,6,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,3161,245,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL617806
,6,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,3162,14788,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL617807
,6,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,3163,14788,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL617808
,6,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,3164,3020,,1,,Autocuration,104698,,,,H,,,,BAO_0000249,B,,CHEMBL617809
,6,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,3165,1742,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL617810
,6,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,3166,17394,,1,,Autocuration,104698,,,Brain,H,955.0,,,BAO_0000249,B,,CHEMBL617811
,6,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,3167,17394,,1,,Autocuration,104698,,,Brain,H,955.0,,,BAO_0000221,B,,CHEMBL617812
,6,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,3168,17394,,1,,Autocuration,104698,,,,H,,,,BAO_0000249,B,,CHEMBL617813
,6,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,3169,14286,,1,,Autocuration,104698,,,,H,,,,BAO_0000249,B,,CHEMBL617814
,6,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,3170,14178,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL617698
,7,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,3171,14178,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617699
,7,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,3172,14178,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617700
,7,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,3173,14178,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000223,B,,CHEMBL617701
,6,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,3174,15034,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL617702
,6,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,3175,1089,Membranes,1,,Autocuration,104698,,,,H,,,,BAO_0000249,B,,CHEMBL617703
,7,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,3176,1089,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL617704
,6,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,3177,16532,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL617705
,7,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,3178,12801,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000223,B,,CHEMBL617706
,6,433.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,3179,15194,,1,,Autocuration,104698,,,,H,,,NG108-15,BAO_0000219,B,,CHEMBL617707
,6,433.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,3180,15194,,1,,Autocuration,104698,,,,H,,,NG108-15,BAO_0000219,B,,CHEMBL617708
,6,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,3181,15194,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL617709
,6,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,3182,15194,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL617710
,6,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,3183,15194,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL882925
,6,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,3184,15194,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL617711
,6,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,3185,10610,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,F,,CHEMBL617712
,7,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,3186,10355,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL617713
,6,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,3187,691,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,F,,CHEMBL617714
,6,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,3188,10611,,1,,Autocuration,104698,,,,H,,,,BAO_0000218,F,,CHEMBL617715
,6,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,3189,12801,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617716
,6,,Inhibition of 5-HT evoked reflex bradycardia in rat.,,3190,10609,,1,,Autocuration,104698,,,,H,,,,BAO_0000218,F,,CHEMBL617717
,6,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,3191,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617718
,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,3192,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617719
,6,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,3193,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617720
,7,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,3194,11454,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,In vivo,,BAO_0000218,F,,CHEMBL617721
,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,3195,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617722
,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,3196,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617723
,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,3197,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617724
,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,3198,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617725
,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,3199,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617726
,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,3200,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617727
,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,3201,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617728
,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,3202,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617729
,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,3203,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617730
,6,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,3204,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617731
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,3205,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617732
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,3206,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617733
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,3207,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617734
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,3208,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL872874
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,3209,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617735
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,3210,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617736
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,3211,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617737
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,3212,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617738
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,3213,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617739
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,3214,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617740
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,3215,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617741
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,3216,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617742
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,3217,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617743
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,3218,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617744
,6,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,3219,11454,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617745
,6,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,3220,670,,1,,Autocuration,104698,,,,H,,,,BAO_0000218,F,,CHEMBL617746
,6,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,3221,670,,1,,Autocuration,104698,,,,H,,,,BAO_0000218,F,,CHEMBL617747
,6,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,3222,10321,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL617748
,6,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,3223,10321,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL618909
,6,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,3224,10321,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL618910
,6,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,3225,10321,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL618911
,6,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,3226,10321,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL618912
,6,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,3227,10322,,1,,Autocuration,104698,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL618913
,6,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,3228,15412,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,F,,CHEMBL618914
,6,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,3229,15412,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,F,,CHEMBL618915
,7,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,3230,15412,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000223,B,,CHEMBL618916
,6,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,3231,15412,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,F,,CHEMBL618917
,7,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,3232,15412,,1,,Intermediate,104698,,,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL618918
,7,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,3233,15412,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL618919
,7,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,3234,17394,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL618920
,6,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,3235,12457,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL618921
,6,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,3236,12457,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL618922
,6,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,3237,12205,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL618923
,6,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,3238,14532,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL618924
,6,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,3239,1122,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL618925
,6,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,3240,5094,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL618926
,9,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,3241,809,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL618927
,9,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,3242,809,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL618928
,9,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,3243,14290,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL618929
,9,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,3244,14290,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL618930
,9,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,3245,14290,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL618931
,9,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,3246,14290,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619594
,9,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,3247,14290,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619595
,9,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,3248,13961,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619596
,9,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,3249,13961,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619755
,9,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,3250,809,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619756
,9,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,3251,809,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619757
,9,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,3252,809,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619758
,9,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,3253,14290,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619759
,9,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,3254,14290,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619760
,9,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,3255,14290,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619761
,9,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,3256,14290,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619762
,9,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,3257,14290,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619763
,9,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,3258,14290,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL617868
,9,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,3259,15034,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000357,B,,CHEMBL617869
,9,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,3260,5094,,1,Cavia porcellus,Intermediate,20033,,10141.0,Striatum,D,2435.0,,,BAO_0000249,B,,CHEMBL882926
,9,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,3261,5094,,1,Cavia porcellus,Intermediate,20033,,10141.0,Striatum,D,2435.0,,,BAO_0000249,B,,CHEMBL617870
,9,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,3262,5399,,1,Cavia porcellus,Intermediate,20033,,10141.0,Striatum,D,2435.0,,,BAO_0000357,B,,CHEMBL617871
,9,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,3263,17394,,1,Cavia porcellus,Intermediate,20033,,10141.0,Striatum,D,2435.0,,,BAO_0000357,B,,CHEMBL617872
,9,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,3264,17394,,1,Cavia porcellus,Intermediate,20033,,10141.0,Striatum,D,2435.0,,,BAO_0000357,B,,CHEMBL617873
,9,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,3265,17394,,1,Cavia porcellus,Intermediate,20033,,10141.0,Striatum,D,2435.0,,,BAO_0000357,B,,CHEMBL617874
,9,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,3266,13961,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619067
,9,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,3267,13961,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619068
,9,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,3268,13961,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619069
,9,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,3269,16946,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000357,B,,CHEMBL619070
,9,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,3270,16946,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000357,B,,CHEMBL619071
,9,,Agonistic activity against 5-hydroxytryptamine 4 receptor,,3271,15034,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000019,F,,CHEMBL619072
,9,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,3272,15034,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000019,F,,CHEMBL619073
,9,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,3273,12918,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000019,F,,CHEMBL619074
,9,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,3274,16946,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000357,B,,CHEMBL619075
,9,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,3275,17394,,1,Cavia porcellus,Intermediate,20033,,10141.0,Striatum,D,2435.0,,,BAO_0000357,B,,CHEMBL619076
,9,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,3276,15034,,1,Cavia porcellus,Intermediate,20033,,10141.0,Striatum,D,2435.0,,,BAO_0000357,B,,CHEMBL619077
,9,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,3277,5094,,1,Cavia porcellus,Intermediate,20033,,10141.0,Striatum,D,2435.0,,,BAO_0000249,B,,CHEMBL619078
,9,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,3278,5094,,1,Cavia porcellus,Intermediate,20033,,10141.0,Striatum,D,2435.0,,,BAO_0000249,B,,CHEMBL619079
,9,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,3279,17358,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,B,,CHEMBL619080
,9,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,3280,12953,,1,Cavia porcellus,Expert,20033,,10141.0,,D,,,,BAO_0000357,B,,CHEMBL619081
,9,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,3281,12953,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000357,B,,CHEMBL619082
,9,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,3282,12953,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000357,B,,CHEMBL619083
,9,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,3283,12953,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000357,B,,CHEMBL619084
,9,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,3284,273,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL859397
,9,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,3285,12918,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619085
,9,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,3286,12919,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619086
,9,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,3287,273,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619087
,9,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,3288,273,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619088
,9,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,3289,13181,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000357,B,,CHEMBL619089
,8,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,3290,13181,,1,Cavia porcellus,Autocuration,168,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL619090
,9,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,3291,15034,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000019,F,,CHEMBL619091
,9,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,3292,5033,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000357,B,,CHEMBL619092
,9,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,3293,1980,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000019,B,,CHEMBL619093
,8,722.0,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,3294,13181,,1,Cavia porcellus,Autocuration,168,,10141.0,,H,,,HEK293,BAO_0000219,B,,CHEMBL619094
,9,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,3295,14287,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000019,B,,CHEMBL619095
,9,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,3296,1317,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000357,B,,CHEMBL857988
,9,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,3297,15316,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000357,B,,CHEMBL619096
,9,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,3298,16429,,1,Cavia porcellus,Intermediate,20033,,10141.0,Striatum,D,2435.0,,,BAO_0000357,B,,CHEMBL619097
,9,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,3299,14818,,1,Cavia porcellus,Intermediate,20033,,10141.0,Hippocampus,D,10000000.0,,,BAO_0000221,B,,CHEMBL619098
,9,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,3300,15194,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000357,B,,CHEMBL619751
,9,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,3301,15194,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000357,B,,CHEMBL619752
,9,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,3302,13961,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL875096
,8,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,3303,5486,,1,,Autocuration,108,,,,H,,,,BAO_0000357,B,,CHEMBL619004
,8,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,3304,16209,,1,,Autocuration,168,,,,H,,,,BAO_0000357,B,,CHEMBL619005
,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,3305,17085,,1,,Autocuration,168,,,,H,,,,BAO_0000019,B,,CHEMBL619006
,8,308.0,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,3306,4199,,1,,Autocuration,168,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL619007
,8,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,3307,15146,,1,,Autocuration,168,,,,H,,,,BAO_0000357,B,,CHEMBL619008
,8,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,3308,5213,,1,,Autocuration,168,,,,H,,,,BAO_0000357,B,,CHEMBL619009
,8,308.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,3309,4829,,1,,Autocuration,168,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL619010
,8,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,3310,17358,,1,,Autocuration,10622,,,,H,,,,BAO_0000357,B,,CHEMBL619011
,8,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,3311,17358,,1,,Autocuration,10622,,,,H,,,,BAO_0000357,B,,CHEMBL619012
,8,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,3312,16946,,1,,Autocuration,10622,,,,H,,,,BAO_0000219,B,,CHEMBL619013
,8,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,3313,17358,,1,,Autocuration,10622,,,,H,,,,BAO_0000357,B,,CHEMBL619014
,8,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,3314,268,,1,,Autocuration,11249,,,Cardiac atrium,H,2081.0,,,BAO_0000019,F,,CHEMBL857503
,8,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,3315,268,,1,,Autocuration,11249,,,Cardiac atrium,H,2081.0,,,BAO_0000019,F,,CHEMBL619015
,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,3316,15086,,1,,Autocuration,11249,,,,H,,,,BAO_0000357,B,,CHEMBL619016
,8,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,3317,14875,,1,,Autocuration,11249,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL619017
,8,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,3318,13267,,1,Sus scrofa,Autocuration,168,,9823.0,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL619018
,8,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,3319,13047,,1,Oryctolagus cuniculus,Autocuration,168,,9986.0,,H,,,,BAO_0000019,B,,CHEMBL619019
,9,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,3320,1650,,1,Rattus norvegicus,Expert,10623,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL619020
,8,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,3321,567,,1,,Autocuration,10623,,,,H,,,,BAO_0000019,F,,CHEMBL619021
,8,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,3322,17358,,1,,Autocuration,10623,,,,H,,,,BAO_0000357,B,,CHEMBL619022
,8,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,3323,188,,1,,Autocuration,10623,,,,H,,,,BAO_0000357,B,,CHEMBL619023
,8,,lntrinsic activity relative to 5-HT receptor,,3324,670,,1,,Autocuration,10623,,,,H,,,,BAO_0000019,F,,CHEMBL619024
,8,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,3325,204,,1,,Autocuration,10623,,,,H,,,,BAO_0000019,F,,CHEMBL619025
,8,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,3326,1946,,1,,Expert,10623,,,,H,,,,BAO_0000019,F,,CHEMBL619026
,8,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,3327,6398,,1,,Autocuration,10623,,,,H,,,,BAO_0000019,F,,CHEMBL619027
,8,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,3328,6398,,1,,Autocuration,10623,,,,H,,,,BAO_0000019,F,,CHEMBL619028
,8,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,3329,17358,,1,,Autocuration,10623,,,,H,,,,BAO_0000019,F,,CHEMBL619029
,8,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,3330,6398,,1,,Autocuration,10623,,,,H,,,,BAO_0000019,F,,CHEMBL619030
,8,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,3331,11752,,1,,Expert,10623,,,,H,,,,BAO_0000357,B,,CHEMBL619031
,8,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,3332,809,,1,,Autocuration,10623,,,,H,,,,BAO_0000019,F,,CHEMBL619032
,9,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,3333,14178,,1,Rattus norvegicus,Expert,10623,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL619033
,8,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,3334,567,,1,,Autocuration,10623,,,,H,,,,BAO_0000357,B,,CHEMBL619034
,8,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,3335,1946,,1,,Autocuration,10623,,,,H,,,,BAO_0000357,B,,CHEMBL619035
,8,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,3336,1946,,1,,Autocuration,10623,,,,H,,,,BAO_0000357,B,,CHEMBL619036
,9,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,3337,13961,,1,Rattus norvegicus,Expert,10623,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL619037
,8,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,3338,6238,,1,,Autocuration,10623,,,Striatum,H,2435.0,,,BAO_0000249,B,,CHEMBL619038
,8,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,3339,14290,,1,,Autocuration,10623,,,,H,,,,BAO_0000249,B,,CHEMBL619039
,8,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,3340,14290,,1,,Expert,10623,,,,H,,,,BAO_0000249,B,,CHEMBL619040
,9,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,3341,809,,1,Rattus norvegicus,Expert,10623,,10116.0,Striatum,D,2435.0,,,BAO_0000019,B,,CHEMBL619041
,8,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,3342,1578,,1,,Autocuration,10623,,,Striatum,H,2435.0,,,BAO_0000019,B,,CHEMBL619042
,8,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,3343,16709,,1,,Expert,10623,,,Striatum,H,2435.0,,,BAO_0000249,B,,CHEMBL619043
,8,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,3344,1946,,1,,Expert,10623,,,Striatum,H,2435.0,,,BAO_0000019,B,,CHEMBL619044
,8,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,3345,15253,,1,,Expert,10623,,,Striatum,H,2435.0,,,BAO_0000249,B,,CHEMBL619045
,8,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,3346,4535,,1,,Expert,10623,,,Striatum,H,2435.0,,,BAO_0000249,B,,CHEMBL619046
,8,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,3347,13961,,1,,Expert,10623,,,,H,,,,BAO_0000249,B,,CHEMBL619047
,8,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,3348,17358,,1,,Autocuration,10623,,,Brain,H,955.0,,,BAO_0000221,F,,CHEMBL619048
,8,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,3349,15847,,1,,Autocuration,10623,,,,H,,,,BAO_0000019,F,,CHEMBL859398
,8,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,3350,15847,,1,,Autocuration,10623,,,,H,,,,BAO_0000019,F,,CHEMBL619049
,8,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,3351,670,,1,,Autocuration,10623,,,,H,,,,BAO_0000019,F,,CHEMBL857886
,8,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,3352,670,,1,,Autocuration,10623,,,,H,,,,BAO_0000019,F,,CHEMBL619050
,8,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,3353,1317,,1,,Autocuration,10623,,,,H,,,,BAO_0000019,F,,CHEMBL620591
,9,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,3354,12936,,1,Rattus norvegicus,Expert,10623,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL620592
,8,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,3355,4535,,1,,Expert,10623,,,Striatum,H,2435.0,,,BAO_0000249,B,,CHEMBL620593
,9,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,3356,14424,,1,Rattus norvegicus,Expert,10623,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL620594
,8,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,3357,14424,,1,,Expert,10623,,,,H,,,,BAO_0000019,F,,CHEMBL875079
,8,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,3358,14424,,1,,Expert,10623,,,,H,,,,BAO_0000019,F,,CHEMBL620595
,9,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,3359,14424,,1,Rattus norvegicus,Expert,10623,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL620596
,8,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,3360,14424,,1,,Autocuration,10623,,,,H,,,,BAO_0000019,F,,CHEMBL620597
,8,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,3361,14424,,1,,Expert,10623,,,,H,,,,BAO_0000019,F,,CHEMBL620598
,8,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,3362,14424,,1,,Expert,10623,,,,H,,,,BAO_0000218,F,,CHEMBL620599
,8,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,3363,14424,,1,,Autocuration,10623,,,,H,,,,BAO_0000019,F,,CHEMBL620600
,8,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,3364,1980,,1,Rattus norvegicus,Autocuration,168,,10116.0,,H,,,,BAO_0000019,F,,CHEMBL620601
,8,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,3365,4639,,1,,Autocuration,168,,,,H,,,,BAO_0000019,F,,CHEMBL620602
,8,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,3366,17358,,1,,Autocuration,168,,,,H,,,,BAO_0000357,B,,CHEMBL620603
,8,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,3367,17358,,1,,Autocuration,168,,,,H,,,,BAO_0000357,B,,CHEMBL620604
,8,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,3368,17358,,1,,Autocuration,168,,,,H,,,,BAO_0000357,B,,CHEMBL620605
,8,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,3369,1558,,1,,Autocuration,168,,,,H,,,,BAO_0000357,B,,CHEMBL620606
,8,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,3370,17358,,1,,Autocuration,168,,,,H,,,,BAO_0000019,F,,CHEMBL620607
,8,,In vitro binding affinity towards 5-HT4 receptor was determined,,3371,16117,,1,,Autocuration,168,,,,H,,,,BAO_0000357,B,,CHEMBL620608
,8,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,3372,17358,,1,,Autocuration,168,,,,H,,,,BAO_0000019,F,,CHEMBL620609
,8,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,3373,17358,,1,,Autocuration,168,,,,H,,,,BAO_0000019,F,,CHEMBL620610
,8,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,3374,17358,,1,,Autocuration,168,,,,H,,,,BAO_0000357,B,,CHEMBL620611
,8,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,3375,17358,,1,,Autocuration,168,,,,H,,,,BAO_0000357,B,,CHEMBL620612
,8,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,3376,17358,,1,,Autocuration,168,,,,H,,,,BAO_0000357,B,,CHEMBL620613
,8,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,3377,17358,,1,,Autocuration,168,,,,H,,,,BAO_0000357,B,,CHEMBL620614
,8,,Binding affinity against 5-Hydroxytryptamine 4 receptor,,3378,1274,,1,,Expert,168,,,,H,,,,BAO_0000357,B,,CHEMBL620615
,6,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,3379,10728,Brain membranes,1,,Autocuration,104698,,,,H,,,,BAO_0000249,B,,CHEMBL857075
,6,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,3380,11695,Brain membranes,1,,Autocuration,104698,,,,H,,,,BAO_0000249,B,,CHEMBL620616
,6,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,3381,11695,Brain membranes,1,,Autocuration,104698,,,,H,,,,BAO_0000249,B,,CHEMBL619411
,6,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,3382,12490,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL619412
,7,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,3383,11828,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL619413
,6,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,3384,12253,,1,,Autocuration,104698,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL619414
,6,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,3385,10561,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL619415
,6,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,3386,10561,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL619416
,6,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,3387,14432,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,F,,CHEMBL619417
,7,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,3388,12936,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000223,B,,CHEMBL619418
,7,,Binding affinity against 5-Hydroxytryptamine 3 receptor,,3389,1274,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000223,B,,CHEMBL619419
,6,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,3390,1980,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL619420
,6,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,3391,670,,1,,Autocuration,104698,,,,H,,,,BAO_0000249,B,,CHEMBL619421
,7,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,3392,968,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL619422
,6,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,3393,14287,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL619423
,6,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,3394,567,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL875080
,6,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,3395,13267,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL619424
,6,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,3396,14826,,1,,Autocuration,104698,,,,H,,,,BAO_0000249,B,,CHEMBL619425
,6,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,3397,15194,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL619426
,6,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,3398,15194,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL619427
,7,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,3399,10394,,1,Rattus norvegicus,Autocuration,104698,,10116.0,,D,,,,BAO_0000223,B,,CHEMBL619645
,9,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,3400,13657,,1,,Expert,10576,,,,D,,,,BAO_0000249,B,,CHEMBL619646
,8,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,3401,1879,,1,,Autocuration,12020,,,Brain,H,955.0,,,BAO_0000221,F,,CHEMBL619647
,8,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,3402,1879,,1,,Autocuration,12020,,,,H,,,,BAO_0000019,F,,CHEMBL619648
,8,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,3403,1879,,1,,Autocuration,12020,,,,H,,,,BAO_0000019,F,,CHEMBL619165
,8,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,3404,204,,1,,Autocuration,12020,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620719
,8,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,3405,1879,,1,,Autocuration,12020,,,,H,,,,BAO_0000019,B,,CHEMBL872924
,8,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,3406,1879,,1,,Autocuration,12020,,,,H,,,,BAO_0000357,B,,CHEMBL620720
,8,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,3407,1879,,1,,Autocuration,12020,,,,H,,,,BAO_0000019,B,,CHEMBL620721
,8,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,3408,1879,,1,,Autocuration,12020,,,,H,,,,BAO_0000019,B,,CHEMBL620722
,6,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,3409,10641,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,B,,CHEMBL620723
,8,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,3410,773,,1,,Autocuration,12020,,,,H,,,,BAO_0000019,B,,CHEMBL620724
,6,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,3411,11952,,1,,Autocuration,104698,,,,H,,,,BAO_0000249,B,,CHEMBL620725
,9,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,3412,14145,,1,Rattus norvegicus,Autocuration,12020,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL620726
,8,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,3413,17066,,1,,Expert,144,,,,H,,,,BAO_0000357,B,,CHEMBL620727
,4,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,3414,6398,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL620728
,0,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,3415,10321,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL620729
,4,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,3416,511,,1,,Autocuration,104714,,,,H,,,,BAO_0000019,F,,CHEMBL858288
,4,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,3417,4639,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL620730
,4,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,3418,4639,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL620731
,4,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,3419,4639,,1,Cavia porcellus,Autocuration,104714,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL620732
,4,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,3420,4639,,1,Cavia porcellus,Autocuration,104714,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL618042
,4,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,3421,4639,,1,Cavia porcellus,Autocuration,104714,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL618043
,4,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,3422,1558,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL618044
,4,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,3423,268,,1,,Autocuration,104714,,,,H,,,,BAO_0000019,F,,CHEMBL618045
,4,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,3424,2474,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL618046
,4,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,3425,5067,,1,,Autocuration,104714,,,,H,,,,BAO_0000019,F,,CHEMBL618047
,4,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,3426,5067,,1,,Autocuration,104714,,,,H,,,,BAO_0000019,F,,CHEMBL875084
,4,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,3427,5067,,1,,Autocuration,104714,,,,H,,,,BAO_0000019,F,,CHEMBL618048
,4,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,3428,5067,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL618049
,4,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,3429,5067,,1,,Autocuration,104714,,,,H,,,,BAO_0000019,F,,CHEMBL619764
,4,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,3430,5067,,1,,Autocuration,104714,,,,H,,,,BAO_0000019,F,,CHEMBL619765
,4,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,3431,5067,,1,,Autocuration,104714,,,,H,,,,BAO_0000019,F,,CHEMBL619766
,4,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,3432,5067,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL619767
,4,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,3433,5067,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL619768
,4,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,3434,5067,,1,,Autocuration,104714,,,,H,,,,BAO_0000019,F,,CHEMBL619769
,4,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,3435,5067,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL619770
,4,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,3436,5067,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL619771
,4,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,3437,14331,,1,,Autocuration,104714,,,,H,,,,BAO_0000219,B,,CHEMBL619772
,4,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,3438,5067,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL619773
,4,433.0,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,3439,6179,,1,,Autocuration,104714,,,,H,,,NG108-15,BAO_0000219,B,,CHEMBL619774
,4,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,3440,4265,,1,,Autocuration,104714,,,,H,,,,BAO_0000019,B,,CHEMBL875083
,4,433.0,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,3441,4265,,1,,Autocuration,104714,,,,H,,,NG108-15,BAO_0000219,B,,CHEMBL620718
,4,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,3442,17358,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL618127
,4,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,3443,17358,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL618128
,4,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,3444,13628,,1,,Autocuration,104714,,,,H,,In vitro,,BAO_0000219,B,,CHEMBL618129
,4,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,3445,4612,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL618130
,4,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,3446,17358,,1,,Autocuration,104714,,,,H,,,,BAO_0000019,F,,CHEMBL618131
,4,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,3447,4639,,1,Cavia porcellus,Autocuration,104714,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL618132
,4,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,3448,4639,,1,Cavia porcellus,Autocuration,104714,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL618133
,4,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,3449,4639,,1,Cavia porcellus,Autocuration,104714,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL618134
,4,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,3450,4639,,1,Cavia porcellus,Autocuration,104714,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL618135
,4,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,3451,511,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL618136
,4,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,3452,1479,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL618137
,4,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,3453,1317,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL618138
,4,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,3454,12146,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL618139
,4,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,3455,12146,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL618140
,4,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,3456,13969,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL618141
,8,,Binding affinity for 5-hydroxytryptamine 2C receptor,,3457,13392,,1,,Expert,108,,,,H,,,,BAO_0000357,B,,CHEMBL873478
,6,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,3458,13392,,1,,Autocuration,104698,,,,H,,,,BAO_0000223,B,,CHEMBL618142
,8,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,3459,14159,,1,,Autocuration,144,,,,H,,,,BAO_0000357,B,,CHEMBL618143
,8,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,3460,1558,,1,,Autocuration,144,,,,H,,,,BAO_0000357,B,,CHEMBL618144
,8,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,3461,16655,,1,,Autocuration,144,,,,H,,,,BAO_0000357,B,,CHEMBL618145
,4,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,3462,13020,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL618146
,4,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,3463,13021,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL618147
,4,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,3464,13020,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL618148
,8,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,3465,10321,,1,,Autocuration,144,,,,H,,,,BAO_0000019,B,,CHEMBL618149
,8,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,3466,15818,,1,,Autocuration,144,,,,H,,,,BAO_0000357,B,,CHEMBL872927
,8,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,3467,15818,,1,,Autocuration,144,,,,H,,,,BAO_0000357,B,,CHEMBL618150
,8,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,3468,17358,,1,,Autocuration,144,,,,H,,,,BAO_0000357,B,,CHEMBL618151
,8,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,3469,2222,,1,,Autocuration,144,,,,H,,,,BAO_0000357,B,,CHEMBL875094
,8,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,3470,10322,,1,,Autocuration,144,,,,H,,,,BAO_0000019,B,,CHEMBL618152
,8,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,3471,16117,,1,,Autocuration,144,,,,H,,,,BAO_0000357,B,,CHEMBL618153
,8,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,3472,17200,,1,,Autocuration,144,,,,H,,,,BAO_0000357,B,,CHEMBL618888
,8,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,3473,17358,,1,,Autocuration,144,,,,H,,,,BAO_0000019,F,,CHEMBL618889
,8,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,3474,16700,,1,,Autocuration,144,,,,H,,,,BAO_0000357,B,,CHEMBL618890
,8,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,3475,1980,,1,,Autocuration,144,,,,H,,,,BAO_0000019,B,,CHEMBL618891
,8,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,3476,1980,,1,,Autocuration,144,,,,H,,,,BAO_0000019,B,,CHEMBL619054
,4,,Binding affinity against the 5-hydroxytryptamine 3 receptor,,3477,12409,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL619055
,8,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,3478,4365,,1,,Autocuration,144,,,,H,,,,BAO_0000357,B,,CHEMBL619056
,8,,Percent efficacy against 5-hydroxytryptamine 3A receptor,,3479,4365,,1,,Autocuration,144,,,,H,,,,BAO_0000019,F,,CHEMBL619057
,8,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,3480,4365,,1,,Autocuration,144,,,,H,,,,BAO_0000357,B,,CHEMBL619058
,9,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,3481,6769,,1,Rattus norvegicus,Expert,12020,,10116.0,,D,,,Oocytes,BAO_0000219,F,,CHEMBL619059
,9,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,3482,6769,,1,Rattus norvegicus,Expert,12020,,10116.0,,D,,,Oocytes,BAO_0000219,F,,CHEMBL619060
,9,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,3483,6769,,1,Rattus norvegicus,Expert,12020,,10116.0,,D,,,Oocytes,BAO_0000219,F,,CHEMBL875095
,9,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,3484,809,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619061
,9,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,3485,809,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,F,,CHEMBL619062
,9,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,3486,14290,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000019,F,,CHEMBL619063
,9,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,3487,17358,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,B,,CHEMBL619064
,9,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,3488,17358,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000357,B,,CHEMBL619065
,9,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,3489,17358,,1,Cavia porcellus,Intermediate,20033,,10141.0,Ileum,D,2116.0,,,BAO_0000221,B,,CHEMBL619066
,8,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,3490,17386,,1,,Autocuration,10209,,,Ileum,H,2116.0,,,BAO_0000221,B,,CHEMBL619775
,8,,Affinity against 5-hydroxytryptamine 7 receptor,,3491,3269,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL619776
,4,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,3492,7721,,1,Cavia porcellus,Autocuration,104841,,10141.0,,H,,,,BAO_0000224,B,,CHEMBL619777
,4,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,3493,7721,,1,Cavia porcellus,Autocuration,104841,,10141.0,,H,,,,BAO_0000224,B,,CHEMBL619778
,4,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,3494,9117,,1,Cavia porcellus,Autocuration,104841,,10141.0,Ileum,H,2116.0,,,BAO_0000221,B,,CHEMBL619779
,4,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,3495,7721,,1,Cavia porcellus,Autocuration,104841,,10141.0,,H,,,,BAO_0000224,B,,CHEMBL619780
,4,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,3496,7721,,1,Cavia porcellus,Autocuration,104841,,10141.0,,H,,,,BAO_0000224,B,,CHEMBL619166
,4,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,3497,15796,,1,Cavia porcellus,Autocuration,104841,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL619167
,4,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,3498,15796,,1,Cavia porcellus,Autocuration,104841,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL619168
,9,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,3499,15650,,1,Homo sapiens,Expert,168,,9606.0,Cardiac atrium,D,2081.0,,,BAO_0000219,B,,CHEMBL619169
,9,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,3500,15650,,1,Homo sapiens,Expert,168,,9606.0,Cardiac atrium,D,2081.0,,,BAO_0000219,B,,CHEMBL619170
,5,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,3501,6866,,1,Homo sapiens,Autocuration,104841,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL619171
,9,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,3502,15650,,1,Homo sapiens,Expert,168,,9606.0,Cardiac atrium,D,2081.0,,,BAO_0000219,F,,CHEMBL619172
,0,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,3503,10063,,1,Mus musculus,Autocuration,22226,,10090.0,,U,,,,BAO_0000019,B,,CHEMBL619173
,0,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,3504,12665,,1,Mus musculus,Autocuration,22226,,10090.0,,U,,,,BAO_0000019,B,,CHEMBL619174
,4,,5-hydroxytryptamine receptor binding affinity was determined in rats,,3505,7504,,1,,Autocuration,104705,,,,H,,,,BAO_0000019,B,,CHEMBL619175
,4,,Binding affinity at rat 5-hydroxytryptamine receptor.,,3506,7504,,1,,Autocuration,104705,,,,H,,,,BAO_0000224,B,,CHEMBL619176
,4,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,3507,7038,,1,,Autocuration,104705,,,,H,,,,BAO_0000019,B,,CHEMBL619177
,4,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,3508,7626,,1,,Autocuration,104705,,,,H,,,,BAO_0000224,B,,CHEMBL619178
,4,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,3509,7626,,1,,Autocuration,104705,,,,H,,,,BAO_0000224,B,,CHEMBL619179
,4,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,3510,7185,,1,,Autocuration,104705,,,Stomach,H,945.0,,,BAO_0000019,F,,CHEMBL619180
,4,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,3511,7185,,1,,Autocuration,104705,,,Stomach,H,945.0,,,BAO_0000019,F,,CHEMBL619181
,4,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,3512,7185,,1,,Autocuration,104705,,,,H,,,,BAO_0000019,F,,CHEMBL619182
,4,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,3513,6960,,1,,Autocuration,104705,,,,H,,,,BAO_0000224,B,,CHEMBL619183
,4,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,3514,6960,,1,,Autocuration,104705,,,,H,,,,BAO_0000224,B,,CHEMBL619184
,8,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,3515,12416,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL619185
,8,,Binding affinity for rat 5-hydroxytryptamine transporter.,,3516,15753,,1,,Expert,12198,,,,H,,,,BAO_0000357,B,,CHEMBL619186
,4,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,3517,8062,,1,,Autocuration,104705,,,,H,,,,BAO_0000019,B,,CHEMBL619187
,5,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,3518,9036,,1,Rattus norvegicus,Autocuration,104705,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL619188
,5,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,3519,15067,,1,Rattus norvegicus,Autocuration,104705,,10116.0,,D,,,,BAO_0000224,B,,CHEMBL619189
,9,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,3520,15753,,1,Rattus norvegicus,Expert,12198,,10116.0,Brain,D,955.0,,,BAO_0000019,F,,CHEMBL619190
,9,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,3521,15753,,1,Rattus norvegicus,Expert,12198,,10116.0,Cerebellum,D,2037.0,,,BAO_0000221,F,,CHEMBL619191
,5,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,3522,15295,,1,Rattus norvegicus,Autocuration,104705,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL619192
,5,,Percent binding affinity against 5-hydroxytryptamine receptor,,3523,6347,,1,Rattus norvegicus,Autocuration,104705,,10116.0,,D,,,,BAO_0000224,B,,CHEMBL619193
,0,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,3524,6763,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL619194
,5,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,3525,12092,,1,Rattus norvegicus,Autocuration,104705,,10116.0,,D,,,,BAO_0000224,B,,CHEMBL619195
,5,,Affinity against 5-hydroxytryptamine receptor was determined,,3526,1579,,1,Rattus norvegicus,Autocuration,104705,,10116.0,,D,,,,BAO_0000224,B,,CHEMBL619196
,5,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,3527,1579,,1,Rattus norvegicus,Autocuration,104705,,10116.0,Stomach,D,945.0,,,BAO_0000019,B,,CHEMBL619197
,9,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,3528,5963,,1,Homo sapiens,Expert,121,,9606.0,,D,,In vitro,,BAO_0000219,B,,CHEMBL619198
,9,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,3529,5963,,1,Homo sapiens,Expert,121,,9606.0,,D,,In vitro,,BAO_0000219,B,,CHEMBL875081
,8,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,3530,5030,,1,,Autocuration,18065,,,,H,,,,BAO_0000357,B,,CHEMBL884712
,8,,Inhibition of 5-hydroxytryptamine reuptake,,3531,15796,,1,,Expert,121,,,,H,,,,BAO_0000357,B,,CHEMBL884710
,8,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,3532,15413,,1,,Autocuration,18065,,,,H,,,,BAO_0000019,F,,CHEMBL619199
,8,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,3533,15413,,1,,Autocuration,18065,,,,H,,,,BAO_0000019,F,,CHEMBL619200
,8,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,3534,15413,,1,,Autocuration,18065,,,,H,,,,BAO_0000019,F,,CHEMBL619201
,8,,Tested for 5-hydroxytryptamine receptor uptake,,3535,12409,,1,,Autocuration,18065,,,,H,,,,BAO_0000019,F,,CHEMBL619202
,9,449.0,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,3536,16909,,1,Homo sapiens,Expert,51,,9606.0,,D,,,CHO,BAO_0000219,B,,CHEMBL619203
,9,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,3537,16909,,1,Homo sapiens,Expert,51,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL619204
,8,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,3538,15629,,1,Homo sapiens,Autocuration,10576,,9606.0,,H,,,,BAO_0000249,B,,CHEMBL619205
,8,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,3539,15629,,1,,Autocuration,10576,,,,H,,,,BAO_0000357,B,,CHEMBL619206
,8,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,3540,15629,,1,,Expert,10576,,,,H,,,,BAO_0000249,B,,CHEMBL619207
,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,3541,10034,,1,,Autocuration,10825,,,Striatum,H,2435.0,,,BAO_0000019,F,,CHEMBL619208
,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,3542,10034,,1,,Autocuration,10825,,,Striatum,H,2435.0,,,BAO_0000019,F,,CHEMBL619209
,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,3543,10034,,1,,Autocuration,10825,,,Striatum,H,2435.0,,,BAO_0000019,F,,CHEMBL619210
,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,3544,10034,,1,,Autocuration,10825,,,Striatum,H,2435.0,,,BAO_0000019,F,,CHEMBL619211
,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,3545,10034,,1,,Autocuration,10825,,,Striatum,H,2435.0,,,BAO_0000019,F,,CHEMBL619212
,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,3546,10034,,1,,Autocuration,10825,,,Striatum,H,2435.0,,,BAO_0000019,F,,CHEMBL620681
,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,3547,10034,,1,,Autocuration,10825,,,Striatum,H,2435.0,,,BAO_0000019,F,,CHEMBL620682
,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,3548,10034,,1,,Autocuration,10825,,,Striatum,H,2435.0,,,BAO_0000019,F,,CHEMBL620683
,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,3549,10034,,1,,Autocuration,10825,,,Striatum,H,2435.0,,,BAO_0000019,F,,CHEMBL620684
,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,3550,10034,,1,,Autocuration,10825,,,Striatum,H,2435.0,,,BAO_0000019,F,,CHEMBL620685
,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,3551,10034,,1,,Autocuration,10825,,,Striatum,H,2435.0,,,BAO_0000019,F,,CHEMBL620686
,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,3552,10034,,1,,Autocuration,10825,,,Limbic system,H,349.0,,,BAO_0000019,F,,CHEMBL620687
,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,3553,10034,,1,,Autocuration,10825,,,Limbic system,H,349.0,,,BAO_0000019,F,,CHEMBL620688
,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,3554,10034,,1,,Autocuration,10825,,,Limbic system,H,349.0,,,BAO_0000019,F,,CHEMBL620689
,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,3555,10034,,1,,Autocuration,10825,,,Limbic system,H,349.0,,,BAO_0000019,F,,CHEMBL620690
,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,3556,10034,,1,,Autocuration,10825,,,Limbic system,H,349.0,,,BAO_0000019,F,,CHEMBL620691
,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,3557,10034,,1,,Autocuration,10825,,,Limbic system,H,349.0,,,BAO_0000019,F,,CHEMBL620692
,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,3558,10034,,1,,Autocuration,10825,,,Limbic system,H,349.0,,,BAO_0000019,F,,CHEMBL620693
,8,,Binding affinity against 5-hydroxytryptamine 4 receptor,,3559,1274,,1,,Expert,168,,,,H,,,,BAO_0000357,B,,CHEMBL620694
,8,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,3560,17358,,1,,Autocuration,168,,,,H,,,,BAO_0000019,F,,CHEMBL857986
,8,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,3561,14532,,1,,Autocuration,168,,,,H,,,,BAO_0000357,B,,CHEMBL620695
,8,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,3562,16989,,1,,Expert,168,,,,H,,,,BAO_0000357,B,,CHEMBL620696
,8,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,3563,17200,,1,,Autocuration,168,,,,H,,,,BAO_0000357,B,,CHEMBL620697
,8,,Binding affinity towards 5-hydroxytryptamine 4 receptor,,3564,15779,,1,,Autocuration,168,,,,H,,,,BAO_0000357,B,,CHEMBL620698
,8,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,3565,15779,,1,,Autocuration,168,,,,H,,,,BAO_0000357,B,,CHEMBL620699
,8,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,3566,15779,,1,,Autocuration,168,,,,H,,,,BAO_0000357,B,,CHEMBL620700
,8,643.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,3567,15650,,1,,Autocuration,168,,,,H,,,COS-7,BAO_0000219,B,,CHEMBL620701
,8,643.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,3568,15650,,1,,Autocuration,168,,,,H,,,COS-7,BAO_0000219,B,,CHEMBL875082
,8,643.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,3569,15650,,1,,Autocuration,168,,,,H,,,COS-7,BAO_0000219,B,,CHEMBL620702
,8,643.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,3570,15650,,1,,Autocuration,168,,,,H,,,COS-7,BAO_0000219,B,,CHEMBL620703
,8,673.0,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,3571,17046,,1,,Autocuration,168,,,,H,,,C6,BAO_0000219,B,,CHEMBL620704
,8,673.0,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,3572,17046,,1,,Expert,168,,,,H,,,C6,BAO_0000219,B,,CHEMBL620705
,8,673.0,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,3573,15650,,1,,Expert,168,,,,H,,,C6,BAO_0000219,B,,CHEMBL620706
,8,673.0,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,3574,17046,,1,,Expert,168,,,,H,,,C6,BAO_0000219,B,,CHEMBL620707
,8,,Binding affinity towards 5-hydroxytryptamine 5 receptor,,3575,17066,,1,,Expert,10624,,,,H,,,,BAO_0000357,B,,CHEMBL620708
,8,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,3576,17200,,1,,Autocuration,105,,,,H,,,,BAO_0000357,B,,CHEMBL620709
,9,,Binding affinity against 5-hydroxytryptamine 5A receptor,,3577,16146,,1,Homo sapiens,Expert,10624,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL620710
,8,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,3578,15250,,1,,Autocuration,10624,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620711
,9,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,3579,6491,,1,Homo sapiens,Expert,10624,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL620712
,9,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,3580,17066,,1,Homo sapiens,Expert,10624,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL620713
,9,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,3581,17066,,1,Homo sapiens,Expert,10624,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL620714
,9,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,3582,4234,,1,Homo sapiens,Expert,10624,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL620715
,8,,Binding affinity towards 5-HT5A receptor,,3583,6013,,1,,Autocuration,10624,,,,H,,,,BAO_0000357,B,,CHEMBL620716
,8,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,3584,17175,,1,,Expert,10624,,,,H,,,,BAO_0000357,B,,CHEMBL620717
,8,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,3585,15818,,1,,Autocuration,10624,,,,H,,,,BAO_0000357,B,,CHEMBL618072
,8,,Binding affinity towards cloned human 5-HT5A receptor was determined,,3586,6166,,1,,Autocuration,10624,,,,H,,,,BAO_0000357,B,,CHEMBL857987
,8,722.0,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,3587,15779,,1,,Autocuration,10624,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL618073
,8,722.0,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,3588,15779,,1,,Autocuration,10624,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL618074
,8,722.0,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,3589,5213,,1,,Autocuration,10624,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL618075
,9,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,3590,17066,,1,Mus musculus,Expert,10625,,10090.0,,D,,,,BAO_0000357,B,,CHEMBL618076
,9,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,3591,17066,,1,Mus musculus,Expert,10625,,10090.0,,D,,,,BAO_0000357,B,,CHEMBL618077
,9,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,3592,17066,,1,Mus musculus,Expert,10625,,10090.0,,D,,,,BAO_0000357,B,,CHEMBL618078
,9,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,3593,17066,,1,Mus musculus,Expert,10625,,10090.0,,D,,,,BAO_0000357,B,,CHEMBL881821
,9,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,3594,17066,,1,Mus musculus,Expert,10625,,10090.0,,D,,,,BAO_0000357,B,,CHEMBL618079
,8,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,3595,17175,,1,,Expert,10625,,,,H,,,,BAO_0000357,B,,CHEMBL618080
,8,722.0,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,3596,16190,,1,,Autocuration,10576,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL618081
,8,722.0,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,3597,16190,,1,,Autocuration,10626,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL618082
,8,,Binding affinity towards 5-HT5a receptor,,3598,4820,,1,,Expert,10624,,,,H,,,,BAO_0000357,B,,CHEMBL618083
,9,,Binding affinity towards 5-hydroxytryptamine 5A receptor,,3599,17066,,1,Homo sapiens,Expert,10624,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL618084
,8,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,3600,17066,,1,,Expert,10624,,,,H,,,,BAO_0000357,B,,CHEMBL618085
,8,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,3601,17175,,1,,Expert,10624,,,,H,,,,BAO_0000357,B,,CHEMBL618086
,8,,Binding affinities against 5-hydroxytryptamine 5A receptor,,3602,16633,,1,,Autocuration,10624,,,,H,,,,BAO_0000357,B,,CHEMBL875092
,8,,Binding affinities towards 5-hydroxytryptamine 5A receptor,,3603,16633,,1,,Autocuration,10624,,,,H,,,,BAO_0000357,B,,CHEMBL618087
,8,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,3604,16700,,1,,Autocuration,10624,,,,H,,,,BAO_0000357,B,,CHEMBL872926
,4,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,3605,4639,,1,Cavia porcellus,Autocuration,104714,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL618088
,4,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,3606,5486,,1,,Autocuration,104714,,,,H,,,,BAO_0000223,B,,CHEMBL618089
,9,,Inhibition of human 5-hydroxytryptamine 6 receptor,,3607,16146,,1,Homo sapiens,Expert,10627,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL618090
,9,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,3608,17273,,1,Homo sapiens,Expert,10627,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL618091
,8,,Inhibition against human 5-hydroxytryptamine 6 receptor,,3609,17687,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL618092
,9,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,3610,6491,,1,Homo sapiens,Expert,10627,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL618093
,8,308.0,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,3611,16190,,1,,Expert,10627,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL618094
,9,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,3612,17066,,1,Homo sapiens,Expert,10627,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL618095
,9,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,3613,17066,,1,Homo sapiens,Expert,10627,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL875093
,9,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,3614,17066,,1,Homo sapiens,Expert,10627,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL618096
,9,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,3615,17066,,1,Homo sapiens,Expert,10627,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL618118
,9,,Binding affinity against 5-hydroxytryptamine 6 receptor,,3616,3555,,1,Homo sapiens,Expert,10627,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL618119
,8,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,3617,5808,,1,,Expert,10627,,,,H,,,,BAO_0000357,B,,CHEMBL618120
,8,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,3618,6013,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL618121
,8,722.0,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,3619,15818,,1,,Expert,10627,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL618122
,8,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,3620,16209,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL618123
,8,722.0,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,3621,3935,,1,,Expert,10627,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL618124
,8,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,3622,15818,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL618125
,9,722.0,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,3623,3805,,1,Homo sapiens,Expert,10627,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL618126
,8,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,3624,16441,,1,,Expert,10627,,,,H,,,,BAO_0000019,B,,CHEMBL618236
,8,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,3625,16441,,1,,Expert,10627,,,,H,,,,BAO_0000019,B,,CHEMBL618237
,8,643.0,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,3626,6786,,1,,Expert,10627,,,,H,,,COS-7,BAO_0000219,B,,CHEMBL618238
,9,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,3627,4234,,1,Homo sapiens,Expert,10627,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL618239
,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,3628,17085,,1,,Autocuration,10627,,,,H,,,,BAO_0000019,B,,CHEMBL618240
,8,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,3629,17200,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL618241
,8,722.0,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,3630,17451,,1,,Autocuration,10627,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL859399
,8,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,3631,3935,,1,,Autocuration,10627,,,,H,,,,BAO_0000019,F,,CHEMBL618242
,8,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,3632,5033,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL857991
,8,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,3633,4540,,1,,Expert,10627,,,,H,,,,BAO_0000357,B,,CHEMBL619951
,9,308.0,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,3634,4540,,1,Homo sapiens,Expert,10627,,9606.0,,D,,,HeLa,BAO_0000219,B,,CHEMBL619952
,9,308.0,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,3635,4540,,1,Homo sapiens,Expert,10627,,9606.0,,D,,,HeLa,BAO_0000219,B,,CHEMBL619953
,8,308.0,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,3636,17296,,1,,Autocuration,10627,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL619954
,8,308.0,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,3637,17296,,1,,Autocuration,10627,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL619955
,8,308.0,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,3638,17296,,1,,Autocuration,10627,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL619956
,8,449.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,3639,15779,,1,,Autocuration,10627,,,,H,,,CHO,BAO_0000219,B,,CHEMBL619957
,8,722.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,3640,15779,,1,,Autocuration,10627,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL619958
,8,722.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,3641,15779,,1,,Autocuration,10627,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL620627
,8,722.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,3642,15779,,1,,Autocuration,10627,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL620628
,8,308.0,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,3643,15779,,1,,Autocuration,10627,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL620629
,8,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,3644,6166,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL620630
,8,308.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,3645,17451,,1,,Autocuration,10627,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL620782
,8,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,3646,15316,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL620783
,8,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,3647,4199,,1,,Expert,10627,,,,H,,,,BAO_0000357,B,,CHEMBL620784
,8,308.0,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,3648,15146,,1,,Expert,10627,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL620785
,8,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,3649,5213,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL857992
,8,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,3650,16429,,1,,Autocuration,10627,,,,H,,,,BAO_0000219,B,,CHEMBL620786
,8,308.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,3651,14818,,1,,Autocuration,10627,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL620787
,8,308.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,3652,4829,,1,,Autocuration,10627,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL620788
,8,308.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,3653,4829,,1,,Autocuration,10627,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL620789
,8,308.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,3654,4829,,1,,Autocuration,10627,,,,H,,,HeLa,BAO_0000219,B,,CHEMBL620790
,8,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,3655,15250,,1,,Autocuration,10628,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620791
,8,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,3656,14423,,1,,Autocuration,10628,,,,H,,,,BAO_0000019,B,,CHEMBL620792
,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,3657,15086,,1,,Autocuration,10628,,,,H,,,,BAO_0000357,B,,CHEMBL620793
,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,3658,4342,,1,,Autocuration,10628,,,,H,,,,BAO_0000357,B,,CHEMBL620794
,9,308.0,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,3659,16190,,1,Homo sapiens,Autocuration,10627,,9606.0,,D,,,HeLa,BAO_0000219,B,,CHEMBL620795
,8,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,3660,4820,,1,,Expert,10627,,,,H,,,,BAO_0000357,B,,CHEMBL620796
,8,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,3661,4639,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL620797
,9,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,3662,17066,,1,Homo sapiens,Expert,10627,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL620798
,8,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,3663,6011,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL620799
,8,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,3664,17066,,1,,Expert,10627,,,,H,,,,BAO_0000357,B,,CHEMBL620800
,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,3665,17515,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL620801
,8,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,3666,5014,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL875100
,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,3667,4373,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL620802
,8,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,3668,17066,,1,,Expert,10627,,,,H,,,,BAO_0000019,F,,CHEMBL620803
,8,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,3669,17066,,1,,Expert,10627,,,,H,,,,BAO_0000019,F,,CHEMBL620804
,8,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,3670,4373,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL620805
,8,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,3671,4687,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL620806
,8,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,3672,16946,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL620807
,8,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,3673,16946,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL620808
,8,,Binding affinities against 5-hydroxytryptamine 6 receptor,,3674,16633,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL620809
,8,,Binding affinities towards 5-hydroxytryptamine 6 receptor,,3675,16633,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL620810
,9,,Binding affinity towards 5-hydroxytryptamine 6 receptor,,3676,17066,,1,Homo sapiens,Expert,10627,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL620811
,8,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,3677,16700,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL620812
,8,,Affinity against 5-hydroxytryptamine 6 receptor,,3678,3269,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL620813
,8,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,3679,5486,,1,,Autocuration,10627,,,,H,,,,BAO_0000357,B,,CHEMBL620814
,9,,Inhibition of human 5-hydroxytryptamine 7 receptor,,3680,16146,,1,Homo sapiens,Expert,10209,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL620815
,8,722.0,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,3681,5014,,1,,Autocuration,10209,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL620816
,8,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,3682,15463,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL620817
,8,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,3683,3805,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL620818
,8,722.0,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,3684,5014,,1,,Expert,10209,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL620819
,9,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,3685,6491,,1,Homo sapiens,Expert,10209,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL620820
,8,449.0,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,3686,16190,,1,,Autocuration,10209,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620821
,9,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,3687,17066,,1,Homo sapiens,Expert,10209,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL620822
,9,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,3688,17066,,1,Homo sapiens,Expert,10209,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL620823
,9,,Binding affinity against 5-hydroxytryptamine 7 receptor,,3689,3555,,1,Homo sapiens,Expert,10209,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL620824
,8,449.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,3690,6588,,1,,Expert,10209,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620825
,8,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,3691,15463,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL872930
,8,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,3692,6013,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL620826
,8,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,3693,16209,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL620827
,8,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,3694,3935,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL620828
,8,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,3695,15818,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL620829
,8,722.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,3696,5014,,1,,Expert,10209,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL620830
,8,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,3697,16441,,1,,Expert,10209,,,,H,,,,BAO_0000019,B,,CHEMBL620831
,8,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,3698,16441,,1,,Expert,10209,,,,H,,,,BAO_0000019,B,,CHEMBL620832
,9,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,3699,4234,,1,Homo sapiens,Expert,10209,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL621548
,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,3700,17085,,1,,Autocuration,10209,,,,H,,,,BAO_0000019,B,,CHEMBL621549
,8,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,3701,17200,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL621550
,8,449.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,3702,17451,,1,,Autocuration,10209,,,,H,,,CHO,BAO_0000219,B,,CHEMBL621551
,8,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,3703,17085,,1,,Autocuration,10209,,,,H,,,,BAO_0000019,B,,CHEMBL621552
,8,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,3704,5104,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL857077
,8,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,3705,5104,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL618158
,9,643.0,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,3706,5033,,1,Homo sapiens,Expert,10209,,9606.0,,D,,,COS-7,BAO_0000219,B,,CHEMBL618159
,8,643.0,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,3707,5486,,1,,Autocuration,10209,,,,H,,,COS-7,BAO_0000219,B,,CHEMBL875101
,9,722.0,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,3708,4540,,1,Homo sapiens,Expert,10209,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL618160
,8,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,3709,6166,,1,,Expert,10209,,,,H,,,,BAO_0000357,B,,CHEMBL618161
,8,722.0,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,3710,17342,,1,,Expert,10209,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL618162
,8,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,3711,17342,,1,,Expert,10209,,,,H,,,,BAO_0000357,B,,CHEMBL618163
,8,,Binding affinity against 5-hydroxytryptamine 7 human receptors,,3712,17296,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL618164
,8,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,3713,16429,,1,,Expert,10209,,,,H,,,,BAO_0000219,B,,CHEMBL618165
,8,722.0,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,3714,15779,,1,,Autocuration,10209,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL618166
,8,722.0,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,3715,15779,,1,,Autocuration,10209,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL857989
,8,722.0,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,3716,15779,,1,,Autocuration,10209,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL619888
,8,722.0,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,3717,15779,,1,,Autocuration,10209,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL619889
,8,722.0,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,3718,15779,,1,,Autocuration,10209,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL619890
,8,449.0,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,3719,17451,,1,,Autocuration,10209,,,,H,,,CHO,BAO_0000219,B,,CHEMBL619891
,8,722.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,3720,4199,,1,,Autocuration,10209,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL619892
,9,722.0,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,3721,4199,,1,,Expert,10209,,,,D,,,HEK293,BAO_0000219,B,,CHEMBL619893
,8,722.0,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,3722,4199,,1,,Autocuration,10209,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL619894
,9,722.0,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,3723,3680,,1,,Intermediate,10209,,,,D,,,HEK293,BAO_0000219,B,,CHEMBL619895
,9,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,3724,3680,,1,,Intermediate,10209,,,,D,,,,BAO_0000357,B,,CHEMBL619896
,8,643.0,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,3725,15316,,1,,Autocuration,10209,,,,H,,,COS-7,BAO_0000219,B,,CHEMBL619897
,8,722.0,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,3726,15146,,1,,Autocuration,10209,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL619898
,8,722.0,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,3727,5213,,1,,Expert,10209,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL619899
,8,722.0,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,3728,5213,,1,,Autocuration,10209,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL619900
,9,722.0,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,3729,14818,,1,Homo sapiens,Expert,10209,,9606.0,,D,,,HEK293,BAO_0000219,B,,CHEMBL619901
,8,722.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,3730,14818,,1,,Autocuration,10209,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL620580
,8,722.0,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,3731,14818,,1,,Autocuration,10209,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL620581
,8,722.0,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,3732,4829,,1,,Autocuration,10209,,,,H,,,HEK293,BAO_0000219,B,,CHEMBL620733
,9,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,3733,17200,,1,Homo sapiens,Autocuration,10209,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL620734
,9,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,3734,17066,,1,Mus musculus,Expert,10022,,10090.0,,D,,,,BAO_0000357,B,,CHEMBL620735
,8,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,3735,14025,,1,Oryctolagus cuniculus,Autocuration,10209,,9986.0,,H,,,,BAO_0000019,B,,CHEMBL620736
,8,449.0,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,3736,15250,,1,,Autocuration,11923,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620737
,8,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,3737,16372,,1,,Autocuration,11923,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620738
,8,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,3738,16372,,1,,Autocuration,11923,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620739
,8,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,3739,16372,,1,,Autocuration,11923,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620740
,8,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,3740,16372,,1,,Autocuration,11923,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620741
,8,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,3741,16372,,1,,Autocuration,11923,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620742
,8,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,3742,16372,,1,,Autocuration,11923,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620743
,8,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,3743,16372,,1,,Autocuration,11923,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620744
,8,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,3744,16372,,1,,Autocuration,11923,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620745
,8,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,3745,16372,,1,,Autocuration,11923,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620746
,8,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,3746,16372,,1,,Autocuration,11923,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620747
,8,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,3747,16372,,1,,Autocuration,11923,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620748
,8,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,3748,16372,,1,,Autocuration,11923,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620749
,8,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,3749,17066,,1,,Expert,11923,,,,H,,,,BAO_0000357,B,,CHEMBL620750
,9,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,3750,17066,,1,Rattus norvegicus,Expert,11923,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL620751
,8,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,3751,17386,,1,,Expert,11923,,,,H,,,,BAO_0000357,B,,CHEMBL620752
,8,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,3752,14423,,1,,Autocuration,11923,,,,H,,,,BAO_0000019,B,,CHEMBL872929
,9,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,3753,15874,,1,Rattus norvegicus,Expert,11923,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL620753
,9,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,3754,15874,,1,Rattus norvegicus,Expert,11923,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL620754
,9,449.0,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,3755,16372,,1,Rattus norvegicus,Expert,11923,,10116.0,,D,,,CHO,BAO_0000219,B,,CHEMBL620755
,8,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,3756,4622,,1,,Autocuration,11923,,,,H,,,,BAO_0000357,B,,CHEMBL620756
,8,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,3757,15086,,1,,Autocuration,11923,,,,H,,,,BAO_0000357,B,,CHEMBL620757
,8,449.0,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,3758,16372,,1,,Autocuration,11923,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620758
,8,449.0,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,3759,16372,,1,,Autocuration,11923,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620759
,8,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,3760,16372,,1,,Autocuration,11923,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620760
,8,449.0,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,3761,16372,,1,,Autocuration,11923,,,,H,,,CHO,BAO_0000219,B,,CHEMBL620761
,8,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,3762,17386,,1,,Autocuration,11923,,,Ileum,H,2116.0,,,BAO_0000221,F,,CHEMBL620762
,8,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,3763,17386,,1,,Autocuration,11923,,,Ileum,H,2116.0,,,BAO_0000221,F,,CHEMBL620763
,8,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,3764,17386,,1,,Autocuration,11923,,,Ileum,H,2116.0,,,BAO_0000221,F,,CHEMBL620764
,9,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,3765,5831,Membranes,1,Rattus norvegicus,Expert,11923,,10116.0,,D,,,,BAO_0000249,B,,CHEMBL857990
,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,3766,4342,,1,,Autocuration,11923,,,,H,,,,BAO_0000357,B,,CHEMBL620765
,8,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,3767,17319,,1,,Expert,11923,,,,H,,,,BAO_0000357,B,,CHEMBL620766
,8,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,3768,17342,,1,,Expert,11923,,,Hypothalamus,H,1898.0,,,BAO_0000019,B,,CHEMBL620767
,8,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,3769,17342,,1,,Autocuration,11923,,,,H,,,,BAO_0000357,B,,CHEMBL620768
,8,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,3770,3680,,1,,Expert,11923,,,Hypothalamus,H,1898.0,,,BAO_0000249,B,,CHEMBL619051
,8,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,3771,3680,,1,,Expert,11923,,,,H,,,,BAO_0000357,B,,CHEMBL619052
,9,722.0,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,3772,17319,,1,Rattus norvegicus,Expert,11923,,10116.0,,D,,,HEK293,BAO_0000219,F,,CHEMBL619053
,9,722.0,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,3773,17319,,1,Rattus norvegicus,Expert,11923,,10116.0,,D,,,HEK293,BAO_0000219,F,,CHEMBL619703
,9,722.0,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,3774,17319,,1,Rattus norvegicus,Autocuration,11923,,10116.0,,D,,,HEK293,BAO_0000219,F,,CHEMBL619704
,8,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,3775,4820,,1,,Expert,10209,,,,H,,,,BAO_0000357,B,,CHEMBL619851
,8,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,3776,4639,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL619852
,8,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,3777,6011,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL619853
,9,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,3778,17066,,1,Homo sapiens,Expert,10209,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL619854
,8,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,3779,17066,,1,,Expert,10209,,,,H,,,,BAO_0000357,B,,CHEMBL619855
,8,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,3780,17515,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL619856
,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,3781,4373,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL619857
,8,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,3782,17066,,1,,Expert,10209,,,,H,,,,BAO_0000019,F,,CHEMBL619858
,8,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,3783,4373,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL619859
,8,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,3784,4373,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL619860
,8,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,3785,4687,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL619861
,8,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,3786,17342,,1,,Expert,10209,,,,H,,,,BAO_0000357,B,,CHEMBL619862
,8,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,3787,16946,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL619863
,8,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,3788,16946,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL619864
,8,,Binding affinities against 5-hydroxytryptamine 7 receptor,,3789,16633,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL872928
,8,,Binding affinities towards 5-hydroxytryptamine 7 receptor,,3790,16633,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL619865
,8,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,3791,17066,,1,,Expert,10209,,,,H,,,,BAO_0000357,B,,CHEMBL619866
,8,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,3792,16700,,1,,Autocuration,10209,,,,H,,,,BAO_0000357,B,,CHEMBL619867
,8,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,3793,17386,,1,,Autocuration,10209,,,Ileum,H,2116.0,,,BAO_0000221,B,,CHEMBL619868
,8,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,3794,14080,,1,,Autocuration,55,,,,H,,,,BAO_0000019,F,,CHEMBL619869
,9,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,3795,14080,,1,Homo sapiens,Expert,55,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL619870
,8,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,3796,409,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL619871
,8,,In vitro inhibition of human recombinant lipoxygenase enzyme,,3797,409,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL619872
,8,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,3798,409,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL619873
,8,,Inhibition of 5-lipoxygenase in human whole blood.,,3799,11090,,1,,Expert,55,,,Blood,H,178.0,,,BAO_0000357,B,,CHEMBL619874
,8,,Inhibition of 5-lipoxygenase in human whole blood.,,3800,11090,,1,,Expert,55,,,Blood,H,178.0,,,BAO_0000357,B,,CHEMBL619875
,8,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,3801,948,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL619876
,8,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,3802,948,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL619877
,8,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,3803,13622,,1,,Expert,55,,,,H,,,,BAO_0000219,F,,CHEMBL619878
,8,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,3804,13622,,1,,Autocuration,55,,,Blood,H,178.0,,,BAO_0000019,F,,CHEMBL619879
,8,,In vitro inhibition of 5-lipoxygenase from human polymorphs,,3805,9637,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL619880
,8,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,3806,11320,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL619881
,8,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,3807,11320,,1,,Expert,55,,,,H,,,,BAO_0000357,B,,CHEMBL619882
,8,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,3808,6838,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL619883
,9,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,3809,17667,,1,Homo sapiens,Expert,55,,9606.0,Blood,D,178.0,,,BAO_0000357,B,,CHEMBL619884
,8,,In vitro potency against human 5-Lipoxygenase,,3810,12703,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL619885
,9,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,3811,14312,,1,Homo sapiens,Expert,55,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL619886
,8,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,3812,14312,,1,,Autocuration,55,,,Blood,H,178.0,,,BAO_0000019,F,,CHEMBL619887
,8,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,3813,5364,,1,,Autocuration,55,,,,H,,,,BAO_0000019,F,,CHEMBL875097
,8,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,3814,951,,1,,Autocuration,55,,,,H,,,,BAO_0000219,B,,CHEMBL618001
,8,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,3815,951,,1,,Autocuration,55,,,,H,,,,BAO_0000219,B,,CHEMBL618002
,8,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,3816,951,,1,,Autocuration,55,,,,H,,,,BAO_0000219,B,,CHEMBL618003
,8,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,3817,951,,1,,Autocuration,55,,,,H,,,,BAO_0000219,B,,CHEMBL618004
,8,,Inhibition of human 5-lipoxygenase in human cells,,3818,12365,,1,,Autocuration,55,,,,H,,,,BAO_0000219,B,,CHEMBL618005
,8,,Inhibition of human neutrophil 5-lipoxygenase,,3819,10603,,1,,Expert,55,,,,H,,,,BAO_0000357,B,,CHEMBL618006
,8,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,3820,10501,,1,,Autocuration,55,,,,H,,,,BAO_0000019,B,,CHEMBL875086
,8,,Inhibition of 5-lipoxygenase from human whole blood,,3821,12281,,1,,Expert,55,,,Blood,H,178.0,,,BAO_0000357,B,,CHEMBL618007
,8,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,3822,2567,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618008
,8,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,3823,2567,,1,,Autocuration,55,,,,H,,,,BAO_0000219,B,,CHEMBL618009
,8,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,3824,10193,,1,,Expert,55,,,,H,,,,BAO_0000357,B,,CHEMBL618010
,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,3825,10193,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618011
,8,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,3826,13623,,1,,Expert,55,,,,H,,,,BAO_0000357,B,,CHEMBL618012
,8,,Tested against 5-lipoxygenase,,3827,12780,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL882927
,8,,Tested for activity against 5-Lipoxygenase (5-LO),,3828,12780,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618013
,8,,Tested for activity against 5-lipoxygenase,,3829,12780,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618014
,8,,Tested for inhibition of 5-HPETE production by human 5-LO,,3830,11966,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618015
,8,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,3831,5364,,1,,Autocuration,55,,,,H,,,,BAO_0000019,F,,CHEMBL618016
,8,,Inhibition of Human 5-lipoxygenase,,3832,13165,,1,,Expert,55,,,,H,,,,BAO_0000357,B,,CHEMBL618017
,8,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,3833,5364,,1,,Autocuration,55,,,,H,,,,BAO_0000019,B,,CHEMBL618018
,8,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,3834,11311,,1,,Autocuration,55,,,,H,,,,BAO_0000219,B,,CHEMBL875087
,8,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,3835,11311,,1,,Autocuration,55,,,,H,,,,BAO_0000219,B,,CHEMBL618019
,8,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,3836,14863,,1,,Autocuration,55,,,,H,,,,BAO_0000019,B,,CHEMBL618020
,8,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,3837,14863,,1,,Autocuration,55,,,,H,,,,BAO_0000019,B,,CHEMBL618021
,8,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,3838,11087,,1,,Autocuration,55,,,Blood,H,178.0,,,BAO_0000357,B,,CHEMBL618022
,8,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,3839,455,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618023
,8,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,3840,13183,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618024
,8,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,3841,10319,,1,,Expert,55,,,,H,,,,BAO_0000019,B,,CHEMBL873950
,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,3842,10193,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618025
,8,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,3843,951,,1,,Autocuration,55,,,,H,,,,BAO_0000219,B,,CHEMBL618026
,8,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,3844,951,,1,,Autocuration,55,,,,H,,,,BAO_0000219,B,,CHEMBL618027
,8,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,3845,951,,1,,Autocuration,55,,,,H,,,,BAO_0000219,B,,CHEMBL618028
,8,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,3846,951,,1,,Autocuration,55,,,,H,,,,BAO_0000219,B,,CHEMBL618029
,8,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,3847,9859,,1,,Expert,55,,,,H,,,,BAO_0000357,B,,CHEMBL618030
,8,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,3848,9859,,1,,Expert,55,,,,H,,,,BAO_0000357,B,,CHEMBL618031
,8,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,3849,9859,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618032
,8,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,3850,2567,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618033
,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,3851,10193,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618034
,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,3852,10193,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL875088
,8,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,3853,949,,1,,Autocuration,55,,,,H,,,,BAO_0000019,B,,CHEMBL618035
,8,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,3854,949,,1,,Autocuration,55,,,,H,,,,BAO_0000019,B,,CHEMBL618036
,8,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,3855,10603,,1,,Expert,55,,,,H,,,,BAO_0000357,B,,CHEMBL618037
,8,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,3856,10603,,1,,Expert,55,,,,H,,,,BAO_0000357,B,,CHEMBL618038
,8,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,3857,10603,,1,,Autocuration,55,,,,H,,,,BAO_0000019,F,,CHEMBL618761
,8,,Inhibition of lipoxygenase at the concentration of 0.1 uM,,3858,10603,,1,,Expert,55,,,,H,,,,BAO_0000357,B,,CHEMBL618762
,8,,Inhibition of lipoxygenase at the concentration of 1 uM,,3859,10603,,1,,Expert,55,,,,H,,,,BAO_0000357,B,,CHEMBL618763
,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,3860,10193,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618764
,9,,Inhibition of 5-Lipoxygenase (5-LOX),,3861,14580,,1,Homo sapiens,Expert,55,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL618765
,8,,Inhibition of 5-lipoxygenase in mouse macrophages.,,3862,11090,,1,,Expert,17087,,,,H,,,,BAO_0000357,B,,CHEMBL618766
,8,,Inhibition of 5-lipoxygenase in mouse macrophages.,,3863,11090,,1,,Expert,17087,,,,H,,,,BAO_0000357,B,,CHEMBL618767
,8,,Inhibitory activity against lipoxygenase-2 in mice,,3864,6339,,1,,Autocuration,17087,,,,H,,,,BAO_0000357,B,,CHEMBL619380
,8,,Inhibitory activity against murine lipoxygenase-2.,,3865,6339,,1,,Expert,17087,,,,H,,,,BAO_0000357,B,,CHEMBL619381
,9,,Inhibition of 5-lipoxygenase from mouse macrophage,,3866,12281,,1,Mus musculus,Expert,17087,,10090.0,,D,,,,BAO_0000357,B,,CHEMBL619382
,8,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,3867,11311,,1,,Autocuration,17087,,,,H,,,,BAO_0000357,B,,CHEMBL619383
,8,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,3868,11089,,1,Sus scrofa,Autocuration,55,,9823.0,,H,,,,BAO_0000019,B,,CHEMBL619384
,8,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,3869,10091,,1,Sus scrofa,Autocuration,55,,9823.0,,H,,,,BAO_0000019,B,,CHEMBL619385
,8,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,3870,14352,,1,Oryctolagus cuniculus,Autocuration,55,,9986.0,,H,,,,BAO_0000019,B,,CHEMBL882928
,9,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,3871,13329,,1,Rattus norvegicus,Expert,12166,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL619386
,8,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,3872,13329,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619387
,8,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,3873,13329,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619388
,8,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,3874,13329,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619389
,8,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,3875,13329,,1,,Expert,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619390
,8,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,3876,13329,,1,,Expert,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619391
,8,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,3877,13329,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619392
,8,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,3878,11311,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619393
,8,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,3879,11311,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619394
,8,702.0,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,3880,105,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619395
,8,702.0,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,3881,105,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619396
,8,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,3882,9138,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619397
,8,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,3883,9138,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619398
,8,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,3884,9138,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619399
,8,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,3885,14427,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619400
,8,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,3886,13329,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619401
,8,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,3887,13329,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619402
,9,663.0,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,3888,14427,,1,Rattus norvegicus,Expert,12166,,10116.0,,D,,,RBL-2H3,BAO_0000219,B,,CHEMBL619403
,8,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,3889,14427,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619404
,8,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,3890,14427,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619405
,8,702.0,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,3891,10293,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619406
,9,702.0,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,3892,338,,1,Rattus norvegicus,Expert,12166,,10116.0,,D,,,RBL-1,BAO_0000219,B,,CHEMBL619407
,8,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,3893,303,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619408
,8,702.0,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,3894,303,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619409
,8,702.0,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,3895,9247,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619410
,8,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,3896,9247,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619753
,8,702.0,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,3897,137,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619754
,8,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,3898,11481,,1,,Expert,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619903
,8,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,3899,11481,,1,,Expert,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619904
,8,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,3900,9029,,1,,Expert,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619905
,8,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,3901,1701,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619906
,8,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,3902,1701,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619907
,8,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,3903,1701,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619908
,8,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,3904,1701,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619909
,8,702.0,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,3905,13358,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,F,,CHEMBL619910
,8,702.0,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,3906,1175,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL882929
,8,702.0,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,3907,8797,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619911
,8,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,3908,8797,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619912
,9,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,3909,577,,1,Rattus norvegicus,Expert,12166,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL619913
,8,702.0,In vitro inhibitory activity against RBL-1 5-LO,,3910,9295,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619914
,8,702.0,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,3911,9295,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619915
,8,702.0,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,3912,9295,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619916
,8,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,3913,9295,,1,,Autocuration,12166,,,,H,,,,BAO_0000218,B,,CHEMBL619917
,8,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,3914,9295,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619918
,8,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,3915,216,,1,,Autocuration,12166,,,,H,,,,BAO_0000218,B,,CHEMBL619919
,8,702.0,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,3916,11090,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL883710
,8,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,3917,11090,,1,,Autocuration,12166,,,Blood,H,178.0,,,BAO_0000019,B,,CHEMBL619920
,8,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,3918,10091,,1,,Expert,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619921
,8,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,3919,10274,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,F,,CHEMBL619922
,8,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,3920,13622,,1,,Autocuration,12166,,,,H,,,,BAO_0000219,F,,CHEMBL619923
,8,702.0,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,3921,12118,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619924
,8,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,3922,12576,,1,,Expert,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619925
,8,702.0,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,3923,9546,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619926
,8,702.0,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,3924,9521,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619927
,8,702.0,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,3925,10626,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619928
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase,,3926,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619929
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,3927,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL875089
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,3928,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619930
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,3929,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619931
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,3930,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619932
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,3931,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619933
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,3932,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619934
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,3933,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619935
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,3934,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619936
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,3935,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619937
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,3936,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619938
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,3937,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619939
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,3938,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619940
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,3939,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL875090
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,3940,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619941
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,3941,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619942
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,3942,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL883711
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,3943,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619943
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,3944,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619944
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,3945,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619945
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,3946,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619946
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,3947,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619947
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,3948,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619948
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,3949,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619949
,8,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,3950,9401,,1,,Expert,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619950
,8,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,3951,10325,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL618050
,8,663.0,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,3952,1556,,1,,Expert,12166,,,,H,,,RBL-2H3,BAO_0000219,F,,CHEMBL875091
,8,663.0,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,3953,1556,,1,,Expert,12166,,,,H,,,RBL-2H3,BAO_0000219,F,,CHEMBL618051
,9,702.0,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,3954,961,,1,Rattus norvegicus,Expert,12166,,10116.0,,D,,,RBL-1,BAO_0000219,B,,CHEMBL618052
,8,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,3955,6838,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL618053
,8,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,3956,10325,,1,,Expert,12166,,,,H,,,,BAO_0000019,B,,CHEMBL618054
,9,702.0,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,3957,9209,,1,Rattus norvegicus,Expert,12166,,10116.0,,D,,,RBL-1,BAO_0000219,B,,CHEMBL618055
,8,702.0,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,3958,11520,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL618056
,8,,In vitro inhibitory activity against 5-lipoxygenase was determined,,3959,137,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL618057
,8,702.0,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,3960,4717,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL618058
,8,702.0,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,3961,10636,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL618059
,9,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,3962,14312,,1,Rattus norvegicus,Expert,12166,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL618060
,8,702.0,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,3963,1203,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL618061
,8,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,3964,1203,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL618062
,8,702.0,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,3965,13622,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL618063
,8,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,3966,9793,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL618064
,9,702.0,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,3967,1143,,1,Rattus norvegicus,Expert,12166,,10116.0,,D,,,RBL-1,BAO_0000219,B,,CHEMBL618065
,9,702.0,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,3968,11854,,1,Rattus norvegicus,Expert,12166,,10116.0,,D,,,RBL-1,BAO_0000219,B,,CHEMBL618066
,8,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,3969,3595,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL618067
,8,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,3970,3595,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL618068
,9,702.0,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,3971,10501,,1,Rattus norvegicus,Expert,12166,,10116.0,,D,,,RBL-1,BAO_0000219,B,,CHEMBL618069
,8,702.0,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,3972,12526,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL618070
,8,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,3973,10034,,1,,Autocuration,10825,,,Limbic system,H,349.0,,,BAO_0000019,F,,CHEMBL618071
,8,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,3974,10034,,1,,Autocuration,10825,,,Limbic system,H,349.0,,,BAO_0000019,F,,CHEMBL619247
,8,,Approximate dose levels for a half maximal reduction of 5-HTP levels,,3975,10034,,1,,Autocuration,10825,,,,H,,,,BAO_0000019,F,,CHEMBL619248
,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,3976,10046,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL619249
,8,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,3977,10046,,1,,Autocuration,10576,,,Hippocampus,H,10000000.0,,,BAO_0000221,B,,CHEMBL619250
,8,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,3978,10046,,1,,Autocuration,10577,,,,H,,,,BAO_0000019,B,,CHEMBL619251
,8,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,3979,12079,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,,,BAO_0000019,F,,CHEMBL619252
,8,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,3980,12079,,1,,Autocuration,55,,,Blood,H,178.0,,,BAO_0000019,F,,CHEMBL619253
,8,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,3981,11311,,1,,Autocuration,12166,,,,H,,,,BAO_0000219,B,,CHEMBL619254
,8,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,3982,12338,,1,,Expert,17140,,,,H,,,,BAO_0000219,B,,CHEMBL619255
,8,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,3983,12143,,1,,Expert,17140,,,,H,,,,BAO_0000219,B,,CHEMBL619256
,8,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,3984,12143,,1,,Autocuration,17140,,,,H,,,,BAO_0000219,B,,CHEMBL875418
,8,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,3985,12143,,1,,Expert,17140,,,,H,,,,BAO_0000219,B,,CHEMBL619257
,8,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,3986,12143,,1,,Autocuration,17140,,,,H,,,,BAO_0000219,B,,CHEMBL619258
,8,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,3987,12365,,1,,Expert,17140,,,,H,,,,BAO_0000357,B,,CHEMBL619259
,8,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,3988,13500,,1,,Expert,17140,,,,H,,,,BAO_0000357,B,,CHEMBL619260
,8,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,3989,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL619261
,8,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,3990,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL619263
,8,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,3991,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL619264
,8,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,3992,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL619265
,8,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,3993,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL619266
,8,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,3994,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL619902
,8,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,3995,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620058
,8,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,3996,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620059
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,3997,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620060
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,3998,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620061
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",,3999,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620062
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,4000,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620063
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",,4001,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620064
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,4002,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620065
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",,4003,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620066
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",,4004,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620067
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",,4005,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620068
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,4006,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620069
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",,4007,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620070
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",,4008,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620071
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",,4009,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620072
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,4010,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620036
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",,4011,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL857702
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",,4012,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620037
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",,4013,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620038
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,4014,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620039
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",,4015,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620040
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",,4016,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620041
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",,4017,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620042
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,4018,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620043
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",,4019,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620044
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",,4020,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620045
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",,4021,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620046
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,4022,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620047
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",,4023,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620048
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",,4024,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL857703
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",,4025,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620049
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,4026,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620050
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,4027,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL620051
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,4028,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL619213
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,4029,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL619214
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,4030,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL619804
,8,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,4031,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL619805
,8,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,4032,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL619806
,8,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,4033,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL619807
,8,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,4034,12832,,1,Canis lupus familiaris,Autocuration,55,,9615.0,Blood,H,178.0,In vivo,,BAO_0000218,F,,CHEMBL619808
,8,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,4035,3595,,1,Canis lupus familiaris,Autocuration,55,,9615.0,,H,,,,BAO_0000218,B,,CHEMBL619809
,8,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,4036,3595,,1,Canis lupus familiaris,Autocuration,55,,9615.0,,H,,,,BAO_0000218,B,,CHEMBL619810
,8,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,4037,3595,,1,Canis lupus familiaris,Autocuration,55,,9615.0,,H,,,,BAO_0000218,B,,CHEMBL619811
,8,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,4038,3595,,1,Canis lupus familiaris,Autocuration,55,,9615.0,,H,,,,BAO_0000218,B,,CHEMBL620769
,8,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,4039,3595,,1,Canis lupus familiaris,Autocuration,55,,9615.0,,H,,,,BAO_0000218,B,,CHEMBL620770
,8,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,4040,3595,,1,Canis lupus familiaris,Autocuration,55,,9615.0,,H,,,,BAO_0000218,B,,CHEMBL620771
,8,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,4041,3595,,1,Canis lupus familiaris,Autocuration,55,,9615.0,,H,,,,BAO_0000218,B,,CHEMBL620772
,8,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,4042,3595,,1,Canis lupus familiaris,Autocuration,55,,9615.0,,H,,,,BAO_0000218,B,,CHEMBL620773
,8,,Ability to inhibit 5-lipoxygenase in guinea pig,,4043,9203,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL620774
,8,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,4044,82,,1,Cavia porcellus,Expert,55,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL620775
,8,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,4045,11090,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL620776
,8,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,4046,12832,,1,Cavia porcellus,Autocuration,55,,10141.0,Blood,H,178.0,,,BAO_0000218,B,,CHEMBL620777
,8,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,4047,1065,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL620778
,8,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,4048,1065,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL620779
,8,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,4049,12832,,1,Cavia porcellus,Expert,55,,10141.0,,H,,,,BAO_0000019,B,,CHEMBL621500
,8,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,4050,12832,,1,Cavia porcellus,Expert,55,,10141.0,,H,,,,BAO_0000019,B,,CHEMBL621501
,8,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,4051,12832,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000019,B,,CHEMBL618098
,8,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,4052,10504,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000019,B,,CHEMBL618099
,8,,Inhibitory activity against 5-lipoxygenase,,4053,7788,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL618100
,8,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,4054,10001,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL618101
,8,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,4055,10193,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL618102
,8,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,4056,13243,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL618103
,8,,Inhibitory activity uM,,4057,13243,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL618104
,8,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,4058,969,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000219,B,,CHEMBL883712
,8,,Inhibitory activity against 5-lipoxygenase at 10 uM,,4059,10001,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL618105
,8,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,4060,7788,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL618106
,8,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,4061,10001,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL618107
,8,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,4062,10193,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL618108
,8,,Inhibitory activity uM,,4063,13243,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL618109
,8,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,4064,13243,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL618110
,8,,Inhibitory activity uM,,4065,13243,,1,Cavia porcellus,Expert,55,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL618111
,8,,Inhibitory activity uM,,4066,13243,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000019,F,,CHEMBL618112
,8,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,4067,10504,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000019,B,,CHEMBL618113
,8,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,4068,7788,,1,Cavia porcellus,Autocuration,55,,10141.0,,H,,,,BAO_0000357,B,,CHEMBL618114
,8,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,4069,10546,,1,Cavia porcellus,Expert,55,,10141.0,Ileum,H,2116.0,,,BAO_0000221,F,,CHEMBL620871
,8,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,4070,13183,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL620872
,8,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,4071,13183,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL620873
,8,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,4072,2578,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL620874
,8,,In vitro inhibition of human 5-Lipoxygenase.,,4073,12780,,1,,Expert,55,,,,H,,,,BAO_0000357,B,,CHEMBL620875
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,4074,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL620876
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,4075,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL620877
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,4076,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL857854
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,,4077,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL620878
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,4078,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL620879
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,4079,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL620880
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,4080,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL620881
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,4081,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL620882
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,4082,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL620883
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,4083,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL620884
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,4084,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL620885
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,,4085,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL620886
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,4086,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL620887
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,4087,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618039
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,4088,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618040
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,,4089,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618041
,0,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,4090,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618216
,0,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,4091,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618217
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,,4092,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618218
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,,4093,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618219
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,,4094,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618220
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,,4095,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618221
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,,4096,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618222
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,4097,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618223
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,4098,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618224
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,,4099,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618225
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,,4100,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618226
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,4101,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618227
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,4102,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618228
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,4103,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618229
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,4104,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618230
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,4105,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618231
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,4106,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618232
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,4107,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618233
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,4108,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618234
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,4109,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618235
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,4110,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618115
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,4111,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618116
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,4112,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL618117
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,4113,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL619968
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,4114,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL619969
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,4115,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL619970
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,,4116,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL619971
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,,4117,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL619972
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,,4118,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL619973
,0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,,4119,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL619974
,0,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,4120,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL619975
,0,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,4121,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000251,B,,CHEMBL619976
,0,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,4122,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL619977
,0,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",,4123,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL619978
,0,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",,4124,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL619979
,0,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,4125,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL619980
,0,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,4126,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL619981
,1,741.0,In vitro inhibition of 7226/S myeloma cancer cell line,,4127,10797,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL619982
,1,993.0,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,4128,6881,,1,Homo sapiens,Intermediate,80698,,9606.0,,N,,,BEL-7404 tumor cell line,BAO_0000219,F,,CHEMBL619983
,1,391.0,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,4129,3838,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL620031
,1,391.0,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,4130,3838,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL620032
,1,505.0,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,4131,12981,,1,Cricetulus griseus,Expert,81264,,10029.0,,N,,,V79,BAO_0000219,F,,CHEMBL620033
,1,505.0,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,4132,12981,,1,Cricetulus griseus,Expert,81264,,10029.0,,N,,,V79,BAO_0000219,F,,CHEMBL620034
,1,1119.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,4133,7653,,1,Rattus norvegicus,Intermediate,80635,,10116.0,,N,,,7800C1 cell line,BAO_0000219,F,,CHEMBL620035
,1,1119.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,4134,7653,,1,Rattus norvegicus,Intermediate,80635,,10116.0,,N,,,7800C1 cell line,BAO_0000219,F,,CHEMBL618318
,1,1119.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,4135,7653,,1,Rattus norvegicus,Intermediate,80635,,10116.0,,N,,,7800C1 cell line,BAO_0000219,F,,CHEMBL618319
,1,1119.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,4136,7653,,1,Rattus norvegicus,Intermediate,80635,,10116.0,,N,,,7800C1 cell line,BAO_0000219,F,,CHEMBL618320
,1,1119.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,4137,7653,,1,Rattus norvegicus,Intermediate,80635,,10116.0,,N,,,7800C1 cell line,BAO_0000219,F,,CHEMBL618321
,1,1119.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,4138,7653,,1,Rattus norvegicus,Intermediate,80635,,10116.0,,N,,,7800C1 cell line,BAO_0000219,F,,CHEMBL883118
,1,391.0,In vitro antitumor activity against renal 786-0 tumor cell lines,,4139,17229,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL883795
,1,391.0,Cytotoxic activity against 786-0 Renal cancer cell line,,4140,12858,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL618322
,1,391.0,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,4141,16325,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL618323
,1,391.0,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,4142,16325,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL618324
,1,391.0,In vitro antitumor activity against human renal 786-0 cell line,,4143,5858,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL618325
,1,391.0,Inhibition of Renal cancer in 786-0 cancer cell lines,,4144,16325,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL875416
,1,391.0,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,4145,14696,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL618326
,1,391.0,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,4146,3786,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL618327
,1,391.0,inhibition of the growth of renal cancer(786-0) cell line,,4147,14696,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619215
,1,391.0,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,4148,14769,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619216
,1,391.0,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,4149,15354,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619217
,1,391.0,The IC50 value was measured on 786-0 cell line in ovarian tumor,,4150,14255,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619218
,1,391.0,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,4151,14255,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619219
,1,391.0,The IC50 value was measured on 786-0 cell line in renal tumor type.,,4152,14255,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619220
,1,391.0,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,4153,14696,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619221
,1,391.0,Tested for cytotoxic activity against renal cancer 786-0 cell line,,4154,12016,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619222
,1,391.0,Compound was tested for growth inhibitory activity against 786-0 cell line,,4155,2597,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL857454
,8,702.0,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,4156,12526,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619223
,8,702.0,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,4157,12526,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619224
,8,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,4158,14799,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619225
,8,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,4159,3595,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619226
,8,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,4160,3595,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619227
,8,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,4161,12767,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619228
,8,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,4162,10997,,1,,Autocuration,12166,,,,H,,,,BAO_0000219,B,,CHEMBL619229
,8,702.0,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,4163,11388,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619230
,8,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,4164,167,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619231
,8,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,4165,167,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619232
,8,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,4166,13744,,1,,Expert,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619233
,8,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,4167,1630,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619234
,8,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,4168,1630,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619235
,9,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,4169,969,,1,Rattus norvegicus,Expert,12166,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL619236
,8,702.0,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,4170,13621,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619237
,8,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,4171,10089,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619238
,8,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,4172,10193,,1,,Expert,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619239
,8,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,4173,11966,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619240
,8,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,4174,12251,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL875417
,8,702.0,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,4175,211,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619241
,8,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,4176,12251,,1,,Expert,12166,,,,H,,,,BAO_0000019,F,,CHEMBL619242
,8,702.0,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,4177,12495,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL883796
,8,,Tested for its inhibitory activity against 5-lipoxygenase,,4178,414,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619243
,8,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,4179,414,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL619244
,8,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,4180,10325,,1,,Expert,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619245
,8,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,4181,11966,,1,,Expert,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619246
,8,702.0,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,4182,165,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619984
,8,702.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,4183,165,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619985
,8,702.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,4184,165,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619986
,8,702.0,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,4185,165,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619987
,8,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,4186,11311,,1,,Autocuration,12166,,,,H,,,,BAO_0000218,B,,CHEMBL619988
,8,702.0,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,4187,11311,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619989
,8,702.0,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,4188,11311,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL619990
,8,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,4189,11311,,1,,Autocuration,12166,,,,H,,,,BAO_0000219,B,,CHEMBL619991
,8,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,4190,11311,,1,,Autocuration,12166,,,,H,,,,BAO_0000219,B,,CHEMBL619992
,8,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,4191,11311,,1,,Autocuration,12166,,,,H,,In vivo,,BAO_0000218,B,,CHEMBL619993
,8,663.0,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,4192,11311,,1,,Autocuration,12166,,,,H,,,RBL-2H3,BAO_0000219,F,,CHEMBL619994
,8,663.0,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,4193,11311,,1,,Autocuration,12166,,,,H,,,RBL-2H3,BAO_0000219,F,,CHEMBL619995
,8,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,4194,11311,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619996
,8,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,4195,11732,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619997
,8,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,4196,11732,,1,,Expert,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619998
,8,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,4197,11087,,1,,Expert,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619999
,8,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,4198,11087,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL620000
,8,702.0,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,4199,11087,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620001
,9,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,4200,11087,,1,Rattus norvegicus,Expert,12166,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL620002
,8,702.0,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,4201,496,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620003
,8,702.0,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,4202,13986,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,F,,CHEMBL620004
,8,,Compound was evaluated for the inhibition of 5-lipoxygenase,,4203,11520,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL874063
,8,702.0,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,4204,10293,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620005
,8,702.0,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,4205,303,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620006
,8,702.0,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,4206,303,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620007
,8,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,4207,9247,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620008
,9,702.0,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,4208,9247,,1,Rattus norvegicus,Expert,12166,,10116.0,,D,,,RBL-1,BAO_0000219,B,,CHEMBL620009
,8,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,4209,9247,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620010
,8,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,4210,9247,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620011
,8,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,4211,9247,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620677
,8,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,4212,9247,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620678
,8,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,4213,9247,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620679
,8,702.0,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,4214,9247,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620680
,9,,Inhibitory activity against 5-lipoxygenase at 10 uM,,4215,11481,,1,Rattus norvegicus,Expert,12166,,10116.0,,D,,,,BAO_0000357,B,,CHEMBL620838
,8,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,4216,105,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL620839
,8,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,4217,9029,,1,,Expert,12166,,,,H,,,,BAO_0000357,B,,CHEMBL620840
,8,702.0,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,4218,1175,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620841
,8,702.0,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,4219,12118,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620842
,8,702.0,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,4220,12118,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620843
,8,702.0,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,4221,12118,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620844
,8,702.0,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,4222,9225,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620845
,8,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,4223,9401,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL620846
,8,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,4224,137,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL873951
,8,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,4225,137,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL620847
,8,702.0,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,4226,4717,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620848
,8,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,4227,3595,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620849
,8,702.0,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,4228,10501,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620850
,8,702.0,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,4229,10501,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620851
,8,702.0,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,4230,10501,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620852
,8,702.0,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,4231,12526,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL875098
,9,702.0,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,4232,14799,,1,Rattus norvegicus,Expert,12166,,10116.0,,D,,,RBL-1,BAO_0000219,B,,CHEMBL620853
,8,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,4233,14799,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL620854
,8,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,4234,3595,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620855
,8,702.0,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,4235,3595,,1,,Expert,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL839884
,8,702.0,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,4236,12526,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620856
,8,702.0,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,4237,12526,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620857
,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,4238,10193,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL620858
,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,4239,10193,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL620859
,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,4240,10193,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL620860
,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,4241,10193,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL620861
,8,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,4242,9138,,1,,Expert,12166,,,,H,,,,BAO_0000357,B,,CHEMBL620862
,8,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,4243,9138,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL620863
,8,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,4244,11966,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL620864
,8,702.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,4245,165,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620865
,8,702.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,4246,165,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620866
,8,663.0,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,4247,11311,,1,,Autocuration,12166,,,,H,,,RBL-2H3,BAO_0000219,B,,CHEMBL620867
,8,663.0,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,4248,11311,,1,,Autocuration,12166,,,,H,,,RBL-2H3,BAO_0000219,B,,CHEMBL620868
,8,663.0,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,4249,11311,,1,,Autocuration,12166,,,,H,,,RBL-2H3,BAO_0000219,F,,CHEMBL620869
,8,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,4250,11311,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,F,,CHEMBL873952
,8,,The compound was tested for inhibition of isolated 5-lipoxygenase,,4251,11311,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL875099
,8,663.0,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,4252,11311,,1,,Autocuration,12166,,,,H,,,RBL-2H3,BAO_0000219,F,,CHEMBL620870
,8,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,4253,11087,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL618261
,8,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,4254,11087,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL618262
,8,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,4255,11087,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619428
,8,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,4256,11087,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619429
,8,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,4257,11087,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL619430
,8,702.0,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,4258,496,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620017
,8,702.0,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,4259,496,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL620018
,8,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,4260,13986,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,F,,CHEMBL620019
,8,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,4261,13986,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,F,,CHEMBL620020
,8,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,4262,13986,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,F,,CHEMBL620021
,8,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,4263,13986,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,F,,CHEMBL620022
,8,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,4264,13986,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,F,,CHEMBL620023
,8,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,4265,13986,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,F,,CHEMBL620024
,8,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,4266,13986,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,F,,CHEMBL620025
,8,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,4267,13986,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,F,,CHEMBL620026
,8,702.0,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,4268,13986,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,F,,CHEMBL620027
,9,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,4269,13986,,1,Rattus norvegicus,Expert,12166,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL620028
,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,4270,10193,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL620029
,8,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,4271,9295,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL620030
,8,702.0,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,4272,4717,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL875415
,8,702.0,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,4273,4717,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL618256
,8,702.0,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,4274,11854,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL618257
,8,702.0,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,4275,11854,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL618258
,8,702.0,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,4276,11854,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL618259
,8,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,4277,10193,,1,,Autocuration,12166,,,,H,,,,BAO_0000019,B,,CHEMBL618260
,8,702.0,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,4278,9295,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL618215
,8,702.0,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,4279,9295,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL618390
,8,702.0,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,4280,9295,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL618391
,8,702.0,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,4281,9295,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL618392
,8,702.0,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,4282,165,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL618393
,8,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,4283,11311,,1,,Autocuration,12166,,,,H,,,,BAO_0000219,B,,CHEMBL618394
,8,702.0,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,4284,10489,,1,Homo sapiens,Expert,12166,,9606.0,,H,,,RBL-1,BAO_0000219,B,,CHEMBL618395
,9,702.0,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,4285,10489,,1,Rattus norvegicus,Expert,12166,,10116.0,,D,,,RBL-1,BAO_0000219,B,,CHEMBL618396
,9,702.0,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,4286,10489,,1,Rattus norvegicus,Expert,12166,,10116.0,,D,,,RBL-1,BAO_0000219,B,,CHEMBL858253
,9,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,4287,14799,,1,Rattus norvegicus,Autocuration,12166,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL618397
,8,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,4288,9295,,1,Glycine max,Autocuration,12054,,3847.0,,H,,,,BAO_0000357,B,,CHEMBL618398
,0,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,4289,16811,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL618399
,8,,In vitro inhibition of 5-Lipoxygenase; Inactive.,,4290,168,,1,,Expert,55,,,,H,,,,BAO_0000357,B,,CHEMBL618400
,8,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,4291,6309,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618401
,8,,Inhibitory concentration against 5-lipoxygenase; No inhibition,,4292,6309,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618402
,8,702.0,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,4293,3092,,1,,Autocuration,55,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL876400
,8,,Inhibitory activity against 5-lipoxygenase.,,4294,168,,1,,Expert,55,,,,H,,,,BAO_0000357,B,,CHEMBL618403
,8,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,4295,168,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618404
,8,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,4296,168,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618405
,8,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,4297,168,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618406
,8,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,4298,12338,,1,,Expert,55,,,,H,,,,BAO_0000019,F,,CHEMBL618407
,8,,Tested for the inhibitory activity against 5-lipoxygenase,,4299,4501,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618408
,8,,Compound was tested for its inhibitory activity against 5-lipoxygenase,,4300,1132,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618409
,8,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,4301,2117,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618410
,8,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,4302,168,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618411
,8,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,4303,168,,1,,Autocuration,55,,,,H,,,,BAO_0000357,B,,CHEMBL618412
,8,702.0,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,4304,13575,,1,,Autocuration,12166,,,,H,,,RBL-1,BAO_0000219,B,,CHEMBL618413
,8,,,,4305,11089,,1,,Autocuration,12166,,,,H,,,,BAO_0000357,B,,CHEMBL618414
,8,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,4306,216,,1,,Autocuration,10102,,,,H,,,,BAO_0000357,B,,CHEMBL618415
,8,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,4307,13165,,1,,Autocuration,10102,,,,H,,,,BAO_0000019,B,,CHEMBL618416
,8,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,4308,3278,,1,,Autocuration,10102,,,,H,,,,BAO_0000357,B,,CHEMBL876401
,8,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,4309,3278,,1,,Expert,10102,,,,H,,,,BAO_0000357,B,,CHEMBL618417
,8,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,4310,11966,,1,,Autocuration,10102,,,,H,,,,BAO_0000357,B,,CHEMBL618418
,8,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,4311,175,,1,,Autocuration,10102,,,,H,,,,BAO_0000357,B,,CHEMBL618419
,8,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,4312,175,,1,,Autocuration,10102,,,,H,,,,BAO_0000357,B,,CHEMBL618420
,8,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,4313,13449,,1,,Autocuration,10102,,,,H,,,,BAO_0000357,B,,CHEMBL618421
,8,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,4314,12014,,1,,Autocuration,11238,,,,H,,,,BAO_0000019,B,,CHEMBL618422
,8,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,4315,12014,,1,,Autocuration,11238,,,,H,,,,BAO_0000019,B,,CHEMBL618423
,8,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,4316,12014,,1,,Autocuration,11238,,,,H,,,,BAO_0000019,B,,CHEMBL618424
,2,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,4317,99,,1,,Intermediate,100284,,,,S,,,,BAO_0000220,B,,CHEMBL618425
,0,,The dark toxicity against 543 human galactophore carcinoma cells,,4318,4349,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000019,F,,CHEMBL618426
,1,390.0,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,4319,4071,,1,Homo sapiens,Expert,80623,,9606.0,,N,,,Panel (56 tumour cell lines),BAO_0000219,F,,CHEMBL618427
,1,345.0,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,4320,17589,,1,Homo sapiens,Expert,80008,,9606.0,,N,,,5637,BAO_0000219,F,,CHEMBL618428
,1,345.0,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,4321,15002,,1,Homo sapiens,Intermediate,80008,,9606.0,,N,,,5637,BAO_0000219,F,,CHEMBL618429
,1,345.0,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,4322,13958,,1,Homo sapiens,Intermediate,80008,,9606.0,,N,,,5637,BAO_0000219,F,,CHEMBL618430
,1,345.0,Growth inhibition against human 5637 cell lines,,4323,17589,,1,Homo sapiens,Expert,80008,,9606.0,,N,,,5637,BAO_0000219,F,,CHEMBL618431
,1,345.0,Antitumor activity against human bladder carcinoma 5637 cells.,,4324,16748,,1,Homo sapiens,Expert,80008,,9606.0,,N,,,5637,BAO_0000219,F,,CHEMBL883799
,1,345.0,Antitumor activity against human bladder carcinoma 5637 cells,,4325,16747,,1,Homo sapiens,Intermediate,80008,,9606.0,,N,,,5637,BAO_0000219,F,,CHEMBL618432
,1,345.0,Antitumor activity against human bladder carcinoma 5637 cells,,4326,16747,,1,Homo sapiens,Intermediate,80008,,9606.0,,N,,,5637,BAO_0000219,F,,CHEMBL618433
,9,,In vitro inhibition of bovine trypsin(Trp).,,4327,15285,,1,Bos taurus,Expert,10443,,9913.0,,D,,,,BAO_0000357,B,,CHEMBL618434
,8,407.0,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,4328,3726,,1,Cercopithecidae,Expert,240,,9527.0,,H,,,CV-1,BAO_0000219,B,,CHEMBL618435
,8,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,4329,5033,,1,,Autocuration,10577,,,,H,,,,BAO_0000357,B,,CHEMBL876402
,6,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,4330,11756,,1,,Autocuration,104698,,,,H,,,,BAO_0000019,F,,CHEMBL618436
,0,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,4331,11953,,1,,Autocuration,22226,,,,U,,In vivo,,BAO_0000218,F,,CHEMBL618437
,9,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,4332,5033,,1,Cavia porcellus,Intermediate,20033,,10141.0,,D,,,,BAO_0000357,B,,CHEMBL618438
,8,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,4333,11347,Microsomes,1,Rattus norvegicus,Expert,17045,,10116.0,,H,,,,BAO_0000251,A,,CHEMBL883800
,8,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,4334,11347,Microsomes,1,Rattus norvegicus,Expert,17045,,10116.0,,H,,,,BAO_0000251,A,,CHEMBL618439
,0,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,4335,1229,,1,,Intermediate,22226,,,,U,,,,BAO_0000019,F,,CHEMBL618440
,0,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,4336,1229,,1,,Intermediate,22226,,,,U,,,,BAO_0000019,F,,CHEMBL618441
,8,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,4337,17588,,1,Trypanosoma brucei,Expert,11938,,5691.0,,H,,,,BAO_0000019,B,,CHEMBL618442
,8,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,4338,17588,,1,Trypanosoma brucei,Autocuration,11938,,5691.0,,H,,,,BAO_0000019,B,,CHEMBL618443
,8,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,4339,17588,,1,Ovis aries,Expert,11938,,9940.0,,H,,,,BAO_0000019,B,,CHEMBL619158
,8,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,4340,17588,,1,Ovis aries,Autocuration,11938,,9940.0,,H,,,,BAO_0000019,B,,CHEMBL620974
,8,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,4341,16485,,1,,Autocuration,11938,,,,H,,,,BAO_0000357,B,,CHEMBL620975
,0,,Average inhibitory concentration against 60 human cell lines was reported,,4342,4337,,1,Homo sapiens,Intermediate,22226,,9606.0,,U,,,,BAO_0000019,F,,CHEMBL620976
,0,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,4343,4112,,1,Homo sapiens,Expert,22226,,9606.0,,U,,,,BAO_0000019,F,,CHEMBL620977
,1,542.0,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,4344,16160,,1,Homo sapiens,Intermediate,80315,,9606.0,,N,,,Panel NCI-60 (60 carcinoma cell lines),BAO_0000219,F,,CHEMBL620978
,1,542.0,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,4345,16160,,1,Homo sapiens,Intermediate,80315,,9606.0,,N,,,Panel NCI-60 (60 carcinoma cell lines),BAO_0000219,F,,CHEMBL620979
,1,542.0,In vitro mean growth inhibitory activity against 60-cell panel,,4346,17376,,1,,Expert,80315,,,,N,,,Panel NCI-60 (60 carcinoma cell lines),BAO_0000219,F,,CHEMBL620980
,1,542.0,In vitro mean growth lethal concentration against 60-cell panel,,4347,17376,,1,,Expert,80315,,,,N,,,Panel NCI-60 (60 carcinoma cell lines),BAO_0000219,F,,CHEMBL620981
,1,542.0,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,4348,17376,,1,,Expert,80315,,,,N,,,Panel NCI-60 (60 carcinoma cell lines),BAO_0000219,F,,CHEMBL620982
,1,542.0,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,4349,17376,,1,,Expert,80315,,,,N,,,Panel NCI-60 (60 carcinoma cell lines),BAO_0000219,F,,CHEMBL620983
,4,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,4350,3241,,1,,Autocuration,104775,,,,H,,,,BAO_0000019,F,,CHEMBL620984
,4,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,4351,3241,,1,,Autocuration,104775,,,,H,,,,BAO_0000019,F,,CHEMBL620985
,8,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,4352,3725,,1,,Expert,275,,,,H,,,,BAO_0000357,B,,CHEMBL620986
,1,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,4353,10805,,1,Plasmodium falciparum,Expert,50425,,5833.0,,N,,,,BAO_0000218,F,,CHEMBL620987
,1,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,4354,10805,,1,Plasmodium falciparum,Expert,50425,,5833.0,,N,,,,BAO_0000218,F,,CHEMBL620988
,1,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,4355,10805,,1,Plasmodium falciparum,Expert,50425,,5833.0,,N,,,,BAO_0000218,F,,CHEMBL620989
,1,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,4356,10805,,1,Plasmodium falciparum,Expert,50425,,5833.0,,N,,,,BAO_0000218,F,,CHEMBL620990
,1,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,4357,10805,,1,Plasmodium falciparum,Intermediate,50425,,5833.0,,N,,,,BAO_0000218,F,,CHEMBL620991
,1,850.0,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,4358,10144,,1,Mus musculus,Intermediate,80628,,10090.0,,N,,,6C3HED,BAO_0000218,F,,CHEMBL620992
,1,850.0,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,4359,10144,,1,Mus musculus,Intermediate,80628,,10090.0,,N,,,6C3HED,BAO_0000218,F,,CHEMBL620993
,1,850.0,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,4360,10144,,1,Mus musculus,Intermediate,80628,,10090.0,,N,,,6C3HED,BAO_0000218,F,,CHEMBL620994
,1,850.0,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,4361,10144,,1,Mus musculus,Intermediate,80628,,10090.0,,N,,,6C3HED,BAO_0000218,F,,CHEMBL620995
,1,850.0,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,4362,10144,,1,Mus musculus,Intermediate,80628,,10090.0,,N,,,6C3HED,BAO_0000218,F,,CHEMBL620996
,1,850.0,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,4363,10144,,1,Mus musculus,Intermediate,80628,,10090.0,,N,,,6C3HED,BAO_0000218,F,,CHEMBL875581
,0,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,4364,10685,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL620997
,0,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,4365,10685,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL620998
,0,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,4366,10685,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL620999
,0,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,4367,10685,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL621000
,0,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,4368,10685,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL621001
,0,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,4369,10685,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL621002
,0,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,4370,10685,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL621003
,0,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,4371,10685,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL621004
,0,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,4372,10685,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL621005
,0,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,4373,10685,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL621006
,0,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,4374,10685,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL621007
,0,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,4375,10144,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,,,BAO_0000218,F,,CHEMBL621008
,0,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,4376,10144,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,,,BAO_0000218,F,,CHEMBL621009
,0,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,4377,10144,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,,,BAO_0000218,F,,CHEMBL857705
,0,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,4378,10144,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,,,BAO_0000218,F,,CHEMBL619828
,0,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,4379,10685,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,,,BAO_0000218,F,,CHEMBL619829
,0,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,4380,10685,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,,,BAO_0000218,F,,CHEMBL619830
,0,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,4381,10685,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,,,BAO_0000218,F,,CHEMBL619831
,0,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,4382,10685,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,,,BAO_0000218,F,,CHEMBL619832
,0,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,4383,10685,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,,,BAO_0000218,A,,CHEMBL619833
,0,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,4384,10685,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,,,BAO_0000218,A,,CHEMBL619834
,0,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,4385,10685,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,,,BAO_0000218,A,,CHEMBL619835
,0,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,4386,10685,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,,,BAO_0000218,A,,CHEMBL619836
,1,850.0,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,4387,8831,,1,Mus musculus,Intermediate,80628,,10090.0,,N,,,6C3HED,BAO_0000218,F,,CHEMBL619837
,0,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,4388,11704,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,F,,CHEMBL619838
,1,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,4389,11704,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619839
,1,850.0,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,,4390,10685,,1,Mus musculus,Intermediate,80628,,10090.0,,N,,In vivo,6C3HED,BAO_0000218,F,,CHEMBL619840
,1,850.0,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,,4391,10685,,1,Mus musculus,Intermediate,80628,,10090.0,,N,,In vivo,6C3HED,BAO_0000218,F,,CHEMBL619841
,1,850.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,4392,11368,,1,Mus musculus,Expert,80628,,10090.0,,N,,,6C3HED,BAO_0000218,F,,CHEMBL857704
,1,850.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,4393,11368,,1,Mus musculus,Intermediate,80628,,10090.0,,N,,,6C3HED,BAO_0000218,F,,CHEMBL619842
,1,850.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,4394,11368,,1,Mus musculus,Expert,80628,,10090.0,,N,,,6C3HED,BAO_0000218,F,,CHEMBL619843
,0,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,4395,17763,,1,Staphylococcus aureus,Autocuration,22226,,1280.0,,U,,,,BAO_0000019,B,,CHEMBL619844
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,,4396,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL857855
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,4397,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL619845
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,,4398,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL619846
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,,4399,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL619847
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,,4400,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL619848
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,,4401,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL620893
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,,4402,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL620894
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,,4403,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL620895
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,4404,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL620896
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,4405,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL620897
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,4406,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL620898
,0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,4407,7411,Microsomes,1,Rattus norvegicus,Autocuration,22226,,10116.0,Liver,U,2107.0,,,BAO_0000251,B,,CHEMBL620899
,0,,The apparent total plasma clearance in monkey,,4408,347,,1,Cercopithecidae,Autocuration,22224,,9527.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL620900
,0,,Compound was evaluated for Hepatic clearance in monkey,,4409,3341,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620901
,0,,Lower clearance in monkey (i.v.) at 0.5 mpk,,4410,17853,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620902
,0,,Plasma clearance in rhesus monkey,,4411,4514,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620903
,0,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,4412,6062,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620904
,0,,Plasma clearance of compound was determined in monkey,,4413,6821,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620905
,0,,Plasma clearance was calculated in rhesus monkey,,4414,6057,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620906
,0,,Plasma clearance in rhesus monkey,,4415,5145,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL875420
,0,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,4416,6641,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620907
,0,,Plasma clearance was evaluated in rhesus,,4417,5472,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620908
,0,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,4418,4257,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620909
,0,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,4419,5546,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620910
,0,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,4420,5334,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620911
,0,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,4421,5334,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620912
,0,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,4422,17509,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620913
,0,,Cmax in monkey after administration of 1 mg/kg iv,,4423,6535,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620914
,0,,Cmax was determine after peroral administration at 10 mpk in Rhesus,,4424,5668,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620915
,0,,Cmax in cynomolgus monkey by iv administration,,4425,5922,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620916
,0,,Cmax in cynomolgus monkey by po administration,,4426,5922,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620917
,0,,Cmax value evaluated in monkey,,4427,6078,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620918
,0,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,4428,2661,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620919
,0,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,,4429,3249,,1,Cercopithecidae,Autocuration,22224,,9527.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL620920
,0,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,,4430,3249,,1,Cercopithecidae,Autocuration,22224,,9527.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL620921
,0,,Maximal plasma concentration in squirrel monkeys,,4431,5553,,1,Cercopithecidae,Autocuration,22224,,9527.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL620922
,0,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,4432,1916,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620923
,0,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,,4433,6227,,1,Cercopithecidae,Autocuration,22224,,9527.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL620924
,0,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,4434,4809,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620925
,0,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,4435,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620926
,0,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,4436,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620927
,0,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,4437,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620928
,0,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,4438,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620929
,0,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,,4439,6221,,1,Cercopithecidae,Autocuration,22224,,9527.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL620930
,0,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,4440,167,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL620931
,0,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,4441,167,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL620932
,0,,Absolute bioavailability was evaluated in monkey,,4442,4257,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620933
,0,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,4443,6221,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620934
,0,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,4444,17667,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620935
,0,,Bioavailability of compound was determined in rhesus monkey,,4445,17267,,1,Macaca mulatta,Autocuration,22224,,9544.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620936
,0,,Bioavailability determined after oral administration in marmoset,,4446,4256,,1,marmosets,Autocuration,22224,,38020.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620937
,0,,Oral bioavailability in cynomolgus monkey,,4447,4256,,1,Macaca fascicularis,Autocuration,22224,,9541.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620938
,0,,Bioavailability in monkey (p.o.) at 2.0 mpk,,4448,17853,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620939
,0,,Bioavailability was evaluated after oral administration in monkey,,4449,16365,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620940
,0,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,4450,1916,,1,Macaca fascicularis,Autocuration,22224,,9541.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620941
,0,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,4451,5334,,1,Macaca mulatta,Autocuration,22224,,9544.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620942
,0,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,4452,5334,,1,Macaca mulatta,Autocuration,22224,,9544.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620943
,0,,Bioavailability of the compound was determined in monkey,,4453,17592,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620944
,0,,Bioavailability in squirrel monkey (dose 5 mg/kg),,4454,1399,,1,Saimiri sciureus,Autocuration,22224,,9521.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620945
,0,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,4455,4809,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620946
,0,,Oral bioavailability in monkey,,4456,3341,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620947
,0,,Compound was tested for bioavailability in squirrel monkey,,4457,64,,1,Saimiri sciureus,Autocuration,22224,,9521.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620948
,0,,Oral bioavailability in Rhesus monkey,,4458,5005,,1,Macaca mulatta,Autocuration,22224,,9544.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620949
,0,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,4459,5005,,1,Macaca mulatta,Autocuration,22224,,9544.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620950
,0,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,4460,5237,,1,Macaca fascicularis,Autocuration,22224,,9541.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620951
,0,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,4461,5237,,1,Macaca fascicularis,Autocuration,22224,,9541.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620952
,0,,Oral bioavailability in monkey (dose 5 mg/kg),,4462,5302,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL875421
,0,,Oral bioavailability of compound at 5 mg/kg in monkey,,4463,17667,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620953
,1,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,4464,6161,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL873491
,1,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,4465,6161,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620954
,1,,Plasma half life determined,,4466,3854,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL620955
,1,,Plasma half life in dog,,4467,993,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL618097
,1,,Plasma half-life in Beagle dogs,,4468,4514,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL618268
,1,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,4469,5334,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL618269
,1,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),,4470,5334,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL618270
,1,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,4471,1466,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618271
,1,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,4472,1466,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL873493
,1,,Tested for the half life period in dog,,4473,5313,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621031
,1,,Tested for the half life period in dog at dosage of 10 mpk,,4474,5313,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621032
,1,,The compound was tested for half life in dog,,4475,3880,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621033
,1,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,4476,3639,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL621034
,1,,The half life was determined,,4477,3880,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621035
,1,,The plasma half-life in dogs,,4478,3918,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL621036
,1,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,4479,16452,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL621037
,1,,Half life in dog,,4480,17796,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL619812
,1,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,4481,5983,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619813
,1,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,4482,1466,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL873335
,1,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,4483,16456,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619814
,1,,Cmax in ferrets after 30 mg/kg oral dose,,4484,6113,,1,Mustela putorius furo,Expert,50506,,9669.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619815
,1,,Emesis in ferrets at 30 mg/kg oral dose,,4485,6113,,1,Mustela putorius furo,Expert,50506,,9669.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL619816
,0,,Bioavailability in cynomolgus monkey,,4486,17796,,1,Macaca fascicularis,Autocuration,22224,,9541.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL619817
,1,,Volume of distribution in cynomolgus,,4487,17796,,1,Macaca fascicularis,Intermediate,100710,,9541.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619818
,0,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,4488,5308,,1,Cavia porcellus,Autocuration,22224,,10141.0,Plasma,U,1969.0,,,BAO_0000218,A,,CHEMBL619819
,0,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,4489,4877,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,,,BAO_0000218,A,,CHEMBL619820
,0,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,4490,4876,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,,,BAO_0000218,A,,CHEMBL875419
,0,,AUC in guinea pig after 3mg/kg oral dose,,4491,4878,,1,Cavia porcellus,Autocuration,22224,,10141.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL619821
,0,,Bioavailability in guinea pig was tested,,4492,5308,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL619822
,0,,Tested for oral bioavailability in guinea pig at 5 mg/kg,,4493,4877,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL619823
,0,,Tested for the oral bioavailability of the compound,,4494,4876,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL619824
,0,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,4495,4876,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL619825
,0,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,4496,5308,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL619826
,0,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,4497,4877,,1,Cavia porcellus,Autocuration,22224,,10141.0,Lung,U,2048.0,In vivo,,BAO_0000218,A,,CHEMBL619827
,0,,Cmax in guinea pig after 3mg/kg oral dose,,4498,4878,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618167
,0,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,4499,5689,,1,Cavia porcellus,Autocuration,22224,,10141.0,Blood,U,178.0,,,BAO_0000019,A,,CHEMBL618168
,0,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,4500,5689,,1,Cavia porcellus,Autocuration,22224,,10141.0,Brain,U,955.0,,,BAO_0000019,A,,CHEMBL618169
,0,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,4501,5689,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,,,BAO_0000019,A,,CHEMBL618170
,0,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,4502,5689,,1,Cavia porcellus,Autocuration,22224,,10141.0,Intestine,U,160.0,,,BAO_0000019,A,,CHEMBL618171
,0,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,4503,5689,,1,Cavia porcellus,Autocuration,22224,,10141.0,Kidney,U,2113.0,,,BAO_0000019,A,,CHEMBL618172
,0,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,4504,5689,,1,Cavia porcellus,Autocuration,22224,,10141.0,Liver,U,2107.0,,,BAO_0000019,A,,CHEMBL618173
,0,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,4505,5689,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,,,BAO_0000019,A,,CHEMBL618174
,0,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,4506,5689,,1,Cavia porcellus,Autocuration,22224,,10141.0,Spleen,U,2106.0,,,BAO_0000019,A,,CHEMBL875408
,0,,Elimination T1/2 in Guinea pig (PO dose),,4507,14465,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL839827
,0,,Partition coefficient was measured as -log (counts per min ),,4508,5689,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,,,BAO_0000019,A,,CHEMBL618175
,0,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,4509,611,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618176
,0,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,4510,611,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618177
,0,,Elimination T1/2 in Guinea pig (PO dose),,4511,14465,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618178
,0,,"Tested for the half life period of the compound, intravenously",,4512,4876,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618179
,0,,Half-life was measured,,4513,5689,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,,,BAO_0000019,A,,CHEMBL873489
,0,,The time required for onset of inotropy after addition of a single dose of delta F75,,4514,7515,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,,,BAO_0000019,A,,CHEMBL618180
,0,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,4515,17667,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618181
,0,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,4516,17667,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618182
,0,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,4517,4727,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618183
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,4518,10107,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618184
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,4519,10107,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618185
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,4520,10107,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618186
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,4521,10107,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618187
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,4522,10107,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618188
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,4523,10107,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875409
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,4524,10107,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618189
,1,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,,4525,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL618190
,1,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,,4526,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL618191
,1,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,,4527,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL618192
,1,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,,4528,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL618193
,1,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,,4529,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL618194
,1,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,,4530,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL618195
,1,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,,4531,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL618196
,1,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,,4532,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL618197
,1,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,,4533,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL618198
,1,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,,4534,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL618199
,1,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,,4535,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL618200
,1,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,,4536,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL618201
,1,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,,4537,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL618202
,1,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,,4538,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL618203
,1,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,,4539,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL618204
,1,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,,4540,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL618205
,1,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,,4541,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL618206
,1,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,,4542,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL618207
,1,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,,4543,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL618208
,1,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,,4544,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL618932
,1,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,,4545,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL618933
,1,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,,4546,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL618934
,1,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,,4547,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL618935
,1,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,,4548,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL618936
,1,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,,4549,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL618937
,1,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,,4550,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL618938
,1,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,,4551,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL619104
,1,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,,4552,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL619105
,1,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,,4553,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL619106
,1,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,,4554,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL619107
,1,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,,4555,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL875410
,1,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,,4556,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL619108
,1,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,,4557,3655,,1,Mus musculus,Intermediate,50594,,10090.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL619109
,1,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,4558,16597,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619110
,1,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,4559,16597,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL619111
,1,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,4560,16597,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619112
,1,,MRT value at a dose of 10 mg/kg peroral administration in mice.,,4561,16597,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619113
,1,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,4562,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619114
,1,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,4563,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL619115
,1,478.0,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,4564,3830,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619116
,1,478.0,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,4565,3829,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619117
,1,478.0,Compound was evaluated for cytotoxicity against A2780 cell lines.,,4566,2040,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619118
,1,478.0,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,4567,15684,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619119
,1,478.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,4568,15684,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619120
,1,478.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,4569,15684,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619121
,1,478.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,4570,15684,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619122
,1,478.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,4571,15684,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619123
,1,478.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,4572,15684,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619124
,1,478.0,Compound was evaluated for cytotoxicity against A2780 cell line,,4573,2859,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619125
,1,478.0,In vitro inhibitory activity against human tumor cell line A2780,,4574,5618,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL875411
,1,478.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,4575,15684,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619126
,1,478.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,4576,15684,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619127
,1,478.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,4577,15684,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619128
,1,478.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,4578,15684,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619129
,1,478.0,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,4579,2113,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619130
,1,478.0,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,4580,2113,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619131
,1,478.0,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,4581,16745,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619132
,1,478.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,4582,16597,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000218,F,,CHEMBL619133
,1,478.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,4583,15684,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619134
,1,478.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,4584,15684,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619135
,1,478.0,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,4585,2040,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619136
,1,478.0,Relative resistance factor in A2780 cisplatin-resistant line,,4586,2040,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619137
,1,478.0,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,4587,16165,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL883713
,1,478.0,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,4588,16165,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL875412
,1,478.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,4589,16597,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000218,F,,CHEMBL619138
,1,478.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,4590,16597,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000218,F,,CHEMBL619262
,1,478.0,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,4591,3992,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619139
,1,478.0,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,4592,10553,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619140
,1,478.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,4593,15608,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619141
,1,478.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,4594,15608,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619142
,1,478.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,4595,15608,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619143
,1,478.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,4596,15608,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619144
,1,478.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,4597,15608,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619145
,1,478.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,4598,15608,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619146
,1,478.0,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,4599,15569,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619147
,1,478.0,Antiproliferative effect of compound on A2780/DX cell line,,4600,17420,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619148
,1,478.0,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,4601,17420,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619149
,1,478.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,4602,15099,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619150
,1,478.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,4603,15099,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619151
,1,478.0,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,4604,17672,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL883794
,1,478.0,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,4605,17672,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619152
,1,478.0,In vitro cytotoxicity against A2780ADR cell line,,4606,17270,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619153
,1,478.0,In vitro cytotoxicity against A2780CIS cell line,,4607,17270,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619154
,1,478.0,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,4608,5574,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619155
,1,478.0,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,4609,2113,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619156
,1,478.0,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,4610,16913,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619157
,1,478.0,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,4611,16913,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619797
,0,,Oral bioavailability of compound in rhesus macaques,,4612,17839,,1,Macaca mulatta,Autocuration,22224,,9544.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL619798
,0,,Oral bioavailability in monkey,,4613,6821,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL619799
,0,,Oral bioavailability evaluated in monkey,,4614,6078,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL619800
,0,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,4615,6535,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL619801
,0,,Oral bioavailability in Rhesus monkey,,4616,4449,,1,Macaca mulatta,Autocuration,22224,,9544.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL619802
,0,,Oral bioavailability was calculated in rhesus monkey,,4617,6057,,1,Macaca mulatta,Autocuration,22224,,9544.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL619803
,0,,Oral bioavailability in cynomolgus monkey,,4618,5922,,1,Macaca fascicularis,Autocuration,22224,,9541.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL619965
,0,,Oral bioavailability in monkey,,4619,5940,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL619966
,0,,Oral bioavailability in monkey,,4620,6265,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL619967
,0,,Oral bioavailability in monkey (dose 1 mg/kg),,4621,6265,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620073
,0,,Oral bioavailability in monkey (dose 5 mg/kg),,4622,6265,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620074
,0,,Oral bioavailability in monkey,,4623,5940,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620075
,0,,Oral bioavailability in monkey,,4624,5940,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620076
,0,,Oral bioavailability in rhesus monkey,,4625,4514,,1,Macaca mulatta,Autocuration,22224,,9544.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620077
,0,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,4626,5546,,1,Macaca mulatta,Autocuration,22224,,9544.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620078
,0,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,4627,5553,,1,Saimiri sciureus,Autocuration,22224,,9521.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620079
,0,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,4628,6641,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620080
,0,,Oral bioavailability in Rhesus monkey,,4629,5472,,1,Macaca mulatta,Autocuration,22224,,9544.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620081
,0,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,4630,5668,,1,Macaca mulatta,Autocuration,22224,,9544.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620082
,0,,Oral bioavailability in monkey at 10 mg/kg of the compound,,4631,5711,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620083
,0,,Bioavailability in Rhesus monkey,,4632,5145,,1,Macaca mulatta,Autocuration,22224,,9544.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620084
,0,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,4633,3443,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL620085
,0,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,4634,3443,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL874595
,0,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,4635,3249,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL873352
,0,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,4636,3249,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620086
,0,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,4637,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620087
,0,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,4638,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620088
,0,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,4639,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620089
,0,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,4640,4809,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620090
,0,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,4641,4809,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620091
,0,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,4642,14294,Microsomes,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000251,A,,CHEMBL620092
,0,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,4643,14294,Microsomes,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000251,A,,CHEMBL620093
,0,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,4644,14294,Microsomes,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000251,A,,CHEMBL620094
,0,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,4645,14294,Microsomes,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000251,A,,CHEMBL620095
,0,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,4646,3443,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620096
,0,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,4647,3443,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620097
,0,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,4648,11271,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL620098
,0,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,4649,3443,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL620099
,0,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,4650,3443,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL620100
,0,,Elimination Half-life of compound was determined in monkey,,4651,6821,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL620101
,0,,Half life of compound was determined in rhesus monkey,,4652,17267,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL620102
,0,,Half life in monkey plasma,,4653,5819,,1,Cercopithecidae,Autocuration,22224,,9527.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL620103
,0,,Half life in monkey plasma; Not detected,,4654,5819,,1,Cercopithecidae,Autocuration,22224,,9527.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL620104
,0,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,4655,1916,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL874596
,0,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,4656,17509,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL873490
,0,,Terminal half life of the compound.,,4657,1399,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL620105
,0,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,4658,1916,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620780
,0,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,4659,4809,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620781
,0,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,4660,5546,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL620956
,0,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,4661,3443,,1,Cercopithecidae,Autocuration,22224,,9527.0,Urine,U,1088.0,,,BAO_0000218,A,,CHEMBL620957
,0,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,4662,3443,,1,Cercopithecidae,Autocuration,22224,,9527.0,Urine,U,1088.0,,,BAO_0000218,A,,CHEMBL620958
,0,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,4663,4257,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620959
,0,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,4664,6221,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620960
,0,,Volume of distribution was evaluated in rhesus,,4665,5472,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620961
,0,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,4666,4727,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620962
,0,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,4667,4727,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620963
,0,,Bioavailability in hamster was determined,,4668,4727,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620964
,0,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,4669,4727,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620965
,0,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,4670,4727,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620966
,0,,Half life of compound was determined in hamster blood,,4671,4727,,1,Cricetulus griseus,Autocuration,22224,,10029.0,Blood,U,178.0,,,BAO_0000221,A,,CHEMBL620967
,0,,Michaelis-Menten constant of the compound.,,4672,1452,,1,Sus scrofa,Autocuration,22224,,9823.0,,U,,,,BAO_0000019,A,,CHEMBL620968
,0,,Vmax value was measured at 0 uM concentration of silyl ether.,,4673,1452,,1,Sus scrofa,Autocuration,22224,,9823.0,,U,,,,BAO_0000019,A,,CHEMBL874597
,0,,Vmax value was measured at 10 uM concentration of silyl ether.,,4674,1452,,1,Sus scrofa,Autocuration,22224,,9823.0,,U,,,,BAO_0000019,A,,CHEMBL620969
,0,,Vmax value was measured at 5 uM concentration of silyl ether.,,4675,1452,,1,Sus scrofa,Autocuration,22224,,9823.0,,U,,,,BAO_0000019,A,,CHEMBL620970
,9,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,4676,11706,,1,Homo sapiens,Expert,235,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL620971
,0,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,4677,1916,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000218,A,,CHEMBL620972
,0,,Compound was evaluated for area under the curve expressed as (h*ug/ml),,4678,17791,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL620973
,0,,Active metabolite of ifosfamide determined in humans; A-Active,,4679,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618243
,0,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,4680,6567,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618244
,0,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,4681,6567,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618245
,0,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,4682,6567,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618246
,0,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,4683,6567,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618247
,0,,Compound was evaluated for oral bioavailability in human,,4684,17791,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000218,A,,CHEMBL618248
,0,,Metabolite of ifosfamide determined in urine; NF-Not found,,4685,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL618249
,0,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,4686,6852,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618250
,0,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,4687,6852,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL874598
,0,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,4688,6852,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618251
,0,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,4689,6852,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618252
,0,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,4690,6852,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618253
,0,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,4691,6852,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618254
,0,,Percent of compound in healthy individuals (Group D),,4692,6852,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618255
,0,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,4693,4397,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,,,BAO_0000251,A,,CHEMBL618983
,0,,Binding towards human plasma protein at 10 uM,,4694,17409,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618984
,0,,Binding towards human plasma protein at 100 uM,,4695,17409,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618985
,0,,Human plasma protein binding activity was determined,,4696,17176,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618986
,0,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,4697,15444,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618987
,0,,Percent binding of compound towards human plasma protein was determined,,4698,17267,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618988
,0,,Plasma clearance in human liver microsomes,,4699,5944,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,In vitro,,BAO_0000251,A,,CHEMBL618989
,0,,In vitro intrinsic clearance in human liver microsome,,4700,5668,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,In vitro,,BAO_0000251,A,,CHEMBL618990
,0,,In vitro intrinsic clearance in human liver microsome,,4701,5669,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,In vitro,,BAO_0000251,A,,CHEMBL618991
,0,,In vitro microsome metabolism clearance in human was determined,,4702,5041,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,In vitro,,BAO_0000251,A,,CHEMBL876725
,0,,In vitro microsome metabolism clearance in human was determined; High,,4703,5041,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,In vitro,,BAO_0000251,A,,CHEMBL618992
,0,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,,4704,5041,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,In vitro,,BAO_0000251,A,,CHEMBL618993
,0,,Pharmacokinetic property (clearance) in human liver microsome,,4705,5676,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,In vitro,,BAO_0000251,A,,CHEMBL618994
,0,,Plasma clearance in human liver microsomes,,4706,5944,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,In vitro,,BAO_0000251,A,,CHEMBL618995
,0,,In vitro clearance in human liver microsomes,,4707,17538,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,In vitro,,BAO_0000251,A,,CHEMBL618996
,0,,Intrinsic clearance in human liver microsomes was determined,,4708,6331,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,In vitro,,BAO_0000251,A,,CHEMBL618997
,0,,Intrinsic clearance in human liver microsomes was determined,,4709,5948,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,In vitro,,BAO_0000251,A,,CHEMBL618998
,0,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,4710,5965,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618999
,0,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,4711,1916,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620223
,0,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,4712,5965,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000218,A,,CHEMBL620224
,0,,Stability in human plasma 2 hr after incubation expressed as percent concentration,,4713,1299,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL620225
,0,,Stability in human plasma 4 hr after incubation expressed as percent concentration,,4714,1299,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL620226
,0,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,4715,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL620227
,0,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,4716,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL876726
,0,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,4717,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL620228
,0,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,4718,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL620229
,1,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,4719,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL620230
,1,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,4720,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL620231
,1,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,4721,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL620232
,1,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,4722,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL620233
,1,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,4723,14294,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL620234
,1,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,4724,14294,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL620235
,1,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,4725,14294,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL620236
,1,,In vitro metabolic potential in mouse liver microsomes,,4726,6251,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL620237
,1,,Ability of compound to bind to plasma protein was evaluated in HSA cells,,4727,17582,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL620238
,1,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,4728,17811,,1,Mus musculus,Intermediate,50594,,10090.0,Adrenal gland,N,2369.0,,,BAO_0000218,A,,CHEMBL620239
,1,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,4729,17811,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL620240
,1,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,4730,17811,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL620241
,1,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,4731,17811,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL876727
,1,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,4732,17811,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL620242
,1,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,4733,17811,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL620243
,1,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,4734,5288,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL620244
,1,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,4735,2717,,1,Mus musculus,Intermediate,50594,,10090.0,Serum,N,1977.0,,,BAO_0000218,A,,CHEMBL620245
,1,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,4736,2717,,1,Mus musculus,Intermediate,50594,,10090.0,Serum,N,1977.0,,,BAO_0000218,A,,CHEMBL620246
,1,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,4737,2717,,1,Mus musculus,Intermediate,50594,,10090.0,Serum,N,1977.0,,,BAO_0000218,A,,CHEMBL620247
,1,,Half life of compound was determined in plasma of mice at 24 mg/Kg,,4738,17753,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL620248
,1,,Half life of compound was determined in plasma of mice at 40 mg/Kg,,4739,17753,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL873497
,1,,Half life of compound was determined in plasma of mice at 5 mg/Kg,,4740,17753,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL620249
,1,,Half life after intraperitoneal administration in mice at 18 uM/kg,,4741,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL620250
,1,,Half life after intraperitoneal administration in mice at 23 uM/kg,,4742,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL620251
,1,,Half life after intraperitoneal administration in mice at 25 uM/kg,,4743,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL620252
,1,,Half life after intraperitoneal administration in mice at 26 uM/kg,,4744,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL620253
,1,,Half life after intravenous administration in mice at 23 uM/kg,,4745,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL620254
,1,,Half life after intravenous administration in mice at 24 uM/kg,,4746,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620255
,1,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,4747,16597,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620256
,1,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,4748,2675,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876728
,1,,Maximum time required to reach Cp max was evaluated in mice after oral administration,,4749,2675,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620257
,1,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,4750,16597,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620258
,1,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,4751,4890,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620259
,1,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,4752,429,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620260
,1,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,,4753,17837,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL620261
,1,,Half life at a dose of 10 mg/kg intravenous administration in mice.,,4754,16597,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620262
,1,,Half life at a dose of 10 mg/kg peroral administration in mice.,,4755,16597,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620263
,1,,Half life in ob/ob mice,,4756,6619,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL620264
,1,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,4757,4066,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620265
,1,,Half-life was measured in mouse,,4758,4239,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL620266
,1,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,4759,5969,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620267
,1,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,4760,8999,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619364
,1,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,4761,8999,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619365
,1,,T2 in brain of mice at the oral dose of 50 mg/kg,,4762,17641,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL619366
,1,,T2 in kidney of mice at the oral dose of 50 mg/kg,,4763,17641,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL619367
,1,,T2 in liver of mice at the oral dose of 50 mg/kg,,4764,17641,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL619368
,1,,T2 in lungs of mice at the oral dose of 50 mg/kg,,4765,17641,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL619369
,1,,T2 in spleen of mice at the oral dose of 50 mg/kg,,4766,17641,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL876729
,1,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,4767,16597,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619370
,1,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,4768,4890,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619371
,1,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,4769,429,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619372
,1,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,4770,429,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620012
,1,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,4771,5969,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620013
,1,478.0,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,4772,16913,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL620014
,1,478.0,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,4773,16913,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL620015
,1,478.0,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,4774,16913,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621010
,1,478.0,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,4775,16913,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621011
,1,478.0,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,4776,16913,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621012
,1,478.0,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,4777,16913,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621013
,1,478.0,In vitro cytotoxicity against A2780TAX cell line,,4778,17270,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621014
,1,481.0,In vitro inhibitory activity against human tumor cell line A2780cis,,4779,5618,,1,Homo sapiens,Intermediate,80017,,9606.0,,N,,,A2780cisR,BAO_0000219,F,,CHEMBL618154
,1,478.0,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,4780,17777,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618155
,1,481.0,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,4781,16112,,1,Homo sapiens,Intermediate,80017,,9606.0,,N,,,A2780cisR,BAO_0000219,F,,CHEMBL618156
,1,481.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,4782,15748,,1,Homo sapiens,Intermediate,80017,,9606.0,,N,,,A2780cisR,BAO_0000219,F,,CHEMBL618157
,1,478.0,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,4783,6633,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618328
,1,478.0,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,4784,16930,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618329
,1,478.0,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,4785,17496,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618330
,1,478.0,In vitro antitumor activity against A2780cisR cell line.,,4786,12989,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618331
,1,478.0,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,4787,4840,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618332
,1,478.0,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,4788,12989,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618333
,1,481.0,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,4789,16745,,1,Homo sapiens,Intermediate,80017,,9606.0,,N,,,A2780cisR,BAO_0000219,F,,CHEMBL618334
,1,478.0,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,4790,16597,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618335
,9,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,4791,16547,,1,Rattus norvegicus,Expert,11736,,10116.0,,D,,,,BAO_0000019,B,,CHEMBL618336
,8,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,4792,16547,,1,,Expert,11736,,,,H,,,,BAO_0000019,F,,CHEMBL618337
,9,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,4793,16547,,1,Rattus norvegicus,Expert,11736,,10116.0,,D,,,,BAO_0000019,F,,CHEMBL618338
,9,722.0,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,4794,15856,,1,Homo sapiens,Expert,278,,9606.0,,D,,,HEK293,BAO_0000219,F,,CHEMBL618339
,9,722.0,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,4795,15856,,1,Homo sapiens,Expert,278,,9606.0,,D,,,HEK293,BAO_0000219,F,,CHEMBL618340
,9,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,4796,16547,,1,Mus musculus,Expert,11831,,10090.0,,D,,,,BAO_0000019,B,,CHEMBL618341
,8,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,4797,16547,,1,,Expert,11831,,,,H,,,,BAO_0000019,F,,CHEMBL618342
,9,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,4798,16547,,1,Mus musculus,Expert,11831,,10090.0,,D,,,,BAO_0000019,F,,CHEMBL618343
,8,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,4799,17402,,1,,Expert,280,,,,H,,,,BAO_0000357,B,,CHEMBL621038
,0,574.0,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,4800,11746,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,T-cells,BAO_0000219,F,,CHEMBL621039
,0,574.0,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,4801,11746,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,T-cells,BAO_0000219,F,,CHEMBL621040
,1,455.0,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,4802,5455,,1,Homo sapiens,Intermediate,80018,,9606.0,,N,,,A-375,BAO_0000219,F,,CHEMBL621041
,1,455.0,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,4803,2068,,1,Homo sapiens,Intermediate,80018,,9606.0,,N,,,A-375,BAO_0000219,F,,CHEMBL621042
,1,455.0,In vitro antitumor activity against A375cell line extracted form melanoma,,4804,2683,,1,Homo sapiens,Intermediate,80018,,9606.0,,N,,,A-375,BAO_0000219,F,,CHEMBL621043
,1,455.0,Inhibition of cell growth in (A375) melan cell line,,4805,15313,,1,Homo sapiens,Expert,80018,,9606.0,,N,,,A-375,BAO_0000219,F,,CHEMBL621044
,1,455.0,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,4806,13739,,1,Homo sapiens,Intermediate,80018,,9606.0,,N,,,A-375,BAO_0000219,F,,CHEMBL621045
,1,455.0,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,4807,13739,,1,Homo sapiens,Intermediate,80018,,9606.0,,N,,,A-375,BAO_0000219,F,,CHEMBL621046
,1,455.0,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,4808,14750,,1,Homo sapiens,Intermediate,80018,,9606.0,,N,,,A-375,BAO_0000219,F,,CHEMBL621047
,1,797.0,Antiproliferative activity measured against A427 human lung carcinoma,,4809,14777,,1,Homo sapiens,Intermediate,80019,,9606.0,,N,,,A-427,BAO_0000219,F,,CHEMBL621048
,1,797.0,Antiproliferative activity measured against A427 human lung carcinoma,,4810,14777,,1,Homo sapiens,Intermediate,80019,,9606.0,,N,,,A-427,BAO_0000219,F,,CHEMBL883798
,1,797.0,Cytotoxicity against lung carcinoma A427 tumor cell lines,,4811,17672,,1,Homo sapiens,Intermediate,80019,,9606.0,,N,,,A-427,BAO_0000219,F,,CHEMBL621049
,1,797.0,Inhibition of large cell lung carcinoma (A427),,4812,14368,,1,Homo sapiens,Intermediate,80019,,9606.0,,N,,,A-427,BAO_0000219,F,,CHEMBL621050
,1,797.0,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,4813,14368,,1,Homo sapiens,Intermediate,80019,,9606.0,,N,,,A-427,BAO_0000219,F,,CHEMBL621051
,1,797.0,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,4814,13866,,1,Homo sapiens,Intermediate,80019,,9606.0,,N,,,A-427,BAO_0000219,F,,CHEMBL621052
,1,797.0,Inhibitory concentration in human lung carcinoma A427 cell line,,4815,2545,,1,Homo sapiens,Intermediate,80019,,9606.0,,N,,,A-427,BAO_0000219,F,,CHEMBL621053
,1,797.0,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,4816,2545,,1,Homo sapiens,Intermediate,80019,,9606.0,,N,,,A-427,BAO_0000219,F,,CHEMBL621054
,0,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,4817,6062,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621055
,0,,Tested for volume of distribution upon iv administration to african green monkey,,4818,4578,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL876398
,0,,Volume of distribution in monkey,,4819,17592,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621056
,0,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,4820,5005,,1,Macaca mulatta,Autocuration,22224,,9544.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621057
,0,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,4821,5005,,1,Macaca mulatta,Autocuration,22224,,9544.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621058
,0,,Pharmacokinetic property(Vdss) in cynomolgus monkey,,4822,5922,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621059
,0,,The distribution volume after intravenous administration in cynomolgus monkeys,,4823,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621060
,0,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,4824,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621061
,0,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,4825,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621062
,0,,Volume displacement was calculated in rhesus monkey,,4826,6057,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621063
,0,,Volume of distribution in steady state was determined in rhesus monkey,,4827,5145,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621064
,0,,Volume of distribution of compound was determined in monkey,,4828,6821,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621065
,0,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,4829,5334,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621066
,0,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,4830,5334,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621067
,0,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,4831,6641,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621068
,0,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,4832,2661,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL876399
,0,,Volume distribution in monkey after administration of 1 mg/kg iv,,4833,6535,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621069
,0,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,4834,4809,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621070
,0,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,4835,6062,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621071
,0,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,4836,3443,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621072
,0,,Oral systemic bioavailability upon iv administration to african green monkey,,4837,4578,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618209
,0,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,4838,4809,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618210
,0,,Baboon plasma free fraction. ,,4839,11271,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL618211
,0,,Area under the curve was calculated in rhesus monkey after iv administration,,4840,6057,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL618212
,0,,Area under the curve was calculated in rhesus monkey after peroral administration,,4841,6057,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL618213
,0,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,4842,17853,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL618214
,0,,Half life period in monkey after 5 mg/kg dose,,4843,5302,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL873492
,0,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,4844,4257,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618272
,0,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,4845,4257,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618273
,0,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,4846,13501,,1,Cercopithecidae,Autocuration,22224,,9527.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL618274
,0,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,4847,5394,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618275
,0,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,4848,2661,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618276
,0,,Compound was evaluated for terminal half life in monkey,,4849,3341,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL618277
,0,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,4850,3045,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618278
,0,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,4851,5005,,1,Macaca mulatta,Autocuration,22224,,9544.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL618279
,0,,Half life of compound was determined in squirrel monkey,,4852,4847,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL618280
,0,,Half life after iv administration in cynomolgus monkey,,4853,4256,,1,Macaca fascicularis,Autocuration,22224,,9541.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618281
,0,,Half life in monkey plasma after administration of 1 mg/kg iv,,4854,6535,,1,Cercopithecidae,Autocuration,22224,,9527.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL618282
,0,,Half life was calculated in rhesus monkey,,4855,6057,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL618283
,0,,Half life in monkey,,4856,17592,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL618284
,0,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,4857,6641,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618285
,0,,Half life was evaluated in rhesus,,4858,5472,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL618286
,0,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,4859,6221,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618287
,0,,Half life period was determine after peroral administration at 10 mpk in Rhesus,,4860,5668,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618288
,0,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,4861,4809,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL876393
,0,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,4862,5546,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618289
,0,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,4863,5553,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618290
,0,,Half-life was calculated in monkey,,4864,6078,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL618291
,0,,Half-life in Squirrel monkey,,4865,5147,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL618292
,0,,Half-life in rhesus monkey,,4866,5145,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL618293
,0,,Half-life was measured in monkey after an iv dose of 1 mg/kg,,4867,6062,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618294
,0,,Half-life period after intravenous administration in cynomolgus monkeys,,4868,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618295
,0,,Half-life period after oral administration in cynomolgus monkeys,,4869,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618296
,0,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,4870,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618297
,0,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,4871,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL618298
,0,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,4872,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL618299
,0,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,4873,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL618300
,0,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,4874,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL618301
,0,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,4875,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL618302
,0,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,4876,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL876394
,0,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,4877,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL618303
,0,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,4878,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL618304
,0,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,4879,1916,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618305
,0,,Oral bioavailability in human,,4880,16643,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618306
,0,,Compound was tested for human plasma protein binding,,4881,17248,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618307
,0,,Compound was tested for human plasma protein binding; Not determined,,4882,17248,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618308
,0,,Protein binding activity of compound in human plasma; % Free,,4883,6241,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618309
,0,,Unbound fraction (plasma),,4884,17716,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618310
,0,,Half life for the hydrolysis of compound in human blood serum,,4885,17605,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL873353
,0,,Half life period in human plasma using phosphate buffer (0.08 M),,4886,17625,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL618311
,0,,Half life period in human plasma using phosphate buffer (0.1 M),,4887,17625,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL618312
,0,,Half-life in human plasma was determined,,4888,17747,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL618313
,0,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,4889,15613,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618314
,0,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,4890,354,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618315
,0,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,4891,3741,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618316
,0,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,4892,3741,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618317
,0,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,4893,3741,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL620138
,0,,Partition coefficient (logP),,4894,17599,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL858280
,0,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,4895,5486,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL620139
,0,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,4896,5600,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000251,A,,CHEMBL620140
,0,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,4897,14294,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL620141
,0,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,4898,14294,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL620142
,0,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,4899,14294,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL620143
,0,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,4900,14294,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000251,A,,CHEMBL620144
,0,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,4901,14294,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000251,A,,CHEMBL620145
,0,,Metabolism of compound in human microsomes; Trace,,4902,14294,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000251,A,,CHEMBL620146
,0,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,,4903,6260,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,,,BAO_0000251,A,,CHEMBL620147
,0,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,4904,6187,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000251,A,,CHEMBL620148
,0,,In vitro metabolic potential in human liver microsomes,,4905,6251,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,,,BAO_0000251,A,,CHEMBL620149
,0,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,4906,3246,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL876412
,0,,Tested for human plasma protein binding of the compound; Not tested,,4907,17313,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL619352
,0,,Compound was tested for percent protein binding (PB) in human,,4908,6227,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL619353
,0,,Protein binding in human plasma,,4909,5530,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000019,A,,CHEMBL619354
,0,,Permeability coefficient (B to A) in Caco-2 cell,,4910,6108,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL619355
,0,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,4911,6108,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL619356
,0,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,4912,2774,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL619357
,0,,In vitro rate of absorption observed as Caco-2 permeability in humans,,4913,16643,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL619358
,0,495.0,Cellular permeability of compound was determined in Caco-2 cells; High,,4914,17582,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,Caco-2,BAO_0000219,A,,CHEMBL619359
,0,495.0,Permeability in Caco-2 cells of compound,,4915,6838,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,Caco-2,BAO_0000219,A,,CHEMBL619360
,0,,Permeability coefficient (A to B) in Caco-2 cell,,4916,6108,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL619361
,0,,Permeability coefficient (B to A) in Caco-2 cell,,4917,6108,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL619362
,0,,Permeability coefficient (Papp) (Caco-2 cell monolayer),,4918,6108,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL619363
,0,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,4919,2146,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618942
,0,,Compound was tested for protein binding in human plasma,,4920,4514,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618943
,0,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,4921,6108,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618944
,0,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,4922,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL618945
,1,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,4923,5969,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618946
,1,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,4924,3277,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876413
,1,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,4925,3802,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618947
,1,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,,4926,2862,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL618948
,1,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,4927,6348,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL618949
,1,,Tmax after intraperitoneal administration in mice at 23 uM/kg,,4928,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL618950
,1,,Tmax after oral administration at 30 mg/kg in ICR mouse,,4929,5781,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618951
,1,,Tmax after peroral administration in mice at 2.4 uM/kg,,4930,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618952
,1,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,4931,4066,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618953
,1,,Tmax in brain of mice at the oral dose of 50 mg/kg,,4932,17641,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL618954
,1,,Tmax in kidney of mice at the oral dose of 50 mg/kg,,4933,17641,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL618955
,1,,Tmax in liver of mice at the oral dose of 50 mg/kg,,4934,17641,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL618956
,1,,Tmax in lungs of mice at the oral dose of 50 mg/kg,,4935,17641,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL618957
,1,,Tmax in mice at 18 uM/kg i.p. administration,,4936,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL618958
,1,,Tmax in mice at 23 uM/kg i.v. administration,,4937,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL618959
,1,,Tmax in mice at 25 uM/kg i.p. administration,,4938,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL618960
,1,,Tmax in mice at 26 uM/kg i.p. administration,,4939,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL876723
,1,,Tmax in spleen of mice at the oral dose of 50 mg/kg,,4940,17641,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL618961
,1,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,4941,16597,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618962
,1,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,4942,16597,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618963
,1,,Tmax value in IRC mice,,4943,5951,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL618964
,1,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,4944,5506,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618965
,1,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,4945,5506,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618966
,1,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,4946,429,,1,Mus musculus,Intermediate,50594,,10090.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL618967
,1,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,4947,429,,1,Mus musculus,Intermediate,50594,,10090.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL618968
,1,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,4948,4066,,1,Mus musculus,Intermediate,50594,,10090.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL618969
,1,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,4949,17734,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL618970
,1,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,4950,17734,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL618971
,1,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,4951,6062,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618972
,1,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,4952,5969,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618973
,1,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,4953,5969,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618974
,1,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,4954,5969,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618975
,1,,Vd in mice,,4955,5980,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618976
,1,,Volume of distribution in mouse,,4956,17592,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618977
,1,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,4957,6348,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876724
,1,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,4958,17753,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618978
,1,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,4959,17753,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618979
,1,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,4960,17753,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618980
,1,,Pharmacokinetic property (vdss) was measured in mouse,,4961,4239,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618981
,1,,Value distribution upon iv administration in mouse,,4962,2862,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618982
,1,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,4963,17734,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620150
,1,,Volume of distribution was evaluated in mice after intravenous administration,,4964,2675,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620151
,1,,Volume of distribution was evaluated in mice after oral administration,,4965,2675,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620152
,1,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,4966,17837,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620153
,1,,Steady state volume of distribution was determined in mice,,4967,5727,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876395
,1,,Volume distribution (steady state) of compound was determined in mouse,,4968,17852,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620154
,1,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,4969,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620155
,1,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,4970,16597,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620156
,1,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,4971,6062,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620157
,1,,Biodistribution of compound (oxidized form) in in kidney tissue,,4972,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL620158
,1,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,,4973,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL620159
,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,4974,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL620160
,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,4975,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL620161
,1,797.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,4976,10708,,1,Homo sapiens,Intermediate,80019,,9606.0,,N,,,A-427,BAO_0000219,F,,CHEMBL620162
,1,500.0,Inhibition of A431 human squamous cell carcinoma cell proliferation,,4977,16597,,1,Homo sapiens,Expert,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL620163
,1,500.0,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,4978,16062,,1,Homo sapiens,Expert,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL620833
,1,500.0,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,4979,16062,,1,Homo sapiens,Expert,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL876396
,1,500.0,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,4980,16958,,1,Homo sapiens,Expert,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL620834
,1,500.0,Inhibition of A431 human carcinoma cell proliferation,,4981,6700,,1,Homo sapiens,Expert,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL620835
,1,500.0,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,4982,17226,,1,Homo sapiens,Expert,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL620836
,1,500.0,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,4983,6828,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL620837
,1,500.0,In vitro cytotoxicity against epidermoid carcinoma cell line,,4984,12314,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621017
,9,500.0,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,4985,13412,,1,Homo sapiens,Expert,9,,9606.0,,D,,,A-431,BAO_0000218,F,,CHEMBL621018
,1,500.0,Antiproliferative activity of compound was measured on human tumor cell line A431.,,4986,13299,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621019
,1,500.0,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,4987,17420,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621020
,1,500.0,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,4988,13678,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621021
,8,500.0,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,4989,14171,,1,,Expert,9,,,,H,,,A-431,BAO_0000219,F,,CHEMBL621022
,1,500.0,Tested for antiproliferative activity against human A431 cells,,4990,6333,,1,Homo sapiens,Expert,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621023
,9,500.0,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,4991,2356,,1,Homo sapiens,Expert,9,,9606.0,,D,,,A-431,BAO_0000219,F,,CHEMBL621024
,1,500.0,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,4992,15578,,1,Homo sapiens,Expert,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621025
,1,500.0,Inhibition of A431 cell proliferation,,4993,5126,,1,Homo sapiens,Expert,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621026
,1,500.0,Cytotoxic effect on A431 human epidermoid carcinoma cells,,4994,6844,,1,Homo sapiens,Expert,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621027
,1,500.0,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,4995,6844,,1,Homo sapiens,Expert,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL876397
,1,500.0,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,4996,4925,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL883797
,1,500.0,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,4997,4925,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621028
,1,500.0,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,4998,13978,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621029
,1,500.0,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,4999,16786,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621030
,8,500.0,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,5000,13412,,1,,Expert,9,,,,H,,,A-431,BAO_0000219,F,,CHEMBL621147
,1,500.0,In vivo antiproliferative activity against A431 cell line,,5001,17824,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000218,F,,CHEMBL621148
,9,500.0,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,5002,12751,,1,Homo sapiens,Expert,9,,9606.0,,D,,,A-431,BAO_0000219,F,,CHEMBL621149
,1,500.0,Inhibition of A431 human epidermoid carcinoma cell proliferation,,5003,12380,,1,Homo sapiens,Expert,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621150
,9,500.0,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,5004,4959,,1,Homo sapiens,Expert,9,,9606.0,,D,,,A-431,BAO_0000219,F,,CHEMBL621151
,1,500.0,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,5005,6333,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621152
,1,500.0,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,5006,6333,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621153
,1,500.0,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,5007,6333,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL884000
,9,,Inhibition of EGFR overexpressing A431 cell proliferation,,5008,5296,,1,Homo sapiens,Expert,9,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL621154
,1,500.0,Inhibition of A431 cell proliferation,,5009,12624,,1,Homo sapiens,Expert,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621155
,9,500.0,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,5010,14926,,1,Homo sapiens,Expert,9,,9606.0,,D,,,A-431,BAO_0000219,F,,CHEMBL621156
,9,500.0,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,5011,14926,,1,Homo sapiens,Expert,9,,9606.0,,D,,,A-431,BAO_0000219,F,,CHEMBL621157
,8,500.0,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,5012,14926,,1,,Expert,9,,,,H,,,A-431,BAO_0000219,F,,CHEMBL621158
,1,500.0,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,5013,15144,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621159
,1,500.0,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,5014,15144,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621160
,1,500.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,5015,5245,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621161
,1,500.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,5016,5245,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621162
,1,500.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,5017,5245,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621163
,1,500.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,5018,5245,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621164
,1,500.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,5019,5245,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621165
,0,,Half-life period in cynomolgus monkey,,5020,5922,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL619159
,0,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",,5021,1116,,1,Cercopithecidae,Autocuration,22224,,9527.0,Plasma,U,1969.0,In vitro,,BAO_0000366,A,,CHEMBL619160
,0,,Longer half-life in monkey (i.v.) at 0.5 mpk,,5022,17853,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL619161
,0,,Plasma half life in monkey,,5023,993,,1,Cercopithecidae,Autocuration,22224,,9527.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL619162
,0,,Plasma half-life in rhesus monkey,,5024,4514,,1,Cercopithecidae,Autocuration,22224,,9527.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL619163
,0,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,5025,5334,,1,Cercopithecidae,Autocuration,22224,,9527.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL619164
,0,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,5026,5334,,1,Cercopithecidae,Autocuration,22224,,9527.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL619320
,0,,Tested for half life upon iv administration to african green monkey,,5027,4578,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL619321
,0,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,5028,2661,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL873336
,0,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,5029,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL619322
,0,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,5030,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL619323
,0,,The time for peak concentration value after oral administration in cynomolgus monkeys,,5031,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL619324
,0,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,5032,11271,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL619325
,0,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,5033,11271,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL876411
,0,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,5034,11271,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL619326
,0,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,5035,11271,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL619327
,0,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,5036,11271,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL619328
,0,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,5037,11271,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL619329
,0,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,5038,11271,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL619330
,0,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,5039,11271,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL619331
,0,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,5040,11271,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL619332
,0,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,5041,11271,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL619333
,0,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,5042,11271,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL619334
,0,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,5043,11271,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL619335
,0,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,5044,11271,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL619336
,0,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,5045,11271,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL619337
,0,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,5046,11271,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL619338
,0,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,5047,11271,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL619339
,1,,Bioavailability in rat (cannulated) (dose 2 mg/kg),,5048,5809,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619340
,1,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,5049,17720,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL873496
,1,,AUC value in rat after IV administration at a dose of 10 mg/kg,,5050,3546,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL619341
,1,,AUC value in rat after oral administration at a dose of 10 mg/kg,,5051,3546,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL619342
,1,,Cmax value in rat after oral administration at a dose of 10 mg/kg,,5052,3546,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619343
,1,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,5053,3546,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619344
,1,,Tmax value in rat after oral administration at a dose of 10 mg/kg,,5054,3546,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619345
,1,,Vc value in rat after IV administration at a dose of 10 mg/kg,,5055,3546,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL619346
,1,,Half life period in rat after IV administration at a dose of 10 mg/kg,,5056,3546,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619347
,0,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,5057,10625,,1,Papio hamadryas,Autocuration,22224,,9557.0,,U,,,,BAO_0000019,A,,CHEMBL619348
,0,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,5058,10625,,1,Papio hamadryas,Autocuration,22224,,9557.0,,U,,,,BAO_0000019,A,,CHEMBL619349
,0,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,5059,10625,,1,Papio hamadryas,Autocuration,22224,,9557.0,,U,,,,BAO_0000019,A,,CHEMBL619350
,0,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,5060,10625,,1,Papio hamadryas,Autocuration,22224,,9557.0,,U,,,,BAO_0000019,A,,CHEMBL619351
,0,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,5061,10625,,1,Papio hamadryas,Autocuration,22224,,9557.0,,U,,,,BAO_0000019,A,,CHEMBL875953
,0,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,5062,10625,,1,Papio hamadryas,Autocuration,22224,,9557.0,,U,,,,BAO_0000019,A,,CHEMBL621716
,0,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,5063,10625,,1,Papio hamadryas,Autocuration,22224,,9557.0,,U,,,,BAO_0000019,A,,CHEMBL621717
,0,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,5064,10625,,1,Papio hamadryas,Autocuration,22224,,9557.0,,U,,,,BAO_0000019,A,,CHEMBL621718
,0,,Area under curve after 1 mpk peroral administration to beagles,,5065,3510,,1,beagle,Autocuration,22224,,9615.0,,U,,,,BAO_0000019,A,,CHEMBL621719
,0,,Area under curve after 2 mpk peroral administration to beagles,,5066,3510,,1,beagle,Autocuration,22224,,9615.0,,U,,,,BAO_0000019,A,,CHEMBL621720
,0,,Cmax value after 1 mpk peroral administration to beagles,,5067,3510,,1,beagle,Autocuration,22224,,9615.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621721
,0,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,5068,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL621722
,0,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,5069,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL621723
,0,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,5070,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL621724
,0,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,5071,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL623443
,0,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,5072,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL623444
,0,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,5073,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL623445
,0,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,5074,7766,,1,Homo sapiens,Autocuration,22224,,9606.0,Urine,U,1088.0,,,BAO_0000019,A,,CHEMBL623446
,0,,Metabolic stability observed at 30 min after administration in human liver microsomes,,5075,16643,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,,,BAO_0000251,A,,CHEMBL623447
,0,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,5076,6852,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL623448
,0,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,5077,6852,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL623449
,0,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,5078,6852,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL623450
,0,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",,5079,6567,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,,,BAO_0000251,A,,CHEMBL623451
,0,,Metabolic stability (% remaining at 30 mins) in human S9.,,5080,6570,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL623452
,0,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,5081,6570,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL623453
,0,,Percent parent compound remaining after 20 min incubation with human liver microsomes,,5082,5237,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,,,BAO_0000251,A,,CHEMBL623454
,0,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,,5083,5237,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,,,BAO_0000251,A,,CHEMBL623455
,0,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,,5084,5237,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,,,BAO_0000251,A,,CHEMBL624371
,0,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,5085,5202,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000218,A,,CHEMBL624372
,0,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,5086,5481,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL624373
,0,,Percent remaining in human plasma after incubation for 60 min at 37 C.,,5087,5481,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL624374
,0,,The percent remaining in human plasma after 30 min was determined,,5088,3956,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL624556
,0,,Conversion rate of the prodrug in human plasma,,5089,5074,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL624557
,0,,Conversion rate of the prodrug in human plasma; ND means no data,,5090,5074,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL624558
,0,,Half life of compound was determined in human blood,,5091,4727,,1,Homo sapiens,Autocuration,22224,,9606.0,Blood,U,178.0,,,BAO_0000221,A,,CHEMBL624559
,0,,Half life of compound was determined in man with once daily dosing,,5092,5965,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL624560
,0,,Half life in human microsomes,,5093,5732,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,In vitro,,BAO_0000251,A,,CHEMBL624561
,0,,Half life in human plasma,,5094,5819,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL624562
,0,,Half life in human plasma; Not detected,,5095,5819,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL624563
,0,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,5096,1916,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624564
,0,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,,5097,6597,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,In vitro,,BAO_0000251,A,,CHEMBL624565
,0,,Half-life in human plasma,,5098,5229,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL875152
,0,,Half-life of the parent prodrug in plasma,,5099,5229,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL624566
,0,,In vitro half life in human plasma was determined,,5100,2192,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,In vitro,,BAO_0000366,A,,CHEMBL873805
,0,,The compound was tested In Vitro for half life in human liver microsomes.,,5101,3032,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,In vitro,,BAO_0000251,A,,CHEMBL624567
,0,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,5102,1916,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624568
,0,,Observed volume of distribution,,5103,17716,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624569
,0,,Oral bioavailability in human,,5104,15778,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624570
,0,,Tested for human plasma protein binding of the compound,,5105,17313,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL624571
,0,,"First order rate constant, k was determined in human plasma",,5106,4231,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL624572
,0,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,5107,4755,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL624573
,0,,Observed rate constant in 80% human plasma at 37 degree Centigrade,,5108,4755,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL875153
,0,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,5109,16907,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,,,BAO_0000251,A,,CHEMBL624574
,0,,The compound was tested for the plasma binding in human,,5110,10839,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL624575
,0,,Plasma protein binding (human),,5111,10839,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL624576
,0,,Compound was evaluated for half-life in human liver microsomes,,5112,3199,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,In vitro,,BAO_0000251,A,,CHEMBL624577
,0,,Half life measured in vitro for its stability in human blood,,5113,1345,,1,Homo sapiens,Autocuration,22224,,9606.0,Blood,U,178.0,In vitro,,BAO_0000221,A,,CHEMBL624578
,0,,Half life in human serum,,5114,4297,,1,Homo sapiens,Autocuration,22224,,9606.0,Serum,U,1977.0,,,BAO_0000019,A,,CHEMBL622796
,0,,Half life in human serum; ND=not determined,,5115,4297,,1,Homo sapiens,Autocuration,22224,,9606.0,Serum,U,1977.0,,,BAO_0000019,A,,CHEMBL622797
,0,,Half life were determined in CEM-SS cell extract in decomposition step 1,,5116,4297,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL622798
,0,,Half life were determined in CEM-SS cell extract in decomposition step 2,,5117,4297,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL622799
,0,,Half life of the in human plasma,,5118,4231,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL622800
,0,,Half life period in human hepatic S9 fraction was determined,,5119,5633,S9,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,In vitro,,BAO_0000220,A,,CHEMBL622801
,0,,Half life period in human liver microsome was determined,,5120,5633,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,In vitro,,BAO_0000251,A,,CHEMBL622802
,0,,Half life period was determined; 6-7,,5121,17791,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL622803
,0,,Half life period was evaluated in human,,5122,17791,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL875154
,0,,Half life time in human plasma,,5123,3160,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL622804
,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,5124,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622805
,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,5125,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL622611
,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,5126,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL622612
,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,5127,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL875160
,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,5128,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL622613
,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,5129,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL622614
,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,5130,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622615
,1,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,,5131,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622616
,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,5132,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622617
,1,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,,5133,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL622618
,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,5134,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL622619
,1,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,5135,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL622620
,1,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,5136,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622621
,1,,Biodistribution of compound (oxidized form) in blood tissue,,5137,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622622
,1,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,5138,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622623
,1,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,5139,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622624
,1,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,5140,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622625
,1,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,5141,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622626
,1,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,5142,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622627
,1,,Biodistribution of compound (oxidized form) in brain tissue of mice,,5143,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622628
,1,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,5144,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622629
,1,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,5145,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622630
,1,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,5146,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622631
,1,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,5147,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622632
,1,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",,5148,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622633
,1,,Biodistribution of compound (oxidized form) in heart tissue of mice,,5149,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL622634
,1,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,5150,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL622635
,1,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,5151,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL875161
,1,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,5152,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL622636
,1,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,5153,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL623335
,1,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,5154,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL623336
,1,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,5155,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL623337
,1,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,5156,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL623338
,1,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,5157,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL623339
,1,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,5158,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL623524
,1,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,5159,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL623525
,1,,Biodistribution of compound (oxidized form) in liver tissue,,5160,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL623526
,1,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,5161,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL623527
,1,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,5162,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL623528
,1,500.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,5163,5245,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL624615
,1,500.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,5164,5245,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621672
,1,500.0,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,5165,16289,,1,,Expert,80852,,,,N,,,A-431,BAO_0000218,F,,CHEMBL621673
,1,500.0,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,5166,16289,,1,,Expert,80852,,,,N,,,A-431,BAO_0000218,F,,CHEMBL621674
,9,500.0,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,5167,16093,,1,Homo sapiens,Expert,9,,9606.0,,D,,,A-431,BAO_0000219,F,,CHEMBL884002
,1,500.0,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,5168,16825,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621850
,1,500.0,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,5169,4848,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL621851
,9,500.0,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,5170,14827,,1,Homo sapiens,Expert,9,,9606.0,,D,,,A-431,BAO_0000219,F,,CHEMBL621852
,9,500.0,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,5171,14827,,1,Homo sapiens,Expert,9,,9606.0,,D,,,A-431,BAO_0000219,F,,CHEMBL621853
,1,500.0,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,5172,16289,,1,,Expert,80852,,,,N,,,A-431,BAO_0000218,F,,CHEMBL621854
,1,500.0,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,5173,16289,,1,,Expert,80852,,,,N,,,A-431,BAO_0000218,F,,CHEMBL621855
,1,500.0,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,5174,16289,,1,,Expert,80852,,,,N,,,A-431,BAO_0000218,F,,CHEMBL623724
,1,500.0,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,5175,16289,,1,,Expert,80852,,,,N,,,A-431,BAO_0000218,F,,CHEMBL623725
,1,500.0,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,5176,16289,,1,,Expert,80852,,,,N,,,A-431,BAO_0000218,F,,CHEMBL623726
,9,500.0,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,5177,16289,,1,Homo sapiens,Expert,9,,9606.0,,D,,,A-431,BAO_0000219,F,,CHEMBL623727
,8,500.0,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,5178,16289,,1,,Expert,9,,,,H,,,A-431,BAO_0000219,F,,CHEMBL623728
,1,500.0,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,5179,16289,,1,,Expert,80852,,,,N,,,A-431,BAO_0000218,F,,CHEMBL623729
,1,500.0,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,5180,16289,,1,,Expert,80852,,,,N,,,A-431,BAO_0000218,F,,CHEMBL623730
,1,500.0,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,5181,16289,,1,,Expert,80852,,,,N,,,A-431,BAO_0000218,F,,CHEMBL623731
,1,500.0,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,5182,14555,,1,Mus musculus,Expert,80852,,10090.0,,N,,,A-431,BAO_0000218,F,,CHEMBL623732
,1,500.0,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,5183,14555,,1,Mus musculus,Expert,80852,,10090.0,,N,,,A-431,BAO_0000218,F,,CHEMBL623733
,1,500.0,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,5184,14555,,1,Mus musculus,Expert,80852,,10090.0,,N,,,A-431,BAO_0000218,F,,CHEMBL623734
,1,500.0,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,5185,14555,,1,Mus musculus,Expert,80852,,10090.0,,N,,,A-431,BAO_0000218,F,,CHEMBL623735
,1,500.0,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,5186,1937,,1,Homo sapiens,Expert,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL623736
,1,500.0,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,5187,13739,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL623737
,1,500.0,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,5188,3558,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL623738
,1,500.0,Dose giving a 50% decrease in the living cell number (A437 cells),,5189,3558,,1,Homo sapiens,Intermediate,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL875168
,1,646.0,In vitro inhibitory concentration against proliferation of A459 cell line.,,5190,17686,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL623739
,1,646.0,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,5191,5305,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL623740
,1,646.0,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,5192,3614,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624424
,1,624.0,In vitro antitumor activity against renal A498 tumor cell lines,,5193,17229,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL624425
,1,624.0,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,5194,15935,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL624426
,1,624.0,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,5195,15935,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL624427
,1,624.0,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,5196,15560,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL624428
,1,624.0,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,5197,13891,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL624429
,1,624.0,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,5198,13891,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL624620
,1,624.0,Cytotoxicity on kidney carcinoma (A-498) cell line,,5199,13788,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL624621
,1,624.0,Compound was evaluated against Human cell line renal A498,,5200,15403,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL624622
,1,624.0,Compound was tested for inhibition of A498 human renal cancer cell line,,5201,1009,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL624623
,1,624.0,Growth inhibitory activity against A498 human cancer cell line,,5202,1043,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL874365
,1,624.0,In vitro antitumor activity against human renal A498 cell line,,5203,5858,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL624624
,1,624.0,In vitro cytotoxic activity against renal (A498) cell line,,5204,5958,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL624625
,1,624.0,In vitro cytotoxic activity against human renal cancer (A498) cell line,,5205,5506,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL624626
,1,624.0,Tested for cytostatic activity against renal A498 cell line,,5206,12781,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL624627
,1,624.0,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,5207,14399,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL883157
,1,624.0,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,5208,5958,,1,Homo sapiens,Expert,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL624628
,0,,Cmax value after 2 mpk peroral administration to beagles,,5209,3510,,1,beagle,Autocuration,22224,,9615.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624629
,0,,Bioavailability,beagle,5210,3510,,1,Canis lupus familiaris,Autocuration,22224,,9615.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL623551
,0,,Bioavailability after 1 mpk peroral administration to beagles,beagle,5211,3510,,1,Canis lupus familiaris,Autocuration,22224,,9615.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL623552
,0,,Bioavailability after 2 mpk peroral administration to beagles,beagle,5212,3510,,1,Canis lupus familiaris,Autocuration,22224,,9615.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL623553
,0,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,5213,3085,,1,Bos taurus,Autocuration,22224,,9913.0,,U,,,,BAO_0000019,A,,CHEMBL623554
,0,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,5214,3085,,1,Bos taurus,Autocuration,22224,,9913.0,,U,,,,BAO_0000019,A,,CHEMBL623555
,0,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,5215,3085,,1,Bos taurus,Autocuration,22224,,9913.0,,U,,,,BAO_0000019,A,,CHEMBL623556
,0,,Solubility against bovine alpha-chymotrypsin,,5216,9372,,1,Bos taurus,Autocuration,22224,,9913.0,,U,,,,BAO_0000019,A,,CHEMBL623557
,0,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,5217,3085,,1,Bos taurus,Autocuration,22224,,9913.0,,U,,,,BAO_0000019,A,,CHEMBL623558
,0,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,5218,3085,,1,Bos taurus,Autocuration,22224,,9913.0,,U,,,,BAO_0000019,A,,CHEMBL623559
,0,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,5219,1469,,1,Bos taurus,Autocuration,22224,,9913.0,Spleen,U,2106.0,,,BAO_0000221,A,,CHEMBL623560
,0,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,5220,4297,,1,Bos taurus,Autocuration,22224,,9913.0,,U,,,,BAO_0000019,A,,CHEMBL623561
,0,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,5221,4297,,1,Bos taurus,Autocuration,22224,,9913.0,,U,,,,BAO_0000019,A,,CHEMBL623562
,0,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,5222,17585,,1,Bos taurus,Autocuration,22224,,9913.0,,U,,,,BAO_0000019,A,,CHEMBL623563
,0,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,5223,1336,,1,Bos taurus,Autocuration,22224,,9913.0,Spleen,U,2106.0,,,BAO_0000221,A,,CHEMBL623564
,0,,Half life in presence of 2 mg/mL BSA at pH 8.8,,5224,3085,,1,Bos taurus,Autocuration,22224,,9913.0,,U,,,,BAO_0000019,A,,CHEMBL873806
,0,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,5225,2857,,1,Bos taurus,Autocuration,22224,,9913.0,,U,,,,BAO_0000019,A,,CHEMBL623565
,0,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,5226,2857,,1,Bos taurus,Autocuration,22224,,9913.0,,U,,,,BAO_0000019,A,,CHEMBL623566
,0,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,5227,2857,,1,Bos taurus,Autocuration,22224,,9913.0,,U,,,,BAO_0000019,A,,CHEMBL623567
,0,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,5228,1540,,1,Bos taurus,Autocuration,22224,,9913.0,,U,,,,BAO_0000019,A,,CHEMBL623568
,1,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,5229,6316,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL623569
,1,,AUC after administration at 100 mg/kg/day in dogs,,5230,17594,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL623570
,1,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,5231,4953,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL624254
,1,,AUC value after 15 mg/kg iv dose in Dogs,,5232,16907,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL624255
,1,,AUC value after 30 mg/kg po dose in Dogs,,5233,16907,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL624256
,1,,AUC value after administration of 4 mg/Kg oral dose in dog,,5234,2959,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL624257
,1,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,5235,17594,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL624258
,1,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,5236,5356,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL875277
,1,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,5237,16807,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622667
,1,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,5238,4527,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622668
,1,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,5239,4527,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622669
,1,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,5240,15660,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622670
,1,,Area under curve determined in dogs after oral administration of 10 mg/kg,,5241,15660,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622671
,1,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,5242,5802,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622672
,1,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,5243,3598,,1,Canis lupus familiaris,Expert,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622673
,1,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,5244,3598,,1,Canis lupus familiaris,Expert,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622674
,1,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,5245,5944,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622675
,1,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,5246,5944,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622676
,1,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,5247,5944,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622677
,1,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,5248,5944,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622678
,1,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,5249,4186,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622679
,1,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,5250,5007,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622680
,1,,Area under curve was determine after peroral administration at 10 mpk in dog,,5251,5668,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622681
,1,,Area under curve was determine after peroral administration at 5 mpk in dog,,5252,5668,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL875278
,1,,Area under curve was determined,,5253,5006,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622682
,1,,Area under curve in dogs,,5254,5006,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622683
,1,,Area under curve in dogs at 10 mg/kg dose fo oral administration,,5255,3771,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622684
,1,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,5256,3771,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622685
,1,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,5257,3771,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622686
,1,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,5258,1916,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618344
,1,,Area under curve value in dog at a dose of 5 mg/kg,,5259,5302,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL875582
,1,,Area under curve was determined after 0.1 mg/kg iv administration in dog,,5260,5600,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618345
,1,,Area under curve was determined after 0.3 mg/kg po administration in dog,,5261,5600,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618346
,1,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,5262,17764,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618347
,1,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,5263,4368,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618348
,0,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,5264,5318,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618349
,0,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,5265,5318,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618350
,0,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,5266,5318,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618351
,0,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,5267,5318,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618352
,0,,Time taken to reduce 50% of the concentration of compound in blood plasma,,5268,14518,,1,Homo sapiens,Autocuration,22224,,9606.0,Blood,U,178.0,,,BAO_0000221,A,,CHEMBL873494
,0,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,5269,2209,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL618353
,0,,Half life in human plasma,,5270,6787,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL618354
,0,,Half life in human plasma was reported,,5271,4898,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL875583
,0,,Half life in human serum,,5272,6072,,1,Homo sapiens,Autocuration,22224,,9606.0,Serum,U,1977.0,,,BAO_0000019,A,,CHEMBL618355
,0,,Half life upon exposure to human plasma,,5273,16907,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL618356
,0,,t1/2 in human microsomes,,5274,5656,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,In vitro,,BAO_0000251,A,,CHEMBL618357
,0,,Half life period in 80% human plasma at 37 degree Centigrade,,5275,4755,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL618358
,0,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,5276,17503,,1,Homo sapiens,Autocuration,22224,,9606.0,Zone of skin,U,14.0,,,BAO_0000221,A,,CHEMBL618359
,0,,Half-life measured in in vitro Cathepsin B assay in human plasma,,5277,12357,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,In vitro,,BAO_0000366,A,,CHEMBL618360
,0,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,5278,3076,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618361
,0,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,,5279,6410,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,In vitro,,BAO_0000251,A,,CHEMBL618362
,0,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,5280,3741,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL618363
,0,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,5281,3741,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL618364
,0,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,5282,3741,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL875584
,0,,Half-life in the CEM cell extracts,,5283,1540,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618365
,0,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,5284,2905,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL873495
,0,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,5285,2905,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL618366
,0,,Half-life was determined,,5286,5523,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618367
,0,,Half-life (human blood stability),,5287,1499,,1,Homo sapiens,Autocuration,22224,,9606.0,Blood,U,178.0,,,BAO_0000221,A,,CHEMBL618368
,0,,Half-life (human blood stability); no data,,5288,1499,,1,Homo sapiens,Autocuration,22224,,9606.0,Blood,U,178.0,,,BAO_0000221,A,,CHEMBL618369
,0,,Half-life in human plasma,,5289,17065,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL618370
,0,,CYP3A4 metabolism half-life (t1/2),,5290,6861,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618371
,0,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,5291,1499,,1,Homo sapiens,Autocuration,22224,,9606.0,Blood,U,178.0,,,BAO_0000221,A,,CHEMBL618372
,0,,In vitro half life in human plasma,,5292,530,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,In vitro,,BAO_0000366,A,,CHEMBL618373
,0,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",,5293,1116,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,In vitro,,BAO_0000366,A,,CHEMBL618374
,0,,In vitro hydrolysis in human plasma,,5294,6695,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,In vitro,,BAO_0000366,A,,CHEMBL618375
,0,,In vitro hydrolysis in human plasma; no data,,5295,6695,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,In vitro,,BAO_0000366,A,,CHEMBL618376
,0,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,,5296,10,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,In vitro,,BAO_0000251,A,,CHEMBL618377
,0,,Plasma half life in human,,5297,993,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL618378
,0,,Stability after incubation with human plasma (at 37 degree C),,5298,15429,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL618379
,0,,T1/2 was evaluated in human plasma,,5299,1675,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL618380
,0,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,5300,2209,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL618381
,0,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,5301,2209,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL618382
,0,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,5302,5318,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL618383
,0,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,5303,2412,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,In vitro,,BAO_0000019,A,,CHEMBL618384
,0,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,5304,2412,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,In vitro,,BAO_0000019,A,,CHEMBL618385
,0,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,5305,2906,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL619099
,0,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,5306,2906,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL619100
,0,,Time taken for 50% to be consumed by serum PON1 was determined,,5307,5495,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL619101
,0,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,5308,5495,,1,Homo sapiens,Autocuration,22224,,9606.0,,U,,,,BAO_0000019,A,,CHEMBL619102
,0,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,5309,4397,Microsomes,1,Homo sapiens,Autocuration,22224,,9606.0,Liver,U,2107.0,,,BAO_0000251,A,,CHEMBL619103
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,5310,2413,,1,Mus sp.,Autocuration,22224,,10095.0,,U,,,,BAO_0000218,A,,CHEMBL619268
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,5311,2413,,1,Mus sp.,Autocuration,22224,,10095.0,,U,,,,BAO_0000218,A,,CHEMBL619269
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,5312,2413,,1,Mus sp.,Autocuration,22224,,10095.0,,U,,,,BAO_0000218,A,,CHEMBL619270
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,5313,2413,,1,Mus sp.,Autocuration,22224,,10095.0,,U,,,,BAO_0000218,A,,CHEMBL619271
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,5314,2413,,1,Mus sp.,Autocuration,22224,,10095.0,,U,,,,BAO_0000218,A,,CHEMBL875585
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,5315,2413,,1,Mus sp.,Autocuration,22224,,10095.0,,U,,,,BAO_0000218,A,,CHEMBL619272
,1,391.0,Compound tested for growth inhibition of renal cancer cell line 786-0,,5316,6058,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619273
,1,391.0,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,5317,17708,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619274
,1,391.0,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,5318,14017,,1,Homo sapiens,Expert,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619275
,1,391.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,5319,16818,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619276
,1,391.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,5320,16818,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619277
,1,391.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,5321,16818,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619278
,1,391.0,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,5322,11970,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619279
,1,391.0,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,5323,12400,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL858458
,1,391.0,Cytotoxic effect on renal cancer line 786-0,,5324,12888,,1,Homo sapiens,Expert,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619280
,1,391.0,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,5325,15300,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619281
,1,391.0,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,5326,14769,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619282
,1,391.0,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,5327,15895,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619283
,1,391.0,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,5328,17376,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619284
,1,391.0,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,5329,14882,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619285
,1,391.0,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,5330,14882,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619286
,1,391.0,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,5331,15176,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619287
,1,391.0,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,5332,12696,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL857455
,1,391.0,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,5333,2496,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL883801
,1,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,5334,11831,,1,Homo sapiens,Intermediate,80641,,9606.0,,N,,,791T cell line,BAO_0000219,F,,CHEMBL619288
,1,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,5335,11831,,1,Homo sapiens,Intermediate,80641,,9606.0,,N,,,791T cell line,BAO_0000219,F,,CHEMBL619289
,1,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,5336,11831,,1,Homo sapiens,Intermediate,80641,,9606.0,,N,,,791T cell line,BAO_0000219,F,,CHEMBL619290
,1,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,5337,11831,,1,Homo sapiens,Intermediate,80641,,9606.0,,N,,,791T cell line,BAO_0000219,F,,CHEMBL619291
,1,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,5338,11831,,1,Homo sapiens,Intermediate,80641,,9606.0,,N,,,791T cell line,BAO_0000219,F,,CHEMBL619292
,1,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,5339,11831,,1,Homo sapiens,Intermediate,80641,,9606.0,,N,,,791T cell line,BAO_0000219,F,,CHEMBL619293
,1,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,5340,11831,,1,Homo sapiens,Intermediate,80641,,9606.0,,N,,,791T cell line,BAO_0000219,F,,CHEMBL619294
,1,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,5341,11831,,1,Homo sapiens,Intermediate,80641,,9606.0,,N,,,791T cell line,BAO_0000219,F,,CHEMBL619295
,1,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,5342,11831,,1,Homo sapiens,Intermediate,80641,,9606.0,,N,,,791T cell line,BAO_0000219,F,,CHEMBL619296
,1,972.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,5343,11831,,1,Homo sapiens,Intermediate,80641,,9606.0,,N,,,791T cell line,BAO_0000219,F,,CHEMBL619297
,1,391.0,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,5344,12782,,1,Homo sapiens,Intermediate,80640,,9606.0,,N,,,786-0,BAO_0000219,F,,CHEMBL619298
,0,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,5345,1229,,1,,Intermediate,22226,,,,U,,,,BAO_0000019,F,,CHEMBL619299
,1,741.0,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,5346,15313,,1,Homo sapiens,Expert,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL619300
,1,741.0,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,5347,15313,,1,Homo sapiens,Expert,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL619301
,1,741.0,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,5348,11544,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL619302
,1,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,5349,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL619303
,1,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,5350,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL619304
,1,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,5351,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL857706
,1,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,5352,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL619305
,1,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,5353,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL619306
,1,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,5354,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL619307
,1,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,5355,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL619308
,1,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,5356,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL619309
,1,741.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,5357,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL619310
,1,624.0,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,5358,14769,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL619311
,1,624.0,Compound was tested for the growth inhibition of A498 renal tumor cell line,,5359,15354,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL619312
,1,624.0,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,5360,17445,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL619313
,1,624.0,In vitro inhibitory concentration against renal cancer cell line A498,,5361,4337,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL619314
,1,624.0,Cytotoxicity against A 498 tumor cell line,,5362,15277,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL619959
,1,624.0,In vitro antitumor activity against A498 human cancer cell line,,5363,4812,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL619960
,1,624.0,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,5364,4812,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL619961
,1,624.0,Inhibitory dose required against A498 human tumor cell lines,,5365,4995,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL619962
,1,624.0,Anticancer activity against one renal cancer (A498 cell line),,5366,5847,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL875586
,1,624.0,In vitro cytotoxicity against melanoma A498 cell line,,5367,6557,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL619963
,1,624.0,Compound was tested for growth inhibitory activity against A498 cell line,,5368,2597,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL619964
,1,624.0,Compound tested for growth inhibition of renal cancer cell line A498,,5369,6058,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL620108
,1,624.0,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,5370,17708,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL620109
,1,624.0,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,5371,15176,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL620110
,1,624.0,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,5372,15300,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL620111
,1,624.0,Tested for cytotoxicity against A498 cell lines in renal cancer,,5373,11970,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL620112
,1,624.0,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,5374,12400,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL620113
,1,624.0,Cytotoxic effect on renal cancer lines A498,,5375,12888,,1,Homo sapiens,Expert,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL620114
,1,624.0,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,5376,3030,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL620115
,1,624.0,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,5377,14769,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL620116
,1,624.0,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,5378,17376,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL620117
,1,624.0,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,5379,16558,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL620118
,1,624.0,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,5380,5194,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL620119
,1,624.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,5381,10708,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL620120
,1,646.0,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,5382,16880,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620121
,1,646.0,Antitumor activity against A549 human lung carcinoma cell line,,5383,10196,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620122
,1,646.0,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,5384,10196,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620123
,1,646.0,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,5385,10196,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620124
,1,646.0,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,5386,12083,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620125
,1,646.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,5387,16464,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620126
,1,646.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,5388,16464,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL883027
,1,646.0,In vitro cytotoxic activity against human lung A549 cell line,,5389,16470,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620127
,1,646.0,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,5390,16470,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620128
,1,646.0,In vitro cytotoxic activity against human lung A549 cell line),,5391,16470,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620129
,1,646.0,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,5392,16470,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620130
,1,646.0,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,5393,16582,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620131
,1,646.0,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,5394,15935,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620132
,1,646.0,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,5395,15935,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620133
,1,646.0,Inhibition of A549 human lung carcinoma cell proliferation,,5396,16597,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620134
,1,646.0,Inhibitory activity against A549 lung adenocarcinoma cell line,,5397,17376,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620135
,1,646.0,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,5398,16496,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620136
,1,646.0,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,5399,16152,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620137
,1,646.0,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,5400,16152,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620268
,1,646.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,5401,16464,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620269
,1,646.0,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,5402,2288,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620270
,1,646.0,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,5403,17350,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620271
,1,646.0,Inhibition of A549 cancer cell proliferation,,5404,4090,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620272
,1,646.0,Inhibition of A549 cancer cell proliferation (Not tested),,5405,4090,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620273
,1,646.0,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,5406,17350,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620274
,1,646.0,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,5407,4197,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620275
,1,646.0,Antiproliferative potency determined as inhibitory concentration against A549 cells,,5408,17072,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620276
,1,646.0,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,5409,17072,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620277
,1,646.0,Cytotoxicity against Renal cell lines A549 was determined,,5410,5194,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620278
,1,,Area under curve was determined in dog after a 3 mg/kg of oral dose,,5411,4257,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL620279
,1,,Area under curve was determined in dog after oral administration at 1 mg/kg,,5412,6123,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL620280
,1,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,5413,1337,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL620281
,1,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,5414,1337,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL620282
,1,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,5415,8833,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621134
,1,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,5416,8833,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621135
,1,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,5417,8833,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621136
,1,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,5418,8833,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621137
,1,,Area under plasma concentration time curve in dog upon oral administration,,5419,17657,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL621138
,1,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,5420,17650,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL875587
,1,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,5421,1977,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621139
,1,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,5422,1977,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621140
,1,,Area under the curve for the compound was obtained when tested in dog,,5423,3132,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621141
,1,,Area under the curve at a dose of 1 mg/kg,,5424,5473,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621142
,1,,Area under the curve at a dose of 1 mg/kg (oral),,5425,5474,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621143
,1,,Area under the curve at i.v. dose of 0.2 mg/kg,,5426,5474,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621144
,1,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,5427,6062,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621145
,1,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,5428,4709,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621146
,1,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,5429,2652,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622567
,1,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,5430,2652,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622568
,1,,Compound was evaluated for area under the curve in dog blood.,,5431,2877,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622569
,1,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,5432,5444,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622570
,1,,AUC in dog after oral dose (1 mg/kg),,5433,5130,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622571
,1,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,5434,6265,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622572
,1,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,5435,4657,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622573
,1,,Pharmacokinetic parameter AUC after intravenous administration to dogs,,5436,16367,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622574
,1,,Pharmacokinetic parameter AUC after oral administration to dogs,,5437,16367,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622575
,1,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,5438,9579,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622576
,1,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,5439,9579,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622577
,1,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,5440,5983,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622578
,1,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,5441,6241,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622579
,1,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,5442,5313,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622580
,1,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,5443,5313,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622581
,1,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,5444,6642,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622582
,1,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,5445,6642,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622583
,1,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,5446,6641,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622584
,1,,Oral AUCN in dog (dosed at 0.5 mpk iv ),,5447,6642,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622585
,1,,Compound was evaluated for oral bioavailability in dog; 90-100,,5448,17791,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622586
,1,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,5449,17655,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL623281
,1,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,5450,17655,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL623282
,1,,PAPP (membrane permeability) in dog kidney cell monolayer assay,,5451,6596,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL623283
,1,,Oral bioavailability in dog,,5452,3880,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL623284
,1,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,5453,16367,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL623285
,1,,Plasma protein binding towards dog plasma at 10 uM,,5454,17409,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL623463
,1,,Plasma protein binding towards dog plasma at 100 uM,,5455,17409,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL875952
,1,,Bioavailability in dog (dose 4 mg/kg p.o.),,5456,2959,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621705
,1,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,5457,13501,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621706
,1,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,5458,4527,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621707
,1,,Bioavailability in dogs,,5459,15145,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621708
,1,,Bioavailability,,5460,4219,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621709
,1,,Oral bioavailability in dog (dose 10 mg/kg),,5461,17538,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621710
,1,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,5462,17538,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621711
,1,,Bioavailability in dog (dose 10.0 mg/kg p.o.),,5463,1466,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621712
,1,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,5464,17650,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621713
,1,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,5465,3132,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621714
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,5466,2413,,1,Mus sp.,Autocuration,22224,,10095.0,,U,,,,BAO_0000218,A,,CHEMBL621715
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,5467,2413,,1,Mus sp.,Autocuration,22224,,10095.0,Liver,U,2107.0,,,BAO_0000218,A,,CHEMBL623717
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,5468,2413,,1,Mus sp.,Autocuration,22224,,10095.0,Liver,U,2107.0,,,BAO_0000218,A,,CHEMBL623718
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,5469,2413,,1,Mus sp.,Autocuration,22224,,10095.0,Liver,U,2107.0,,,BAO_0000218,A,,CHEMBL623719
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,5470,2413,,1,Mus sp.,Autocuration,22224,,10095.0,,U,,,,BAO_0000218,A,,CHEMBL623720
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,5471,2413,,1,Mus sp.,Autocuration,22224,,10095.0,,U,,,,BAO_0000218,A,,CHEMBL623721
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,5472,2413,,1,Mus sp.,Autocuration,22224,,10095.0,Muscle tissue,U,2385.0,,,BAO_0000218,A,,CHEMBL623722
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,5473,2413,,1,Mus sp.,Autocuration,22224,,10095.0,Muscle tissue,U,2385.0,,,BAO_0000218,A,,CHEMBL623723
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,5474,2413,,1,Mus sp.,Autocuration,22224,,10095.0,Muscle tissue,U,2385.0,,,BAO_0000218,A,,CHEMBL618543
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,5475,2413,,1,Mus sp.,Autocuration,22224,,10095.0,Spleen,U,2106.0,,,BAO_0000218,A,,CHEMBL618544
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,5476,2413,,1,Mus sp.,Autocuration,22224,,10095.0,Spleen,U,2106.0,,,BAO_0000218,A,,CHEMBL875155
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,5477,2413,,1,Mus sp.,Autocuration,22224,,10095.0,,U,,,,BAO_0000218,A,,CHEMBL618545
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,5478,2413,,1,Mus sp.,Autocuration,22224,,10095.0,,U,,,,BAO_0000218,A,,CHEMBL618546
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,5479,2413,,1,Mus sp.,Autocuration,22224,,10095.0,,U,,,,BAO_0000218,A,,CHEMBL623529
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,5480,2413,,1,Mus sp.,Autocuration,22224,,10095.0,,U,,,,BAO_0000218,A,,CHEMBL623530
,0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,5481,2413,,1,Mus sp.,Autocuration,22224,,10095.0,,U,,,,BAO_0000218,A,,CHEMBL621764
,0,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,5482,17827,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL621765
,0,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,5483,17827,,1,Cercopithecidae,Autocuration,22224,,9527.0,Cerebellum,U,2037.0,,,BAO_0000019,A,,CHEMBL621766
,0,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,5484,17827,,1,Cercopithecidae,Autocuration,22224,,9527.0,Frontal cortex,U,1870.0,,,BAO_0000019,A,,CHEMBL621767
,0,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,5485,17827,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL621768
,0,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,5486,17827,,1,Cercopithecidae,Autocuration,22224,,9527.0,Striatum,U,2435.0,,,BAO_0000019,A,,CHEMBL621769
,0,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,5487,17827,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL621770
,0,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,5488,17827,,1,Cercopithecidae,Autocuration,22224,,9527.0,Cerebellum,U,2037.0,,,BAO_0000019,A,,CHEMBL621771
,0,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,5489,17827,,1,Cercopithecidae,Autocuration,22224,,9527.0,Frontal cortex,U,1870.0,,,BAO_0000019,A,,CHEMBL621772
,0,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,5490,17827,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL621773
,0,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,5491,17827,,1,Cercopithecidae,Autocuration,22224,,9527.0,Striatum,U,2435.0,,,BAO_0000019,A,,CHEMBL621774
,0,,Compound was evaluated for oral bioavailability in rats,,5492,17791,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL621775
,0,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,,5493,17667,,1,Cercopithecidae,Autocuration,22224,,9527.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL621776
,0,,Half life period was evaluated in monkey,,5494,17791,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL621777
,0,,Half-life in rhesus monkeys by intravenous administration of dose,,5495,110,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL875162
,1,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,5496,5781,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL621778
,1,,AUC after intraperitoneal administration of 100 mg/kg in mice,,5497,17734,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL621779
,1,,AUC value was determined after oral administration,,5498,17718,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622479
,1,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,5499,4573,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622480
,1,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,5500,3277,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622481
,1,,Area under curve by ioral administration in mouse,,5501,2862,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622482
,1,,Area under curve by iv administration in mouse,,5502,2862,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622483
,1,,Area under curve at 0-8 hr in IRC mice after peroral administration,,5503,5951,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622484
,1,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,5504,17729,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622641
,1,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,5505,17728,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622642
,1,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,5506,17728,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622643
,1,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,5507,17729,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622644
,1,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,5508,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL622645
,1,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,5509,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL622646
,1,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,5510,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL621238
,1,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,5511,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL621239
,1,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,5512,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL621240
,1,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,5513,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL621241
,1,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,5514,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL621242
,1,741.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,5515,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL620350
,1,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,5516,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL620351
,1,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,5517,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL620352
,1,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,5518,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL620353
,1,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,5519,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL620354
,1,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,5520,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL620355
,1,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,5521,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL620356
,1,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,5522,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL620357
,1,741.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,5523,9424,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL620358
,1,741.0,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,5524,9424,,1,Homo sapiens,Expert,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL620359
,1,741.0,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,5525,11544,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL620360
,1,741.0,Cytotoxicity of compound against 8226/DOX1V cells,,5526,17378,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL620361
,1,741.0,Cytotoxicity of compound against 8226/S cells,,5527,17378,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL620362
,1,741.0,Inhibitory concentration against 8226 myeloma cancer cell line,,5528,17079,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL620363
,1,741.0,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,5529,17079,,1,Homo sapiens,Intermediate,80433,,9606.0,,N,,,RPMI-8226,BAO_0000219,F,,CHEMBL620364
,1,854.0,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,5530,13466,,1,Homo sapiens,Intermediate,80647,,9606.0,,N,,,833K,BAO_0000219,F,,CHEMBL620365
,1,854.0,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,5531,13466,,1,Homo sapiens,Intermediate,80647,,9606.0,,N,,,833K,BAO_0000219,F,,CHEMBL620366
,1,854.0,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,5532,2392,,1,Homo sapiens,Expert,80647,,9606.0,,N,,,833K,BAO_0000219,F,,CHEMBL620367
,1,854.0,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,5533,2392,,1,Homo sapiens,Intermediate,80647,,9606.0,,N,,,833K,BAO_0000219,F,,CHEMBL620368
,0,,Inhibitory activity against caspase-1,,5534,6608,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL620369
,8,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,5535,10199,,1,Enterococcus faecalis,Autocuration,45,,1351.0,,H,,,,BAO_0000357,B,,CHEMBL620370
,1,705.0,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,5536,17749,,1,Homo sapiens,Intermediate,80648,,9606.0,,N,,,8701-BC,BAO_0000219,F,,CHEMBL620371
,1,705.0,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,5537,17749,,1,Homo sapiens,Intermediate,80648,,9606.0,,N,,,8701-BC,BAO_0000219,F,,CHEMBL620372
,0,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,5538,1229,,1,,Intermediate,22226,,,,U,,,,BAO_0000019,F,,CHEMBL876492
,0,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,5539,1229,,1,,Intermediate,22226,,,,U,,,,BAO_0000019,F,,CHEMBL620373
,0,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,5540,1229,,1,,Intermediate,22226,,,,U,,,,BAO_0000019,F,,CHEMBL620374
,0,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,5541,6390,,1,,Autocuration,22226,,,,U,,,,BAO_0000019,B,,CHEMBL620375
,0,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,5542,16219,,1,Streptococcus pyogenes,Autocuration,22226,,1314.0,,U,,,,BAO_0000019,F,,CHEMBL857902
,0,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,5543,16219,,1,Streptococcus pyogenes,Autocuration,22226,,1314.0,,U,,,,BAO_0000019,F,,CHEMBL620376
,8,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,5544,17043,,1,,Autocuration,11922,,,,H,,,,BAO_0000357,B,,CHEMBL620377
,1,324.0,Tested for in vitro cytotoxic potency of compound in 9KB assay,,5545,6929,,1,Homo sapiens,Intermediate,81115,,9606.0,,N,,,KB ,BAO_0000219,F,,CHEMBL620378
,1,324.0,Tested for in vitro cytotoxic potency of compound in 9KB assay,,5546,6929,,1,Homo sapiens,Intermediate,81115,,9606.0,,N,,,KB ,BAO_0000219,A,,CHEMBL620379
,0,,In vitro cytotoxicity of compound was tested against 9KB cells.,,5547,7083,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000219,F,,CHEMBL620380
,1,392.0,Cytotoxic concentration against 9L cells was determined on day 3,,5548,12446,,1,Rattus norvegicus,Intermediate,80653,,10116.0,,N,,,9L,BAO_0000219,F,,CHEMBL884006
,1,392.0,Tested in vitro for anticancer activity against 9L cells,,5549,15345,,1,Rattus norvegicus,Expert,80653,,10116.0,,N,,,9L,BAO_0000219,F,,CHEMBL620381
,1,392.0,Tested in vitro for anticancer activity against 9L cells; Not determined,,5550,15345,,1,Rattus norvegicus,Expert,80653,,10116.0,,N,,,9L,BAO_0000219,F,,CHEMBL620382
,1,646.0,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,5551,6301,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620383
,1,646.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,5552,4833,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL876493
,1,646.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,5553,4833,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620384
,1,646.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,5554,4833,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620385
,1,646.0,Cytotoxicity against human lung carcinoma A549 cell line,,5555,13330,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620386
,9,646.0,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,5556,17517,,1,Homo sapiens,Expert,25,,9606.0,,D,,,A549,BAO_0000219,F,,CHEMBL620387
,9,646.0,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,5557,17517,,1,Homo sapiens,Expert,25,,9606.0,,D,,,A549,BAO_0000219,F,,CHEMBL621404
,1,646.0,"In vitro growth inhibition of A549, lung carcinoma",,5558,14425,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621405
,1,646.0,"In vitro growth inhibition of A549, lung carcinoma.",,5559,14425,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621406
,1,646.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,5560,5228,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621407
,1,646.0,Cytotoxic activity against human lung cancer A549 cell line was determined,,5561,5351,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621408
,1,646.0,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,5562,12198,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL885345
,1,646.0,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,5563,13891,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621409
,1,646.0,Cytotoxicity in A549 (human carcinoma) cell line.,,5564,5677,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL876034
,1,646.0,Cytotoxicity on lung carcinoma (A-549) cell line,,5565,13788,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621410
,1,646.0,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,5566,13384,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621411
,1,646.0,Effective dose of compound against replication of A549 cell line was evaluated,,5567,6726,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621412
,1,646.0,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,5568,3455,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621413
,1,646.0,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,5569,5726,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621414
,1,646.0,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,5570,5726,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621415
,1,646.0,The compound was evaluated for antiproliferative activity against A549 cell line,,5571,3936,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621416
,1,646.0,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,5572,14991,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621417
,1,646.0,Concentration required for growth inhibition of human lung carcinoma cell line A549,,5573,5243,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621418
,1,646.0,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,5574,12858,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621419
,1,646.0,Growth inhibition against A549 cell line was evaluated,,5575,6776,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621420
,1,646.0,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,5576,16558,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL875823
,1,646.0,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,5577,4583,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621421
,1,646.0,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,5578,13514,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621422
,1,646.0,Chemosensitivity against DT-diaphorase rich A549 cell lines,,5579,15166,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL884014
,1,646.0,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,5580,13873,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621423
,1,646.0,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,5581,6447,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621424
,1,646.0,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,5582,2068,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621425
,1,646.0,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,5583,1863,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621426
,1,646.0,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,5584,13873,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621427
,1,646.0,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,5585,13873,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621428
,1,646.0,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,5586,13873,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621429
,1,646.0,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,5587,579,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621430
,1,646.0,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,5588,579,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621431
,1,646.0,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,5589,4584,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621432
,1,646.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,5590,5421,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621433
,1,646.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,5591,5421,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL875824
,1,646.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,5592,5421,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621434
,1,646.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,5593,5421,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621435
,1,646.0,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,5594,14188,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621436
,1,646.0,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,5595,14188,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621437
,1,646.0,Compound was tested for the growth inhibition of A549 lung tumor cell line,,5596,15354,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621438
,1,646.0,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,5597,14253,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621439
,1,646.0,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,5598,13873,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621440
,1,,Oral bioavailability in dog (conscious),,5599,3043,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621441
,1,,Compound was evaluated for the oral bioavailability after oral administration in dog.,,5600,3045,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621442
,1,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,5601,3022,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621443
,1,,Oral bioavailability in dog,,5602,4453,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621444
,1,,Oral bioavailability in dog,,5603,1696,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625133
,1,,Oral bioavailability in dog,,5604,5045,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625134
,1,,Oral bioavailability in dog (fasted),,5605,5356,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625135
,1,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,5606,17764,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625136
,1,,Oral bioavailability in dog,,5607,6448,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625137
,1,,Oral bioavailability in dog,,5608,1475,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625138
,1,,Percent bioavailability in dog,,5609,3788,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625139
,1,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,5610,3639,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL872264
,1,,Oral bioavailability in dog,,5611,13397,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625140
,1,,The compound was evaluated for bioavailability in dogs; 34-44,,5612,2137,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624436
,1,,Bioavailability in dog (dose 4 mg/kg p.o.),,5613,2959,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624437
,1,,Oral bioavailability in dog,,5614,6448,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL872261
,1,,8 hour trough Blood level in dog was measured after administration of compound,,5615,6084,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624438
,1,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,,5616,3639,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624439
,1,,C24 after oral administration at 5 mg/kg,,5617,6316,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624440
,1,,Clearance after oral and iv dosing in dogs,,5618,5238,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624441
,1,,Clearance of the drug was measured in the plasma of dog,,5619,17796,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL624442
,1,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,5620,2652,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624443
,1,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,5621,5654,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624444
,1,,Clearance of compound was determined in dogs,,5622,6621,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624445
,1,,Clearance on i.v. administration of 2 mg/kg was measured in dog,,5623,6505,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624446
,1,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,5624,5802,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624447
,1,,Plasma clearance in dog was determined,,5625,17267,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624448
,1,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,5626,4521,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624449
,1,,Plasma clearance in dog after administration of 0.25 mg/kg iv,,5627,6535,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624450
,1,,Plasma clearance in dog after administration of 1 mg/kg iv,,5628,6535,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875942
,1,,Plasma clearance in dogs,,5629,6535,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624451
,1,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,5630,5542,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624452
,1,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,5631,5199,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624453
,1,,Plasma clearance after 15 mg/kg iv dose in Dogs,,5632,16907,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624454
,1,,Plasma clearance after 30 mg/kg po dose in Dogs,,5633,16907,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624455
,1,,Plasma administration to dogs,,5634,16367,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624456
,1,,Plasma clearance was determined,,5635,5505,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624457
,1,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,5636,6215,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624458
,1,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,5637,1466,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624459
,2,,Intrinsic clearance in human liver microsomes,,5638,5007,Microsomes,1,Homo sapiens,Intermediate,102164,,9606.0,Liver,S,2107.0,In vitro,,BAO_0000251,A,,CHEMBL624460
,2,,Intrinsic clearance in human liver microsomes,,5639,5007,Microsomes,1,Homo sapiens,Intermediate,102164,,9606.0,Liver,S,2107.0,In vitro,,BAO_0000251,A,,CHEMBL624461
,1,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,5640,16452,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875943
,1,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,5641,16452,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624462
,1,,Clearance in dog (dose 1 mg/kg i.v.),,5642,16452,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624463
,1,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,5643,6221,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624464
,1,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,5644,5007,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624465
,1,,Plasma clearance after peroral administration at 10 mpk in dog,,5645,5668,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624466
,1,,Plasma clearance after peroral administration at 5 mpk in dog,,5646,5668,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624467
,1,,Plasma clearance after peroral administration at 5 mg/kg in dog,,5647,5668,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624468
,1,,Plasma clearance was measured in dog,,5648,15660,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624469
,1,,Plasma clearance was measured in dog,,5649,15660,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624470
,1,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,5650,5983,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624471
,1,,Total clearance was determined after 0.1 mg/kg iv administration in dog,,5651,5600,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624472
,1,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,5652,17764,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622775
,1,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,5653,6039,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622776
,1,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,5654,6039,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622777
,1,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,5655,6039,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622778
,1,,Clearance by intravenous administration of 1.2 mg/kg in dog,,5656,4368,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622779
,1,,Clearance by iv administration in dogs at a dose of 1 mg/kg,,5657,4305,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622780
,1,,Clearance value was evaluated in dog plasma,,5658,1918,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622781
,1,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,5659,6005,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622782
,1,,Compound was tested for plasma clearance in dog,,5660,4839,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622783
,1,,Pharmacokinetic property (Plasma clearance) was measured in dog,,5661,4239,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622784
,1,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,5662,17729,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622785
,1,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,5663,17728,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622786
,1,,Area under curve value in mouse at a dose of 10 mg/kg,,5664,5302,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622787
,1,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,5665,5506,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL875949
,1,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,5666,5506,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622788
,1,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,5667,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,F,,CHEMBL622789
,1,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,5668,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,F,,CHEMBL622790
,1,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,5669,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,F,,CHEMBL622791
,1,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,5670,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,F,,CHEMBL622792
,1,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,5671,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622793
,1,,Area under curve was determined for the compound at 24 mg/Kg,,5672,17753,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622794
,1,,Area under curve was determined for the compound at 40 mg/Kg,,5673,17753,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622795
,1,,Area under curve was determined for the compound at 5 mg/Kg,,5674,17753,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621803
,1,,Area under the curve for the compound is obtained at dose 25 mg/kg,,5675,3132,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621804
,1,,Area under the curve for the compound was obtained when tested in mouse,,5676,3132,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621805
,1,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,5677,17837,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621806
,1,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,5678,17837,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621807
,1,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,5679,6062,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621808
,1,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,5680,4066,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621809
,1,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,5681,16597,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621810
,1,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,5682,14239,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL875164
,1,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,5683,14239,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621811
,1,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,5684,4890,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621812
,1,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,5685,429,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621813
,1,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,5686,429,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621814
,1,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,5687,5969,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621815
,1,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,5688,5969,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621816
,1,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,5689,5969,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621817
,1,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,5690,6091,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621818
,1,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,5691,6091,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621819
,1,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,5692,6091,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621820
,1,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,5693,6091,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621821
,1,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,5694,6178,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621822
,1,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,5695,6178,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619474
,1,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,5696,6619,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619475
,1,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,5697,6619,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619476
,1,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,5698,3760,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619477
,1,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,5699,3760,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619478
,1,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,5700,3760,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619479
,1,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,5701,3760,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619480
,1,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,5702,3192,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619481
,1,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,5703,3192,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619482
,1,,Area under the curve was evaluated in mice after intravenous administration,,5704,2675,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619483
,1,,Area under the curve was evaluated in mice after oral administration,,5705,2675,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619484
,1,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,5706,16597,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL619485
,1,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,5707,16597,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL619486
,1,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,5708,16597,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619487
,1,,AUMC after intraperitoneal administration of 100 mg/kg in mice,,5709,17734,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619488
,1,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,,5710,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL620106
,1,392.0,The compound was tested in vitro for anticancer activity against 9L cells,,5711,15345,,1,,Intermediate,80653,,,,N,,,9L,BAO_0000219,F,,CHEMBL620107
,0,,Anti proliferation activity determined; Weak effect,,5712,2181,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000019,F,,CHEMBL620283
,0,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,5713,2181,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000219,F,,CHEMBL875176
,0,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,5714,2181,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000219,F,,CHEMBL620284
,0,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,5715,2181,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000219,F,,CHEMBL623515
,0,,The cytotoxic activity was in vitro tested by 9PS assay method,,5716,10486,,1,Mus musculus,Autocuration,22226,,10090.0,,U,,,,BAO_0000019,F,,CHEMBL623516
,0,,The cytotoxic activity was in vitro tested by 9PS assay method.,,5717,10486,,1,Mus musculus,Autocuration,22226,,10090.0,,U,,,,BAO_0000019,F,,CHEMBL623517
,0,,Partition coefficient (logD6.5),,5718,15508,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL857878
,1,478.0,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,5719,5242,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL623518
,1,455.0,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,5720,16167,,1,Homo sapiens,Intermediate,80018,,9606.0,,N,,,A-375,BAO_0000219,F,,CHEMBL624195
,1,500.0,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,5721,4782,,1,Homo sapiens,Expert,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL624196
,9,500.0,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,5722,16093,,1,Homo sapiens,Expert,9,,9606.0,,D,,,A-431,BAO_0000219,F,,CHEMBL624197
,1,624.0,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,5723,2596,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL624198
,1,624.0,in vitro cytotoxicity against A 498 cancer cell line,,5724,2596,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL621287
,1,624.0,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,5725,3239,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL621288
,1,624.0,Cytotoxic activity against A 498 renal cancer cell lines.,,5726,1847,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL876496
,1,624.0,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,5727,10553,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL621289
,0,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,5728,16219,,1,Staphylococcus aureus,Autocuration,22226,,1280.0,,U,,,,BAO_0000019,F,,CHEMBL621290
,0,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,5729,16219,,1,Staphylococcus aureus,Autocuration,22226,,1280.0,,U,,,,BAO_0000019,F,,CHEMBL621291
,0,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,5730,16219,,1,Staphylococcus aureus,Autocuration,22226,,1280.0,,U,,,,BAO_0000019,F,,CHEMBL621292
,0,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,5731,16219,,1,Staphylococcus aureus,Autocuration,22226,,1280.0,,U,,,,BAO_0000019,F,,CHEMBL621293
,1,646.0,Inhibitory concentration required against A 549 lung cancer cell line,,5732,4782,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621294
,1,646.0,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,5733,11805,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621295
,1,646.0,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,5734,11805,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL884007
,1,646.0,In vitro cytotoxicity against lung cancer A 549 cell lines,,5735,2007,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621296
,1,646.0,Compound was tested for its cytotoxicity against A 549 cell line,,5736,4594,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621297
,1,646.0,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,5737,6018,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL839828
,1,646.0,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,5738,6018,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620397
,1,646.0,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,5739,3599,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620398
,1,646.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,5740,2551,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620399
,1,646.0,In vitro inhibition of A549 (human lung cancer) cell growth.,,5741,16132,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620400
,1,646.0,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,5742,16132,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620401
,1,646.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,5743,2551,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620402
,1,646.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,5744,2551,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620403
,0,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,5745,11913,,1,,Autocuration,22226,,,,U,,,,BAO_0000218,F,,CHEMBL620404
,4,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,5746,12621,,1,,Autocuration,104694,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620405
,4,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,5747,12621,,1,,Autocuration,104694,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620406
,4,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,5748,12621,,1,,Autocuration,104694,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620407
,4,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,5749,12621,,1,,Autocuration,104694,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620408
,4,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,5750,12621,,1,,Autocuration,104694,,,,H,,In vivo,,BAO_0000218,F,,CHEMBL620409
,1,624.0,Inhibition of A-498 human Renal cell proliferation,,5751,3600,,1,Homo sapiens,Expert,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL620410
,0,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,5752,1796,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000019,F,,CHEMBL620411
,0,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,5753,1796,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000019,F,,CHEMBL620412
,0,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,5754,1796,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000019,F,,CHEMBL876596
,1,622.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,5755,16464,,1,Homo sapiens,Expert,80012,,9606.0,,N,,,A 172,BAO_0000219,F,,CHEMBL620413
,1,622.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,5756,16464,,1,Homo sapiens,Intermediate,80012,,9606.0,,N,,,A 172,BAO_0000219,F,,CHEMBL620414
,1,622.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,5757,16464,,1,Homo sapiens,Intermediate,80012,,9606.0,,N,,,A 172,BAO_0000219,F,,CHEMBL620415
,1,646.0,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,5758,13617,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620416
,1,646.0,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,5759,4584,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620417
,1,646.0,Cytotoxic activity evaluated against A549 tumor cells,,5760,13799,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620418
,1,646.0,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,5761,16726,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620419
,1,646.0,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,5762,16109,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620420
,1,646.0,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,5763,16109,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620421
,1,646.0,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,5764,15474,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620422
,1,646.0,Cytotoxicity of compound against A549 cell line,,5765,6851,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620423
,1,646.0,Cytotoxicity against human lung cell carcinoma A549 cell line,,5766,17534,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620424
,1,646.0,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,5767,2621,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620425
,1,646.0,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,5768,830,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620426
,1,646.0,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,5769,14255,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620427
,1,646.0,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,5770,14255,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620428
,1,646.0,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,5771,1590,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620429
,1,646.0,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,5772,6146,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620430
,1,646.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,5773,17427,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL839887
,1,646.0,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,5774,5280,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620431
,1,646.0,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,5775,16786,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL884010
,1,646.0,In vitro cytotoxicity against A549 (human lung cancer),,5776,5895,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620538
,1,646.0,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,5777,14297,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620539
,1,646.0,In vivo antiproliferative activity against A549 cell line,,5778,17824,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000218,F,,CHEMBL623373
,1,646.0,Inhibition of non-small-cell lung adenocarcinoma (A549),,5779,14368,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL623374
,1,646.0,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,5780,14368,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL623375
,1,646.0,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,5781,14254,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL623376
,1,646.0,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,5782,15897,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL623377
,1,646.0,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,5783,13866,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL623378
,1,646.0,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,5784,13370,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL623379
,1,646.0,Inhibitory activity against A549 lung cancer cell line,,5785,4862,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL623380
,1,646.0,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,5786,4862,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL623381
,1,646.0,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,5787,4862,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL623382
,1,646.0,Inhibitory concentration against A549 (lung cancer) cell line,,5788,15970,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL623383
,1,646.0,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,5789,17713,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL623384
,1,646.0,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,5790,4833,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL623385
,1,646.0,Activity against A549 cancer cell line.,,5791,13736,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL623386
,1,646.0,The compound was evaluated for cytotoxicity against A549 cell line,,5792,4312,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL884105
,1,646.0,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,5793,5421,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL623387
,1,646.0,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,5794,5421,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621568
,1,646.0,Growth inhibitory activity was measured for human A549 tumor cell line.,,5795,14717,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621569
,1,646.0,Inhibitory activity against A549 lung cancer cell line,,5796,4634,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621570
,1,646.0,Inhibitory activity against A549 cell line; inactive,,5797,1149,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621571
,1,646.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,5798,5421,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621572
,1,646.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,5799,5421,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621573
,1,646.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,5800,5421,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621574
,1,646.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,5801,3320,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621575
,1,646.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,5802,3320,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621576
,1,646.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,5803,3320,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621577
,1,646.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,5804,3320,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621578
,1,646.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,5805,3320,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621579
,1,646.0,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,5806,5726,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621580
,1,,Plasma clearance (in vivo) in mongrel dogs was determined,,5807,17800,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621581
,1,,Plasma clearance was measured in dog,,5808,5985,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621582
,1,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,5809,5530,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621583
,1,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,5810,5530,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621584
,1,,Tested for plasma clearance in dog,,5811,4839,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL621585
,1,,The compound was tested for clearance in dog plasma.,,5812,3639,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621586
,1,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,5813,4838,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875835
,1,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,5814,4137,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621587
,1,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,5815,5017,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL621588
,1,,In vitro clearance in dog liver microsomes,,5816,17538,Microsomes,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Liver,N,2107.0,In vitro,,BAO_0000218,A,,CHEMBL621589
,1,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,5817,6161,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621590
,1,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,5818,6161,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621591
,1,,Plasma clearance in dog,,5819,1696,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621592
,1,,Clearance rate in dog,,5820,6762,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621593
,1,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,5821,5932,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL621594
,1,,Clearance in dogs,,5822,6305,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621595
,1,,Plasma clearance in dogs,,5823,4942,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621596
,1,,Plasma clearance was determined,,5824,4219,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621597
,1,,Lower clearance in dog (i.v.) at 0.5 mpk,,5825,17853,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621598
,1,,Plasma clearance in Beagle dogs,,5826,4514,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621599
,1,,Plasma clearance (Clp) in dog,,5827,6448,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875836
,1,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,5828,6227,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621600
,1,,Plasma clearance (pharmacokinetic parameter) in dog was determined,,5829,6227,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621601
,1,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,5830,6062,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618474
,1,,Plasma clearance of compound was determined in dog,,5831,6821,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618475
,1,,Plasma clearance after intravenous administration of 1 mg/kg in dog,,5832,4709,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624524
,1,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,5833,4521,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624525
,1,,Plasma clearance in dog was determined,,5834,5374,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624526
,1,,Plasma clearance was calculated in dog,,5835,6057,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624527
,1,,Plasma clearance at the dose of 2 mg/kg in dog,,5836,4727,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624528
,1,,Plasma clearance in dog,,5837,5145,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624529
,1,,Plasma clearance in dog,,5838,17657,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624530
,1,,Plasma clearance in dog; Unable to calculate,,5839,17657,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624531
,1,,Plasma clearance in rhesus monkey,,5840,5145,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624532
,1,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,5841,6642,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624533
,1,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,5842,6641,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624534
,1,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,5843,6642,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624535
,1,,Plasma clearance was evaluated in dog,,5844,5472,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624536
,1,,Plasma clearance was evaluated in dog; Not tested,,5845,5472,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624537
,1,,Plasma clearance was evaluated in rhesus,,5846,5472,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624538
,1,,Plasma clearance was evaluated in rhesus; Not tested,,5847,5472,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624539
,1,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,5848,4257,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624540
,1,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,5849,6679,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624541
,1,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,5850,5546,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624542
,1,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,5851,6348,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624543
,1,,Clearance value at a dose of 0.2 mg/kg i.v.,,5852,5474,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624544
,1,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,,5853,6316,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624545
,1,,Cmax after oral dose of compound at 3 mg/kg in dogs,,5854,17594,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624546
,1,,Cmax after single intravenous bolus of 1 mg/kg in dogs,,5855,17594,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875957
,1,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,5856,5802,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624547
,1,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,5857,6535,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624548
,1,,Cmax in dog after administration of 1 mg/kg iv,,5858,6535,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624549
,1,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,,5859,1466,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624550
,1,,Cmax on p.o. administration of 10 mg/kg was measured in dog,,5860,6505,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621613
,1,,Cmax was determine after peroral administration at 10 mpk in dog,,5861,5668,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621614
,1,,Cmax was determine after peroral administration at 5 mpk in dog,,5862,5668,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623431
,1,,Cmax was determine after peroral administration at 5 mg/kg in dog,,5863,5668,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623432
,1,,Cmax after 0.3 mg/kg po administration in dog,,5864,5600,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623433
,1,,Cmax after peroral administration in dogs at 2.4 uM/kg,,5865,17764,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623434
,1,,Cmax in dog after oral administration at 1 mg/kg,,5866,6123,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623435
,1,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,5867,6123,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623436
,1,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,5868,6757,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875958
,1,,Cmax value after 15 mg/kg iv dose in Dogs,,5869,16907,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623437
,1,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,5870,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL623438
,1,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,5871,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL623439
,1,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,5872,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL623440
,1,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,5873,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL623441
,1,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,5874,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL623442
,1,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,5875,7767,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623469
,1,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,5876,7767,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623470
,1,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,5877,7767,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623471
,1,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,5878,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL623472
,1,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,5879,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL623473
,1,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,5880,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL623474
,1,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,5881,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL623475
,1,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,5882,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL623476
,1,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,5883,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL623477
,1,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,,5884,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL621896
,1,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,5885,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL621897
,1,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,5886,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL621898
,1,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,5887,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL621899
,1,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,5888,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL621900
,1,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,5889,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL621901
,1,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,5890,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL621902
,1,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,5891,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL621903
,1,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,5892,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL622587
,1,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,5893,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL620285
,1,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,5894,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL875285
,1,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,5895,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL620286
,1,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,5896,7767,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620287
,1,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,5897,7767,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620288
,1,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,5898,7767,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620289
,1,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,5899,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL620290
,1,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,5900,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL620291
,1,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,5901,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL620292
,1,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,5902,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL620293
,1,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,5903,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL620294
,1,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,5904,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL618614
,1,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,5905,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL618615
,1,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,5906,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL618616
,1,622.0,Cytotoxicity against A-172 human tumor cell lines,,5907,2036,,1,Homo sapiens,Expert,80012,,9606.0,,N,,,A 172,BAO_0000219,F,,CHEMBL618617
,1,622.0,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,5908,2357,,1,Homo sapiens,Intermediate,80012,,9606.0,,N,,,A 172,BAO_0000219,F,,CHEMBL618618
,1,623.0,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,5909,1457,,1,Homo sapiens,Intermediate,80014,,9606.0,,N,,,A204,BAO_0000219,F,,CHEMBL618619
,1,478.0,Tested for antiproliferative activity against A-2780 tumoral cell line,,5910,4379,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618620
,1,455.0,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,5911,1093,,1,Homo sapiens,Intermediate,80018,,9606.0,,N,,,A-375,BAO_0000219,F,,CHEMBL618621
,1,455.0,Tested in vitro against A-375 cell line human melanoma,,5912,12152,,1,Homo sapiens,Intermediate,80018,,9606.0,,N,,,A-375,BAO_0000219,F,,CHEMBL618622
,1,797.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,5913,16464,,1,Homo sapiens,Expert,80019,,9606.0,,N,,,A-427,BAO_0000219,F,,CHEMBL618623
,1,797.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,5914,16464,,1,Homo sapiens,Intermediate,80019,,9606.0,,N,,,A-427,BAO_0000219,F,,CHEMBL618624
,1,797.0,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,5915,16582,,1,Homo sapiens,Expert,80019,,9606.0,,N,,,A-427,BAO_0000219,F,,CHEMBL618625
,1,797.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,5916,16464,,1,Homo sapiens,Intermediate,80019,,9606.0,,N,,,A-427,BAO_0000219,F,,CHEMBL618626
,1,797.0,Antitumor activity on A-427 lung carcinoma cell lines,,5917,10413,,1,Homo sapiens,Intermediate,80019,,9606.0,,N,,,A-427,BAO_0000219,F,,CHEMBL618627
,1,797.0,Cytotoxic activity against human A-427 lung tumor cell line,,5918,6418,,1,Homo sapiens,Intermediate,80019,,9606.0,,N,,,A-427,BAO_0000219,F,,CHEMBL618628
,1,797.0,In vitro antitumor effects against human A-427 cell lines.,,5919,17134,,1,Homo sapiens,Expert,80019,,9606.0,,N,,,A-427,BAO_0000219,F,,CHEMBL618629
,1,797.0,In vitro inhibition of A-427 (human lung cancer) cell growth.,,5920,16132,,1,Homo sapiens,Expert,80019,,9606.0,,N,,,A-427,BAO_0000219,F,,CHEMBL618630
,1,797.0,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,5921,16132,,1,Homo sapiens,Intermediate,80019,,9606.0,,N,,,A-427,BAO_0000219,F,,CHEMBL618631
,1,797.0,Cytotoxic activity of compound against A-427 lung human tumor cell line,,5922,16780,,1,Homo sapiens,Intermediate,80019,,9606.0,,N,,,A-427,BAO_0000219,F,,CHEMBL618632
,1,500.0,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,5923,4085,,1,Homo sapiens,Expert,80852,,9606.0,,N,,,A-431,BAO_0000219,F,,CHEMBL618633
,1,624.0,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,5924,1276,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL619315
,1,624.0,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,5925,3498,,1,Homo sapiens,Expert,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL619316
,1,624.0,Cytotoxicity against human kidney carcinoma A-498cell lines,,5926,1169,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL619317
,1,624.0,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,5927,4450,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL619318
,1,624.0,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,5928,3311,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL619319
,1,624.0,Antitumor cytotoxic activity against A-498 cell line was determined,,5929,4461,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL619739
,1,624.0,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,5930,3311,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL619740
,1,624.0,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,5931,3311,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL883158
,1,624.0,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,5932,1457,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL884012
,1,624.0,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,5933,3664,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL619741
,1,624.0,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,5934,15895,,1,Homo sapiens,Intermediate,80021,,9606.0,,N,,,A498,BAO_0000219,F,,CHEMBL619742
,1,646.0,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,5935,11843,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL876610
,1,646.0,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,5936,11843,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619743
,1,646.0,In vitro antiproliferative activity against human A-549 NSCL cell line,,5937,17705,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619744
,1,646.0,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,5938,17705,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619745
,1,646.0,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,5939,4369,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619746
,1,646.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,5940,4369,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619747
,1,646.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,5941,4369,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619748
,1,646.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,5942,4369,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619749
,1,646.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,5943,4369,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619750
,1,646.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,5944,4369,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624014
,1,646.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,5945,4369,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624015
,1,646.0,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,5946,4787,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL885344
,1,646.0,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,5947,4787,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL623224
,1,646.0,Cytotoxic activity against A-549 cell line,,5948,6513,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL623225
,1,646.0,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,5949,6690,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL622698
,1,646.0,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,5950,6690,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL622699
,1,646.0,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,5951,12263,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL622700
,1,646.0,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,5952,1054,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL622701
,1,646.0,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,5953,1359,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL622702
,1,646.0,Cytotoxic activity against human lung carcinoma (A-549) cell line,,5954,3547,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL622703
,1,646.0,Cytotoxic activity towards A-549 cells,,5955,5771,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL622704
,1,646.0,"In vitro percent inhibition of A549, lung carcinoma.",,5956,14425,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL622705
,1,646.0,"In vitro percent inhibition of A549, lung carcinoma",,5957,14425,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL622706
,1,646.0,"In vitro percent inhibition of A549, lung carcinoma.",,5958,14425,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL622707
,1,646.0,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,5959,14425,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL622708
,1,646.0,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,5960,5280,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL622709
,1,646.0,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,5961,15176,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL622710
,1,646.0,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,5962,15300,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL622711
,1,646.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,5963,17824,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000218,F,,CHEMBL622712
,1,646.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,5964,17824,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000218,F,,CHEMBL622713
,1,646.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,5965,17824,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000218,F,,CHEMBL622714
,1,646.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,5966,17824,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000218,F,,CHEMBL622715
,1,646.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,5967,17824,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000218,F,,CHEMBL622716
,1,646.0,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,5968,17824,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL622717
,1,646.0,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,5969,17528,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000218,F,,CHEMBL622718
,1,646.0,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,5970,6870,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL622719
,1,646.0,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,5971,6870,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL622720
,1,646.0,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,5972,6870,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL622721
,1,646.0,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,5973,6870,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL622722
,1,646.0,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,5974,16726,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL876030
,1,646.0,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,5975,6170,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620206
,1,646.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,5976,6583,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620207
,1,646.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,5977,6583,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620208
,1,646.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,5978,6583,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620209
,1,646.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,5979,6583,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620210
,1,646.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,5980,6583,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621639
,1,646.0,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,5981,17321,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621640
,1,646.0,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,5982,17528,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621641
,1,646.0,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,5983,12888,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621642
,1,646.0,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,5984,4312,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621643
,1,646.0,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,5985,4312,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621644
,1,646.0,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,5986,4312,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL621645
,1,646.0,In vitro antiproliferative activity against A549 cell line,,5987,17737,,1,Mus musculus,Intermediate,80682,,10090.0,,N,,,A549,BAO_0000219,F,,CHEMBL621646
,1,646.0,Synergism with indomethacin in A549 cells,,5988,6630,,1,,Intermediate,80682,,,,N,,,A549,BAO_0000219,F,,CHEMBL621647
,1,646.0,Synergism with tolmetin in A549 cells,,5989,6630,,1,,Intermediate,80682,,,,N,,,A549,BAO_0000219,F,,CHEMBL621648
,1,646.0,Synergism with sulindac in A549 cells,,5990,6630,,1,,Intermediate,80682,,,,N,,,A549,BAO_0000219,F,,CHEMBL621649
,1,646.0,Antagonism of indomethacin in A549 cells,,5991,6630,,1,,Intermediate,80682,,,,N,,,A549,BAO_0000219,F,,CHEMBL621650
,1,646.0,Antagonism of sulindac in A549 cells,,5992,6630,,1,,Intermediate,80682,,,,N,,,A549,BAO_0000219,F,,CHEMBL621651
,1,646.0,Antagonism of tolmetin in A549 cells,,5993,6630,,1,,Intermediate,80682,,,,N,,,A549,BAO_0000219,F,,CHEMBL621652
,1,646.0,Synergism with indomethacin in A549 cells,,5994,6630,,1,,Intermediate,80682,,,,N,,,A549,BAO_0000219,F,,CHEMBL621653
,1,646.0,Synergism with sulindac in A549 cells,,5995,6630,,1,,Intermediate,80682,,,,N,,,A549,BAO_0000219,F,,CHEMBL621654
,1,646.0,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,5996,6630,,1,,Intermediate,80682,,,,N,,,A549,BAO_0000219,F,,CHEMBL621655
,1,,Cmax value after 30 mg/kg po dose in Dogs,,5997,16907,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621656
,1,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,5998,5944,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621657
,1,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,5999,5944,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621658
,1,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,6000,5944,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621659
,1,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,6001,5944,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621660
,1,,Cmax value after administration of 4 mg/Kg oral dose in dog,,6002,2959,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621661
,1,,Cmax value in dog,,6003,6241,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621662
,1,,Cmax value in dogs after oral administration at 1 mg/kg,,6004,6241,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621663
,1,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,6005,2652,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621664
,1,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,,6006,1806,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL621665
,1,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,,6007,1806,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL621666
,1,,Concentration maxima after oral dosing in dogs,,6008,1021,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621667
,1,,Concentration maxima after oral dosing in dogs; not available,,6009,1021,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876738
,1,,Concentration maxima after oral dosing in dogs; not available,,6010,1021,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621668
,1,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,6011,5444,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621669
,1,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,6012,5444,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621670
,1,,In vivo maximal concentration was calculated at 1 mg/kg in dog,,6013,5444,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621671
,1,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,6014,5444,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622360
,1,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,6015,5444,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622361
,1,,Cmax in dog plasma after oral dose (1 mg/kg),,6016,5130,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622362
,1,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,,6017,3249,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622363
,1,,Maximal plasma concentration at a dose of 1 mg/kg,,6018,5473,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622364
,1,,Maximal plasma concentration at a dose of 1 mg/kg (oral),,6019,5474,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622365
,1,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,,6020,4657,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622533
,1,,Maximum concentration of compound in dog was evaluated.,,6021,3031,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622534
,1,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,6022,4527,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622535
,1,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,6023,4186,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876739
,1,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,6024,5007,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622536
,1,,Maximum concentration obtained in dog plasma was determined,,6025,3132,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622537
,1,,Maximum concentration was determined,,6026,5006,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622538
,1,,Maximum concentration at the dose of 2 mg/kg in dog,,6027,4727,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627867
,1,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,6028,1916,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627868
,1,,Maximum concentration was evaluated in dog plasma,,6029,1918,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627869
,1,,Maximum concentration was evaluated after 75 min after administration in dog,,6030,3045,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627870
,1,,Maximum plasma concentration determined in dog after oral administration of 17b,,6031,9579,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627871
,1,,Maximum plasma concentration determined in dog after oral administration of 2b,,6032,9579,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627872
,1,,Maximum plasma concentration in dog,,6033,933,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627873
,1,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,,6034,17839,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627874
,1,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,,6035,17839,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627875
,1,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,,6036,17839,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627876
,1,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,,6037,17839,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627877
,1,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,6038,6348,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627878
,1,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,,6039,16367,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627879
,1,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,6040,1337,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL875355
,1,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,6041,1337,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627880
,1,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,6042,5199,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627881
,1,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,6043,17650,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627882
,1,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,6044,6679,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627883
,1,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,,6045,5356,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL628526
,1,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,,6046,5356,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL628527
,1,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,,6047,6227,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL628528
,1,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,,6048,6227,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL628529
,1,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,,6049,6227,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL628530
,1,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,,6050,6227,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL625243
,1,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,,6051,3598,,1,Canis lupus familiaris,Expert,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL625244
,1,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,6052,4368,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625245
,1,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,6053,6265,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625246
,1,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,6054,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL625247
,1,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,6055,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Urine,N,1088.0,In vivo,,BAO_0000218,A,,CHEMBL625248
,1,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,,6056,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Urine,N,1088.0,In vivo,,BAO_0000218,A,,CHEMBL625249
,1,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,,6057,7767,,1,Mus musculus,Intermediate,50594,,10090.0,Urine,N,1088.0,In vivo,,BAO_0000218,A,,CHEMBL625250
,1,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,6058,17811,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL625251
,1,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,6059,17811,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL875356
,1,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,6060,17827,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL625252
,1,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,6061,17827,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL625253
,1,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,6062,17827,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL625254
,1,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,6063,17827,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL625255
,1,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,6064,17827,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL625256
,1,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,6065,17827,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL625257
,1,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,6066,17827,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL625258
,1,,Compound was evaluated for washout rate in mice (Radiolabeled compound),,6067,17827,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL625259
,1,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,6068,17827,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL625260
,1,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,6069,17827,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL625261
,1,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,6070,17827,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL625262
,1,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,6071,17827,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622639
,1,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,6072,17257,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622640
,1,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,6073,17257,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622812
,1,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,6074,17257,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622813
,1,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,6075,17257,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622814
,1,,Time at maximum activity in mice (Radiolabeled compound),,6076,17827,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622815
,1,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,6077,3760,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL625342
,1,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,6078,3760,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL625343
,1,,Binding towards mouse plasma protein at 10 uM,,6079,17409,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL877591
,1,,Binding towards mouse plasma protein at 100 uM,,6080,17409,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL625344
,1,,Bioavailability was evaluated in mice after intravenous administration,,6081,2675,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625345
,1,,Bioavailability was evaluated in mice after oral administration,,6082,2675,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625346
,1,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,6083,3132,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625347
,1,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,6084,3132,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625348
,1,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,6085,16597,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625349
,1,,Oral bioavailability in mouse,,6086,2862,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625350
,1,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,6087,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL882952
,1,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,6088,846,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL625351
,1,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,6089,846,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL625352
,1,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,6090,846,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL877592
,1,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,6091,846,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL625353
,1,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,6092,846,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL625354
,1,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,6093,846,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL626019
,1,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,6094,846,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL626020
,1,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,6095,846,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL626021
,1,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,6096,846,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL626022
,1,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,6097,846,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL626192
,1,646.0,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,6098,1276,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL626193
,1,646.0,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,6099,3498,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL626194
,1,646.0,Cytotoxicity against human lung carcinoma A-549 cell lines,,6100,1169,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL626195
,1,646.0,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,6101,4450,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL626196
,1,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549,,6102,358,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL626197
,1,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,6103,358,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL626198
,1,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,6104,358,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL626199
,1,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,6105,358,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL626200
,1,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,6106,358,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL626201
,1,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,6107,358,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL626202
,1,646.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,6108,358,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL626203
,1,646.0,In vitro cytotoxicity against A-549 human lung cancer cells,,6109,15167,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL626204
,1,646.0,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,6110,4139,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624701
,1,646.0,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,6111,833,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624702
,1,646.0,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,6112,15718,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624703
,1,646.0,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,6113,12373,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624704
,1,646.0,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,6114,637,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624705
,1,646.0,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,6115,14867,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624706
,1,646.0,Antitumor cytotoxic activity against A-549 cell line was determined,,6116,4461,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624707
,1,646.0,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,6117,5406,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624708
,1,646.0,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,6118,4457,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624709
,1,646.0,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,6119,1386,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL884107
,1,646.0,Antitumoral activity was assayed against A-549 cell line,,6120,3265,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624710
,1,646.0,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,6121,2359,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624711
,1,646.0,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,6122,4457,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624712
,1,646.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,6123,12454,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624713
,1,646.0,Compound was tested for inhibition of cell growth of A-549 cells,,6124,1481,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624714
,1,646.0,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,6125,1750,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624715
,1,646.0,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,6126,5065,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624716
,1,646.0,In vitro cytotoxicity against A549-human lung carcinoma cells.,,6127,808,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619505
,1,646.0,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,6128,16364,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619506
,1,646.0,Cytotoxic activity against A-549 cell lines.,,6129,1847,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619507
,1,646.0,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,6130,1747,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619508
,1,646.0,Cytotoxicity against human A549 non small cell lung cell lines,,6131,1003,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619509
,1,646.0,Inhibition of cell growth in (A-549) lung cell line,,6132,15313,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619510
,1,646.0,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,6133,3122,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619511
,1,646.0,In vitro antitumor activity against A-549 tumor cells.,,6134,16049,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619512
,1,646.0,In vitro antitumor effects against human A-549 cell lines.,,6135,17134,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619513
,1,646.0,In vitro cytotoxic activity of compound against A-549 cell line,,6136,6406,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619514
,1,646.0,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,6137,627,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619515
,1,646.0,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,6138,12307,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619516
,1,646.0,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,6139,17861,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL884005
,1,646.0,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,6140,6682,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619517
,1,646.0,Inhibitory concentration of compound against A-549 cell line,,6141,6663,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619518
,1,646.0,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,6142,2454,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619519
,1,646.0,cytotoxic activity against leukemia (A-549) cancer cell line,,6143,14709,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL876489
,1,646.0,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,6144,15718,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619520
,1,646.0,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,6145,15718,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619521
,1,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,6146,17130,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619522
,1,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,6147,17130,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619523
,1,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,6148,17130,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619524
,1,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,6149,17130,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619525
,1,646.0,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,6150,6630,,1,,Intermediate,80682,,,,N,,,A549,BAO_0000219,F,,CHEMBL619526
,1,646.0,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,6151,16726,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619527
,1,646.0,Cytotoxicity against A549 cells; No cytotoxicity,,6152,17846,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619528
,1,646.0,Cytotoxicity against human lung carcinoma (A549) cell lines,,6153,3415,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619529
,1,646.0,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,6154,3415,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619530
,1,646.0,In vitro anticancer activity against human lung (A549) cell line,,6155,5609,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL876490
,1,646.0,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,6156,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619531
,1,646.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,6157,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619532
,1,646.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,6158,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619533
,1,646.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,6159,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619534
,1,646.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,6160,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620164
,1,646.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,6161,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620165
,1,646.0,Inhibition of A549 human lung tumor cell proliferation,,6162,16295,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620166
,1,646.0,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,6163,16825,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620167
,1,646.0,In vitro cytotoxicity against human tumor cell line A549,,6164,3439,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620168
,1,646.0,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,6165,10870,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620338
,1,646.0,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,6166,4845,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620339
,1,646.0,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,6167,5822,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620340
,1,646.0,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,6168,5822,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620341
,1,646.0,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,6169,5822,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL876491
,1,646.0,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,6170,16381,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620342
,1,646.0,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,6171,16381,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620343
,1,646.0,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,6172,16381,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620344
,1,646.0,In vitro anticancer activity against human lung (A549) cell line,,6173,5609,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620345
,1,646.0,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,6174,4644,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620346
,1,646.0,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,6175,4644,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620347
,1,646.0,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,6176,4644,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620348
,1,646.0,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,6177,4644,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620349
,1,646.0,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,6178,5822,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL618667
,1,646.0,Percentage inhibition of human lung carcinoma (A549) cell lines,,6179,3415,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL618668
,1,646.0,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,6180,16726,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL876031
,1,646.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,6181,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL618759
,1,646.0,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,6182,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL618760
,1,646.0,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,6183,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619000
,1,646.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,6184,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619001
,1,646.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,6185,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619002
,1,646.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,6186,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619003
,1,646.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,6187,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619597
,1,646.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,6188,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619598
,1,646.0,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,6189,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619599
,1,646.0,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,6190,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619600
,1,646.0,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,6191,16726,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619601
,1,646.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,6192,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619602
,1,646.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,6193,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619603
,1,646.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,6194,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619604
,1,646.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,6195,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619605
,1,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,6196,6084,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619606
,1,,Pharmacokinetic activity (Cmax) in dog,,6197,6084,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876032
,1,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,6198,4809,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619607
,1,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,6199,5983,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619608
,1,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,6200,6251,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619609
,1,,Cmax in dog plasma after 30mg/kg oral dose,,6201,5932,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL619610
,1,,Tested for the peak blood level in dog,,6202,4273,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL619611
,1,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,6203,5313,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619612
,1,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,6204,5313,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619613
,1,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,,6205,6221,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL619614
,1,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,6206,4709,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL619615
,1,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,6207,167,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL619616
,1,,Final plasma concentration in dogs after oral administration at 1 mg/kg,,6208,6241,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL619617
,1,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,6209,344,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL619618
,1,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,6210,344,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL876033
,1,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,6211,344,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL619619
,1,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,6212,2189,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL619620
,1,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,6213,2189,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL619621
,1,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,6214,2189,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL619622
,1,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,6215,2189,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL618874
,1,,Absolute bioavailability was evaluated in dog,,6216,4257,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618875
,1,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,6217,6221,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618876
,1,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,6218,6215,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618877
,1,,Bioavailability in dog,,6219,17267,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618878
,1,,Bioavailability in dog,,6220,6621,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618879
,1,,Bioavailability after intravenous administration in dogs,,6221,3854,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618880
,1,,Bioavailability after peroral administration in dogs,,6222,3854,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618881
,1,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,6223,5007,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618882
,1,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,6224,4333,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624226
,1,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,,6225,4333,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624227
,1,,Bioavailability,,6226,5006,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624228
,1,,Bioavailability,,6227,5199,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624229
,1,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,6228,4368,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624230
,1,,Bioavailability in dog,,6229,3771,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624231
,1,,Bioavailability in dog,,6230,4953,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624232
,1,,Bioavailability in dog,,6231,5064,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625127
,1,,Bioavailability in dog,,6232,17657,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625128
,1,,Bioavailability in dog,,6233,17796,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621675
,1,,Bioavailability in dog (p.o.) at 2.0 mpk,,6234,17853,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621676
,1,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,6235,4521,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621677
,1,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,6236,4521,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621678
,1,,Bioavailability in dog,,6237,5006,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621679
,1,,Bioavailability was evaluated after oral administration in dog,,6238,16365,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621680
,1,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,6239,1916,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621681
,1,,Bioavailability was evaluated in dog,,6240,1918,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876740
,1,,Bioavailability in dog,,6241,4239,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621682
,1,,Bioavailability in dog,,6242,6505,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621683
,1,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,6243,5334,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621684
,1,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,6244,5334,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621685
,1,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,6245,4809,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621686
,1,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,6246,6348,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621687
,1,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,6247,6005,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621688
,1,,Bioavailability of compound in dog was determined after peroral administration,,6248,17804,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621689
,1,,Oral bioavailability in dog,,6249,3184,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621690
,1,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,6250,1806,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621691
,1,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,6251,1806,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875941
,1,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,6252,1806,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621692
,1,,Bioavailability in dog,,6253,4839,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621693
,1,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,6254,5017,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621694
,1,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,6255,846,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621695
,1,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,6256,846,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621696
,1,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,6257,846,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621697
,1,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,6258,846,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621698
,1,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,6259,846,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL623420
,1,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,6260,846,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL623421
,1,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,6261,846,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL623422
,1,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,6262,846,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL623423
,1,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,6263,846,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL623424
,1,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,6264,846,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL623425
,1,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,6265,846,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL623426
,1,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,6266,846,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL623427
,1,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,6267,846,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL623428
,1,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,6268,846,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL875947
,1,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,6269,846,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL623429
,1,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,6270,846,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL623430
,1,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,6271,846,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL622588
,1,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,6272,846,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL622589
,1,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,6273,846,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL622751
,1,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,6274,846,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL622752
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,6275,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL622753
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,6276,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL622647
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,6277,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL875163
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,6278,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL622648
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,6279,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL622649
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,,6280,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,,CCRF S-180,BAO_0000218,A,,CHEMBL622650
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,,6281,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,,CCRF S-180,BAO_0000218,A,,CHEMBL622651
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,,6282,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,,CCRF S-180,BAO_0000218,A,,CHEMBL622652
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,,6283,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,,CCRF S-180,BAO_0000218,A,,CHEMBL622653
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,,6284,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,,CCRF S-180,BAO_0000218,A,,CHEMBL622654
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,,6285,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,,CCRF S-180,BAO_0000218,A,,CHEMBL622655
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,,6286,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,,CCRF S-180,BAO_0000218,A,,CHEMBL622656
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,,6287,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,,CCRF S-180,BAO_0000218,A,,CHEMBL622657
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,,6288,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,,CCRF S-180,BAO_0000218,A,,CHEMBL622658
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,,6289,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,,CCRF S-180,BAO_0000218,A,,CHEMBL622659
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,,6290,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,,CCRF S-180,BAO_0000218,A,,CHEMBL624630
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,,6291,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,,CCRF S-180,BAO_0000218,A,,CHEMBL624631
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,,6292,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,,CCRF S-180,BAO_0000218,A,,CHEMBL624632
,1,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,6293,17130,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624633
,1,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,6294,17130,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624634
,1,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,6295,17130,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624635
,1,646.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,6296,17130,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624636
,1,646.0,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,6297,3263,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL857055
,1,646.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,6298,6663,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624637
,1,646.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,6299,6663,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624638
,1,646.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,6300,6663,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL874366
,1,646.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,6301,6663,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624639
,1,646.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,6302,6663,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624640
,1,646.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,6303,6663,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624641
,1,646.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,6304,6663,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624642
,1,646.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,6305,6663,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624643
,1,646.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,6306,6663,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624644
,1,646.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,6307,6663,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL624645
,1,646.0,The compound was evaluated for its cytotoxic potency against A-549 cell line,,6308,3983,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619445
,1,646.0,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,6309,11141,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL839886
,1,646.0,Cytotoxic activity of compound against A-549 tumor cell line.,,6310,5076,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619446
,1,646.0,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,6311,3311,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619447
,1,646.0,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,6312,3311,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619448
,1,646.0,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,6313,3311,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619449
,1,646.0,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,6314,5076,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619450
,1,646.0,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,6315,4150,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619451
,1,646.0,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,6316,2150,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619452
,1,646.0,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,6317,4644,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619453
,1,646.0,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,6318,263,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL874367
,1,646.0,Cytotoxic concentration against A-549 tumor cells.,,6319,11333,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619454
,1,646.0,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,6320,11333,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619455
,1,646.0,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,6321,15895,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619456
,1,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,6322,16677,,1,Acinetobacter baumannii,Expert,50191,,470.0,,N,,,,BAO_0000218,F,,CHEMBL619457
,1,,Activity against Acinetobacter calcoaceticus (AC54),,6323,10624,,1,Acinetobacter calcoaceticus,Intermediate,50192,,471.0,,N,,,,BAO_0000218,F,,CHEMBL619458
,1,,In vitro antifungal activity against Aspergillus flavus CM74,,6324,16717,,1,Aspergillus flavus,Expert,50274,,5059.0,,N,,,,BAO_0000218,F,,CHEMBL619459
,1,,In vitro antifungal activity against Aspergillus flavus CM74,,6325,16717,,1,Aspergillus flavus,Expert,50274,,5059.0,,N,,,,BAO_0000218,F,,CHEMBL619460
,1,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,6326,5513,,1,Aspergillus fumigatus,Intermediate,50416,,746128.0,,N,,,,BAO_0000218,F,,CHEMBL619461
,1,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,6327,15962,,1,Aspergillus fumigatus,Intermediate,50416,,746128.0,,N,,,,BAO_0000218,F,,CHEMBL619462
,1,,Antimicrobial activity against Aspergillus fumigatus (MIC),,6328,15962,,1,Aspergillus fumigatus,Intermediate,50416,,746128.0,,N,,,,BAO_0000218,F,,CHEMBL620388
,1,,Antimicrobial activity against Aspergillus fumigatus (MIC),,6329,15962,,1,Aspergillus fumigatus,Intermediate,50416,,746128.0,,N,,,,BAO_0000218,F,,CHEMBL620389
,1,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,6330,15962,,1,Aspergillus fumigatus,Intermediate,50416,,746128.0,,N,,,,BAO_0000218,F,,CHEMBL620390
,1,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,6331,16717,,1,Aspergillus fumigatus,Expert,50416,,746128.0,,N,,,,BAO_0000218,F,,CHEMBL620391
,1,,In vitro antifungal activity against Aspergillus fumigatus 48238E,,6332,16717,,1,Aspergillus fumigatus,Expert,50416,,746128.0,,N,,,,BAO_0000218,F,,CHEMBL621073
,1,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,6333,8117,,1,Actinomyces naeslundii,Intermediate,50296,,1655.0,,N,,,,BAO_0000218,F,,CHEMBL621074
,1,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,6334,8117,,1,Actinomyces viscosus,Intermediate,50366,,1656.0,,N,,,,BAO_0000218,F,,CHEMBL621075
,1,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,6335,15472,,1,Acanthocheilonema viteae,Intermediate,50535,,6277.0,,N,,,,BAO_0000218,F,,CHEMBL619554
,1,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,6336,15472,,1,Acanthocheilonema viteae,Intermediate,50535,,6277.0,,N,,,,BAO_0000218,F,,CHEMBL619555
,1,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,6337,16443,,1,Aggregatibacter actinomycetemcomitans,Intermediate,50169,,714.0,,N,,,,BAO_0000218,F,,CHEMBL619556
,1,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,6338,16443,,1,Aggregatibacter actinomycetemcomitans,Intermediate,50169,,714.0,,N,,,,BAO_0000218,F,,CHEMBL619557
,1,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,6339,16443,,1,Aggregatibacter actinomycetemcomitans,Intermediate,50169,,714.0,,N,,,,BAO_0000218,F,,CHEMBL619558
,1,646.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,6340,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619559
,1,646.0,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,6341,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619560
,1,646.0,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,6342,16381,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619561
,1,646.0,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,6343,16381,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619562
,1,646.0,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,6344,16381,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619563
,1,646.0,GI values against A549 cells (lung cancer),,6345,16381,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL857457
,1,646.0,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,6346,17206,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619564
,1,646.0,Inhibitory activity against A549 human adenocarcinoma,,6347,16325,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619565
,1,646.0,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,6348,10708,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000218,F,,CHEMBL619566
,1,646.0,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,6349,10708,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000218,F,,CHEMBL619567
,1,646.0,Inhibitory activity against A549 lung adenocarcinoma cell line,,6350,17376,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619568
,1,646.0,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,6351,17376,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619569
,1,646.0,Cytotoxicity against human A549 lung cells,,6352,17488,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619570
,1,646.0,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,6353,17404,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000218,F,,CHEMBL619571
,1,646.0,Growth inhibition of A549 (human lung carcinoma) cell line.,,6354,10958,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619572
,1,646.0,Effective dose required for inhibitory activity against A549 human tumor cell line.,,6355,17099,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619573
,1,646.0,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,6356,17099,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619574
,1,646.0,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,6357,4096,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619575
,1,646.0,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,6358,4096,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619576
,1,646.0,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,6359,4096,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619577
,1,646.0,In vitro inhibitory activity against A549 tumor cell culture,,6360,2525,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619578
,1,646.0,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,6361,2525,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL884009
,1,646.0,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,6362,5302,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619579
,1,646.0,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,6363,16325,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619580
,1,646.0,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,6364,16939,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619581
,1,646.0,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,6365,17229,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619582
,1,646.0,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,6366,17380,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619583
,1,646.0,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,6367,17380,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL876502
,1,646.0,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,6368,1903,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619584
,1,646.0,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,6369,3838,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619585
,1,646.0,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,6370,14696,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619586
,1,646.0,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,6371,3838,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619587
,1,646.0,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,6372,1522,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619588
,1,646.0,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,6373,12400,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619589
,1,646.0,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,6374,14696,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619590
,1,646.0,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,6375,14769,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619591
,1,646.0,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,6376,14696,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619592
,1,646.0,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,6377,1888,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL619593
,1,646.0,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,6378,12016,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620217
,1,646.0,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,6379,6058,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620218
,1,646.0,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,6380,17708,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620219
,1,646.0,Antitumor activity against A549/ATCC cell line,,6381,12301,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL620220
,1,646.0,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,6382,11970,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL625141
,1,646.0,In vitro cytotoxicity against A549/ATCC cell line.,,6383,11818,,1,Homo sapiens,Expert,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL625142
,1,646.0,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,6384,12400,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL625143
,1,646.0,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,6385,3381,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL625144
,1,646.0,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,6386,17376,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL622474
,1,646.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,6387,10708,,1,Homo sapiens,Intermediate,80682,,9606.0,,N,,,A549,BAO_0000219,F,,CHEMBL884104
,0,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,6388,2964,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000219,F,,CHEMBL622475
,0,,Compound was tested for oral bioavailability in dogs,,6389,5005,,1,Canis lupus familiaris,Intermediate,22224,,9615.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL622476
,1,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,6390,6229,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875831
,1,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,6391,6229,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622477
,1,,Oral bioavailability in dog,,6392,5374,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622478
,1,,Compound was tested for the oral bioavailability in dog; No availability,,6393,5374,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623172
,1,,Oral bioavailability in dog (dose 5 mg/kg),,6394,6265,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623173
,1,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,6395,5654,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623174
,1,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,6396,5654,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623175
,1,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,6397,16456,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623340
,1,,Oral bioavailability in dog (dose 5 mg/kg),,6398,5302,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623341
,1,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,6399,3624,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623342
,1,,Oral bioavailability of active FTIs in dogs,,6400,16452,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623343
,1,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,6401,5802,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623344
,1,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,6402,3598,,1,Canis lupus familiaris,Expert,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623345
,1,,Oral bioavailability in dog,,6403,17839,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875832
,1,,Oral bioavailability in dog,,6404,6762,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623346
,1,,Oral bioavailability in dog,,6405,6821,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623347
,1,,Oral bioavailability of compound was determined in dog; Not tested,,6406,6821,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623348
,1,,Oral bioavailability in dog,,6407,5210,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623349
,1,,Oral bioavailability (10 mg/kg) was determined in dog,,6408,6227,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623350
,1,,Oral bioavailability,,6409,761,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623351
,1,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,6410,761,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623352
,1,,Oral bioavailability administered in solution in rats,,6411,761,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623353
,1,,Oral bioavailability after 30 mg/kg po dose in Dogs,,6412,16907,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875833
,1,,Oral bioavailability at a dose of 1 mg/kg in dogs,,6413,5474,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623354
,1,,Oral bioavailability in dog (dose 1 mg/kg p.o.),,6414,6535,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623355
,1,,Oral bioavailability in Dog; ND = not determined,,6415,6535,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623356
,1,,Oral bioavailability in dog,,6416,3352,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623357
,1,,Oral bioavailability in dog,,6417,6168,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623358
,1,,Oral bioavailability in dog,,6418,5988,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623359
,1,,Oral bioavailability in dog,,6419,4942,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623360
,1,,Oral bioavailability in dogs; No data,,6420,4942,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623361
,1,,Oral bioavailability measured in dogs,,6421,14541,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623362
,1,,Oral bioavailability in dog,,6422,4449,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623363
,1,,Oral bioavailability was calculated in dog,,6423,6057,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623364
,1,,Oral bioavailability after 0.3 mg/kg po administration in dog,,6424,5600,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875834
,1,,Oral bioavailability in dog (i.v. dosing),,6425,5542,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623365
,1,,Oral bioavailability in dog,,6426,5542,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623366
,1,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,6427,5546,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623367
,1,,Oral bioavailability in Beagle dogs,,6428,4514,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623368
,1,,Oral bioavailability in dog,,6429,3624,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623369
,1,,Oral bioavailability in dog,,6430,3854,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623370
,1,,Oral bioavailability in dog,,6431,5836,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623371
,1,,Oral bioavailability in dog,,6432,5940,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623372
,1,,Oral bioavailability in dog,,6433,6168,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621351
,1,,Oral bioavailability in dog,,6434,6227,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621352
,1,,Oral bioavailability in dog,,6435,6251,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621353
,1,,Oral bioavailability in dog,,6436,6448,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621354
,1,,Oral bioavailability in dog,,6437,6647,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621355
,1,,Oral bioavailability in dog,,6438,5940,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621356
,1,,Oral bioavailability in dog,,6439,933,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621357
,1,,Oral bioavailability in dog,,6440,5210,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621358
,1,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,6441,6642,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621359
,1,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,6442,6641,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621360
,1,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,6443,6642,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621361
,1,,Oral bioavailability in dog,,6444,5472,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621362
,1,,Oral bioavailability in dog,,6445,5985,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621363
,1,,Oral bioavailability in dog,,6446,15660,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621364
,1,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,6447,5530,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621166
,1,,Oral bioavailability in dog (dose 1 mg/kg i.v.),,6448,5530,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621167
,1,,Oral bioavailability (F) in dogs,,6449,6305,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621168
,1,,Oral bioavailability in dog,,6450,5210,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621169
,1,,Bioavailability in dog,,6451,5238,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875950
,1,,Oral bioavailability in dog (dose 10 mg/kg),,6452,5668,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621170
,1,,Oral bioavailability after peroral administration at 5 mpk in Dog,,6453,5668,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621171
,1,,Oral bioavailability in dog (dose 5 mg/kg),,6454,5668,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621172
,1,,Oral bioavailability in dog (dose 10 mg/kg),,6455,6084,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621173
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,,6456,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,,CCRF S-180,BAO_0000218,A,,CHEMBL621174
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,,6457,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,,CCRF S-180,BAO_0000218,A,,CHEMBL621175
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,,6458,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,,CCRF S-180,BAO_0000218,A,,CHEMBL621176
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,,6459,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,,CCRF S-180,BAO_0000218,A,,CHEMBL621177
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,,6460,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,,CCRF S-180,BAO_0000218,A,,CHEMBL621178
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,,6461,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,,CCRF S-180,BAO_0000218,A,,CHEMBL621179
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,,6462,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,,CCRF S-180,BAO_0000218,A,,CHEMBL621180
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,,6463,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,,CCRF S-180,BAO_0000218,A,,CHEMBL875951
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,,6464,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,,CCRF S-180,BAO_0000218,A,,CHEMBL621181
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,,6465,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,,CCRF S-180,BAO_0000218,A,,CHEMBL621182
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,,6466,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,,CCRF S-180,BAO_0000218,A,,CHEMBL621183
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,,6467,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,,CCRF S-180,BAO_0000218,A,,CHEMBL621184
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,6468,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL621185
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,6469,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL621186
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,6470,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL621187
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,6471,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL621188
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,6472,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL621189
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,,6473,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,,CCRF S-180,BAO_0000218,A,,CHEMBL621190
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,,6474,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,,CCRF S-180,BAO_0000218,A,,CHEMBL618520
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,,6475,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,,CCRF S-180,BAO_0000218,A,,CHEMBL621739
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,,6476,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,,CCRF S-180,BAO_0000218,A,,CHEMBL621740
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,,6477,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,,CCRF S-180,BAO_0000218,A,,CHEMBL621741
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,6478,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL621742
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,6479,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL621743
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,6480,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL621744
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,6481,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL621745
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,6482,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL621746
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,6483,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL621747
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,6484,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL621748
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,6485,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL621749
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,6486,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL621750
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,6487,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL621751
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,,6488,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,,CCRF S-180,BAO_0000218,A,,CHEMBL621752
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,,6489,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,,CCRF S-180,BAO_0000218,A,,CHEMBL621753
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,,6490,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,,CCRF S-180,BAO_0000218,A,,CHEMBL875955
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,,6491,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,,CCRF S-180,BAO_0000218,A,,CHEMBL621754
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,,6492,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,,CCRF S-180,BAO_0000218,A,,CHEMBL621755
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,,6493,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,,CCRF S-180,BAO_0000218,A,,CHEMBL621756
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,,6494,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,,CCRF S-180,BAO_0000218,A,,CHEMBL624199
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,,6495,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,,CCRF S-180,BAO_0000218,A,,CHEMBL624200
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,,6496,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,,CCRF S-180,BAO_0000218,A,,CHEMBL624375
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,,6497,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,,CCRF S-180,BAO_0000218,A,,CHEMBL624376
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,,6498,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,,CCRF S-180,BAO_0000218,A,,CHEMBL624377
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,,6499,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,,CCRF S-180,BAO_0000218,A,,CHEMBL624378
,1,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,6500,12269,,1,aeinetobacter anitrotap,Intermediate,50067,,107673.0,,N,,,,BAO_0000218,F,,CHEMBL857901
,1,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,6501,12269,,1,Acinetobacter calcoaceticus subsp. anitratus,Intermediate,50067,,107673.0,,N,,,,BAO_0000218,F,,CHEMBL875274
,1,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,6502,12269,,1,Acinetobacter calcoaceticus subsp. anitratus,Intermediate,50067,,107673.0,,N,,,,BAO_0000218,F,,CHEMBL624379
,1,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,6503,12269,,1,aeinetobacter anitrotap,Intermediate,50067,,107673.0,,N,,,,BAO_0000218,F,,CHEMBL624380
,1,,Activity against Acinetobacter calcoaceticus (AC54),,6504,10624,,1,Acinetobacter calcoaceticus,Intermediate,50192,,471.0,,N,,,,BAO_0000218,F,,CHEMBL624381
,1,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,6505,17216,,1,Anolis carolinensis,Intermediate,50714,,28377.0,,N,,,,BAO_0000218,F,,CHEMBL624382
,1,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,6506,17216,,1,Anolis carolinensis,Intermediate,50714,,28377.0,,N,,,,BAO_0000218,F,,CHEMBL624383
,1,,Chlorohexidine coefficient for Actinomyces naeslundii 631,,6507,9560,,1,Actinomyces naeslundii,Intermediate,50296,,1655.0,,N,,,,BAO_0000218,F,,CHEMBL624384
,1,,Chlorohexidine coefficient for Actinomyces naeslundii B74,,6508,9560,,1,Actinomyces naeslundii,Intermediate,50296,,1655.0,,N,,,,BAO_0000218,F,,CHEMBL624385
,1,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,6509,9560,,1,Actinomyces naeslundii,Intermediate,50296,,1655.0,,N,,,,BAO_0000218,F,,CHEMBL624386
,1,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,6510,9560,,1,Actinomyces naeslundii,Intermediate,50296,,1655.0,,N,,,,BAO_0000218,F,,CHEMBL624387
,1,,Plaque bactericidal index against Actinomyces naeslundii 631,,6511,9560,,1,Actinomyces naeslundii,Intermediate,50296,,1655.0,,N,,,,BAO_0000218,F,,CHEMBL624388
,1,,Plaque bactericidal index against Actinomyces naeslundii N/9,,6512,9560,,1,Actinomyces naeslundii,Intermediate,50296,,1655.0,,N,,,,BAO_0000218,F,,CHEMBL624389
,1,,Plaque bactericidal index against Actinomyces naeslundii B74,,6513,9560,,1,Actinomyces naeslundii,Intermediate,50296,,1655.0,,N,,,,BAO_0000218,F,,CHEMBL624390
,1,,Plaque bactericidal index against Actinomyces naeslundii N/3,,6514,9560,,1,Actinomyces naeslundii,Intermediate,50296,,1655.0,,N,,,,BAO_0000218,F,,CHEMBL875275
,1,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,6515,114,,1,Artemia salina,Intermediate,50056,,85549.0,,N,,,,BAO_0000218,F,,CHEMBL624391
,1,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,6516,114,,1,Artemia salina,Intermediate,50056,,85549.0,,N,,,,BAO_0000218,F,,CHEMBL623636
,1,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,6517,10841,,1,Ascaris suum,Intermediate,50532,,6253.0,,N,,,,BAO_0000218,F,,CHEMBL623637
,1,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,6518,10841,,1,Ascaris suum,Intermediate,50532,,6253.0,,N,,,,BAO_0000218,F,,CHEMBL623638
,1,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,6519,10841,,1,Ascaris suum,Intermediate,50532,,6253.0,,N,,,,BAO_0000218,F,,CHEMBL623639
,1,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,6520,10841,,1,Ascaris suum,Intermediate,50532,,6253.0,,N,,,,BAO_0000218,F,,CHEMBL623640
,1,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,6521,10841,,1,Ascaris suum,Intermediate,50532,,6253.0,,N,,,,BAO_0000218,F,,CHEMBL623641
,1,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,6522,10841,,1,Ascaris suum,Intermediate,50532,,6253.0,,N,,,,BAO_0000218,F,,CHEMBL623642
,1,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,6523,10841,,1,Ascaris suum,Intermediate,50532,,6253.0,,N,,,,BAO_0000218,F,,CHEMBL623643
,1,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,6524,10841,,1,Ascaris suum,Intermediate,50532,,6253.0,,N,,,,BAO_0000218,F,,CHEMBL623644
,1,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,6525,10841,,1,Ascaris suum,Intermediate,50532,,6253.0,,N,,,,BAO_0000218,F,,CHEMBL623645
,1,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,6526,10841,,1,Ascaris suum,Intermediate,50532,,6253.0,,N,,,,BAO_0000218,F,,CHEMBL623646
,1,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,6527,10841,,1,Ascaris suum,Intermediate,50532,,6253.0,,N,,,,BAO_0000218,F,,CHEMBL623647
,1,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,6528,10841,,1,Ascaris suum,Intermediate,50532,,6253.0,,N,,,,BAO_0000218,F,,CHEMBL623648
,1,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,6529,8117,,1,Actinomyces viscosus,Intermediate,50366,,1656.0,,N,,,,BAO_0000218,F,,CHEMBL623649
,1,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,6530,8117,,1,Actinomyces viscosus,Intermediate,50366,,1656.0,,N,,,,BAO_0000218,F,,CHEMBL623650
,1,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,6531,9560,,1,Actinomyces viscosus,Intermediate,50366,,1656.0,,N,,,,BAO_0000218,F,,CHEMBL623651
,1,,Chlorohexidine coefficient for Actinomyces viscosus M-100,,6532,9560,,1,Actinomyces viscosus,Expert,50366,,1656.0,,N,,,,BAO_0000218,F,,CHEMBL623652
,1,,Chlorohexidine coefficient for Actinomyces viscosus M-626,,6533,9560,,1,Actinomyces viscosus,Intermediate,50366,,1656.0,,N,,,,BAO_0000218,F,,CHEMBL623653
,1,,Chlorohexidine coefficient for Actinomyces viscosus T14V,,6534,9560,,1,Actinomyces viscosus,Intermediate,50366,,1656.0,,N,,,,BAO_0000218,F,,CHEMBL623654
,1,,Plaque bactericidal index against Actinomyces viscosus 8A06,,6535,9560,,1,Actinomyces viscosus,Intermediate,50366,,1656.0,,N,,,,BAO_0000218,F,,CHEMBL623655
,1,,Plaque bactericidal index against Actinomyces viscosus M-100,,6536,9560,,1,Actinomyces viscosus,Intermediate,50366,,1656.0,,N,,,,BAO_0000218,F,,CHEMBL623656
,1,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,6537,9560,,1,Actinomyces viscosus,Expert,50366,,1656.0,,N,,,,BAO_0000218,F,,CHEMBL623657
,1,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,6538,9560,,1,Actinomyces viscosus,Intermediate,50366,,1656.0,,N,,,,BAO_0000218,F,,CHEMBL623658
,1,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,6539,9560,,1,Actinomyces viscosus,Intermediate,50366,,1656.0,,N,,,,BAO_0000218,F,,CHEMBL623659
,1,,Plaque bactericidal index against Actinomyces viscosus 626,,6540,9560,,1,Actinomyces viscosus,Intermediate,50366,,1656.0,,N,,,,BAO_0000218,F,,CHEMBL623660
,1,,Plaque bactericidal index against Actinomyces viscosus T14V,,6541,9560,,1,Actinomyces viscosus,Intermediate,50366,,1656.0,,N,,,,BAO_0000218,F,,CHEMBL623661
,1,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,6542,10986,,1,Acanthocheilonema viteae,Intermediate,50535,,6277.0,,N,,,,BAO_0000218,F,,CHEMBL875281
,1,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,6543,10986,,1,Acanthocheilonema viteae,Intermediate,50535,,6277.0,,N,,,,BAO_0000218,F,,CHEMBL623662
,1,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,6544,10986,,1,Acanthocheilonema viteae,Intermediate,50535,,6277.0,,N,,,,BAO_0000218,F,,CHEMBL623663
,1,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,6545,10986,,1,Acanthocheilonema viteae,Intermediate,50535,,6277.0,,N,,,,BAO_0000218,F,,CHEMBL623664
,1,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,6546,10986,,1,Acanthocheilonema viteae,Intermediate,50535,,6277.0,,N,,,,BAO_0000218,F,,CHEMBL623665
,1,165.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,6547,10708,,1,Homo sapiens,Intermediate,80023,,9606.0,,N,,,A673,BAO_0000219,F,,CHEMBL621856
,1,645.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,6548,10708,,1,Homo sapiens,Intermediate,80661,,9606.0,,N,,,A704,BAO_0000219,F,,CHEMBL620432
,0,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,6549,416,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,,BAO_0000219,F,,CHEMBL620433
,1,625.0,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,6550,14354,,1,Mus musculus,Intermediate,80024,,10090.0,,N,,,A9,BAO_0000219,F,,CHEMBL620434
,1,625.0,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,6551,14354,,1,Mus musculus,Intermediate,80024,,10090.0,,N,,,A9,BAO_0000219,F,,CHEMBL620435
,1,625.0,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,6552,5116,,1,Homo sapiens,Intermediate,80024,,9606.0,,N,,,A9,BAO_0000219,F,,CHEMBL620436
,1,625.0,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,6553,5116,,1,Homo sapiens,Intermediate,80024,,9606.0,,N,,,A9,BAO_0000219,F,,CHEMBL876597
,1,874.0,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,6554,15694,,1,Homo sapiens,Expert,81037,,9606.0,,N,,,Human ovarian carcinoma cell line,BAO_0000219,F,,CHEMBL620437
,1,625.0,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,6555,13038,,1,Mus musculus,Expert,80024,,10090.0,,N,,,A9,BAO_0000219,F,,CHEMBL620438
,1,625.0,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,6556,13038,,1,Mus musculus,Expert,80024,,10090.0,,N,,,A9,BAO_0000219,F,,CHEMBL620439
,1,625.0,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,6557,10923,,1,Mus musculus,Expert,80024,,10090.0,,N,,,A9,BAO_0000219,F,,CHEMBL619657
,1,625.0,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,6558,10923,,1,Mus musculus,Intermediate,80024,,10090.0,,N,,,A9,BAO_0000219,F,,CHEMBL619658
,1,625.0,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,6559,10923,,1,Mus musculus,Intermediate,80024,,10090.0,,N,,,A9,BAO_0000219,F,,CHEMBL619659
,8,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,6560,10923,,1,,Expert,10649,,,,H,,,,BAO_0000019,F,,CHEMBL619660
,1,625.0,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,6561,10923,,1,Mus musculus,Intermediate,80024,,10090.0,,N,,,A9,BAO_0000219,F,,CHEMBL619661
,1,625.0,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,6562,10923,,1,Mus musculus,Intermediate,80024,,10090.0,,N,,,A9,BAO_0000219,F,,CHEMBL619662
,1,975.0,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,6563,8158,,1,Cricetulus griseus,Intermediate,80663,,10029.0,,N,,,AA6,BAO_0000219,F,,CHEMBL619663
,0,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,6564,15494,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000219,F,,CHEMBL619664
,0,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,6565,15494,,1,Homo sapiens,Autocuration,22226,,9606.0,,U,,,,BAO_0000219,F,,CHEMBL619665
,1,974.0,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,6566,12348,,1,Homo sapiens,Intermediate,80662,,9606.0,,N,,,AA5,BAO_0000219,F,,CHEMBL883244
,1,974.0,Cytotoxicity was measured against AA5/HIV-1(IIIB),,6567,12348,,1,Homo sapiens,Intermediate,80662,,9606.0,,N,,,AA5,BAO_0000219,F,,CHEMBL884011
,1,974.0,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,6568,2726,,1,Homo sapiens,Intermediate,80662,,9606.0,,N,,,AA5,BAO_0000219,F,,CHEMBL619666
,1,379.0,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,6569,2726,,1,Homo sapiens,Intermediate,80566,,9606.0,,N,,,U-937,BAO_0000219,F,,CHEMBL619667
,1,274.0,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,6570,10747,,1,Cricetulus griseus,Intermediate,80578,,10029.0,,N,,,UV4,BAO_0000219,F,,CHEMBL619668
,1,185.0,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,6571,11005,,1,Cricetulus griseus,Expert,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL619669
,1,185.0,Average intracellular compound concentration when the hypoxic SER=1.6,,6572,12687,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL876608
,1,185.0,Average intracellular compound concentration when the hypoxic SER=1.6.,,6573,12687,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL619670
,1,185.0,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,6574,12687,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL619671
,1,185.0,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,6575,12687,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL619672
,1,185.0,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,6576,12687,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL619673
,1,185.0,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,6577,13436,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL619674
,1,185.0,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,6578,13435,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL619675
,1,185.0,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,6579,13302,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL619676
,1,185.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,6580,12687,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL619677
,1,185.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,6581,12687,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,A,,CHEMBL619678
,1,185.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,6582,12687,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,A,,CHEMBL619679
,1,185.0,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,6583,12878,,1,Cricetulus griseus,Expert,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,A,,CHEMBL619680
,1,185.0,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,6584,12878,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,A,,CHEMBL621457
,1,185.0,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,6585,14367,,1,Cricetulus griseus,Expert,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL876609
,1,185.0,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,6586,14367,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL621458
,1,185.0,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,6587,12398,,1,hampster,Expert,80089,,36483.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL621459
,1,185.0,Aerobic growth inhibition in Chinese hamster cell line AA8,,6588,12878,,1,Cricetulus griseus,Expert,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL621460
,1,185.0,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,6589,13820,,1,Cricetulus griseus,Expert,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL621461
,1,185.0,Inhibition of growth under aerobic conditions in AA8 cells,,6590,13436,,1,Cricetulus griseus,Expert,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL621462
,1,,Oral bioavailability in dog (dose 10 mg/kg),,6591,6084,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621463
,1,,Oral bioavailability in dog at 10 mg/kg of the compound,,6592,5711,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621464
,1,,Oral bioavailability in dog (dose 5 uM/kg),,6593,4353,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621465
,1,,Oral bioavailability in dog (dose 5 uM/kg),,6594,4353,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621466
,1,,Oral bioavailability in dog (mongrel),,6595,17800,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621467
,1,,Oral bioavailability in dog (dose 10 mg/kg),,6596,3994,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621468
,1,,Oral bioavailability in dog (dose 10 mg/kg),,6597,3994,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL876734
,1,,Bioavailability in dog,,6598,5145,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618476
,1,,Bioavailability in dog (dose 1 mg/kg i.v.),,6599,16452,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618477
,1,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,6600,16452,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618478
,1,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,6601,5983,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618479
,1,,Bioavailability in dog,,6602,4273,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618480
,1,,Bioavailability in dog (dose 3-10 mg/kg),,6603,12500,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618481
,1,,The compound was tested for bioavailability of compound in plasma of dog; Complete,,6604,12500,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL618482
,1,,Oral bioavailability in dog,,6605,3639,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618483
,1,,Oral bioavailability in dog,,6606,3880,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618484
,1,,Bioavailability in dog,,6607,4838,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618485
,1,,oral bioavailability was measured in dogs,,6608,15600,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618486
,1,,Compound was tested for plasma protein binding in dog; Not determined,,6609,17248,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618487
,1,,Compound was tested for plasma protein binding of dog,,6610,17248,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618488
,1,,Compound was tested for plasma protein binding of dog; Not determined,,6611,17248,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL876735
,1,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,6612,17443,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618489
,1,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,6613,4186,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618490
,1,,Half life was determined,,6614,3749,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618491
,1,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,6615,3249,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618492
,1,,Half life was evaluated in dog,,6616,3022,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL873354
,1,,Half life was determined,,6617,3749,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618493
,1,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,6618,2517,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618494
,1,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),,6619,2517,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL618495
,1,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),,6620,2517,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL618496
,1,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),,6621,2517,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL618497
,1,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),,6622,2517,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL618498
,1,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),,6623,2517,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL618499
,1,,LogP in dog,,6624,3639,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL876736
,1,,Partition coefficient (logP),,6625,6227,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618500
,1,,Partition coefficient in dog,,6626,6227,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL857831
,1,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,6627,17764,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618501
,1,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,6628,4809,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618502
,1,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,6629,5600,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618503
,1,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,6630,14294,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618504
,1,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,6631,14294,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618505
,1,,Metabolism of compound in dog S9 microsomes; Trace,,6632,14294,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618506
,1,,In vitro metabolic potential in dog liver microsomes,,6633,6251,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL618507
,1,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,6634,3748,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876737
,1,,Oral bioavailability in dog,,6635,2713,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618508
,1,,Oral bioavailability in dog,,6636,6512,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618509
,1,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,6637,6679,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618510
,1,,The compound was tested for bioavailability in dogs,,6638,3749,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618511
,1,,The compound was tested for oral bioavailability in dogs,,6639,3749,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618512
,1,,Oral bioavailability in dog,,6640,6742,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618513
,1,,Compound was tested for percent protein binding (PB) in dog,,6641,6227,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618514
,1,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,6642,6874,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL620052
,1,,Compound was evaluated for plasma clearance.,,6643,2877,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL620053
,1,,The compound was tested for plasma clearance in dog,,6644,12500,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL620054
,1,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,,6645,12500,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL620055
,1,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,6646,4709,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL620056
,1,,In vitro relative rate of metabolism was determined in dog liver microsomes,,6647,5542,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL620057
,1,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,6648,17594,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618939
,1,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,6649,2652,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618940
,1,,Half life after intravenous administration in dogs at 1.2 uM/kg,,6650,17764,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618941
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,,6651,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,,CCRF S-180,BAO_0000218,A,,CHEMBL624473
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,,6652,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,,CCRF S-180,BAO_0000218,A,,CHEMBL624474
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,,6653,6599,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,,CCRF S-180,BAO_0000218,A,,CHEMBL624475
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,6654,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL624476
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,6655,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL623478
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,6656,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL623479
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,6657,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL623480
,1,42.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,6658,6599,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,CCRF S-180,BAO_0000218,A,,CHEMBL623481
,1,,C2 in brain of mice at the oral dose of 50 mg/kg,,6659,17641,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL623482
,1,,C2 in kidney of mice at the oral dose of 50 mg/kg,,6660,17641,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL623483
,1,,C2 in liver of mice at the oral dose of 50 mg/kg,,6661,17641,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL623484
,1,,C2 in lungs of mice at the oral dose of 50 mg/kg,,6662,17641,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL623485
,1,,C2 in spleen of mice at the oral dose of 50 mg/kg,,6663,17641,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL623486
,1,,Plasma clearance in mouse,,6664,17852,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623487
,1,,Clearance of compound after intravenous administration in mice at 24 uM/kg,,6665,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623488
,1,,Clearance from mouse blood following i.v. administration of 10 mg/kg,,6666,17837,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623489
,1,,Clearance was evaluated in mice after intravenous administration,,6667,2675,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875157
,1,,Clearance was evaluated in mice after oral administration,,6668,2675,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623490
,1,,Pharmacokinetic property (Plasma clearance) was measured in mouse,,6669,4239,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623491
,1,,Plasma clearance of compound was determined at 40 mg/Kg,,6670,17753,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623492
,1,,Plasma clearance of at 24 mg/Kg,,6671,17753,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623493
,1,,Plasma clearance at 24 mg/Kg,,6672,17753,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623494
,1,,Plasma clearance at 5 mg/Kg,,6673,17753,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623495
,1,,Plasma clearance in mice,,6674,5727,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623496
,1,,Plasma clearance value upon iv administration in mouse,,6675,2862,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623497
,1,,Total plasma clearance in mice,,6676,5980,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623498
,1,,Clearance in mouse,,6677,17592,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623499
,1,,Clearance value was determined,,6678,17718,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623500
,1,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,6679,16597,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623501
,0,,Calculated partition coefficient (clogP),,6680,17384,,1,,Intermediate,22229,,,,U,,,,BAO_0000100,P,,CHEMBL875158
,1,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,6681,6062,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623502
,1,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,6682,17734,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623503
,1,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,6683,6348,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623504
,1,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,6684,5969,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623505
,1,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,6685,5969,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623506
,1,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,6686,5969,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623507
,1,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,6687,16597,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623508
,1,,Cmax after oral administration at 30 mg/kg in ICR mouse,,6688,5781,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623509
,1,,Cmax after peroral administration in mice at 2.4 uM/kg,,6689,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875159
,1,,Cmax in brain of mice at the oral dose of 50 mg/kg,,6690,17641,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL623510
,1,,Cmax in kidney of mice at the oral dose of 50 mg/kg,,6691,17641,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL623511
,1,,Cmax in liver of mice at the oral dose of 50 mg/kg,,6692,17641,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL623512
,1,,Cmax in lungs of mice at the oral dose of 50 mg/kg,,6693,17641,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL623513
,1,,Cmax in mice at 18 uM/kg i.p. administration,,6694,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL623514
,1,,Cmax in mice at 23 uM/kg i.v. administration,,6695,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL622609
,1,,Cmax in mice at 24 uM/kg i.p. administration,,6696,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL622610
,1,,Cmax in mice at 25 uM/kg i.p. administration,,6697,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL621823
,1,,Cmax in mice at 26 uM/kg i.p. administration,,6698,17764,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL621824
,1,,Cmax in spleen of mice at the oral dose of 50 mg/kg,,6699,17641,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL621825
,1,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,6700,16597,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621826
,1,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,6701,16597,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621827
,1,,Cmax value was determined,,6702,5727,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621828
,1,,Cmax value in IRC mice,,6703,5951,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621829
,1,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,6704,5506,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621830
,1,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,6705,5506,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621831
,1,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,6706,14239,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL621832
,1,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",,6707,4890,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624579
,1,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,6708,429,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624580
,1,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,6709,10986,,1,Acanthocheilonema viteae,Intermediate,50535,,6277.0,,N,,,,BAO_0000218,F,,CHEMBL624581
,1,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,6710,10986,,1,Acanthocheilonema viteae,Intermediate,50535,,6277.0,,N,,,,BAO_0000218,F,,CHEMBL624582
,1,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,6711,10986,,1,Acanthocheilonema viteae,Intermediate,50535,,6277.0,,N,,,,BAO_0000218,F,,CHEMBL624583
,1,455.0,Inhibitory activity against human tumor cell line A0375 melanoma.,,6712,13227,,1,Homo sapiens,Intermediate,80018,,9606.0,,N,,,A-375,BAO_0000219,F,,CHEMBL624584
,9,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,6713,4481,Brain membranes,1,Rattus norvegicus,Expert,12512,,10116.0,,D,,,,BAO_0000249,B,,CHEMBL624585
,9,,Forskolin-induced cAMP production at human A1 adenosine receptor,,6714,16931,,1,Homo sapiens,Expert,114,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL875165
,8,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,6715,3850,,1,,Autocuration,114,,,,H,,,CHO,BAO_0000219,F,,CHEMBL619490
,8,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,6716,3850,,1,,Autocuration,114,,,,H,,,CHO,BAO_0000219,F,,CHEMBL619491
,8,449.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,6717,3850,,1,,Expert,114,,,,H,,,CHO,BAO_0000219,F,,CHEMBL619492
,8,449.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,6718,3850,,1,,Expert,114,,,,H,,,CHO,BAO_0000219,F,,CHEMBL619493
,8,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,6719,3850,,1,,Autocuration,114,,,,H,,,CHO,BAO_0000219,F,,CHEMBL619494
,8,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,6720,3850,,1,,Autocuration,114,,,,H,,,CHO,BAO_0000219,F,,CHEMBL619495
,8,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,6721,3850,,1,,Autocuration,114,,,,H,,,CHO,BAO_0000219,F,,CHEMBL619496
,9,449.0,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,6722,3850,,1,Homo sapiens,Expert,114,,9606.0,,D,,,CHO,BAO_0000219,F,,CHEMBL619497
,8,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,6723,3850,,1,,Autocuration,114,,,,H,,,CHO,BAO_0000219,F,,CHEMBL619498
,8,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,6724,3850,,1,,Autocuration,114,,,,H,,,CHO,BAO_0000219,F,,CHEMBL619499
,8,449.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,6725,3850,,1,,Expert,114,,,,H,,,CHO,BAO_0000219,F,,CHEMBL619500
,8,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,6726,3850,,1,,Autocuration,114,,,,H,,,CHO,BAO_0000219,F,,CHEMBL619501
,8,449.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,6727,3850,,1,,Expert,114,,,,H,,,CHO,BAO_0000219,F,,CHEMBL619502
,8,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,6728,3850,,1,,Autocuration,114,,,,H,,,CHO,BAO_0000219,F,,CHEMBL619503
,8,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,6729,3850,,1,,Autocuration,114,,,,H,,,CHO,BAO_0000219,F,,CHEMBL619504
,8,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,6730,3850,,1,,Autocuration,114,,,,H,,,CHO,BAO_0000219,F,,CHEMBL621298
,8,449.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,6731,3850,,1,,Expert,114,,,,H,,,CHO,BAO_0000219,F,,CHEMBL621299
,8,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,6732,3850,,1,,Autocuration,114,,,,H,,,CHO,BAO_0000219,F,,CHEMBL621300
,8,449.0,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,6733,3850,,1,,Autocuration,114,,,,H,,,CHO,BAO_0000219,F,,CHEMBL621301
,8,449.0,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,6734,3850,,1,,Expert,114,,,,H,,,CHO,BAO_0000219,F,,CHEMBL621302
,1,164.0,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,6735,12680,,1,Oryctolagus cuniculus,Intermediate,80013,,9986.0,,N,,,A10,BAO_0000219,F,,CHEMBL621303
,0,164.0,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,6736,1313,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,A10,BAO_0000219,F,,CHEMBL621304
,0,164.0,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,6737,1313,,1,Rattus norvegicus,Autocuration,22226,,10116.0,,U,,,A10,BAO_0000219,F,,CHEMBL621305
,1,164.0,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,6738,17567,,1,Rattus norvegicus,Intermediate,80013,,10116.0,,N,,,A10,BAO_0000219,F,,CHEMBL621306
,1,164.0,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,6739,17567,,1,Rattus norvegicus,Intermediate,80013,,10116.0,,N,,,A10,BAO_0000219,F,,CHEMBL618444
,1,164.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,6740,11819,,1,Rattus norvegicus,Intermediate,80013,,10116.0,,N,,,A10,BAO_0000219,F,,CHEMBL618445
,1,185.0,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,6741,13436,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL618446
,1,185.0,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,6742,12687,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL618447
,1,185.0,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,6743,12651,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL618448
,1,185.0,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,6744,13300,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL618449
,1,185.0,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,6745,15296,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL618637
,1,185.0,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,6746,15328,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL618638
,1,185.0,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,6747,13302,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL618639
,1,185.0,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,6748,14367,,1,Cricetulus griseus,Expert,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL618640
,1,185.0,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,6749,17002,,1,Cricetulus griseus,Expert,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL618641
,1,185.0,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,6750,13436,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL618642
,1,185.0,Inhibitory activity against aerobic growth of AA8 cells.,,6751,13435,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL618643
,1,185.0,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,6752,10503,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,A,,CHEMBL884013
,1,185.0,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,6753,10503,,1,Cricetulus griseus,Expert,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL622723
,1,185.0,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,6754,10503,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL622724
,1,185.0,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,6755,15090,,1,Cricetulus griseus,Expert,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL622725
,1,185.0,Cytotoxicity against AA8 cell line,,6756,10368,,1,Cricetulus griseus,Expert,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL622726
,1,185.0,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,6757,12651,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL622727
,1,185.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,6758,12687,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,A,,CHEMBL622728
,1,185.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,6759,12687,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL622729
,1,185.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,6760,12687,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,A,,CHEMBL622730
,1,185.0,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,6761,1890,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL622731
,1,185.0,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,6762,10747,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL622732
,1,185.0,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,6763,10747,,1,Cricetulus griseus,Intermediate,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL622733
,0,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,6764,11616,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,,BAO_0000218,F,,CHEMBL622734
,1,185.0,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,6765,11616,,1,Cricetulus griseus,Expert,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL622735
,0,185.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,6766,3471,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL618746
,0,185.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,6767,3471,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL618747
,0,185.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,6768,3471,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL620540
,0,185.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,6769,3471,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL620541
,0,185.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,6770,3471,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL620542
,0,185.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,6771,3471,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL620543
,0,185.0,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,6772,3471,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL618832
,1,185.0,Concentration required to reduce AA8 cell survival by 10%,,6773,11616,,1,Cricetulus griseus,Expert,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL618833
,0,185.0,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,6774,2656,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL618834
,0,185.0,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,6775,10518,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL618835
,0,185.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,6776,10518,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL618836
,0,185.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,6777,10518,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL618837
,0,185.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,6778,10518,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL618838
,0,185.0,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,6779,16156,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL618839
,0,185.0,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,6780,2656,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL618840
,0,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,6781,11005,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,,BAO_0000019,F,,CHEMBL618841
,0,185.0,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,6782,11942,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL618842
,0,185.0,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,6783,2128,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL618843
,1,,Half life period after 15 mg/kg iv dose in Dogs,,6784,16907,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618844
,1,,Half life period after 30 mg/kg po dose in Dogs,,6785,16907,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618845
,1,,Half life was measured after oral 2b administration (tested in 6 dogs),,6786,9579,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618846
,1,,Half life was measured in dog after oral 17b administration,,6787,9579,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618847
,1,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,6788,9579,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618848
,1,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,6789,9579,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618849
,1,,Tmax value after 15 mg/kg iv dose in Dogs,,6790,16907,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618850
,1,,Tmax value after 30 mg/kg po dose in Dogs,,6791,16907,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618851
,1,,Compound was evaluated for its half life when administered intravenously in dog,,6792,3184,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL873815
,1,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,6793,5017,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL618852
,1,,Elimination Half-life of compound was determined in dog,,6794,6821,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618853
,1,,Half life of compound in dog following oral administration,,6795,17839,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618854
,1,,Half life of compound was determined in dog,,6796,17267,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618855
,1,,Half life of compound was determined in dog blood,,6797,4727,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL618856
,1,,Half life after oral and iv dosing in dogs,,6798,5238,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875827
,1,,Half life in dogs in hours,,6799,4942,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618857
,1,,Half life on i.v. administration of 2 mg/kg was measured in dog,,6800,6505,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618858
,1,,t1/2 in dog after oral dose (1 mg/kg),,6801,5130,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618859
,1,,Half life was evaluated in dog,,6802,1475,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618860
,1,,Half life period of compound was determined after intravenous administration at 2 mg/kg,,6803,17804,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618861
,1,,Half life period of compound was determined after peroral administration at 2 mg/kg,,6804,17804,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622539
,1,,Half life period (10 mg/kg) was determined in dog,,6805,6084,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622540
,1,,Half life period (10 mg/kg) was determined in dog,,6806,6084,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL873803
,1,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,6807,5542,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL873804
,1,,Half life period by po administration in dog at a dose of 0.3 mg/kg,,6808,5542,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624311
,1,,Half life period in dog,,6809,6084,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624312
,1,,Half life period in dogs after oral administration at 1 mg/kg,,6810,6241,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624313
,1,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,6811,1916,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624314
,1,,Half-life of compound was determined in dogs,,6812,6621,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624315
,1,,Half-life in dog plasma,,6813,1696,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL624316
,1,,Half-life in mongrel dogs was determined,,6814,17800,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624317
,1,,Half-life in dog upon oral administration,,6815,17657,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624318
,1,,Half-life in dog upon oral administration; Unable to calculate,,6816,17657,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624319
,1,,Half-life was measured in dog,,6817,4239,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624496
,1,,Half-life was measured in dog,,6818,5985,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624497
,1,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,6819,9932,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624498
,1,,Oral half life was determined,,6820,5199,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624499
,1,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,,6821,5199,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624500
,1,,Plasma half life was evaluated,,6822,1475,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL624501
,1,,Plasma half life was evaluated in Dog,,6823,1475,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL623666
,1,,Plasma half life was evaluated in dog,,6824,1475,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL623667
,1,,T1/2 (Half-life) was after oral administration at 5 mg/kg,,6825,6316,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623668
,1,,Tested for the half life value in dog,,6826,4883,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL623669
,1,,Maximum time at the dose of 2 mg/kg in dog,,6827,4727,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623670
,1,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,6828,1916,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623671
,1,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,6829,1337,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL875945
,1,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,6830,1337,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL623672
,1,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,6831,6265,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623673
,1,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,6832,4809,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623674
,1,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,6833,5983,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623675
,1,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,6834,5313,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL872526
,1,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,6835,5313,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623676
,1,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,6836,17650,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623677
,1,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,6837,5199,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623678
,1,,Time taken for maximum plasma concentration in dog,,6838,933,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL623679
,1,,Time to reach Cmax after oral administration to dogs,,6839,16367,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623680
,1,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,6840,6348,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623681
,1,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,6841,6316,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623682
,1,,Tmax after peroral administration (1 mg/kg) was determined in dog,,6842,6215,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623683
,1,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,6843,3598,,1,Canis lupus familiaris,Expert,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623684
,1,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,6844,4527,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622745
,1,,Tmax after peroral administration in dogs at 2.4 uM/kg,,6845,17764,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622746
,1,,In vivo Cmax in mice at dose of 100 mg/kg,,6846,5969,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622747
,1,,In vivo Cmax in mice at dose of 50 mg/kg,,6847,5969,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622748
,1,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,6848,4573,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622749
,1,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,6849,3277,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622750
,1,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,,6850,17734,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623411
,1,,Maximum concentration obtained in mouse plasma was determined,,6851,3132,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL875946
,1,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,,6852,3132,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623412
,1,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,6853,6348,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623413
,1,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,,6854,17729,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623414
,1,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,,6855,17729,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623415
,1,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,,6856,17729,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623416
,1,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,,6857,17728,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623417
,1,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,,6858,17728,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623418
,1,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,,6859,17728,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623419
,1,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,6860,4066,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622816
,1,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,6861,6178,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623313
,1,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,6862,6178,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623314
,1,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,6863,3760,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876788
,1,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,6864,3760,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623315
,1,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,6865,3760,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623316
,1,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,6866,3760,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623317
,1,,Cmax in male mice after 2 mg/kg oral dose,,6868,5961,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623319
,1,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,6869,6137,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623320
,1,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,6870,3802,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623321
,1,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,6871,3535,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL623322
,1,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,6872,3535,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL623323
,1,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,6873,3535,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL623324
,1,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,6874,3535,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL623325
,1,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,6875,3535,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL623326
,1,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,6876,3535,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL623327
,1,,Maximum concentration in plasma upon oral administration in mouse,,6877,2862,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL623328
,1,,Maximum plasma concentration was evaluated in mice after oral administration,,6878,2675,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL623329
,1,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,,6879,2675,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623330
,1,,Dose at which the compound induced fecal excretion in mice,,6880,5399,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL876789
,1,164.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,6893,11819,,1,Rattus norvegicus,Expert,80013,,10116.0,,N,,,A10,BAO_0000219,F,,CHEMBL623333
,1,164.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,6894,11819,,1,Rattus norvegicus,Expert,80013,,10116.0,,N,,,A10,BAO_0000219,F,,CHEMBL623334
,1,164.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,6895,11819,,1,Rattus norvegicus,Expert,80013,,10116.0,,N,,,A10,BAO_0000219,F,,CHEMBL627536
,1,164.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,6896,11819,,1,Rattus norvegicus,Expert,80013,,10116.0,,N,,,A10,BAO_0000219,F,,CHEMBL627537
,1,164.0,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,6897,16361,,1,Rattus norvegicus,Intermediate,80013,,10116.0,,N,,,A10,BAO_0000219,F,,CHEMBL627538
,1,393.0,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,6898,2288,,1,Homo sapiens,Intermediate,80655,,9606.0,,N,,,A121,BAO_0000219,F,,CHEMBL884106
,1,393.0,Anticancer activity against human ovarian carcinoma A121 cells,,6899,10404,,1,Homo sapiens,Intermediate,80655,,9606.0,,N,,,A121,BAO_0000219,F,,CHEMBL625294
,1,393.0,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,6900,14790,,1,Homo sapiens,Intermediate,80655,,9606.0,,N,,,A121,BAO_0000219,F,,CHEMBL625295
,1,393.0,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,6901,14790,,1,Homo sapiens,Intermediate,80655,,9606.0,,N,,,A121,BAO_0000219,F,,CHEMBL625296
,1,393.0,Growth inhibition of human ovarian carcinoma (A121) cell line,,6902,14253,,1,Homo sapiens,Expert,80655,,9606.0,,N,,,A121,BAO_0000219,F,,CHEMBL625297
,1,393.0,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,6903,13617,,1,Homo sapiens,Expert,80655,,9606.0,,N,,,A121,BAO_0000219,F,,CHEMBL625298
,1,393.0,Cytotoxicity against human A121 ovarian cells,,6904,1003,,1,Homo sapiens,Intermediate,80655,,9606.0,,N,,,A121,BAO_0000219,F,,CHEMBL625960
,1,393.0,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,6905,830,,1,Homo sapiens,Intermediate,80655,,9606.0,,N,,,A121,BAO_0000219,F,,CHEMBL625961
,1,393.0,In vitro cytotoxicity against human ovarian carcinoma A21,,6906,12307,,1,Homo sapiens,Intermediate,80655,,9606.0,,N,,,A121,BAO_0000219,F,,CHEMBL625962
,1,393.0,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,6907,14254,,1,Homo sapiens,Intermediate,80655,,9606.0,,N,,,A121,BAO_0000219,F,,CHEMBL624717
,1,393.0,Inhibitory activity of compound against human A121 ovarian cell line.,,6908,13370,,1,Homo sapiens,Intermediate,80655,,9606.0,,N,,,A121,BAO_0000219,F,,CHEMBL624718
,1,393.0,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,6909,14790,,1,Homo sapiens,Intermediate,80655,,9606.0,,N,,,A121,BAO_0000219,F,,CHEMBL624719
,1,393.0,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,6910,3614,,1,Homo sapiens,Intermediate,80655,,9606.0,,N,,,A121,BAO_0000219,F,,CHEMBL624720
,1,622.0,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,6911,2664,,1,Homo sapiens,Intermediate,80012,,9606.0,,N,,,A 172,BAO_0000219,F,,CHEMBL624721
,1,622.0,In vitro cytotoxicity against A172 human tumor cell lines.,,6912,2037,,1,Homo sapiens,Expert,80012,,9606.0,,N,,,A 172,BAO_0000219,F,,CHEMBL624722
,1,622.0,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,6913,14539,,1,Homo sapiens,Intermediate,80012,,9606.0,,N,,,A 172,BAO_0000219,F,,CHEMBL877597
,1,622.0,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,6914,2836,,1,Homo sapiens,Intermediate,80012,,9606.0,,N,,,A 172,BAO_0000219,F,,CHEMBL624723
,1,622.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,6915,10708,,1,Homo sapiens,Intermediate,80012,,9606.0,,N,,,A 172,BAO_0000219,F,,CHEMBL624724
,4,,Association constant against A2 adenosine receptor,,6916,8975,,1,Canis lupus familiaris,Autocuration,104729,,9615.0,,H,,,,BAO_0000224,B,,CHEMBL624725
,1,1085.0,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,6917,7645,,1,fish,Intermediate,80656,,,,N,,,A2,BAO_0000219,F,,CHEMBL624726
,5,,Ratio of Ki for adenosine A2 and A1 receptor binding,,6918,11377,,1,Rattus norvegicus,Autocuration,104713,,10116.0,,D,,,,BAO_0000224,B,,CHEMBL857535
,1,623.0,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,6919,13528,,1,Homo sapiens,Expert,80014,,9606.0,,N,,,A204,BAO_0000219,F,,CHEMBL624727
,1,623.0,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,6920,10160,,1,Homo sapiens,Expert,80014,,9606.0,,N,,,A204,BAO_0000219,F,,CHEMBL624728
,1,404.0,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,6921,15144,,1,Homo sapiens,Intermediate,80015,,9606.0,,N,,,A2058,BAO_0000219,F,,CHEMBL624729
,1,973.0,Growth inhibition against Human squamous cell line(A 253),,6922,13160,,1,Homo sapiens,Intermediate,80657,,9606.0,,N,,,A253 cell line,BAO_0000219,F,,CHEMBL624730
,1,973.0,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,6923,12898,,1,Homo sapiens,Intermediate,80657,,9606.0,,N,,,A253 cell line,BAO_0000219,F,,CHEMBL624731
,1,973.0,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,6924,13069,,1,Homo sapiens,Intermediate,80657,,9606.0,,N,,,A253 cell line,BAO_0000219,F,,CHEMBL624732
,1,973.0,Growth inhibition of A253 cell lines.,,6925,15984,,1,Homo sapiens,Intermediate,80657,,9606.0,,N,,,A253 cell line,BAO_0000219,F,,CHEMBL883245
,1,973.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,6926,15564,,1,Homo sapiens,Intermediate,80657,,9606.0,,N,,,A253 cell line,BAO_0000219,F,,CHEMBL624733
,1,973.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,6927,15564,,1,Homo sapiens,Intermediate,80657,,9606.0,,N,,,A253 cell line,BAO_0000219,F,,CHEMBL624734
,1,973.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,6928,15564,,1,Homo sapiens,Intermediate,80657,,9606.0,,N,,,A253 cell line,BAO_0000219,F,,CHEMBL624735
,1,478.0,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,6929,4720,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621780
,1,478.0,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,6930,16112,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL877598
,1,478.0,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,6931,16597,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621781
,1,478.0,Cytotoxicity against human cancer cell lines A2780 (ovarian),,6932,16378,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621782
,1,478.0,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,6933,16085,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621783
,1,478.0,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,6934,16317,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621784
,1,478.0,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,6935,15748,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621785
,1,478.0,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,6936,16597,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621968
,1,478.0,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,6937,16597,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621969
,1,478.0,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,6938,16597,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621970
,1,478.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,6939,15608,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621971
,1,478.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,6940,15608,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621972
,1,478.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,6941,15608,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL884108
,0,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,6942,15296,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,,BAO_0000019,F,,CHEMBL623826
,0,185.0,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,6943,10251,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,A,,CHEMBL623827
,0,185.0,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,6944,10251,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL623828
,0,185.0,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,6945,10251,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL623829
,0,185.0,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,6946,10251,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL623830
,0,,Growth inhibition against CHO-derived cell line AA8,,6947,11858,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,,BAO_0000019,F,,CHEMBL623831
,0,185.0,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,6948,11858,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL623832
,1,185.0,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,6949,11616,,1,hampster,Expert,80089,,36483.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL623833
,1,185.0,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,6950,11616,,1,Cricetulus griseus,Expert,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL623834
,0,185.0,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,6951,10518,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL623835
,0,185.0,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,6952,11396,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL623836
,0,185.0,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,6953,10518,,1,Cricetulus griseus,Autocuration,22224,,10029.0,,U,,,CHO-AA8,BAO_0000219,F,,CHEMBL623837
,1,185.0,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,6954,11616,,1,Cricetulus griseus,Expert,80089,,10029.0,,N,,,CHO-AA8,BAO_0000219,F,,CHEMBL623838
,8,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,6955,14837,,1,,Autocuration,12675,,,,H,,,,BAO_0000019,F,,CHEMBL623839
,8,,Number of binding sites (n) of isolated serum protein AAG,,6956,14837,,1,,Autocuration,12675,,,,H,,,,BAO_0000019,F,,CHEMBL623840
,3,,Association constant for binding to AATT duplex,,6957,16037,,1,,Intermediate,22222,,,,M,,,,BAO_0000225,B,,CHEMBL623841
,1,416.0,Inhibition of ABAE human fibroblast cell proliferation,,6958,16597,,1,Homo sapiens,Expert,100090,,9606.0,,N,,,ABAE,BAO_0000219,F,,CHEMBL623842
,1,1064.0,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,6959,8831,,1,Mus musculus,Intermediate,80668,,10090.0,,N,,,AC755,BAO_0000218,F,,CHEMBL623843
,9,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,6960,13419,,1,Oryctolagus cuniculus,Expert,102444,,9986.0,,D,,,,BAO_0000218,F,,CHEMBL618669
,9,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,6961,13419,,1,Oryctolagus cuniculus,Expert,102444,,9986.0,,D,,In vivo,,BAO_0000218,F,,CHEMBL618670
,8,,Inhibitory activity against angiotensin-converting enzyme (ACE).,,6962,15778,,1,,Autocuration,69,,,,H,,,,BAO_0000357,B,,CHEMBL618671
,8,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,6963,15778,,1,,Autocuration,69,,,,H,,,,BAO_0000357,B,,CHEMBL618672
,1,978.0,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,6964,12988,,1,Homo sapiens,Intermediate,80669,,9606.0,,N,,,ACH-2 cell line,BAO_0000219,F,,CHEMBL618673
,1,978.0,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,6965,12988,,1,Homo sapiens,Intermediate,80669,,9606.0,,N,,,ACH-2 cell line,BAO_0000219,F,,CHEMBL618674
,0,998.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,6966,12988,,1,Human immunodeficiency virus 1,Autocuration,22224,,11676.0,,U,,,T cell line,BAO_0000219,F,,CHEMBL618675
,0,998.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,6967,12988,,1,Human immunodeficiency virus 1,Autocuration,22224,,11676.0,,U,,,T cell line,BAO_0000219,F,,CHEMBL618676
,0,998.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,6968,12988,,1,Human immunodeficiency virus 1,Autocuration,22224,,11676.0,,U,,,T cell line,BAO_0000219,F,,CHEMBL618677
,1,626.0,Inhibition of growth of renal cancer ACHN cell line,,6969,11843,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL618678
,1,626.0,Inhibition of growth of ACHN renal cancer cell line,,6970,16939,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL618679
,1,626.0,Inhibitory concentration required against ACHN renal cancer cell line,,6971,4782,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL618680
,1,626.0,Concentration required to inhibit growth of human renal (ACHN) cell line,,6972,6310,,1,Homo sapiens,Expert,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL618681
,1,626.0,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,6973,6310,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL618682
,1,626.0,Cytotoxic activity against ACHN Renal cancer cell line,,6974,12858,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL618683
,1,626.0,Cytotoxicity evaluation against ACHN renal cancer cells,,6975,17380,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL618684
,1,626.0,In vitro antitumor activity against human renal ACHN cell line,,6976,5858,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL618685
,1,626.0,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,6977,3838,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL876499
,1,626.0,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,6978,3838,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL618686
,1,626.0,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,6979,5406,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL618687
,1,626.0,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,6980,4071,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL618688
,1,626.0,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,6981,4071,,1,Homo sapiens,Expert,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL618689
,1,626.0,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,6982,4071,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL618690
,1,626.0,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,6983,15002,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL618691
,1,626.0,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,6984,14769,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL619373
,1,626.0,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,6985,13958,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL884008
,1,626.0,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,6986,1665,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL619374
,1,626.0,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,6987,15354,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL619375
,1,626.0,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,6988,15354,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL619376
,1,626.0,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,6989,13978,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL619377
,1,626.0,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,6990,6798,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL619378
,1,,Tmax value after administration of 4 mg/Kg oral dose in dog,,6991,2959,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL872527
,1,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,6992,9932,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL876500
,1,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,6993,5546,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL619379
,1,,Volume distribution after 15 mg/kg iv dose in Dogs,,6994,16907,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619538
,1,,Volume distribution after 30 mg/kg po dose in Dogs,,6995,16907,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619539
,1,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,6996,4257,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619540
,1,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,6997,4305,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619541
,1,,Volume of distribution was evaluated in dog,,6998,5472,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619542
,1,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,6999,6062,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619543
,1,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,7000,3598,,1,Canis lupus familiaris,Expert,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL619544
,1,,The compound was tested for volume of distribution in dog,,7001,12500,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619545
,1,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,7002,12500,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619546
,1,,Vd (1 mg/kg) was determined in dog (in vivo),,7003,6227,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619547
,1,,Vd in dog,,7004,6227,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619548
,1,,Volume distribution was determined,,7005,4219,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619549
,1,,Volume of distribution in dog,,7006,1696,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619550
,1,,Volume of distribution by as 4 fold increase by iv administration in dogs,,7007,5542,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876501
,1,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,7008,5199,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619551
,1,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,7009,6348,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619552
,1,,Volume distribution at the dose of 2 mg/kg in dog,,7010,4727,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619553
,1,,Steady state volume of distribution was determined,,7011,16367,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618722
,1,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,7012,2652,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618723
,1,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,7013,16452,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618724
,1,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,7014,16452,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618725
,1,,Bioavailability in dog (dose 1 mg/kg i.v.),,7015,16452,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618726
,1,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,7016,5334,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618727
,1,,Pharmacokinetic property (vdss) was measured in dog,,7017,4239,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624233
,1,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,7018,4709,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624234
,1,,Vdss was determined after iv 0.1 mg/kg administration in dog,,7019,5600,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624235
,1,,Volume displacement was calculated in dog,,7020,6057,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624236
,1,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,7021,5654,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624237
,1,,Volume distribution constant was determined,,7022,5505,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624238
,1,,Volume distribution at a dose of 1 uM/kg in dog was determined,,7023,4527,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624239
,1,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,7024,4521,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875829
,1,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,7025,4521,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624240
,1,,Volume distribution (Vdss) was measured in dog,,7026,15660,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624241
,1,,Volume distribution (Vdss) was measured in dog,,7027,15660,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624242
,1,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,7028,6679,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624243
,1,,Volume of distribution in steady state was determined in dog,,7029,5145,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624244
,1,,Volume of distribution of compound was determined in dog,,7030,6821,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624245
,1,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,7031,4137,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624246
,1,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,7032,5334,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624247
,1,,Volume of distribution (Vdss) was measured in dog,,7033,15660,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624248
,1,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,7034,6642,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624249
,1,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,7035,6641,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624250
,1,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,7036,6642,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624251
,1,,Maximum rate of depolarization of the upstroke of the action potential,,7037,11659,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624252
,1,,Steady state volume distribution in dog,,7038,6448,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624253
,1,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,7039,5474,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624950
,1,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,7040,1466,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624951
,1,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,7041,6535,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875830
,1,,Volume distribution in dog after administration of 1 mg/kg iv,,7042,6535,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624952
,1,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,7043,17764,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624953
,1,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,7044,6215,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624954
,1,,Vss on i.v. administration of 2 mg/kg was measured in dog,,7045,6505,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624955
,1,,Vss was determined,,7046,3639,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624956
,1,,Vss in dog,,7047,3639,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL625129
,1,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,7048,6062,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625130
,1,,Volume distribution in dogs,,7049,4942,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625131
,1,,Volume of distribution in dog,,7050,17796,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625132
,1,,Tested for the oral bioavailability in dog,,7051,4883,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL872263
,1,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,7060,17837,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624336
,1,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,7061,17729,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624337
,1,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,7062,17729,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624338
,1,,Bioavailability was measured in mouse,,7063,4239,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624339
,1,,Bioavailability in mouse,,7064,17592,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624340
,1,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,7065,6348,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624341
,1,,Bioavailability in mouse,,7066,2801,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624342
,1,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,7067,2801,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624343
,1,,Oral bioavailability in mouse,,7068,17718,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624344
,1,,Oral availability at 50 mg/kg po in male mice,,7069,5727,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624345
,1,,Oral bioavailability in mouse (dose 10 mg/kg),,7070,5302,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624346
,1,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,7071,3598,,1,Mus musculus,Expert,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624347
,1,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,7072,5961,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624348
,1,,Oral bioavailability in mouse,,7074,6091,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622754
,1,,Oral bioavailability in vivo in mice;ND=Not determined,,7075,6091,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622755
,1,,Oral bioavailability in mouse at 10 mg/kg of the compound,,7076,5711,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622756
,1,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,7077,17728,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622757
,1,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,7078,17728,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622758
,1,,Tested for bioavailability of the compound,,7079,3802,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622759
,1,,Tested for half life at the dose of 10 mg/kg when administered intravenously,,7080,3802,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622760
,1,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,7081,14029,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622761
,1,,The plasma half life of compound was determined on heparin prepared by human plasma. ,,7082,14029,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622762
,1,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,7083,14029,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622763
,1,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,7084,14029,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622764
,1,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,7085,14029,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622765
,1,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,7086,17753,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,F,,CHEMBL622766
,1,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,7087,17753,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622767
,1,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,7088,17753,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622768
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,7089,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL875948
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,7090,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622769
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,7091,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622770
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,7092,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622771
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,7093,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622772
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,7094,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622773
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,7095,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622774
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,7096,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL621725
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,7097,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL621726
,1,478.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,7098,15608,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621727
,1,478.0,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,7099,3290,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622413
,1,478.0,Compound was evaluated for cytotoxicity against A2780 cell line,,7100,2859,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622414
,1,478.0,Inhibition of A2780 cell clonogenic assay,,7101,15688,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622415
,1,478.0,Cytotoxic effect on ovarian cancer cell line (A2780),,7102,5642,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL884001
,1,478.0,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,7103,6633,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622416
,1,478.0,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,7104,3906,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622417
,1,478.0,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,7105,6788,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622590
,1,478.0,Antiproliferative activity against human A2780 cells,,7106,17582,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622591
,1,478.0,Inhibition of human A2780 cell proliferation,,7107,17764,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622592
,1,478.0,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,7108,17764,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622593
,1,478.0,Inhibition of human A2780 cell proliferation (No data),,7109,17764,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622594
,1,478.0,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,7110,2815,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622595
,1,478.0,Compound was evaluated against human Ovarian carcinoma cell line A2780,,7111,16930,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622596
,1,478.0,Growth inhibition against A2780 wild-type ovarian cell lines,,7112,17777,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622597
,1,478.0,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,7113,17777,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622598
,5,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,7114,16936,,1,Homo sapiens,Autocuration,104766,,9606.0,,D,,,,BAO_0000019,F,,CHEMBL622599
,1,478.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,7115,13759,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622600
,1,478.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,7116,13759,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622601
,1,478.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,7117,13759,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622602
,1,478.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,7118,13759,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622603
,1,478.0,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,7119,15292,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622604
,1,478.0,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,7120,15292,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622605
,1,478.0,In vitro inhibition of human ovarian cell line A2780,,7121,15069,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622606
,1,478.0,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,7122,15069,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619463
,1,478.0,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,7123,14073,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619464
,1,478.0,Concentration required to inhibit A2780-cell growth by 50%,,7124,14553,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619465
,1,478.0,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,7125,13040,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619466
,1,478.0,Cytotoxic effect on human ovarian (A2780) cancer cell line,,7126,6891,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619467
,1,478.0,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,7127,15569,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619468
,1,478.0,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,7128,14190,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619469
,1,478.0,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,7129,15014,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619470
,1,478.0,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,7130,15014,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619471
,1,478.0,Cytotoxicity against human ovarian carcinoma A2780 cell line,,7131,17496,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619472
,1,478.0,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,7132,13617,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL619473
,1,478.0,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,7133,13617,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL874368
,1,478.0,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,7134,13617,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL884003
,1,478.0,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,7135,13617,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622690
,1,478.0,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,7136,17672,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622691
,1,478.0,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,7137,4544,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL622692
,1,478.0,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,7138,4544,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL623406
,1,478.0,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,7139,16317,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL884004
,1,478.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,7140,15099,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL623407
,1,478.0,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,7141,13978,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL623408
,1,478.0,In vitro antitumor activity against A2780 cell line.,,7142,12989,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL623409
,1,478.0,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,7143,5574,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL623410
,1,478.0,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,7144,13528,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL623576
,1,626.0,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,7145,12782,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL623577
,1,626.0,The IC50 value was measured on ACHN cell line in renal tumor type.,,7146,14255,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL623578
,1,626.0,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,7147,16364,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL623579
,1,626.0,In vitro lethal concentration against most sensitive ACHN cell line,,7148,17376,,1,Homo sapiens,Expert,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL623580
,1,626.0,Tested for cytotoxic activity against renal cancer ACHN cell line,,7149,12016,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL623581
,1,626.0,Compound tested for growth inhibition of renal cancer cell line ACHN,,7150,6058,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL857456
,1,626.0,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,7151,17708,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL623582
,1,626.0,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,7152,15176,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL623583
,1,626.0,In vitro anticancer activity against ACHN renal cancer cell line,,7153,2806,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL623584
,1,626.0,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,7154,15300,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL623585
,1,626.0,Percent selectivity was evaluated in renal ACHN cell lines,,7155,16364,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL623586
,1,626.0,In vitro inhibitory activity against renal ACHN cancer cell line,,7156,13859,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL623587
,1,626.0,Tested for cytotoxicity against ACHN cell lines in renal cancer,,7157,11970,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL875279
,1,626.0,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,7158,2450,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL623588
,1,626.0,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,7159,12696,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL623589
,1,626.0,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,7160,12400,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL623590
,1,626.0,Cytotoxic effect on renal cancer line ACHN,,7161,12888,,1,Homo sapiens,Expert,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL623591
,1,626.0,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,7162,3156,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL623592
,1,626.0,In vitro inhibition of Renal Cancer ACHN cell lines,,7163,3381,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL623593
,1,626.0,Antitumor activity against human renal adenocarcinoma ACHN cells,,7164,16747,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL623594
,1,626.0,Antitumor activity against human renal adenocarcinoma ACHN cells.,,7165,16748,,1,Homo sapiens,Expert,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL621833
,1,626.0,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,7166,12062,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL621834
,1,626.0,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,7167,14769,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL621835
,1,626.0,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,7168,15895,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL621836
,1,626.0,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,7169,17376,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL621837
,1,626.0,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,7170,14882,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL875280
,1,626.0,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,7171,14882,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL621838
,1,626.0,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,7172,15661,,1,Homo sapiens,Intermediate,80025,,9606.0,,N,,,ACHN,BAO_0000219,F,,CHEMBL621839
,0,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,7173,9680,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL621840
,8,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,7174,14579,,1,,Autocuration,10647,,,,H,,,,BAO_0000019,F,,CHEMBL621841
,1,468.0,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,7175,17290,,1,Cytomegalovirus,Expert,50529,,10358.0,,N,,,HEL,BAO_0000218,F,,CHEMBL622979
,1,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,7176,17290,,1,Cytomegalovirus,Intermediate,50529,,10358.0,,N,,,,BAO_0000218,F,,CHEMBL876595
,8,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,7177,15891,,1,,Autocuration,12159,,,,H,,,,BAO_0000357,B,,CHEMBL620221
,8,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,7178,15890,,1,,Autocuration,12159,,,,H,,,,BAO_0000357,B,,CHEMBL620222
,1,979.0,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,7179,3801,,1,Bos taurus,Intermediate,80670,,9913.0,,N,,,ADDP cell line,BAO_0000219,F,,CHEMBL620506
,1,980.0,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,7180,9222,,1,Mus musculus,Intermediate,80671,,10090.0,,N,,,ADJ/PC6,BAO_0000219,F,,CHEMBL620507
,1,980.0,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,7181,9222,,1,Mus musculus,Intermediate,80671,,10090.0,,N,,,ADJ/PC6,BAO_0000219,F,,CHEMBL620508
,1,980.0,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,7182,7257,,1,Mus musculus,Intermediate,80671,,10090.0,,N,,,ADJ/PC6,BAO_0000219,F,,CHEMBL620509
,1,980.0,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,7183,7257,,1,Mus musculus,Intermediate,80671,,10090.0,,N,,,ADJ/PC6,BAO_0000219,F,,CHEMBL620510
,1,980.0,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,7184,7257,,1,Mus musculus,Intermediate,80671,,10090.0,,N,,,ADJ/PC6,BAO_0000219,A,,CHEMBL620511
,1,980.0,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,7185,8084,,1,Mus musculus,Intermediate,80671,,10090.0,,N,,,ADJ/PC6,BAO_0000219,F,,CHEMBL620512
,0,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,7186,14943,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,,,BAO_0000019,F,,CHEMBL620513
,0,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,7187,14943,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,,,BAO_0000019,F,,CHEMBL620514
,0,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,7188,14943,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,,,BAO_0000019,F,,CHEMBL620515
,0,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,7189,10524,,1,Bacillus subtilis,Autocuration,22224,,1423.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620516
,1,,AUC value in dog after IV administration at a dose of 5 mg/kg,,7190,3546,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL620517
,1,,AUC value in dog after oral administration at a dose of 5 mg/kg,,7191,3546,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL620518
,1,,Cmax value in dog after oral administration at a dose of 5 mg/kg,,7192,3546,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620519
,1,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,7193,3546,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621386
,1,,Tmax value in dog after oral administration at a dose of 5 mg/kg,,7194,3546,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621387
,1,,Compound was evaluated for its clearance when administered intravenously in dog,,7195,3184,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621388
,1,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,7196,16456,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621389
,1,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,7197,4809,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621390
,0,,Calculated partition coefficient (clogP),,7198,4219,,1,,Intermediate,22229,,,,U,,,,BAO_0000100,P,,CHEMBL621391
,1,,Half life in dog,,7199,3748,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621392
,1,,Time taken for EC90 was determined when tested in dog,,7200,3132,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621393
,1,,Half life (iv) was determined,,7201,4219,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621394
,1,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,7202,16907,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL621395
,1,,Area under the curve was calculated in dog after iv administration,,7203,6057,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621396
,1,,Area under the curve was calculated in dog after peroral administration,,7204,6057,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621397
,1,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,7205,17853,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621398
,1,,pKa was evaluated in dog,,7206,3639,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618818
,1,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,7207,14541,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618819
,1,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,7208,16456,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618820
,1,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,7209,16456,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL873810
,1,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,7210,2652,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876606
,1,,Compound was evaluated for the half-life (t 1/2) in hours,,7211,3624,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618821
,1,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,7212,1337,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL618822
,1,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,7213,1337,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL618823
,1,,Half life after intravenous administration of 1 mg/kg in dog,,7214,4709,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618824
,1,,Half life was measured in dog,,7215,15660,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618825
,1,,Half life period in dog after 5 mg/kg dose,,7216,5302,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618826
,1,,Half life period was evaluated in dog; 4-4.8,,7217,17791,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618827
,1,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,7218,6348,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618828
,1,,Half-life was determined in dog after a3 mg/kg of iv dose,,7219,4257,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618829
,1,,Half-life was determined,,7220,3771,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618830
,1,,Half life in dogs,,7221,6305,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618831
,1,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,,7222,13501,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL619489
,1,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,7223,17594,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619649
,1,,Compound was evaluated for the half life period after iv administration in Beagle dog.,,7224,3045,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876607
,1,,Compound was evaluated for the half life period after oral administration in conscious dog.,,7225,3043,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619650
,1,,Compound was tested for half life in dog,,7226,4839,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL619651
,1,,Compound was tested for its half life in dog,,7227,4839,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL619652
,1,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,7228,5802,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619653
,1,,Half life of compound in dog was determined,,7229,17839,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL619654
,1,,Half life (iv) was determined,,7230,4219,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619655
,1,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,7231,13966,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL619656
,1,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,7232,3994,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL873812
,1,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,7233,3994,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,F,,CHEMBL621365
,1,,Half life in dog,,7234,4453,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621366
,1,,Half life in dog plasma,,7235,6535,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL621367
,1,,Half life in dog plasma after administration of 0.25 mg/kg iv,,7236,6535,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL621368
,1,,Half life in dog plasma after administration of 1 mg/kg iv,,7237,6535,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL621369
,1,,Half life in dog plasma was determined at dose 10 mg/kg,,7238,3132,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL621370
,1,,Half life in dog was determined,,7239,5374,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621371
,1,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,7240,5007,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621372
,1,,Half life upon exposure to human plasma,,7241,16907,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL621373
,1,,Half life was calculated in dog,,7242,6057,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621374
,1,,Half life was determined,,7243,5006,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621375
,1,,Half life was determined,,7244,5473,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621376
,1,,Half life by intravenous administration of 1.2 mg/kg in dog,,7245,4368,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619624
,1,,Half life in dog,,7246,6448,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL875840
,1,,Half life in dog after intra venous administration of the compound,,7247,4353,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL619625
,1,,Half life in dog after intra venous administration of the compound; ND means Not determined,,7248,4353,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL619626
,1,,Half life in dog after po administration of the compound,,7249,4353,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619627
,1,,Half life in dog after po administration of the compound; ND means Not determined,,7250,4353,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL873817
,1,,Half life in dog at the single oral dose of 1 mg/kg,,7251,6265,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619628
,1,,Half life in dogs,,7252,5006,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL619629
,1,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,7253,5356,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619630
,1,,Half life in rat,,7254,405,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL619631
,1,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,7255,6642,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619632
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,7256,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL619633
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,7257,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL875841
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,7258,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL619634
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,7259,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL619635
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,7260,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL619636
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,7261,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Gut,N,10000004.0,In vivo,,BAO_0000218,A,,CHEMBL619637
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,7262,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Gut,N,10000004.0,In vivo,,BAO_0000218,A,,CHEMBL619638
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,7263,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Gut,N,10000004.0,In vivo,,BAO_0000218,A,,CHEMBL619639
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,7264,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Gut,N,10000004.0,In vivo,,BAO_0000218,A,,CHEMBL619640
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,7265,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Gut,N,10000004.0,In vivo,,BAO_0000218,A,,CHEMBL619641
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,7266,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Gut,N,10000004.0,In vivo,,BAO_0000218,A,,CHEMBL619642
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,7267,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Gut,N,10000004.0,In vivo,,BAO_0000218,A,,CHEMBL619643
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,7268,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL619644
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,7269,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621112
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,7270,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621113
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,7271,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621114
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,7272,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621115
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,7273,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621116
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,7274,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621117
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,7275,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621118
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,7276,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621119
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,7277,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621120
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,7278,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621757
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,7279,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621758
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,7280,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621759
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,7281,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621760
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,7282,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL621761
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,7283,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL621762
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,7284,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL621763
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,7285,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL624502
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,7286,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL624503
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,7287,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL624504
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,7288,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL624505
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,7289,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL624506
,1,478.0,In vitro cytotoxicity against A2780 (human ovarian cancer),,7290,5895,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL624507
,1,478.0,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,7291,6338,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL624508
,1,478.0,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,7292,15163,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL624509
,1,478.0,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,7293,15163,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL624510
,1,478.0,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,7294,15000,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL875956
,1,478.0,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,7295,15000,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL839885
,1,478.0,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,7296,14729,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL624511
,1,478.0,In vitro cytotoxicity against A2780 cell line,,7297,17270,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL624512
,1,478.0,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,7298,5685,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL624513
,1,478.0,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,7299,3563,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL624514
,1,478.0,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,7300,17753,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000218,F,,CHEMBL618547
,1,478.0,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,7301,16317,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618548
,1,478.0,Inhibition of tubulin polymerization in analogy of ca.,,7302,16936,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618549
,1,478.0,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,7303,3801,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618550
,1,478.0,Cytotoxic effect in ovarian cancer cell line (A2780),,7304,6181,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618551
,1,478.0,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,7305,5318,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618552
,1,478.0,Tested for the cytotoxicity in A2780 ovarian cell line,,7306,4840,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618553
,1,478.0,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,7307,15748,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618554
,1,478.0,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,7308,15748,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618555
,1,481.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,7309,15748,,1,,Intermediate,80017,,,,N,,,A2780cisR,BAO_0000219,F,,CHEMBL618556
,1,481.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,7310,15748,,1,,Intermediate,80017,,,,N,,,A2780cisR,BAO_0000219,F,,CHEMBL618557
,1,481.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,7311,15748,,1,,Intermediate,80017,,,,N,,,A2780cisR,BAO_0000219,F,,CHEMBL618558
,1,481.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,7312,15748,,1,,Intermediate,80017,,,,N,,,A2780cisR,BAO_0000219,F,,CHEMBL618559
,1,478.0,In vivo log of cells killed after administration of compound in A2780 cell line,,7313,17753,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000218,F,,CHEMBL618560
,1,478.0,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,,7314,17753,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,In vivo,A2780,BAO_0000218,F,,CHEMBL618561
,1,478.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,7315,16936,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618562
,1,478.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,7316,16936,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618563
,1,478.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,7317,16936,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618564
,1,478.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,7318,16936,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618565
,1,478.0,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,7319,17528,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000218,F,,CHEMBL618566
,1,478.0,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,7320,6633,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618567
,1,478.0,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,7321,15000,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618568
,1,478.0,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,7322,17528,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL618569
,1,478.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,7323,16936,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621857
,1,478.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,7324,16936,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621858
,1,478.0,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,7325,16936,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621859
,1,478.0,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,7326,16936,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621860
,1,478.0,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,7327,16936,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621861
,1,478.0,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,7328,16936,,1,Homo sapiens,Expert,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621862
,1,478.0,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,7329,16936,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621863
,1,478.0,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,7330,16936,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621864
,1,478.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,7331,16936,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621865
,1,478.0,In vitro antiproliferative activity against A2780 cell line,,7332,17737,,1,Mus musculus,Intermediate,81034,,10090.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621866
,1,478.0,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,7333,17764,,1,Mus musculus,Expert,81034,,10090.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621867
,1,478.0,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,7334,3830,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL621868
,1,478.0,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,7335,3829,,1,Homo sapiens,Intermediate,81034,,9606.0,,N,,,A2780,BAO_0000219,F,,CHEMBL875282
,1,,Vc value in dog after IV administration at a dose of 5 mg/kg,,7336,3546,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621869
,1,,Half life period in dog after IV administration at a dose of 5 mg/kg,,7337,3546,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621870
,0,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,7338,5668,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL621871
,0,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,7339,3443,,1,Cercopithecidae,Autocuration,22224,,9527.0,Plasma,U,1969.0,,,BAO_0000218,A,,CHEMBL621243
,0,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,7340,3443,,1,Cercopithecidae,Autocuration,22224,,9527.0,Plasma,U,1969.0,,,BAO_0000218,A,,CHEMBL621244
,0,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,7341,4256,,1,Macaca fascicularis,Autocuration,22224,,9541.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621245
,0,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,7342,4256,,1,Macaca fascicularis,Autocuration,22224,,9541.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621246
,0,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,7343,4256,,1,Macaca fascicularis,Autocuration,22224,,9541.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621247
,0,,Oral Bioavailability in rat,,7344,4256,,1,Rattus norvegicus,Autocuration,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618386
,0,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,7345,1916,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL618387
,0,,Area under curve value in monkey at a dose of 5 mg/kg,,7346,5302,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL618388
,0,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,7347,4257,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL618389
,0,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,7348,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL618574
,0,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,7349,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL618575
,0,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,7350,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL618576
,0,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,7351,6078,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL618577
,0,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,7352,6078,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL876487
,0,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,7353,6062,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL618578
,0,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,7354,2661,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL618579
,0,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,7355,2661,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL618580
,0,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,7356,5394,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL618581
,0,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,7357,4397,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL618582
,0,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,7358,17509,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL618583
,0,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,7359,17509,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL618584
,0,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,7360,6641,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618585
,0,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,7361,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000218,A,,CHEMBL618586
,0,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,7362,3443,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618587
,0,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,7363,3443,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618588
,0,,Binding towards monkey plasma protein at 10 uM,,7364,17409,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL618589
,0,,Binding towards monkey plasma protein at 100 uM,,7365,17409,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL618590
,0,,Apparent bioavailability in squirrel monkey was determined,,7366,1052,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL872262
,0,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,7367,13501,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618591
,0,,Bioavailability in monkey (dose 2 mg/kg),,7368,17509,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618592
,0,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,7369,5394,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL876488
,0,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,7370,2661,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618593
,0,,Bioavailability in monkey (i.d. dosing),,7371,11219,,1,monkey,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618594
,0,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,7372,3045,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL618595
,0,,Clearance of the drug was measured in cynomolgus,,7373,17796,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,,,BAO_0000019,A,,CHEMBL621469
,0,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,7374,1399,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621470
,0,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,7375,2661,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621471
,0,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,7376,5005,,1,Macaca mulatta,Autocuration,22224,,9544.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL621472
,0,,Plasma clearance in rhesus monkey was determined,,7377,17267,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621473
,0,,Plasma clearance in monkey after administration of 1 mg/kg iv,,7378,6535,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621474
,0,,Plasma clearance in cynomolgus monkey,,7379,5922,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621475
,0,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,7380,6221,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621476
,0,,Plasma clearance after peroral administration at 10 mpk in Rhesus,,7381,5668,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624290
,0,,The total clearance was determined after intravenous administration in cynomolgus monkeys,,7382,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624291
,0,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,7383,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624292
,0,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,7384,5355,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624293
,0,,Tested for Clearance upon iv administration to african green monkey,,7385,4578,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624294
,0,,Clearance in monkey,,7386,17592,,1,Cercopithecidae,Autocuration,22224,,9527.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624295
,1,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,7387,6641,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624296
,1,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,7388,6642,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624297
,1,,Half life was evaluated after intravenous administration to dogs,,7389,16367,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624298
,1,,Half life was evaluated in dog,,7390,5472,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624299
,1,,Half life was evaluated in dog,,7391,5474,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624300
,1,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,7392,5654,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624301
,1,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,7393,6227,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624302
,1,,Half life period after intravenous administration in dog,,7394,6227,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876026
,1,,Half life period after oral administration (2.5 mg/kg) in dog was determined,,7395,6221,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624303
,1,,Half life period at a dose of 1 uM/kg in dog was determined,,7396,4527,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624304
,1,,Half life period was determine after peroral administration at 10 mpk in dog,,7397,5668,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624305
,1,,Half life period was determine after peroral administration at 5 mpk in dog,,7398,5668,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624306
,1,,Half life period was determined,,7399,3854,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624307
,1,,Half life period was determined,,7400,5505,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624308
,1,,Half life period by iv administration in dog at a dose of 6 mg/kg,,7401,6251,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624309
,1,,Half life period was evaluated in dog,,7402,1918,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624310
,1,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,7403,5546,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625003
,1,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,7404,4809,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625004
,1,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,7405,6215,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625005
,1,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,7406,4527,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL873813
,1,,Half-life after oral dose of compound at 3 mg/kg in dogs,,7407,17594,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625006
,1,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,7408,17839,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625007
,1,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,7409,17839,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876027
,1,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,7410,17839,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625008
,1,,Half-life of compound in dog following p.o. administration of 1 mg/kg,,7411,17839,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625009
,1,,Half-life of compound in plasma of dog was determined,,7412,5210,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL625010
,1,,Half-life of compound was determined in dogs,,7413,5210,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL625011
,1,,Half-life after administration of 4 mg/Kg oral dose in dog,,7414,2959,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621553
,1,,Half-life after intravenous administration of 1 mg/kg/h in dog,,7415,4137,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621554
,1,,Half-life in Dog,,7416,5064,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621555
,1,,Half-life in Dog,,7417,5147,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621556
,1,,Half-life in dog,,7418,5145,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621557
,1,,Half-life in dog after oral administration at 1 mg/kg,,7419,6123,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621558
,1,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,7420,6123,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621559
,1,,Half-life in dogs,,7421,4333,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621560
,1,,Half-life in dogs; ND indicates not determined,,7422,4333,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL876028
,1,,Half-life in plasma of dog,,7423,12500,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL621561
,1,,Half-life in plasma of dog at dose of 3-10 mgkg,,7424,12500,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL621562
,1,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,7425,6005,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621563
,1,,Half-life was measured in dog after an iv dose of 1 mg/kg,,7426,6062,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621564
,1,,Half-life was measured in dogs after an oral dose of 10 uM/kg,,7427,17650,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621565
,1,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,7428,5530,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621566
,1,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,7429,5530,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621567
,1,,Half-life of the compound after 0.3 mg/kg po administration in dog,,7430,5600,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622978
,1,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,7431,6039,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL873814
,1,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,7432,6039,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623219
,1,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,7433,6039,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624477
,1,,t1/2 in dog,,7434,6227,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624478
,1,,Half-life period measured in dogs,,7435,14541,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624479
,1,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,7436,4521,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624480
,1,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,7437,4521,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623595
,1,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,7438,6679,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623596
,1,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",,7439,1116,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vitro,,BAO_0000218,A,,CHEMBL623597
,1,,In vivo half life period was calculated at 1 mg/kg in dog,,7440,5444,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623598
,1,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,7441,5444,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623599
,1,,Longer half-life in dog (i.v.) at 0.5 mpk,,7442,17853,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623600
,1,,Oral bioavailability in dog (dose 5 uM/kg),,7443,4353,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623601
,1,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,7444,16452,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623602
,1,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,7445,16452,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623603
,1,,Bioavailability in dog (dose 1 mg/kg i.v.),,7446,16452,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623604
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,7447,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL623605
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,7448,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL623606
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,7449,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL623607
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,7450,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL623608
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,7451,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL623609
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,7452,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL623610
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,7453,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL623611
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,7454,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL623612
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,7455,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL623613
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,7456,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL623614
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,7457,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL623615
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,7458,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL623616
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,7459,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL623617
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,7460,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL875944
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,7461,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL623618
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,7462,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL623619
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,7463,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL623620
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,7464,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL623621
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,7465,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL623622
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,7466,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL623623
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,7467,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL623624
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,7468,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL618521
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,7469,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL618522
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,7470,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL618523
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,7471,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL618524
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,7472,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL618525
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,7473,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL624586
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,7474,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL624587
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,7475,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL624588
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,7476,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL624589
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,7477,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL624590
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,7478,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL624591
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,7479,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL624592
,1,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,7480,10107,,1,Mus musculus,Intermediate,50594,,10090.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL624593
,1,,Oral bioavailability in rat,,7481,4689,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624594
,1,,Tested for the bioavailability in rat,,7482,4950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624595
,1,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,7483,5328,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624596
,1,,Bioavailability in rat,,7484,406,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624597
,1,,Bioavailability in rat,,7485,12500,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624598
,1,,Bioavailability in rat (dose 3-10 mg/kg),,7486,12500,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624599
,1,,Bioavailability in rat,,7487,5247,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875166
,1,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,7488,4186,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624600
,1,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,7489,4186,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624601
,1,,Half life after oral administration was determined in rats at 6 mg/kg,,7490,6647,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624602
,1,,Half life was determined,,7491,6484,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624603
,1,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,7492,3249,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624604
,1,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,,7493,6281,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624605
,1,,Half life in rats,,7494,3307,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624606
,1,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,,7495,12058,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL624607
,1,,Hill coefficient of the compound,,7496,8833,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624608
,1,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,7497,3193,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624609
,1,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,7498,3193,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624610
,1,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,7499,3193,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624611
,1,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,7500,3193,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624612
,1,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,7501,3193,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL875167
,1,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,7502,3193,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624613
,1,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,7503,3193,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624614
,1,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,7504,5960,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624392
,1,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,,7505,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL624393
,1,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,,7506,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL624394
,1,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,,7507,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL624395
,1,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,,7508,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL624396
,1,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,,7509,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL624397
,1,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,,7510,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,In vivo,,BAO_0000218,A,,CHEMBL624398
,1,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,,7511,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,In vivo,,BAO_0000218,A,,CHEMBL624399
,1,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,,7512,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,In vivo,,BAO_0000218,A,,CHEMBL624400
,1,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,,7513,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,In vivo,,BAO_0000218,A,,CHEMBL624401
,1,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,,7514,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,In vivo,,BAO_0000218,A,,CHEMBL624402
,1,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,7515,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL624403
,1,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,,7516,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL624404
,1,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,,7517,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL624405
,1,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,7518,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL624406
,1,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,,7519,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL624407
,1,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,,7520,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL624408
,1,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,7521,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL618644
,1,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,,7522,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL618645
,1,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,,7523,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL618646
,1,,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,7524,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL618647
,1,,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,,7525,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL618648
,1,,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,,7526,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL618649
,1,,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,7527,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL618650
,1,,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,,7528,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL618651
,1,,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,,7529,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL876497
,1,,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,7530,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL618652
,1,,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,,7531,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL618653
,1,,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,,7532,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL618654
,1,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,,7533,6351,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618655
,1,,Compound was tested for solubility in water,,7534,1465,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618656
,0,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),,7535,5182,,1,,Intermediate,22229,,,,U,,,,BAO_0000100,P,,CHEMBL618657
,1,,Solubility was determined,,7536,17847,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618658
,1,,solubility in water (ug/mL) at 37 degree C.,,7537,15339,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618659
,1,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,,7538,5202,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618660
,1,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,,7539,1088,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618661
,1,,Half life in rats,,7540,3169,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL873807
,1,,Half life in Dawley rat,,7541,5353,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618662
,1,,Half life period after 3 mg/kg iv administration,,7542,2864,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618663
,1,,Half life period after 3 mg/kg iv administration in rat,,7543,2864,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618664
,1,,Half life period after 3 mg/kg iv administration in the rat,,7544,2864,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618665
,1,,Half life period in female Sprague-Dawley rats,,7545,6362,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL876498
,1,,Half life period in rat,,7546,6249,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618666
,1,,Half-life in rats was determined,,7547,3169,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL620440
,1,,Half-life in rats with metabolic oxidation,,7548,3169,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL620441
,1,,Half-life in rats,,7549,3169,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL620442
,1,,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,7550,17260,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620443
,1,,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,7551,17260,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620444
,1,,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,7552,17260,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620445
,1,,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,7553,17260,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620446
,1,,Biological half-life measured in plasma of rat,,7554,2879,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL620447
,1,,Biological half-life measured in plasma of rat; 22-25,,7555,2879,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL621129
,1,,Biological half-life measured in plasma of rat; 9-16,,7556,2879,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL621130
,1,,Compound was evaluated for its half life when administered intravenously in rat,,7557,3184,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL873808
,1,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,,7558,4891,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876598
,1,,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,,7559,429,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621131
,1,,Half life (T1/2) after oral administration in rat,,7560,5656,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621132
,1,,Half life of compound after iv administration of 20 mg/kg dose in rat,,7561,4413,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621133
,1,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,7562,3598,,1,Rattus norvegicus,Expert,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621312
,1,,Half life of compound was determined in rat,,7563,17267,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621313
,1,,Half life of compound was determined in rat blood,,7564,4727,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL621314
,1,,Half life at 1 mg/kg was determined in rat,,7565,17651,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621315
,1,,Half life at 10 mg/kg was determined in rat,,7566,17651,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621316
,1,,Half life in rats,,7567,401,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621317
,1,,Half life in rats in hours,,7568,4942,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621318
,1,,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,7569,17735,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621319
,1,,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,,7570,6056,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621377
,1,,Half life was determined,,7571,5213,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621378
,1,,Half life after i.v. administration,,7572,6616,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876599
,1,,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,,7573,5937,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621379
,1,,Half life in rat plasma,,7574,5819,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL621380
,1,,Half life in rat plasma; Not detected,,7575,5819,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL621381
,1,,Half life in rats,,7576,6803,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618515
,1,,Half life period of compound was determined after peroral administration,,7577,17804,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618516
,1,,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,,7578,17804,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618517
,1,,Half life period in rat,,7579,5948,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618518
,1,,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,7580,1916,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618519
,1,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,7581,1916,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618698
,1,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,,7582,1916,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618862
,1,,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,7583,4890,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618863
,1,,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,,7584,17764,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618864
,1,,Half life time in rat the dose of 2 mg/kg,,7585,4727,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618865
,1,,Half-life 24 hr after 10 mg/kg iv administration in rats,,7586,17509,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618866
,1,,Half-life 24 hr after 2 mg/kg iv administration in rats,,7587,17509,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618867
,1,,Half-life consistent with the observed metabolic steady state in rats,,7588,6597,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL875828
,1,,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,7589,17735,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618868
,1,,Half-life for oxidative metabolic stability was determined using male human,,7590,6597,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618869
,1,,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",,7591,17670,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618870
,1,,Half-life in rat plasma,,7592,1696,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL618871
,1,,Half-life in rat plasma was determined,,7593,1742,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL618872
,1,,Half-life in rats was determined,,7594,17800,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL873816
,0,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,,7595,12923,,1,,Autocuration,22224,,,,U,,,,BAO_0000218,A,,CHEMBL618873
,0,,Area under curve after oral dose of 0.1 mg//kg,,7596,11954,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL621602
,0,,Area under curve after oral dose of 0.3 mg/kg,,7597,11954,,1,,Autocuration,22224,,,,U,,,,BAO_0000218,A,,CHEMBL621603
,0,,Area under curve after oral dose of 1 mg/kg,,7598,11954,,1,,Autocuration,22224,,,,U,,,,BAO_0000218,A,,CHEMBL621604
,0,,Area under curve after oral dose of 10 mg/kg,,7599,11954,,1,,Autocuration,22224,,,,U,,,,BAO_0000218,A,,CHEMBL621605
,0,,Area under curve after oral dose of 23.4 mg/kg,,7600,11954,,1,,Autocuration,22224,,,,U,,,,BAO_0000218,A,,CHEMBL621606
,0,,Area under curve after oral dose of 3 mg/kg,,7601,11954,,1,,Autocuration,22224,,,,U,,,,BAO_0000218,A,,CHEMBL621607
,0,,Area under curve after oral dose of 3.87 mg/kg,,7602,11954,,1,,Autocuration,22224,,,,U,,,,BAO_0000218,A,,CHEMBL621608
,0,,Area under curve was determined,,7603,5237,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL621609
,0,,Area under curve at a dose of 10 mg/kg,,7604,4026,,1,,Autocuration,22224,,,,U,,,,BAO_0000218,A,,CHEMBL621610
,1,,Area under curve was determined; ND=No data,,7605,5237,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621611
,1,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,7606,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621612
,1,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,7607,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622308
,1,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,7608,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622309
,1,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,,7609,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622310
,1,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,7610,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622311
,1,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,,7611,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622312
,1,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,7612,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622931
,1,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,,7613,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622932
,1,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,7614,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622736
,1,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,7615,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622737
,1,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,7616,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622738
,1,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,,7617,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622739
,1,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,7618,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622740
,1,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,,7619,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622741
,1,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,7620,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622742
,1,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,,7621,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622743
,1,,AUC in mice,,7622,11637,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622744
,0,,Area under curve was measured from the graph obtained from concentration Vs time,,7623,11149,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL624134
,0,,Area under curve value of compound per hour after oral administration,,7624,10016,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL624135
,1,,Area under curve was determined after oral administration in rats,,7625,17796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624136
,1,,Area under curve was determined after oral administration in rats; No data,,7626,17796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624137
,1,,Area under curve was determined after oral administration in rats;No data,,7627,17796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624320
,1,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,7628,12923,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624321
,1,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,,7629,15372,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624322
,1,,Area under curve was determined for the compound after iv dose of 5.06 in rats,,7630,15372,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624323
,1,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,,7631,15372,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624324
,1,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,,7632,15372,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624325
,1,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,,7633,15372,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624326
,1,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,,7634,15372,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624327
,1,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,,7635,15372,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624328
,1,,Area under curve was determined in Dogs after peroral administration,,7636,14169,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL627848
,1,,Area under curve was determined in Rats after peroral administration,,7637,14169,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627849
,1,,Area under curve was determined in carotid blood of rat when administered intradermally,,7638,14258,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627850
,1,,Area under curve was determined in portal blood of rat when administered intradermally,,7639,14258,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627851
,1,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,7640,15011,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL627852
,1,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,7641,15011,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL627853
,1,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,7642,15011,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL627854
,1,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,7643,15011,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL627855
,1,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),,7644,15011,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL627856
,1,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,7645,15011,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL875339
,1,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),,7646,15011,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL627857
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,,7647,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL627858
,1,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,,7648,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL627859
,1,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,,7649,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL627860
,1,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,,7650,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL627019
,1,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,,7651,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL627020
,1,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,,7652,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL627021
,1,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,,7653,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL627022
,1,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,,7654,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627023
,1,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,,7655,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL627024
,1,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,,7656,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL627025
,1,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,,7657,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL627026
,1,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,,7658,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL627027
,1,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,,7659,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL627028
,1,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,,7660,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL627029
,1,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,,7661,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL627030
,1,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,,7662,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL627031
,1,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,,7663,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL627032
,1,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,,7664,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL627033
,1,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,,7665,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627034
,1,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,,7666,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL627035
,1,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,,7667,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL627036
,1,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,,7668,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL875340
,1,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,,7669,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL627037
,1,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,,7670,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL627038
,1,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,,7671,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL627039
,1,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,,7672,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL627040
,1,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,,7673,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL624663
,1,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,,7674,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL625963
,1,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,,7675,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL876799
,1,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,,7676,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL626133
,1,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,,7677,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626134
,1,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,7678,6295,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626135
,1,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,7679,6296,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626136
,1,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,,7680,6296,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626137
,1,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,7681,6295,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626138
,1,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,7682,6296,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626139
,1,,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,7683,17260,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626140
,1,,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,7684,17260,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626141
,1,,C24h in rat p.o. at 20 mg/kg concentration,,7685,17686,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626142
,1,,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,7686,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL627930
,1,,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,,7687,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL627931
,1,,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,,7688,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL627932
,1,,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,7689,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL627933
,1,,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,,7690,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL627934
,1,,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,,7691,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL627935
,1,,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,,7692,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL627936
,1,,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,,7693,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL627937
,1,,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,,7694,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL627938
,1,,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,,7695,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL627939
,1,,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,,7696,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL627940
,1,,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,,7697,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL627941
,1,,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,7698,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL876800
,1,,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,,7699,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL627942
,1,,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,,7700,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL627943
,1,,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,,7701,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL627944
,1,,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,,7702,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL627945
,1,,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,,7703,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL628584
,1,,Biodistribution in rat blood in the presence of GdDTPA at 15 min,,7704,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL628585
,1,,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,,7705,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL628586
,1,,Biodistribution in rat blood in the presence of GdDTPA at 30 min,,7706,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL628587
,1,,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,,7707,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL628588
,1,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,,7708,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL628589
,1,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,,7709,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL625304
,1,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,,7710,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL625305
,1,,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,,7711,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL625306
,1,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,,7712,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL625307
,1,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,,7713,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL625308
,1,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,,7714,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL627740
,1,,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,,7715,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL627741
,1,,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,7716,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL627742
,1,,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,,7717,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL627743
,1,,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,,7718,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL627744
,1,,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,,7719,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL627745
,1,,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,,7720,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL627746
,1,,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,,7721,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL627747
,1,,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,,7722,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL876810
,1,,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,,7723,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL627748
,1,,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,,7724,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL627749
,1,,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,7725,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL627750
,1,,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,,7726,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL618728
,1,,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,,7727,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL618729
,1,,Biodistribution in rat bone in the presence of GdDTPA at 15 min,,7728,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL618730
,1,,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,,7729,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL618731
,1,,Biodistribution in rat bone in the presence of GdDTPA at 30 min,,7730,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL618732
,1,,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,,7731,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL618733
,1,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,,7732,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL618734
,1,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,,7733,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL618735
,1,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,,7734,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL876602
,1,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,,7735,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL618736
,1,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,,7736,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL618737
,1,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,,7737,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL618738
,1,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,,7738,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL618739
,1,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,,7739,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL618740
,1,,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,7740,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL618741
,1,,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,,7741,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL618742
,1,,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,,7742,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL618743
,1,,Half-life from rat plasma at a single oral dose of 25 mg/kg,,7743,17752,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL618744
,1,,Half-life in male rat,,7744,5610,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618745
,1,,Half-life in rat after peroral administration at 10 mg/kg concentration,,7745,5939,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620479
,1,,Half-life in rat after peroral administration at 5 mg/kg concentration,,7746,5939,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620480
,1,,Half-life in rat at a dose of 3 mg/kg,,7747,17771,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620481
,1,,Half-life was evaluated in rats,,7748,1974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL620482
,1,,Half-life was measured in rat,,7749,4239,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL876603
,1,,Half-life period for the compound was determined in rats at 50 mg/kg dose,,7750,6681,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620483
,1,,Half-life period in rats after intravenous administration at 5 mg/kg,,7751,17752,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620484
,1,,Half-life period in rat at 10 mg/kg,,7752,6046,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620485
,1,,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",,7753,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620486
,1,,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",,7754,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620487
,1,,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",,7755,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620488
,1,,Half-life time in rat the dose of 2 mg/kg,,7756,4727,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620489
,1,,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,,7757,1088,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620490
,1,,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,,7758,5610,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620491
,1,,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",,7759,3032,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL876604
,1,,Oral half life was determined,,7760,5199,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620492
,1,,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",,7761,14941,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620493
,1,,Pharmacokinetic property (t1/2) in rat,,7762,4408,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620494
,1,,Plasma elimination half-life was determined,,7763,2552,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL620495
,1,,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,7764,5199,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL620496
,1,,Plasma half life was observed after intravenous administration in rat,,7765,15662,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL620497
,1,,Plasma half-life was determined,,7766,1465,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL620498
,1,,Plasma half-life following oral administration in Fisher rats,,7767,1446,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL620499
,1,,Plasma half-life in rat,,7768,6824,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL620500
,1,,Plasmatic Half-life after intravenous administration to rat,,7769,17533,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL873809
,1,,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,7770,5979,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620501
,1,,Terminal half life after intravenous administration (1 mg/kg) in rat,,7771,4689,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620502
,1,,Terminal half life in Rat at a oral dose of 5 mg/kg,,7772,4689,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620503
,1,,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,7773,2463,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620504
,1,,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,,7774,4883,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876605
,1,,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,,7775,4883,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620505
,1,,plasma half life was observed after intravenous administration in rat,,7776,15662,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL873811
,1,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,7777,3598,,1,Rattus norvegicus,Expert,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624016
,1,,Half life of compound determined in rat,,7778,4576,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624017
,1,,Mean residence time determined in rat,,7779,4576,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624018
,1,,Plasma half life determined in rat,,7780,4576,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624019
,1,,Compound was evaluated for Tmax in brain after intravenous administration in male rats,,7781,4910,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL624020
,1,,Compound was evaluated for pharmacokinetic parameter maximum time period,,7782,4891,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624201
,1,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,7783,429,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL872528
,1,,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,7784,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624202
,1,,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,7785,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624203
,1,,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,7786,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624350
,1,,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,7787,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621320
,1,,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,7788,17582,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621321
,1,,Maximum time (Tmax) required to reach Cmax in rats,,7789,4026,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621322
,1,,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,7790,4890,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621323
,1,,Maximum time of clearance of compound in rats after peroral administration,,7791,6571,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621324
,1,,Maximum time at the dose of 2 mg/kg in rat,,7792,4727,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621325
,1,,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,,7793,17651,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL875837
,1,,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,,7794,17651,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL621326
,1,,Tmax in Guinea pig (PO dose),,7795,14465,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621327
,1,,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",,7796,14941,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621328
,1,,Pharmacokinetic parameter (Tmax) in rat,,7797,5960,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621329
,1,,Pharmacokinetic parameter (Tmax) was estimated,,7798,5022,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621330
,1,,Pharmacokinetic property (Tmax) in rat,,7799,4408,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621331
,1,,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,7800,5983,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621332
,1,,T max in Rat at a oral dose of 5 mg/kg,,7801,4689,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621333
,1,,T max was determined at 10 mg/kg po dose in rats,,7802,2792,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621334
,1,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),,7803,15011,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621335
,1,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,,7804,14180,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621336
,1,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,,7805,14180,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621337
,1,,Area under curve was measured after i.v. administration into Beagle dog.,,7806,14599,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621338
,1,,Area under curve was measured after iv administration into Beagle dog,,7807,14599,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL875838
,1,,Area under curve was measured after po administration into Beagle dog,,7808,14599,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621339
,1,,Area under curve was measured after po administration into Beagle dog.,,7809,14599,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621340
,0,,Area under curve was measured at peroral dose of 3 mg/kg,,7810,15675,,1,,Autocuration,22224,,,,U,,,,BAO_0000218,A,,CHEMBL621341
,0,,Area under curve was measured by using concentration Vs time,,7811,12706,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL621342
,0,,Area under curve was measured by using concentration Vs time; not tested,,7812,12706,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL621343
,1,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),,7813,9750,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621344
,1,,Area under curve(AUC) was measured in mice after oral administration.,,7814,9750,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621345
,0,,Area under curve(AUC) value of the compound,,7815,14691,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL621346
,0,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,,7816,14691,,1,,Autocuration,22224,,,,U,,,,BAO_0000218,A,,CHEMBL621347
,1,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,,7817,14691,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621348
,0,,Area under curve(carotid artery) was determined by the availability in blood,,7818,2939,,1,,Autocuration,22224,,,Blood,U,178.0,,,BAO_0000019,A,,CHEMBL621349
,0,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,,7819,2939,,1,,Autocuration,22224,,,Blood,U,178.0,,,BAO_0000019,A,,CHEMBL621350
,0,,Area under curve(carotid artery) was determined by the availability in blood; No data,,7820,2939,,1,,Autocuration,22224,,,Blood,U,178.0,,,BAO_0000019,A,,CHEMBL875839
,0,,Area under curve(portal vein) was determined by the availability in blood,,7821,2939,,1,,Autocuration,22224,,,Blood,U,178.0,,,BAO_0000019,A,,CHEMBL620211
,0,,Area under curve(portal vein) was determined by the availability in blood; ND means no data,,7822,2939,,1,,Autocuration,22224,,,Blood,U,178.0,,,BAO_0000019,A,,CHEMBL620212
,0,,Area under curve(portal vein) was determined by the availability in blood; No data,,7823,2939,,1,,Autocuration,22224,,,Blood,U,178.0,,,BAO_0000019,A,,CHEMBL620213
,1,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,7824,9552,,1,Macaca mulatta,Intermediate,50797,,9544.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL620214
,1,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,7825,9552,,1,Macaca mulatta,Intermediate,50797,,9544.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL620215
,1,,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,,7826,9552,,1,Macaca mulatta,Intermediate,50797,,9544.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL620216
,1,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",,7827,9552,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL620888
,1,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",,7828,9552,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL620889
,0,,Area under plasma concentration vs time curve observed in rats for 0-3 h,,7829,9552,,1,,Autocuration,22224,,,Plasma,U,1969.0,,,BAO_0000019,A,,CHEMBL620890
,1,,Area under plasma time curve determined in male rat,,7830,11911,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL620891
,0,,Area under the MAP curve measured over 5 min.,,7831,16618,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL620892
,1,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,,7832,14387,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621079
,1,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,,7833,14387,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL621080
,1,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,,7834,12836,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621081
,1,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,,7835,12836,,1,Cricetinae,Intermediate,100712,,10026.0,,N,,,,BAO_0000218,A,,CHEMBL621082
,1,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,,7836,12836,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621083
,1,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,,7837,14339,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621084
,1,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,,7838,14339,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621085
,1,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,,7839,14339,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621086
,1,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,7840,10524,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621087
,1,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),,7841,9994,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622607
,1,,Serum AUC in marmosets (IV dose),,7842,11325,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622608
,0,,Area under the curve after intravenous administration at a dose of 10 umol/kg,,7843,12536,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL624481
,0,,Area under the curve after intravenous administration at a dose of 2 umol/kg,,7844,12536,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL624482
,0,,Area under the curve after intravenous administration at a dose of 4 umol/kg,,7845,12536,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL624483
,0,,Area under the curve after intravenous administration at a dose of 40 umol/kg,,7846,12536,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL624484
,0,,Area under the curve after intravenous administration at a dose of 5 umol/kg,,7847,12536,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL624485
,1,,Area under the curve for fumarate salt was evaluated in F344 Rats.,,7848,15556,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624486
,0,,Area under the curve for the compound was calculated.,,7849,2809,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL624487
,0,,Area under the curve in concentration/ time,,7850,9511,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL624488
,1,,Area under the curve administered intraintestinal in rats.,,7851,12818,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624489
,1,,Area under the curve administered intravenously in rats.,,7852,12818,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625184
,0,,Area under the curve during intravenous administration,,7853,15118,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL625185
,0,,Area under the curve during intravenous administration; Not determined,,7854,15118,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL875954
,0,,Area under the curve during systemic administration,,7855,15118,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL625186
,0,,Area under the curve during systemic administration; Not determined,,7856,15118,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL625187
,0,,Area under the curve was calculated for the compound.,,7857,2632,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL625188
,1,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,,7858,14346,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL625189
,1,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,,7859,14346,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL625190
,1,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,,7860,14346,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621733
,1,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,,7861,14346,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621734
,1,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,,7862,11149,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621735
,1,,Clearance of the drug was measured in the plasma of rat; No data,,7863,17796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL621736
,1,,The pharmacokinetic parameter plasma clearance in vivo in rats,,7864,5247,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL621737
,1,,Plasma clearance at the dose of 2 mg/kg in rat,,7865,4727,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621738
,1,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,7866,5654,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622806
,1,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,7867,5654,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623519
,1,,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,7868,17260,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623520
,1,,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,,7869,17065,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623521
,1,,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,7870,17671,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623522
,1,,Clearance rate in rat,,7871,6672,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623523
,1,,Clearance rate in rat,,7872,6673,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623690
,1,,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,7873,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623691
,1,,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,7874,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623692
,1,,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,7875,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623693
,1,,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,7876,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623694
,1,,Clearance of compound after iv administration of 20 mg/kg dose in rat,,7877,4413,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623695
,1,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,,7878,2661,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623696
,1,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,,7879,2661,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623697
,0,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,7880,5005,,1,Macaca mulatta,Intermediate,22224,,9544.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623698
,0,,Compound was tested for its plasma clearance rate in Sprague Dawley rats,,7881,5005,,1,Rattus norvegicus,Intermediate,22224,,10116.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623699
,1,,Mean (%CV) PK parameters for CL(mL/min/kg).,,7882,15765,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623700
,1,,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,,7883,3747,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623701
,1,,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,,7884,16366,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623702
,1,,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,,7885,4199,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623703
,1,,Plasma clearance in rat was determined,,7886,17267,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623704
,1,,Plasma clearance in rat after administration of 2 mg/kg iv,,7887,6535,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623705
,1,,Plasma clearance in rat after administration of 2 mg/kg iv,,7888,6535,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623706
,1,,Plasma clearance was determined,,7889,5041,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623707
,1,,Plasma clearance in rat,,7890,5960,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623708
,1,,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,,7891,5937,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623709
,1,,Plasma clearance in rat by iv administration,,7892,5871,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623710
,1,,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,,7893,5874,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623711
,1,,Plasma clearance in rat p.o.,,7894,6504,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623712
,1,,Plasma clearance in rats,,7895,6803,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623713
,1,,Plasma clearance was determined; ND denotes no data,,7896,5041,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623714
,1,,Plasma clearance was determined; ND denotes not determined,,7897,5041,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623715
,1,,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,7898,1916,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623716
,1,,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,7899,5199,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622980
,1,,Plasma administration to rats,,7900,16367,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622981
,1,,Plasma clearance of the compound in female Sprague-Dawley rats,,7901,6362,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622982
,1,,Plasma clearance was observed after intravenous administration in rat,,7902,15662,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622983
,1,,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,,7903,6215,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622984
,1,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,,7904,1466,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622985
,1,,plasma clearance was observed after intravenous administration in rat,,7905,15662,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623631
,1,,In vivo CL/F determined,,7906,4723,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623632
,1,,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,,7907,2792,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623633
,1,,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,,7908,2792,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623634
,1,,Compound was tested for the lower blood clearance in rat,,7909,5213,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623635
,1,,Evaluated for the low clearance in rat (in vivo),,7910,4687,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621195
,1,,Pharmacokinetic property (CLb)of the compound was determined in rat,,7911,3371,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621196
,1,,Rapid clearance after intravenous administration in rat was determined,,7912,4690,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875287
,1,,Clearance measured in rat,,7913,5702,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621197
,1,,Compound was evaluated for plasma clearance in rat,,7914,740,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL621198
,1,,Low plasma clearance was calculated in rat,,7915,4853,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL621199
,1,,Pharmacokinetic property (Clp) in rat,,7916,5789,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621200
,1,,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,,7917,4527,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621201
,1,,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,,7918,4527,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621202
,1,,Plasma clearance after IV dosing at 0.5 mg/kg in rat,,7919,6518,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621203
,1,,Plasma clearance after IV dosing at 1 mg/kg in rat,,7920,6518,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621204
,1,,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,,7921,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621205
,1,,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,,7922,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621206
,1,,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,,7923,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621207
,1,,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,,7924,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621208
,1,,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,,7925,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621209
,1,,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,,7926,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL876484
,1,,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,7927,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621210
,1,,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,,7928,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621211
,1,,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,,7929,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621212
,1,,Biodistribution in rat heart in the presence of GdDTPA at 15 min,,7930,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621213
,1,,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,,7931,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621214
,1,,Biodistribution in rat heart in the presence of GdDTPA at 30 min,,7932,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621215
,1,,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,,7933,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621216
,1,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,,7934,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621217
,1,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,,7935,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621218
,1,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,,7936,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621219
,1,,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,,7937,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621220
,1,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,,7938,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621221
,1,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,,7939,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621222
,1,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,,7940,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621223
,1,,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,,7941,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL876485
,1,,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,7942,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621224
,1,,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,,7943,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621225
,1,,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,,7944,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621226
,1,,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,,7945,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621227
,1,,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,,7946,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621228
,1,,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,,7947,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621229
,1,,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,,7948,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621230
,1,,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,,7949,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621231
,1,,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,,7950,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621232
,1,,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,7951,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621233
,1,,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,,7952,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621234
,1,,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,,7953,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621235
,1,,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,7954,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621236
,1,,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,,7955,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621237
,1,,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,,7956,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL876486
,1,,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,,7957,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL622436
,1,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,,7958,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL622437
,1,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,,7959,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL622438
,1,,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,,7960,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622439
,1,,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,,7961,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622440
,1,,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,,7962,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622441
,1,,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,,7963,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622442
,1,,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,,7964,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622443
,1,,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,,7965,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622444
,1,,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,,7966,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622445
,1,,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,,7967,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622446
,1,,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,7968,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622447
,1,,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,,7969,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622448
,1,,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,,7970,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622449
,1,,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,,7971,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622450
,1,,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,,7972,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622451
,1,,Biodistribution in rat liver in the presence of GdDTPA at 15 min,,7973,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622452
,1,,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,,7974,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622453
,1,,Biodistribution in rat liver in the presence of GdDTPA at 30 min,,7975,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622454
,1,,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,,7976,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622455
,1,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,,7977,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL876024
,1,,T max was determined at 3 mg/kg po dose in rats,,7978,2792,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622456
,1,,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",,7979,15078,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622457
,1,,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",,7980,15078,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622458
,1,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,,7981,15022,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622459
,1,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,,7982,15022,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL873343
,1,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,,7983,15022,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622460
,1,,Time for maximum plasma concentration determined in rat,,7984,4576,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622461
,1,,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,,7985,6681,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622462
,1,,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,,7986,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622463
,1,,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,,7987,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622464
,1,,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,,7988,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622465
,1,,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,,7989,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622466
,1,,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,,7990,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622467
,1,,Time of maximum plasma concentration in rat,,7991,6824,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622468
,1,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,7992,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL876025
,1,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,7993,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622469
,1,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,7994,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622470
,1,,Time required to reach maximum concentration (Cmax) after oral administration in rat,,7995,15662,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622471
,1,,Time required to reach maximum concentration in rat plasma,,7996,1742,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622472
,1,,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,,7997,2774,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622473
,1,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,,7998,5199,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624282
,1,,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,,7999,12873,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624283
,1,,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,,8000,12873,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624284
,1,,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,8001,1916,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624285
,1,,Time to reach Cmax after oral administration to rats,,8002,16367,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624286
,1,,Time to reach Cmax when a dose of 1 mg/kg is administered orally,,8003,16366,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624287
,1,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,,8004,216,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624288
,1,,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,,8005,6410,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624289
,1,,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,,8006,6410,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL873344
,1,,Tmax after peroral administration (10 mg/kg) was determined in rat,,8007,6215,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619623
,1,,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,,8008,3598,,1,Rattus norvegicus,Expert,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621399
,1,,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,,8009,4527,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621400
,1,,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",,8010,17670,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621401
,1,,Tmax was determined,,8011,1465,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621402
,1,,Tmax was determined,,8012,2552,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621403
,1,,Tmax after oral administration in rat,,8013,5656,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621121
,1,,Tmax after peroral administration in rats at 2.4 uM/kg,,8014,17764,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL872525
,1,,Tmax in male rat,,8015,5610,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621122
,1,,Tmax in rat at 10 mg/kg,,8016,6046,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621123
,1,,Tmax in rat by po administration at a dose of 40 mg/kg,,8017,5874,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621124
,1,,Tmax in rats,,8018,17596,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621125
,1,,Tmax was measured in rats after peroral administration at 5 mg/kg,,8019,17804,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621126
,1,,Tmax value after oral dose at a dose of 10 mg/kg in rats.,,8020,1908,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621127
,1,,Tmax value after administration of 20 mg/Kg oral dose in rat,,8021,2959,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621128
,1,,Tmax value at a dose of 10 mg/kg in male SD rats,,8022,6757,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618263
,1,,Tmax value at a dose of 100 mg/kg in male SD rats,,8023,6757,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618264
,1,,Tmax value at a dose of 50 mg/kg in male SD rats,,8024,6757,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618265
,1,,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,8025,4186,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL618266
,1,,time required to reach maximum concentration (Cmax) after oral administration in rat,,8026,15662,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618267
,1,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),,8027,429,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL618450
,1,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),,8028,429,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL618451
,1,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,8029,5546,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618452
,1,,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,,8030,3173,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL618453
,1,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,,8031,3173,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL618454
,1,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,,8032,3173,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL618455
,1,,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,,8033,4257,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618456
,1,,Compound distribution in rat tissues was determined,,8034,6011,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618457
,1,,Volume of distribution was evaluated in rat,,8035,5472,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618458
,1,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,,8036,14346,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618459
,1,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,,8037,14346,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL876733
,1,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,,8038,14346,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL618460
,1,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,,8039,14346,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618461
,0,,Area under the curve was determined after oral administration (300 uM/Kg),,8040,15469,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL618462
,1,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,,8041,14346,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618463
,1,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,,8042,14346,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618464
,1,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,,8043,14346,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618465
,1,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,,8044,14346,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618466
,1,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,,8045,14346,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618467
,1,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,,8046,15372,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618468
,1,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,,8047,12935,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL618469
,1,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,,8048,12935,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL618470
,0,,Plasma drug AUC in rat (PO dose),,8049,14813,,1,,Autocuration,22224,,,,U,,,,BAO_0000218,A,,CHEMBL618471
,1,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,,8050,15792,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL618472
,0,,Area under was determined at a dose of 30 mg/kg,,8051,3579,,1,,Autocuration,22224,,,,U,,,,BAO_0000218,A,,CHEMBL618473
,1,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,,8052,12487,,1,Mustela putorius furo,Intermediate,50506,,9669.0,,N,,,,BAO_0000218,A,,CHEMBL621699
,1,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,,8053,12487,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621700
,1,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,,8054,12487,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621701
,1,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,,8055,12487,,1,Mustela putorius furo,Intermediate,50506,,9669.0,,N,,,,BAO_0000218,A,,CHEMBL621702
,1,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,,8056,12487,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621703
,1,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,,8057,12487,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL621704
,1,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",,8058,12902,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624259
,1,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",,8059,12902,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624260
,1,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",,8060,12902,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624430
,1,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",,8061,12902,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624431
,1,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",,8062,12902,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624432
,1,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",,8063,12902,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624433
,1,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",,8064,12902,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624434
,1,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",,8065,12902,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624435
,1,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,,8066,12745,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL618570
,1,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,8067,12745,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL618571
,1,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,,8068,12745,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL618572
,1,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,8069,12745,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL618573
,1,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,,8070,12745,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619267
,1,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,8071,12745,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619431
,1,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,,8072,12745,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619432
,1,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,8073,12745,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619433
,0,,AUC in mice after oral dose (50 mg/kg),,8074,13298,,1,,Autocuration,22224,,,Plasma,U,1969.0,,,BAO_0000218,A,,CHEMBL619434
,1,,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,,8075,12226,,1,Mus musculus,Intermediate,50594,,10090.0,Serum,N,1977.0,,,BAO_0000218,A,,CHEMBL619435
,0,,AUC (0-4 hr) ug/ml/h,,8076,12634,,1,,Autocuration,22224,,,Plasma,U,1969.0,,,BAO_0000019,A,,CHEMBL619436
,1,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,,8077,14810,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL619437
,0,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,,8078,13889,,1,,Autocuration,22224,,,,U,,,,BAO_0000218,A,,CHEMBL619438
,1,,Compound was evaluated for Area under curve in mice,,8079,10018,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL619439
,1,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,8080,8758,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL619440
,0,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,8081,8758,,1,,Autocuration,22224,,,,U,,,,BAO_0000218,F,,CHEMBL619441
,1,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,8082,8758,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL619442
,0,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,,8083,2249,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL875156
,0,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,,8084,2249,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL619443
,0,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,,8085,2249,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL619444
,0,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,,8086,2249,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL623464
,1,,Compound was evaluated for area under curve when administered through oral route in mouse,,8087,15115,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL623465
,1,,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,,8088,6518,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623466
,1,,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,,8089,6518,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623467
,1,,Plasma clearance in rat,,8090,6249,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623468
,1,,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,8091,2463,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622660
,1,,Plasma clearance rate in Sprague-Dawley rats,,8092,4969,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622661
,1,,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,,8093,17720,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL622662
,1,,Pharmacokinetic property (total body clearance) in rat,,8094,3457,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622663
,1,,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,,8095,5983,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622664
,1,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,8096,6295,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622665
,1,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,8097,6296,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622666
,1,,Cl in rat i.v. at 2 mg/kg concentration,,8098,17686,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621615
,1,,Clearance of compound after intravenous administration in rats at 24 uM/kg,,8099,17764,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621616
,1,,Clearance was determined,,8100,5503,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621617
,1,,Clearance by intravenous administration of 3.4 mg/kg in rat,,8101,4368,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621618
,1,,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,8102,6005,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621619
,1,,Clearance rate after i.v. administration in rats,,8103,5031,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621620
,1,,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,8104,4890,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621786
,1,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,8105,5182,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621787
,1,,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,,8106,5979,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621788
,1,,Clearance (Cl) after oral administration in rat,,8107,5656,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621789
,1,,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,,8108,17804,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621790
,1,,Compound was tested for plasma clearance in rat,,8109,4839,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL621791
,1,,In vitro microsome metabolism clearance in rat was determined,,8110,5041,Microsomes,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vitro,,BAO_0000218,A,,CHEMBL621792
,1,,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,,8111,5041,Microsomes,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vitro,,BAO_0000218,A,,CHEMBL621793
,1,,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,8112,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621794
,1,,In vivo plasma clearance was determined,,8113,5496,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL621795
,1,,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,,8114,5739,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621796
,1,401.0,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,,8115,5676,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,Hepatocyte,BAO_0000218,A,,CHEMBL621797
,1,,Pharmacokinetic property (Plasma clearance) was measured in rat,,8116,4239,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621798
,1,,Pharmacokinetic property (clearance) in rat i.v.,,8117,5676,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621799
,1,,"Plasma Clearance was evaluated in rats, iv",,8118,1918,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621800
,1,,Plasma clearance (in vivo) in rats was determined,,8119,17800,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621801
,1,,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,,8120,6056,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621802
,1,,Plasma clearance was determined,,8121,5496,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618596
,1,,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,,8122,5939,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618597
,1,,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,,8123,5939,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618598
,1,,Plasma clearance in rats,,8124,17752,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618599
,1,,Plasma clearance rate determined in rat,,8125,4576,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618600
,1,,Plasma clearance was determined in rat,,8126,6011,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618601
,1,,Plasma clearance was determined,,8127,5510,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618602
,1,,Plasma clearance value in rat,,8128,5948,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618603
,1,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,,8129,6125,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,Ex vivo,,BAO_0000218,A,,CHEMBL618604
,1,,Clearance in rat,,8130,4839,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618605
,1,,Total body clearance in rat i.v. at 2 mg/kg concentration,,8131,17686,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618606
,1,,Clearance of compound in rats after intravenous administration,,8132,6571,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618607
,1,,Clearance after iv administration to rats,,8133,3364,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618608
,1,,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,8134,13569,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618609
,1,,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,8135,13569,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618610
,1,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,8136,13569,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618611
,1,,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,8137,13569,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618612
,1,,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,8138,13569,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618613
,1,,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,8139,13569,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621076
,1,,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,8140,13569,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621077
,1,,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",,8141,17670,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621078
,1,,Clearance in rat,,8142,5970,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621251
,1,,Clearance in rat after oral administration at 10 mg/kg,,8143,6495,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621252
,1,,Clearance in rat.,,8144,4590,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621253
,1,,Clearance rate following an oral dose of 20 mg/kg in rats,,8145,6193,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621254
,1,,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,,8146,2832,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621255
,1,,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,,8147,1052,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL621256
,1,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,,8148,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL621257
,1,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,,8149,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL621258
,1,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,,8150,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL621259
,1,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,,8151,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL621260
,1,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,,8152,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL876494
,1,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,,8153,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL621261
,1,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,,8154,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL621262
,1,,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,8155,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL621263
,1,,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,,8156,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL621264
,1,,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,,8157,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL621265
,1,,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,,8158,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL621266
,1,,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,,8159,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL621267
,1,,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,,8160,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL621268
,1,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,,8161,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL621269
,1,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,,8162,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL621270
,1,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,,8163,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL621271
,1,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,,8164,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL621272
,1,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,,8165,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL621273
,1,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,,8166,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL621274
,1,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,,8167,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL876495
,1,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,,8168,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL621275
,1,,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,,8169,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL621276
,1,,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,,8170,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL621277
,1,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,,8171,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL621278
,1,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,,8172,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL621279
,1,,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),,8173,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL621280
,1,,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,,8174,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL621281
,1,,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,,8175,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL621282
,1,,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,,8176,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL621283
,1,,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,,8177,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL621284
,1,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,,8178,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL621285
,1,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,,8179,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL621286
,1,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,,8180,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL623220
,1,,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,,8181,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL623221
,1,,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,,8182,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL876029
,1,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,,8183,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL623222
,1,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,,8184,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL623223
,1,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,,8185,9866,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL621445
,1,,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,8186,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL621446
,1,,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,,8187,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL621447
,1,,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,,8188,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL619681
,1,,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,,8189,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL619682
,1,,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,,8190,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL619683
,1,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,8191,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL619684
,1,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,,8192,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL619685
,1,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,,8193,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL619686
,1,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,,8194,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL619687
,1,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,,8195,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL619688
,1,,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,8196,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL619689
,1,,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,,8197,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL619690
,1,,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,,8198,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL619691
,1,,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,,8199,6062,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619692
,1,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,,8200,3598,,1,Rattus norvegicus,Expert,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL619693
,1,,Vc value after IV dose at a dose of 5 mg/kg in rats.,,8201,1908,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619694
,1,,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,,8202,17596,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619695
,1,,Compound was evaluated for pharmacokinetic parameter volume of distribution,,8203,4891,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619696
,1,,Compound was evaluated for volume of distribution in rat,,8204,740,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619697
,1,,Steady state volume distribution was determined; steady state(ss),,8205,16366,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619698
,1,,Steady state volume of distribution after iv administration to rats,,8206,3364,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619699
,1,,Steady state volume of distribution dosing at 3 mg/kg iv,,8207,2552,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619700
,1,,The compound was evaluated for volume of distribution in rat,,8208,406,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619701
,1,,The compound was tested for volume of distribution in rat,,8209,12500,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL619702
,1,,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,,8210,12500,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620335
,1,,Volume distribution (VD) after oral administration in rat,,8211,5656,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620336
,1,,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,8212,17671,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620337
,1,,Volume distribution in rat,,8213,1094,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620520
,1,,Volume distribution in rat,,8214,5833,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620521
,1,,Volume distribution in rat after peroral administration at 10 mg/kg,,8215,5939,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875825
,1,,Volume distribution in rat after peroral administration at 5 mg/kg,,8216,5939,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620522
,1,,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,8217,6005,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620523
,1,,Volume of distribution in rat.,,8218,1696,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620524
,1,,Volume of distribution in rat,,8219,6672,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620525
,1,,Volume of distribution in rat,,8220,6673,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620526
,1,,Volume of distribution in rat by iv administration,,8221,5871,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620527
,1,,Volume of distribution in rats,,8222,6803,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620528
,1,,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,8223,5199,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620529
,1,,Volume distribution at the dose of 2 mg/kg in rat,,8224,4727,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL620530
,1,,Steady state volume of distribution was determined,,8225,16367,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620531
,0,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,8226,5005,,1,Macaca mulatta,Intermediate,22224,,9544.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620532
,0,,Compound was tested for its plasma volume distribution in Sprague Dawley rats,,8227,5005,,1,Rattus norvegicus,Intermediate,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620533
,0,,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,,8228,5005,,1,Rattus norvegicus,Intermediate,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620534
,1,,Mean (%CV) PK parameters for Vdss(mL/kg).,,8229,15765,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620535
,1,,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,,8230,2792,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875826
,1,,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,,8231,2792,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620536
,1,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,8232,5334,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620537
,1,,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,,8233,5334,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618526
,1,,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,,8234,5739,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618527
,1,,Pharmacokinetic property (Vdss) in rat,,8235,5789,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618528
,1,,Pharmacokinetic property (vdss) was measured in rat,,8236,4239,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618529
,1,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,,8237,4709,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618530
,1,,Volume of distribution in rat,,8238,6642,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618531
,1,,The pharmacokinetic parameter volume of distribution in vivo in rats,,8239,5247,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618532
,1,,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,,8240,17720,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL618533
,1,,Vdss in rat i.v. at 2 mg/kg concentration,,8241,17686,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618534
,1,,Volume distribution after intravenous administration (1 mg/kg) in rat,,8242,4689,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618535
,1,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,8243,5654,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618536
,1,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,8244,5654,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618537
,1,,Volume distribution at a dose of 10 uM/kg in rat was determined,,8245,4527,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618538
,1,,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,8246,4521,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618539
,1,,Volume distribution was calculated in rat,,8247,6057,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618540
,1,,Volume distribution was determined,,8248,5510,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618541
,1,,Volume of distribution after intravenous administration was evaluated in rat,,8249,2938,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618542
,1,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,8250,6679,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622544
,1,,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",,8251,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622545
,1,,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,8252,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622546
,1,,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",,8253,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622547
,1,,Volume of distribution in steady state was determined in rat,,8254,5145,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622548
,1,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,,8255,6467,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622549
,1,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,8256,6467,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622550
,1,,Compound was evaluated for area under curve when administered through oral route to mouse,,8257,15115,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622551
,1,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,8258,8758,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622552
,1,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,8259,8758,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622553
,0,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,,8260,8267,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,F,,CHEMBL622554
,1,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,,8261,8267,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622555
,1,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,8262,14239,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622556
,1,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,8263,14239,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622557
,1,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,,8264,10754,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL622558
,1,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,,8265,10754,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL622559
,1,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,,8266,10754,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL622560
,1,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,,8267,14681,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622561
,1,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,,8268,14681,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622562
,1,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,8269,14681,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622563
,0,,Concentration of compound in Central nervous system,,8270,13118,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL622564
,0,,Concentration of compound in Central nervous system; Not detectable,,8271,13118,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL622565
,1,,"Concentration of diester in the blood, following oral administration in mice",,8272,13318,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL622566
,1,,"Concentration of monoester in the blood, following oral administration in mice",,8273,13318,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL624515
,1,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,,8274,13318,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL624516
,0,,Evaluated for Pharmacokinetic property: Area under the curve,,8275,15692,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL624517
,1,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,,8276,14839,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL624518
,1,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,,8277,14839,,1,Macaca fascicularis,Intermediate,100710,,9541.0,,N,,,,BAO_0000218,A,,CHEMBL624519
,1,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,,8278,14839,,1,Macaca fascicularis,Intermediate,100710,,9541.0,,N,,,,BAO_0000218,A,,CHEMBL624520
,1,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,,8279,14839,,1,Macaca fascicularis,Intermediate,100710,,9541.0,,N,,,,BAO_0000218,A,,CHEMBL624521
,1,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,,8280,14839,,1,Macaca fascicularis,Intermediate,100710,,9541.0,,N,,,,BAO_0000218,A,,CHEMBL624522
,1,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,,8281,14839,,1,Macaca fascicularis,Intermediate,100710,,9541.0,,N,,,,BAO_0000218,A,,CHEMBL624523
,1,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,8282,14839,,1,Macaca fascicularis,Intermediate,100710,,9541.0,,N,,,,BAO_0000218,A,,CHEMBL624409
,1,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",,8283,14839,,1,Macaca fascicularis,Intermediate,100710,,9541.0,,N,,,,BAO_0000218,A,,CHEMBL624410
,1,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,8284,14839,,1,Macaca fascicularis,Intermediate,100710,,9541.0,,N,,,,BAO_0000218,A,,CHEMBL624411
,1,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",,8285,14839,,1,Macaca fascicularis,Intermediate,100710,,9541.0,,N,,,,BAO_0000218,A,,CHEMBL623531
,1,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",,8286,14839,,1,Macaca fascicularis,Intermediate,100710,,9541.0,,N,,,,BAO_0000218,A,,CHEMBL623532
,1,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",,8287,14839,,1,Macaca fascicularis,Intermediate,100710,,9541.0,,N,,,,BAO_0000218,A,,CHEMBL623533
,1,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,8288,14839,,1,Macaca fascicularis,Intermediate,100710,,9541.0,,N,,,,BAO_0000218,A,,CHEMBL623534
,1,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,,8289,14839,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL623535
,1,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,,8290,14839,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL623536
,1,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,,8291,14839,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL623537
,1,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,,8292,14839,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL623538
,1,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,,8293,14839,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL623539
,1,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,,8294,14839,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL623540
,1,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",,8295,14839,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL623541
,1,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",,8296,14839,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL623542
,1,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",,8297,14839,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL623543
,1,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",,8298,14839,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL623544
,1,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",,8299,14839,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL623545
,1,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",,8300,14839,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL623546
,1,,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,,8301,5408,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623547
,1,,High i.v. clearance in Dawley rats,,8302,6827,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623548
,1,,In vitro clearance in rat liver microsomes,,8303,17538,Microsomes,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vitro,,BAO_0000218,A,,CHEMBL623549
,1,,Intrinsic clearance in rat liver microsomes was determined,,8304,6331,Microsomes,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vitro,,BAO_0000218,A,,CHEMBL623550
,1,401.0,Intrinsic clearance in rat hepatocytes was determined,,8305,5948,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vitro,Hepatocyte,BAO_0000218,A,,CHEMBL875276
,1,,Plasma Clearance was determined,,8306,4026,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621872
,1,,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,,8307,6647,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621873
,1,,Plasma clearance in rat.,,8308,1696,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621874
,1,,Plasma clearance in rats,,8309,6597,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621875
,1,,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,,8310,347,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621876
,1,,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,,8311,16423,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621877
,1,,Plasma clearance was measured in rat,,8312,2879,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621878
,1,,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,8313,4883,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621879
,1,,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",,8314,5328,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL621880
,1,,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,,8315,5160,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621881
,1,,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,8316,17582,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621882
,1,,Total clearance at 1 mg/kg was determined in rat,,8317,17651,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875283
,1,,Total clearance at 10 mg/kg was determined in rat,,8318,17651,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621883
,1,,Clearance in rat,,8319,6596,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621884
,1,,Plasma clearance rate determined in rats,,8320,4796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621885
,1,,Clearance of compound in rat was evaluated,,8321,6850,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621886
,1,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,,8322,5932,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL621887
,1,,Pharmacokinetic property (blood clearance) in rat,,8323,3371,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621888
,1,,Plasma clearance in rat,,8324,2083,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621889
,1,,Plasma clearance in rats,,8325,4942,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621890
,1,,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,,8326,6838,Microsomes,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vitro,,BAO_0000218,A,,CHEMBL621891
,1,,Clearance in Dawley rat,,8327,5353,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621892
,1,,Clearance rat,,8328,6641,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621893
,1,,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),,8329,6641,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621894
,1,,Clearance rat; Not determined,,8330,6641,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621895
,1,,Clearance rate was determined in rat at a dose of 1 mpk i.v.,,8331,6444,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875284
,1,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,8332,6444,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618699
,1,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,8333,6444,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618700
,1,,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,8334,6211,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618701
,1,,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",,8335,12873,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL876600
,1,,Clearance of compound in rat after 1 mg/kg i.v. administration,,8336,6570,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618702
,1,,Compound was evaluated for Hepatic clearance in rat,,8337,3341,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618703
,1,,In vivo clearance after 5 mg/kg dose,,8338,4891,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618704
,1,,Compound was tested for plasma clearance in rats,,8339,1094,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL618705
,1,,Hepatic clearance after intravenous administration was evaluated in rat,,8340,2938,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618706
,1,,Lower clearance in rat (i.v.) at 0.5 mpk,,8341,17853,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618707
,1,,Pharmacokinetic parameter expressed as plasma clearance in rat,,8342,6049,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL618708
,1,,Pharmacokinetic property (Clp) in rat,,8343,5789,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618709
,1,,Plasma clearance in Sprague-Dawley rats,,8344,4514,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618710
,1,,Plasma clearance (Clp) in rat,,8345,6448,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618711
,1,,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,,8346,6062,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618712
,1,,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,,8347,5710,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618713
,1,,Plasma clearance after intravenous administration of 1 mg/kg in rat,,8348,4709,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618714
,1,,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,8349,4521,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618715
,1,,Plasma clearance in rat was determined,,8350,1742,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618716
,1,,Plasma clearance measured in rat,,8351,6057,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876601
,1,,Plasma clearance was calculated in rat,,8352,6057,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618717
,1,,Plasma clearance in rat,,8353,5145,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618718
,1,,Plasma clearance in rat,,8354,5833,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618719
,1,,Plasma clearance in rat,,8355,6453,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618720
,1,,Plasma clearance in rat,,8356,6640,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618721
,1,,Plasma clearance in rats,,8357,6305,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621477
,1,,Plasma clearance in rat,,8358,6642,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621478
,1,,Plasma clearance was evaluated in rat,,8359,5472,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621479
,1,,Plasma clearance was evaluated in rat; Not tested,,8360,5472,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621480
,1,,Plasma clearance rate was determined for the compound in rat,,8361,5144,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621481
,1,,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",,8362,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621482
,1,,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,8363,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621483
,1,,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",,8364,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621484
,1,,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,,8365,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621485
,1,,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,,8366,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL621486
,1,,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,8367,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL621487
,1,,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,,8368,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL621488
,1,,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,,8369,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL621489
,1,,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,,8370,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL621490
,1,,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,,8371,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL621491
,1,,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,8372,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621492
,1,,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,,8373,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621493
,1,,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,,8374,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621494
,1,,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,,8375,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621495
,1,,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,,8376,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621496
,1,,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,8377,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL621497
,1,,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,,8378,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL621498
,1,,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,,8379,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL621499
,1,,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,,8380,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL618634
,1,,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,,8381,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL618635
,1,,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,8382,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL618636
,1,,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,,8383,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL619737
,1,,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,,8384,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL619738
,1,,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,,8385,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL624329
,1,,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,,8386,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL624330
,1,,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,8387,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL624331
,1,,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,,8388,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL624332
,1,,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,,8389,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL624333
,1,,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,,8390,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL624334
,1,,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,,8391,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL624335
,1,,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,8392,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL620016
,1,,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,,8393,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL620169
,1,,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,,8394,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL620170
,1,,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,,8395,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL620171
,1,,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,,8396,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL620172
,1,,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,8397,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL620173
,1,,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,,8398,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL620174
,1,,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,,8399,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL620175
,1,,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,,8400,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL620176
,1,,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,,8401,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL620177
,1,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,8402,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Cerebellum,N,2037.0,,,BAO_0000218,A,,CHEMBL620178
,1,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,8403,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Cerebellum,N,2037.0,,,BAO_0000218,A,,CHEMBL620179
,1,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,,8404,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL620180
,1,,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,,8405,6570,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620181
,1,,Volume of distribution of compound in rats after intravenous administration,,8406,6571,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620182
,1,,Volume of distribution in rat,,8407,6453,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620183
,1,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,,8408,6444,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620184
,1,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,8409,6444,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620185
,1,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,8410,6444,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620186
,1,,Volume of distribution was determined in Dawley rat,,8411,5353,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620187
,1,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,8412,5334,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620188
,1,,Volume of distribution was reported in Sprague-Dawley rat,,8413,5334,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620189
,1,,Volumes of distribution in rat after peroral administration,,8414,6641,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620190
,1,,Volumes of distribution in rat after po administration,,8415,6641,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620191
,1,,Volumes of distribution in rat after po administration; Not determined,,8416,6641,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620192
,1,,Pharmacokinetic property (Volume) in rat i.v.,,8417,5676,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620193
,1,,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,,8418,6410,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620194
,1,,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",,8419,17670,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876730
,1,,Volume distribution in rat after oral administration at 10 mg/kg,,8420,6495,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620195
,1,,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,,8421,5408,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620196
,1,,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,8422,4883,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620197
,1,,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,,8423,6647,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620198
,1,,Volume of distribution in rats,,8424,6495,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620199
,1,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,,8425,2661,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620200
,1,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,,8426,2661,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620201
,1,,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,8427,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620202
,1,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,8428,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620203
,1,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,,8429,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620204
,1,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,8430,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620205
,1,,Pharmacokinetic parameter (Vss) in rat,,8431,5960,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624664
,1,,Pharmacokinetic property (Volume) in rat i.v.,,8432,5676,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624665
,1,,Pharmacokinetic property (Vss) in rat,,8433,5948,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624666
,1,,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,8434,5979,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624667
,1,,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,,8435,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624668
,1,,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,8436,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624669
,1,,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,8437,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624670
,1,,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,8438,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624671
,1,,Steady state volume distribution in rat,,8439,6448,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624672
,1,,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",,8440,12873,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624673
,1,,Steady state volume of distribution determined in rat,,8441,4576,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624674
,1,,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,8442,17582,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624675
,1,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,,8443,1466,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621728
,1,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,,8444,5182,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621729
,1,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,,8445,5182,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621730
,1,,Volume distribution in rat after administration of 2 mg/kg iv,,8446,6535,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621731
,1,,Volume distribution in rat after administration of 2 mg/kg iv,,8447,6535,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621732
,1,,Volume in steady state distribution value was determined,,8448,5041,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621908
,1,,Volume in steady state distribution value was determined; ND denotes no data,,8449,5041,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875347
,1,,Volume in steady state distribution value was determined; ND denotes not determined,,8450,5041,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621909
,1,,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,,8451,17065,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621910
,1,,Volume of distribution at steady state was evaluated in rats,,8452,6597,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621911
,1,,Volume of distribution at steady state was observed after intravenous administration in rat,,8453,15662,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621912
,1,,Volume of distribution in steady state was determined in rat,,8454,6485,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621913
,1,,Volume of distribution in steady state was determined in rat,,8455,17655,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621914
,1,,Volume of distribution after i.v. administration,,8456,6616,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621915
,1,,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,8457,1916,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621916
,1,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,8458,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL621917
,1,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,8459,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL621918
,1,,Biodistribution of compound (oxidized form) in spleen tissue,,8460,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL621919
,1,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,8461,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL621920
,1,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,8462,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL621921
,1,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,8463,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL622401
,1,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,8464,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL875348
,1,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,8465,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL622402
,1,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,,8466,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622403
,1,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,8467,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622404
,1,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,,8468,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622405
,1,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",,8469,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622406
,1,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,8470,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622407
,1,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,,8471,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL622408
,1,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",,8472,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL622409
,1,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,8473,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL622410
,1,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,,8474,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL622411
,1,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",,8475,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL627864
,1,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,8476,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL627865
,1,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,,8477,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL627866
,1,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,8478,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL627751
,1,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,,8479,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL627752
,1,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",,8480,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL627753
,1,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,8481,16438,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL627754
,1,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,,8482,12467,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL627755
,1,,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),,8483,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL627756
,1,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),,8484,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL627757
,1,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),,8485,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL627758
,1,,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),,8486,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL627759
,1,,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),,8487,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL627760
,1,,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),,8488,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL627761
,1,,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),,8489,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL876811
,1,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),,8490,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL627762
,1,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),,8491,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL627763
,1,,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),,8492,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL627764
,1,,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),,8493,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL627765
,1,,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),,8494,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL627766
,1,,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),,8495,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL627767
,1,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),,8496,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL627768
,1,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),,8497,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL628422
,1,,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),,8498,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL628423
,1,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,,8499,5089,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628424
,1,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,,8500,5089,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628425
,1,,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,,8501,4257,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628426
,1,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,8502,6679,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628427
,1,,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,8503,5546,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626938
,1,,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,8504,6141,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626939
,1,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,8505,5334,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626940
,1,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,8506,5334,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626941
,1,,Plasma clearance was reported in Sprague-Dawley rat,,8507,5334,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626942
,1,,Plasma clearance after intravenous administration (1 mg/kg) in rat,,8508,4689,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876812
,1,,Plasma clearance of compound in rats was evaluated,,8509,6848,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626943
,1,,Plasma clearance of compound in rats was evaluated; ND indicates not determined,,8510,6848,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626944
,1,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,,8511,6467,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626945
,1,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,8512,6467,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626946
,1,,Plasma clearance rate in Sprague-Dawley rats,,8513,4956,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626856
,1,,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),,8514,5529,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626857
,1,,The compound was evaluated for plasma clearance in rat,,8515,406,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626858
,1,,Total plasma clearance in rat,,8516,17655,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627018
,1,,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,,8517,3293,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL625331
,1,,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,,8518,4075,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL625332
,1,,C max was determined at 10 mg/kg po dose in rats,,8519,2792,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL877590
,1,,C max was determined at 3 mg/kg po dose in rats,,8520,2792,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625333
,1,,Cmax after repeated oral dose of compound at 1 mg/kg in rats,,8521,17594,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625334
,1,,Cmax after single intravenous bolus of 1 mg/kg in rats,,8522,17594,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625335
,1,,Cmax of compound at 5 mg/kg after po administration was determined in rat,,8523,4762,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625336
,1,,Cmax 24 hr after 10 mg/kg oral administration in rats,,8524,17509,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625337
,1,,Cmax 24 hr after 2 mg/kg oral administration in rats,,8525,17509,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625338
,1,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,,8526,1466,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL625339
,1,,Cmax in rat after administration of 2 mg/kg iv,,8527,6535,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625340
,1,,Cmax in rat after administration of 2 mg/kg iv,,8528,6535,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625341
,1,,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,,8529,3169,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622687
,1,,Cmax wa determined in rat plasma at 30 mg/kg after po administration,,8530,6515,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622688
,1,,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,,8531,11149,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622689
,1,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,,8532,11149,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL620295
,1,,Cmax after 10 mg/kg oral administration in rat,,8533,17858,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620296
,1,,Cmax after IV dosing at 0.5 mg/kg in rat; no data,,8534,6518,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620297
,1,,Cmax after IV dosing at 1 mg/kg in rat; no data,,8535,6518,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620298
,1,,Cmax after oral administration at 20 mpk in rats,,8536,4426,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620299
,1,,Cmax after oral administration at 20 mpk in rats; Not performed.,,8537,4426,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620300
,1,,Cmax after oral administration at 20 mpk in rats d; Not performed.,,8538,4426,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620301
,1,,Cmax after oral administration in rat,,8539,5656,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620302
,1,,Cmax after oral administration at a dose of 2 mg/kg in rat,,8540,6518,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620303
,1,,Cmax after oral administration at a dose of 4 mg/kg in rat,,8541,6518,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620304
,1,,Cmax in rats after 20 mg/kg oral dose,,8542,6113,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620305
,1,,Cmax after peroral administration in rats at 2.4 uM/kg,,8543,17764,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620306
,1,,Cmax at the dose of 2 mg/Kg administered perorally in rats,,8544,4756,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620307
,1,,Cmax at the dose of 5 mg/Kg administered perorally in rats,,8545,4756,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620308
,1,,Cmax by administering at 20 mg/kg p.o. in rats,,8546,6402,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620309
,1,,Cmax in male rat,,8547,5610,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620310
,1,,Cmax in rat,,8548,5207,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620311
,1,,Cmax in rat,,8549,6011,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620312
,1,,Cmax in rat,,8550,6504,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620313
,1,,Cmax in rat at 10 mg/kg,,8551,6046,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620314
,1,,Cmax in rat at the dose of 1 mg/kg i.v.,,8552,6504,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620315
,1,,Cmax in rat by po administration at a dose of 40 mg/kg,,8553,5874,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620316
,1,,Cmax in rat p.o. at 20 mg/kg concentration,,8554,17686,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620317
,1,,Cmax in rats,,8555,5836,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620318
,1,,Cmax in rats,,8556,17596,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620319
,1,,Cmax was evaluated after 20 uM/kg of peroral administration,,8557,16423,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620320
,1,,Cmax was measured in rats after peroral administration at 3 mg/kg,,8558,17804,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620321
,1,,Cmax value after oral dose at a dose of 10 mg/kg in rats.,,8559,1908,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620322
,1,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,,8560,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL620323
,1,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,8561,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Frontal cortex,N,1870.0,,,BAO_0000218,A,,CHEMBL620324
,1,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,8562,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Frontal cortex,N,1870.0,,,BAO_0000218,A,,CHEMBL620325
,1,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,,8563,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Hippocampus,N,10000000.0,,,BAO_0000218,A,,CHEMBL620326
,1,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,,8564,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Hippocampus,N,10000000.0,,,BAO_0000218,A,,CHEMBL620327
,1,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,,8565,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL620328
,1,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,,8566,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL620329
,1,,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,,8567,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Midbrain,N,1891.0,,,BAO_0000218,A,,CHEMBL620330
,1,,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,,8568,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Midbrain,N,1891.0,,,BAO_0000218,A,,CHEMBL875286
,1,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,8569,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL620331
,1,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,8570,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL620332
,1,,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,8571,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Striatum,N,2435.0,,,BAO_0000218,A,,CHEMBL620333
,1,,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,8572,13950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Striatum,N,2435.0,,,BAO_0000218,A,,CHEMBL620334
,1,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,8573,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL621015
,1,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,8574,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL621016
,1,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,8575,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL621191
,1,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,8576,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL621192
,1,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,8577,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL621193
,1,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,8578,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL621194
,1,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,8579,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624204
,1,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,8580,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624205
,1,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,8581,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624206
,1,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,8582,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624207
,1,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,8583,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624208
,1,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,8584,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624209
,1,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,8585,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624210
,1,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,8586,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624211
,1,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,8587,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624212
,1,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,8588,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624213
,1,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,8589,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL876611
,1,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,8590,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624214
,1,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,8591,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624215
,1,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,8592,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624216
,1,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,8593,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624217
,1,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,8594,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624218
,1,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,8595,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624219
,1,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,8596,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624220
,1,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,8597,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624221
,1,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,8598,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624222
,1,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,8599,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624223
,1,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,8600,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624224
,1,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,8601,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624225
,1,,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,,8602,17764,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622420
,1,,Volume of steady state distribution after i.v. administration in rats,,8603,5031,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622421
,1,,Vss after intravenous administration (5.0 mg/kg) was determined in rat,,8604,6215,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622422
,1,,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,8605,17671,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622423
,1,,Vss was determined,,8606,17752,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622424
,1,,Vss in rat,,8607,6596,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622425
,1,,Vss was evaluated after 10 uM/kg of intra arterial administration,,8608,16423,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876612
,1,,volume of distribution at steady state was observed after intravenous administration in rat,,8609,15662,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622426
,1,,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,,8610,6062,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622427
,1,,Pharmacokinetic (PK) parameter Vz in rat,,8611,5874,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622428
,1,,Volume distribution in rats,,8612,4942,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622429
,1,,Volume of distribution in rat; No data,,8613,17796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622430
,1,,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,8614,4890,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622431
,1,,% absorption predicted from in vitro rat ileum transport studies,,8615,15765,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Ileum,N,2116.0,,,BAO_0000218,A,,CHEMBL622432
,1,,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,8616,13569,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622433
,1,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,8617,13569,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622434
,1,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,,8618,13569,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622435
,1,,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),,8619,13569,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618748
,1,,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,8620,13569,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618749
,1,,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,8621,13569,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618750
,1,,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,8622,13569,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618751
,1,,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,8623,13569,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618752
,1,,Oral bioavailability in rat,,8624,4576,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618753
,1,,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,,8625,750,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL618754
,1,,Oral bioavailability in rat,,8626,750,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618755
,1,,Oral bioavailability in rat,,8627,4590,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618756
,1,,Oral bioavailability in rat,,8628,1716,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618757
,1,,Bioavailability in rat,,8629,1974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618758
,1,,Oral bioavailability in rat (dose 30 mg/kg),,8630,4502,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621088
,1,,Pharmacokinetic property (cLogP) in rat,,8631,3371,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621089
,1,,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,,8632,9099,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,F,,CHEMBL621090
,1,,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,,8633,9099,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,F,,CHEMBL621091
,1,,Clearance in rat.,,8634,4590,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876731
,1,,Compound was evaluated for its clearance when administered intravenously in rat,,8635,3184,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621092
,1,,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,8636,16456,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621093
,1,,Blood: Brain distribution ratio is determined in rat,,8637,4199,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621094
,1,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,,8638,4199,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621095
,1,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,,8639,4199,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621096
,1,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,8640,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621097
,1,,Percent dose excreted in 0-48 hours administered ip to male rat,,8641,7449,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,F,,CHEMBL621098
,1,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,8642,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Cerebellum,N,2037.0,,,BAO_0000218,A,,CHEMBL621099
,1,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,8643,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Cerebellum,N,2037.0,,,BAO_0000218,A,,CHEMBL621100
,1,,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,8644,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Cerebellum,N,2037.0,,,BAO_0000218,A,,CHEMBL621101
,1,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,8645,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Cerebellum,N,2037.0,,,BAO_0000218,A,,CHEMBL621102
,1,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,8646,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Cerebellum,N,2037.0,,,BAO_0000218,A,,CHEMBL876732
,1,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,8647,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621103
,1,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,8648,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621104
,1,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,8649,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621105
,1,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,8650,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621106
,1,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,8651,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621107
,1,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,8652,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621108
,1,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,8653,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621109
,1,,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),,8654,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621110
,1,,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),,8655,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL621111
,1,,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),,8656,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622541
,1,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),,8657,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622542
,1,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),,8658,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622543
,1,,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),,8659,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL624412
,1,,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),,8660,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL624413
,1,,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),,8661,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL624414
,1,,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),,8662,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL624415
,1,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),,8663,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL624416
,1,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),,8664,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL624417
,1,,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),,8665,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL624418
,1,,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),,8666,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL624419
,1,,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),,8667,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL624420
,1,,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),,8668,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL624421
,1,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),,8669,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL624422
,1,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),,8670,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL624423
,1,,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),,8671,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL625123
,1,,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),,8672,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL625124
,1,,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),,8673,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL625125
,1,,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),,8674,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL625126
,1,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),,8675,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL626947
,1,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),,8676,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL626948
,1,,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),,8677,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL626949
,1,,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),,8678,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL626950
,1,,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),,8679,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL626951
,1,,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),,8680,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL626952
,1,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),,8681,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL626953
,1,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),,8682,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL626954
,1,,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),,8683,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL626955
,1,,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),,8684,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL626956
,1,,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),,8685,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL626957
,1,,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),,8686,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL626958
,1,,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),,8687,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL626959
,1,,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),,8688,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL626960
,1,,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),,8689,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL626961
,1,,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),,8690,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL627589
,1,,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),,8691,17208,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL627590
,1,,Time taken for EC90 was determined when tested in mouse,,8692,3132,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL627591
,1,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,,8693,3132,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL627592
,1,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,8694,16597,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627593
,1,,Half life in mice,,8695,5727,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL627594
,1,,Half life period in mouse after 10 mg/Kg dose,,8696,5302,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876813
,1,,Half life period in mouse after 10 mg/kg dose,,8697,5302,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627595
,1,,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,8698,6348,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627596
,1,,Cmax value at 5 mg/kg po was determined in rat,,8699,5964,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627597
,1,,Cmax value evaluated in rat,,8700,6078,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627598
,1,,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,,8701,5206,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL627599
,1,,Cmax value after administration of 20 mg/Kg oral dose in rat,,8702,2959,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627600
,1,,Cmax value at 1 mg/kg po in rat,,8703,5964,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627601
,1,,Cmax value at 5 mg/kg po in rat,,8704,5964,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627776
,1,,Cmax value at a dose of 10 mg/kg in male SD rats,,8705,6757,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627777
,1,,Cmax value at a dose of 100 mg/kg in male SD rats,,8706,6757,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627778
,1,,Cmax value at a dose of 50 mg/kg in male SD rats,,8707,6757,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627779
,1,,Cmax value in rats at 10 mg/kg,,8708,17617,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876814
,1,,Cmax value was evaluated in rats at a dose of 20 mg/kg,,8709,1445,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627780
,1,,Cmax value was determined after peroral administration of 20 mg/kg in rat,,8710,6082,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627781
,1,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,8711,1446,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627782
,1,,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,,8712,5407,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627783
,1,,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,,8713,2690,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627784
,1,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,,8714,2661,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627785
,1,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,,8715,2661,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627786
,1,,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,,8716,4891,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627787
,1,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,,8717,2807,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627788
,1,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,,8718,2807,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626579
,1,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,,8719,2807,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626580
,1,,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,,8720,3634,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876815
,1,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,,8721,1881,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626581
,1,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,,8722,1881,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626582
,1,,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,,8723,429,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626583
,1,,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,8724,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626205
,1,,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,8725,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626206
,1,,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,8726,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626207
,1,,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,8727,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623882
,1,,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,,8728,17582,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623883
,1,,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,,8729,17582,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623884
,1,,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",,8730,3032,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623885
,1,,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,,8731,6295,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623886
,1,,Maximal concentration in rat was determined,,8732,6619,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623887
,1,,Maximal concentration after i.v. administration,,8733,6616,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623888
,1,,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,,8734,3249,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623889
,1,,Maximal plasma concentration in rat after oral administration at 50 mg/kg,,8735,17791,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623890
,1,,Cmax in rat plasma after oral dose (50 mg/Kg),,8736,17791,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623891
,1,,Maximal plasma concentration was determined.,,8737,1360,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623892
,1,,Maximal plasma drug concentration was determined,,8738,2552,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623893
,1,,Maximal concentration in rats after peroral administration,,8739,6571,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL877616
,1,,Maximum concentration in rat after 2 mg/kg peroral administration,,8740,6570,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623894
,1,,Maximum concentration in rat plasma after 5 mg/kg oral gavage,,8741,6567,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623895
,1,,Maximum concentration of compound in rat was evaluated.,,8742,3031,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623896
,1,,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,,8743,3436,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623897
,1,,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,,8744,3436,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623898
,1,,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,,8745,2083,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623899
,1,,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,,8746,3436,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623900
,1,,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,,8747,4527,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623901
,1,,Maximum concentration was evaluated in rats,,8748,1974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623902
,1,,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,,8749,3307,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Cerebrospinal fluid,N,1359.0,In vivo,,BAO_0000218,A,,CHEMBL623903
,1,,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,,8750,3307,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623904
,1,,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,8751,1916,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL877617
,1,,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,,8752,1500,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623905
,1,,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,,8753,1500,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623906
,1,,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,8754,4186,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623907
,1,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,8755,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623908
,1,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,,8756,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623909
,1,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,8757,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623910
,1,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,8758,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623911
,1,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,8759,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623912
,1,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,8760,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624616
,1,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,8761,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624617
,1,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,8762,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624618
,1,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,8763,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624619
,1,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,8764,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624794
,1,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,8765,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624795
,1,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,8766,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623921
,1,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,8767,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623922
,1,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,8768,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623923
,1,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,8769,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623924
,1,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,8770,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623925
,1,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,8771,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623926
,1,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,8772,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623927
,1,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,8773,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623928
,1,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,8774,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623929
,1,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,8775,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623930
,1,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,8776,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL623931
,1,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,8777,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL622165
,1,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,8778,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL621249
,1,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,8779,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL621250
,1,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,8780,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL621448
,1,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,8781,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL621449
,1,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,8782,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL621450
,1,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,8783,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL621451
,1,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,8784,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL621452
,1,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,8785,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL621453
,1,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,8786,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL621454
,1,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,8787,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL621455
,1,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,8788,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL621456
,1,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,8789,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL625145
,1,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,8790,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL875847
,1,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,8791,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL625146
,1,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,8792,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL625147
,1,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,8793,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL625148
,1,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,8794,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL625149
,1,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,8795,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL625150
,1,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,8796,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL625151
,1,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,8797,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL625152
,1,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,8798,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL625153
,1,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,8799,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL625154
,1,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,8800,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL625155
,1,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,8801,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625156
,1,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,8802,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624354
,1,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,8803,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Hippocampus,N,10000000.0,,,BAO_0000218,A,,CHEMBL624355
,1,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,8804,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Hippocampus,N,10000000.0,,,BAO_0000218,A,,CHEMBL624356
,1,,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,8805,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Hippocampus,N,10000000.0,,,BAO_0000218,A,,CHEMBL624357
,1,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,8806,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Hippocampus,N,10000000.0,,,BAO_0000218,A,,CHEMBL624358
,1,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,8807,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Striatum,N,2435.0,,,BAO_0000218,A,,CHEMBL624359
,1,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,8808,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Striatum,N,2435.0,,,BAO_0000218,A,,CHEMBL624360
,1,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,8809,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Striatum,N,2435.0,,,BAO_0000218,A,,CHEMBL624361
,1,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,8810,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Striatum,N,2435.0,,,BAO_0000218,A,,CHEMBL624362
,1,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,8811,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Striatum,N,2435.0,,,BAO_0000218,A,,CHEMBL624363
,1,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,8812,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL624364
,1,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,8813,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL624365
,1,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,8814,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL624366
,1,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,8815,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL624367
,1,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,8816,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL624368
,1,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,8817,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL624369
,1,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,8818,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL624370
,1,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,8819,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL625069
,1,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,8820,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL625070
,1,,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,8821,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL626051
,1,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,8822,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL626052
,1,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,8823,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL626053
,1,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,8824,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL626054
,1,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,8825,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL626055
,1,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,8826,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL626056
,1,,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,8827,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL626057
,1,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,8828,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL625193
,1,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,8829,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL625194
,1,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,8830,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL625195
,1,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,8831,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL625196
,1,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,8832,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL625197
,1,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,8833,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL625198
,1,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,8834,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL627929
,1,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,8835,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL627074
,1,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,8836,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL627075
,1,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,8837,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL627076
,1,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,8838,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL627077
,1,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,8839,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL627078
,1,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),,8840,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL627079
,1,,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,,8841,4573,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL873824
,1,,Half life in mouse plasma was determined at dose 25 mg/kg,,8842,3132,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627080
,1,,Half life was determined,,8843,17718,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL627081
,1,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,8844,17728,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627082
,1,,Half-life in male mice after 1 mg/kg intravenous dose,,8845,5961,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627083
,1,,Half life in mice plasma,,8847,17731,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL627085
,1,,Half life in mouse,,8848,17592,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL627086
,1,,Half life in mouse plasma at dose 25 mg/kg,,8849,3132,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627087
,1,,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,,8850,17729,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627088
,1,,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,,8851,17729,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627089
,1,,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,,8852,17729,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627090
,1,,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,8853,3277,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627091
,1,,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",,8854,3760,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627092
,1,,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",,8855,3760,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876785
,1,,Half-life by iv administration in mouse,,8856,2862,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627093
,1,,Half-life by oral administration in mouse,,8857,2862,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627094
,1,,Half-life in mice,,8858,5980,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL627095
,1,,Half-life using mouse brain homogenate,,8859,6159,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL627096
,1,,Half-life was measured in mice,,8860,6254,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL627097
,1,,Half-life was measured in mouse after an iv dose of 1 mg/kg,,8861,6062,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627098
,1,,Half-life period was determined in mouse blood,,8862,1574,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL627099
,1,,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",,8863,56,,1,Mus musculus,Intermediate,50594,,10090.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL627100
,1,,Plasma half life in mouse,,8864,993,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL627101
,1,,Stability of the peptide in the presence of mouse serum,,8865,6652,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL627102
,1,,Terminal half life of compound was determined in mouse,,8866,17852,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL627103
,1,,Terminal half life was evaluated in mice after intravenous administration,,8867,2675,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627104
,1,,Terminal half life was evaluated in mice after oral administration,,8868,2675,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627105
,1,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,,8869,499,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL876786
,1,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,,8870,499,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL873825
,1,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,,8871,499,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL627106
,1,,half life period is evaluated by administering intravenously at 25 mg/kg in mice,,8872,14239,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626336
,1,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",,8873,5506,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL877462
,1,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",,8874,5506,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626337
,1,,Half life after intraperitoneal administration of 100 mg/kg in mice,,8875,17734,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL626338
,1,,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,,8876,17728,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626339
,1,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,8877,17728,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626340
,1,,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,,8878,17728,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625377
,1,,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,,8879,17728,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625378
,1,,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,,8880,17728,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625379
,0,,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),,8881,14294,Microsomes,1,Sus scrofa,Autocuration,22224,,9823.0,,U,,,,BAO_0000251,A,,CHEMBL625380
,0,,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),,8882,14294,Microsomes,1,Sus scrofa,Autocuration,22224,,9823.0,,U,,,,BAO_0000251,A,,CHEMBL625381
,0,,Stability to porcine renal DHP-I,,8883,6056,,1,Sus scrofa,Autocuration,22224,,9823.0,,U,,,,BAO_0000019,A,,CHEMBL625382
,0,,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,,8884,1317,,1,Sus scrofa,Autocuration,22224,,9823.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL873828
,0,,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,,8885,1317,,1,Sus scrofa,Autocuration,22224,,9823.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL625383
,0,,Half-life of the parent prodrug in porcine esterase solution,,8886,5229,,1,Sus scrofa,Autocuration,22224,,9823.0,,U,,,,BAO_0000019,A,,CHEMBL625384
,0,,"First order rate constant, k was determined in in pig liver Esterase",,8887,4231,,1,Sus scrofa,Autocuration,22224,,9823.0,,U,,,,BAO_0000019,A,,CHEMBL625385
,0,,Half life of the in pig liver Esterase,,8888,4231,,1,Sus scrofa,Autocuration,22224,,9823.0,Liver,U,2107.0,,,BAO_0000221,A,,CHEMBL625386
,0,,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,,8889,5318,,1,Sus scrofa,Autocuration,22224,,9823.0,Liver,U,2107.0,,,BAO_0000221,A,,CHEMBL623571
,0,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,,8890,5318,,1,Sus scrofa,Autocuration,22224,,9823.0,Liver,U,2107.0,,,BAO_0000221,A,,CHEMBL623572
,0,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,,8891,5318,,1,Sus scrofa,Autocuration,22224,,9823.0,Liver,U,2107.0,,,BAO_0000221,A,,CHEMBL623573
,0,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,,8892,3305,,1,Sus scrofa,Autocuration,22224,,9823.0,Liver,U,2107.0,,,BAO_0000221,A,,CHEMBL623574
,0,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,,8893,3305,,1,Sus scrofa,Autocuration,22224,,9823.0,Liver,U,2107.0,,,BAO_0000221,A,,CHEMBL623575
,0,,Half-life in the presence of pig liver esterase(PLE) was evaluated.,,8894,2842,,1,Sus scrofa,Autocuration,22224,,9823.0,Liver,U,2107.0,,,BAO_0000221,A,,CHEMBL623749
,0,,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,,8895,2842,,1,Sus scrofa,Autocuration,22224,,9823.0,Liver,U,2107.0,,,BAO_0000221,A,,CHEMBL623750
,0,,Half-life in vitro in pig liver,,8896,889,,1,Sus scrofa,Autocuration,22224,,9823.0,Liver,U,2107.0,In vitro,,BAO_0000221,A,,CHEMBL623751
,0,,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,,8897,1904,,1,Sus scrofa,Autocuration,22224,,9823.0,Liver,U,2107.0,,,BAO_0000221,A,,CHEMBL623752
,1,,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,8898,4186,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623753
,1,,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,,8899,2774,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623754
,1,,Maximum concentration in rat plasma was determined,,8900,1742,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623755
,1,,Maximum concentration in rats,,8901,3169,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623756
,1,,Maximum concentration in rats at 1-2 hours,,8902,3169,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623757
,1,,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,,8903,2081,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623758
,1,,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,,8904,3307,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL623759
,1,,Maximum concentration at the dose of 2 mg/kg in rat,,8905,4727,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623760
,1,,Maximum concentration was evaluated in rats,,8906,6597,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623761
,1,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,,8907,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623762
,1,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,,8908,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL877594
,1,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,,8909,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623763
,1,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,,8910,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623764
,1,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,,8911,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623765
,1,,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,,8912,2591,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL623766
,1,,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,,8913,2591,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL623767
,1,,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,,8914,2591,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL623768
,1,,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,,8915,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623769
,1,,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,,8916,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623770
,1,,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,,8917,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623771
,1,,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,,8918,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623772
,1,,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,,8919,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623773
,1,,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,,8920,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623774
,1,,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,,8921,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623775
,1,,Cmax in rat (PO dose),,8922,14465,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623776
,1,,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,8923,4723,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622191
,1,,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,,8924,4723,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622192
,1,,Maximum plasma concentration determined in rat,,8925,4576,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622193
,1,,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,,8926,12873,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622194
,1,,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,,8927,12873,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622195
,1,,Maximum plasma concentration in rat,,8928,6824,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622196
,1,,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,,8929,17065,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622197
,1,,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,,8930,2932,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622198
,1,,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,,8931,2932,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622199
,1,,Maximum plasma concentration of compound was measured in rat,,8932,2879,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622200
,1,,Maximum plasma concentration after 20 mg/kg oral administration in rat,,8933,2864,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622201
,1,,Maximum plasma concentration after oral administration to rats,,8934,16367,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623990
,1,,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,8935,17717,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623991
,1,,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",,8936,17717,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623992
,1,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,8937,17717,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623993
,1,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,,8938,17717,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623994
,1,,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,,8939,17720,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,F,,CHEMBL623995
,1,,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,,8940,17720,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,F,,CHEMBL623996
,1,,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,,8941,17720,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,F,,CHEMBL623997
,1,,Maximum plasma concentration dosed orally in rats,,8942,4516,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623998
,1,,Maximum plasma concentration dosed orally in rats after 6 hours,,8943,4516,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623999
,1,,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,,8944,4516,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624000
,1,,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,,8945,5199,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624001
,1,,Maximum plasma concentration in rat after po administration,,8946,17538,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624002
,1,,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",,8947,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624003
,1,,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",,8948,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624004
,1,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,8949,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624005
,1,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,8950,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624006
,1,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,8951,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624007
,1,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,8952,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624008
,1,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,8953,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624009
,1,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,8954,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL874387
,1,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,8955,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624010
,1,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,8956,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624011
,1,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,8957,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624012
,1,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,8958,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624013
,1,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,8959,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624736
,1,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,8960,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624737
,1,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,8961,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624738
,1,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,8962,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624739
,1,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,8963,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624740
,1,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,8964,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624896
,1,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,8965,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624897
,1,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,8966,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624108
,1,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,8967,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624109
,1,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,8968,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624110
,1,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,8969,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624111
,1,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,8970,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624112
,1,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,8971,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624113
,1,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,8972,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL619709
,1,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,8973,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL619710
,1,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,8974,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL619711
,1,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,8975,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL619712
,1,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,8976,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL619713
,1,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,8977,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL619714
,1,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,8978,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL619715
,1,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,8979,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL619716
,1,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,8980,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL619717
,1,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,8981,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL619718
,1,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,8982,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL619719
,1,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,8983,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL875329
,1,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,8984,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL619720
,1,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,8985,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL619721
,1,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,8986,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL619722
,1,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,8987,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL619723
,1,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,8988,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL619724
,1,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,8989,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL619725
,1,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,8990,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL619726
,1,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,8991,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL619727
,1,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,8992,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL619728
,1,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,8993,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL619729
,1,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,8994,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL619730
,1,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,8995,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL619731
,1,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,8996,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL619732
,1,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,8997,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL619733
,1,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,8998,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL619734
,1,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,8999,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL619735
,1,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,9000,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL875330
,1,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,9001,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL628465
,1,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,9002,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL628466
,1,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,9003,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL628467
,1,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,9004,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL628468
,1,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,9005,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL628469
,1,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,9006,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL628470
,1,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,9007,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL628471
,1,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,9008,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL628472
,1,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,9009,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,In vivo,,BAO_0000218,A,,CHEMBL625191
,1,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,9010,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,In vivo,,BAO_0000218,A,,CHEMBL625192
,1,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,9011,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,In vivo,,BAO_0000218,A,,CHEMBL875337
,1,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,9012,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,In vivo,,BAO_0000218,A,,CHEMBL626341
,1,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,9013,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,In vivo,,BAO_0000218,A,,CHEMBL626342
,1,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,9014,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL621943
,1,,Half life in rats,,9015,3748,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621944
,1,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,,9016,15765,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621945
,1,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),,9017,4871,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621946
,1,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,,9018,4871,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621947
,1,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),,9019,4872,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621948
,1,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,,9020,4872,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621949
,1,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),,9021,5413,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621950
,1,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,,9022,5413,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621951
,1,,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,,9023,15272,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL621952
,1,,Stability (%) in rat liver microsomes,,9024,4689,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL621953
,1,,Area under curve was calculated after intravenous administration,,9025,6057,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621954
,1,,Area under the curve was calculated after iv administration in rat,,9026,6057,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621955
,1,,Area under the curve was calculated in rat after peroral administration,,9027,6057,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621956
,1,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,9028,6211,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621957
,1,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,,9029,5710,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621958
,1,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,,9030,5710,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621959
,1,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,,9031,17853,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621960
,1,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,,9032,17853,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621961
,1,,p value of the compound,,9033,15765,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621962
,1,,p value of the compound,,9034,15765,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,F,,CHEMBL876787
,1,,p value of the compound,,9035,15765,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621963
,1,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,9036,6175,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Stomach,N,945.0,,,BAO_0000218,A,,CHEMBL622637
,1,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,9037,6175,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Stomach,N,945.0,,,BAO_0000218,A,,CHEMBL622638
,1,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,9038,6175,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Stomach,N,945.0,,,BAO_0000218,A,,CHEMBL626561
,0,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),,9039,7991,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,,,BAO_0000019,F,,CHEMBL626562
,0,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),,9040,429,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,,,BAO_0000218,A,,CHEMBL626563
,0,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),,9041,429,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,,,BAO_0000218,A,,CHEMBL626564
,0,,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,9042,6253,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL626565
,0,,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,9043,6253,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL626566
,0,,Clearance rate in rabbits,,9044,3615,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL626567
,0,,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,9045,4059,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL626568
,0,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,9046,5124,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL626569
,0,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,9047,5124,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL626570
,0,,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,9048,5124,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL626571
,0,,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,,9049,429,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL626572
,0,,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,9050,4059,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626573
,0,,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,,9051,9659,Microsomes,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,Liver,U,2107.0,,,BAO_0000251,A,,CHEMBL626574
,0,,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,,9052,9659,Microsomes,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,Liver,U,2107.0,,,BAO_0000251,A,,CHEMBL626575
,0,,Dose at which bioavailability of intravenously administered compound was tested in rabbit,,9053,3639,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,,,BAO_0000218,A,,CHEMBL626576
,0,,Dose at which bioavailability of perorally administered compound was tested in rabbit,,9054,3639,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,,,BAO_0000218,A,,CHEMBL626577
,0,,The compound was tested for its bioavailability in rabbit (by oral dosage).,,9055,3639,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL626578
,0,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,9056,5124,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL625263
,0,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,9057,5124,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL625264
,0,,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,9058,5124,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL625265
,0,,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),,9059,14294,Microsomes,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,,,BAO_0000251,A,,CHEMBL625266
,0,,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),,9060,14294,Microsomes,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,,,BAO_0000251,A,,CHEMBL876796
,0,,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,,9061,429,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL625267
,0,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,9062,5124,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL625268
,0,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,9063,5124,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL625269
,0,,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,9064,5124,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL624689
,0,,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,,9065,429,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624690
,0,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),,9066,429,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,Urine,U,1088.0,,,BAO_0000218,A,,CHEMBL624691
,0,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),,9067,429,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,Urine,U,1088.0,,,BAO_0000218,A,,CHEMBL624692
,0,,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,,9068,4059,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624693
,0,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,9069,4137,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624694
,0,,In vitro Biological half-life in crude homogenate of rabbit renal cortex,,9070,11672,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,In vitro,,BAO_0000221,A,,CHEMBL877596
,0,,Time within which only 10% of the drug was degraded,,9071,12886,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,,,BAO_0000019,A,,CHEMBL624695
,0,,Half life period in rabbit liver homogenate,,9072,3853,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,Liver,U,2107.0,,,BAO_0000221,A,,CHEMBL624696
,0,,Half life value in rabbits,,9073,3615,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,,,BAO_0000019,A,,CHEMBL624697
,0,,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,9074,6253,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,Blood,U,178.0,In vivo,,BAO_0000218,A,,CHEMBL624698
,0,,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,9075,6253,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,Blood,U,178.0,In vivo,,BAO_0000218,A,,CHEMBL624699
,0,,Half-life period in rabbits following intravenous administration at 2 mg/kg,,9076,6077,,1,Oryctolagus cuniculus,Autocuration,22224,,9986.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624700
,1,,AUC 0-8 hr value in rats at 10 mg/kg,,9077,17617,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622903
,1,,AUC after administration at 2000 mg/kg/day in rats,,9078,17594,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622904
,1,,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,,9079,6149,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622905
,1,,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,9080,17260,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622906
,1,,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,9081,17260,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622907
,1,,AUC in rat after oral administration at 10.5 mg/kg dose,,9082,6644,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622908
,1,,AUC in rat after oral administration at 11.2 mg/kg dose,,9083,6644,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622909
,1,,AUC in rat after oral administration at 9.7 mg/kg dose,,9084,6644,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622910
,1,,AUC in rat brain after oral administration at 10 mg/kg,,9085,6495,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL622911
,1,,AUC in rat p.o.,,9086,6504,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622912
,1,,AUC in rat p.o. at 20 mg/kg concentration,,9087,17686,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622913
,1,,AUC in rat plasma after oral administration at 10 mg/kg,,9088,6495,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622914
,1,,AUC in rats,,9089,216,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622915
,1,,AUC value after IV dose at a dose of 5 mg/kg in rats.,,9090,1908,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622916
,1,,AUC value after oral dose at a dose of 10 mg/kg in rats.,,9091,1908,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622917
,1,,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,9092,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622918
,1,,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,,9093,216,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622919
,1,,Maximum plasma concentration was evaluated in rat,,9094,6049,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622920
,1,,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,9095,2463,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622921
,1,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,9096,6679,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622922
,1,,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,,9097,6681,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622923
,1,,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,9098,4890,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL877604
,1,,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,,9099,6410,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622924
,1,,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,,9100,6410,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622925
,1,,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,,9101,16366,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622926
,1,,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,,9102,6227,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623625
,1,,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,,9103,3598,,1,Rattus norvegicus,Expert,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623626
,1,,Maximum plasma drug concentration was determined,,9104,1465,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623627
,1,,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,,9105,4368,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623628
,1,,Mean peak plasma concentration was observed after intravenous administration in rat,,9106,15662,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623629
,1,,Mean peak plasma concentration was observed after oral administration in rat,,9107,15662,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623630
,1,,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,,9108,5355,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623804
,1,,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,,9109,5355,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623805
,1,,Peak oral plasma concentration was determined in rats by oral administration,,9110,1567,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623806
,1,,Peak plasma concentration (Cmax) was determined,,9111,4026,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623807
,1,,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,,9112,6193,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623808
,1,,Peak plasma concentration (Cmax) in rats,,9113,4026,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623809
,1,,Peak plasma concentration at 1 mg/kg peroral administration,,9114,6485,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623810
,1,,Peak plasma concentration in rat,,9115,17655,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623811
,1,,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",,9116,14941,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623812
,1,,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,,9117,5394,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL877605
,1,,Pharmacokinetic property (Cmax) in rat,,9118,4408,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623813
,1,,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,9119,5983,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623814
,1,,Cmax in rat after 3mg/kg oral dose,,9120,4878,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623815
,1,,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,Sprague-Dawley,9121,5862,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623816
,1,,Cmax in rats after 20 mg/kg oral dose,,9122,4517,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623145
,1,,Cmax in rat plasma after 30mg/kg oral dose,,9123,5932,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623146
,1,,Plasma concentration after oral administration of 100 mg/kg to rats,,9124,5436,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623147
,1,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,9125,4910,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL623042
,1,,Tested for the Cmax in rat at 10 mg/kg per orally,,9126,4950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623043
,1,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,9127,15078,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623044
,1,,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",,9128,15078,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623045
,1,,Bioavailability as oral Cmax in rats at 30 mins,,9129,3360,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623046
,1,,Bioavailability as oral Cmax in rats at 6hr,,9130,3360,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623226
,1,,The maximum concentration of compound was measured at the dose of 100 umol/kg,,9131,15022,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623227
,1,,The maximum concentration of compound was measured at the dose of 300 umol/kg,,9132,15022,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623228
,1,,The maximum concentration of compound was measured at the dose of 30 umol/kg,,9133,15022,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623229
,1,,The maximum plasma levels for the compounds were determined by LC-MS.,,9134,5160,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623230
,1,,mean peak plasma concentration was observed after intravenous administration in rat,,9135,15662,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623231
,1,,mean peak plasma concentration was observed after oral administration in rat,,9136,15662,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623232
,1,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,,9137,4709,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623233
,1,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,,9138,3535,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623234
,1,,Concentration in plasma (portal) following oral dose in rats at 1 hr,,9139,3535,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623235
,1,,Concentration in plasma (portal) following oral dose in rats at 2 hr,,9140,3535,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623236
,1,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,,9141,3535,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623237
,1,,Concentration in plasma (systemic) following oral dose in rats at 1 hr,,9142,3535,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623238
,1,,Concentration in plasma (systemic) following oral dose in rats at 2 hr,,9143,3535,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623239
,0,,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,,9144,5005,,1,Rattus norvegicus,Intermediate,22224,,10116.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623240
,1,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",,9145,6326,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Hypothalamus,N,1898.0,,,BAO_0000218,A,,CHEMBL623241
,1,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",,9146,6326,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Hypothalamus,N,1898.0,,,BAO_0000218,A,,CHEMBL623242
,1,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",,9147,6326,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL874394
,1,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",,9148,6326,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623243
,1,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,9149,17411,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623244
,1,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,9150,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL623245
,1,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,9151,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL623246
,1,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,9152,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL623247
,1,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,9153,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL623248
,1,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,9154,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL623249
,1,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,9155,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625072
,1,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,9156,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625073
,1,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,9157,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625074
,1,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,9158,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625075
,1,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,,9159,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625076
,1,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,9160,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625077
,1,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,9161,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625078
,1,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,9162,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL874395
,1,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,9163,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625079
,1,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,9164,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625080
,1,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,9165,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625081
,1,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,9166,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625082
,1,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,9167,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625083
,1,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,9168,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625084
,1,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,9169,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625085
,1,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,9170,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625086
,1,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,9171,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625087
,1,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,9172,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625088
,1,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,9173,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL622205
,1,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,9174,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL622206
,1,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,9175,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL622207
,1,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,9176,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL622366
,1,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,9177,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL622367
,1,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,9178,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL875331
,1,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,9179,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL622368
,1,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,9180,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622369
,1,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,9181,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622370
,1,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,9182,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622371
,1,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,9183,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622372
,1,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,9184,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622373
,1,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,9185,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622374
,1,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,9186,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622375
,1,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,9187,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622376
,1,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,9188,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622377
,1,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,9189,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622378
,1,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,9190,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622379
,1,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,9191,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622380
,1,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,9192,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622381
,1,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,9193,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622382
,1,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,,9194,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622383
,1,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,9195,6175,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Stomach,N,945.0,,,BAO_0000218,A,,CHEMBL875332
,1,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,9196,6175,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Stomach,N,945.0,,,BAO_0000218,A,,CHEMBL622384
,1,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,9197,6175,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Stomach,N,945.0,,,BAO_0000218,A,,CHEMBL622385
,1,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,9198,6175,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Stomach,N,945.0,,,BAO_0000218,A,,CHEMBL622386
,1,,The compound was tested for the plasma binding in rat,,9199,10839,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622387
,1,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",,9200,16459,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622388
,1,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",,9201,16459,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622389
,1,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",,9202,16459,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622390
,1,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),,9203,16459,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622391
,1,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),,9204,16459,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622392
,1,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),,9205,16459,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622393
,1,,Plasma level at 2 hr after administration of the compound,,9206,3278,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622394
,1,,plasma level at 2 hr after administration of the compound,,9207,3278,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622395
,1,,Stability in rat serum measured as % recovery at 1 min,,9208,4684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Serum,N,1977.0,,,BAO_0000218,A,,CHEMBL622396
,1,,Stability in rat serum measured as % recovery at 10 min,,9209,4684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Serum,N,1977.0,,,BAO_0000218,A,,CHEMBL624894
,1,,Stability in rat serum measured as % recovery at 10 mins,,9210,4684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Serum,N,1977.0,,,BAO_0000218,A,,CHEMBL624895
,1,,Stability in rat serum measured as % recovery at 2 hr,,9211,4684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Serum,N,1977.0,,,BAO_0000218,A,,CHEMBL624058
,1,,Stability in rat serum measured as % recovery at 3 min,,9212,4684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Serum,N,1977.0,,,BAO_0000218,A,,CHEMBL624059
,1,,Stability in rat serum measured as % recovery at 3 mins,,9213,4684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Serum,N,1977.0,,,BAO_0000218,A,,CHEMBL624060
,1,,Stability in rat serum measured as % recovery at 5 min,,9214,4684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Serum,N,1977.0,,,BAO_0000218,A,,CHEMBL624061
,1,,Stability in rat serum measured as % recovery at 5 mins,,9215,4684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Serum,N,1977.0,,,BAO_0000218,A,,CHEMBL624062
,1,,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,9216,16456,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624063
,1,,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,9217,16456,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624064
,1,,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,,9218,723,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL624065
,1,,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,,9219,723,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL624066
,1,,Half life tested in mature male rat at a dose of 30 mg/kg,,9220,5160,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL877490
,1,,Half life after intravenous administration of 1 mg/kg in rat,,9221,4709,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL874442
,1,,Half life period after administration (30 mg/kg) in rat,,9222,5633,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626890
,1,,Half life period in rat after 5 mg/Kg dose,,9223,5302,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626891
,1,,Half life period in rat after 5 mg/kg dose,,9224,5302,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626892
,1,,Half life period was determined,,9225,17791,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626893
,1,,Half life period was evaluated in rat,,9226,17791,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626894
,1,,Half life period was evaluated in rat; 0.5-1.0,,9227,17791,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626895
,1,,Half life period was evaluated in rat; 5.9-7.5,,9228,17791,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626896
,1,,Half-life in rat plasma,,9229,14512,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626897
,1,,Half-life time in rat was determined,,9230,6230,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626898
,1,,Terminal half-life after iv administration to rats,,9231,3364,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626899
,1,,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,,9232,6874,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626900
,1,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,,9233,857,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626901
,1,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),,9234,858,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626902
,1,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),,9235,858,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626903
,1,,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,,9236,5355,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL874443
,1,,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,,9237,5355,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626904
,1,,Half life in rats,,9238,6305,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626905
,1,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,,9239,13501,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL873830
,1,,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,,9240,17594,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626906
,1,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,9241,4186,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL631076
,1,,Biological half-life was measured in plasma of rats,,9242,2932,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL631077
,1,,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,,9243,17065,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL631078
,1,,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,,9244,15765,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL631079
,1,,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,,9245,2713,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL631080
,1,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,,9246,2661,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL631081
,1,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,,9247,2661,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL631239
,1,,Compound was evaluated for plasma half life in rat,,9248,740,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL631240
,1,,AUC value at a dose of 5 mg/kg (p.o.) in rats,,9249,6597,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL631241
,1,,AUC value after administration of 20 mg/Kg oral dose in rat,,9250,2959,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL631242
,1,,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,,9251,17594,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL631243
,1,,AUC0-96 after administration at 50 mg/kg,,9252,17596,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL874444
,1,,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,,9253,17594,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL631244
,1,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",,9254,3293,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631245
,1,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,,9255,6757,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627162
,1,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,,9256,6757,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627163
,1,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,,9257,6757,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627164
,1,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,,9258,5979,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL627165
,1,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,,9259,5979,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627166
,1,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,,9260,5979,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627167
,1,,Area under curve (AUC) at a dose of 30 mg/kg in rats,,9261,4026,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627822
,1,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,9262,5355,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627823
,1,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,,9263,5355,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627824
,1,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,9264,5355,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627825
,1,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,,9265,5633,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627826
,1,,Area under curve (Pharmacokinetic property) was determined,,9266,1716,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627827
,1,,Area under curve (Pharmacokinetic property) of the compound; Not determined,,9267,1716,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627828
,1,,Area under curve after intravenous administration (1 mg/kg) in rat,,9268,4689,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627829
,1,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,,9269,4527,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627830
,1,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,,9270,4527,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627831
,1,,Area under curve in male SD rats was observed after oral administration in rat,,9271,15662,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627832
,1,,Area under curve of compound after iv administration of 20 mg/kg dose in rat,,9272,4413,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627833
,1,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,,9273,3598,,1,Rattus norvegicus,Expert,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627834
,1,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,,9274,3598,,1,Rattus norvegicus,Expert,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628004
,1,,Area under curve at 5 mg/kg po was determined in rat,,9275,5964,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628005
,1,,Area under curve in Rat at a oral dose of 5 mg/kg,,9276,4689,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628006
,1,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,9277,4186,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628007
,1,,Area under curve was determined,,9278,5510,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625676
,1,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,,9279,17858,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631309
,1,,Area under curve after intravenous administration at 3 mg/kg,,9280,17804,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631310
,1,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,,9281,6106,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631311
,1,,Area under curve at 4 hr in rat,,9282,5964,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631312
,1,,Area under curve at a dose of 30 mg/kg,,9283,4026,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631313
,1,,Area under curve at the dose of 2 mg/Kg administered perorally in rats,,9284,4756,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631314
,1,,Area under curve at the dose of 5 mg/Kg administered perorally in rats,,9285,4756,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631315
,1,,Area under curve for a 2-mpk po dose in SD rats,,9286,5862,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631316
,1,,Area under curve in SD rats,,9287,5862,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631317
,1,,Area under curve in rat after oral administration at 13 mg/kg dose,,9288,6644,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL874471
,1,,Area under curve in rat by po administration at 0-24 hr,,9289,5871,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631318
,1,,Area under curve in rat plasma,,9290,5919,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL631319
,1,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,,9291,5939,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631320
,1,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,,9292,5939,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631321
,1,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,,9293,10,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631322
,1,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,,9294,11149,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631323
,1,,Area under curve value in rat at a dose of 5 mg/kg,,9295,5302,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631324
,1,,Area under curve was determined after oral administration in rats,,9296,17796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631325
,1,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,9297,4890,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631326
,1,,Area under curve was determined after peroral administration in rat,,9298,6011,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631327
,1,,Area under curve was determined at a dose 30 mpk administered orally.,,9299,5375,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631328
,1,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,,9300,17764,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631329
,1,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,,9301,4368,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627217
,1,,Area under curve was determined in male rat,,9302,5610,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626352
,1,,Area under curve was determined in rat after PO administration,,9303,5833,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626353
,1,,Area under curve was determined in rat after a 3 mg/kg of oral dose,,9304,4257,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626354
,1,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,,9305,5937,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626355
,1,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,,9306,5932,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626356
,1,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,,9307,5932,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626357
,1,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,9308,17411,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626358
,1,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,9309,17411,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626359
,1,,Peak plasma concentration in rat at a dose of 3 mg/kg,,9310,17771,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626360
,1,,Plasma concentration at 2 hr in rats was evaluated.,,9311,1628,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626361
,1,,Plasma concentration at 2 hr in rats was evaluated; Not available,,9312,1628,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626362
,1,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,9313,17411,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626363
,1,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,9314,4910,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626970
,1,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,,9315,4910,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626971
,1,,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,9316,4910,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626972
,1,,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,,9317,4910,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626973
,1,,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,9318,4910,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626974
,1,,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,,9319,4910,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL874592
,1,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,,9320,5510,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626975
,1,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,,9321,5510,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626976
,1,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,,9322,5510,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626977
,1,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,,9323,5510,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626978
,1,,PK study was carried to determine the relative absorption ranking in rat.,,9324,16427,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626979
,1,,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,,9325,4689,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626980
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",,9326,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL626981
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",,9327,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL626982
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",,9328,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL626983
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",,9329,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL622522
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",,9330,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL622523
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",,9331,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL622524
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",,9332,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL622525
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",,9333,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL622526
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",,9334,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL619849
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",,9335,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL619850
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",,9336,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL623864
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",,9337,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL623865
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",,9338,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL623866
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",,9339,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL623867
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",,9340,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL877615
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",,9341,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL623868
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",,9342,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL623869
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",,9343,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL623870
,1,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,9344,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL623871
,1,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,9345,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL623872
,1,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,9346,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622129
,1,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,9347,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622130
,1,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,9348,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622131
,1,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,9349,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622132
,1,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,9350,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622133
,1,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,9351,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622134
,1,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,9352,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622135
,1,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,9353,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622136
,1,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,9354,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL622137
,1,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,9355,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL622138
,1,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,9356,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL623017
,1,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,9357,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL623018
,1,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,9358,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL623019
,1,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,9359,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL623020
,1,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,,9360,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL623021
,1,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,9361,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL623022
,1,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,9362,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL623023
,1,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,9363,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL623024
,1,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,9364,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL623025
,1,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,9365,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL620545
,1,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,9366,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL620546
,1,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,9367,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL620547
,1,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,9368,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL620548
,1,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,9369,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL620549
,1,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,9370,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL620550
,1,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,9371,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL620551
,1,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,9372,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL620552
,1,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,9373,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL620553
,1,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,9374,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL620554
,1,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,9375,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL875845
,1,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,9376,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL620555
,1,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,9377,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL620556
,1,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,9378,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL620557
,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,9379,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL620558
,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,9380,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL620559
,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,9381,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622939
,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,9382,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622940
,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,9383,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622941
,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,9384,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622942
,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,9385,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622943
,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,9386,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622944
,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,9387,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622945
,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,9388,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622946
,1,,Compound was evaluated for terminal half life in rat,,9389,3341,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622947
,1,,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,,9390,3634,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622948
,1,,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,,9391,3634,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622949
,1,,Compound was tested for its half life in rat,,9392,4839,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622950
,0,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,9393,5005,,1,Macaca mulatta,Intermediate,22224,,9544.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622951
,0,,Compound was tested for its plasma half life in Sprague Dawley rats,,9394,5005,,1,Rattus norvegicus,Intermediate,22224,,10116.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL622952
,0,,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,,9395,5005,,1,Rattus norvegicus,Intermediate,22224,,10116.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL622953
,1,,Compound was tested for plasma half-life period in rat,,9396,1094,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL873818
,1,,Elimination half life after i.v. administration of compound in rats,,9397,5031,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622954
,1,,Elimination half-life after IV dosing at 0.5 mg/kg in rat,,9398,6518,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622955
,1,,Elimination half-life after IV dosing at 1 mg/kg in rat,,9399,6518,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875229
,1,,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,,9400,6518,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622956
,1,,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,,9401,6518,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622957
,1,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,9402,5408,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622958
,1,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,9403,5408,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622959
,1,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,9404,5408,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622960
,1,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,9405,5408,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622961
,1,,Evaluated for the half life in rat (in vivo),,9406,4687,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622962
,1,,Hafl life in rat,,9407,6640,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622963
,1,,Hafl life rat,,9408,6640,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622964
,1,,Hafl life rat,,9409,6641,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622965
,1,,Hafl life rat; Not determined,,9410,6640,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622966
,1,,Hafl life rat; Not determined,,9411,6641,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622967
,1,,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,9412,17411,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL622968
,1,,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,9413,17411,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622969
,1,,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,9414,17411,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL875327
,1,,Half life in rat after 1 mg/kg i.v. administration,,9415,6570,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628638
,1,,Half life in rat after 2 mg/kg peroral administration,,9416,6570,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628639
,1,,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,9417,17411,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625840
,1,,Half life of 10 mg/kg oral dose determined in rats,,9418,4722,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625841
,1,,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,9419,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625842
,1,,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,9420,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625843
,1,,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,9421,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625844
,1,,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,9422,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL873822
,1,,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,9423,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625845
,1,,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,9424,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627059
,1,,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,,9425,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627060
,1,,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,9426,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627061
,1,,Half life of compound at 5 mg/kg after po administration was determined in rat,,9427,4762,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627709
,1,,Half life of compound determined after intravenous administration to rat,,9428,5327,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627710
,1,,Half life of compound was determined in rat,,9429,4847,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627711
,1,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,9430,17720,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627712
,1,,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,9431,4723,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627713
,1,,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,,9432,4723,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627714
,0,,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,9433,4256,,1,Macaca fascicularis,Intermediate,22224,,9541.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL627889
,0,,Half life determined in rat by intravenous administration,,9434,4256,,1,Rattus norvegicus,Intermediate,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL627890
,1,,Half life determined in rats after iv administration,,9435,4722,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627891
,1,,Half life in rat plasma after administration of 2 mg/kg iv,,9436,6535,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627892
,1,,Half life in rat plasma after administration of 2 mg/kg iv,,9437,6535,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627893
,1,,Half life in rat plasma was determined,,9438,1435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL627894
,1,,Half life in rat plasma was determined; NA means not applicable,,9439,1435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL627895
,1,,Half life in rat was tested,,9440,5206,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627896
,1,,Half life measured in rat plasma,,9441,6080,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL627897
,1,,Half life recorded in rats,,9442,4449,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627898
,1,,Half life was calculated,,9443,6057,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627899
,1,,Half life was calculated in rat,,9444,6057,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL873823
,1,,Half life was determined,,9445,3747,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627900
,1,,Half life after 10 mg/kg oral administration in rat,,9446,17858,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627901
,1,,Half life after administering orally a dose of 10 mg/kg to a fasting rat,,9447,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627902
,1,,Half life after administering orally a dose of 30 mg/kg,,9448,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627903
,1,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,,9449,5031,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627904
,1,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,,9450,4722,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627905
,1,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,,9451,6078,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627906
,1,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,,9452,6078,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627907
,1,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,,9453,6078,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL876783
,1,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,,9454,6078,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627908
,1,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,,9455,17065,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627909
,1,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,,9456,1353,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627910
,1,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),,9457,1353,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627911
,1,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),,9458,1353,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627912
,1,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),,9459,1353,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627913
,1,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),,9460,1353,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627914
,1,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,,9461,16423,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627915
,1,,Area under the curve was evaluated after 20 uM/kg of peroral administration,,9462,16423,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627916
,1,,Area under the curve was measured in rat after an iv dose of 1 mg/kg,,9463,6062,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627917
,1,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,,9464,6056,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627918
,1,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,,9465,5182,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627919
,1,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,,9466,6410,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627920
,1,,Area under the curve was evaluated at an oral dose of 30 mg/kg,,9467,6410,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627921
,1,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,9468,4723,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627922
,1,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,9469,4723,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL876784
,1,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,9470,4723,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627923
,1,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,9471,4723,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626208
,1,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,9472,4723,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626209
,1,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,9473,4723,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626210
,1,,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,9474,2463,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL627994
,1,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,,9475,4709,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627995
,1,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,,9476,4075,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627996
,1,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,,9477,5394,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627997
,1,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,,9478,2661,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627998
,1,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,,9479,2661,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628640
,1,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,,9480,2661,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628641
,1,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,,9481,2661,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628642
,1,,Compound was evaluated for area under the curve expressed as (h*ug/ml),,9482,17791,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628643
,1,,Compound was tested for area under curve in rat,,9483,2591,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628644
,1,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,,9484,6567,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628645
,1,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,9485,6211,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628646
,1,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),,9486,5529,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628647
,1,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,9487,5408,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628648
,1,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,9488,5408,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625358
,1,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,9489,5408,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625359
,1,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,9490,5408,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625360
,1,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),,9491,429,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625361
,1,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),,9492,429,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625362
,1,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),,9493,429,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625363
,1,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,9494,4796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625364
,1,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,9495,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625365
,1,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,9496,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625366
,1,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,9497,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625367
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",,9498,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL625368
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",,9499,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL625369
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",,9500,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL625370
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",,9501,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL625371
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",,9502,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL625372
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",,9503,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL625373
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",,9504,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625374
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",,9505,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL877593
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",,9506,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625375
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",,9507,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625376
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",,9508,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL621973
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",,9509,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL621974
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",,9510,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL621975
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",,9511,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622166
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",,9512,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622167
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",,9513,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622168
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",,9514,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622169
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",,9515,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL622170
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",,9516,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL622171
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",,9517,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL622172
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",,9518,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL622173
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",,9519,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL622174
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",,9520,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL622175
,1,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",,9521,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL622176
,1,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",,9522,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL622177
,1,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",,9523,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL622178
,1,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",,9524,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL622179
,1,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",,9525,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL622180
,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,9526,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622181
,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,9527,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622182
,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,9528,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622183
,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,9529,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622184
,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,9530,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622185
,1,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,9531,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622186
,1,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,9532,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622187
,1,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,9533,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625002
,1,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,,9534,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622090
,1,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,9535,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622091
,1,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,9536,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622092
,1,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,9537,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622093
,1,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,9538,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622094
,1,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,9539,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622095
,1,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,9540,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622264
,1,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,9541,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL622265
,1,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,9542,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL622266
,1,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,9543,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL622267
,1,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,9544,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL622268
,1,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,9545,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL622269
,1,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,9546,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL625071
,1,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,9547,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL621621
,1,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,9548,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL621622
,1,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,9549,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL621623
,1,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,9550,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL621624
,1,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,9551,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL621625
,1,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,9552,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL621626
,1,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,9553,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL621627
,1,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,9554,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL621628
,1,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,9555,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL875328
,1,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,9556,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL621629
,1,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,9557,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL621630
,1,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,9558,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL621631
,1,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,9559,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL621632
,1,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,9560,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL621633
,1,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,9561,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL621634
,1,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,9562,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL621635
,1,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,9563,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL621636
,1,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,9564,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL621637
,1,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,9565,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL621638
,1,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,9566,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618883
,1,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,9567,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL618884
,1,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,9568,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628627
,1,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,9569,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628628
,1,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,9570,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628629
,1,,Half life after administering orally a dose of 3 mg/kg,,9571,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628630
,1,,Half life after administering orally a dose of 3 mg/kg to a fasting rat,,9572,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628631
,1,,Half life after administering intravenously a dose of 1 mg/kg,,9573,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628632
,1,,Half life after oral dosing in rats,,9574,526,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628633
,1,,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,,9575,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628634
,1,,Half life by intravenous administration of 3.4 mg/kg in rat,,9576,4368,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627789
,1,,Half life in rat,,9577,3371,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627790
,1,,Half life in rat,,9578,6448,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627791
,1,,Half life in rat,,9579,6453,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627792
,1,,Half life in rat after intravenous administration of the compound,,9580,4353,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627793
,1,,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,,9581,4353,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627794
,1,,Half life in rat after po administration of the compound,,9582,4353,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627795
,1,,Half life in rat after po administration of the compound; ND means Not determined,,9583,4353,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627796
,1,,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,,9584,4353,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL875335
,1,,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,,9585,4353,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627797
,1,,Half life in rat i.v.,,9586,5789,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627798
,1,,Half life in rat i.v. at 2 mg/kg concentration,,9587,17686,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627799
,1,,Half life in rats,,9588,6495,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627800
,1,,Half life in rats after intravenous administration,,9589,484,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627801
,1,,Half life in rats at the dose of 1.0 mpk by i.v. administration,,9590,6467,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627802
,1,,Half life in rat,,9591,6642,,1,Rattus norvegicus,Expert,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627803
,1,,Half life was evaluated after intravenous administration to rats,,9592,16367,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL873820
,1,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),,9593,1369,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627804
,1,,Half life was evaluated in rat,,9594,5472,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627805
,1,,Half life was evaluated in rat,,9595,6049,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627806
,1,,Half life was evaluated in rat; Not tested,,9596,5472,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627107
,1,,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,,9597,16366,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627108
,1,,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,,9598,11149,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627109
,1,,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,,9599,11149,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL627110
,0,,Half life was measured in monkey at dose of 10 mg/kg by po administration,,9600,2891,,1,Primates,Intermediate,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL627111
,0,,Half life was measured in monkey at dose of 10 mg/kg by po administration,,9601,2891,,1,Primates,Intermediate,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL627112
,0,,Half life was measured in rat at dose of 30 mg/kg by iv administration,,9602,2891,,1,Rattus norvegicus,Intermediate,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL627113
,0,,Half life was measured in rat at dose of 30 mg/kg by po administration,,9603,2891,,1,Rattus norvegicus,Intermediate,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL627114
,1,,Half life (t1/2) was determined,,9604,4026,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627115
,1,,Half life period at a dose of 10 uM/kg in rat was determined,,9605,4527,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627116
,1,,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,,9606,4527,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627117
,1,,Half life period was determined,,9607,5503,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627118
,1,,Half life period after intravenous administration at 20 mpk in rats,,9608,4426,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627119
,1,,Half life period after intravenous administration at 20 mpk in rats; Not performed.,,9609,4426,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627120
,1,,Half life period after intravenous administration in rat,,9610,6109,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626922
,1,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,9611,5654,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626923
,1,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,9612,5654,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626924
,1,,Half life period in 80% rat plasma at 37 degree Centigrade,,9613,4755,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626925
,1,,Half life period in SD rats,,9614,5862,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626926
,1,,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),,9615,1515,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626927
,1,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),,9616,1515,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626928
,1,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,9617,1515,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626929
,1,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,9618,1515,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626930
,1,,Half life period in rat,,9619,5960,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626931
,1,,Half life period in rat,,9620,6103,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626932
,1,,Half life period in rat,,9621,6317,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626933
,1,,Half life period in rat after oral administration at 10.5 mg/kg dose,,9622,6644,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL873826
,1,,Half life period in rat after oral administration at 11.2 mg/kg dose,,9623,6644,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626934
,1,,Half life period in rat after oral administration at 13 mg/kg dose,,9624,6644,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626935
,1,,Half life period in rat after oral administration at 9.7 mg/kg dose,,9625,6644,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626936
,1,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,9626,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626937
,1,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,9627,6295,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625906
,1,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,9628,6296,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625907
,1,,PK study was carried to determine AUC (area under curve) value in rat,,9629,16427,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625908
,1,,Pharmacokinetic parameter AUC after intravenous administration to rats,,9630,16367,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625909
,1,,Pharmacokinetic parameter AUC after oral administration to rats,,9631,16367,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625910
,1,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,,9632,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625911
,1,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,,9633,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625912
,1,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,,9634,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626538
,1,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,,9635,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL876794
,1,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,,9636,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626539
,1,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,,9637,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626540
,1,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,,9638,5394,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626541
,1,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,,9639,5394,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626542
,1,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,,9640,2792,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626543
,1,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,,9641,2792,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626544
,1,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,,9642,2792,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626545
,1,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,,9643,2792,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626546
,1,,Pharmacokinetic parameter area under curve was reported,,9644,5334,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626547
,1,,Pharmacokinetic property (AUC) in rat,,9645,4408,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626548
,1,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,,9646,5983,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626549
,1,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,,9647,4397,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626550
,1,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,,9648,4397,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626551
,1,,Pharmacokinetic property was determined,,9649,5491,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623777
,1,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,,9650,5491,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623778
,1,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,,9651,5491,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623779
,1,,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,9652,4199,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL623780
,1,,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,,9653,4199,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622015
,1,,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,,9654,4199,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622016
,1,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",,9655,5173,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622017
,1,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",,9656,5173,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622018
,1,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",,9657,5173,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622019
,1,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",,9658,5173,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622020
,1,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,,9659,16366,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622021
,1,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,,9660,16366,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622022
,1,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,,9661,5327,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622023
,1,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,,9662,6681,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622024
,1,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),,9663,12873,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622693
,1,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),,9664,12873,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622694
,1,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,9665,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622695
,1,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,9666,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622696
,1,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",,9667,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622697
,1,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",,9668,6619,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622874
,1,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",,9669,6619,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622875
,1,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,9670,10363,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622876
,1,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,9671,4796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622877
,1,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,9672,4910,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622878
,1,,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,,9673,4910,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622879
,1,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,,9674,4839,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL877602
,1,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,9675,15078,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622880
,1,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",,9676,15078,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622881
,1,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,9677,15078,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622882
,1,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",,9678,15078,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622883
,1,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",,9679,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL622884
,1,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",,9680,11450,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL622885
,1,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,9681,8151,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622886
,1,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,9682,8151,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622887
,1,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,9683,8151,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL622888
,1,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9684,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622889
,1,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9685,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622890
,1,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9686,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622891
,1,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9687,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL877603
,1,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9688,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622892
,1,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9689,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622893
,1,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9690,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622894
,1,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9691,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622895
,1,,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,,9692,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622896
,1,,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9693,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL622897
,1,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9694,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL622898
,1,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9695,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL622899
,1,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9696,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL622900
,1,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9697,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL624114
,1,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9698,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL624115
,1,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9699,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL624116
,1,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9700,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL624117
,1,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9701,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL624118
,1,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9702,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL624119
,1,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9703,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL624120
,1,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9704,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL624121
,1,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9705,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL624122
,1,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9706,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL624123
,1,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9707,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL624124
,1,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9708,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL624125
,1,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9709,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL624126
,1,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9710,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL624127
,1,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9711,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL624128
,1,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9712,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL624129
,1,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9713,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL624130
,1,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9714,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL622340
,1,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9715,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL622341
,1,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9716,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL622342
,1,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9717,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL622343
,1,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9718,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL622344
,1,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9719,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Intestine,N,160.0,In vivo,,BAO_0000218,A,,CHEMBL622345
,1,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9720,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL622346
,1,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9721,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL622347
,1,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9722,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL622348
,1,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9723,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL622349
,1,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,9724,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622350
,1,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,9725,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622351
,1,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,9726,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622352
,1,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,9727,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622353
,1,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,9728,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622354
,1,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,9729,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622355
,1,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,9730,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622356
,1,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,9731,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622357
,1,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,9732,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622358
,1,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,9733,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622359
,1,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,9734,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL874393
,1,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,9735,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622872
,1,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,9736,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622873
,1,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,9737,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623047
,1,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,9738,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623048
,1,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,9739,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623049
,1,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,9740,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623050
,1,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,9741,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623051
,1,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,9742,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623052
,1,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,9743,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626343
,1,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,9744,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626344
,1,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,9745,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626345
,1,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,9746,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626346
,1,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,9747,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626347
,1,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,9748,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626348
,1,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,9749,16434,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626349
,1,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,9750,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,F,,CHEMBL626350
,1,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,9751,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626351
,1,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,9752,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627650
,1,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,9753,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,F,,CHEMBL627651
,1,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,9754,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627652
,1,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,9755,16435,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627653
,1,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,,9756,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627654
,1,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,,9757,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627835
,1,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,,9758,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627836
,1,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,,9759,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627837
,1,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,,9760,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627838
,1,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,,9761,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL875338
,1,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,,9762,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627839
,1,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,,9763,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627840
,1,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,,9764,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627841
,1,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,,9765,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627842
,1,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,,9766,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627843
,1,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,,9767,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627844
,1,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,,9768,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627845
,1,,Half life period in rat by iv administration at a dose of 3 mg/kg,,9769,5874,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627846
,1,,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),,9770,1515,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL627847
,1,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),,9771,1515,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL873821
,1,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,9772,1515,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626079
,1,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,9773,1515,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626080
,1,,Half life period was evaluated in rat plasma,,9774,5491,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626081
,1,,Half life period was evaluated in rat plasma; Not tested,,9775,5491,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL875344
,1,,Half life period was evaluated in rats,,9776,1918,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626082
,1,,"Half life period was evaluated in rats, iv",,9777,1918,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626250
,1,,Half life period after intravenous administration at 5 mg/kg in rat,,9778,6113,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626251
,1,,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,9779,5546,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626252
,1,,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,,9780,5553,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626253
,1,,Half life stability of compound was evaluated in rat plasma,,9781,4188,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626254
,1,,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,,9782,6215,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626255
,1,,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,9783,6141,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626256
,1,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,9784,5182,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626257
,1,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,,9785,5182,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626258
,1,,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,,9786,5710,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626259
,1,,Half in rat i.v.,,9787,5789,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626260
,1,,Half period in rat after intravenous administration,,9788,6011,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875345
,1,,Half-life after repeated oral dose of compound at 1 mg/kg in rats,,9789,17594,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626261
,1,,Half-life measured in in vitro Cathepsin B assay in rat liver,,9790,12357,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vitro,,BAO_0000218,A,,CHEMBL626262
,1,,Half-life of compound was determined in rats,,9791,5210,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626263
,1,,Half-life at 10 mg/kg in rat upon intravenous administration,,9792,17596,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625270
,1,,Half-life determined in rat,,9793,6672,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625271
,1,,Half-life determined in rat,,9794,6673,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625272
,1,,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,,9795,4910,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL625273
,1,,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",,9796,3741,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL625274
,1,,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,9797,17671,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625275
,1,,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,,9798,4910,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL625276
,1,,Half-life in rat plasma,,9799,17537,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL625277
,1,,Half-life in rat plasma was determined,,9800,4965,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL625278
,1,,Half-life in rat plasma; Not tested,,9801,17537,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL625279
,1,,Half-life in rat serum,,9802,6124,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Serum,N,1977.0,,,BAO_0000218,A,,CHEMBL625280
,1,,Half-life in rat serum; na is not available,,9803,6124,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Serum,N,1977.0,,,BAO_0000218,A,,CHEMBL876797
,1,,Half-life was calculated in rat,,9804,6078,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625281
,1,,Half-life was calculated in rat plasma,,9805,17668,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL873827
,1,,Half-life was determined,,9806,3185,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625282
,1,,Half-life was determined,,9807,4883,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625283
,1,,Half-life after administration of 20 mg/Kg oral dose in rat,,9808,2959,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625284
,1,,Half-life after administration of 3.2 mg/kg intravenously in male rat,,9809,4029,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625285
,1,,Half-life after intravenous administration in female rat,,9810,4029,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625286
,1,,Half-life after intravenous administration in male rat,,9811,4029,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625287
,1,,Half-life after intravenous dose in rat,,9812,6180,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625288
,1,,Half-life in a rat liver homogenate preparation,,9813,1557,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625289
,1,,Half-life in plasma of rat,,9814,12500,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL625290
,1,,Half-life in plasma of rat at dose of 3-10 mgkg,,9815,12500,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL876798
,1,,Half-life in rat,,9816,5064,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625291
,1,,Half-life in rat,,9817,5145,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625292
,1,,Half-life in rat,,9818,5147,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625293
,1,,Half-life in rat,,9819,5833,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622832
,1,,Half-life in rat,,9820,6596,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622833
,1,,Half-life in rat,,9821,17655,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622834
,1,,Half-life in rat after oral administration at 10 mg/kg,,9822,6495,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622835
,1,,Half-life in rat after po administration at a dose of 10 mg/kg,,9823,17538,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622836
,1,,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,,9824,17538,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622837
,1,,Half-life in rat at 3 mg/kg dose administered intravenously,,9825,10,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622838
,1,,Half-life in rat brain homogenate,,9826,17669,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL622839
,1,,Half-life in rat plasma,,9827,17065,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622840
,1,,Half-life in rats,,9828,4333,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622841
,1,,Half-life in Dawley rats,,9829,6827,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622842
,1,,Half-life in vitro in rat plasma,,9830,889,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vitro,,BAO_0000218,A,,CHEMBL622843
,1,,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,,9831,889,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vitro,,BAO_0000218,A,,CHEMBL622844
,1,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",,9832,3747,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622845
,1,,The area under the curve of compound was measured at the dose of 100 umol/kg,,9833,15022,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622846
,1,,The area under the curve of compound was measured at the dose of 300 umol/kg,,9834,15022,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622847
,1,,The area under the curve of compound was measured at the dose of 30 umol/kg,,9835,15022,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622848
,1,,Bioavailability as oral AUC in rats,,9836,3360,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622849
,1,,The plasma concentration versus time curve (AUC) was determined,,9837,5334,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622850
,1,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,9838,17411,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL876807
,1,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,9839,17411,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622851
,1,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,9840,17411,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622852
,1,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,,9841,6570,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622853
,1,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,,9842,6570,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622854
,1,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,9843,17411,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622855
,1,,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",,9844,14941,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622856
,1,,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",,9845,14941,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622857
,1,,AUC in rat after po administration at a dose of 10 mg/kg,,9846,17538,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622858
,1,,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,,9847,17752,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622859
,1,,Area under curve value 24 hr after 10 mg/kg iv administration in rats,,9848,17509,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622860
,1,,Area under curve value 24 hr after 10 mg/kg oral administration in rats,,9849,17509,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622861
,1,,Area under curve value 24 hr after 2 mg/kg iv administration in rats,,9850,17509,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622862
,1,,Area under curve value 24 hr after 2 mg/kg oral administration in rats,,9851,17509,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622863
,1,,Area under curve value 6 hr after po administration in rat,,9852,17509,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623817
,1,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,9853,17717,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623818
,1,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",,9854,17717,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623819
,1,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,9855,17717,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623820
,1,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,,9856,17717,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623821
,1,,AUC normalized for dose (AUCN) in rat,,9857,6642,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL623822
,1,,Area under curve in rat after p.o. administration,,9858,6640,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623823
,1,,Area under curve in rat after p.o. administration,,9859,6641,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623824
,1,,Area under curve in rat after p.o. administration; Not determined,,9860,6641,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623825
,1,,Area under curve in rat after peroral administration,,9861,6641,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622070
,1,,Area under curve (carotid artery) value of the compound,,9862,3603,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622071
,1,,Bioavailability expressed as the area under curve of rat carotid artery,,9863,3550,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622072
,1,,Area under curve in male SD rats was observed after intravenous administration in rat,,9864,15662,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622073
,1,,Area under curve of the compound was determined,,9865,17720,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622074
,1,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,,9866,5407,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622075
,1,,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,,9867,17752,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622076
,1,,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,,9868,17752,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622077
,1,,Area under curve (portal vein) value of the compound,,9869,3603,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622078
,1,,Bioavailability expressed as the area under curve of rat portal vein,,9870,3550,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622079
,1,,Area Under plasma concentration time curve in rat upon peroral administration,,9871,17655,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622080
,1,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,,9872,17582,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL877612
,1,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,,9873,17582,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622081
,1,,Compound was evaluated for oral bioavailability in rats,,9874,17791,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622082
,1,,Compound was evaluated for oral bioavailability in rats after iv administration,,9875,17791,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622083
,1,,Compound was evaluated for oral bioavailability in rats; 30-80,,9876,17791,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622084
,1,,Compound was evaluated for oral bioavailability in rats; 50-60,,9877,17791,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622085
,1,,Compound was evaluated for oral bioavailability in rats; no data,,9878,17791,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622086
,1,,Compound was evaluated for oral bioavailability in rats; peptide,,9879,17791,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622087
,1,,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",,9880,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL622088
,1,,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",,9881,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL622089
,1,,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",,9882,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL623685
,1,,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",,9883,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL623686
,1,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9884,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL623687
,1,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9885,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL623688
,1,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9886,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL623689
,1,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9887,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Stomach,N,945.0,In vivo,,BAO_0000218,A,,CHEMBL622485
,1,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9888,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,In vivo,,BAO_0000218,A,,CHEMBL622486
,1,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9889,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,In vivo,,BAO_0000218,A,,CHEMBL877613
,1,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9890,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,In vivo,,BAO_0000218,A,,CHEMBL622487
,1,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9891,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,In vivo,,BAO_0000218,A,,CHEMBL622488
,1,,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,9892,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL622489
,1,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,9893,6899,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL622490
,1,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,9894,6899,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL622491
,1,,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,,9895,6899,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL622492
,1,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,9896,6899,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL622493
,1,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,9897,6899,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL622494
,1,,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,9898,8677,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL622495
,1,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,,9899,6899,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622496
,1,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,9900,6899,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL622497
,1,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,,9901,2189,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622498
,1,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,,9902,2189,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL624918
,1,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,,9903,2189,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL624919
,1,,Biodistribution of compound in rat blood after 5 min of administration,,9904,10839,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL624920
,1,,Biodistribution of compound in rat blood after 5 min of administration.,,9905,10839,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL624921
,1,,Biodistribution of compound in rat brain after 5 min of administration,,9906,10839,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL624922
,1,,Biodistribution of compound in rat heart after 5 min of administration,,9907,10839,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL624923
,1,,Biodistribution of compound in rat heart after 5 min of administration.,,9908,10839,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL624924
,1,,Biodistribution of compound in rat kidney after 5 min of administration,,9909,10839,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL624925
,1,,Biodistribution of compound in rat kidney after 5 min of administration.,,9910,10839,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL624926
,1,,Biodistribution of compound in rat liver after 5 min of administration,,9911,10839,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL624927
,1,,Biodistribution of compound in rat liver after 5 min of administration.,,9912,10839,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL874402
,1,,Biodistribution of compound in rat lung after 5 min of administration,,9913,10839,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL624928
,1,,Biodistribution of compound in rat lung after 5 min of administration.,,9914,10839,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL624929
,1,,Biodistribution of compound in rat muscle after 5 min of administration,,9915,10839,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL624930
,1,,Biodistribution of compound in rat muscle after 5 min of administration.,,9916,10839,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL624931
,1,,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,9917,4043,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624932
,1,,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,9918,4043,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL624933
,1,,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,9919,4043,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL624934
,1,,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,9920,4043,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL624935
,1,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,9921,4043,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624936
,1,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,9922,4043,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624937
,1,,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,9923,4043,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL624938
,1,,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,9924,4043,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,,,BAO_0000218,A,,CHEMBL624939
,1,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,9925,4043,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624940
,1,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,9926,4043,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL874403
,1,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,,9927,1446,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624941
,1,,Dose required to lower urine osmolality to 300 mOsm/kg in rat,,9928,9971,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL624942
,1,,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,,9929,9971,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL624943
,1,,% Bioavailability after 1 day of the drug administration in rats,,9930,5765,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624944
,1,,% Bioavailability after 4 day of the drug administration in rats,,9931,5765,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624945
,1,,Absolute bioavailability was evaluated in rat,,9932,4257,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624946
,1,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,,9933,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624947
,1,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,,9934,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624948
,1,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,,9935,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624949
,1,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,,9936,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL622025
,1,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,,9937,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL622026
,1,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,,9938,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL622027
,1,,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,,9939,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL622028
,1,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,,9940,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL622029
,1,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,,9941,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL622208
,1,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,,9942,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL622209
,1,,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,,9943,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL622210
,1,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,,9944,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622211
,1,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,,9945,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622212
,1,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,,9946,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622213
,1,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,,9947,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL874404
,1,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,,9948,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL620452
,1,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,,9949,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL620453
,1,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,,9950,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL620454
,1,,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,,9951,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL624067
,1,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,,9952,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624068
,1,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,,9953,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Female gonad,N,992.0,,,BAO_0000218,A,,CHEMBL624069
,1,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,,9954,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Female gonad,N,992.0,,,BAO_0000218,A,,CHEMBL624070
,1,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,,9955,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Female gonad,N,992.0,,,BAO_0000218,A,,CHEMBL624071
,1,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,,9956,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Uterus,N,995.0,,,BAO_0000218,A,,CHEMBL624072
,1,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,,9957,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Uterus,N,995.0,,,BAO_0000218,A,,CHEMBL624073
,1,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,,9958,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Uterus,N,995.0,,,BAO_0000218,A,,CHEMBL624788
,1,,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,,9959,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Uterus,N,995.0,,,BAO_0000218,A,,CHEMBL624789
,1,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,,9960,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624790
,1,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,,9961,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624791
,1,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,,9962,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624792
,1,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,,9963,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624793
,1,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,,9964,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL877491
,1,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,,9965,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL624957
,1,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,,9966,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL624958
,1,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,,9967,13091,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,,,BAO_0000218,A,,CHEMBL624959
,1,,Dissociation constant was determined,,9968,11977,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624960
,1,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",,9969,14941,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624961
,1,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,9970,15078,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624962
,1,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",,9971,15078,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624963
,1,,Observed rate constant in 80% rat plasma at 37 degree Centigrade,,9972,4755,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624964
,1,,LogP value was evaluated in the in situ rat gut perfusion assay,,9973,589,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624965
,1,,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,9974,17582,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624966
,1,,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,,9975,5031,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624967
,1,,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,,9976,17764,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624968
,1,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,,9977,17720,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624969
,1,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,,9978,2862,,1,Rattus norvegicus,Expert,50597,,10116.0,,N,,,,BAO_0000218,F,,CHEMBL624970
,1,,Half-life was evaluated after 10 uM/kg of intra arterial administration,,9979,16423,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624971
,1,,Half-life was evaluated after 20 uM/kg of peroral administration,,9980,16423,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624972
,1,,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,9981,6005,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624973
,1,,Half-life was evaluated in plasma of rat,,9982,2938,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL624974
,1,,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,,9983,6410,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624975
,1,,Half-life was evaluated in rats at an oral dose of 30 mg/kg,,9984,6410,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL877492
,1,,Half-life was measured in rat after an iv dose of 1 mg/kg,,9985,6062,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624976
,1,,Half-life period of compound in rats after peroral administration,,9986,6571,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624977
,1,,Half-life period of compound was measured in rat plasma.,,9987,3136,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626848
,1,,Half-life period of compound was measured in rat plasma; ND is not determined,,9988,3136,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626849
,1,,Half-life period of compound was measured in rat plasma; not determined,,9989,3136,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626850
,1,,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,9990,4521,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626851
,1,,Half-life period in rat by iv administration,,9991,5871,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626852
,1,,Half-life period in rats following intravenous administration at 2 mg/kg,,9992,6077,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626853
,1,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,9993,6679,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626854
,1,,Half-life period was determined for the compound in rat,,9994,5144,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627486
,1,,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",,9995,4498,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627487
,1,,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",,9996,4498,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627488
,1,,Half-life value after IV dose at a dose of 5 mg/kg in rats.,,9997,1908,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627489
,1,,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,9998,6211,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627490
,1,,Half-life was determined in rat after intravenous administration (0.5 mg/kg),,9999,5529,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL873829
,1,,Half-life was determined in rat at a dose of 1 mpk i.v.,,10000,6444,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627655
,1,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,10001,6444,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625994
,1,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,10002,6444,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625995
,1,,Half-life in rat,,10003,5207,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625996
,1,,In vitro half life in rat plasma,,10004,530,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vitro,,BAO_0000218,A,,CHEMBL625850
,1,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",,10005,1116,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vitro,,BAO_0000218,A,,CHEMBL625851
,1,,In vitro half life in rat,,10006,3219,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vitro,,BAO_0000218,A,,CHEMBL625852
,1,,In vivo half life period after intravenous administration in rat,,10007,6109,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625853
,1,,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,10008,17582,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625854
,1,,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,10009,17582,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL874450
,1,,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,10010,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625855
,1,,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,10011,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625856
,1,,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,10012,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625857
,1,,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,10013,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL873831
,1,,Longer half-life in rat (i.v.) at 0.5 mpk,,10014,17853,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625858
,1,,Longer half-life in rat (p.o.) at 2.0 mpk,,10015,17853,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625859
,1,,Pharmacokinetic property (half life) in rat,,10016,3457,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625860
,1,,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,,10017,2792,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625861
,1,,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,,10018,2792,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625862
,1,,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,,10019,2792,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625863
,1,,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,,10020,2792,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625864
,1,,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,,10021,5739,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625865
,1,,Pharmacokinetic half time was determined intravenously in rats.,,10022,15765,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625866
,1,,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,,10023,6567,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL625867
,1,,Plasma half life of hydrolysis of the compound,,10024,2448,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL625868
,1,,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,,10025,5423,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL625869
,1,,Plasma half life period was calculated in rat,,10026,4853,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL874451
,1,,Plasma half-life in Sprague-Dawley rats,,10027,4514,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL625870
,1,,Plasma half-life in Sprague-Dawley rats; Not determined,,10028,4514,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL625871
,1,,Plasma half-life in rats,,10029,1500,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL625872
,1,,Plasma half-life in rats; <MQL,,10030,1500,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL625873
,1,,Plasma half-life period (0-8 h) was determined,,10031,5334,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL625874
,1,,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,,10032,5334,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL625875
,1,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,10033,5334,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL625876
,1,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,10034,5334,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL631258
,1,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,,10035,4956,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL631259
,1,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,,10036,4956,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL631260
,1,,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",,10037,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL631261
,1,,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",,10038,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL631262
,1,,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",,10039,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL631263
,1,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",,10040,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631264
,1,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",,10041,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631265
,1,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",,10042,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631266
,1,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",,10043,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631267
,1,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",,10044,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631268
,1,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",,10045,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631269
,1,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",,10046,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL631270
,1,,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,10047,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL631271
,1,,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",,10048,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL631272
,1,,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",,10049,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL631273
,1,,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",,10050,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL631274
,1,,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",,10051,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL631275
,1,,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",,10052,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL626984
,1,,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",,10053,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL626985
,1,,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,10054,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL626986
,1,,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",,10055,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL626987
,1,,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",,10056,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL626988
,1,,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",,10057,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL626989
,1,,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",,10058,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL626990
,1,,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",,10059,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL626991
,1,,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",,10060,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL626992
,1,,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",,10061,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL626993
,1,,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",,10062,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL874593
,1,,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",,10063,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL626994
,1,,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",,10064,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL626995
,1,,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",,10065,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL626190
,1,,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",,10066,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL626191
,1,,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",,10067,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL626364
,1,,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",,10068,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL626365
,1,,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",,10069,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL626366
,1,,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",,10070,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL626367
,1,,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",,10071,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL626368
,1,,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",,10072,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL626369
,1,,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",,10073,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL626370
,1,,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",,10074,4498,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626371
,1,,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",,10075,4498,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626372
,1,,Bioavailability after a dose of 10 mg/kg p.o.,,10076,3603,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626373
,1,,Bioavailability after peroral administration (10 mg/kg) was determined in rat,,10077,6215,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626374
,1,,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,,10078,5710,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626375
,1,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),,10079,5710,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626376
,1,,Bioavailability in rat po was determined,,10080,5676,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626377
,1,,Bioavailability of compound at 10 mg/kg in rat after oral administration,,10081,17667,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626378
,1,,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,,10082,17667,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626379
,1,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,10083,6848,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626380
,1,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,10084,6848,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626381
,1,,Bioavailability in rat,,10085,17267,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626382
,1,,Bioavailability in rat (Sprague-Dawley) (female),,10086,6362,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626383
,1,,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,10087,17671,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL874652
,1,,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),,10088,17671,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626384
,1,,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,,10089,4333,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626385
,1,,Bioavailability in rat at an oral dose of 2 mg/kg,,10090,6077,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626386
,1,,Bioavailability in rat,,10091,3278,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626387
,1,,Bioavailability in rat,,10092,5964,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626388
,1,,Bioavailability in rat,,10093,4884,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626389
,1,,Bioavailability in rat,,10094,4905,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626390
,1,,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,,10095,4884,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626391
,1,,Bioavailability in rat,,10096,6850,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626392
,1,,Oral bioavailability in rat,,10097,2864,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626393
,1,,Bioavailability was determined in rat,,10098,5780,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623026
,1,,Bioavailability,,10099,1465,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623027
,1,,Bioavailability,,10100,5199,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623028
,1,,Bioavailability in rat after 1 day dosing,,10101,5765,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623029
,1,,Bioavailability in rat after 4 day dosing,,10102,5765,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623030
,1,,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,,10103,6518,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623031
,1,,Bioavailability after IV dosing at 1 mg/kg in rat; no data,,10104,6518,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623032
,1,,Bioavailability after oral administration at a dose of 2 mg/kg in rat,,10105,6518,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623033
,1,,Bioavailability after oral administration at a dose of 4 mg/kg in rat,,10106,6518,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623034
,1,,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,,10107,2083,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623035
,1,,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,10108,17260,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623036
,1,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,10109,4956,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623037
,1,,Bioavailability by intravenous administration of 3.4 mg/kg in rat,,10110,4368,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623038
,1,,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,,10111,17752,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL874385
,1,,Bioavailability in rat (Fisher) (fasted),,10112,1446,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623039
,0,,Bioavailability in monkey after po administration of 10 mg/kg dose,,10113,2891,,1,Primates,Intermediate,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL623040
,0,,Oral bioavailability in monkey (dose 10 mg/kg),,10114,2891,,1,Primates,Intermediate,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL623041
,1,,Bioavailability in rat,,10115,6672,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623741
,1,,Bioavailability in rat,,10116,6673,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623742
,1,,Bioavailability in rat,,10117,17655,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623743
,1,,Bioavailability in rat,,10118,17796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623744
,1,,Bioavailability in rat (dose 2.0 mg/kg p.o.),,10119,17853,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623745
,1,,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),,10120,4521,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623746
,1,,Oral bioavailability in rat (dose 5 mg/kg p.o.),,10121,4940,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623747
,0,,Bioavailability in rat after po administration of 30 mg/kg dose,,10122,2891,,1,Rattus norvegicus,Intermediate,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL623748
,0,,Bioavailability in rat after po administration of 30 mg/kg dose,,10123,2891,,1,Rattus norvegicus,Intermediate,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL623916
,1,,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,10124,4521,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623917
,1,,Bioavailability in rat (dose 2 mg/kg i.v.),,10125,17686,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623918
,1,,Bioavailability in rat,,10126,17796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL874386
,1,,Bioavailability in rat; Only traces detected in rat plasma,,10127,17796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL623919
,1,,Bioavailability in rat,,10128,5064,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623920
,1,,Bioavailability upon oral administration of compound,,10129,5147,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623148
,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),,10130,1916,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623149
,1,,Bioavailability in rat,,10131,6049,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623150
,1,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",,10132,1445,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623151
,1,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",,10133,1445,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623152
,1,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,,10134,2862,,1,Rattus norvegicus,Expert,50597,,10116.0,,N,,,,BAO_0000218,F,,CHEMBL623153
,1,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,,10135,2862,,1,Rattus norvegicus,Expert,50597,,10116.0,,N,,,,BAO_0000218,F,,CHEMBL623154
,1,,In vitro and metabolic stability was determined,,10136,4194,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623155
,1,,In vitro metabolic stability in rat hepatocytes,,10137,4194,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623156
,1,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,,10138,5486,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623157
,1,401.0,Metabolic rate for compound was observed in rat hepatocytes,,10139,17582,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vitro,Hepatocyte,BAO_0000218,A,,CHEMBL623158
,1,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,,10140,5600,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623159
,1,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),,10141,14294,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL874390
,1,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),,10142,14294,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623160
,1,,Metabolism of compound in rat S9 microsomes; Trace,,10143,14294,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623161
,1,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,,10144,17847,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623162
,1,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,,10145,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623163
,1,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,,10146,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623164
,1,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,,10147,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623165
,1,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,,10148,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623166
,1,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,,10149,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624983
,1,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,,10150,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624984
,1,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,,10151,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624985
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,,10152,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622970
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,,10153,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622971
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,,10154,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622972
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,,10155,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622973
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,,10156,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622974
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,,10157,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622975
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,,10158,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622976
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,,10159,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622977
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,10160,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624351
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,,10161,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624352
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,10162,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624353
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,,10163,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622397
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,,10164,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622398
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,,10165,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622399
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,10166,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL622400
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,,10167,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628428
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,,10168,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628590
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,10169,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628591
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,,10170,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628592
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,10171,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628593
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,,10172,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL875333
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,10173,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628594
,1,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,,10174,4969,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL628595
,1,,Stability in rat plasma was determined,,10175,6737,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL628596
,1,,Stability in rat plasma was determined; ND= no data,,10176,6737,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL628597
,1,,Tested for plasma half life period in rat (0-8 hr),,10177,5089,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL628598
,1,,Tested for plasma half life period in rat (0-8 hr); Not determined,,10178,5089,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL628599
,1,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,,10179,1466,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628600
,1,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,,10180,1466,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628601
,1,,Tested for the half life in rat,,10181,4950,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628602
,1,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,,10182,2412,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vitro,,BAO_0000218,A,,CHEMBL628603
,1,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,,10183,2412,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vitro,,BAO_0000218,A,,CHEMBL628604
,1,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,,10184,2412,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vitro,,BAO_0000218,A,,CHEMBL628605
,1,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,,10185,2412,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vitro,,BAO_0000218,A,,CHEMBL628606
,1,,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,,10186,2412,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vitro,,BAO_0000218,A,,CHEMBL628607
,1,,The biological half life the compound was measured at the dose of 100 umol/kg,,10187,15022,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628608
,1,,The biological half life the compound was measured at the dose of 30 umol/kg,,10188,15022,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628609
,1,,The compound was evaluated for plasma half life period in rat,,10189,406,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL628610
,1,,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",,10190,15078,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL873819
,1,,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",,10191,15078,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628611
,1,,The pharmacokinetic parameter half-life period in vivo in rats,,10192,5247,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628612
,1,,"The pharmacokinetic property, Half-life was determined",,10193,5041,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628613
,1,,"The pharmacokinetic property, Half-life in rat in vivo",,10194,5041,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628614
,1,,"The pharmacokinetic property, Half-life was determined; ND denotes no data",,10195,5041,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628615
,1,,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",,10196,5041,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628616
,1,,The plasma half life period in rats,,10197,3918,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL627924
,1,,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,,10198,2906,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL627925
,1,,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,10199,6467,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627926
,1,,t1/2 (apparent elimination)of the compound was determined,,10200,5510,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627927
,1,,t1/2 value in rat,,10201,3788,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627928
,1,,Half life in rat,,10202,17796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627539
,1,,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",,10203,12873,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL876790
,1,,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,,10204,5983,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL858186
,1,,Half-life period in fasted rats,,10205,15765,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627540
,1,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,,10206,2661,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627541
,1,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,,10207,2661,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627715
,1,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,10208,429,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627716
,1,,Maximum time required to achieve Cmax was determined in rat,,10209,17655,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627717
,1,,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,10210,17717,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627718
,1,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,10211,17717,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627719
,1,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,,10212,17717,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627720
,1,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,,10213,6570,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627721
,1,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,,10214,6570,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627722
,1,,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,10215,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627723
,1,,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,10216,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626058
,1,,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,10217,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626059
,1,,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,10218,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626060
,1,,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,,10219,17720,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626061
,1,,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,10220,4723,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876791
,1,,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,,10221,4723,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626062
,1,,Tmax at the dose of 2 mg/Kg administered perorally in rats,,10222,4756,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626063
,1,,Tmax at the dose of 5 mg/Kg administered perorally in rats,,10223,4756,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626064
,1,,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,,10224,17720,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626065
,1,,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,,10225,17720,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626066
,1,,tmax upon peroral administration of 10.0 mg/Kg dose in rat,,10226,1466,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626067
,1,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,,10227,7449,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,F,,CHEMBL626068
,1,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,,10228,7449,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,F,,CHEMBL626069
,1,,Percent total excretion of 3-methoxyacetaminophen glucuronide,,10229,7449,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,F,,CHEMBL626070
,1,,Percent total excretion of N-methoxyacetaminophen glucuronide,,10230,7449,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,F,,CHEMBL626071
,1,,Percent total excretion of N-methoxyacetaminophen sulfate,,10231,7449,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,F,,CHEMBL626072
,1,,Percent total excretion of acetaminophen,,10232,7449,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,F,,CHEMBL626073
,1,,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",,10233,7768,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Thyroid gland,N,2046.0,,,BAO_0000218,A,,CHEMBL626741
,1,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",,10234,17655,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626742
,1,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,,10235,17735,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626743
,1,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,10236,5960,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL876792
,1,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,10237,17735,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626744
,1,,Compound was tested for antidiuretic activity in rats,,10238,7116,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626745
,1,,AUC in rat after 3mg/kg oral dose,,10239,4878,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626746
,1,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,,10240,5939,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626747
,1,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,,10241,5939,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626748
,1,,Bioavailability administered orally at a dose of 10 mg/kg to rats,,10242,16367,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626749
,1,,Oral Bioavailability was determined,,10243,16366,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626750
,1,,Oral bioavailability in rat,,10244,4426,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626751
,1,,Oral bioavailability in rat; Not performed.,,10245,4426,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626913
,1,,Bioavailability,,10246,5041,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626914
,1,,Bioavailability was determined; ND denotes no data,,10247,5041,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626915
,1,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,,10248,1500,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626916
,1,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,,10249,1500,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626917
,1,,Binding towards rat plasma protein at 10 uM,,10250,17409,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626918
,1,,Binding towards rat plasma protein at 100 uM,,10251,17409,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626919
,1,,Bioavailability in rat (dose 20 mg/kg p.o.),,10252,2959,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626920
,1,,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,,10253,13501,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621976
,1,,Bioavailability in rat after 5 mg/kg oral gavage,,10254,6567,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL877599
,1,,Bioavailability in rat,,10255,6571,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621977
,1,,Bioavailability in rat (dose 1 mg/kg i.v.),,10256,6715,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621978
,1,,Bioavailability in rat (dose 3 mg/kg p.o.),,10257,6715,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621979
,1,,Oral bioavailability in rat,,10258,2932,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621980
,1,,Bioavailability of the compound in rats after administration of 30 mg/kg,,10259,4171,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621981
,1,,Bioavailability after administration of 10 mg/kg in rats,,10260,17509,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621982
,1,,Bioavailability after administration of 2 mg/kg in rats,,10261,17509,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL882953
,1,,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,,10262,4527,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621983
,1,,Bioavailability in dogs was determined; high,,10263,4026,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621984
,1,,Bioavailability in monkey after intravenous administration at 1 mpk,,10264,6659,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621985
,1,,Bioavailability in monkey after peroral administration at 10 mpk,,10265,6659,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621986
,1,,Bioavailability in rat after intravenous administration at 1 mpk,,10266,6659,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621987
,1,,Bioavailability in rat after intravenous administration at 2 mpk,,10267,6659,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL877600
,1,,Bioavailability in rat after peroral administration at 30 mpk,,10268,6659,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621988
,1,,Bioavailability in rat after peroral administration at at 100 mpk,,10269,6659,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL621989
,1,,Bioavailability in rats was evaluated,,10270,6597,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621990
,1,,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,,10271,1202,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621991
,1,,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,,10272,1202,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621992
,1,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,,10273,1202,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621993
,1,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,,10274,1202,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621994
,1,,Bioavailability in rat,,10275,5207,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621995
,1,,Bioavailability in rat,,10276,5970,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621996
,1,,Oral bioavailability in rat (dose 10 mg/kg),,10277,17538,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621997
,1,,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,,10278,17538,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621998
,1,,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,,10279,1466,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621999
,1,,Oral bioavailability in rat,,10280,2879,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622000
,1,,Bioavailability was measured in rat after oral administration; 2-4,,10281,2879,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622001
,1,,Bioavailability was measured in rat after oral administration; 3-7,,10282,2879,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622002
,1,,Bioavailability in rat (intraduodenal administration),,10283,3777,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622003
,1,,Bioavailability in rat (intraduodenal administration),,10284,3777,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL877601
,1,,Oral bioavailability in rat,,10285,3777,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624871
,1,,Oral bioavailability in rat,,10286,3777,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622004
,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),,10287,5423,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL882954
,1,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,,10288,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622005
,1,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,,10289,16365,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622006
,1,,Bioavailability was measured in rat,,10290,4239,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622007
,1,,Bioavailability was reported,,10291,5438,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622008
,1,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,10292,5334,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622009
,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,10293,5334,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622010
,1,,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,10294,4199,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622011
,1,,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),,10295,4199,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622012
,1,,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),,10296,4199,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622013
,1,,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,10297,4890,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622014
,1,,Bioavailability was determined at 3 mg/kg po dose in rats,,10298,2792,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624749
,1,,Oral bioavailability in rat (dose 2 mg/kg),,10299,5529,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624750
,1,,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",,10300,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624751
,1,,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,10301,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624752
,1,,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,10302,6685,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624753
,1,,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,,10303,6005,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624754
,1,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,10304,6410,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624755
,1,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,10305,6410,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624756
,1,,Bioavailability in rat,,10306,6103,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624757
,1,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,10307,6410,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624758
,1,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,10308,6410,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622270
,1,,Bioavailability in rat (Sprague-Dawley),,10309,5353,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622271
,1,,Bioavailability in rat at the dose of 2 mg/kg,,10310,4727,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622272
,1,,Oral bioavailability in rat,,10311,17804,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622273
,1,,Bioavailability in rat (cannulated) (dose 2 mg/kg),,10312,5809,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622274
,1,,Bioavailability value of compound in rats was determined after peroral administration,,10313,17804,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622275
,1,,Oral bioavailability in rat (dose 20 mg/kg),,10314,3634,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622276
,1,,Oral bioavailability in rat,,10315,3341,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622277
,1,,Oral bioavailability in rat (dose 5 mg/kg),,10316,2690,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622278
,1,,Oral bioavailability in rat,,10317,3184,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622279
,1,,Oral bioavailability in rat,,10318,740,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622280
,1,,Compound was evaluated for oral bioavailability in rats; 15-27 %,,10319,1806,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624083
,1,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,,10320,4891,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624084
,1,,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),,10321,3634,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624085
,1,,Compound was tested for bioavailability in rats,,10322,64,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624086
,1,,Bioavailability in rat,,10323,4839,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624087
,1,,Oral bioavailability in rat,,10324,1094,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624088
,0,,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,,10325,5005,,1,Macaca mulatta,Intermediate,22224,,9544.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624089
,0,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,10326,5005,,1,Rattus norvegicus,Intermediate,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624090
,1,,Evaluated for the bioavailability in rat (in vivo),,10327,4687,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624091
,1,,F value of compound in rats was determined after peroral administration,,10328,17804,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624092
,1,,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,10329,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624093
,1,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,10330,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624094
,1,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,10331,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624095
,1,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,10332,5974,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624096
,1,,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",,10333,1088,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624097
,1,,Maximum fall in carotid flow in rat,,10334,1742,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624098
,1,,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,,10335,4689,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL874392
,1,,Oral bioavailability in rat (dose 5 mg/kg),,10336,2463,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624099
,1,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,10337,5654,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624100
,1,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,10338,5654,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624101
,1,,Oral bioavailability in rat (male Wistar),,10339,6874,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624102
,1,,Oral bioavailability after administration (30 mg/kg) in rat; good,,10340,5633,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624103
,1,,Oral bioavailability at the dose of 2 mg/kg in rat,,10341,5496,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624104
,1,,Oral bioavailability determined in rats,,10342,2358,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624105
,1,,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),,10343,16456,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624106
,1,,Oral bioavailability in rat (dose single 10 mg/kg),,10344,5302,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624107
,1,,Oral bioavailability in rat (dose single 10 mg/kg),,10345,5302,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623943
,1,,Oral bioavailability in rat (dose 5 mg/kg,,10346,5302,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623944
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,,10347,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623945
,1,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,,10348,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623946
,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,,10349,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623947
,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,,10350,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623948
,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,,10351,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623949
,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,,10352,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623950
,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,,10353,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL874398
,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,,10354,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623951
,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,,10355,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623952
,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,,10356,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623953
,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,,10357,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623954
,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,,10358,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623955
,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,,10359,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623956
,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,,10360,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627807
,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,,10361,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627808
,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,,10362,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627809
,1,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,,10363,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627810
,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",,10364,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627811
,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",,10365,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627812
,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",,10366,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627813
,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",,10367,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627814
,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",,10368,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL875336
,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",,10369,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627815
,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",,10370,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627816
,1,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",,10371,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627817
,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",,10372,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627818
,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",,10373,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627819
,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",,10374,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627820
,1,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",,10375,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627821
,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,10376,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628464
,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,,10377,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626239
,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,,10378,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626240
,1,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,,10379,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626241
,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,,10380,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626242
,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,,10381,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626243
,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,,10382,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626244
,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,,10383,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626907
,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,10384,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626908
,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,10385,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626909
,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,10386,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626910
,1,,Percent total excretion of acetaminophen cysteine conjugate,,10387,7449,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,F,,CHEMBL875342
,1,,Percent total excretion of acetaminophen glucuronide,,10388,7449,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,F,,CHEMBL626911
,1,,Percent total excretion of acetaminophen sulfate,,10389,7449,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,F,,CHEMBL626912
,1,,Percent total excretion of acetaminophen-mercapturic acid,,10390,7449,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,F,,CHEMBL627065
,1,,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,,10391,3172,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL627066
,1,,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,10392,16456,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627067
,0,,Biodistribution of compound in rat muscle after 5 min of administration,,10393,10839,,1,ratrat,Autocuration,22224,,8656.0,Muscle tissue,U,2385.0,In vivo,,BAO_0000218,A,,CHEMBL627068
,0,,Biodistribution of compound in rat muscle after 5 min of administration.,,10394,10839,,1,ratrat,Autocuration,22224,,8656.0,Muscle tissue,U,2385.0,In vivo,,BAO_0000218,A,,CHEMBL627069
,0,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,10395,5334,,1,Ovis aries,Autocuration,22224,,9940.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL627070
,0,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,10396,5334,,1,Ovis aries,Autocuration,22224,,9940.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL627071
,0,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,10397,5334,,1,Ovis aries,Autocuration,22224,,9940.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL627072
,0,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,10398,5334,,1,Ovis aries,Autocuration,22224,,9940.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL627073
,0,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,10399,5334,,1,Ovis aries,Autocuration,22224,,9940.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL625387
,0,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,10400,5334,,1,Ovis aries,Autocuration,22224,,9940.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL625388
,0,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,10401,5334,,1,Ovis aries,Autocuration,22224,,9940.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL625389
,0,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,10402,5334,,1,Ovis aries,Autocuration,22224,,9940.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL875343
,1,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),,10403,1735,,1,Serpentes,Intermediate,50497,,8570.0,,N,,,,BAO_0000218,A,,CHEMBL876795
,1,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,,10404,1469,,1,Serpentes,Intermediate,50497,,8570.0,,N,,,,BAO_0000218,A,,CHEMBL626552
,1,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,,10405,1336,,1,Serpentes,Intermediate,50497,,8570.0,,N,,,,BAO_0000218,A,,CHEMBL626553
,0,,The human biological plasma half life of the compound,,10406,12403,,1,Homo sapiens,Autocuration,22224,,9606.0,Plasma,U,1969.0,,,BAO_0000366,A,,CHEMBL626554
,1,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,10407,8151,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Urine,N,1088.0,,,BAO_0000218,A,,CHEMBL626555
,1,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,,10408,8004,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626556
,1,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,,10409,8004,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626557
,1,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,,10410,8004,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626558
,1,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,,10411,8004,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626559
,1,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,,10412,8004,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626560
,1,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,,10413,8004,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL876803
,1,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,,10414,8004,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627964
,1,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,,10415,8004,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627965
,1,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,,10416,8004,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627966
,1,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,,10417,8004,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627967
,1,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,,10418,8004,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627968
,1,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,,10419,8004,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627969
,1,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,,10420,8004,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627970
,1,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,,10421,8004,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL627971
,1,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,,10422,8004,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL627972
,9,,Dissociation constant against binding to human cyclophilin A,,10423,15917,,1,Homo sapiens,Expert,180,,9606.0,,D,,,,BAO_0000357,B,,CHEMBL856029
,8,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,,10424,12396,,1,Bos taurus,Expert,11591,,9913.0,,H,,,,BAO_0000019,B,,CHEMBL627973
,0,,-Log C was determined by performing the electroshock minimum test,,10425,7065,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL627974
,0,,-Log C was determined by performing the foot shock test,,10426,7065,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL627975
,0,,-Log C was determined by performing the incl screen test,,10427,7065,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL627976
,0,,-Log C was determined by performing the maximum electroshock test,,10428,7065,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL627977
,0,,-Log C was determined by performing the pentylenetetrazole test,,10429,7065,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL627978
,0,,Tested for experimental arotinoid inhibitory dose,,10430,12415,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL627979
,0,,Negative log transformed activity,,10431,10256,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL876804
,0,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",,10432,7991,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL627980
,1,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,,10433,14342,,1,Cavia porcellus,Intermediate,50512,,10141.0,,N,,,,BAO_0000218,A,,CHEMBL627981
,1,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,,10434,14342,,1,Cavia porcellus,Intermediate,50512,,10141.0,,N,,,,BAO_0000218,A,,CHEMBL627982
,1,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,,10435,14342,,1,Cavia porcellus,Intermediate,50512,,10141.0,,N,,,,BAO_0000218,A,,CHEMBL627983
,1,,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,,10436,14342,,1,Cavia porcellus,Intermediate,50512,,10141.0,Ileum,N,2116.0,,,BAO_0000218,A,,CHEMBL627984
,0,,Solubility in water was determined; values expressed as -log,,10437,6047,,1,,Autocuration,22229,,,,U,,,,BAO_0000100,P,,CHEMBL627985
,0,,Ratio of Kcat to that of Km was determined,,10438,17269,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL627986
,0,,Observed first order rate constant,,10439,10026,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL627987
,0,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,,10440,14583,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL627988
,1,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,,10441,2661,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627989
,1,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,,10442,2661,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627990
,1,,Oral Bioavailability after administration of 10 mg/kg in male rat,,10443,4029,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876805
,1,,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),,10444,17735,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627991
,1,,Oral bioavailability in rat,,10445,4576,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627992
,1,,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,,10446,17582,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627993
,1,,Oral bioavailability at 1 mg/kg was determined in rat,,10447,17651,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622817
,1,,Oral bioavailability at 10 mg/kg was determined in rat,,10448,17651,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622818
,1,,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",,10449,17670,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622819
,1,,Oral bioavailability in rat,,10450,5045,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL872267
,1,,Oral bioavailability in rat,,10451,1696,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622820
,1,,Oral bioavailability after intravenous administration in rats at 24 uM/kg,,10452,17764,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622821
,1,,Oral bioavailability in rat,,10453,6448,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622822
,1,,Oral bioavailability in rat,,10454,6596,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622823
,1,,Oral bioavailability in rat,,10455,17547,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622824
,1,,Oral bioavailability in rat at a dose of 3 mg/kg,,10456,17771,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622825
,1,,Oral bioavailability in rat after oral administration at 10 mg/kg,,10457,6495,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622901
,1,,Oral bioavailability in rat,,10458,4558,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622902
,1,,Oral bioavailability in rat,,10459,17596,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621844
,1,,Oral bioavailability in Dawley rats,,10460,6827,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621845
,1,,Oral bioavailability,,10461,4026,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621846
,1,,Oral bioavailability in rat (dose 30 mg/kg),,10462,10,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621847
,1,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,10463,17717,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL877609
,1,,Bioavailability in rat (dose 3 mg/kg i.v.),,10464,17717,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621848
,1,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,10465,17717,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL621849
,1,,Oral bioavailability in rat (dose 60 mg/kg p.o.),,10466,17717,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622030
,1,,Percent oral bioavailability determined in rats,,10467,4796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622031
,1,,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,10468,4883,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622032
,1,,The compound was evaluated for bioavailability in rats; 32-51,,10469,2137,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622033
,1,,Bioavailability in rat (dose 20 mg/kg p.o.),,10470,2959,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622034
,1,,Oral bioavailability in rat,,10471,1361,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622035
,1,,Bioavailability percent in rat at the dose of 2 mg/kg,,10472,4727,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL882966
,1,,Bioavailability was evaluated after 20 uM/kg of peroral administration,,10473,16423,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622036
,1,,Oral bioavailability in rat,,10474,5206,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622037
,1,,Oral bioavailability in rat,,10475,6448,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622038
,1,,Bioavailability in rats,,10476,17723,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622039
,1,,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,,10477,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622040
,1,,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,,10478,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622041
,1,,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,,10479,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622042
,1,,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,,10480,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622043
,1,,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,,10481,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL622044
,1,,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,,10482,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL622045
,1,,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,,10483,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL622046
,1,,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,,10484,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL622047
,1,,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,,10485,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Bone,N,10000001.0,In vivo,,BAO_0000218,A,,CHEMBL877610
,1,,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,,10486,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622048
,1,,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,,10487,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622049
,1,,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,,10488,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622050
,1,,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,,10489,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622051
,1,,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,,10490,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622052
,1,,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,,10491,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622053
,1,,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,,10492,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622054
,1,,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,,10493,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622055
,1,,Oral bioavailability in rats was determined; High,,10494,5237,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622056
,1,,Oral bioavailability in the rat was determined,,10495,5503,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622057
,1,,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,,10496,15765,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628008
,1,,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),,10497,15660,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622058
,1,,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,10498,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622059
,1,,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,10499,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622060
,1,,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,10500,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622061
,1,,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,10501,5978,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622062
,1,,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,,10502,5656,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622063
,1,,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,,10503,3598,,1,Rattus norvegicus,Expert,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL877611
,1,,Oral bioavailability of compound in Sprague Dawley rats,,10504,4216,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622064
,1,,Oral bioavailability of compound in rat,,10505,17839,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622065
,1,,Oral bioavailability in rat (dose 2 mg/kg),,10506,6570,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622066
,1,,Oral bioavailability of compound in rat was determined,,10507,5334,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622067
,1,,Oral bioavailability of compound in rats,,10508,6886,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622068
,1,,Oral bioavailability of compound was determined in rats,,10509,5210,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622069
,1,,Oral bioavailability at a dose of 30 mg/kg in rats,,10510,4170,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624796
,1,,Oral bioavailability in rat (dose 10 mg/kg),,10511,6028,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624797
,1,,Oral bioavailability in rat (dose 10 mg/kg),,10512,6028,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623053
,1,,Oral bioavailability evaluated in rat,,10513,6078,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623054
,1,,Oral bioavailability in fasted rat,,10514,6168,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623055
,1,,Oral bioavailability in fed rat,,10515,6168,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623056
,1,,Oral bioavailability in rat (mature male) (dose 30 mg/kg),,10516,5160,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623057
,1,,Oral bioavailability in rat,,10517,6057,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623058
,1,,Oral bioavailability in rat (dose 10 mg/kg p.o.),,10518,6535,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623059
,1,,Oral bioavailability in rat after administration of 10 mg/kg po,,10519,6535,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623060
,1,,Oral bioavailability in rat,,10520,4194,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623061
,1,,Oral bioavailability in rat,,10521,6230,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623062
,1,,Oral bioavailability in rat,,10522,6619,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623063
,1,,Oral bioavailability in rat,,10523,17607,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623064
,1,,Oral bioavailability in ratrs,,10524,4942,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623065
,1,,Oral bioavailability in rat,,10525,4942,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623066
,1,,Oral bioavailability in rat,,10526,6646,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623067
,1,,Oral bioavailability in rats was determined; High,,10527,5237,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623068
,1,,Oral bioavailability in rat,,10528,6646,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623069
,1,,Oral bioavailability in rat,,10529,4449,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623070
,1,,Oral bioavailability was calculated in rat,,10530,6057,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623071
,1,,Oral bioavailability,,10531,2552,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623072
,1,,Oral bioavailability,,10532,5496,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623073
,1,,Oral bioavailability,,10533,6484,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623074
,1,,Oral bioavailability,,10534,6485,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623075
,1,,Oral bioavailability after i.v. administration,,10535,6616,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623076
,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,10536,4969,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623077
,1,,Oral bioavailability in rat (Sprague-Dawley),,10537,5862,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623078
,1,,Oral bioavailability in Sprague-Dawley rats,,10538,4514,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623079
,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,10539,4514,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623080
,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,10540,4514,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623081
,1,,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,,10541,5546,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623082
,1,,Oral bioavailability in fasted rat,,10542,6168,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL874400
,1,,Oral bioavailability in fed rat,,10543,6168,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623083
,1,,Oral bioavailability in rat,,10544,3624,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623084
,1,,Oral bioavailability in rat,,10545,5213,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623085
,1,,Oral bioavailability in rat,,10546,5496,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623086
,1,,Oral bioavailability in rat,,10547,5553,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623087
,1,,Oral bioavailability in rat,,10548,5833,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623088
,1,,Oral bioavailability in rat,,10549,5836,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623089
,1,,Oral bioavailability in rat,,10550,5865,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623090
,1,,Oral bioavailability in rat,,10551,5960,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623091
,1,,Oral bioavailability in rat,,10552,6249,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623092
,1,,Oral bioavailability in rat,,10553,6448,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623093
,1,,Oral bioavailability in rat,,10554,6453,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL874401
,1,,Oral bioavailability in rat,,10555,6640,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623094
,1,,Oral bioavailability in rat,,10556,17607,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623095
,1,,Oral bioavailability in rat after peroral administration at 10 mg/kg,,10557,5939,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623096
,1,,Oral bioavailability in rat after peroral administration at 5 mg/kg,,10558,5939,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624913
,1,,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),,10559,6281,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624914
,1,,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,,10560,5874,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624915
,1,,Oral bioavailability in rat; Not measured,,10561,5213,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624916
,1,,Oral bioavailability in rat,,10562,4964,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL624917
,1,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,,10563,11020,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625157
,1,,In vitro metabolic potential in rat liver microsomes,,10564,6251,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625158
,1,,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",,10565,1568,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625159
,1,,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",,10566,3032,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625160
,1,,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,,10567,3748,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625161
,1,,Oral bioavailability in rat,,10568,401,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625162
,1,,Oral bioavailability in rat,,10569,6512,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625163
,1,,Oral bioavailability in rats at 10 mg/kg,,10570,17617,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625164
,1,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,10571,6679,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625165
,1,,Oral bioavailability in rat,,10572,6742,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625166
,1,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,,10573,589,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625167
,1,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,,10574,589,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625168
,1,,Plasma clearance of the compound,,10575,3185,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625169
,1,,Plasma clearance at 10 mg/kg in rat upon intravenous administration,,10576,17596,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626264
,1,,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,,10577,2713,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626265
,1,,The compound was tested for plasma clearance in rat,,10578,12500,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626266
,1,,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,,10579,12500,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626267
,1,,Plasma concentration upon oral administration of 1 mg/Kg in rats,,10580,2713,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626268
,1,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,,10581,1446,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626269
,1,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,,10582,6227,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626270
,1,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,,10583,4709,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626271
,1,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",,10584,5510,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626272
,1,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,10585,5510,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626273
,1,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,10586,5510,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL875346
,1,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",,10587,5510,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626274
,1,,Compound was tested for protein binding in rat plasma,,10588,4514,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626275
,1,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,,10589,2713,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624646
,1,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,,10590,2713,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624647
,1,,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,,10591,5340,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL624648
,1,,Area under curve ratio was determined (po/iv) in rat,,10592,12058,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624649
,1,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,,10593,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624650
,1,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,,10594,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624651
,1,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,,10595,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624652
,1,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,,10596,6495,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624653
,1,,Ratio of AUCbrain to AUCplasma,,10597,6078,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624654
,1,,Ratio of brain to plasma,,10598,5656,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624655
,1,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,,10599,4910,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624656
,1,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,10600,4910,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624657
,1,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,10601,4910,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624658
,1,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,,10602,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624659
,1,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,,10603,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624660
,1,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,,10604,10130,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624661
,1,,Steady state brain :blood ratio was determined,,10605,5213,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624662
,1,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,10606,4910,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625199
,1,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,10607,4910,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625200
,1,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,,10608,4910,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625201
,1,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,10609,4910,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625202
,1,,Percentage recovery after 3h incubation with rat hapatocytes was determined,,10610,2083,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625203
,1,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,,10611,2082,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625204
,1,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,,10612,2082,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625205
,1,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,,10613,6351,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625206
,0,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",,10614,14583,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL625207
,0,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,,10615,14583,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL625208
,1,495.0,In vivo absorption in Caco-2 cell line monolayers was determined,,10616,4608,,1,Homo sapiens,Intermediate,50587,,9606.0,,N,,,Caco-2,BAO_0000218,A,,CHEMBL625209
,0,,Calculated partition coefficient (clogP),,10617,13668,,1,,Autocuration,22229,,,,U,,,,BAO_0000100,P,,CHEMBL625210
,1,,Area under curve was determine after peroral administration at 10 mpk in Rat,,10618,5669,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625211
,1,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,10619,5669,,1,Macaca mulatta,Intermediate,50797,,9544.0,,N,,,,BAO_0000218,A,,CHEMBL625212
,1,,Area under curve was determine after peroral administration at 160 mpk in Rat,,10620,5669,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625213
,1,,Area under curve was determine after peroral administration at 20 mpk in Rat,,10621,5669,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625214
,1,,Area under curve was determine after peroral administration at 50 mpk in Rat,,10622,5669,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL874542
,0,,Calculated partition coefficient (clogP) (AlogP),,10623,6472,,1,,Autocuration,22229,,,,U,,,,BAO_0000100,P,,CHEMBL625215
,0,,Activated partial thromboplastin time measured,,10624,15106,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL625216
,0,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),,10625,15207,,1,,Autocuration,22224,,,,U,,,,BAO_0000100,P,,CHEMBL625217
,0,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),,10626,15207,,1,,Autocuration,22224,,,,U,,,,BAO_0000100,P,,CHEMBL625218
,1,,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,,10627,13941,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622864
,1,,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,,10628,13941,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622865
,1,,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,,10629,13941,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622866
,1,,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,,10630,13941,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL622867
,1,,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,,10631,15240,,1,Cavia porcellus,Intermediate,50512,,10141.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL876808
,0,,AUC in brain,,10632,10655,,1,,Autocuration,22224,,,Brain,U,955.0,,,BAO_0000019,A,,CHEMBL627725
,0,,AUC in serum,,10633,10655,,1,,Autocuration,22224,,,Serum,U,1977.0,,,BAO_0000019,A,,CHEMBL627726
,0,,AUC was determined,,10634,6504,,1,,Autocuration,22224,,,Plasma,U,1969.0,,,BAO_0000019,A,,CHEMBL627727
,0,,AUC of the compound.,,10635,10615,,1,,Autocuration,22224,,,Plasma,U,1969.0,,,BAO_0000019,A,,CHEMBL627728
,0,,AUC value (0-4 hr),,10636,10353,,1,,Autocuration,22224,,,Plasma,U,1969.0,,,BAO_0000019,A,,CHEMBL627729
,0,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",,10637,14907,,1,,Autocuration,22224,,,Plasma,U,1969.0,,,BAO_0000019,A,,CHEMBL627730
,0,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,,10638,14907,,1,,Autocuration,22224,,,Plasma,U,1969.0,,,BAO_0000019,A,,CHEMBL627731
,0,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",,10639,14907,,1,,Autocuration,22224,,,Plasma,U,1969.0,,,BAO_0000019,A,,CHEMBL627732
,0,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",,10640,14907,,1,,Autocuration,22224,,,Plasma,U,1969.0,,,BAO_0000019,A,,CHEMBL627733
,1,,AUC(area under curve) was determined after intravenous administration in rats,,10641,16359,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL627734
,1,,AUC(area under curve) was determined after oral administration in rats,,10642,16359,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL627735
,1,,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,,10643,15240,,1,Cavia porcellus,Intermediate,50512,,10141.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL627736
,1,,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,,10644,15240,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL876809
,0,,Area Under Curve after oral dosing of 100 uM/Kg,,10645,15469,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL627737
,0,,Area Under Curve after oral dosing of 30 uM/Kg,,10646,15469,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL627738
,0,,Area Under Curve was measured by ploting the graph between concentration verses time,,10647,13520,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL627739
,1,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,,10648,17025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL626143
,0,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,,10649,17025,,1,Simiiformes,Autocuration,22224,,314293.0,,U,,,,BAO_0000218,A,,CHEMBL626144
,1,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,,10650,17025,,1,Oryctolagus cuniculus,Intermediate,50592,,9986.0,,N,,,,BAO_0000218,A,,CHEMBL626145
,1,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,,10651,17025,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626146
,1,,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,,10652,12032,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL626147
,0,,Area under curve (AUC) was determined,,10653,10291,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL626148
,0,,Area under curve (AUC) following ip administration at 1 mg/kg,,10654,5767,,1,,Autocuration,22224,,,,U,,,,BAO_0000218,A,,CHEMBL626149
,0,,Area under curve (AUC) was determined; ND is Not determined,,10655,1434,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL626150
,1,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,,10656,14925,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL626151
,1,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,,10657,14925,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL626152
,1,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,,10658,14925,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL626153
,0,,Area under curve (AUR) was determined,,10659,1434,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL626154
,0,,Area under curve at 1 uM/dg administered intravenously,,10660,11883,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL626155
,0,,Area under curve at 10 uM/dg administered perorally,,10661,11883,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL626156
,0,,Area under curve at 2 uM/dg administered intravenously,,10662,11883,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL626157
,0,,Area under curve at 20 uM/dg administered perorally,,10663,11883,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL626158
,1,,Area under curve at a peroral dose of 3 mg/kg in dog,,10664,15233,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL626159
,1,,Area under curve at a peroral dose of 3 mg/kg in rat,,10665,15233,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626160
,1,,Area under curve at an iv dose of 1 mg/kg in dog,,10666,15233,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL626161
,1,,Area under curve at an iv dose of 1 mg/kg in rat,,10667,15233,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626162
,0,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,,10668,12978,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL626163
,0,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,,10669,12978,,1,,Autocuration,22224,,,,U,,,,BAO_0000019,A,,CHEMBL626164
,1,,Area under curve measured as conc vs time after intravenous administration to mice.,,10670,11355,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL626165
,1,,Area under curve measured as conc vs time after peroral administration to mice.,,10671,11355,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,,,BAO_0000218,A,,CHEMBL626166
,1,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,10672,12923,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL626167
,1,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,,10673,12923,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL626168
,1,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,,10674,12923,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL877463
,1,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,,10675,12923,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL626169
,1,,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,,10676,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL626170
,1,,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,,10677,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL626171
,1,,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,,10678,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL626172
,1,,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,,10679,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL626173
,1,,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,,10680,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL626174
,1,,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,,10681,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL626175
,1,,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,,10682,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL626176
,1,,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,,10683,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL626177
,1,,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,,10684,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL622499
,1,,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,,10685,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622500
,1,,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,,10686,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622501
,1,,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,,10687,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622502
,1,,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,,10688,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622503
,1,,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,,10689,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL877614
,1,,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,,10690,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL624839
,1,,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,,10691,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL624840
,1,,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,,10692,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL624841
,1,,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,,10693,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL624842
,1,,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,,10694,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL624843
,1,,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,,10695,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL624844
,1,,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,,10696,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL624845
,1,,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,,10697,17738,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL621904
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,,10698,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL621905
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,,10699,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL874382
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,,10700,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL621906
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,,10701,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL621907
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,,10702,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622096
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,,10703,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL622097
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,,10704,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL622098
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,,10705,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL622099
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,,10706,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,In vivo,,BAO_0000218,A,,CHEMBL622100
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,,10707,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL622101
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,,10708,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL622102
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,,10709,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,In vivo,,BAO_0000218,A,,CHEMBL622103
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,,10710,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622104
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,,10711,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622105
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,,10712,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL622106
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,,10713,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL622107
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,,10714,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL622108
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,,10715,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,In vivo,,BAO_0000218,A,,CHEMBL622109
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,,10716,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL622110
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,,10717,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL622111
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,,10718,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Muscle tissue,N,2385.0,In vivo,,BAO_0000218,A,,CHEMBL874383
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,,10719,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL622112
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,,10720,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL622113
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,,10721,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Zone of skin,N,14.0,In vivo,,BAO_0000218,A,,CHEMBL622114
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,,10722,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL622115
,1,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,,10723,11195,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Spleen,N,2106.0,In vivo,,BAO_0000218,A,,CHEMBL622116
,1,,Oral bioavailability in rat,,10724,6193,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622117
,1,,Oral bioavailability in rat,,10725,6803,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622118
,1,,Oral bioavailability in rats at 6 mg/kg,,10726,6647,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622119
,1,,Oral bioavailability in rat (dose 6 mg/kg),,10727,6647,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622120
,1,,Oral bioavailability in rats at 6 mg/kg dose; Not tested,,10728,6647,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622121
,1,,Oral bioavailability in rat,,10729,6640,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622122
,1,,Oral bioavailability in rat,,10730,6641,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622123
,1,,Oral bioavailability in rat,,10731,6641,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622124
,1,,Bioavailability in rat,,10732,6642,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622125
,1,,Oral bioavailability,,10733,5472,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622126
,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,10734,6141,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620455
,1,,Oral bioavailability in rat,,10735,4390,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620456
,1,,Oral bioavailability in rat,,10736,5472,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620457
,1,,Oral bioavailability was evaluated; Not tested,,10737,5472,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620458
,1,,Oral bioavailability,,10738,5438,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620459
,1,,Oral bioavailability in rat by oral dosing,,10739,4883,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620460
,1,,Oral bioavailability in rat (dose 10 mg/kg p.o.),,10740,1908,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620461
,1,,Oral bioavailability in rat (Sprague-Dawley),,10741,4853,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620462
,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,10742,4853,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620463
,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,10743,4853,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620464
,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,10744,4853,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620465
,1,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),,10745,4853,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620466
,1,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,,10746,4853,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620467
,1,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,,10747,4853,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620468
,1,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,,10748,12873,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620469
,1,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,,10749,12873,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620470
,1,,Oral bioavailability in rat,,10750,3169,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620471
,1,,Oral bioavailability in rat,,10751,6305,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620472
,1,,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,,10752,4762,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620473
,1,,Oral bioavailability in rat,,10753,17847,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620474
,1,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),,10754,6211,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620475
,1,,Oral bioavailability in rat,,10755,6011,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620476
,1,,Oral bioavailability in rat,,10756,6317,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620477
,1,,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,,10757,6644,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620478
,1,,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,,10758,6644,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618768
,1,,Oral bioavailability in rat after oral administration at 13 mg/kg dose,,10759,6644,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618769
,1,,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,,10760,6644,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618770
,1,,Oral bioavailability (dose 20 mg/kg p.o.),,10761,6113,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618771
,1,,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,,10762,5937,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618772
,1,,Oral bioavailability in rat at 10 mg/kg of the compound,,10763,5711,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618773
,1,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,10764,17717,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875842
,1,,Bioavailability in rat (dose 3 mg/kg i.v.),,10765,17717,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618774
,1,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,10766,17717,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618775
,1,,Oral bioavailability in rat (dose 60 mg/kg p.o.),,10767,17717,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618776
,1,,Percent bioavailability (F) in rats after iv administration,,10768,4722,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618777
,1,,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,,10769,4722,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618778
,1,,Bioavailability in rat (dose 5 uM/kg p.o.),,10770,4353,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618779
,1,,Oral bioavailability,,10771,15662,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618780
,1,,Bioavailability in rat (dose 2 mg/kg p.o.),,10772,4756,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618781
,1,,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,,10773,4756,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618782
,1,,Oral bioavailability in rat (dose 20 mg/kg),,10774,3436,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618783
,1,,Oral bioavailability in rat,,10775,17800,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618784
,1,,Percent oral bioavailability evaluated in rat,,10776,15762,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618785
,1,,Oral bioavailability in rat,,10777,5089,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618786
,1,,Percent oral bioavailability in rat; Not determined,,10778,5089,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618787
,1,,Oral bioavailability in rat,,10779,3185,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618788
,1,,Bioavailability in rat,,10780,5145,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618789
,1,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),,10781,3457,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618790
,1,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),,10782,3457,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618791
,1,,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,,10783,5983,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875843
,1,,Oral bioavailability in rat (dose 20 mg/kg p.o.),,10784,5739,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL618792
,1,,Cmax at a dose of 30 mg/kg in rat,,10785,3579,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623395
,0,,Cmax in monkeys at a dose of 1 mg/kg,,10786,17788,,1,Simiiformes,Autocuration,22224,,314293.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL623396
,1,,Cmax in rat,,10787,14956,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623397
,1,,Cmax in rats at a dose of 1 mg/kg,,10788,17788,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623398
,1,,Cmax was measured in mice after an oral dose of 50 mg/kg.,,10789,9750,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL623399
,0,,"Cmax value at a dose of 12.7 uM/kg, po",,10790,12767,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL623400
,0,,"Cmax value at a dose of 6.3 uM/kg, iv",,10791,12767,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL623401
,0,,"Cmax value at a dose of 7.1 uM/kg, iv",,10792,12767,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL623402
,0,,Cmax value of compound was determined after 1 hr,,10793,12703,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL623403
,0,,Cmax value of the compound,,10794,15778,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL623404
,1,,Cmax value administered intraintestinal in rats.,,10795,12818,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625997
,1,,Cmax value administered perorally was determined in rat; Not determined,,10796,14964,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625998
,0,,Cmax value at the dose of 2.3 mg/kg,,10797,15808,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL625999
,0,,Cmax value at the dose of 5 mg/kg,,10798,15808,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL626000
,0,,Cmax value in the period of 8 hr after dosing. ,,10799,15778,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL626001
,0,,Cmax value at a oral dose of 20 mg/kg; Not tested,,10800,3715,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL626002
,0,,Cmax value at a oral dose of 20 mg/kg,,10801,3715,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL626003
,1,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,10802,1446,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626004
,1,,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,,10803,15240,,1,Cavia porcellus,Intermediate,50512,,10141.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626005
,1,,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,,10804,15240,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626006
,1,,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,,10805,14810,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626007
,1,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,10806,14239,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626008
,1,,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,,10807,12555,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Liver,N,2107.0,In vivo,,BAO_0000218,A,,CHEMBL626009
,1,,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,,10808,10754,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626010
,1,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,,10809,10754,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL626011
,1,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,,10810,10754,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL626012
,1,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,,10811,10754,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL626013
,1,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,,10812,10754,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL626014
,1,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,,10813,10754,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL877496
,1,,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,,10814,14600,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL626015
,1,,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,,10815,14600,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL626016
,1,,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,,10816,14600,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,F,,CHEMBL626017
,1,,Bioavailability as maximal plasma concentration in dogs,,10817,13543,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626018
,1,,Bioavailability as maximal plasma concentration in dogs,,10818,13543,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626692
,1,,Bioavailability as maximal plasma concentration in rats,,10819,13543,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626693
,0,,Bioavailability as maximal plasma concentration in rats,,10820,13543,,1,Rattus norvegicus,Autocuration,22224,,10116.0,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626694
,1,,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,10821,14600,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL626695
,1,,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,10822,14600,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL626696
,1,,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,10823,14600,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL626697
,1,,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,,10824,14600,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL626859
,1,,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,10825,14600,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL626860
,1,,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,10826,14600,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL626861
,1,,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,10827,14681,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626296
,0,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,,10828,15905,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL626297
,0,,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,,10829,15905,,1,,Autocuration,22224,,,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626298
,1,,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",,10830,13304,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626299
,1,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,,10831,15137,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626300
,1,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,,10832,15137,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626301
,1,,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,,10833,15137,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626962
,1,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,,10834,15137,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626963
,1,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,,10835,15137,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626964
,1,,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,,10836,14839,,1,Macaca fascicularis,Intermediate,100710,,9541.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626965
,1,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,10837,14839,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626966
,1,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,10838,14839,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626967
,1,,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,,10839,14839,,1,Macaca fascicularis,Intermediate,100710,,9541.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626968
,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,,10840,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL626969
,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,,10841,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL627126
,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,,10842,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL631276
,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,,10843,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL631277
,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,,10844,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL631278
,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,,10845,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL874457
,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,,10846,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL631279
,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,,10847,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL631280
,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,,10848,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL631281
,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,,10849,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL631968
,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,,10850,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL631969
,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,,10851,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL631970
,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,,10852,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL631971
,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,,10853,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL631972
,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,,10854,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL630435
,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,,10855,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL630436
,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,,10856,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL630437
,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,,10857,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL630438
,1,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,,10858,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Heart,N,948.0,,,BAO_0000218,A,,CHEMBL630439
,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,,10859,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL630440
,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,,10860,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL630441
,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,,10861,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL630442
,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,,10862,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL625234
,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,,10863,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL625235
,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,,10864,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL625236
,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,,10865,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL625237
,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,,10866,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL626125
,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,,10867,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL626126
,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,,10868,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL626127
,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,,10869,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL626128
,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,,10870,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL626129
,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,,10871,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL626130
,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,,10872,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL626131
,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,,10873,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL626132
,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,,10874,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL626752
,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,,10875,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL626753
,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,,10876,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL626754
,1,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,,10877,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Kidney,N,2113.0,,,BAO_0000218,A,,CHEMBL626755
,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,,10878,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL626756
,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,,10879,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL626757
,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,,10880,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL626758
,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,,10881,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL626759
,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,,10882,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL626760
,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,10883,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL626394
,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,,10884,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL626395
,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),,10885,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL626396
,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,10886,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL626397
,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,10887,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL626398
,1,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,10888,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL626399
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,,10889,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL874653
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,10890,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626400
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,10891,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626401
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,10892,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626402
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,10893,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626403
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,10894,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626404
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,,10895,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626405
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,10896,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625529
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,10897,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625530
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,10898,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625531
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,10899,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625532
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,10900,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625533
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,,10901,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL875474
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,10902,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625534
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,10903,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625535
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,10904,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625536
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,10905,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625537
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,10906,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625538
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,,10907,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625539
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,10908,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625540
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,10909,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625541
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,10910,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625542
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,10911,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625543
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,10912,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL625544
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,,10913,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL625545
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,10914,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL625546
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,,10915,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL625547
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,10916,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL625548
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,10917,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL625549
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,10918,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL625550
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,10919,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL625551
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,10920,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL875475
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,10921,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL625552
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,10922,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL625553
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,10923,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL625554
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,10924,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL625555
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,10925,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL625556
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,,10926,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624986
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,10927,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624987
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,10928,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624988
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,,10929,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL624989
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,,10930,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL624990
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,,10931,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL874391
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,,10932,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL624991
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,,10933,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL624992
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,,10934,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL624993
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,,10935,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL624994
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,,10936,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL624995
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,,10937,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL624996
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,,10938,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL624997
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,,10939,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL624998
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,,10940,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL624999
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,,10941,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL882955
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,,10942,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL625000
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,,10943,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL625001
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,,10944,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL625089
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,,10945,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL625090
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,,10946,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL625091
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,,10947,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL625092
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,,10948,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL625093
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,,10949,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL625094
,1,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,,10950,9025,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Artery,N,1637.0,In vivo,,BAO_0000218,A,,CHEMBL625095
,1,,Compound was evaluated for its bioavailability in the dogs,,10951,2249,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625096
,1,,Compound was evaluated for its bioavailability in the rats,,10952,2249,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625097
,0,,Compound was evaluated for oral bioavailability,,10953,17515,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL882956
,1,,Compound was evaluated for percentage of Oral bioavailability in rats,,10954,14541,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625098
,0,,Bioavailability in guinea pig,,10955,12797,,1,Cavia porcellus,Autocuration,22224,,10141.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL625099
,1,,Compound was evaluated for the oral bioavailability in rat,,10956,12797,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625100
,1,,Compound was evaluated for the oral bioavailability in dog,,10957,12797,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625101
,1,,Compound was evaluated for the oral bioavailability in rat,,10958,12797,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL874396
,0,,Bioavailability in dog (dosed i.v.),,10959,11727,,1,Canis lupus familiaris,Autocuration,22224,,9615.0,,U,,In vivo,,BAO_0000218,F,,CHEMBL625102
,1,,Compound was tested for in vivo bioavailability in dog,,10960,13249,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625103
,1,,Compound was tested for in vivo bioavailability in hamsters,,10961,13249,,1,Cricetinae,Intermediate,100712,,10026.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625104
,0,,Compound was tested for in vivo bioavailability in monkey,,10962,13249,,1,Simiiformes,Autocuration,22224,,314293.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL625105
,1,,Compound was tested for in vivo bioavailability in rat,,10963,13249,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625106
,0,,Oral bioavailability in mouse,,10964,9552,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL625107
,1,,Compound was tested for percent of oral bioavailability in mice; 56-74,,10965,9552,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625108
,0,,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),,10966,14839,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL625109
,0,,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),,10967,14839,,1,Macaca fascicularis,Autocuration,22224,,9541.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL625110
,0,,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),,10968,14839,,1,Macaca fascicularis,Autocuration,22224,,9541.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL625111
,1,,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),,10969,14839,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625112
,1,,Oral bioavailability in nude mice,,10970,14839,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL875334
,0,,Bioavailability in monkey (i.d. dosing),,10971,11219,,1,Primates,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL628617
,0,,Bioavailability in rat,,10972,9552,,1,Rattus norvegicus,Autocuration,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL628618
,0,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,,10973,11732,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL628619
,0,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,,10974,11732,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL628620
,1,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,10975,14839,,1,Macaca fascicularis,Intermediate,100710,,9541.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628621
,1,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,10976,14839,,1,Macaca fascicularis,Intermediate,100710,,9541.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628622
,1,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,10977,14839,,1,Macaca fascicularis,Intermediate,100710,,9541.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL628623
,1,,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,,10978,14839,,1,Macaca fascicularis,Intermediate,100710,,9541.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL628624
,1,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,10979,14839,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL628625
,1,,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,,10980,14839,,1,Macaca fascicularis,Intermediate,100710,,9541.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL628626
,1,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,10981,14839,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627041
,1,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,10982,14839,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627042
,1,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,10983,14839,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627043
,0,,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,,10984,13932,,1,,Autocuration,22224,,,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627044
,1,,Cmax in mouse plasma,,10985,11637,,1,Mus musculus,Intermediate,50594,,10090.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627045
,0,,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,,10986,11637,,1,,Autocuration,22224,,,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627046
,1,,Maximal plasma concentration in rat,,10987,13960,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627047
,1,,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,,10988,15905,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL627048
,1,,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,,10989,14062,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627049
,1,,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,,10990,14062,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627050
,1,,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,,10991,14062,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627051
,1,,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,,10992,14062,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627052
,1,,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,,10993,14062,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627053
,1,,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,,10994,14062,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627054
,1,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,10995,15011,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627055
,1,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,10996,15011,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627056
,1,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,10997,15011,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627057
,1,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,10998,15011,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL627058
,1,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,10999,15011,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626211
,0,,Maximum Concentration of the compound.,,11000,10291,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL626212
,1,,Maximum Concentration was measured after iv administration into Beagle dog,,11001,14599,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626213
,1,,Maximum Concentration was measured after iv administration into Beagle dog.,,11002,14599,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626214
,1,,Maximum Concentration was measured after po administration into Beagle dog,,11003,14599,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626215
,1,,Maximum Concentration was measured after po administration into Beagle dog.,,11004,14599,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626216
,0,,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,,11005,12767,,1,,Autocuration,22224,,,Blood,U,178.0,In vivo,,BAO_0000218,A,,CHEMBL626217
,0,,Maximum blood level reached after an iv dose of 12.2 uM/kg,,11006,12767,,1,,Autocuration,22224,,,Blood,U,178.0,In vivo,,BAO_0000218,A,,CHEMBL626218
,0,,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,,11007,12767,,1,,Autocuration,22224,,,Blood,U,178.0,In vivo,,BAO_0000218,A,,CHEMBL626219
,0,,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,,11008,12767,,1,,Autocuration,22224,,,Blood,U,178.0,In vivo,,BAO_0000218,A,,CHEMBL626220
,0,,Maximum blood level reached after an oral dose of 5.0 mg/kg,,11009,12767,,1,,Autocuration,22224,,,Blood,U,178.0,In vivo,,BAO_0000218,A,,CHEMBL626221
,0,,Maximum blood level reached at dose of 10.6 uM/kg orally,,11010,12767,,1,,Autocuration,22224,,,Blood,U,178.0,In vivo,,BAO_0000218,A,,CHEMBL626222
,1,,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,,11011,14706,,1,Cavia porcellus,Intermediate,50512,,10141.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626223
,1,,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,,11012,14706,,1,Cavia porcellus,Intermediate,50512,,10141.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626224
,1,,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,,11013,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL626225
,1,,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,,11014,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL626226
,1,,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,,11015,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL626227
,1,,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,,11016,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,In vivo,,BAO_0000218,A,,CHEMBL626228
,1,,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,11017,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626229
,1,,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,,11018,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626921
,1,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,,11019,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876793
,1,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,,11020,14793,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625309
,1,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,11021,10524,,1,Bacillus subtilis,Intermediate,50278,,1423.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625310
,0,,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,,11022,11871,,1,Simiiformes,Autocuration,22224,,314293.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL625311
,1,,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,,11023,11871,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625312
,0,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,,11024,3437,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL625313
,1,,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,,11025,12038,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625314
,1,,Maximum concentration in male rats after iv administration of 20 mg/kg,,11026,12038,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625315
,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,,11027,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625316
,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,,11028,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625317
,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,,11029,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625318
,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,,11030,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625319
,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,,11031,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625320
,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,,11032,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625321
,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,,11033,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625322
,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,,11034,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL876801
,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,,11035,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625323
,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,,11036,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625324
,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,,11037,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625325
,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,,11038,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625326
,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,,11039,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625327
,1,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,,11040,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL625328
,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,,11041,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL625329
,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,,11042,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL625330
,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,,11043,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL627774
,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,,11044,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL627775
,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,,11045,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL627949
,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,,11046,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL627950
,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,,11047,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL627951
,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,,11048,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL627952
,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,,11049,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL627953
,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,,11050,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL627954
,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,,11051,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL627955
,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,,11052,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL627956
,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,,11053,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL876802
,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,,11054,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL627957
,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,,11055,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL627958
,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,,11056,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL627959
,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,,11057,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL627960
,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,,11058,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL627961
,1,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,,11059,8418,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Lung,N,2048.0,,,BAO_0000218,A,,CHEMBL627962
,1,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,11060,9796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL627963
,1,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,11061,9796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624759
,1,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,11062,9796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624760
,1,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,11063,9796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624761
,1,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,11064,9796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL877607
,1,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,11065,9796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL624762
,1,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,11066,9796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL624763
,1,,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,11067,9796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL624764
,1,,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,11068,9796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL624765
,1,,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,11069,9796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Liver,N,2107.0,,,BAO_0000218,A,,CHEMBL624766
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,11070,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624767
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,,11071,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624768
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,11072,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624769
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,11073,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624770
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,11074,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624771
,1,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,11075,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624772
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,,11076,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624773
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,11077,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624774
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,11078,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624775
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,11079,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624776
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,11080,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624777
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,11081,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624778
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,,11082,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624779
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,11083,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624780
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,11084,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624781
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,11085,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL877608
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,11086,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624782
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,11087,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624783
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,,11088,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624784
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,11089,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624785
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,11090,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624786
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,11091,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624787
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,11092,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL628676
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,,11093,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621842
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,11094,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL621843
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,11095,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623873
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,11096,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623874
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,11097,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623875
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,11098,6996,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL623876
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,,11099,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL623877
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,11100,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL623878
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,,11101,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL623879
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,11102,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL623880
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,11103,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL623881
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,11104,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL623957
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,11105,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL623958
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,11106,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL623959
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,11107,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL623960
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,11108,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL623961
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,11109,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL623962
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,11110,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624676
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,11111,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624677
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,,11112,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624678
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,11113,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624679
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,11114,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624680
,0,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,,11115,11732,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL624849
,0,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,,11116,11732,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL624850
,0,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,,11117,11732,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL874399
,0,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,,11118,11732,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL624851
,0,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,,11119,11732,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL624852
,0,,Oral bioavailability in rat (dose 10 mg/kg),,11120,13359,,1,Rattus norvegicus,Autocuration,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624853
,0,,Oral bioavailability in rat (Sprague-Dawley),,11121,16618,,1,Rattus norvegicus,Autocuration,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624854
,0,,Oral bioavailability in rat,,11122,13960,,1,Rattus norvegicus,Autocuration,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624855
,0,,Oral bioavailability in rats was determined in vivo,,11123,13917,,1,Rattus norvegicus,Autocuration,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624856
,0,,Oral bioavailability in dog,,11124,14266,,1,Canis lupus familiaris,Autocuration,22224,,9615.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL882957
,0,,Oral bioavailability of compound in monkey,,11125,12359,,1,Simiiformes,Autocuration,22224,,314293.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL624857
,1,,Oral bioavailability of compound in rat,,11126,12359,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622202
,0,,Bioavailability in rat of PMEA prodrug,,11127,12359,,1,Rattus norvegicus,Autocuration,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL622203
,1,,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,,11128,12359,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625522
,0,,Serum conc at 3 hours following 25 mg/kg dose,,11129,10791,,1,Macaca mulatta,Autocuration,22224,,9544.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL622868
,0,,Urine conc 0-5 hours following 25 mg/kg dose,,11130,10791,,1,Macaca mulatta,Autocuration,22224,,9544.0,Urine,U,1088.0,In vivo,,BAO_0000218,A,,CHEMBL622869
,0,,Urine conc 0-24 hours following 25 mg/kg dose,,11131,10791,,1,Macaca mulatta,Autocuration,22224,,9544.0,Urine,U,1088.0,In vivo,,BAO_0000218,A,,CHEMBL622870
,0,,Oral bioavailability in African green monkeys; 20-25,,11132,138,,1,Chlorocebus aethiops,Autocuration,22224,,9534.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL622871
,1,,Oral bioavailability in cynomolgus monkey.,,11133,14521,,1,Macaca fascicularis,Intermediate,100710,,9541.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620560
,0,,Oral bioavailability in dog,,11134,13953,,1,Canis lupus familiaris,Autocuration,22224,,9615.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620561
,1,,Oral bioavailability in dog at 10 mg/kg oral dose,,11135,12836,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620562
,1,,Oral bioavailability in hamster at 10 mg/kg oral dose,,11136,12836,,1,Cricetinae,Intermediate,100712,,10026.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620563
,1,,Oral bioavailability in rat at 10 mg/kg oral dose,,11137,12836,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620564
,0,,Oral bioavailability in rat,,11138,14521,,1,Rattus norvegicus,Autocuration,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL872265
,0,,Oral bioavailability in rat,,11139,13953,,1,Rattus norvegicus,Autocuration,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620565
,0,,Oral bioavailability,,11140,6799,,1,Eutheria,Autocuration,22224,,9347.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620566
,0,,Oral bioavailability was determined; range 49-102%,,11141,11311,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL620567
,1,,Oral bioavailability was determined in dogs,,11142,4013,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620568
,0,,Oral bioavailability in rat,,11143,4013,,1,Rattus norvegicus,Autocuration,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620569
,0,,Oral bioavailability,,11144,17591,,1,Eutheria,Autocuration,22224,,9347.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620570
,0,,Oral bioavailability was determined; Not orally available,,11145,17591,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL620571
,1,,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),,11146,15011,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL620572
,0,,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),,11147,15011,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620573
,0,,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,,11148,15011,,1,Mus musculus,Autocuration,22224,,10090.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620574
,0,,Oral bioavailability in Rhesus monkey,,11149,9552,,1,Macaca mulatta,Autocuration,22224,,9544.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620575
,0,,Oral bioavailability in dog (female mongrel),,11150,9552,,1,Canis lupus familiaris,Autocuration,22224,,9615.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620576
,0,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,,11151,3639,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL875846
,0,,Oral bioavailability in dog,,11152,13397,,1,Canis lupus familiaris,Autocuration,22224,,9615.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620577
,0,,Percentage Bioavailability was evaluated.,,11153,3031,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL620578
,0,,Bioavailability in rat administered i.d.,,11154,12818,,1,Rattus norvegicus,Autocuration,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL620579
,0,,Bioavailability,,11155,4847,,1,Eutheria,Autocuration,22224,,9347.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL621248
,0,,Bioavailability in dog (male Beagle) i.v. administration,,11156,12421,,1,Canis lupus familiaris,Autocuration,22224,,9615.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL625390
,0,,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",,11157,11966,,1,Rattus norvegicus,Autocuration,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL625391
,0,,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),,11158,11218,,1,Primates,Autocuration,22224,,9443.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL872266
,0,,Oral bioavailability in rat (Sprague-Dawley) (male),,11159,13129,,1,Rattus norvegicus,Autocuration,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL625392
,1,,The oral bioavailability was measured on rats after oral administration,,11160,12350,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625393
,1,,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,11161,2231,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625394
,1,,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,11162,2231,,1,Macaca mulatta,Intermediate,50797,,9544.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625395
,0,,Bioavailability in rat (dose 10 mg/kg i.d.),,11163,12187,,1,Rattus norvegicus,Autocuration,22224,,10116.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL625396
,0,,Bioavailability in dog (male Beagle) i.v. administration,,11164,12421,,1,Canis lupus familiaris,Autocuration,22224,,9615.0,,U,,In vivo,,BAO_0000218,A,,CHEMBL625397
,1,,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,11165,13256,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625398
,1,,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,11166,13256,,1,Mus musculus,Intermediate,50594,,10090.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL625399
,1,,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,11167,13256,,1,Mus musculus,Intermediate,50594,,10090.0,Cerebellum,N,2037.0,In vivo,,BAO_0000218,A,,CHEMBL626074
,1,,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,11168,13256,,1,Mus musculus,Intermediate,50594,,10090.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626075
,1,,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,11169,2231,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626076
,1,,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,11170,2231,,1,Macaca mulatta,Intermediate,50797,,9544.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626077
,1,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),,11171,12178,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,In vivo,,BAO_0000218,A,,CHEMBL626078
,0,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),,11172,12178,,1,,Autocuration,22224,,,Blood,U,178.0,In vivo,,BAO_0000218,A,,CHEMBL625846
,0,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),,11173,12178,,1,,Autocuration,22224,,,Blood,U,178.0,In vivo,,BAO_0000218,A,,CHEMBL625847
,1,,Maximum concentration observed in rats at an oral dose of 50 mg/kg,,11174,15633,,1,Rattus norvegicus,Expert,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL625848
,1,,Maximum concentration of compound in plasma administered orally to rats,,11175,14258,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL625849
,1,,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",,11176,14224,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626023
,1,,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",,11177,14224,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626024
,1,,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",,11178,14224,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626025
,0,,Maximum concentration after 10 mg/kg by oral administration,,11179,5566,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL626026
,0,,Maximum concentration at a dose of 1.5 mg/kg,,11180,16935,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL626027
,0,,Maximum concentration at a dose of 2.0 mg/kg,,11181,16935,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL626028
,1,,Maximum concentration in dog plasma,,11182,14224,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626029
,0,,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,,11183,12536,,1,,Autocuration,22224,,,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626030
,0,,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,,11184,12536,,1,,Autocuration,22224,,,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626031
,0,,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,,11185,12536,,1,,Autocuration,22224,,,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626032
,0,,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,,11186,12536,,1,,Autocuration,22224,,,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626033
,0,,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,,11187,12536,,1,,Autocuration,22224,,,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626034
,1,,Maximum concentration in plasma after oral administration in dog (25 mg/kg),,11188,9994,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626035
,0,,Maximum concentration in plasma at Tmax,,11189,1434,,1,,Autocuration,22224,,,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626036
,1,,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,,11190,12836,,1,Canis lupus familiaris,Expert,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626037
,1,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,,11191,12836,,1,Cricetinae,Intermediate,100712,,10026.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626038
,1,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,,11192,12836,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626039
,1,,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,,11193,12545,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626040
,1,,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,,11194,13856,,1,Oryctolagus cuniculus,Intermediate,50592,,9986.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626041
,0,,Maximum concentration was calculated,,11195,3550,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL626042
,0,,Maximum concentration was calculated.,,11196,2632,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL626043
,0,,Maximum concentration at a peroral dose of 10 mg/kg,,11197,5566,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL626044
,0,,Maximum concentration of the drug at 10 uM/dg administered perorally,,11198,11883,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL626045
,0,,Maximum concentration of the drug at 2 uM/dg administered intravenously,,11199,11883,,1,,Autocuration,22224,,,,U,,In vivo,,BAO_0000218,A,,CHEMBL626046
,1,,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",,11200,14122,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626047
,1,,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",,11201,14122,,1,Cricetinae,Intermediate,100712,,10026.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626048
,1,,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",,11202,14122,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626049
,1,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,,11203,12542,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626050
,1,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,,11204,12542,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL874541
,1,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,,11205,12542,,1,Cricetinae,Intermediate,100712,,10026.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622826
,1,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,,11206,12542,,1,Cricetinae,Intermediate,100712,,10026.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622827
,1,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,,11207,12542,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622828
,1,,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,,11208,14080,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL622829
,1,,Maximum concentration reached following intravenous administration in male rat,,11209,11911,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL876806
,1,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,,11210,13204,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622830
,1,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,,11211,13204,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL622831
,1,,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,,11212,14346,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626794
,1,,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,,11213,14346,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626795
,1,,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,,11214,14346,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626796
,1,,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,,11215,14346,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626797
,1,,Maximum drug concentration is determined after oral dosing in rats.,,11216,14127,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626798
,1,,Maximum observed concentration in oral (5 mg/kg) fasted dogs,,11217,14339,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626799
,1,,Maximum observed concentration in oral (5 mg/kg) fed dogs,,11218,14339,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,In vivo,,BAO_0000218,A,,CHEMBL626800
,0,,Maximum plasma concentration,,11219,13494,,1,,Autocuration,22224,,,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626801
,1,,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,,11220,14925,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL876816
,1,,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,,11221,14474,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626802
,1,,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,,11222,14474,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,Plasma,N,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626803
,0,,Maximum plasma concentration following oral administration of 30 umol/kg,,11223,13917,,1,,Autocuration,22224,,,Plasma,U,1969.0,In vivo,,BAO_0000218,A,,CHEMBL626804
,1,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,,11224,9796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626805
,1,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,11225,9796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626309
,1,,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,11226,9796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626310
,1,,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,11227,9796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626311
,1,,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,11228,9796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Plasma,N,1969.0,,,BAO_0000218,A,,CHEMBL626312
,1,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,11229,9796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Uterus,N,995.0,,,BAO_0000218,A,,CHEMBL626313
,1,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,11230,9796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Uterus,N,995.0,,,BAO_0000218,A,,CHEMBL626314
,1,,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,11231,9796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Uterus,N,995.0,,,BAO_0000218,A,,CHEMBL626315
,1,,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,11232,9796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Uterus,N,995.0,,,BAO_0000218,A,,CHEMBL626316
,1,,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,11233,9796,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Uterus,N,995.0,,,BAO_0000218,A,,CHEMBL626317
,1,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),,11234,8363,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626318
,1,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),,11235,8363,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626319
,1,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),,11236,8363,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626320
,1,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),,11237,8363,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL875053
,1,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),,11238,8363,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626321
,1,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),,11239,8363,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626322
,1,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),,11240,8363,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626323
,1,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),,11241,8363,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626324
,1,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),,11242,8363,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626325
,1,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),,11243,8363,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626326
,1,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),,11244,8363,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626327
,1,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),,11245,8363,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL626328
,1,,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",,11246,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL626329
,1,,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",,11247,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL626330
,1,,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",,11248,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL626331
,1,,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",,11249,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL626332
,1,,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",,11250,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL626333
,1,,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",,11251,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL626334
,1,,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",,11252,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL626335
,1,,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",,11253,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Blood,N,178.0,,,BAO_0000218,A,,CHEMBL624798
,1,,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",,11254,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL624799
,1,,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",,11255,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL624800
,1,,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",,11256,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL624801
,1,,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",,11257,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL624802
,1,,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",,11258,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL624803
,1,,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",,11259,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL624804
,1,,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",,11260,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL624805
,1,,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",,11261,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,Brain,N,955.0,,,BAO_0000218,A,,CHEMBL624806
,1,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",,11262,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624807
,1,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",,11263,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624808
,1,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",,11264,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624809
,1,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",,11265,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624810
,1,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",,11266,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL877618
,1,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",,11267,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624811
,1,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",,11268,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624812
,1,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",,11269,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624813
,1,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",,11270,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624814
,1,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",,11271,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624815
,1,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",,11272,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624816
,1,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",,11273,8684,,1,Rattus norvegicus,Intermediate,50597,,10116.0,,N,,,,BAO_0000218,A,,CHEMBL624817
,1,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,11274,6996,,1,Canis lupus familiaris,Intermediate,50588,,9615.0,,N,,,,BAO_0000218,A,,CHEMBL624818
